SNP O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
sodium O
nitroprusside O
on O
HIF-1 O
activation O
is O
not O
dependent O
on O
nitric O
oxide-soluble O
guanylyl O
cyclase O
pathway.Adaptation O
to O
hypoxia O
and O
maintenance O
of O
O(2) O
homeostasis O
involve O
a O
wide O
range O
of O
responses O
that O
occur O
at O
different O
organizational O
levels O
in O
the O
body O
. O
One O
of O
the O
most O
important O
transcription O
factors O
that O
activate O
the O
expression O
of O
O(2)-regulated O
genes O
is O
hypoxia-inducible O
factor O
1 O
(HIF-1) O
. O
Nitric O
oxide O
(NO) O
mediates O
a O
variety O
of O
biological O
effects O
including O
relaxation O
of O
blood O
vessels O
and O
cytotoxicity O
of O
activated O
macrophages O
. O
We O
investigated O
the O
effect O
of O
the O
clinically O
used O
nitrates O
nitroglycerin O
(NTG) O
, O
isosorbide O
dinitrate O
(ISDN) O
, O
and O
sodium O
nitroprusside O
(SNP) O
on O
HIF-1-mediated O
transcriptional O
responses O
to O
hypoxia O
. O
We O
demonstrate O
that O
among O
the O
three O
nitrates O
, O
only O
SNP O
inhibits O
HIF-1 O
activation O
in O
response O
to O
hypoxia O
. O
In O
contrast O
, O
NTG O
or O
ISDN O
does O
not O
affect O
HIF-1 O
activity O
. O
SNP O
inhibits O
the O
accumulation O
of O
HIF-1alpha O
, O
the O
regulatory O
subunit O
of O
HIF-1 O
, O
and O
the O
transcriptional O
activation O
of O
HIF-1alpha B
via O
a O
mechanism O
that O
is O
not O
dependent O
on O
either O
NO O
or O
soluble O
guanylate O
cyclase O
. O

anthocyanidins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

[3H]RX821002 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Activation O
of O
alpha O
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidate.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor O
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O
intraperitoneal O
injection O
of O
etomidate O
in O
wild-type O
and O
in O
alpha2A-receptor-deficient O
mice O
, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate O
in O
mice O
does O
not O
require O
the O
alpha2A-receptor O
subtype O
. O
Intravenous O
injection O
of O
etomidate O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors B
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors O
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O
. O

dehydroepiandrosterone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 B
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

halothane O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
G O
protein-coupled O
receptors O
as O
direct O
targets O
of O
inhaled O
anesthetics.The O
molecular O
pharmacology O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine B
rhodopsin I
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O
revealed O
that O
halothane O
contacts O
an O
amino O
acid O
residue O
(Trp265) O
lining O
the O
ligand O
binding O
cavity O
in O
the O
transmembrane O
core O
of O
the O
receptor O
. O
The O
predicted O
functional O
consequence O
, O
competition O
between O
halothane O
and O
the O
ligand O
retinal O
, O
was O
shown O
here O
by O
spectroscopy O
and O
is O
known O
to O
exist O
in O
vivo O
. O
These O
data O
suggest O
that O
competition O
with O
endogenous O
ligands O
may O
be O
a O
general O
mechanism O
of O
the O
action O
of O
halothane O
at O
this O
large O
family O
of O
signaling O
proteins O
. O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Protective O
Effects O
of O
a O
Purified O
Saponin O
Mixture O
from O
Astragalus O
corniculatus O
Bieb. O
, O
in O
vivo O
Hepatotoxicity O
Models.In O
this O
study O
, O
the O
in O
vivo O
effects O
of O
a O
purified O
saponin O
mixture O
(PSM) O
, O
obtained O
from O
Astragalus O
corniculatus O
Bieb. O
, O
were O
investigated O
using O
two O
in O
vivo O
hepatotoxicity O
models O
based O
on O
liver O
damage O
caused O
by O
paracetamol O
(PC) O
and O
carbon O
tetrachloride O
(CCl4 O
) O
. O
The O
effects O
of O
PSM O
were O
compared O
with O
silymarin O
. O
Male O
Wistar O
rats O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate O
dehydrogenase O
( O
LDH) B
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

I3A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
( O
PKC) B
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC O
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC O
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosine O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O
spiralis O
, O
a O
nematode O
parasite O
, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 O
and O
MIP-2 O
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O
by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10 O
, O
20 O
, O
30 O
and O
40 O
days O
post-treatment O
. O
In O
these O
experiments O
, O
mimosine O
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced O
. O
In O
addition O
, O
we O
found O
that O
MCP-1 O
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine O
, O
while O
MIP-2 B
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O
inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T O
. O
spiralis O
. O
Our O
studies O
suggest O
that O
mimosine O
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O
cell O
cycle O
of O
white O
blood O
cells O
. O
This O
study O
suggests O
for O
the O
first O
time O
the O
premise O
that O
mimosine O
acts O
as O
an O
anti-inflammatory O
compound O
. O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Monocarboxylate O
transporters O
in O
the O
central O
nervous O
system O
: O
distribution O
, O
regulation O
and O
function O
. O
Monocarboxylate B
transporters I
(MCTs) O
are O
proton-linked O
membrane O
carriers O
involved O
in O
the O
transport O
of O
monocarboxylates O
such O
as O
lactate O
, O
pyruvate O
, O
as O
well O
as O
ketone O
bodies O
. O
They O
belong O
to O
a O
larger O
family O
of O
transporters O
composed O
of O
14 O
members O
in O
mammals O
based O
on O
sequence O
homologies O
. O
MCTs O
are O
found O
in O
various O
tissues O
including O
the O
brain O
where O
three O
isoforms O
, O
MCT1 O
, O
MCT2 O
and O
MCT4 O
, O
have O
been O
described O
. O
Each O
of O
these O
isoforms O
exhibits O
a O
distinct O
regional O
and O
cellular O
distribution O
in O
rodent O
brain O
. O
At O
the O
cellular O
level O
, O
MCT1 O
is O
expressed O
by O
endothelial O
cells O
of O
microvessels O
, O
by O
ependymocytes O
as O
well O
as O
by O
astrocytes O
. O
MCT4 O
expression O
appears O
to O
be O
specific O
for O
astrocytes O
. O
By O
contrast O
, O
the O
predominant O
neuronal O
monocarboxylate O
transporter O
is O
MCT2 O
. O
Interestingly O
, O
part O
of O
MCT2 O
immunoreactivity O
is O
located O
at O
postsynaptic O
sites O
, O
suggesting O
a O
particular O
role O
of O
monocarboxylates O
and O
their O
transporters O
in O
synaptic O
transmission O
. O
In O
addition O
to O
variation O
in O
expression O
during O
development O
and O
upon O
nutritional O
modifications O
, O
new O
data O
indicate O
that O
MCT O
expression O
is O
regulated O
at O
the O
translational O
level O
by O
neurotransmitters O
. O
Understanding O
how O
transport O
of O
monocarboxylates O
is O
regulated O
could O
be O
of O
particular O
importance O
not O
only O
for O
neuroenergetics O
but O
also O
for O
areas O
such O
as O
functional O
brain O
imaging O
, O
regulation O
of O
food O
intake O
and O
glucose O
homeostasis O
, O
or O
for O
central O
nervous O
system O
disorders O
such O
as O
ischaemia O
and O
neurodegenerative O
diseases O
. O

sulindac O
sulfide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF B
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

O-methylserine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Crystal O
structure O
of O
the O
pyridoxal-5'-phosphate-dependent O
serine O
dehydratase O
from O
human O
liver.L-serine O
dehydratase O
(SDH) O
, O
a O
member O
of O
the O
beta-family O
of O
pyridoxal O
phosphate-dependent O
(PLP) O
enzymes O
, O
catalyzes O
the O
deamination O
of O
L-serine O
and O
L-threonine O
to O
yield O
pyruvate O
or O
2-oxobutyrate O
. O
The O
crystal O
structure O
of O
L-serine O
dehydratase O
from O
human O
liver O
(hSDH) O
has O
been O
solved O
at O
2.5 O
A-resolution O
by O
molecular O
replacement O
. O
The O
structure O
is O
a O
homodimer O
and O
reveals O
a O
fold O
typical O
for O
beta-family O
PLP-dependent O
enzymes O
. O
Each O
monomer O
serves O
as O
an O
active O
unit O
and O
is O
subdivided O
into O
two O
distinct O
domains O
: O
a O
small O
domain O
and O
a O
PLP-binding O
domain O
that O
covalently O
anchors O
the O
cofactor O
. O
Both O
domains O
show O
the O
typical O
open O
alpha/beta O
architecture O
of O
PLP O
enzymes O
. O
Comparison O
with O
the O
rSDH- B
(PLP-OMS) O
holo-enzyme O
reveals O
a O
large O
structural O
difference O
in O
active O
sites O
caused O
by O
the O
artifical O
O-methylserine O
. O
Furthermore O
, O
the O
activity O
of O
hSDH-PLP O
was O
assayed O
and O
it O
proved O
to O
show O
catalytic O
activity O
. O
That O
suggests O
that O
the O
structure O
of O
hSDH-PLP O
is O
the O
first O
structure O
of O
the O
active O
natural O
holo-SDH O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
( O
DAT) B
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

BLT-4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1- B
mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI O
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

d-methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
( O
SERT) B
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT O
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O
behavioral O
, O
neural O
and O
cognitive O
demand O
. O
In O
autoshaping O
task O
a O
dose-response O
curve O
for O
METH O
was O
determined O
. O
METH O
(1.0mg/kg) O
impaired O
short-term O
memory O
(STM; O
lasting O
less O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping O
, O
indicating O
that O
METH O
had O
long-lasting O
effects O
in O
the O
latter O
task O
. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT O
in O
autoshaping O
new O
untrained O
vs O
. O
trained O
treated O
(METH O
, O
FLX O
, O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT O
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH O
SERT O
binding O
in O
several O
areas O
including O
hippocampus O
and O
cortex O
decreased O
, O
more O
remarkably O
in O
the O
trained O
animals O
. O
In O
contrast O
, O
FLX O
improved O
memory O
, O
increased O
SERT O
binding O
, O
prevented O
the O
METH O
amnesic O
effect O
and O
re-established O
the O
SERT O
binding O
. O
In O
general O
, O
memory O
and O
amnesia O
seemed O
to O
make O
SERT O
more O
vulnerable O
to O
drugs O
effects O
. O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues O
. O
Aldose B
reductase I
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O
the O
ocular O
media O
of O
mice O
with O
experimental O
uveitis O
. O
Accordingly O
, O
these O
results O
suggest O
BGG O
is O
a O
potential O
therapy O
for O
inflammatory O
diseases O
. O

nandrolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR B
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

Spiperone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha B
1B I
adrenoceptors I
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O
and O
7.8 O
respectively) O
. O
The O
selective O
alpha O
1D O
antagonist O
BMY O
7378 O
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors O
. O
5 O
. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha O
1D-adrenoceptors O
(r O
= O
0.96) O
, O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O
1B O
(r O
= O
0.46) O
subtypes O
. O
6 O
. O
Noradrenaline-mediated O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

Am80 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antimyeloma O
effects O
of O
a O
novel O
synthetic O
retinoid O
Am80 O
(Tamibarotene) O
through O
inhibition O
of O
angiogenesis.In O
multiple O
myeloma O
(MM) O
, O
the O
interaction O
between O
myeloma O
cells O
and O
bone O
marrow O
microenvironment O
has O
an O
important O
role O
in O
the O
pathogenesis O
of O
MM O
. O
We O
first O
examined O
the O
inducing O
effect O
of O
myeloma O
cells O
on O
migration O
of O
human O
umbilical O
vein O
vascular O
endothelial O
cells O
(HUVECs) O
. O
Five O
myeloma O
cell O
lines O
produced O
varying O
amounts O
of O
VEGF O
, O
and O
migration O
of O
HUVECs O
was O
induced O
by O
coculture O
with O
myeloma O
cells O
. O
We O
next O
examined O
the O
inhibitory O
effect O
of O
a O
novel O
synthetic O
retinoid O
Am80 O
(Tamibarotene) O
on O
both O
myeloma O
cells O
and O
HUVECs O
. O
Am80 O
is O
specific O
for O
the O
retinoic-acid O
receptor-alpha/beta O
, O
and O
has O
therapeutic O
effects O
in O
all-trans O
retinoic O
acid O
resistant O
acute O
promyelocytic O
leukemia O
. O
Am80 O
slightly O
inhibited O
the O
growth O
of O
both O
myeloma O
cells O
and O
HUVECs O
, O
and O
remarkably O
inhibited O
the O
growth O
of O
HUVECs O
stimulated O
by O
VEGF O
. O
Am80 O
showed O
little O
growth O
inhibition O
of O
bone O
marrow O
stromal O
cells O
(BMSCs) O
, O
but O
it O
markedly O
inhibited O
migration O
of O
HUVECs O
by O
cocultured O
myeloma O
cells O
. O
Am80 O
inhibited O
VEGF-induced O
phosphorylation O
of O
VEGF O
receptor O
. O
In O
addition O
, O
VEGF- B
induced O
formation O
of O
tube-like O
structures O
in O
vitro O
and O
neovascularization O
in O
mouse O
corneas O
were O
significantly O
inhibited O
by O
Am80 O
. O
These O
findings O
clearly O
demonstrate O
that O
Am80 O
is O
a O
potential O
inhibitor O
of O
angiogenesis O
caused O
by O
the O
interaction O
between O
vascular O
endothelial O
cells O
and O
myeloma O
cells O
, O
and O
might O
be O
a O
useful O
therapeutic O
agent O
against O
MM O
. O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR- B
ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
. O
Possible O
mechanisms O
contributing O
to O
the O
incomplete O
oral O
bioavailability O
of O
dasatinib O
in O
animals O
were O
investigated O
. O
METHODS O
: O
Metabolic O
stability O
of O
dasatinib O
was O
measured O
after O
incubation O
with O
liver O
microsomes O
(either O
NADPH- O
or O
UDPGA-fortified) O
and O
isolated O
hepatocytes O
obtained O
from O
mouse O
, O
rat O
, O
dog O
, O
monkey O
, O
and O
human O
. O
In O
all O
cases O
, O
substrate O
depletion O
over O
time O
was O
measured O
, O
and O
appropriate O
scaling O
factors O
were O
used O
to O
predict O
in O
vivo O
clearance O
. O
Pharmacokinetics O
of O
dasatinib O
were O
determined O
in O
mice O
, O
rats O
, O
dogs O
, O
and O
monkeys O
after O
administration O
of O
single O
intravenous O
or O
oral O
doses O
. O
In O
addition O
, O
the O
routes O
of O
excretion O
were O
investigated O
after O
administration O
of O
dasatinib O
to O
bile O
duct O
cannulated O
(BDC) O
rats O
. O
Absorption O
and O
first-pass O
metabolism O
were O
evaluated O
as O
possible O
reasons O
for O
the O
incomplete O
oral O
bioavailability O
using O
various O
in O
vitro O
and O
in O
vivo O
models O
like O
Caco-2 O
cells O
, O
P-glycoprotein O
(P-gp) O
knockout O
mice O
, O
and O
intra-portal O
dosing O
in O
rats O
. O
RESULTS O
: O
In O
vivo O
systemic O
plasma O
clearance O
values O
of O
dasatinib O
were O
62 O
, O
26 O
, O
25 O
, O
and O
34 O
ml/min/kg O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
, O
respectively O
. O
Scaling O
of O
in O
vitro O
hepatocyte O
and O
liver O
microsomal O
data O
gave O
reasonably O
good O
predictions O
of O
in O
vivo O
clearances O
across O
all O
species O
. O
Percent O
distribution O
in O
blood O
cells O
ranged O
from O
43% O
in O
mouse O
to O
57% O
in O
dog O
. O
Dasatinib O
showed O
high O
volumes O
of O
distribution O
(>3 O
l/kg) O
and O
high O
serum O
protein O
binding O
values O
(>90%) O
in O
all O
four O
species O
tested O
. O
Oral O
bioavailability O
of O
dasatinib O
ranged O
from O
14% O
in O
the O
mouse O
to O
34% O
in O
the O
dog O
. O
In O
rats O
, O
bioavailability O
after O
an O
intraportal O
dose O
was O
comparable O
to O
that O
after O
intra-arterial O
administration O
. O
In O
BDC O
rats O
, O
less O
than O
15% O
of O
an O
intravenous O
dose O
was O
excreted O
unchanged O
in O
urine O
, O
bile O
, O
and O
the O
gastrointestinal O
tract O
, O
suggesting O
that O
dasatinib O
is O
cleared O
primarily O
via O
metabolism O
. O
Dasatinib O
has O
high O
intrinsic O
permeability O
in O
Caco-2 O
cells O
, O
however O
, O
the O
efflux O
ratio O
was O
approximately O
two-fold O
indicating O
that O
it O
may O
be O
a O
substrate O
for O
an O
intestinal O
efflux O
transporter O
. O
However O
, O
in O
vivo O
studies O
in O
P-gp O
knockout O
mice O
versus O
wild-type O
mice O
showed O
no O
difference O
in O
the O
amount O
of O
dasatinib O
remaining O
unabsorbed O
in O
the O
gastrointestinal O
tract O
, O
suggesting O
that O
P-gp O
may O
not O
be O
responsible O
for O
the O
incomplete O
bioavailability O
. O
CONCLUSIONS O
: O
Dasatinib O
shows O
intermediate O
clearance O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
, O
and O
distributes O
extensively O
in O
those O
species O
. O
Oxidative O
metabolism O
appears O
to O
be O
the O
predominant O
clearance O
pathway O
. O
The O
incomplete O
oral O
bioavailability O
may O
be O
due O
to O
both O
incomplete O
absorption O
and O
high O
first-pass O
metabolism O
. O
However O
, O
the O
efflux O
transporter O
, O
P-glycoprotein O
does O
not O
appear O
to O
be O
limiting O
oral O
absorption O
. O

ALD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 B
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

Minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Minocycline O
inhibits O
cytochrome B
c I
release O
and O
delays O
progression O
of O
amyotrophic O
lateral O
sclerosis O
in O
mice.Minocycline O
mediates O
neuroprotection O
in O
experimental O
models O
of O
neurodegeneration O
. O
It O
inhibits O
the O
activity O
of O
caspase-1 O
, O
caspase-3 O
, O
inducible O
form O
of O
nitric O
oxide O
synthetase O
(iNOS) O
and O
p38 O
mitogen-activated O
protein O
kinase O
(MAPK) O
. O
Although O
minocycline O
does O
not O
directly O
inhibit O
these O
enzymes O
, O
the O
effects O
may O
result O
from O
interference O
with O
upstream O
mechanisms O
resulting O
in O
their O
secondary O
activation O
. O
Because O
the O
above-mentioned O
factors O
are O
important O
in O
amyotrophic O
lateral O
sclerosis O
(ALS) O
, O
we O
tested O
minocycline O
in O
mice O
with O
ALS O
. O
Here O
we O
report O
that O
minocycline O
delays O
disease O
onset O
and O
extends O
survival O
in O
ALS O
mice O
. O
Given O
the O
broad O
efficacy O
of O
minocycline O
, O
understanding O
its O
mechanisms O
of O
action O
is O
of O
great O
importance O
. O
We O
find O
that O
minocycline O
inhibits O
mitochondrial O
permeability-transition-mediated O
cytochrome O
c O
release O
. O
Minocycline-mediated O
inhibition O
of O
cytochrome O
c O
release O
is O
demonstrated O
in O
vivo O
, O
in O
cells O
, O
and O
in O
isolated O
mitochondria O
. O
Understanding O
the O
mechanism O
of O
action O
of O
minocycline O
will O
assist O
in O
the O
development O
and O
testing O
of O
more O
powerful O
and O
effective O
analogues O
. O
Because O
of O
the O
safety O
record O
of O
minocycline O
, O
and O
its O
ability O
to O
penetrate O
the O
blood-brain O
barrier O
, O
this O
drug O
may O
be O
a O
novel O
therapy O
for O
ALS O
. O

auranofin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 B
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

crizotinib O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Novel O
therapeutic O
targets O
in O
non-small O
cell O
lung O
cancer.Oncogenic O
driver O
mutations O
frequently O
occur O
in O
lung O
cancer O
and O
play O
role O
in O
carcinogenesis O
. O
These O
mutations O
are O
usually O
associated O
with O
distinct O
clinical O
and O
histological O
features O
and O
are O
attractive O
targets O
for O
anticancer O
therapy O
. O
Recently O
, O
several O
molecularly O
distinct O
phenotypes O
of O
NSCLC O
based O
on O
specific O
and O
mutually O
exclusive O
genetic O
derangements O
have O
been O
described O
. O
Few O
targets O
like O
epidermal O
growth O
factor O
receptor O
(EGFR) O
mutations O
and O
anaplastic O
lymphoma O
kinase O
( O
ALK) B
gene O
rearrangements O
have O
successfully O
been O
targeted O
with O
EGFR O
tyrosine O
kinase O
inhibitors O
(TKIs) O
and O
crizotinib O
, O
respectively O
. O
Many O
more O
inhibitors O
of O
specific O
driver O
mutations O
involving O
genes O
like O
ROS O
, O
c-MET O
, O
FGFR O
, O
mTOR O
, O
IGFR O
and O
RET O
are O
currently O
under O
development O
. O
However O
, O
efforts O
to O
target O
some O
mutated O
genes O
like O
K-RAS O
have O
been O
unsuccessful O
. O
Moreover O
, O
the O
emerging O
challenge O
of O
acquired O
resistance O
to O
initially O
effective O
therapy O
is O
becoming O
another O
major O
concern O
. O
In O
this O
review O
recent O
data O
on O
novel O
molecular O
targets O
and O
their O
future O
prospects O
are O
discussed O
. O

androgens O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase O
inhibitors O
in O
breast O
cancer.Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 O
enzyme O
complex O
called O
aromatase B
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O
Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O
the O
substrate O
, O
is O
converted O
by O
the O
enzyme O
to O
a O
reactive O
intermediate O
, O
and O
results O
in O
inactivation O
of O
aromatase O
. O
These O
third-generation O
aromatase O
inhibitors O
are O
currently O
approved O
as O
first-line O
therapy O
for O
the O
treatment O
of O
postmenopausal O
women O
with O
metastatic O
estrogen-dependent O
breast O
cancer O
. O
The O
use O
of O
an O
aromatase O
inhibitor O
as O
initial O
therapy O
, O
or O
after O
treatment O
with O
tamoxifen O
, O
is O
now O
recommended O
as O
adjuvant O
hormonal O
therapy O
for O
postmenopausal O
women O
with O
hormone-dependent O
breast O
cancer O
. O
Several O
clinical O
studies O
of O
aromatase O
inhibitors O
focus O
on O
the O
use O
of O
these O
agents O
in O
the O
adjuvant O
setting O
, O
for O
the O
treatment O
of O
early O
breast O
cancer O
. O
Recently O
published O
results O
show O
improved O
responses O
with O
these O
agents O
compared O
with O
tamoxifen O
. O

kurarinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol B
acyltransferase I
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT O
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha B
1A-adrenoceptor- I
mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

N(5) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Contrasting O
effects O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric O
oxide O
synthases O
(EC O
1.14.13.39) O
. O
Here O
we O
compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine B
reductase I
(EC O
1.6.99.7) O
and O
phenylalanine O
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O
Substitution O
at O
N(5) O
occurs O
at O
a O
position O
critical O
to O
the O
redox O
cycle O
of O
the O
cofactor O
in O
phenylalanine O
hydroxylase/dihydropteridine O
reductase O
. O
We O
also O
included O
N(2)'-methyl O
H(4)biopterin O
, O
a O
derivative O
substituted O
at O
a O
position O
not O
directly O
involved O
in O
redox O
cycling O
, O
as O
a O
control O
. O
As O
compared O
with O
N(5)-methyl O
H(4)biopterin O
, O
N(5)-formyl O
H(4)biopterin O
bound O
with O
twice O
the O
capacity O
but O
stimulated O
nitric O
oxide O
synthase O
to O
a O
lesser O
extent O
. O
Depending O
on O
the O
substituent O
used O
, O
N(5)-substituted O
derivatives O
were O
redox-active O
: O
N(5)-methyl- O
and O
N(5)-hydroxyl O
methyl O
H(4)biopterin O
, O
but O
not O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
, O
reduced O
2,6-dichlorophenol O
indophenol O
. O
N(5)-Substituted O
H(4)biopterin O
derivatives O
were O
not O
oxidized O
to O
products O
serving O
as O
substrates O
for O
dihydropteridine O
reductase O
and,depending O
on O
the O
substituent O
, O
were O
competitive O
inhibitors O
of O
phenylalanine O
hydroxylase O
: O
N(5)-methyl- O
and O
N(5)-hydroxymethyl O
H(4)biopterin O
inhibited O
phenylalanine O
hydroxylase O
, O
whereas O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
had O
no O
effect O
. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine O
hydroxylase O
and O
nitric O
oxide O
synthase O
by O
H(4)biopterin O
. O
They O
are O
compatible O
with O
a O
novel O
, O
non-classical O
, O
redox-active O
contribution O
of O
H(4)biopterin O
to O
the O
catalysis O
of O
the O
nitric O
oxide O
synthase O
reaction O
. O

monoamine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular B
monoamine I
transporter-2 I
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

Ca2+ O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ O
affinity O
of O
cardiac B
troponin I
C I
.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) O
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase O
inhibition) O
. O
Three O
mutants O
(S37G O
, O
V44Q O
, O
and O
L48Q) O
were O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) O
sensitivity O
, O
partial O
loss O
of O
ATPase O
inhibition O
, O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac O
(c)TnCs O
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O
MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B B
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS O
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O
doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

PhIP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 B
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

gentamicin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Apolipoprotein O
E3 O
(apoE3) O
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 O
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density O
lipoprotein O
(LDL) O
receptor O
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1-dependent O
glucose O
transport O
in O
pig O
proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O
model O
of O
gentamicin O
C O
(GMC)-induced O
reduction O
in O
SGLT1 B
activity O
, O
we O
examined O
whether O
ligands O
for O
megalin O
protect O
LLC-PK1 O
cells O
from O
the O
GMC-induced O
reduction O
in O
SGLT1 O
activity O
. O
We O
employed O
apolipoprotein O
E3 O
(apoE3) O
and O
lactoferrin O
as O
ligands O
for O
megalin O
. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3 O
, O
lactoferrin O
and O
bovine O
serum O
albumin O
with O
or O
without O
100 O
microg/ml O
of O
GMC O
, O
and O
the O
SGLT1-dependent O
methyl O
alpha-D-glucopyranoside O
(AMG) O
uptake O
and O
levels O
of O
SGLT1 O
expression O
were O
determined O
. O
As O
a O
result O
, O
we O
demonstrated O
that O
the O
apoE3 O
significantly O
protects O
these O
cells O
from O
GMC-induced O
reduction O
in O
AMG O
uptake O
, O
but O
neither O
lactoferrin O
nor O
albumin O
does O
. O
In O
accord O
with O
a O
rise O
in O
AMG O
uptake O
activity O
, O
the O
mRNA O
and O
protein O
levels O
of O
SGLT1 O
were O
apparently O
up-regulated O
in O
the O
presence O
of O
apoE3 O
. O
Furthermore O
, O
we O
found O
that O
the O
uptake O
of O
[3H] O
gentamicin O
is O
decreased O
by O
apoE3 O
, O
and O
that O
apoE3 O
showed O
obvious O
protection O
against O
the O
GMC-dependent O
N-acetyl-beta-D-glucosamidase O
(NAG) O
release O
from O
LLC-PK1 O
cells O
. O
Thus O
, O
these O
results O
indicate O
that O
apoE3 O
could O
be O
a O
valuable O
tool O
for O
the O
prevention O
of O
aminoglycoside O
nephrotoxicity O
. O

ibuprofen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cyclooxygenase O
and O
5-lipoxygenase O
inhibitors O
protect O
against O
mononuclear O
phagocyte O
neurotoxicity.Neuroinflammation O
and O
oxidative O
stress O
are O
believed O
to O
be O
contributing O
factors O
to O
neurodegeneration O
in O
normal O
aging O
, O
as O
well O
as O
in O
age-related O
neurological O
disorders O
. O
Reactive O
microglia O
are O
found O
in O
increased O
numbers O
in O
aging O
brain O
and O
are O
prominently O
associated O
with O
lesions O
in O
such O
age-related O
degenerative O
conditions O
as O
Alzheimer's O
disease O
(AD) O
, O
Parkinson's O
disease O
(PD) O
and O
amyotrophic O
lateral O
sclerosis O
(ALS) O
. O
In O
vitro O
, O
stimulated O
microglia O
or O
microglial-like O
cells O
secrete O
neurotoxic O
materials O
and O
are O
generators O
of O
free O
radicals O
through O
their O
respiratory O
burst O
system O
. O
Agents O
that O
suppress O
microglial O
activation O
are O
therefore O
candidates O
for O
neuroprotection O
. O
We O
have O
developed O
quantitative O
in O
vitro O
assays O
for O
measuring O
neurotoxicity O
of O
microglia O
or O
other O
mononuclear O
phagocytes O
. O
Neuronal O
like O
SH-SY5Y O
cells O
are O
cultured O
in O
supernatants O
from O
activated O
cells O
of O
the O
human O
monocytic O
THP-1 O
line O
and O
their O
survival O
is O
followed O
. O
Respiratory O
burst O
is O
directly O
measured O
on O
the O
activated O
cells O
. O
We O
tested O
inhibitors O
of O
the O
cyclooxygenase O
(COX) O
or O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX O
pathway O
generates O
inflammatory O
prostaglandins O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1 O
/ O
COX-2 B
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O
5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
. O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O
inhibitors O
. O
The O
data O
suggest O
that O
both O
COX O
inhibitors O
and O
5-LOX O
inhibitors O
may O
be O
neuroprotective O
in O
vivo O
by O
suppressing O
toxic O
actions O
of O
microglia/macrophages O
, O
and O
that O
combinations O
of O
the O
two O
might O
have O
greater O
therapeutic O
potential O
than O
single O
inhibitors O
of O
either O
class O
. O

spiroxatrine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
2-(2-Aminoethyl)-quinoline O
(D-1997) O
: O
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like O
receptors O
in O
the O
canine O
basilar O
artery.This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline O
derivative O
, O
2-(2-aminoethyl)-quinoline O
(D-1997) O
, O
in O
the O
canine O
isolated O
basilar O
artery O
. O
For O
comparison O
, O
the O
effects O
of O
D-1997 O
were O
also O
evaluated O
on O
rat O
aorta O
. O
Canine O
basilar O
artery O
and O
rat O
aortic O
rings O
were O
prepared O
and O
mounted O
in O
organ O
baths O
to O
record O
isometric O
tension O
changes O
. O
The O
contractile O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
compared O
with O
those O
produced O
by O
5-hydroxytryptamine O
(5-HT) O
and O
the O
5-HT O
receptor O
agonist O
quipazine O
. O
Thus O
, O
4-HT O
(10(-10)-10(-6)M) O
, O
D-1997 O
(3.1 O
x O
10(-8)-10(-4) O
M) O
and O
quipazine O
(3.1 O
x O
10(-7)-10(-4) O
M) O
each O
caused O
concentration-dependent O
contractions O
of O
the O
canine O
basilar O
artery O
with O
a O
rank O
order O
of O
agonist O
potency O
of O
5-HT O
> O
D-1997 O
> O
quipazine O
. O
5-HT O
and O
D-1997 O
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A B
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

pemetrexed O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Cellular O
and O
pharmacogenetics O
foundation O
of O
synergistic O
interaction O
of O
pemetrexed O
and O
gemcitabine O
in O
human O
non-small-cell O
lung O
cancer O
cells.Gemcitabine O
and O
pemetrexed O
are O
effective O
agents O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
(NSCLC) O
, O
and O
the O
present O
study O
investigates O
cellular O
and O
genetic O
aspects O
of O
their O
interaction O
against O
A549 O
, O
Calu-1 O
, O
and O
Calu-6 O
cells O
. O
Cells O
were O
treated O
with O
pemetrexed O
and O
gemcitabine O
, O
and O
their O
interaction O
was O
assessed O
using O
the O
combination O
index O
. O
The O
role O
of O
drug O
metabolism O
in O
gemcitabine O
cytotoxicity O
was O
examined O
with O
inhibitors O
of O
deoxycytidine O
kinase O
(dCK) O
, O
5'-nucleotidase O
, O
and O
cytidine O
deaminase O
, O
whereas O
the O
role O
of O
pemetrexed O
targets O
, O
thymidylate O
synthase O
(TS) O
, O
dihydrofolate O
reductase O
(DHFR) O
, O
and O
glycinamide O
ribonucleotide O
formyltransferase O
(GARFT) O
in O
drug O
chemosensitivity O
was O
analyzed O
in O
cytotoxicity O
rescue O
studies O
. O
The O
effect O
of O
gemcitabine O
and O
pemetrexed O
on O
Akt O
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay O
, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug O
. O
Synergistic O
cytotoxicity O
was O
demonstrated O
, O
and O
pemetrexed O
significantly O
decreased O
the O
amount O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK B
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O
of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O
. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt O
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O
genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed O
enhances O
dCK O
and O
hENT1 O
expression O
, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O
for O
rational O
development O
of O
chemotherapy O
combinations O
. O

U0126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK B
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

NaAsO(2) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium O
arsenite.Arsenic O
compounds O
that O
are O
often O
found O
in O
drinking O
water O
increase O
the O
risk O
of O
developmental O
brain O
disorders O
. O
In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro-2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase-3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins; O
enhanced O
cyan O
fluorescence O
protein O
(ECFP) O
and O
Venus O
, O
to O
determine O
whether O
sodium O
arsenite O
(NaAsO(2); O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
μM) O
affects O
both O
neurite O
outgrowth O
and/or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O
We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O
SCAT3-expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
μM O
NaAsO(2) O
, O
but O
not O
by O
1 O
μM O
, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus O
, O
an O
endpoint O
of O
caspase-3 O
activity O
, O
was O
not O
changed O
. O
However O
, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis O
, O
but O
not O
necrosis O
, O
was O
significantly O
induced O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau B
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
. O

niflumic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibitory O
effects O
of O
non-steroidal O
anti-inflammatory O
drugs O
on O
4-methylumbelliferone O
glucuronidation O
in O
recombinant O
human B
UDP-glucuronosyltransferase I
1A9 I
--potent O
inhibition O
by O
niflumic O
acid.The O
inhibitory O
potencies O
of O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
on O
UDP-glucuronosyltransferase O
(UGT) O
1A9 O
activity O
were O
investigated O
in O
recombinant O
human O
UGT1A9 O
using O
4-methylumbelliferone O
(4-MU) O
as O
a O
substrate O
for O
glucuronidation O
. O
4-MU O
glucuronidation O
(4-MUG) O
showed O
Michaelis-Menten O
kinetics O
with O
a O
Km O
value O
of O
6.7 O
microM O
. O
The O
inhibitory O
effects O
of O
the O
following O
seven O
NSAIDs O
were O
investigated O
: O
acetaminophen O
, O
diclofenac O
, O
diflunisal O
, O
indomethacin O
, O
ketoprofen O
, O
naproxen O
and O
niflumic O
acid O
. O
Niflumic O
acid O
had O
the O
most O
potent O
inhibitory O
effect O
on O
4-MUG O
with O
an O
IC50 O
value O
of O
0.0341 O
microM O
. O
The O
IC50 O
values O
of O
diflunisal O
, O
diclofenac O
and O
indomethacin O
were O
1.31 O
, O
24.2 O
, O
and O
34.1 O
microM O
, O
respectively O
, O
while O
acetaminophen O
, O
ketoprofen O
and O
naproxen O
showed O
less O
potent O
inhibition O
. O
Niflumic O
acid O
, O
diflunisal O
, O
diclofenac O
and O
indomethacin O
inhibited O
4-MUG O
competitively O
with O
Ki O
values O
of O
0.0275 O
, O
0.710 O
, O
53.3 O
and O
69.9 O
microM O
, O
respectively O
, O
being O
similar O
to O
each O
IC50 O
value O
. O
In O
conclusion O
, O
of O
the O
seven O
NSAIDs O
investigated O
, O
niflumic O
acid O
was O
the O
most O
potent O
inhibitor O
of O
recombinant O
UGT1A9 O
via O
4-MUG O
in O
a O
competitive O
manner O
. O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor O
antagonism.H1-receptor O
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O
anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O
on O
mast O
cell O
function O
. O
In O
low O
concentrations O
in O
vitro O
, O
antihistamines O
have O
been O
found O
to O
inhibit O
immunologically O
stimulated O
mast O
cell O
mediator O
release O
, O
with O
the O
IC50 O
in O
the O
nanomolar O
to O
micromolar O
range O
, O
while O
at O
higher O
concentrations O
they O
induce O
histamine O
release O
. O
The O
potency O
of O
these O
drugs O
in O
producing O
such O
effects O
is O
unrelated O
to O
their O
H1-receptor O
blocking O
activity O
. O
Furthermore O
the O
sedative O
effects O
of O
these O
therapeutic O
agents O
limit O
the O
tolerable O
administrable O
dose O
and O
thus O
the O
degree O
of O
H1-receptor O
blockade O
achievable O
within O
the O
airways O
. O
The O
recent O
development O
of O
H1-receptor O
antagonists O
devoid O
of O
clinical O
sedative O
effects O
has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines O
which O
achieve O
a O
greater O
degree O
of O
H1-receptor B
blockade O
within O
the O
airways O
, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine O
in O
this O
condition O
. O
Furthermore O
, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
cetirizine O
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin O
activity O
of O
clinical O
relevance O
. O
However O
, O
of O
these O
agents O
both O
loratadine O
and O
cetirizine O
possess O
additional O
actions O
likely O
to O
be O
of O
relevance O
to O
asthma O
. O
Pretreatment O
with O
loratadine O
has O
been O
shown O
to O
reduce O
the O
recovery O
of O
both O
histamine O
and O
prostaglandin O
D2 O
(PGD2) O
in O
nasal O
lavage O
fluid O
following O
nasal O
allergen O
challenge O
, O
a O
finding O
interpreted O
as O
indicative O
of O
in O
vivo O
mast O
cell O
stabilization O
, O
and O
cetirizine O
has O
been O
shown O
in O
vivo O
at O
therapeutic O
doses O
to O
inhibit O
allergen-induced O
eosinophil O
chemotaxis O
. O
Thus O
while O
both O
these O
agents O
offer O
the O
potential O
of O
an O
oral O
therapy O
for O
asthma O
based O
on O
an O
H1-receptor O
antagonist O
, O
their O
additional O
actions O
do O
not O
make O
them O
ideally O
suited O
to O
the O
exploration O
of O
the O
role O
of O
histamine O
in O
asthma.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O

acetylcholine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase B
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O
the O
manifestations O
of O
Alzheimer's O
disease O
. O
Cochrane O
reviews O
of O
each O
ChEI O
for O
Alzheimer's O
disease O
have O
been O
completed O
(Birks O
2005 O
, O
Birks O
2005b O
and O
Loy O
2005) O
. O
Despite O
the O
evidence O
from O
the O
clinical O
studies O
and O
the O
intervening O
clinical O
experience O
the O
debate O
on O
whether O
ChEIs O
are O
effective O
continues O
. O
OBJECTIVES O
: O
To O
assess O
the O
effects O
of O
donepezil O
, O
galantamine O
and O
rivastigmine O
in O
people O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
. O
SEARCH O
STRATEGY O
: O
The O
Cochrane O
Dementia O
and O
Cognitive O
Improvement O
Group's O
Specialized O
Register O
was O
searched O
using O
the O
terms O
'donepezil' O
, O
'E2020' O
 O
, O
'Aricept' O
 O
, O
galanthamin* O
galantamin* O
reminyl O
, O
rivastigmine O
, O
exelon O
, O
"ENA O
713" O
and O
ENA-713 O
on O
12 O
June O
2005 O
. O
This O
Register O
contains O
up-to-date O
records O
of O
all O
major O
health O
care O
databases O
and O
many O
ongoing O
trial O
databases O
. O
SELECTION O
CRITERIA O
: O
All O
unconfounded O
, O
blinded O
, O
randomized O
trials O
in O
which O
treatment O
with O
a O
ChEI O
was O
compared O
with O
placebo O
or O
another O
ChEI O
for O
patients O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
. O
DATA O
COLLECTION O
AND O
ANALYSIS O
: O
Data O
were O
extracted O
by O
one O
reviewer O
(JSB) O
, O
pooled O
where O
appropriate O
and O
possible O
, O
and O
the O
pooled O
treatment O
effects O
, O
or O
the O
risks O
and O
benefits O
of O
treatment O
estimated O
. O
MAIN O
RESULTS O
: O
The O
results O
of O
13 O
randomized O
, O
double O
blind O
, O
placebo O
controlled O
trials O
demonstrate O
that O
treatment O
for O
periods O
of O
6 O
months O
and O
one O
year O
, O
with O
donepezil O
, O
galantamine O
or O
rivastigmine O
at O
the O
recommended O
dose O
for O
people O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
produced O
improvements O
in O
cognitive O
function O
, O
on O
average O
-2.7 O
points O
(95%CI O
-3.0 O
to O
-2.3) O
, O
in O
the O
midrange O
of O
the O
70 O
point O
ADAS-Cog O
Scale O
. O
Study O
clinicians O
blind O
to O
other O
measures O
rated O
global O
clinical O
state O
more O
positively O
in O
treated O
patients O
. O
Benefits O
of O
treatment O
were O
also O
seen O
on O
measures O
of O
activities O
of O
daily O
living O
and O
behaviour O
. O
None O
of O
these O
treatment O
effects O
are O
large O
. O
There O
is O
nothing O
to O
suggest O
the O
effects O
are O
less O
for O
patients O
with O
severe O
dementia O
or O
mild O
dementia O
, O
although O
there O
is O
very O
little O
evidence O
for O
other O
than O
mild O
to O
moderate O
dementia.More O
patients O
leave O
ChEI O
treatment O
groups O
, O
approximately O
29 O
% O
, O
on O
account O
of O
adverse O
events O
than O
leave O
the O
placebo O
groups O
(18%) O
. O
There O
is O
evidence O
of O
more O
adverse O
events O
in O
total O
in O
the O
patients O
treated O
with O
a O
ChEI O
than O
with O
placebo O
. O
Although O
many O
types O
of O
adverse O
event O
were O
reported O
, O
nausea O
, O
vomiting O
, O
diarrhoea O
, O
were O
significantly O
more O
frequent O
in O
the O
ChEI O
groups O
than O
in O
placebo O
. O
There O
are O
four O
studies O
, O
all O
supported O
by O
one O
of O
the O
pharmaceutical O
companies O
, O
in O
which O
two O
ChEIs O
were O
compared O
, O
two O
studies O
of O
donepezil O
compared O
with O
galantamine O
, O
and O
two O
of O
donepezil O
compared O
with O
rivastigmine O
. O
In O
three O
studies O
the O
patients O
were O
not O
blinded O
to O
treatment O
, O
only O
the O
fourth O
, O
DON O
vs O
RIV/Bullock O
is O
double O
blind O
. O
Two O
of O
the O
studies O
provide O
little O
evidence O
, O
they O
are O
of O
12 O
weeks O
duration O
, O
which O
is O
barely O
long O
enough O
to O
complete O
the O
drug O
titration O
. O
There O
is O
no O
evidence O
from O
DON O
vs O
GAL/Wilcock O
of O
a O
treatment O
difference O
between O
donepezil O
and O
galantamine O
at O
52 O
weeks O
for O
cognition O
, O
activities O
of O
daily O
living O
, O
the O
numbers O
who O
leave O
the O
trial O
before O
the O
end O
of O
treatment O
, O
the O
number O
who O
suffer O
any O
adverse O
event O
, O
or O
any O
specific O
adverse O
event O
. O
There O
is O
no O
evidence O
from O
DON O
vs O
RIV/Bullock O
of O
a O
difference O
between O
donepezil O
and O
rivastigmine O
for O
cognitive O
function O
, O
activities O
of O
daily O
living O
and O
behavioural O
disturbance O
at O
two O
years O
. O
Fewer O
patients O
suffer O
adverse O
events O
on O
donepezil O
than O
rivastigmine O
. O
AUTHORS' O
CONCLUSIONS O
: O
The O
three O
cholinesterase O
inhibitors O
are O
efficacious O
for O
mild O
to O
moderate O
Alzheimer's O
disease O
. O
It O
is O
not O
possible O
to O
identify O
those O
who O
will O
respond O
to O
treatment O
prior O
to O
treatment O
. O
There O
is O
no O
evidence O
that O
treatment O
with O
a O
ChEI O
is O
not O
cost O
effective O
. O
Despite O
the O
slight O
variations O
in O
the O
mode O
of O
action O
of O
the O
three O
cholinesterase O
inhibitors O
there O
is O
no O
evidence O
of O
any O
differences O
between O
them O
with O
respect O
to O
efficacy O
. O
There O
appears O
to O
be O
less O
adverse O
effects O
associated O
with O
donepezil O
compared O
with O
rivastigmine O
. O
It O
may O
be O
that O
galantamine O
and O
rivastigmine O
match O
donepezil O
in O
tolerability O
if O
a O
careful O
and O
gradual O
titration O
routine O
over O
more O
than O
three O
months O
is O
used O
. O
Titration O
with O
donepezil O
is O
more O
straightforward O
and O
the O
lower O
dose O
may O
be O
worth O
consideration O
. O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs B
at O
clinically O
relevant O
concentrations O
. O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A B
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

reserpine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 B
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

Anandron O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
pure O
antiandrogen O
RU O
23908 O
(Anandron) O
, O
a O
candidate O
of O
choice O
for O
the O
combined O
antihormonal O
treatment O
of O
prostatic O
cancer O
: O
a O
review.The O
nonsteroidal O
antiandrogen O
RU O
23908 O
( O
Anandron O
) O
weakly O
interacts O
with O
the O
prostatic O
cytosolic O
androgen B
receptor I
and O
shows O
a O
fast O
dissociation O
rate O
. O
When O
administered O
to O
immature O
castrated O
rats O
up O
to O
the O
daily O
dose O
of O
100 O
mg/kg O
, O
it O
is O
devoid O
of O
any O
androgenic O
activity O
but O
efficiently O
blocks O
the O
growth-promoting O
activity O
of O
androgens O
on O
ventral O
prostate O
and O
seminal O
vesicle O
weight O
, O
thus O
showing O
the O
characteristics O
of O
a O
pure O
antiandrogen O
. O
In O
intact O
animals O
, O
on O
the O
other O
hand O
, O
the O
antiandrogen O
administered O
alone O
exerts O
only O
a O
partial O
inhibition O
of O
prostate O
and O
seminal O
vesicle O
weight O
. O
This O
is O
due O
to O
the O
property O
of O
the O
pure O
antiandrogen O
to O
neutralize O
the O
inhibitory O
feedback O
effect O
of O
androgens O
at O
the O
pituitary O
level O
on O
the O
LH O
responsiveness O
to O
LHRH O
, O
as O
illustrated O
in O
vitro O
in O
rat O
anterior O
pituitary O
cells O
in O
culture O
as O
well O
as O
in O
vivo O
in O
intact O
and O
castrated O
animals O
. O
In O
intact O
animals O
, O
neutralization O
of O
the O
inhibitory O
feedback O
action O
of O
endogenous O
androgens O
leads O
to O
an O
increased O
LH O
and O
testosterone O
secretion O
, O
which O
partly O
overcomes O
the O
direct O
action O
of O
the O
antiandrogen O
at O
the O
level O
of O
the O
prostate O
and O
seminal O
vesicles O
. O
In O
fact O
, O
the O
plasma O
testosterone O
concentration O
is O
more O
than O
doubled O
6 O
hr O
after O
the O
administration O
of O
10 O
mg O
of O
RU O
23908 O
while O
plasma O
LH O
and O
testosterone O
levels O
are O
increased O
by O
7- O
and O
17-fold O
, O
respectively O
, O
after O
14 O
days O
of O
similar O
daily O
treatment O
. O
Efficient O
neutralization O
of O
the O
androgenic O
action O
at O
the O
prostatic O
level O
in O
intact O
animals O
thus O
requires O
prevention O
of O
this O
escape O
phenomenon O
through O
inhibition O
of O
LH O
secretion O
. O
Although O
inhibition O
of O
LH O
release O
can O
be O
achieved O
by O
estrogen O
and O
progestins O
, O
an O
optimal O
inhibitory O
effect O
on O
the O
prostate O
is O
obtained O
by O
the O
combined O
administration O
of O
the O
antiandrogen O
with O
an O
LHRH O
agonist O
that O
causes O
a O
specific O
blockage O
of O
testicular O
androgen O
biosynthesis O
as O
well O
as O
an O
inhibition O
of O
the O
LH O
responsiveness O
to O
LHRH O
. O

Prostacyclin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue B
factor I
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue O
factor O
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

loperamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Loperamide O
, O
an O
opiate O
analog O
, O
differently O
modifies O
the O
adrenocorticotropin O
responses O
to O
corticotropin-releasing O
hormone O
and O
lysine O
vasopressin O
in O
patients O
with O
Addison's O
disease.Loperamide O
is O
a O
peripheral O
opiate O
agonist O
able O
to O
inhibit O
ACTH O
secretion O
. O
In O
this O
work O
, O
the O
interactions O
between O
loperamide O
and O
two O
ACTH O
secretagogues O
, O
lysine O
vasopressin O
(LVP) O
and O
corticotropin-releasing O
hormone O
(CRH) O
, O
were O
investigated O
in O
patients O
with O
Addison's O
disease O
. O
After O
loperamide O
(16 O
mg O
orally) O
or O
placebo O
administration O
, O
5 O
patients O
received O
LVP O
(0.06 O
IU/kg O
i.v O
. O
over O
1 O
h) O
and O
6 O
patients O
received O
oCRH O
(1 O
micrograms/kg O
i.v O
. O
as O
bolus) O
. O
In O
all O
patients O
loperamide O
induced O
a O
significant O
fall O
in O
plasma O
ACTH O
levels O
. O
LVP O
increased O
ACTH O
levels O
after O
both O
loperamide O
(from O
48 O
+/- O
17.3 O
to O
a O
peak O
of O
95 O
+/- O
21 O
pmol/l) O
and O
placebo O
(from O
231 O
+/- O
59.5 O
to O
365 O
+/- O
86.6 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
not O
significant O
. O
CRH O
caused O
a O
rise O
in O
plasma O
ACTH O
after O
both O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
. O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH O
on O
ACTH B
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O
on O
some O
suprapituitary O
factors O
modulating O
the O
ACTH O
response O
is O
suggested O
. O

Lu O
AF21934 O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ O
receptor.Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor-selective O
orthosteric O
agonist O
, O
LSP1-2111 O
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration O
. O
Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
, O
and O
brain-penetrant O
positive O
allosteric O
modulator O
(PAM) O
of O
the O
mGlu(4) B
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH) O
, O
four-plate O
, O
marble-burying O
and O
Vogel's O
conflict O
tests O
. O
In O
all O
models O
, O
except O
Vogel's O
conflict O
test O
, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine O
receptor O
antagonist O
flumazenil O
(10 O
mg/kg) O
and O
was O
not O
serotonin-dependent O
, O
as O
it O
persisted O
in O
serotonin-deficient O
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) O
receptors O
by O
WAY100635 O
, O
or O
5-HT(2A/2C) O
receptors O
by O
ritanserin O
. O
These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu O
AF21934 O
in O
rodents O
. O
Lu O
AF21934 O
did O
not O
produce O
antidepressant-like O
effects O
in O
the O
tail O
suspension O
test O
(TST) O
in O
mice; O
however O
, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O
mice O
that O
were O
not O
habituated O
to O
activity O
cages O
. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic O
Glutamate O
Receptors' O
. O

CCl(4) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rosmarinic O
acid O
ameliorates O
acute O
liver O
damage O
and O
fibrogenesis O
in O
carbon O
tetrachloride-intoxicated O
mice.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
therapeutic O
potential O
of O
rosmarinic O
acid O
(RA) O
, O
a O
natural O
phenolic O
, O
in O
the O
treatment O
of O
acute O
liver O
toxicity O
. O
RA O
at O
10 O
, O
25 O
and O
50mg/kg O
was O
administered O
by O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O
growth O
factor-beta1 O
(TGF-β1) O
and O
alpha-smooth O
muscle O
actin O
(α-SMA) O
expression O
, O
suggesting O
suppression O
of O
profibrotic O
response O
. O
Furthermore O
, O
RA O
significantly O
inhibited O
the O
CCl(4)-induced O
apoptosis O
, O
which O
was O
evident O
from O
decreased O
cleavage O
of O
caspase-3 B
. O
The O
hepatoprotective O
activity O
of O
RA O
coincided O
with O
enhanced O
NF-E2-related O
factor O
2 O
(Nrf2) O
and O
heme O
oxygenase-1 O
(HO-1) O
expression O
. O
The O
results O
of O
this O
study O
indicates O
that O
RA O
possesses O
antioxidant O
, O
anti-inflammatory O
, O
antiapoptotic O
and O
antifibrotic O
activity O
against O
acute O
liver O
toxicity O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 B
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

Prednisolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapid O
glucocorticoid O
receptor-mediated O
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin O
releasing O
hormone O
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone O
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol O
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid B
receptor- I
mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
( O
pIR) B
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O

wogonoside O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 B
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) B
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O
1.3 O
mg/day) O
and O
haloperidol O
(HAL O
, O
n O
= O
11 O
, O
8.5 O
+/- O
5.5 O
mg/day) O
. O
MATERIALS O
AND O
METHODS O
: O
Each O
patient O
underwent O
two O
PET O
scans O
with O
3-N-[(11)C]methylspiperone O
(target O
: O
frontal O
5-HT(2A)) O
, O
[(11)C]SCH23390 O
(striatal O
D(1)) O
or O
[(11)C]raclopride O
(striatal O
D(2)) O
. O
RO O
was O
calculated O
as O
the O
percentage O
reduction O
of O
specific O
binding O
in O
comparison O
with O
healthy O
controls O
. O
RESULTS O
: O
D(2)-RO O
under O
FLX O
was O
between O
50% O
and O
70% O
, O
indicating O
an O
ED(50) O
of O
about O
0.7 O
ng/ml O
serum O
. O
5-HT(2A) O
and O
D(1)-RO O
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean O
, O
SEM) O
. O
Under O
HAL O
, O
D(1)-RO O
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero O
. O
CONCLUSIONS O
: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) O
and O
D(1) O
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol O
, O
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation O
. O
Therefore O
, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
, O
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism O
. O
However O
, O
these O
data O
suggest O
that O
mechanisms O
other O
than O
D(1) O
or O
5-HT(2A) O
antagonism O
may O
contribute O
to O
flupentixol's O
efficacy O
on O
negative O
symptoms O
. O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ B
channels I
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

TZDs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase.Thiazolidinediones O
(TZDs) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase B
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase O
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism O
. O
Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O
or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
activity O
, O
and O
osteocalcin O
production O
were O
measured O
. O
TZDs O
inhibited O
estradiol O
production O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

sarin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Success O
of O
pyridostigmine O
, O
physostigmine O
, O
eptastigmine O
and O
phosphotriesterase O
treatments O
in O
acute O
sarin O
intoxication.The O
acute O
toxicity O
of O
organophosphorus O
(OP) O
compounds O
in O
mammals O
is O
due O
to O
their O
irreversible O
inhibition O
of O
acetylcholinesterase O
(AChE) O
in O
the O
nervous O
system O
, O
which O
leads O
to O
increased O
synaptic O
acetylcholine O
levels O
. O
The O
protective O
actions O
of O
intravenously O
(i.v.) O
administered O
pyridostigmine O
, O
physostigmine O
, O
eptastigmine O
, O
and O
an O
organophosphate O
hydrolase O
, O
phosphotriesterase O
, O
in O
acute O
sarin O
intoxication O
were O
studied O
in O
mice O
. O
The O
acute O
intragastric O
(i.g.) O
toxicity O
(LD50) O
of O
sarin O
with O
and O
without O
the O
pretreatments O
was O
tested O
by O
the O
up-and-down O
method O
. O
The O
mice O
received O
pyridostigmine O
(0.06 O
mg/kg O
body O
weight) O
, O
physostigmine O
(0.09 O
mg/kg O
body O
weight) O
, O
the O
physostigmine O
derivative O
eptastigmine O
(0.90 O
mg/kg O
body O
weight) O
or O
phosphotriesterase O
(104 O
U/g O
, O
10.7 O
microg/g O
body O
weight) O
10 O
min O
prior O
to O
the O
i.g O
. O
administration O
of O
sarin O
. O
Physostigmine O
was O
also O
administered O
with O
phosphotriesterase O
. O
Phosphotriesterase O
was O
the O
most O
effective O
antidote O
in O
sarin O
intoxication O
. O
The O
LD50 O
value O
for O
sarin O
increased O
3.4-fold O
in O
mice O
receiving O
phosphotriesterase O
. O
Physostigmine O
was O
the O
most O
effective O
carbamate O
in O
sarin O
exposure O
. O
The O
protective O
ratios O
of O
physostigmine O
and O
pyridostigmine O
were O
1.5- O
and O
1.2-1.3-fold O
, O
respectively O
. O
Eptastigmine O
did O
not O
give O
any O
protection O
against O
sarin O
toxicity O
. O
Both O
the O
phosphotriesterase O
and O
physostigmine O
treatments O
protected O
the O
brain O
AChE O
activities O
measured O
24 O
h O
after O
sarin O
exposure O
. O
In O
phosphotriesterase O
and O
physostigmine-treated O
mice O
, O
a O
4- O
and O
2-fold O
higher O
sarin O
dose O
, O
respectively O
, O
was O
needed O
to O
cause O
a O
50% O
inhibition O
of O
brain O
AChE B
activity O
. O
Moreover O
, O
the O
combination O
of O
phosphotriesterase-physostigmine O
increased O
the O
LD50 O
value O
for O
sarin O
4.3-fold O
. O
The O
animals O
pretreated O
with O
phosphotriesterase-ephysostigmine O
tolerated O
four O
times O
the O
lethal O
dose O
in O
control O
animals O
, O
furthermore O
their O
survival O
time O
was O
2-3 O
h O
in O
comparison O
to O
20 O
min O
in O
controls O
. O
In O
conclusion O
, O
phosphotriesterase O
and O
physostigmine O
were O
the O
most O
effective O
treatments O
against O
sarin O
intoxication O
. O
However O
, O
eptastigmine O
did O
not O
provide O
any O
protection O
against O
sarin O
toxicity O
. O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC- B
selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

rilmenidine O
acts O
as O
NOT O
for O
what O
entity O
? O
Species-specific O
pharmacological O
properties O
of O
human O
alpha(2A)-adrenoceptors.On O
the O
basis O
of O
data O
obtained O
in O
rabbits O
, O
the O
imidazoline O
receptor O
ligand O
rilmenidine O
has O
been O
suggested O
to O
decrease O
blood O
pressure O
in O
humans O
by O
activating O
central O
alpha(2A)-adrenoceptors O
. O
A O
prerequisite O
for O
this O
hypothesis O
was O
the O
unproved O
assumption O
that O
rabbit O
and O
human O
alpha(2A)-adrenoceptors O
are O
equally O
activated O
by O
rilmenidine O
. O
Because O
alpha(2A)-adrenoceptors O
in O
the O
brain O
and O
on O
cardiovascular O
sympathetic O
nerve O
terminals O
are O
identical O
, O
the O
latter O
were O
used O
as O
a O
model O
for O
the O
former O
to O
confirm O
or O
disprove O
this O
assumption O
. O
Human O
atrial O
appendages O
and O
rabbit O
pulmonary O
arteries O
were O
used O
to O
determine O
the O
potencies O
of O
alpha(2)-adrenoceptor O
agonists O
in O
inhibiting O
the O
electrically O
(2 O
Hz) O
evoked O
[(3)H]norepinephrine O
release O
and O
of O
antagonists O
in O
counteracting O
the O
alpha(2)-adrenoceptor-mediated O
inhibition O
induced O
by O
moxonidine O
. O
In O
the O
rabbit O
pulmonary O
artery O
, O
rilmenidine O
and O
oxymetazoline O
are O
potent O
full O
agonists O
, O
whereas O
in O
the O
human O
atrial O
appendages O
they O
are O
antagonists O
at O
the O
alpha(2)-autoreceptors O
, O
sharing O
this O
property O
with O
rauwolscine O
, O
phentolamine O
, O
and O
idazoxan O
. O
In O
contrast O
, O
prazosin O
is O
ineffective O
. O
In O
addition O
, O
a O
partial O
nucleotide O
and O
amino O
acid O
sequence O
of O
the O
rabbit O
alpha(2A)-adrenoceptor O
(a O
region O
known O
to O
substantially O
influence O
the O
pharmacological O
characteristics O
of O
the O
alpha(2)-adrenoceptor) O
revealed O
marked O
differences O
between O
the O
rabbit O
and O
the O
human O
alpha(2A)-adrenoceptor O
. O
The O
sympathetic O
nerves O
of O
both O
the O
human O
atrial O
appendages O
and O
rabbit O
pulmonary O
artery O
are O
endowed O
with O
alpha(2A)-autoreceptors O
, O
at O
which O
, O
however O
, O
both O
rilmenidine O
and O
oxymetazoline O
exhibit O
different O
properties O
(antagonism O
and O
agonism O
, O
respectively) O
. O
The O
antagonistic O
property O
of O
rilmenidine O
at O
human O
alpha(2A)-adrenoceptors O
indicates O
that O
in O
contrast O
to O
the O
suggestion O
based O
on O
rabbit O
data O
, O
the O
hypotensive O
property O
of O
the O
drug O
in O
humans O
is O
not O
due O
to O
activation O
of O
alpha(2A)-adrenoceptors B
but O
other O
, O
presumably O
I(1)-imidazoline O
receptors O
, O
are O
probably O
involved O
. O

Cobalt O
chloride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Cross-talk O
between O
constitutive O
androstane O
receptor O
and O
hypoxia-inducible O
factor O
in O
the O
regulation O
of O
gene O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF B
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O
in O
the O
liver O
of O
untreated O
mice O
and O
that O
the O
complex O
dissociates O
upon O
PB O
treatment O
. O
Taken O
together O
these O
results O
suggest O
that O
CAR O
and O
HIF-α O
interact O
and O
reciprocally O
modulate O
the O
functions O
of O
each O
other O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Impaired O
in O
vivo O
binding O
of O
MeCP2 O
to O
chromatin O
in O
the O
absence O
of O
its O
DNA O
methyl-binding O
domain.MeCP2 O
is O
a O
methyl-CpG-binding O
protein O
that O
is O
a O
main O
component O
of O
brain O
chromatin O
in O
vertebrates O
. O
In O
vitro O
studies O
have O
determined O
that O
in O
addition O
to O
its O
specific O
methyl-CpG-binding O
domain O
(MBD) O
MeCP2 O
also O
has O
several O
chromatin O
association O
domains O
. O
However O
, O
the O
specific O
interactions O
of O
MeCP2 O
with O
methylated O
or O
non-methylated O
chromatin O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood O
. O
We O
analysed O
the O
role O
of O
the O
MBD O
in O
MeCP2- B
chromatin O
associations O
in O
vivo O
using O
an O
MeCP2 O
mutant O
Rett O
syndrome O
mouse O
model O
(Mecp2(tm)(1)(.)(1)(Jae)) O
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N-terminal O
truncation O
of O
the O
protein O
, O
including O
most O
of O
the O
MBD O
. O
Our O
results O
show O
that O
in O
mutant O
mice O
, O
the O
truncated O
form O
of O
MeCP2 O
(ΔMeCP2) O
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver O
, O
albeit O
at O
50% O
of O
its O
wild-type O
(wt) O
counterpart O
. O
In O
contrast O
to O
the O
punctate O
nuclear O
distribution O
characteristic O
of O
wt O
MeCP2 O
, O
ΔMeCP2 O
exhibits O
both O
diffuse O
nuclear O
localization O
and O
a O
substantial O
retention O
in O
the O
cytoplasm O
, O
suggesting O
a O
dysfunction O
of O
nuclear O
transport O
. O
In O
mutant O
brain O
tissue O
, O
neuronal O
nuclei O
are O
smaller O
, O
and O
ΔMeCP2 O
chromatin O
is O
digested O
faster O
by O
nucleases O
, O
producing O
a O
characteristic O
nuclease-resistant O
dinucleosome O
. O
Although O
a O
fraction O
of O
ΔMeCP2 O
is O
found O
associated O
with O
nucleosomes O
, O
its O
interaction O
with O
chromatin O
is O
transient O
and O
weak O
. O
Thus O
, O
our O
results O
unequivocally O
demonstrate O
that O
in O
vivo O
the O
MBD O
of O
MeCP2 O
together O
with O
its O
adjacent O
region O
in O
the O
N-terminal O
domain O
are O
critical O
for O
the O
proper O
interaction O
of O
the O
protein O
with O
chromatin O
, O
which O
cannot O
be O
replaced O
by O
any O
other O
of O
its O
protein O
domains O
. O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Neoechinulin O
A O
suppresses O
amyloid-β O
oligomer-induced O
microglia O
activation O
and O
thereby O
protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 B
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin O
A O
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
AD O
. O

DMBT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMBT O
is O
mediated O
by O
downregulation O
of O
VEGF O
and O
MMP-9 O
through O
Akt O
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O
In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O
series O
of O
brartemicin O
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activity O
against O
invasion O
. O
Among O
the O
synthetic O
analogs O
tested O
, O
DMBT O
, O
6,6'-bis O
(2,3-dimethoxybenzoyl)-a,a-d-trehalose O
, O
was O
found O
to O
be O
the O
most O
potent O
anti-invasive O
agent O
. O
But O
the O
effects O
of O
DMBT O
on O
breast O
cancer O
cells O
were O
not O
known O
. O
In O
this O
study O
, O
the O
effects O
of O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt B
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

Prazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Expressions O
and O
mechanical O
functions O
of O
alpha1-adrenoceptor O
subtypes O
in O
hamster O
ureter.We O
characterized O
the O
alpha(1)-adrenoceptor O
subtypes O
in O
hamster O
ureters O
according O
to O
gene O
and O
protein O
expressions O
and O
contractile O
function O
. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively O
, O
for O
alpha(1A)- O
, O
alpha(1B)- O
and O
alpha(1D)-adrenoceptors O
in O
hamster O
ureteral O
smooth O
muscle O
. O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O
for O
humans O
, O
alpha(1A)-adrenoceptor O
antagonists O
could O
become O
useful O
medication O
for O
stone O
passage O
in O
urolithiasis O
patients O
. O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) O
exchanger O
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
tyrosine O
kinase O
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine B
kinase I
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F B
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

Rg1 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
to O
ginsenoside O
Rg1 O
protection O
against O
β-amyloid O
peptide-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α B
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

menadione O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 B
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin B
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O
produced O
significant O
, O
dose-related O
decreases O
in O
systolic O
and O
diastolic O
blood O
pressure O
(BP) O
in O
hypertensive O
patients O
, O
and O
the O
BP O
response O
was O
enhanced O
by O
pretreatment O
with O
hydrochlorothiazide O
. O
The O
effects O
of O
enalkiren O
on O
PRA O
and O
BP O
are O
prolonged O
despite O
its O
relatively O
short O
elimination O
phase O
plasma O
half-life O
(1.6 O
h) O
. O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients O
. O
The O
observed O
dissociation O
between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements O
, O
despite O
complete O
suppression O
of O
PRA O
, O
are O
unexplained O
phenomena O
. O
The O
results O
of O
clinical O
trials O
with O
enalkiren O
are O
encouraging O
, O
and O
suggest O
that O
renin O
inhibitors O
may O
be O
safe O
, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension O
. O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating.Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1 B
/ O
GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O
the O
long-lived O
shut O
conformations O
, O
thereby O
reducing O
the O
open O
probability O
of O
the O
receptor O
with O
no O
change O
in O
the O
mean O
open O
time O
. O
In O
addition O
, O
ifenprodil O
selectively O
affected O
the O
area O
of O
shut O
time O
constants O
, O
but O
not O
the O
time O
constants O
themselves O
. O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke O
, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic O
. O

buspirone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
exposure O
of O
highly O
toxic O
aconitine O
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome O
P450 O
3A O
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography-tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone.Aconitum O
species O
are O
widely O
used O
to O
treat O
rheumatism O
, O
cardiovascular O
diseases O
, O
and O
tumors O
in O
China O
and O
other O
Asian O
countries O
. O
The O
herbs O
are O
always O
used O
with O
drugs O
such O
as O
paclitaxel O
. O
Aconitine O
(AC) O
is O
one O
of O
the O
main O
bioactive/high-toxic O
alkaloids O
of O
Aconitum O
roots O
. O
AC O
is O
metabolized O
by O
cytochrome O
P450 O
(CYP) O
3A O
. O
However O
, O
whether O
AC O
inhibits/induces O
CYP3A O
, O
which O
causes O
drug-drug O
interaction O
(DDI) O
is O
unclear O
. O
Our O
study O
aims O
to O
explore O
the O
potent O
effects O
of O
AC O
, O
as O
a O
marker O
component O
of O
Aconitum O
, O
on O
CYP3A B
using O
the O
probe O
buspirone O
in O
rats O
. O
The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone O
were O
evaluated O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone O
metabolism O
and O
Western O
blot O
. O
Buspirone O
and O
its O
major O
metabolites O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
were O
determined O
using O
a O
newly O
validated O
UPLC-MS/MS O
method O
. O
Single O
dose O
and O
7-day O
AC O
administration O
at O
0.125mg/kg O
had O
no O
effect O
on O
CYP3A O
activity O
since O
no O
change O
in O
the O
formation O
of O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
liver O
microsomes O
were O
also O
not O
affected O
by O
7-day O
AC O
pretreatment O
at O
0.125mg/kg O
. O
Therefore O
, O
AC O
neither O
inhibits O
nor O
induces O
CYP3A O
in O
rats O
, O
indicating O
AC O
does O
not O
cause O
CYP3A-related O
DDI O
in O
the O
liver O
. O

flecainide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preferential O
block O
of O
late O
sodium O
current O
in O
the O
LQT3 O
DeltaKPQ O
mutant O
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide.Flecainide O
block O
of O
Na(+) O
current O
(I(Na)) O
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long O
QT O
syndrome O
3 O
(LQT3) O
sodium O
channel O
alpha O
subunit O
mutation O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ B
I(Na) O
was O
more O
sensitive O
to O
flecainide O
, O
and O
flecainide O
preferentially O
inhibited O
late O
I(Na) O
(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
80 O
+/- O
9 O
and O
19 O
+/- O
2 O
microM O
(n O
= O
31) O
respectively O
. O
UDB O
of O
peak O
I(Na) O
was O
greater O
and O
developed O
more O
slowly O
during O
pulse O
trains O
for O
DeltaKPQ O
than O
for O
WT O
. O
The O
IC(50) O
value O
for O
UDB O
of O
peak O
I(Na) O
for O
WT O
was O
29 O
+/- O
4 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
11 O
+/- O
1 O
microM O
(n O
= O
26) O
. O
For O
DeltaKPQ O
, O
UDB O
of O
late O
I(Na) O
was O
greater O
than O
for O
peak O
I(Na) O
. O
Recovery O
from O
block O
was O
slower O
for O
DeltaKPQ O
than O
for O
WT O
. O
We O
conclude O
that O
DeltaKPQ O
interacts O
differently O
with O
flecainide O
than O
with O
WT O
, O
leading O
to O
increased O
block O
and O
slowed O
recovery O
, O
especially O
for O
late O
I(Na) O
. O
These O
data O
provide O
insights O
into O
mechanisms O
for O
flecainide O
block O
and O
provide O
a O
rationale O
at O
the O
cellular O
and O
molecular O
level O
that O
open O
channel O
block O
may O
be O
a O
useful O
pharmacological O
property O
for O
treatment O
of O
LQT3 O
. O

Histamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor B
antagonism.H1-receptor O
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O
anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O
on O
mast O
cell O
function O
. O
In O
low O
concentrations O
in O
vitro O
, O
antihistamines O
have O
been O
found O
to O
inhibit O
immunologically O
stimulated O
mast O
cell O
mediator O
release O
, O
with O
the O
IC50 O
in O
the O
nanomolar O
to O
micromolar O
range O
, O
while O
at O
higher O
concentrations O
they O
induce O
histamine O
release O
. O
The O
potency O
of O
these O
drugs O
in O
producing O
such O
effects O
is O
unrelated O
to O
their O
H1-receptor O
blocking O
activity O
. O
Furthermore O
the O
sedative O
effects O
of O
these O
therapeutic O
agents O
limit O
the O
tolerable O
administrable O
dose O
and O
thus O
the O
degree O
of O
H1-receptor O
blockade O
achievable O
within O
the O
airways O
. O
The O
recent O
development O
of O
H1-receptor O
antagonists O
devoid O
of O
clinical O
sedative O
effects O
has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines O
which O
achieve O
a O
greater O
degree O
of O
H1-receptor O
blockade O
within O
the O
airways O
, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine O
in O
this O
condition O
. O
Furthermore O
, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
cetirizine O
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin O
activity O
of O
clinical O
relevance O
. O
However O
, O
of O
these O
agents O
both O
loratadine O
and O
cetirizine O
possess O
additional O
actions O
likely O
to O
be O
of O
relevance O
to O
asthma O
. O
Pretreatment O
with O
loratadine O
has O
been O
shown O
to O
reduce O
the O
recovery O
of O
both O
histamine O
and O
prostaglandin O
D2 O
(PGD2) O
in O
nasal O
lavage O
fluid O
following O
nasal O
allergen O
challenge O
, O
a O
finding O
interpreted O
as O
indicative O
of O
in O
vivo O
mast O
cell O
stabilization O
, O
and O
cetirizine O
has O
been O
shown O
in O
vivo O
at O
therapeutic O
doses O
to O
inhibit O
allergen-induced O
eosinophil O
chemotaxis O
. O
Thus O
while O
both O
these O
agents O
offer O
the O
potential O
of O
an O
oral O
therapy O
for O
asthma O
based O
on O
an O
H1-receptor O
antagonist O
, O
their O
additional O
actions O
do O
not O
make O
them O
ideally O
suited O
to O
the O
exploration O
of O
the O
role O
of O
histamine O
in O
asthma.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O

doxycycline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
matrix O
metalloproteinases O
(MMPs) O
as O
a O
potential O
strategy O
to O
ameliorate O
hypertension-induced O
cardiovascular O
alterations.A O
group O
of O
proteases O
, O
the O
matrix O
metalloproteinases O
(MMPs) O
are O
well O
known O
for O
their O
capacity O
to O
degrade O
extracellular O
matrix O
(ECM) O
proteins O
. O
Particularly O
MMP-2 O
and O
MMP-9 O
contribute O
to O
the O
degradation O
and O
reorganization O
of O
the O
ECM O
components O
and O
are O
involved O
in O
the O
pathophysiology O
of O
cardiovascular O
remodeling O
. O
Imbalanced O
MMP O
activity O
promotes O
vascular O
smooth O
muscle O
cells O
and O
migration O
and O
proliferation O
and O
endothelial O
dysfunction O
, O
thus O
resulting O
in O
increased O
cardiovascular O
stiffness O
and O
hypertrophy O
. O
Furthermore O
, O
MMP-2 O
cleaves O
non-ECM O
protein O
substrates O
including O
cellular O
receptors O
and O
intracellular O
proteins O
, O
thus O
causing O
cardiac O
and O
vascular O
dysfunction O
. O
It O
is O
now O
becoming O
clear O
that O
increased O
MMP O
activity O
promotes O
long-lasting O
cardiovascular O
structural O
and O
functional O
alterations O
in O
both O
experimental O
and O
clinical O
hypertension O
, O
and O
this O
alteration O
may O
contribute O
to O
sustained O
hypertension O
and O
its O
complications O
. O
Other O
pathogenic O
mechanisms O
including O
activation O
of O
the O
renin-angiotensin-aldosterone O
system O
and O
oxidative O
stress O
activate O
and O
upregulate O
MMPs O
. O
Therefore O
, O
MMP O
inhibition O
may O
prevent O
the O
deleterious O
consequences O
of O
hypertension O
to O
the O
cardiovascular O
system O
. O
This O
review O
article O
will O
focus O
on O
growing O
evidence O
supporting O
the O
relevance O
of O
MMPs O
in O
hypertension O
and O
the O
effects O
of O
MMP O
inhibitors O
. O
Particularly O
, O
the O
effects O
of O
doxycycline O
used O
as O
a O
non O
selective O
MMP B
inhibitor O
in O
experimental O
and O
clinical O
studies O
will O
be O
discussed O
. O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 B
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramide O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase B
A2' I
in O
ceramide-signalling O
to O
nucleus O
. O

Tinzaparin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Binding O
between O
heparin O
and O
the O
integrin O
VLA-4.Heparin O
possesses O
antimetastatic O
effects O
that O
were O
related O
to O
various O
molecular O
mechanisms O
beyond O
anticoagulant O
activities O
. O
The O
ability O
of O
heparin O
to O
interfere O
with O
the O
function O
of O
adhesion O
receptors O
in O
the O
metastatic O
course O
appears O
as O
a O
promising O
therapeutic O
approach O
. O
This O
refers O
to O
numerous O
findings O
that O
heparin O
attenuates O
metastasis O
in O
a O
selectin-dependent O
manner O
. O
We O
recently O
demonstrated O
that O
heparin O
interferes O
with O
the O
integrin O
VLA-4 O
on O
murine O
melanoma O
cells O
binding O
to O
VCAM-1 O
. O
To O
confirm O
this O
activity O
and O
to O
obtain O
further O
insight O
into O
molecular O
recognition O
of O
heparin O
by O
VLA-4 O
, O
we O
investigated O
the O
inhibition O
of O
VLA-4 O
mediated O
binding O
of O
human O
melanoma O
MV3 O
cells O
to O
immobilised O
VCAM-1 O
by O
different O
heparins O
. O
The O
size O
of O
heparin O
has O
an O
important O
impact O
on O
inhibition O
. O
Unfractionated O
heparin O
(UFH) O
and O
tinzaparin O
, O
a O
low-molecular-weight O
heparin O
(LMWH) O
representing O
a O
mean O
of O
about O
18-20 O
monomers O
, O
displayed O
high O
inhibitory O
activity O
. O
Fractionating O
tinzaparin O
to O
14-18 O
monomers O
reduced O
inhibition O
slightly O
, O
while O
the O
pentasaccharide O
fondaparinux O
was O
without O
effects O
. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin O
by O
VLA-4 O
, O
a O
surface O
acoustic O
wave-biosensor O
was O
applied O
. O
A O
VLA-4 O
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin O
compared O
to O
VCAM-1 O
. O
Tinzaparin O
binds O
to O
VLA-4 B
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M) O
, O
which O
clearly O
indicates O
specific O
molecular O
recognition O
. O
Furthermore O
, O
tinzaparin O
displays O
a O
nearly O
identical O
k(off) O
compared O
to O
VCAM-1 O
(5.13 O
x O
10(-3) O
s(-1) O
versus O
3.44 O
x O
10(-3) O
s(-1)) O
which O
is O
evident O
for O
interference O
with O
the O
ligand O
binding O
. O
The O
data O
provide O
evidence O
for O
a O
direct O
confirmation O
of O
heparin O
binding O
to O
VLA-4 O
and O
thus O
, O
contribute O
to O
understand O
the O
antimetastatic O
activity O
of O
heparin O
. O

MDA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
MDA O
and O
MDMA O
on O
phosphatidyl O
inositol O
turnover O
in O
cultured O
cells O
expressing O
5-HT2A O
or O
5-HT2C O
receptors.The O
effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
3,4-methylenedioxyamphetamine O
(MDA) O
and O
its O
N-methyl O
analog O
3,4-methylenedioxymethamphetamine O
(MDMA) O
on O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A O
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A B
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

lavandulyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol O
acyltransferase O
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT B
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- B
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

fentanyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Murine O
chromosomal O
location O
of O
the O
mu O
and O
kappa O
opioid O
receptor O
genes O
. O
Opioid B
receptors I
are O
the O
membrane O
proteins O
that O
mediate O
the O
pain-relieving O
effect O
of O
opioid O
drugs O
, O
such O
as O
morphine O
and O
fentanyl O
as O
well O
as O
endogenous O
opioid O
peptides O
enkephalins O
and O
endorphins O
. O
Using O
cDNAs O
for O
the O
mu O
and O
the O
kappa O
opioid O
receptors O
, O
we O
mapped O
the O
chromosomal O
locations O
of O
their O
genes O
in O
mouse O
. O
Multilocus O
cross O
analysis O
located O
the O
mu O
receptor O
gene O
Oprm O
on O
Chr O
10 O
and O
the O
kappa O
receptor O
gene O
Oprk1 O
on O
Chr O
1 O
. O
Both O
genes O
are O
near O
centromere O
, O
with O
no O
markers O
more O
centromeric O
. O
These O
data O
indicate O
that O
the O
two O
opioid O
receptors O
are O
different O
gene O
products O
, O
ruling O
out O
the O
possibility O
that O
they O
may O
be O
differential O
splicing O
products O
from O
the O
same O
gene O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) B
channel I
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

captopril O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase O
A O
(MMP-2) O
by O
batimastat O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting B
enzyme I
inhibitor O
, O
captopril O
, O
on O
metalloproteinase O
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro O
, O
and O
on O
local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice O
. O
The O
effect O
of O
BB-94 O
and O
captopril O
on O
the O
survival O
of O
the O
3LL-tumor-bearing O
mice O
was O
also O
examined O
. O
Here O
we O
report O
that O
captopril O
treatment O
resulted O
in O
decreased O
transcription O
and O
protein O
levels O
of O
gelatinase O
A O
by O
3LL O
cells O
. O
Both O
BB-94 O
and O
captopril O
also O
prevented O
substrate O
degradation O
by O
gelatinase O
A O
and O
B O
released O
in O
conditioned O
medium O
by O
cultured O
cells O
. O
Treatment O
of O
tumor-bearing O
animals O
with O
BB-94 O
(i.p.) O
or O
captopril O
(in O
drinking O
water) O
resulted O
in O
significant O
inhibition O
of O
the O
mean O
tumor O
volume O
(25 O
and O
33% O
respectively) O
and O
of O
the O
mean O
lung O
metastasis O
number O
(26 O
and O
29% O
respectively) O
. O
When O
both O
agents O
were O
given O
, O
they O
acted O
in O
synergy O
, O
resulting O
in O
51 O
and O
80% O
inhibition O
of O
tumor O
growth O
and O
metastasis O
. O
The O
survival O
time O
of O
the O
mice O
treated O
with O
both O
BB-94 O
and O
captopril O
was O
also O
significantly O
longer O
compared O
with O
the O
groups O
treated O
with O
each O
agent O
alone O
or O
with O
the O
vehicle O
. O
Our O
data O
support O
the O
hypothesis O
of O
an O
essential O
role O
of O
metalloproteinase(s) O
in O
the O
metastatic O
process O
. O
Moreover O
, O
blockade O
of O
invasion O
, O
angiogenesis O
and O
other O
processes O
mediated O
by O
metalloproteinases O
may O
underlie O
the O
anti-tumor O
and O
anti-metastatic O
effect O
of O
BB-94 O
and O
captopril O
and O
their O
combination O
. O
It O
is O
conceivable O
that O
this O
combination O
could O
be O
tested O
in O
selected O
clinical O
conditions O
as O
an O
adjuvant O
modality O
to O
cytotoxic O
therapy O
. O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
( O
AChE) B
 O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O
. O

Wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated B
protein I
kinase I
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A B
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

phillyrin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phillyrin O
attenuates O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
through O
the O
activation O
of O
LKB1/AMP-activated O
protein O
kinase-dependent O
signalling.Phillyrin O
, O
an O
active O
constituent O
found O
in O
many O
medicinal O
plants O
and O
certain O
functional O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS B
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 O
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2 O
/ O
STAT3 B
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

ASA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
( O
COX) B
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX O
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O
trilisate) O
pre-treatment O
on O
ASA-induced O
adverse O
reactions O
in O
nine O
patients O
. O
Pulmonary O
function O
tests O
, O
nasal O
symptoms O
score O
, O
PNIF O
and O
serum O
salicylate O
levels O
were O
monitored O
following O
challenges O
with O
threshold O
doses O
of O
ASA O
. O
Trilisate O
administered O
at O
a O
dose O
of O
3000 O
mg O
daily O
for O
3 O
days O
, O
offered O
a O
moderate O
protection O
against O
ASA-induced O
symptoms; O
it O
diminished O
the O
severity O
and/or O
delayed O
the O
appearance O
of O
FEV1 O
fall O
. O
Maximal O
decreases O
in O
FEV1 O
as O
well O
as O
reaction O
intensity O
indexes O
were O
significantly O
lower O
(P O
less O
than O
0.02 O
and O
P O
less O
than O
0.002 O
, O
respectively) O
after O
trilisate O
pre-treatment O
as O
compared O
to O
placebo O
. O
Trilisate O
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients O
. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate O
is O
unknown O
, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate O
and O
ASA O
on O
cyclo-oxygenase O
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant O
patients O
. O

C2-ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramide O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 B
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

all-trans O
retinoic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Characterization O
of O
insulin-like O
growth O
factor-binding O
protein-related O
proteins O
(IGFBP-rPs) O
1 O
, O
2 O
, O
and O
3 O
in O
human O
prostate O
epithelial O
cells O
: O
potential O
roles O
for O
IGFBP-rP1 O
and O
2 O
in O
senescence O
of O
the O
prostatic O
epithelium.Insulin-like O
growth O
factor O
(IGF)-binding O
protein O
(IGFBP)-related O
proteins O
(IGFBP-rPs) O
are O
newly O
described O
cysteine-rich O
proteins O
that O
share O
significant O
aminoterminal O
structural O
similarity O
with O
the O
conventional O
IGFBPs O
and O
are O
involved O
in O
a O
diversity O
of O
biological O
functions O
, O
including O
growth O
regulation O
. O
IGFBP-rP1 O
(MAC25/Angiomodulin/prostacyclin-stimulating O
factor) O
is O
a O
potential O
tumor-suppressor O
gene O
that O
is O
differentially O
expressed O
in O
meningiomas O
, O
mammary O
and O
prostatic O
cancers O
, O
compared O
with O
their O
malignant O
counterparts O
. O
We O
have O
previously O
shown O
that O
IGFBP-rP1 O
is O
preferentially O
produced O
by O
primary O
cultures O
of O
human O
prostate O
epithelial O
cells O
(HPECs) O
and O
by O
poorly O
tumorigenic O
P69SV40T O
cells O
, O
compared O
with O
the O
cancerous O
prostatic O
LNCaP O
, O
DU145 O
, O
PC-3 O
, O
and O
M12 O
cells O
. O
We O
now O
show O
that O
IGFBP-rP1 O
increases O
during O
senescence O
of O
HPEC O
. O
IGFBP-rP2 O
(also O
known O
as O
connective O
tissue O
growth O
factor) O
, O
a O
downstream O
effector O
of O
transforming O
growth O
factor O
(TGF)-beta O
and O
modulator O
of O
growth O
for O
both O
fibroblasts O
and O
endothelial O
cells O
, O
was O
detected O
in O
most O
of O
the O
normal O
and O
malignant O
prostatic O
epithelial O
cells O
tested O
, O
with O
a O
marked O
up-regulation O
of O
IGFBP-rP2 O
during O
senescence O
of O
HPEC O
. O
Moreover O
, O
IGFBP-rP2 B
noticeably O
increased O
in O
response O
to O
TGF-beta1 O
and O
all-trans O
retinoic O
acid O
(atRA) O
in O
HPEC O
and O
PC-3 O
cells O
, O
and O
it O
decreased O
in O
response O
to O
IGF-I O
in O
HPEC O
. O
IGFBP-rP3 O
[nephroblastoma O
overexpressed O
(NOV)] O
, O
the O
protein O
product O
of O
the O
NOV O
protooncogene O
, O
was O
not O
detected O
in O
HPEC O
but O
was O
expressed O
in O
the O
tumorigenic O
DU145 O
and O
PC-3 O
cells O
. O
It O
was O
also O
synthesized O
by O
the O
SV40-T O
antigen-transformed O
P69 O
and O
malignant O
M12 O
cells O
, O
where O
it O
was O
down-regulated O
by O
atRA O
. O
These O
observations O
suggest O
biological O
roles O
of O
IGFBP-rPs O
in O
the O
human O
prostate O
. O
IGFBP-rP1 O
and O
IGFBP-rP2 O
are O
likely O
to O
negatively O
regulate O
growth O
, O
because O
they O
seem O
to O
increase O
during O
senescence O
of O
the O
prostate O
epithelium O
and O
in O
response O
to O
growth O
inhibitors O
(TGF-beta1 O
and O
atRA) O
. O
Although O
the O
data O
collected O
on O
IGFBP-rP3 O
in O
prostate O
are O
modest O
, O
its O
role O
as O
a O
growth O
stimulator O
and/or O
protooncogene O
is O
supported O
by O
its O
preferential O
expression O
in O
cancerous O
cells O
and O
its O
down-regulation O
by O
atRA O
. O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Silica O
nanoparticles-induced O
cytotoxicity O
, O
oxidative O
stress O
and O
apoptosis O
in O
cultured O
A431 O
and O
A549 O
cells.In O
medicine O
, O
the O
use O
of O
silica O
nanoparticles O
(SiO(2) O
NPs) O
offers O
new O
perspectives O
in O
biosensor O
, O
drug O
delivery O
and O
cancer O
therapy O
. O
However O
, O
questions O
about O
potential O
toxic O
and O
deleterious O
effects O
of O
SiO(2) O
NPs O
have O
also O
been O
raised O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
induction O
of O
cytotoxicity O
, O
oxidative O
stress O
and O
apoptosis O
by O
SiO(2) O
NPs O
(size O
15 O
nm) O
in O
human O
skin O
epithelial O
(A431) O
and O
human O
lung O
epithelial O
(A549) O
cells O
. O
SiO(2) O
NPs O
(concentration O
range O
25-200 O
µg/ml) O
induced O
dose-dependent O
cytotoxicity O
in O
both O
types O
of O
cells O
, O
which O
was O
demonstrated O
by O
cell O
viability O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O
SiO(2) O
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 B
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Warfarin O
dose O
and O
the O
pharmacogenomics O
of O
CYP2C9 O
and O
VKORC1 O
- O
rationale O
and O
perspectives.Warfarin O
is O
the O
most O
widely O
prescribed O
oral O
anticoagulant O
, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O
VKORC1) O
, O
demographic O
, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin O
dosage O
, O
could O
potentially O
minimize O
the O
risk O
of O
over O
dose O
during O
warfarin O
induction O
. O

5-(dipentylamino)-5-oxo-pentanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin B
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v O
. O
CCK-8 O
or O
ceruletide O
(caerulein) O
. O
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 O
in O
the O
rat O
and O
is O
protective O
against O
ceruletide- O
, O
taurocholate- O
and O
diet-induced O
pancreatitis O
. O
Lorglumide O
is O
therefore O
a O
useful O
pharmacological O
tool O
to O
study O
the O
functions O
of O
CCK O
. O
For O
its O
pharmacological O
properties O
, O
its O
relatively O
low O
toxicity O
and O
because O
it O
is O
active O
also O
after O
oral O
administration O
, O
lorglumide O
is O
a O
candidate O
for O
diagnostic O
or O
therapeutic O
use O
in O
man O
when O
an O
involvement O
of O
CCK O
is O
suspected O
. O

OSI-774 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Emerging O
role O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
therapy O
for O
advanced O
malignancy O
: O
focus O
on O
NSCLC.Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer O
. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based O
therapy O
vs O
. O
best O
supportive O
care O
, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate O
. O
Just O
as O
importantly O
, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O
life O
. O
Newer O
agents O
, O
including O
the O
taxanes O
, O
vinorelbine O
, O
gemcitabine O
, O
and O
irinotecan O
, O
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer O
. O
Despite O
their O
contributions O
, O
we O
have O
reached O
a O
therapeutic O
plateau O
, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40% O
. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal B
growth I
factor I
receptor I
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O
Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O
persist O
. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular O
, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds O
. O
Both O
gefitinib O
and O
erlotinib O
have O
shown O
clinical O
activity O
in O
pretreated O
, O
advanced O
non-small-cell O
lung O
cancer O
, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib O
in O
combination O
with O
standard O
cytotoxic O
therapy O
, O
to O
our O
chagrin O
, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone O
. O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Resveratrol O
attenuates O
hepatotoxicity O
of O
rats O
exposed O
to O
arsenic O
trioxide.Arsenic O
trioxide O
(As(2)O(3)) O
is O
an O
environmental O
pollutant O
and O
potent O
toxicant O
to O
humans O
. O
However O
, O
it O
also O
shows O
substantial O
anti-cancer O
activity O
in O
individuals O
with O
acute O
promyelocytic O
leukemia O
(APL) O
. O
Unfortunately O
, O
As(2)O(3)-treated O
leukemia O
patients O
suffer O
hepatotoxicity O
. O
Resveratrol O
has O
been O
demonstrated O
to O
have O
efficient O
antioxidant O
and O
antineoplastic O
activities O
. O
The O
study O
that O
how O
As(2)O(3) O
in O
combination O
with O
resveratrol O
affects O
hepatotoxicity O
and O
arsenic O
accumulation O
in O
the O
liver O
is O
lacking O
, O
and O
the O
present O
study O
tackles O
this O
question O
. O
Wistar O
rats O
were O
injected O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol+As(2)O(3) O
group O
, O
activities O
of O
superoxide B
dismutase I
, O
catalase O
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O
that O
use O
of O
resveratrol O
as O
post-remission O
therapy O
of O
APL O
and O
adjunctive O
therapy O
in O
patients O
with O
chronic O
exposure O
to O
arsenic O
may O
decrease O
arsenic O
hepatotoxicity O
. O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neoechinulin O
A O
suppresses O
amyloid-β O
oligomer-induced O
microglia O
activation O
and O
thereby O
protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
( O
ASK-1) B
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin O
A O
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
AD O
. O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
( O
Nrf2) B
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

Vitamin O
K2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Vitamin O
K2 O
covalently O
binds O
to O
Bak O
and O
induces O
Bak B
-mediated O
apoptosis.Vitamin O
K2 O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

cDDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
Re-evaluation O
of O
the O
Role O
of O
hCTR1 O
, O
the O
Human O
High O
Affinity O
Cu O
Transporter O
in O
Pt-Drug O
Entry O
into O
Human O
Cells.Cisplatin O
(cDDP) O
is O
an O
anti-cancer O
drug O
used O
in O
a O
number O
of O
malignancies O
including O
testicular O
, O
ovarian O
, O
cervical O
, O
bladder O
, O
lung O
, O
head O
, O
and O
neck O
cancers O
. O
Its O
use O
is O
limited O
by O
the O
development O
of O
resistance O
, O
often O
rationalized O
via O
effects O
on O
cellular O
uptake O
. O
It O
has O
been O
claimed O
that O
hCTR1 O
, O
the O
human B
high I
affinity I
copper I
transporter I
, O
is O
the O
major O
entry O
pathway O
for O
cDDP O
and O
related O
drugs O
via O
a O
mechanism O
that O
mimics O
copper O
. O
This O
is O
an O
unexpected O
property O
of O
hCTR1 O
, O
a O
highly O
selective O
copper O
(I) O
transporter O
. O
We O
compared O
the O
uptake O
rates O
of O
copper O
with O
cDDP O
(and O
several O
analogs) O
into O
HEK293 O
cells O
over-expressing O
wild-type O
or O
mutant O
hCTR1 O
, O
mouse O
embryonic O
fibroblasts O
(mefs) O
that O
do O
or O
do O
not O
express O
CTR1 O
, O
and O
human O
ovarian O
tumor O
cells O
, O
sensitive O
or O
resistant O
to O
cDDP O
. O
We O
have O
also O
compared O
the O
effects O
of O
extracellular O
copper O
, O
which O
causes O
regulatory O
endocytosis O
of O
hCTR1 O
, O
to O
those O
of O
cDDP O
. O
We O
confirm O
the O
correlation O
between O
higher O
hCTR1 O
levels O
and O
higher O
Pt-drug O
uptake O
in O
tumor O
cells O
sensitive O
to O
the O
drug O
. O
However O
, O
we O
show O
that O
hCTR1 O
is O
not O
the O
major O
entry O
route O
of O
platinum-drugs O
and O
that O
the O
copper O
transporter O
is O
not O
internalized O
in O
response O
to O
extracellular O
drug O
. O
Our O
data O
suggest O
the O
major O
entry O
pathway O
for O
platinum-drugs O
is O
not O
saturable O
at O
relevant O
concentrations O
and O
not O
protein-mediated O
. O
Clinical O
trials O
have O
been O
initiated O
that O
depend O
upon O
regulating O
membrane O
levels O
of O
hCTR1 O
. O
If O
reduced O
drug O
uptake O
is O
a O
major O
factor O
in O
resistance O
, O
hCTR1 O
is O
unlikely O
to O
be O
a O
productive O
target O
in O
attempts O
to O
enhance O
efficacy O
, O
although O
the O
proteins O
involved O
in O
copper O
homeostasis O
may O
play O
a O
role O
. O

S-adenosylmethionine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Methionine O
adenosyltransferase O
II O
beta O
subunit O
gene O
expression O
provides O
a O
proliferative O
advantage O
in O
human O
hepatoma.BACKGROUND O
& O
AIMS O
: O
Of O
the O
2 O
genes O
(MAT1A O
, O
MAT2A) O
encoding O
methionine O
adenosyltransferase O
, O
the O
enzyme O
that O
synthesizes O
S-adenosylmethionine O
, O
MAT1A O
, O
is O
expressed O
in O
liver O
, O
whereas O
MAT2A O
is O
expressed O
in O
extrahepatic O
tissues O
. O
In O
liver O
, O
MAT2A O
expression O
associates O
with O
growth O
, O
dedifferentiation O
, O
and O
cancer O
. O
Here O
, O
we O
identified O
the O
beta O
subunit O
as O
a O
regulator O
of O
proliferation O
in O
human O
hepatoma O
cell O
lines O
. O
The O
beta O
subunit O
has O
been O
cloned O
and O
shown O
to O
lower O
the O
K(m) O
of O
methionine O
adenosyltransferase O
II O
alpha2 O
(the O
MAT2A B
product) O
for O
methionine O
and O
to O
render O
the O
enzyme O
more O
susceptible O
to O
S-adenosylmethionine O
inhibition O
. O
METHODS O
: O
Methionine O
adenosyltransferase O
II O
alpha2 O
and O
beta O
subunit O
expression O
was O
analyzed O
in O
human O
and O
rat O
liver O
and O
hepatoma O
cell O
lines O
and O
their O
interaction O
studied O
in O
HuH7 O
cells O
. O
beta O
Subunit O
expression O
was O
up- O
and O
down-regulated O
in O
human O
hepatoma O
cell O
lines O
and O
the O
effect O
on O
DNA O
synthesis O
determined O
. O
RESULTS O
: O
We O
found O
that O
beta O
subunit O
is O
expressed O
in O
rat O
extrahepatic O
tissues O
but O
not O
in O
normal O
liver O
. O
In O
human O
liver O
, O
beta O
subunit O
expression O
associates O
with O
cirrhosis O
and O
hepatoma O
. O
beta O
Subunit O
is O
expressed O
in O
most O
(HepG2 O
, O
PLC O
, O
and O
Hep3B) O
but O
not O
all O
(HuH7) O
hepatoma O
cell O
lines O
. O
Transfection O
of O
beta O
subunit O
reduced O
S-adenosylmethionine O
content O
and O
stimulated O
DNA O
synthesis O
in O
HuH7 O
cells O
, O
whereas O
down-regulation O
of O
beta O
subunit O
expression O
diminished O
DNA O
synthesis O
in O
HepG2 O
. O
The O
interaction O
between O
methionine O
adenosyltransferase O
II O
alpha2 O
and O
beta O
subunit O
was O
demonstrated O
in O
HuH7 O
cells O
. O
CONCLUSIONS O
: O
Our O
findings O
indicate O
that O
beta O
subunit O
associates O
with O
cirrhosis O
and O
cancer O
providing O
a O
proliferative O
advantage O
in O
hepatoma O
cells O
through O
its O
interaction O
with O
methionine O
adenosyltransferase O
II O
alpha2 O
and O
down-regulation O
of O
S-adenosylmethionine O
levels O
. O

noradrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Analysis O
of O
alpha O
1L-adrenoceptor O
pharmacology O
in O
rat O
small O
mesenteric O
artery.1 O
. O
To O
illuminate O
the O
controversy O
on O
alpha B
1A- I
or O
alpha O
1L-adrenoceptor O
involvement O
in O
noradrenaline-mediated O
contractions O
of O
rat O
small O
mesenteric O
artery O
(SMA) O
, O
we O
have O
studied O
the O
effects O
of O
subtype-selective O
alpha O
1-adrenoceptor O
agonists O
and O
antagonists O
under O
different O
experimental O
conditions O
. O
2 O
. O
The O
agonist O
potency O
order O
in O
rat O
SMA O
was O
: O
A61603 O
>> O
SKF89748-A O
> O
cirazoline O
> O
noradrenaline O
> O
ST-587 O
> O
methoxamine O
. O
Prazosin O
antagonized O
all O
agonists O
with O
a O
low O
potency O
(pA2 O
: O
8.29-8.80) O
indicating O
the O
involvement O
of O
alpha O
1L-rather O
than O
alpha O
1A-adrenoceptors O
. O
3 O
. O
The O
putative O
alpha O
1L-adrenoceptor O
antagonist O
JTH-601 O
, O
but O
not O
the O
alpha O
1B-adrenoceptor O
antagonist O
chloroethylclonidine O
(10 O
microM) O
antagonized O
noradrenaline-induced O
contractions O
of O
SMA O
. O
The O
potency O
of O
the O
selective O
alpha O
1D-adrenoceptor O
antagonist O
BMY O
7378 O
against O
noradrenaline O
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha O
1A-adrenoceptor O
antagonist O
RS-17053 O
against O
noradrenaline O
(pKB O
= O
8.35 O
+/- O
0.10) O
and O
against O
the O
selective O
alpha O
1A-adrenoceptor O
agonist O
A-61603 O
(pKB O
= O
8.40 O
+/- O
0.09) O
were O
too O
low O
to O
account O
for O
alpha O
1D- O
and O
alpha O
1A-adrenoceptor O
involvement O
. O
4 O
. O
The O
potency O
of O
RS-17053 O
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature O
, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O
via O
KCl O
or O
U46619 O
. O
5 O
. O
Selective O
protection O
of O
a O
putative O
alpha O
1A-adrenoceptor O
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine O
also O
failed O
to O
increase O
the O
potency O
of O
RS-17053 O
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603) O
. O
6 O
. O
Combined O
concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin O
, O
which O
does O
not O
discriminate O
between O
alpha O
1A- O
and O
alpha O
1L-adrenoceptors O
, O
and O
RS-17053 O
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA O
. O
7 O
. O
In O
summary O
, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha O
1-adrenoceptor O
mediating O
noradrenaline-induced O
contraction O
displays O
a O
distinct O
alpha O
1L-adrenoceptor O
pharmacology O
. O
This O
study O
does O
not O
provide O
evidence O
for O
the O
hypothesis O
that O
alpha O
1L-adrenoceptors O
represent O
an O
affinity O
state O
of O
the O
alpha O
1A-adrenoceptor O
in O
functional O
assays O
. O
Furthermore O
, O
there O
is O
no O
co-existing O
alpha O
1A-adrenoceptor O
in O
the O
SMA O
. O

prunetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
prunetin O
via O
the O
suppression O
of O
NF-κB B
pathway.Prunetin O
is O
an O
O-methylated O
isoflavone O
, O
which O
is O
found O
in O
Prunus O
yedoensis O
. O
To O
date O
no O
report O
has O
been O
published O
on O
anti-inflammatory O
activities O
of O
prunetin O
. O
In O
the O
present O
study O
, O
the O
anti-inflammatory O
effect O
of O
prunetin O
on O
LPS-stimulated O
RAW O
264.7 O
macrophage O
and O
LPS-induced O
septic O
shock O
model O
were O
investigated O
. O
Inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-6 O
(IL-6) O
, O
and O
interleukin-1β O
(IL-1β) O
expressions O
were O
determined O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR) O
. O
To O
elucidate O
its O
underlying O
mechanism O
, O
nuclear O
factor-kappa O
B O
(NF-κb) O
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

phenylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 O
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 B
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Catalytic O
properties O
of O
mouse O
carbonic O
anhydrase O
V.A O
cDNA O
encoding O
the O
mouse O
carbonic O
anhydrase O
V O
gene O
was O
isolated O
by O
reverse O
transcription O
and O
polymerase O
chain O
reaction O
from O
BALB/c O
mouse O
liver O
mRNA O
. O
Vectors O
containing O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic O
anhydrase O
(CA) O
V O
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
, O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA B
II I
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA O
V O
are O
not O
due O
to O
the O
presence O
of O
tyrosine O
at O
position O
64 O
. O

EGTA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 B
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

Nor-NOHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine B
transporter I
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

meclofenamate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Meclofenamic O
acid O
and O
diclofenac O
, O
novel O
templates O
of O
KCNQ2/Q3 O
potassium O
channel O
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O
voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current O
. O
Furthermore O
, O
the O
KCNQ2 O
and O
KCNQ3 O
channel O
alpha O
subunits O
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 O
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 B
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics O
. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O
KCNQ2 O
than O
on O
KCNQ3 O
channel O
alpha O
subunits O
. O
In O
contrast O
, O
they O
did O
not O
enhance O
KCNQ1 O
K(+) O
currents O
. O
Both O
openers O
increased O
KCNQ2/Q3 O
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential O
. O
In O
cultured O
cortical O
neurons O
, O
meclofenamate O
and O
diclofenac O
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials O
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pain O
. O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage B
colony I
stimulating I
factor I
(M-CSF) I
receptor I
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

pranlukast O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cysteinyl O
leukotriene-dependent O
interleukin-5 O
production O
leading O
to O
eosinophilia O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O
antagonists O
(pranlukast O
and O
MCI-826) O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 B
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O
weeks O
. O
At O
the O
fifth O
challenge O
, O
the O
effects O
of O
CysLT O
antagonists O
and O
an O
anti-IL-5 O
antibody O
(TRFK-5) O
on O
the O
occurrence O
of O
LAR O
, O
and O
blood O
and O
lung O
eosinophilia O
, O
which O
appeared O
at O
5 O
h O
after O
challenge O
, O
were O
examined O
. O
The O
time-course O
of O
IL-5 O
activity O
in O
the O
serum O
after O
the O
challenge O
was O
evaluated O
by O
measuring O
in O
vitro O
'eosinophil O
survival O
prolongation O
activity' O
. O
The O
influence O
of O
CysLT O
antagonists O
on O
IL-5 O
activity O
was O
assessed O
. O
RESULTS O
: O
CysLT O
antagonists O
and O
TRFK-5 O
completely O
abolished O
blood O
and O
lung O
eosinophilia O
. O
LAR O
was O
suppressed O
by O
both O
MCI-826 O
and O
TRFK-5 O
by O
40-50% O
. O
Sera O
obtained O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

naltrindole O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindole-derived O
ligands O
at O
the O
κ-opioid B
receptor I
.Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid O
receptor O
antagonists O
in O
the O
treatment O
of O
mood O
disorders O
. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action O
, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor O
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O
effects O
in O
mice O
, O
reducing O
the O
antinociceptive O
actions O
of O
U50,488 O
(10 O
mg/kg) O
at O
28 O
and O
21 O
days O
post-injection O
, O
respectively O
. O
Interestingly O
, O
while O
5'-AMN O
and O
5'-MABN O
were O
not O
κ-selective O
, O
both O
compounds O
did O
show O
significant O
antidepressant- O
and O
anxiolytic-like O
effects O
at O
7-14 O
days O
post-injection O
in O
mice O
. O

MDZ O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Time-dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A B
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses O
. O
5 O
. O
Some O
physiological O
compounds O
such O
as O
cytokines O
might O
be O
involved O
in O
decreasing O
the O
CYP3A O
activity O
to O
maintain O
homeostasis O
of O
the O
body O
. O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase B
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O
a O
difluoromethylene O
linker O
, O
replacement O
of O
the O
para-cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole O
derivative O
with O
IC50 O
values O
against O
aromatase O
and O
steroid O
sulfatase O
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM O
, O
respectively O
. O
The O
parent O
phenol O
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay O
. O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA-induced O
reductions O
in O
SERT B
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin O
, O
but O
may O
occur O
in O
response O
to O
some O
other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA O
. O

4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Kinetic O
and O
stereochemical O
studies O
on O
novel O
inactivators O
of O
C-terminal O
amidation.C-terminal O
amidation O
, O
a O
required O
post-translational O
modification O
for O
the O
bioactivation O
of O
many O
neuropeptides O
, O
entails O
sequential O
enzymic O
action O
by O
peptidylglycine O
alpha-mono-oxygenase O
(PAM O
, O
EC O
1.14.17.3) O
and O
peptidylamidoglycolate O
lyase O
(PGL O
, O
EC O
4.3.2.5) O
. O
Here O
we O
introduce O
novel O
compounds O
in O
which O
an O
olefinic O
functionality O
is O
incorporated O
into O
peptide O
analogues O
as O
the O
most O
potent O
turnover-dependent O
inactivators O
of O
PAM O
. O
Kinetic O
parameters O
for O
PAM O
inactivation O
by O
4-oxo-5-acetamido-6-phenyl-hex-2-enoic O
acid O
and O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
were O
obtained O
by O
using O
both O
the O
conventional O
dilution O
assay O
method O
and O
the O
more O
complex O
progress O
curve O
method O
. O
The O
results O
obtained O
from O
the O
progress O
curve O
method O
establish O
that O
these O
compounds O
exhibit O
the O
kinetic O
characteristics O
of O
pure O
competitive O
inactivators O
(i.e O
. O
no O
ESI O
complex O
forms O
during O
inactivation) O
. O
On O
the O
basis O
of O
k(inact)/K(i) O
values O
, O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
almost O
two O
orders O
of O
magnitude O
more O
potent O
than O
benzoylacrylate O
, O
a O
chemically O
analogous O
olefinic O
inactivator O
that O
lacks O
the O
peptide O
moiety O
. O
Stereochemical O
studies O
established O
that O
PAM B
inactivation O
by O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
stereospecific O
with O
respect O
to O
the O
moiety O
at O
the O
P(2) O
position O
, O
which O
is O
consistent O
with O
previous O
results O
with O
substrates O
and O
reversible O
inhibitors O
. O
In O
contrast O
, O
2 O
, O
4-dioxo-5-acetamido-6-phenylhexanoic O
acid O
, O
which O
is O
a O
competitive O
inhibitor O
with O
respect O
to O
ascorbate O
, O
exhibits O
a O
low O
degree O
of O
stereospecificity O
in O
binding O
to O
the O
ascorbate O
sites O
of O
both O
PAM O
and O
dopamine-beta-hydroxylase O
. O

acetyl-CoA O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Redesign O
of O
carnitine O
acetyltransferase O
specificity O
by O
protein O
engineering.In O
eukaryotes O
, O
L-carnitine O
is O
involved O
in O
energy O
metabolism O
by O
facilitating O
beta-oxidation O
of O
fatty O
acids O
. O
Carnitine B
acetyltransferases I
(CrAT) O
catalyze O
the O
reversible O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O
mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
. O
Kinetic O
constants O
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O
to O
methionine O
in O
carnitine O
octanoyltransferase O
(COT) O
decreased O
activity O
toward O
its O
natural O
substrates O
, O
medium- O
and O
long-chain O
acyl-CoAs O
, O
and O
increased O
activity O
toward O
short-chain O
acyl-CoAs O
. O
Another O
CrAT O
mutant O
, O
M564A O
, O
was O
prepared O
and O
tested O
in O
the O
same O
way O
, O
with O
similar O
results O
. O
We O
conclude O
that O
Met564 O
blocks O
the O
entry O
of O
medium- O
and O
long-chain O
acyl-CoAs O
to O
the O
catalytic O
site O
of O
CrAT O
. O
Three-dimensional O
models O
of O
wild-type O
and O
mutated O
CrAT O
and O
COT O
support O
this O
hypothesis O
. O
We O
show O
for O
the O
first O
time O
that O
a O
single O
amino O
acid O
is O
able O
to O
determine O
the O
substrate O
specificity O
of O
CrAT O
and O
COT O
. O

COC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT B
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O
VMAT2 O
as O
a O
target O
that O
enables O
the O
rewarding O
and O
addictive O
actions O
of O
these O
drugs O
, O
based O
on O
imaging O
, O
neurochemical O
, O
biochemical O
, O
cell O
biological O
, O
genetic O
, O
and O
immunohistochemical O
evidence O
. O
The O
presence O
of O
VMAT2 O
in O
noradrenergic O
, O
serotoninergic O
, O
histaminergic O
, O
and O
potentially O
trace O
aminergic O
neurons O
invites O
consideration O
of O
a O
wider O
role O
for O
aminergic O
neurotransmission O
in O
AMPH O
and O
COC O
abuse O
and O
addiction O
. O

imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KIT B
D816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

nateglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 B
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
IFNα O
converts O
IL-22 O
into O
a O
cytokine O
efficiently O
activating O
STAT1 O
and O
its O
downstream O
targets.Besides O
their O
antiviral O
activity O
, O
type O
I O
Interferons O
(IFN) O
display O
context-specific O
immunomodulation O
. O
In O
contrast O
to O
long-known O
IFNα/β O
, O
Interleukin O
(IL)-22 O
is O
an O
anti-bacterial O
, O
largely O
tissue O
protective O
cytokine O
that O
recently O
gained O
attention O
. O
Herein O
, O
cellular O
IFNα/IL-22 O
interactions O
are O
investigated O
. O
We O
report O
that O
pre-conditioning O
of O
epithelial O
cells O
with O
IFNα O
initiated O
dramatic O
changes O
in O
IL-22 O
signaling O
normally O
dominated O
by O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT)-3 O
. O
Specifically O
, O
by O
using O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 B
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O
characteristics O
of O
IFNα/β O
in O
clinical O
therapy O
and O
expose O
margins O
of O
tissue O
protection O
by O
IL-22 O
application O
. O

methylphenidate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O
current O
study O
, O
SHR O
, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT B
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methyl O
transfer O
in O
glycine O
N-methyltransferase O
. O
A O
theoretical O
study.Density O
functional O
theory O
calculations O
using O
the O
hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl O
transfer O
step O
in O
glycine O
N-methyltransferase O
( O
GNMT) B
 O
. O
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine O
(SAM)-dependent O
methylation O
of O
glycine O
to O
form O
sarcosine O
. O
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O
GNMT O
complexed O
with O
SAM O
and O
acetate O
. O
Several O
quantum O
chemical O
models O
with O
different O
sizes O
, O
employing O
up O
to O
98 O
atoms O
, O
were O
used O
. O
The O
calculations O
demonstrate O
that O
the O
suggested O
mechanism O
, O
where O
the O
methyl O
group O
is O
transferred O
in O
a O
single O
S(N)2 O
step O
, O
is O
thermodynamically O
plausible O
. O
By O
adding O
or O
eliminating O
various O
groups O
at O
the O
active O
site O
, O
it O
was O
furthermore O
demonstrated O
that O
hydrogen O
bonds O
to O
the O
amino O
group O
of O
the O
glycine O
substrate O
lower O
the O
reaction O
barrier O
, O
while O
hydrogen O
bonds O
to O
the O
carboxylate O
group O
raise O
the O
barrier O
. O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Does O
aspirin O
acetylate O
multiple O
cellular O
proteins O
? O
(Review).Aspirin O
is O
a O
salicylate O
drug O
that O
is O
extensively O
used O
for O
its O
anti-inflammatory O
, O
antipyretic O
, O
analgesic O
and O
anti-thrombotic O
effects O
. O
More O
recently O
, O
it O
has O
been O
shown O
to O
decrease O
the O
incidence O
of O
cancers O
of O
epithelial O
origin O
. O
In O
most O
cases O
, O
aspirin O
is O
relatively O
safe O
. O
However O
, O
it O
does O
cause O
a O
host O
of O
adverse O
effects O
and O
toxicities O
, O
including O
gastrointestinal O
bleeding O
, O
ulcerations O
, O
nephrotoxicity O
and O
hypersensitivity O
reactions O
. O
Although O
the O
inhibition O
of O
cyclooxygenases B
by O
aspirin O
, O
which O
leads O
to O
its O
anti-inflammatory/analgesic O
properties O
, O
has O
been O
well O
studied O
, O
the O
mechanisms O
involved O
in O
its O
chemopreventive O
effects O
as O
well O
as O
some O
of O
its O
adverse O
effects O
are O
as O
yet O
ill-defined O
. O
Studies O
over O
the O
past O
decades O
suggest O
that O
, O
besides O
cyclooxygenases O
, O
aspirin O
acetylates O
other O
cellular O
proteins O
. O
These O
studies O
used O
radiolabeled O
3H O
or O
14C O
aspirin O
, O
the O
only O
approach O
used O
to O
date O
for O
the O
detection O
of O
proteins O
acetylated O
by O
aspirin O
. O
In O
a O
recent O
study O
using O
protein-specific O
anti-acetyl O
lysine O
antibodies O
and O
immunological O
methods O
, O
we O
demonstrated O
the O
ability O
of O
aspirin O
to O
acetylate O
the O
tumor O
suppressor O
protein O
p53 O
. O
In O
this O
review O
, O
we O
present O
current O
research O
from O
the O
literature O
on O
the O
aspirin-induced O
acetylation O
of O
proteins O
. O
We O
also O
describe O
an O
immunological O
approach O
to O
detecting O
acetylated O
proteins O
in O
aspirin-treated O
cells O
, O
and O
demonstrate O
that O
multiple O
proteins O
are O
acetylated O
. O
Since O
post-translational O
modification O
of O
proteins O
, O
such O
as O
acetylation O
, O
may O
lead O
to O
the O
alteration O
of O
their O
function O
, O
it O
is O
possible O
that O
some O
of O
the O
hitherto O
unexplained O
beneficial O
or O
adverse O
effects O
of O
aspirin O
could O
occur O
as O
a O
result O
of O
these O
modifications O
. O
The O
identification O
of O
these O
novel O
acetylation O
targets O
of O
aspirin O
represents O
a O
new O
area O
for O
investigation O
. O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 B
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

rivastigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rivastigmine O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Alzheimer's O
disease O
(AD) O
is O
the O
commonest O
cause O
of O
dementia O
affecting O
older O
people O
. O
One O
of O
the O
therapeutic O
strategies O
aimed O
at O
ameliorating O
the O
clinical O
manifestations O
of O
Alzheimer's O
disease O
is O
to O
enhance O
cholinergic O
neurotransmission O
in O
relevant O
parts O
of O
the O
brain O
by O
the O
use O
of O
cholinesterase O
inhibitors O
to O
delay O
the O
breakdown O
of O
acetylcholine O
released O
into O
synaptic O
clefts O
. O
Tacrine O
, O
the O
first O
of O
the O
cholinesterase O
inhibitors O
to O
undergo O
extensive O
trials O
for O
this O
purpose O
, O
was O
associated O
with O
significant O
adverse O
effects O
including O
hepatotoxicity O
. O
Other O
cholinesterase B
inhibitors O
, O
including O
rivastigmine O
, O
with O
superior O
properties O
in O
terms O
of O
specificity O
of O
action O
and O
low O
risk O
of O
adverse O
effects O
, O
have O
now O
been O
introduced O
. O
Rivastigmine O
has O
received O
approval O
for O
use O
in O
60 O
countries O
including O
all O
member O
states O
of O
the O
European O
Union O
and O
the O
USA O
. O
OBJECTIVES O
: O
To O
determine O
the O
clinical O
efficacy O
and O
safety O
of O
rivastigmine O
for O
patients O
with O
dementia O
of O
Alzheimer's O
type O
. O
SEARCH O
STRATEGY O
: O
The O
Specialized O
Register O
of O
the O
Cochrane O
Dementia O
and O
Cognitive O
Improvement O
Group O
(CDCIG) O
, O
The O
Cochrane O
Library O
, O
MEDLINE O
, O
EMBASE O
, O
PsycINFO O
, O
CINAHL O
and O
LILACS O
were O
searched O
on O
27 O
March O
2008 O
using O
the O
terms O
: O
Rivastigmine O
OR O
exelon O
OR O
ENA O
OR O
"SDZ O
ENA O
713" O
 O
. O
The O
CDCIG O
Specialized O
Register O
contains O
records O
from O
all O
major O
health O
care O
databases O
(The O
Cochrane O
Library O
, O
MEDLINE O
, O
EMBASE O
, O
PsycINFO O
, O
CINAHL O
, O
LILACS) O
as O
well O
as O
from O
many O
clinical O
trials O
registries O
and O
grey O
literature O
sources O
. O
SELECTION O
CRITERIA O
: O
All O
unconfounded O
, O
double-blind O
, O
randomized O
trials O
in O
which O
treatment O
with O
rivastigmine O
was O
administered O
to O
patients O
with O
dementia O
of O
the O
Alzheimer's O
type O
for O
more O
than O
two O
weeks O
and O
its O
effects O
compared O
with O
those O
of O
placebo O
in O
a O
parallel O
group O
of O
patients O
. O
DATA O
COLLECTION O
AND O
ANALYSIS O
: O
One O
reviewer O
(JSB) O
applied O
study O
selection O
criteria O
, O
assessed O
the O
quality O
of O
studies O
and O
extracted O
data O
. O
MAIN O
RESULTS O
: O
Nine O
trials O
, O
involving O
4775 O
participants O
, O
were O
included O
in O
the O
analyses O
. O
Use O
of O
rivastigmine O
in O
high O
doses O
was O
associated O
with O
statistically O
significant O
benefits O
on O
several O
measures O
. O
High-dose O
rivastigmine O
(6 O
to O
12 O
mg O
daily) O
was O
associated O
with O
a O
two-point O
improvement O
in O
cognitive O
function O
on O
the O
ADAS-Cog O
score O
compared O
with O
placebo O
(weighted O
mean O
difference O
-1.99 O
, O
95% O
confidence O
interval O
-2.49 O
to O
-1.50 O
, O
on O
an O
intention-to-treat O
basis) O
and O
a O
2.2 O
point O
improvement O
in O
activities O
of O
daily O
living O
assessed O
on O
the O
Progressive O
Deterioration O
Scale O
(weighted O
mean O
difference O
-2.15 O
, O
95% O
confidence O
interval O
-3.16 O
to O
-1.13 O
, O
on O
an O
intention-to-treat O
basis) O
at O
26 O
weeks O
. O
At O
lower O
doses O
(4 O
mg O
daily O
or O
lower) O
differences O
were O
in O
the O
same O
direction O
but O
were O
statistically O
significant O
only O
for O
cognitive O
function O
. O
There O
were O
statistically O
significantly O
higher O
numbers O
of O
events O
of O
nausea O
, O
vomiting O
, O
diarrhoea O
, O
anorexia O
, O
headache O
, O
syncope O
, O
abdominal O
pain O
and O
dizziness O
among O
patients O
taking O
high-dose O
rivastigmine O
than O
among O
those O
taking O
placebo O
. O
There O
was O
some O
evidence O
that O
adverse O
events O
might O
be O
less O
common O
with O
more O
frequent O
, O
smaller O
doses O
of O
rivastigmine O
. O
The O
2008 O
update O
includes O
a O
new O
study O
testing O
two O
types O
of O
rivastigmine O
transdermal O
patch O
, O
one O
delivering O
a O
higher O
dose O
than O
previously O
tested O
(17.4 O
mg/day) O
and O
a O
smaller O
patch O
delivering O
9.6 O
mg/day O
. O
The O
efficacy O
of O
the O
smaller O
patch O
was O
not O
significantly O
different O
compared O
with O
the O
capsules O
of O
similar O
daily O
dose O
, O
but O
was O
associated O
with O
significantly O
fewer O
adverse O
events O
of O
nausea O
, O
vomiting O
, O
dizziness O
and O
asthenia O
. O
The O
efficacy O
of O
the O
larger O
patch O
was O
not O
significantly O
different O
compared O
with O
the O
smaller O
patch O
, O
but O
the O
smaller O
patch O
was O
associated O
with O
significantly O
fewer O
adverse O
events O
of O
nausea O
, O
vomiting O
, O
weight O
loss O
and O
dizziness O
. O
There O
appears O
to O
be O
advantages O
associated O
with O
the O
smaller O
patch O
compared O
with O
both O
the O
higher O
dose O
patch O
and O
the O
6-12 O
mg/day O
capsules O
. O
AUTHORS' O
CONCLUSIONS O
: O
Rivastigmine O
appears O
to O
be O
beneficial O
for O
people O
with O
mild O
to O
moderate O
Alzheimer's O
disease O
. O
In O
comparisons O
with O
placebo O
, O
improvements O
were O
seen O
in O
the O
rate O
of O
decline O
of O
cognitive O
function O
, O
activities O
of O
daily O
living O
, O
and O
severity O
of O
dementia O
with O
daily O
doses O
of O
6 O
to O
12 O
mg O
. O
Adverse O
events O
were O
consistent O
with O
the O
cholinergic O
actions O
of O
the O
drug O
. O
A O
transdermal O
patch O
has O
been O
tested O
in O
one O
trial O
, O
and O
there O
is O
evidence O
that O
the O
lower O
dose O
smaller O
patch O
is O
associated O
with O
fewer O
side O
effects O
than O
the O
capsules O
or O
the O
higher O
dose O
larger O
patch O
and O
has O
comparable O
efficacy O
to O
both O
. O
This O
review O
has O
not O
examined O
economic O
data O
. O

diglycerides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

phenelzine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
( O
MAO) B
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

V(5+) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR- B
dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
glycogen O
synthase O
kinase-3β/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagin-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O
that O
cinobufagin O
potently O
inhibited O
the O
proliferation O
of O
U2OS O
, O
MG63 O
and O
SaOS-2 O
cells O
. O
Significant O
increases O
in O
G2/M O
cell-cycle O
arrest O
and O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K) O
/ O
Akt B
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Effects O
of O
17α-ethynylestradiol-induced O
cholestasis O
on O
the O
pharmacokinetics O
of O
doxorubicin O
in O
rats O
: O
reduced O
biliary O
excretion O
and O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein B
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O
changes O
of O
doxorubicin O
with O
respect O
to O
the O
changes O
in O
its O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
EEC O
rats O
. O
2 O
. O
The O
pharmacokinetic O
study O
of O
doxorubicin O
after O
intravenous O
administration O
of O
its O
hydrochloride O
was O
conducted O
along O
with O
the O
investigation O
of O
bile O
flow O
rate O
and O
hepatobiliary O
excretion O
of O
doxorubicin O
in O
control O
and O
EEC O
rats O
. O
3 O
. O
The O
significantly O
greater O
AUC O
(58.7% O
increase) O
of O
doxorubicin O
in O
EEC O
rats O
was O
due O
to O
the O
slower O
CL O
(32.9% O
decrease) O
. O
The O
slower O
CL O
was O
due O
to O
the O
reduction O
of O
hepatic O
biliary O
excretion O
(67.0% O
decrease) O
and O
hepatic O
CYP3A O
subfamily-mediated O
metabolism O
(21.9% O
decrease) O
of O
doxorubicin O
. O
These O
results O
might O
have O
broader O
implications O
to O
understand O
the O
altered O
pharmacokinetics O
and/or O
pharmacologic O
effects O
of O
doxorubicin O
via O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
experimental O
and O
clinical O
estrogen-induced O
cholestasis O
. O

decitabine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effects O
of O
5-aza-2'-deoxycytidine O
on O
fetal O
hemoglobin O
levels O
, O
red O
cell O
adhesion O
, O
and O
hematopoietic O
differentiation O
in O
patients O
with O
sickle O
cell O
disease.Fetal O
hemoglobin O
(HbF) O
decreases O
polymerization O
of O
sickle O
hemoglobin O
(HbS) O
and O
improves O
outcomes O
in O
sickle O
cell O
disease O
(SSD) O
. O
Therefore O
, O
a O
therapeutic O
goal O
in O
SSD O
is O
pharmacologic O
reactivation O
of O
HbF O
. O
Silencing O
of O
the O
gamma-globin O
(HbF) O
gene O
is O
associated O
with O
DNA O
methylation O
. O
The O
cytosine O
analog O
5-aza-2'-deoxycytidine O
(decitabine) O
hypomethylates O
DNA O
by O
inhibiting O
DNA O
methyltransferase O
. O
We O
examined O
if O
subcutaneous O
decitabine O
could O
increase O
HbF B
levels O
and O
improve O
SSD O
pathophysiology O
without O
cytotoxicity O
. O
Eight O
symptomatic O
SSD O
patients O
resistant O
or O
intolerant O
of O
standard O
treatment O
with O
hydroxyurea O
received O
decitabine O
0.2 O
mg/kg O
subcutaneously O
1 O
to O
3 O
times O
per O
week O
in O
2 O
cycles O
of O
6-week O
duration O
. O
Treatment O
decreased O
neutrophils O
and O
increased O
mean O
HbF O
(6.5% O
to O
20.4% O
, O
P O
<.0001) O
and O
mean O
total O
hemoglobin O
(76 O
to O
96 O
g/L O
[7.6 O
to O
9.6 O
g/dL] O
, O
P O
<.001) O
. O
Features O
of O
vaso-occlusive O
crisis O
pathophysiology O
such O
as O
red O
cell O
adhesion O
, O
endothelial O
damage O
, O
and O
coagulation O
pathway O
activity O
significantly O
improved O
. O
gamma-Globin O
gene O
promoter O
methylation O
decreased O
, O
and O
platelets O
and O
the O
proportion O
of O
megakaryocytes O
and O
erythroid O
cells O
in O
the O
marrow O
increased O
without O
a O
decrease O
in O
marrow O
cellularity O
, O
consistent O
with O
a O
DNA O
hypomethylating O
, O
noncytotoxic O
mechanism O
of O
action O
. O
Weekly O
subcutaneous O
decitabine O
produces O
cumulative O
increases O
in O
HbF O
and O
total O
hemoglobin O
through O
a O
noncytotoxic O
mechanism O
of O
action O
. O
Chronic O
dosing O
and O
sustained O
increases O
in O
hemoglobin O
F O
and O
total O
hemoglobin O
levels O
may O
be O
possible O
. O
Further O
studies O
in O
SSD O
and O
thalassemia O
are O
indicated O
. O

5-dimethylaminonaphthalene-1sulfonyl O
(dansyl) O
Glu-Gly-Arg-(DEGR)-chloromethylketone O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Activation-dependent O
exposure O
of O
the O
inter-EGF O
sequence O
Leu83-Leu88 O
in O
factor O
Xa O
mediates O
ligand O
binding O
to O
effector O
cell O
protease O
receptor-1.Binding O
of O
factor O
Xa O
to O
human O
umbilical O
vein O
endothelial O
cells O
(HUVEC) O
is O
contributed O
by O
effector O
cell O
protease O
receptor-1 O
(EPR-1) O
. O
The O
structural O
requirements O
of O
this O
recognition O
were O
investigated O
. O
Factor O
Xa O
or O
catalytically O
inactive O
5-dimethylaminonaphthalene-1sulfonyl O
(dansyl) O
Glu-Gly-Arg-(DEGR)-chloromethylketone- O
factor B
Xa I
bound O
indistinguishably O
to O
HUVEC O
and O
EPR-1 O
transfectants O
, O
and O
inhibited O
equally O
well O
the O
binding O
of O
125I-factor O
Xa O
to O
these O
cells O
. O
Similarly O
, O
factor O
Xa O
active O
site O
inhibitors O
TAP O
or O
NAP5 O
did O
not O
reduce O
ligand O
binding O
to O
EPR-1 O
. O
A O
factor O
X O
peptide O
duplicating O
the O
inter-EGF O
sequence O
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- O
(Gly) O
inhibited O
factor O
V/Va-independent O
prothrombin O
activation O
by O
HUVEC O
and O
blocked O
binding O
of O
125I-factor O
Xa O
to O
these O
cells O
in O
a O
dose-dependent O
manner O
(IC50 O
approximately O
20-40 O
microM) O
. O
In O
contrast O
, O
none O
of O
the O
other O
factor O
X O
peptides O
tested O
or O
a O
control O
peptide O
with O
the O
inter-EGF O
sequence O
in O
scrambled O
order O
was O
effective O
. O
A O
recombinant O
chimeric O
molecule O
expressing O
the O
factor O
X O
sequence O
Leu83-Leu88 O
within O
a O
factor O
IX O
backbone O
inhibited O
binding O
of O
125I-factor O
Xa O
to O
HUVEC O
and O
EPR-1 O
transfectants O
in O
a O
dose-dependent O
fashion O
, O
while O
recombinant O
factor O
IX O
or O
plasma O
IXa O
had O
no O
effect O
. O
An O
antibody O
generated O
against O
the O
factor O
X O
peptide O
83-88 O
, O
and O
designated O
JC15 O
, O
inhibited O
125I-factor O
Xa O
binding O
to O
HUVEC O
. O
The O
JC15 O
antibody O
bound O
to O
factor O
Xa O
and O
the O
recombinant O
IX/X83-88 O
chimera O
in O
a O
concentration O
dependent O
manner O
, O
while O
no O
specific O
reactivity O
with O
factors O
X O
or O
IXa O
was O
observed O
. O
Furthermore O
, O
binding O
of O
125I-factor O
Xa O
to O
immobilized O
JC15 O
was O
inhibited O
by O
molar O
excess O
of O
unlabeled O
factor O
Xa O
, O
but O
not O
by O
comparable O
concentrations O
of O
factors O
X O
or O
IXa O
. O
These O
findings O
identify O
the O
inter-EGF O
sequence O
Leu83-Leu88 O
in O
factor O
Xa O
as O
a O
novel O
recognition O
site O
for O
EPR-1 O
, O
and O
suggest O
its O
potential O
role O
as O
a O
protease O
activation-dependent O
neo-epitope O
. O
This O
interacting O
motif O
may O
help O
elucidate O
the O
contribution O
of O
factor O
Xa O
to O
cellular O
assembly O
of O
coagulation O
and O
vascular O
injury O
. O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 O
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL B
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Juglone O
, O
isolated O
from O
Juglans O
mandshurica O
Maxim O
, O
induces O
apoptosis O
via O
down-regulation O
of O
AR O
expression O
in O
human O
prostate O
cancer O
LNCaP O
cells.Juglone O
is O
a O
natural O
compound O
which O
has O
been O
isolated O
from O
Juglans O
mandshurica O
Maxim O
. O
Recent O
studies O
have O
shown O
that O
juglone O
had O
various O
pharmacological O
effects O
such O
as O
anti-viral O
, O
anti-bacterial O
and O
anti-cancer O
. O
However O
, O
its O
anti-cancer O
activity O
on O
human O
prostate O
cancer O
LNCaP O
cell O
has O
not O
been O
examined O
. O
Thus O
, O
the O
current O
study O
was O
designed O
to O
elucidate O
the O
molecular O
mechanism O
of O
apoptosis O
induced O
by O
juglone O
in O
androgen-sensitive O
prostate O
cancer O
LNCaP O
cells O
. O
MTT O
assay O
was O
performed O
to O
examine O
the O
anti-proliferative O
effect O
of O
juglone O
. O
Occurrence O
of O
apoptosis O
was O
detected O
by O
Hoechst O
33342 O
staining O
and O
flow O
cytometry O
in O
LNCaP O
cells O
treated O
with O
juglone O
for O
24h O
. O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
( O
PSA) B
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR O
expression O
. O
Therefore O
, O
our O
results O
indicated O
that O
juglone O
may O
be O
a O
potential O
candidate O
of O
drug O
for O
androgen-sensitive O
prostate O
cancer O
. O

d-methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation O
. O
Serotonin B
transporter I
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT O
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O
behavioral O
, O
neural O
and O
cognitive O
demand O
. O
In O
autoshaping O
task O
a O
dose-response O
curve O
for O
METH O
was O
determined O
. O
METH O
(1.0mg/kg) O
impaired O
short-term O
memory O
(STM; O
lasting O
less O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping O
, O
indicating O
that O
METH O
had O
long-lasting O
effects O
in O
the O
latter O
task O
. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT O
in O
autoshaping O
new O
untrained O
vs O
. O
trained O
treated O
(METH O
, O
FLX O
, O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT O
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH O
SERT O
binding O
in O
several O
areas O
including O
hippocampus O
and O
cortex O
decreased O
, O
more O
remarkably O
in O
the O
trained O
animals O
. O
In O
contrast O
, O
FLX O
improved O
memory O
, O
increased O
SERT O
binding O
, O
prevented O
the O
METH O
amnesic O
effect O
and O
re-established O
the O
SERT O
binding O
. O
In O
general O
, O
memory O
and O
amnesia O
seemed O
to O
make O
SERT O
more O
vulnerable O
to O
drugs O
effects O
. O

Aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein B
kinase I
D1 I
-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells.Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O
network O
(TGN) O
through O
activation O
of O
phosphatidylinositol O
4-kinaseIIIβ O
(PI4KIIIβ) O
. O
We O
report O
rapid O
ENaCγ O
translocation O
to O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O
cortical O
collecting O
duct O
cells O
, O
which O
was O
significantly O
impaired O
in O
PKD1 O
shRNA-mediated O
knockdown O
cells O
. O
In O
PKD1-deficient O
cells O
, O
the O
ouabain-sensitive O
current O
was O
significantly O
reduced O
and O
Na(+)/K(+)-ATPase O
α O
and O
β O
subunits O
showed O
aberrant O
localization O
. O
PKD1 O
and O
PI4KIIIβ O
localize O
to O
the O
TGN O
, O
and O
aldosterone O
induced O
an O
interaction O
between O
PKD1 O
and O
PI4KIIIβ O
following O
aldosterone O
treatment O
. O
This O
study O
reveals O
a O
novel O
mechanism O
for O
rapid O
regulation O
of O
ENaC O
and O
the O
Na(+)/K(+)-ATPase O
, O
via O
directed O
trafficking O
through O
PKD1-PI4KIIIβ O
signalling O
at O
the O
level O
of O
the O
TGN O
. O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive B
nitric-oxide I
synthase I
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

celecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 O
inhibitors O
has O
not O
been O
clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 B
inhibitors O
celecoxib O
and O
rofecoxib O
. O
METHODS O
: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O
(FDA) O
Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
renal O
failure O
submitted O
to O
the O
FDA O
. O
A O
MEDLINE O
search O
of O
the O
English O
language O
literature O
was O
also O
performed O
to O
identify O
published O
cases O
of O
renal O
failure O
associated O
with O
celecoxib O
and O
rofecoxib O
. O
RESULTS O
: O
One O
hundred O
twenty-two O
and O
142 O
domestic O
US O
cases O
of O
celecoxib O
and O
rofecoxib-associated O
renal O
failure O
, O
respectively O
, O
were O
identified O
in O
the O
AERS O
database O
. O
The O
literature O
search O
identified O
19 O
cases O
of O
acute O
renal O
impairment O
in O
association O
with O
celecoxib O
and O
rofecoxib O
. O
In O
addition O
, O
drug O
regulatory O
authorities O
in O
the O
UK O
, O
Canada O
, O
and O
Australia O
have O
received O
about O
50 O
reports O
of O
renal O
failure O
with O
celecoxib O
and O
rofecoxib O
. O
Descriptive O
statistics O
of O
the O
AERS O
cases O
have O
been O
summarised O
in O
this O
report O
. O
CONCLUSIONS O
: O
Data O
from O
AERS O
and O
published O
case O
reports O
suggest O
that O
use O
of O
both O
these O
drugs O
is O
associated O
with O
renal O
effects O
similar O
to O
that O
of O
conventional O
nonselective O
NSAIDs O
. O
Physicians O
should O
be O
aware O
that O
serious O
or O
life-threatening O
renal O
failure O
has O
been O
reported O
in O
patients O
with O
normal O
or O
impaired O
renal O
function O
after O
short-term O
therapy O
with O
celecoxib O
and O
rofecoxib O
. O
Patients O
at O
greatest O
risk O
for O
renal O
injury O
are O
those O
with O
pre-existing O
renal O
impairment O
, O
heart O
failure O
, O
liver O
dysfunction O
, O
those O
taking O
diuretics O
and/or O
ACE O
inhibitors O
, O
and O
the O
elderly O
. O
Kidney O
function O
should O
be O
monitored O
closely O
for O
any O
signs O
of O
potential O
renal O
injuries O
soon O
after O
initiating O
treatment O
with O
these O
agents O
, O
especially O
in O
high-risk O
populations O
. O
In O
addition O
, O
healthcare O
practitioners O
should O
adequately O
warn O
patients O
of O
the O
signs O
and O
symptoms O
of O
serious O
renal O
toxicity O
, O
and O
of O
the O
need O
for O
them O
to O
see O
their O
physician O
promptly O
if O
they O
occur O
. O
Celecoxib O
and O
rofecoxib O
are O
not O
recommended O
for O
use O
in O
patients O
with O
advanced O
renal O
disease O
. O

cibenzoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) O
exchanger O
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT O
/ O
DAT B
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

tricyclic O
bispyran O
sulfone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase B
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
(SCH O
900229) O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

AMPH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O
VMAT2 O
as O
a O
target O
that O
enables O
the O
rewarding O
and O
addictive O
actions O
of O
these O
drugs O
, O
based O
on O
imaging O
, O
neurochemical O
, O
biochemical O
, O
cell O
biological O
, O
genetic O
, O
and O
immunohistochemical O
evidence O
. O
The O
presence O
of O
VMAT2 O
in O
noradrenergic O
, O
serotoninergic O
, O
histaminergic O
, O
and O
potentially O
trace O
aminergic O
neurons O
invites O
consideration O
of O
a O
wider O
role O
for O
aminergic O
neurotransmission O
in O
AMPH O
and O
COC O
abuse O
and O
addiction O
. O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
is O
a O
target O
for O
modification O
by O
lipid O
electrophiles.Oxidation O
of O
membrane O
phospholipids O
is O
associated O
with O
inflammation O
, O
neurodegenerative O
disease O
, O
and O
cancer O
. O
Oxyradical O
damage O
to O
phospholipids O
results O
in O
the O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation O
. O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O
cloned O
from O
a O
human O
brain O
library O
. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart O
, O
liver O
and O
lung O
. O
Within O
the O
brain O
, O
erg3 O
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal O
, O
parietal O
and O
occipital O
lobes O
. O
Transient O
expression O
of O
erg3 O
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) O
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 O
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 B
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR O
/PDGFR B
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

amiloride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pseudohypoaldosteronism O
type O
1 O
and O
the O
genes O
encoding O
prostasin O
, O
alpha-spectrin O
, O
and O
Nedd4.Pseudohypoaldosteronism O
type O
1 O
(PHA1) O
, O
a O
rare O
disorder O
of O
infancy O
, O
presents O
with O
potential O
life-threatening O
salt O
wasting O
and O
failure O
to O
thrive O
. O
Thus O
far O
, O
PHA1 O
has O
been O
attributed O
to O
mutations O
affecting O
the O
mineralocorticoid O
receptor O
or O
any O
of O
the O
three O
subunits O
assembling O
the O
amiloride-sensitive O
epithelial O
sodium O
channel O
( O
ENaC) B
 O
. O
However O
, O
a O
lot O
of O
patients O
with O
a O
phenotype O
resembling O
PHA1 O
, O
show O
no O
defects O
in O
these O
proteins O
, O
making O
it O
likely O
that O
further O
genes O
are O
involved O
in O
the O
aetiology O
of O
this O
disease O
. O
Recent O
studies O
have O
elucidated O
additional O
participants O
(alpha-spectrin O
and O
members O
of O
the O
families O
of O
transmembrane O
serine O
proteases O
, O
ubiquitin-protein O
ligases O
, O
and O
serum- O
and O
glucocorticoid-regulated O
kinases O
, O
respectively) O
regulating O
and/or O
interacting O
in O
the O
complex O
pathway O
of O
sodium O
retention O
in O
the O
amiloride-sensitive O
distal O
nephron O
. O
This O
led O
us O
to O
investigate O
whether O
PHA1 O
can O
also O
be O
associated O
with O
mutations O
in O
some O
of O
these O
genes O
. O
Our O
data O
suggest O
that O
at O
least O
the O
prostasin O
gene O
might O
be O
excluded O
as O
a O
causative O
locus O
. O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Age O
dependent O
differences O
in O
the O
regulation O
of O
hippocampal O
steroid O
hormones O
and O
receptor O
genes O
: O
relations O
to O
motivation O
and O
cognition O
in O
male O
rats.Estrogen O
and O
estrogenic O
functions O
are O
age-dependently O
involved O
in O
the O
modulation O
of O
learning O
, O
memory O
and O
mood O
in O
female O
humans O
and O
animals O
. O
However O
, O
the O
investigation O
of O
estrogenic O
effects O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone-binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid B
receptors I
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O
respect O
to O
spatial O
learning O
and O
memory O
, O
whereas O
no O
difference O
was O
found O
between O
the O
12-week-old O
and O
24-week-old O
rats O
. O
The O
trained O
8-week-old O
rats O
exhibited O
increased O
gene O
expression O
of O
ERα O
compared O
with O
the O
untrained O
rats O
in O
this O
age O
group O
as O
well O
as O
the O
trained O
12-week-old O
and O
24-week-old O
rats O
. O
The O
concentrations O
of O
estradiol O
and O
testosterone O
, O
however O
, O
were O
generally O
higher O
in O
the O
24-week-old O
rats O
than O
in O
the O
8-week-old O
and O
12-week-old O
rats O
. O
The O
ERα O
mRNA O
concentrations O
correlated O
positively O
with O
behavior O
that O
indicate O
general O
learning O
motivation O
. O
These O
results O
suggest O
a O
specific O
role O
of O
ERα O
in O
the O
age-related O
differences O
in O
motivation O
and O
subsequent O
success O
in O
the O
task O
. O
Thus O
, O
estrogen O
and O
estrogenic O
functions O
may O
play O
a O
more O
prominent O
role O
in O
young O
male O
behavior O
and O
development O
than O
has O
been O
previously O
assumed O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Drug O
binding O
interactions O
in O
the O
inner O
cavity O
of O
HERG O
channels O
: O
molecular O
insights O
from O
structure-activity O
relationships O
of O
clofilium O
and O
ibutilide O
analogs.Block O
of O
human O
ether-a-go-go O
related O
gene O
(hERG) O
K(+) O
channels O
by O
otherwise O
useful O
drugs O
is O
the O
most O
common O
cause O
of O
long O
QT O
syndrome O
, O
a O
disorder O
of O
cardiac O
repolarization O
that O
predisposes O
patients O
to O
potentially O
fatal O
arrhythmias O
. O
This O
undesirable O
long O
QT O
side O
effect O
has O
been O
a O
major O
reason O
for O
the O
withdrawal O
of O
medications O
from O
the O
pharmaceutical O
market O
. O
Understanding O
the O
molecular O
basis O
of O
hERG O
block O
is O
therefore O
essential O
to O
facilitate O
the O
design O
of O
safe O
drugs O
. O
Binding O
sites O
for O
hERG B
blockers O
have O
been O
mapped O
within O
the O
inner O
cavity O
of O
the O
channel O
and O
include O
aromatic O
residues O
in O
the O
S6 O
helix O
(Tyr-652 O
, O
Phe-656) O
and O
residues O
in O
the O
pore O
helix O
(Thr-623 O
, O
Ser-624 O
, O
Val-625) O
. O
We O
used O
mutagenesis O
of O
these O
residues O
, O
combined O
with O
an O
investigation O
of O
hERG O
block O
by O
close O
analogs O
of O
clofilium O
and O
ibutilide O
, O
to O
assess O
how O
specific O
alterations O
in O
drug O
structure O
affected O
potency O
and O
binding O
interactions O
. O
Although O
changing O
the O
basic O
nitrogen O
from O
quaternary O
to O
tertiary O
accelerated O
the O
onset O
of O
block O
, O
the O
IC(50) O
and O
kinetics O
for O
recovery O
from O
block O
were O
similar O
. O
In O
contrast O
, O
analogs O
with O
different O
para-substituents O
on O
the O
phenyl O
ring O
had O
significantly O
different O
potencies O
for O
wild-type O
hERG O
block O
. O
The O
highest O
potency O
was O
achieved O
with O
polar O
or O
electronegative O
para-substituents O
, O
whereas O
neutral O
para-substituents O
had O
potencies O
more O
than O
100-fold O
lower O
. O
Results O
from O
mutagenesis O
and O
molecular O
modeling O
studies O
suggest O
that O
phenyl O
ring O
para-substituents O
influence O
drug O
interactions O
with O
Thr-623 O
, O
Ser-624 O
, O
and O
Tyr-652 O
and O
strongly O
affect O
binding O
affinity O
. O
Together O
, O
these O
findings O
suggest O
that O
modifying O
the O
para-substituent O
could O
be O
a O
useful O
strategy O
for O
reducing O
hERG O
potency O
and O
increasing O
the O
safety O
margin O
of O
compounds O
in O
development O
. O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET O
/ O
DAT B
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

bromfenac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6- B
catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

carbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Selective O
inhibitors O
and O
tailored O
activity O
probes O
for O
lipoprotein-associated O
phospholipase O
A(2).Lipoprotein-associated O
phospholipase O
A(2) O
(Lp-PLA(2) O
or O
PLA(2)G7) O
binds O
to O
low-density O
lipoprotein O
(LDL) O
particles O
, O
where O
it O
is O
thought O
to O
hydrolyze O
oxidatively O
truncated O
phospholipids O
. O
Lp-PLA(2) O
has O
also O
been O
implicated O
as O
a O
pro-tumorigenic O
enzyme O
in O
human O
prostate O
cancer O
. O
Several O
inhibitors O
of O
Lp-PLA(2) O
have O
been O
described O
, O
including O
darapladib O
, O
which O
is O
currently O
in O
phase O
3 O
clinical O
development O
for O
the O
treatment O
of O
atherosclerosis O
. O
The O
selectivity O
that O
darapladib O
and O
other O
Lp-PLA(2) O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) B
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

etomidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Activation O
of O
alpha O
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidate.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor O
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O
intraperitoneal O
injection O
of O
etomidate O
in O
wild-type O
and O
in O
alpha2A-receptor-deficient O
mice O
, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate O
in O
mice O
does O
not O
require O
the O
alpha2A-receptor O
subtype O
. O
Intravenous O
injection O
of O
etomidate O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- B
and I
alpha2C-receptors I
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors O
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O
. O

Clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Agmatine O
: O
an O
endogenous O
clonidine-displacing O
substance O
in O
the O
brain.Clonidine O
, O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha B
2-adrenergic I
and I
imidazoline I
receptors I
. O
The O
endogenous O
ligand O
for O
imidazoline O
receptors O
may O
be O
a O
clonidine-displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
, O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
, O
a O
noncatecholamine O
ligand O
at O
alpha O
2-adrenergic O
receptors O
and O
may O
act O
as O
a O
neurotransmitter O
. O

N O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 B
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sitagliptin.Sitagliptin O
, O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin B
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) O
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O
glipizide O
. O
Sitagliptin O
had O
a O
generally O
neutral O
effect O
on O
bodyweight O
. O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Low-Dose O
Dexamethasone O
Treatment O
Promotes O
Pro-Survival O
Signalling O
Pathway O
In O
Adult O
Rat O
Prefrontal O
Cortex.Synthetic O
glucocorticoid O
dexamethasone O
(DEX) O
, O
a O
highly O
potent O
anti-inflammatory O
and O
immunosuppressive O
agent O
, O
is O
widely O
used O
in O
treatments O
of O
brain O
cancer O
, O
inflammatory O
and O
autoimmune O
diseases O
. O
The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low-dose O
subchronic O
DEX O
treatment O
(100 O
μg/kg O
for O
8 O
consecutive O
days) O
exerts O
long-term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O
prefrontal O
cortex O
(PFC) O
by O
examining O
the O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 O
protein O
and O
enhanced O
Bcl-2 B
/ O
Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX-treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O
change O
apoptotic O
markers O
in O
rat O
PFC O
. O
This O
mechanism O
might O
be O
relevant O
for O
DEX-induced O
apoptosis O
resistance O
observed O
during O
and O
after O
chemotherapy O
of O
patients O
with O
brain O
tumours O
. O
© O
2013 O
British O
Society O
for O
Neuroendocrinology O
. O

Ozone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Effects O
of O
ozone O
and O
fine O
particulate O
matter O
(PM(2.5)) O
on O
rat O
system O
inflammation O
and O
cardiac O
function.In O
order O
to O
understand O
the O
toxic O
mechanisms O
of O
cardiovascular O
system O
injuries O
induced O
by O
ambient O
PM(2.5) O
and/or O
ozone O
, O
a O
subacute O
toxicological O
animal O
experiment O
was O
designed O
with O
exposure O
twice O
a O
week O
for O
3 O
continuous O
weeks O
. O
Wistar O
rats O
were O
randomly O
categorized O
into O
8 O
groups O
(n=6) O
: O
1 O
control O
group O
, O
3 O
groups O
exposed O
to O
fine O
particulate O
matters O
(PM(2.5)) O
alone O
at O
3 O
doses O
(0.2 O
, O
0.8 O
, O
or O
3.2 O
mg/rat) O
, O
1 O
group O
to O
ozone O
(0.81 O
ppm) O
alone O
and O
3 O
groups O
to O
ozone O
plus O
PM(2.5) O
at O
3 O
doses O
(0.2 O
, O
0.8 O
, O
or O
3.2 O
mg/rat) O
. O
Heart O
rate O
(HR) O
and O
electrocardiogram O
(ECG) O
was O
monitored O
at O
approximately O
24-h O
both O
after O
the O
3rd O
exposure O
and O
the O
last O
(6th) O
exposure O
, O
and O
systolic O
blood O
pressure O
(SBP) O
was O
monitored O
at O
approximately O
24-h O
after O
the O
6th O
exposure O
. O
Biomarkers O
of O
systemic O
inflammation O
and O
injuries O
(CRP O
, O
IL-6 O
, O
LDH O
, O
CK) O
, O
heart O
oxidative O
stress O
(MDA O
, O
SOD) O
and O
endothelial O
function O
(ET-1 O
, O
VEGF) O
were O
analyzed O
after O
the O
6th O
exposure O
. O
Additionally O
, O
myocardial O
ultrastructural O
alterations O
were O
observed O
under O
transmission O
electron O
microscopy O
(TEM) O
for O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD B
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O
exposure O
could O
cause O
inflammation O
, O
endothelial O
function O
and O
ANS O
injuries O
, O
and O
ozone O
potentiated O
these O
effects O
induced O
by O
PM(2.5) O
. O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos B
 O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

terbinafine O
acts O
as O
NOT O
for O
what O
entity O
? O
Molecular O
mechanism O
of O
terbinafine O
resistance O
in O
Saccharomyces O
cerevisiae.Ten O
mutants O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
resistant O
to O
the O
antimycotic O
terbinafine O
were O
isolated O
after O
chemical O
or O
UV O
mutagenesis O
. O
Molecular O
analysis O
of O
these O
mutants O
revealed O
single O
base O
pair O
exchanges O
in O
the O
ERG1 O
gene O
coding O
for O
squalene O
epoxidase O
, O
the O
target O
of O
terbinafine O
. O
The O
mutants O
did O
not O
show O
cross-resistance O
to O
any O
of O
the O
substrates O
of O
various O
pleiotropic O
drug O
resistance O
efflux O
pumps O
tested O
. O
The O
ERG1 O
mRNA O
levels O
in O
the O
mutants O
did O
not O
differ O
from O
those O
in O
the O
wild-type O
parent O
strains O
. O
Terbinafine O
resistance O
was O
transmitted O
with O
the O
mutated O
alleles O
in O
gene O
replacement O
experiments O
, O
proving O
that O
single O
amino O
acid O
substitutions O
in O
the O
Erg1 O
protein O
were O
sufficient O
to O
confer O
the O
resistance O
phenotype O
. O
The O
amino O
acid O
changes O
caused O
by O
the O
point O
mutations O
were O
clustered O
in O
two O
regions O
of O
the O
Erg1 O
protein O
. O
Seven O
mutants O
carried O
the O
amino O
acid O
substitutions O
F402L O
(one O
mutant) O
, O
F420L O
(one O
mutant) O
, O
and O
P430S O
(five O
mutants) O
in O
the O
C-terminal O
part O
of O
the O
protein; O
and O
three O
mutants O
carried O
an O
L251F O
exchange O
in O
the O
central O
part O
of O
the O
protein O
. O
Interestingly O
, O
all O
exchanges O
identified O
involved O
amino O
acids O
which O
are O
conserved O
in O
the O
squalene O
epoxidases O
of O
yeasts O
and O
mammals O
. O
Two O
mutations O
that O
were O
generated O
by O
PCR O
mutagenesis O
of O
the O
ERG1 B
gene O
and O
that O
conferred O
terbinafine O
resistance O
mapped O
in O
the O
same O
regions O
of O
the O
Erg1 O
protein O
, O
with O
one O
resulting O
in O
an O
L251F O
exchange O
and O
the O
other O
resulting O
in O
an O
F433S O
exchange O
. O
The O
results O
strongly O
indicate O
that O
these O
regions O
are O
responsible O
for O
the O
interaction O
of O
yeast O
squalene O
epoxidase O
with O
terbinafine O
. O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B B
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

gemcitabine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Cellular O
and O
pharmacogenetics O
foundation O
of O
synergistic O
interaction O
of O
pemetrexed O
and O
gemcitabine O
in O
human O
non-small-cell O
lung O
cancer O
cells.Gemcitabine O
and O
pemetrexed O
are O
effective O
agents O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
(NSCLC) O
, O
and O
the O
present O
study O
investigates O
cellular O
and O
genetic O
aspects O
of O
their O
interaction O
against O
A549 O
, O
Calu-1 O
, O
and O
Calu-6 O
cells O
. O
Cells O
were O
treated O
with O
pemetrexed O
and O
gemcitabine O
, O
and O
their O
interaction O
was O
assessed O
using O
the O
combination O
index O
. O
The O
role O
of O
drug O
metabolism O
in O
gemcitabine O
cytotoxicity O
was O
examined O
with O
inhibitors O
of O
deoxycytidine O
kinase O
(dCK) O
, O
5'-nucleotidase O
, O
and O
cytidine O
deaminase O
, O
whereas O
the O
role O
of O
pemetrexed O
targets O
, O
thymidylate O
synthase O
(TS) O
, O
dihydrofolate O
reductase O
(DHFR) O
, O
and O
glycinamide O
ribonucleotide O
formyltransferase O
(GARFT) O
in O
drug O
chemosensitivity O
was O
analyzed O
in O
cytotoxicity O
rescue O
studies O
. O
The O
effect O
of O
gemcitabine O
and O
pemetrexed O
on O
Akt O
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay O
, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug O
. O
Synergistic O
cytotoxicity O
was O
demonstrated O
, O
and O
pemetrexed O
significantly O
decreased O
the O
amount O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK O
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O
of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK B
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O
. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt O
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O
genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed O
enhances O
dCK O
and O
hENT1 O
expression O
, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O
for O
rational O
development O
of O
chemotherapy O
combinations O
. O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Locally O
administered O
prostaglandin O
E2 O
prevents O
aeroallergen-induced O
airway O
sensitization O
in O
mice O
through O
immunomodulatory O
mechanisms.Prostaglandin O
E2 O
attenuates O
airway O
pathology O
in O
asthmatic O
patients O
and O
exerts O
a O
protective O
effect O
in O
antigen-sensitized O
mice O
when O
administered O
systemically O
. O
We O
aimed O
to O
establish O
the O
consequences O
of O
intranasal O
PGE2 O
administration O
on O
airway O
reactivity O
to O
aeroallergens O
in O
mice O
and O
reveal O
the O
underlying O
immunoinflammatory O
mechanisms O
. O
PGE2 O
was O
administered O
either O
daily O
during O
a O
10-day O
exposure O
to O
house O
dust O
mite O
(HDM) O
extracts O
or O
for O
limited O
intervals O
. O
Airway O
hyperreactivity O
was O
measured O
by O
whole-body O
and O
invasive O
plethysmography O
. O
The O
phenotypes O
of O
lung O
immune O
cells O
and O
cytokine O
production O
were O
analysed O
by O
flow O
cytometry O
and O
ELISA O
, O
respectively O
. O
Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 O
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM O
. O
Lung O
inflammation O
, O
IL-4 O
production O
, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short-term O
treatment O
with O
PGE2 O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 B
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O
a O
shift O
in O
the O
balance O
of O
dendritic O
cells O
towards O
a O
tolerogenic O
profile O
. O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
characterization O
of O
a O
novel O
human O
phosphodiesterase O
that O
hydrolyzes O
both O
cAMP O
and O
cGMP O
(PDE10A).cDNA O
encoding O
a O
novel O
phosphodiesterase O
(PDE) O
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A O
. O
The O
deduced O
amino O
acid O
sequence O
contains O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O
the O
amino-terminal O
portion O
of O
the O
molecule O
and O
a O
catalytic O
domain O
that O
is O
16-47% O
identical O
in O
amino O
acid O
sequence O
to O
those O
of O
other O
PDE O
families O
. O
Recombinant O
PDE10A B
transfected O
and O
expressed O
in O
COS-7 O
cells O
hydrolyzed O
cAMP O
and O
cGMP O
with O
Km O
values O
of O
0.26 O
and O
7.2 O
microM O
, O
respectively O
, O
and O
Vmax O
with O
cGMP O
was O
almost O
twice O
that O
with O
cAMP O
. O
Of O
the O
PDE O
inhibitors O
tested O
, O
dipyridamole O
was O
most O
effective O
, O
with O
IC50 O
values O
of O
1.2 O
and O
0.45 O
microM O
for O
inhibition O
of O
cAMP O
and O
cGMP O
hydrolysis O
, O
respectively O
. O
cGMP O
inhibited O
hydrolysis O
of O
cAMP O
, O
and O
cAMP O
inhibited O
cGMP O
hydrolysis O
with O
IC50 O
values O
of O
14 O
and O
0.39 O
microM O
, O
respectively O
. O
Thus O
, O
PDE10A O
exhibited O
properties O
of O
a O
cAMP O
PDE O
and O
a O
cAMP-inhibited O
cGMP O
PDE O
. O
PDE10A O
transcripts O
were O
particularly O
abundant O
in O
the O
putamen O
and O
caudate O
nucleus O
regions O
of O
brain O
and O
in O
thyroid O
and O
testis O
, O
and O
in O
much O
lower O
amounts O
in O
other O
tissues O
. O
The O
PDE10A O
gene O
was O
located O
on O
chromosome O
6q26 O
by O
fluorescent O
in O
situ O
hybridization O
analysis O
. O
PDE10A O
represents O
a O
new O
member O
of O
the O
PDE O
superfamily O
, O
exhibiting O
unique O
kinetic O
properties O
and O
inhibitor O
sensitivity O
. O

guggulsterone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Bile O
acids O
induce O
cdx2 O
expression O
through O
the O
farnesoid O
x O
receptor O
in O
gastric O
epithelial O
cells.Clinical O
and O
experimental O
studies O
showed O
that O
the O
reflux O
of O
bile O
into O
the O
stomach O
contributes O
to O
the O
induction O
of O
intestinal O
metaplasia O
of O
the O
stomach O
and O
gastric O
carcinogenesis O
. O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 B
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

p-bromophenacyl O
bromide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2 B
) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

AICAR O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMP-activated O
protein O
kinase-dependent O
and O
-independent O
mechanisms O
underlying O
in O
vitro O
antiglioma O
action O
of O
compound O
C.We O
investigated O
the O
effect O
of O
compound O
C O
, O
a O
well-known O
inhibitor O
of O
the O
intracellular O
energy O
sensor O
AMP-activated O
protein O
kinase O
(AMPK) O
, O
on O
proliferation O
and O
viability O
of O
human O
U251 O
and O
rat O
C6 O
glioma O
cell O
lines O
. O
Compound O
C O
caused O
G(2)/M O
cell O
cycle O
block O
, O
accompanied O
by O
apoptotic O
glioma O
cell O
death O
characterized O
by O
caspase O
activation O
, O
phosphatidylserine O
exposure O
and O
DNA O
fragmentation O
. O
The O
mechanisms O
underlying O
the O
pro-apoptotic O
action O
of O
compound O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK O
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK B
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O
The O
small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O
and O
apoptosis O
in O
U251 O
glioma O
cells O
. O
In O
conclusion O
, O
our O
data O
indicate O
that O
AMPK O
inhibition O
is O
required O
, O
but O
not O
sufficient O
for O
compound O
C-mediated O
apoptotic O
death O
of O
glioma O
cells O
. O

Fc11a O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
novel O
benzo[d]imidazole O
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 O
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
, O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
, O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 B
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Energy O
depletion O
of O
bovine O
mammary O
epithelial O
cells O
activates O
AMPK O
and O
suppresses O
protein O
synthesis O
through O
inhibition O
of O
mTORC1 O
signaling.The O
molecular O
mechanisms O
by O
which O
cellular O
energy O
status O
regulates O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK O
at O
Thr172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 B
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O
associated O
with O
a O
marked O
increase O
in O
Ser792 O
phosphorylation O
on O
raptor O
. O
Collectively O
, O
the O
results O
suggest O
that O
activation O
of O
AMPK O
represses O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
through O
inhibition O
of O
mTORC1 O
signaling O
. O

LTB(4) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
( O
LTA(4)H) B
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H O
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases O
, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
(IBD) O
. O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Heteromtoxin O
(HmTx) O
, O
a O
novel O
heterodimeric O
phospholipase O
A(2) O
from O
Heterometrus O
laoticus O
scorpion O
venom.Heteromtoxin O
(HmTx) O
is O
a O
group O
III O
phospholipase O
A(2) O
produced O
in O
Heterometrus O
laoticus O
, O
in O
Thailand O
. O
In O
this O
study O
, O
HmTx O
was O
purified O
from O
venom O
by O
separation O
chromatography O
, O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx B
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

p-bromophenacyl O
bromide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 B
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

ketoconazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ketoconazole O
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan.Ambrisentan O
is O
an O
endothelin O
type O
A O
(ET(A))-selective O
receptor O
antagonist O
that O
is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4 O
. O
The O
potential O
for O
ketoconazole O
, O
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4 O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
and O
its O
oxidative O
metabolite O
, O
4-hydroxymethyl O
ambrisentan O
, O
was O
assessed O
in O
an O
open-label O
, O
nonrandomized O
, O
2-period O
, O
single-sequence O
study O
in O
16 O
healthy O
men O
. O
Participants O
received O
a O
single O
dose O
of O
ambrisentan O
10 O
mg O
alone O
and O
after O
4 O
days O
of O
ketoconazole O
400 O
mg O
administered O
once O
daily O
. O
In O
the O
presence O
of O
multiple O
doses O
of O
ketoconazole O
, O
single-dose O
ambrisentan O
AUC(0-infinity) O
estimate O
was O
increased O
by O
35.3% O
, O
whereas O
C(max) O
was O
increased O
by O
20.0% O
. O
For O
the O
4-hydroxymethyl O
ambrisentan O
metabolite O
, O
AUC(0-infinity) O
estimate O
was O
decreased O
by O
4.0% O
, O
whereas O
C(max) O
was O
decreased O
by O
16.5% O
. O
Concomitant O
administration O
of O
ambrisentan O
and O
ketoconazole O
was O
well O
tolerated O
. O
In O
summary O
, O
ketoconazole O
had O
no O
clinically O
significant O
effect O
on O
the O
pharmacokinetics O
or O
safety O
profile O
of O
ambrisentan; O
therefore O
, O
no O
changes O
in O
ambrisentan O
dose O
should O
be O
necessary O
when O
the O
drug O
is O
administered O
concomitantly O
with O
known O
CYP3A4 B
inhibitors O
. O

DEX-P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Time-dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A B
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses O
. O
5 O
. O
Some O
physiological O
compounds O
such O
as O
cytokines O
might O
be O
involved O
in O
decreasing O
the O
CYP3A O
activity O
to O
maintain O
homeostasis O
of O
the O
body O
. O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin B
dependent I
kinase I
2 I
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

Minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Minocycline O
inhibits O
cytochrome O
c O
release O
and O
delays O
progression O
of O
amyotrophic O
lateral O
sclerosis O
in O
mice.Minocycline O
mediates O
neuroprotection O
in O
experimental O
models O
of O
neurodegeneration O
. O
It O
inhibits O
the O
activity O
of O
caspase-1 O
, O
caspase-3 O
, O
inducible O
form O
of O
nitric O
oxide O
synthetase O
(iNOS) O
and O
p38 O
mitogen-activated O
protein O
kinase O
(MAPK) O
. O
Although O
minocycline O
does O
not O
directly O
inhibit O
these O
enzymes O
, O
the O
effects O
may O
result O
from O
interference O
with O
upstream O
mechanisms O
resulting O
in O
their O
secondary O
activation O
. O
Because O
the O
above-mentioned O
factors O
are O
important O
in O
amyotrophic O
lateral O
sclerosis O
(ALS) O
, O
we O
tested O
minocycline O
in O
mice O
with O
ALS O
. O
Here O
we O
report O
that O
minocycline O
delays O
disease O
onset O
and O
extends O
survival O
in O
ALS O
mice O
. O
Given O
the O
broad O
efficacy O
of O
minocycline O
, O
understanding O
its O
mechanisms O
of O
action O
is O
of O
great O
importance O
. O
We O
find O
that O
minocycline O
inhibits O
mitochondrial O
permeability-transition-mediated O
cytochrome O
c O
release O
. O
Minocycline-mediated O
inhibition O
of O
cytochrome B
c I
release O
is O
demonstrated O
in O
vivo O
, O
in O
cells O
, O
and O
in O
isolated O
mitochondria O
. O
Understanding O
the O
mechanism O
of O
action O
of O
minocycline O
will O
assist O
in O
the O
development O
and O
testing O
of O
more O
powerful O
and O
effective O
analogues O
. O
Because O
of O
the O
safety O
record O
of O
minocycline O
, O
and O
its O
ability O
to O
penetrate O
the O
blood-brain O
barrier O
, O
this O
drug O
may O
be O
a O
novel O
therapy O
for O
ALS O
. O

chloramine O
T O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
In O
vitro O
simulation O
of O
therapeutic O
plasmatic O
fibrinolysis.One O
type O
of O
therapy O
for O
thromboembolism O
is O
plasmatic O
thrombolysis O
. O
Several O
plasminogen O
activators O
(PA) O
are O
clinically O
available O
, O
including O
urokinase O
(u-PA) O
, O
tissue O
plasminogen O
activator O
(t-PA) O
, O
streptokinase O
(SK) O
, O
plasminogen-streptokinase-activator-complex O
(PSAC) O
, O
or O
mutants O
of O
t-PA O
such O
as O
reteplase O
(RP) O
or O
tenecteplase O
(TP) O
. O
Therapeutic O
plasmatic O
fibrinolysis O
was O
simulated O
, O
using O
the O
PA O
at O
relevant O
plasma O
concentrations O
, O
and O
plasmin O
(Pli) O
and O
PA O
activities O
were O
determined O
. O
Normal O
citrated O
plasma O
was O
supplemented O
with O
31 O
to O
1,000 O
IU/mL O
u-PA O
, O
0.31 O
to O
20 O
microg/mL O
t-PA O
, O
125 O
to O
4,000 O
IU/mL O
SK O
, O
12.5 O
to O
400 O
U/mL O
PSAC O
, O
125 O
to O
4,000 O
U/mL O
RP O
, O
or O
0.31 O
to O
10 O
microg/mL O
TP O
. O
Ten O
IU/mL O
urokinase O
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O
patients O
, O
that O
was O
previously O
oxidized O
with O
the O
singlet O
oxygen O
(1O2) O
donor O
chloramine O
T O
(CT) O
, O
to O
destroy O
plasmatic B
PAI-1 I
and O
alpha2-antiplasmin O
. O
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C) O
, O
50-microL O
samples O
were O
withdrawn O
and O
added O
to O
100 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT O
. O
For O
determination O
of O
plasmin O
activity O
, O
10 O
microL O
thereof O
was O
incubated O
with O
150 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
100 O
microL O
20 O
mM O
CT O
preoxidized O
(15 O
minutes O
37 O
degrees O
C) O
pooled O
normal O
citrate O
buffered O
EDTA-plasma O
for O
30 O
minutes O
(37 O
degrees O
C) O
. O
For O
determination O
of O
[PA+Pli]-activity O
, O
arginine O
was O
added O
after O
this O
incubation O
. O
25-microL O
6 O
mM O
Val-Leu-Lys-pNA O
were O
added O
and O
deltaA/h O
at O
room O
temperature O
(RT) O
was O
monitored O
, O
using O
a O
microtiterplate O
reader O
. O
[PA+Pli]-Pli O
= O
PA O
. O
The O
PA O
concentration O
required O
to O
induce O
25% O
[ED25] O
of O
the O
maximally O
inducible O
Pli-activity O
in O
plasma O
(= O
1 O
U/mL O
= O
45 O
mg/L O
= O
0.53 O
micromol/L O
active O
Pli; O
deltaA O
= O
363 O
+/- O
8 O
mA/h O
RT) O
after O
10 O
minutes O
(37 O
degrees O
C) O
were O
320 O
IU/mL O
u-PA O
, O
8 O
microg/mL O
t-PA O
, O
140 O
U/mL O
PSAC O
, O
6,000 O
IU/mL O
SK O
, O
720 O
U/mL O
RP O
, O
and O
approximately O
150 O
microg/mL O
TP O
. O
The O
approximate O
activity O
half-lives O
of O
the O
PA O
in O
plasma O
were O
30 O
minutes O
for O
u-PA O
, O
30 O
minutes O
for O
t-PA O
, O
greater O
than O
80 O
minutes O
for O
SK O
, O
greater O
than O
80 O
minutes O
for O
PSAC O
, O
50 O
minutes O
for O
RP O
, O
and O
80 O
minutes O
for O
TP O
. O
The O
present O
study O
shows--for O
the O
first O
time--a O
combined O
kinetic O
in O
vitro O
simulation O
of O
the O
plasmatic O
activity O
of O
six O
different O
PAs O
. O
At O
clinically O
used O
concentrations O
, O
RP O
induces O
the O
highest O
plasmatic O
Pli O
activity O
. O
Due O
to O
unselective O
generation O
of O
plasmin O
in O
plasma O
, O
all O
PA O
are O
of O
some O
danger O
in O
inducing O
severe O
hemorrhagias O
. O
Clinical O
thrombolysis O
might O
be O
improved O
by O
usage O
of O
more O
physiologic O
activators O
of O
thrombolysis O
, O
such O
as O
activators O
of O
polymorphonuclear O
neutrophils O
. O

Pranlukast O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pranlukast O
, O
a O
leukotriene O
receptor O
antagonist O
, O
inhibits O
interleukin-5 O
production O
via O
a O
mechanism O
distinct O
from O
leukotriene O
receptor O
antagonism.BACKGROUND O
: O
Pranlukast O
, O
a O
cysteinyl O
leukotriene O
receptor O
1 O
( O
CysLTR1) B
antagonist O
, O
inhibits O
not O
only O
airway O
smooth O
muscle O
contraction O
, O
but O
also O
allergic O
inflammation O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
mechanism O
of O
pranlukast-induced O
interleukin-5 O
(IL-5) O
inhibition O
in O
allergic O
inflammation O
. O
METHODS O
: O
Surgically O
resected O
human O
lung O
tissue O
was O
passively O
sensitized O
in O
vitro O
with O
mite-allergen-sensitized O
sera O
, O
followed O
by O
stimulation O
with O
mite O
allergen O
after O
pretreatment O
of O
the O
tissue O
with O
pranlukast O
, O
dexamethasone O
, O
or O
both O
. O
The O
IL-5 O
protein O
level O
in O
the O
culture O
medium O
was O
measured O
, O
and O
in O
situ O
hybridization O
of O
IL-5 O
and O
CysLTR1 O
mRNA O
was O
performed O
using O
lung O
tissues O
. O
RESULTS O
: O
Pretreatment O
of O
lung O
tissues O
with O
pranlukast O
alone O
significantly O
decreased O
the O
amount O
of O
IL-5 O
protein O
in O
the O
culture O
medium O
by O
40% O
. O
The O
combination O
of O
pranlukast O
and O
dexamethasone O
synergistically O
enhanced O
this O
effect O
. O
Quantitative O
in O
situ O
hybridization O
with O
image O
analysis O
revealed O
abundant O
expression O
of O
IL-5 O
mRNA O
in O
eosinophils O
, O
lymphocytes O
, O
and O
mast O
cells O
in O
sensitized O
and O
allergen-stimulated O
lung O
tissues O
. O
CysLTR1 O
mRNA O
was O
detected O
in O
macrophages O
, O
smooth O
muscle O
cells O
, O
eosinophils O
, O
and O
mast O
cells O
, O
but O
was O
less O
expressed O
in O
lymphocytes O
. O
Pranlukast-induced O
inhibition O
of O
IL-5 O
mRNA O
expression O
was O
noted O
in O
various O
cells O
, O
irrespective O
of O
their O
CysLTR1 O
mRNA O
expression O
status O
. O
In O
addition O
, O
cysteinyl O
leukotrienes O
per O
se O
failed O
to O
upregulate O
the O
IL-5 O
production O
. O
CONCLUSION O
: O
Our O
results O
indicate O
that O
pranlukast O
inhibits O
IL-5 O
synthesis O
via O
a O
mechanism O
distinct O
from O
CysLTR1 O
antagonism O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF B
/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
Activity O
of O
Swertiamarin O
is O
due O
to O
an O
Active O
Metabolite O
, O
Gentianine O
, O
that O
Upregulates O
PPAR-γ O
Gene O
Expression O
in O
3T3-L1 O
cells.We O
have O
previously O
shown O
the O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ O
, O
GLUT-4 B
and O
adiponectin O
. O
These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Nizatidine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidine O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
(LY139037) O
, O
a O
selective O
histamine B
H2-receptor I
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O
bullfrog O
. O
Nizatidine O
was O
8.9 O
times O
as O
active O
as O
cimetidine O
on O
basal O
acid O
secretion O
of O
the O
chronic O
gastric O
fistula O
rats O
after O
s.c O
. O
administration O
. O
Against O
acid O
secretion O
from O
the O
vagally O
innervated O
gastric O
fistula O
and O
Heidenhain O
pouch O
of O
dogs O
stimulated O
with O
submaximal O
doses O
of O
histamine O
, O
methacholine O
and O
gastrin O
, O
nizatidine O
was O
, O
respectively O
, O
6.5 O
, O
5 O
and O
4.7 O
times O
as O
active O
as O
cimetidine O
by O
i.v O
. O
administration O
. O
Nizatidine O
was O
very O
well O
absorbed O
from O
the O
gut O
and O
was O
5 O
to O
10 O
times O
as O
active O
as O
cimetidine O
on O
gastric O
acid O
secretion O
of O
dogs O
induced O
by O
submaximal O
and O
maximal O
doses O
of O
histamine O
when O
given O
p.o O
. O
Equal O
molar O
doses O
of O
nizatidine O
showed O
equal O
peak O
effects O
when O
given O
i.v. O
, O
s.c O
. O
or O
i.m O
. O
Pharmacological O
data O
indicate O
that O
nizatidine O
is O
safe O
and O
effective O
as O
an O
agent O
for O
the O
control O
of O
excessive O
gastric O
acid O
secretion O
. O

PI(4,5)P2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cis-silencing O
of O
PIP5K1B O
evidenced O
in O
Friedreich's O
ataxia O
patient O
cells O
results O
in O
cytoskeleton O
anomalies.Friedreich's O
ataxia O
(FRDA) O
is O
a O
progressive O
neurodegenerative O
disease O
characterized O
by O
ataxia O
, O
variously O
associating O
heart O
disease O
, O
diabetes O
mellitus O
and/or O
glucose O
intolerance O
. O
It O
results O
from O
intronic O
expansion O
of O
GAA O
triplet O
repeats O
at O
the O
FXN O
locus O
. O
Homozygous O
expansions O
cause O
silencing O
of O
the O
FXN O
gene O
and O
subsequent O
decreased O
expression O
of O
the O
encoded O
mitochondrial O
frataxin O
. O
Detailed O
analyses O
in O
fibroblasts O
and O
neuronal O
tissues O
from O
FRDA O
patients O
have O
revealed O
profound O
cytoskeleton O
anomalies O
. O
So O
far O
, O
however O
, O
the O
molecular O
mechanism O
underlying O
these O
cytoskeleton O
defects O
remains O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol B
4-phosphate I
5-kinase I
β I
type I
I I
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O
suppressed O
this O
phenotype O
in O
FRDA O
cells O
. O
In O
addition O
to O
provide O
new O
insights O
into O
the O
consequences O
of O
the O
FXN O
gene O
expansion O
, O
these O
findings O
raise O
the O
question O
whether O
PIP5K1B O
silencing O
may O
contribute O
to O
the O
variable O
manifestation O
of O
this O
complex O
disease O
. O

methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
( O
VMAT2) B
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 O
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

prostaglandin O
E O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated B
(HVA) I
Ca2+ I
channels I
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Genome-wide O
screen O
for O
modulation O
of O
hepatic O
apolipoprotein O
A-I O
(ApoA-I) O
secretion.Control O
of O
plasma O
cholesterol O
levels O
is O
a O
major O
therapeutic O
strategy O
for O
management O
of O
coronary O
artery O
disease O
(CAD) O
. O
Although O
reducing O
LDL O
cholesterol O
(LDL-c) O
levels O
decreases O
morbidity O
and O
mortality O
, O
this O
therapeutic O
intervention O
only O
translates O
into O
a O
25-40% O
reduction O
in O
cardiovascular O
events O
. O
Epidemiological O
studies O
have O
shown O
that O
a O
high O
LDL-c O
level O
is O
not O
the O
only O
risk O
factor O
for O
CAD; O
low O
HDL O
cholesterol O
(HDL-c) O
is O
an O
independent O
risk O
factor O
for O
CAD O
. O
Apolipoprotein O
A-I O
(ApoA-I) O
is O
the O
major O
protein O
component O
of O
HDL-c O
that O
mediates O
reverse O
cholesterol O
transport O
from O
tissues O
to O
the O
liver O
for O
excretion O
. O
Therefore O
, O
increasing O
ApoA-I O
levels O
is O
an O
attractive O
strategy O
for O
HDL-c O
elevation O
. O
Using O
genome-wide O
siRNA O
screening O
, O
targets O
that O
regulate O
hepatocyte O
ApoA-I O
secretion O
were O
identified O
through O
transfection O
of O
21,789 O
siRNAs O
into O
hepatocytes O
whereby O
cell O
supernatants O
were O
assayed O
for O
ApoA-I O
. O
Approximately O
800 O
genes O
were O
identified O
and O
triaged O
using O
a O
convergence O
of O
information O
, O
including O
genetic O
associations O
with O
HDL-c O
levels O
, O
tissue-specific O
gene O
expression O
, O
druggability O
assessments O
, O
and O
pathway O
analysis O
. O
Fifty-nine O
genes O
were O
selected O
for O
reconfirmation; O
40 O
genes O
were O
confirmed O
. O
Here O
we O
describe O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I B
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

L-arginine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase B
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dopamine O
D(2) O
receptor-induced O
COX-2-mediated O
production O
of O
prostaglandin O
E(2) O
in O
D(2)-transfected O
Chinese O
hamster O
ovary O
cells O
without O
simultaneous O
administration O
of O
a O
Ca(2+)-mobilizing O
agent.We O
have O
earlier O
demonstrated O
that O
dopamine O
stimulates O
the O
liberation O
of O
the O
prostaglandin O
E(2) O
(PGE(2)) O
precursor O
, O
arachidonic O
acid O
, O
in O
Chinese O
hamster O
ovary O
cells O
transfected O
with O
the O
rat O
dopamine O
D(2) O
receptor O
(long O
isoform) O
, O
also O
without O
concomitant O
administration O
of O
a O
Ca(2+)-releasing O
agent O
[Nilsson O
et O
al. O
, O
Br O
J O
Pharmacol O
1998;124:1651-8] O
. O
In O
the O
present O
report O
, O
we O
show O
that O
dopamine O
, O
under O
the O
same O
conditions O
, O
also O
induces O
a O
concentration-dependent O
increase O
in O
the O
production O
of O
PGE(2) O
, O
with O
a O
maximal O
effect O
of O
235% O
at O
approximately O
100 O
microM O
, O
and O
with O
an O
EC(50) O
of O
794 O
nM O
. O
The O
effect O
was O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
, O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase B
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O
reinforce O
previous O
assumptions O
that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O
this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

palmitoylcarnitine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Structural O
model O
of O
carnitine O
palmitoyltransferase O
I O
based O
on O
the O
carnitine O
acetyltransferase O
crystal.CPT O
I O
( O
carnitine B
palmitoyltransferase I
I) I
catalyses O
the O
conversion O
of O
palmitoyl-CoA O
into O
palmitoylcarnitine O
in O
the O
presence O
of O
L-carnitine O
, O
facilitating O
the O
entry O
of O
fatty O
acids O
into O
mitochondria O
. O
We O
propose O
a O
3-D O
(three-dimensional) O
structural O
model O
for O
L-CPT O
I O
(liver O
CPT O
I) O
, O
based O
on O
the O
similarity O
of O
this O
enzyme O
to O
the O
recently O
crystallized O
mouse O
carnitine O
acetyltransferase O
. O
The O
model O
includes O
607 O
of O
the O
773 O
amino O
acids O
of O
L-CPT O
I O
, O
and O
the O
positions O
of O
carnitine O
, O
CoA O
and O
the O
palmitoyl O
group O
were O
assigned O
by O
superposition O
and O
docking O
analysis O
. O
Functional O
analysis O
of O
this O
3-D O
model O
included O
the O
mutagenesis O
of O
several O
amino O
acids O
in O
order O
to O
identify O
putative O
catalytic O
residues O
. O
Mutants O
D477A O
, O
D567A O
and O
E590D O
showed O
reduced O
L-CPT O
I O
activity O
. O
In O
addition O
, O
individual O
mutation O
of O
amino O
acids O
forming O
the O
conserved O
Ser685-Thr686-Ser687 O
motif O
abolished O
enzyme O
activity O
in O
mutants O
T686A O
and O
S687A O
and O
altered O
K(m) O
and O
the O
catalytic O
efficiency O
for O
carnitine O
in O
mutant O
S685A O
. O
We O
conclude O
that O
the O
catalytic O
residues O
are O
His473 O
and O
Asp477 O
, O
while O
Ser687 O
probably O
stabilizes O
the O
transition O
state O
. O
Several O
conserved O
lysines O
, O
i.e O
. O
Lys455 O
, O
Lys505 O
, O
Lys560 O
and O
Lys561 O
, O
were O
also O
mutated O
. O
Only O
mutants O
K455A O
and O
K560A O
showed O
decreases O
in O
activity O
of O
50% O
. O
The O
model O
rationalizes O
the O
finding O
of O
nine O
natural O
mutations O
in O
patients O
with O
hereditary O
L-CPT O
I O
deficiencies O
. O

MAC13243 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thiourea O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
, O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA B
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA O
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

glutamate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 B
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

SB216763 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

methionine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase O
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin B
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles O
. O
17864-L(x) O
loaded O
EGa1-PEG O
nanoparticles O
were O
internalized O
by O
clathrin-mediated O
endocytosis O
and O
ultimately O
digested O
in O
lysosomes O
. O
The O
intracellular O
routing O
of O
EGa1 O
targeted O
nanoparticles O
leads O
to O
a O
successful O
release O
of O
the O
kinase O
inhibitor O
in O
the O
cell O
and O
inhibition O
of O
proliferation O
whereas O
the O
non-targeted O
formulations O
had O
no O
antiproliferative O
effects O
on O
14C O
cells O
. O
The O
drug O
loaded O
targeted O
nanoparticles O
were O
as O
effective O
as O
the O
free O
drug O
in O
vitro O
. O
These O
results O
demonstrate O
that O
multikinase O
inhibitor O
loaded O
nanoparticles O
are O
interesting O
nanomedicines O
for O
the O
treatment O
of O
EGFR-positive O
cancers O
. O

L-proline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
L-proline O
accumulation O
and O
freeze O
tolerance O
of O
Saccharomyces O
cerevisiae O
are O
caused O
by O
a O
mutation O
in O
the O
PRO1 O
gene O
encoding O
gamma-glutamyl O
kinase.We O
previously O
isolated O
a O
mutant O
which O
showed O
a O
high O
tolerance O
to O
freezing O
that O
correlated O
with O
higher O
levels O
of O
intracellular O
L-proline O
derived O
from O
L-proline O
analogue-resistant O
mutants O
. O
The O
mutation O
responsible O
for O
the O
analogue O
resistance O
and O
L-proline O
accumulation O
was O
a O
single O
nuclear O
dominant O
mutation O
. O
By O
introducing O
the O
mutant-derived O
genomic O
library O
into O
a O
non-L-proline-utilizing O
strain O
, O
the O
mutant O
was O
found O
to O
carry O
an O
allele O
of O
the O
wild-type O
PRO1 O
gene O
encoding O
gamma-glutamyl O
kinase O
, O
which O
resulted O
in O
a O
single O
amino O
acid O
replacement; O
Asp O
(GAC) O
at O
position O
154 O
was O
replaced O
by O
Asn O
(AAC) O
. O
Interestingly O
, O
the O
allele O
of O
PRO1 O
was O
shown O
to O
enhance O
the O
activities O
of O
gamma-glutamyl O
kinase O
and O
gamma-glutamyl B
phosphate I
reductase I
, O
both O
of O
which O
catalyze O
the O
first O
two O
steps O
of O
L-proline O
synthesis O
from O
L-glutamate O
and O
which O
together O
may O
form O
a O
complex O
in O
vivo O
. O
When O
cultured O
in O
liquid O
minimal O
medium O
, O
yeast O
cells O
expressing O
the O
mutated O
gamma-glutamyl O
kinase O
were O
found O
to O
accumulate O
intracellular O
L-proline O
and O
showed O
a O
prominent O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O
wild-type O
PRO1 O
gene O
. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl O
kinase O
results O
in O
stabilization O
of O
the O
complex O
or O
has O
an O
indirect O
effect O
on O
gamma-glutamyl O
phosphate O
reductase O
activity O
, O
which O
leads O
to O
an O
increase O
in O
L-proline O
production O
in O
Saccharomyces O
cerevisiae O
. O
The O
approach O
described O
in O
this O
paper O
could O
be O
a O
practical O
method O
for O
breeding O
novel O
freeze-tolerant O
yeast O
strains O
. O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescein O
Conjugates O
as O
GluN1 B
/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B O
. O
To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound O
, O
ifenprodil O
. O
We O
performed O
chemical O
modifications O
of O
ifenprodil O
at O
the O
benzylic O
position O
and O
on O
the O
phenol O
ring O
by O
introducing O
secondary O
amine O
or O
amide O
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary O
amide O
functions O
as O
spacers O
. O
The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O
the O
inhibition O
of O
NMDA-induced O
Ca(2+) O
influx O
by O
calcium O
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1-1A O
and O
GluN2B O
. O
Further O
investigations O
revealed O
that O
this O
probe O
had O
a O
neuroprotective O
effect O
equivalent O
to O
that O
of O
ifenprodil O
in O
a O
standard O
test O
for O
neurotoxicity O
. O
Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil O
, O
we O
demonstrated O
that O
they O
displaced O
[(3) O
H]ifenprodil O
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Modulation O
of O
the O
JAK/ERK/STAT O
signaling O
in O
melanocortin-induced O
inhibition O
of O
local O
and O
systemic O
responses O
to O
myocardial O
ischemia/reperfusion.The O
janus O
kinases O
(JAK) O
, O
extracellular O
signal-regulated O
kinases O
(ERK) O
and O
signal O
transducers O
and O
activators O
of O
transcription O
(STAT) O
pathways O
have O
been O
shown O
to O
play O
a O
cardioprotective O
role O
. O
We O
previously O
gave O
evidence O
that O
melanocortins O
afford O
cardioprotection O
in O
conditions O
of O
myocardial O
ischemia/reperfusion O
. O
Here O
we O
aimed O
to O
investigate O
the O
influence O
of O
melanocortins O
on O
the O
JAK/ERK/STAT O
signaling O
in O
cardiac O
and O
systemic O
responses O
to O
prolonged O
myocardial O
ischemia/reperfusion O
. O
Ischemia O
was O
produced O
in O
rats O
by O
ligature O
of O
the O
left O
anterior O
descending O
coronary O
artery O
for O
30min O
. O
At O
the O
end O
of O
the O
2-h O
reperfusion O
, O
western O
blot O
analysis O
of O
the O
cardioprotective O
transcription O
factors O
pJAK2 O
, O
pERK1/2 O
, O
pTyr-STAT3 O
and O
pSer-STAT3 O
, O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O
(NDP- O
α-MSH) B
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK O
and O
ERK O
pathways O
with O
AG490 O
and O
U0126 O
, O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O
(STAT O
unrelated) O
signaling O
pathway O
. O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Modulation O
of O
the O
JAK/ERK/STAT O
signaling O
in O
melanocortin-induced O
inhibition O
of O
local O
and O
systemic O
responses O
to O
myocardial O
ischemia/reperfusion.The O
janus O
kinases O
(JAK) O
, O
extracellular O
signal-regulated O
kinases O
(ERK) O
and O
signal O
transducers O
and O
activators O
of O
transcription O
(STAT) O
pathways O
have O
been O
shown O
to O
play O
a O
cardioprotective O
role O
. O
We O
previously O
gave O
evidence O
that O
melanocortins O
afford O
cardioprotection O
in O
conditions O
of O
myocardial O
ischemia/reperfusion O
. O
Here O
we O
aimed O
to O
investigate O
the O
influence O
of O
melanocortins O
on O
the O
JAK/ERK/STAT O
signaling O
in O
cardiac O
and O
systemic O
responses O
to O
prolonged O
myocardial O
ischemia/reperfusion O
. O
Ischemia O
was O
produced O
in O
rats O
by O
ligature O
of O
the O
left O
anterior O
descending O
coronary O
artery O
for O
30min O
. O
At O
the O
end O
of O
the O
2-h O
reperfusion O
, O
western O
blot O
analysis O
of O
the O
cardioprotective O
transcription O
factors O
pJAK2 O
, O
pERK1/2 O
, O
pTyr-STAT3 O
and O
pSer-STAT3 O
, O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe(7)] O
α-melanocyte-stimulating B
hormone I
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK O
and O
ERK O
pathways O
with O
AG490 O
and O
U0126 O
, O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O
(STAT O
unrelated) O
signaling O
pathway O
. O

ADP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuroprotective O
role O
of O
ATP-sensitive O
potassium O
channels O
in O
cerebral O
ischemia.ATP-sensitive O
potassium O
(K(ATP)) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O
An O
increase O
in O
the O
ADP/ATP O
ratio O
opens O
K(ATP) B
channels I
, O
leading O
to O
membrane O
hyperpolarization O
. O
K(ATP) O
channels O
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O
hippocampus O
and O
cortex O
. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons O
. O
In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6.2 O
subunit O
of O
the O
K(ATP) O
channels O
increases O
ischemic O
infarction O
, O
and O
overexpression O
of O
the O
Kir6.2 O
subunit O
reduces O
neuronal O
injury O
from O
ischemic O
insults O
. O
These O
findings O
provide O
the O
basis O
for O
a O
practical O
strategy O
whereby O
activation O
of O
endogenous O
K(ATP) O
channels O
reduces O
cellular O
damage O
resulting O
from O
cerebral O
ischemic O
stroke O
. O
K(ATP) O
channel O
modulators O
may O
prove O
to O
be O
clinically O
useful O
as O
part O
of O
a O
combination O
therapy O
for O
stroke O
management O
in O
the O
future O
. O

RS79948 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Involvement O
of O
serotonin O
5-HT3 O
receptors O
in O
the O
modulation O
of O
noradrenergic O
transmission O
by O
serotonin O
reuptake O
inhibitors O
: O
a O
microdialysis O
study O
in O
rat O
brain.RATIONALE O
: O
Selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
in O
addition O
to O
being O
able O
to O
enhance O
serotonergic O
neurotransmission O
, O
are O
able O
to O
modulate O
other O
brain O
systems O
involved O
in O
depression O
. O
OBJECTIVES O
: O
This O
study O
evaluates O
the O
neurochemical O
effect O
of O
the O
SSRI O
citalopram O
on O
brain O
noradrenergic O
activity O
and O
the O
serotonin O
receptor O
involved O
in O
this O
effect O
. O
METHODS O
: O
Dual-probe O
microdialysis O
in O
the O
locus O
coeruleus O
(LC) O
and O
prefrontal O
cortex O
(PFC) O
was O
performed O
in O
freely O
awake O
rats O
. O
RESULTS O
: O
Systemic O
citalopram O
(10 O
mg/kg O
, O
i.p.) O
increased O
noradrenaline O
(NA) O
in O
the O
LC O
(E O
max O
= O
141 O
± O
13 O
%) O
and O
simultaneously O
decreased O
NA O
in O
the O
PFC O
(Emax O
= O
-46 O
± O
7 O
%) O
. O
In O
the O
local O
presence O
into O
the O
LC O
of O
the O
α2-adrenoceptor B
antagonist O
RS79948 O
(1 O
μM) O
, O
systemic O
citalopram O
increased O
NA O
in O
the O
LC O
(Emax O
= O
157 O
± O
25 O
%) O
and O
PFC O
(Emax O
= O
175 O
± O
24 O
%) O
. O
Local O
citalopram O
(0.1-100 O
μM) O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O
-38 O
± O
9 O
%) O
. O
Local O
LC O
citalopram O
effect O
was O
abolished O
by O
LC O
presence O
of O
the O
5-HT3 O
receptor O
antagonist O
MDL72222 O
(1 O
μM) O
but O
not O
the O
5-HT1/2 O
receptor O
antagonist O
methiothepin O
(1 O
μM) O
. O
Systemic O
citalopram O
in O
the O
LC O
presence O
of O
MDL72222 O
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O
%) O
. O
Local O
citalopram O
into O
the O
PFC O
enhanced O
NA O
(Emax O
= O
376 O
± O
18 O
%) O
in O
the O
area O
, O
which O
was O
prevented O
by O
MDL72222 O
. O
CONCLUSIONS O
: O
The O
SSRI O
citalopram O
modulates O
central O
noradrenergic O
neurotransmission O
by O
activation O
, O
through O
endogenous O
serotonin O
, O
of O
5-HT3 O
receptors O
expressed O
in O
the O
somatodendritic O
(LC) O
and O
terminal O
(PFC) O
areas O
, O
which O
subsequently O
promote O
an O
enhancement O
of O
local O
NA O
. O
Therefore O
, O
5-HT3 O
receptors O
and O
somatodendritic O
α2-adrenoceptors O
in O
the O
LC O
play O
an O
important O
role O
in O
the O
global O
effect O
of O
SSRIs O
. O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase O
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
, O
leading O
to O
the O
formation O
of O
prostaglandins O
. O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O
utilizing O
a O
baculovirus O
expression O
system O
. O
hCOX-1 O
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 B
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Thymidine O
kinase O
and O
thymidine O
phosphorylase O
level O
as O
the O
main O
predictive O
parameter O
for O
sensitivity O
to O
TAS-102 O
in O
a O
mouse O
model.TAS-102 O
is O
a O
new O
oral O
anti-cancer O
drug O
preparation O
, O
composed O
of O
a O
1:0.5 O
mixture O
(on O
a O
molar O
basis) O
of O
alpha,alpha,alpha-trifluorothymidine O
(FTD) O
and O
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione O
hydrochloride O
(TPI) O
. O
TAS-102 O
currently O
undergoing O
clinical O
trials O
, O
has O
been O
demonstrated O
to O
have O
at O
least O
two O
mechanisms O
, O
inhibition O
of O
TS O
and O
incorporation O
into O
DNA O
. O
We O
hypothesized O
that O
the O
thymidine O
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O
activity O
of O
TAS-102 O
. O
In O
the O
present O
study O
, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine B
phosphorylase I
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O
, O
tumor O
growth O
and O
TS O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O
TP O
ratio O
. O
There O
was O
a O
significant O
correlation O
(p=0.04) O
between O
tumor O
growth O
inhibition O
and O
this O
ratio O
. O
These O
results O
suggested O
that O
the O
activation O
and O
degradation O
pattern O
of O
FTD O
plays O
an O
important O
role O
in O
the O
efficacy O
of O
TAS-102 O
and O
that O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
response O
to O
TAS-102 O
therapy O
. O
We O
also O
studied O
the O
influence O
of O
TPI O
on O
the O
capacity O
of O
exogenous O
dThd O
to O
reverse O
FTD-dependent O
growth O
inhibition O
. O
Thymidine O
(dThd) O
levels O
rescued O
the O
effect O
of O
FTD O
in O
vitro O
and O
significantly O
increased O
in O
serum O
after O
administration O
of O
TAS-102 O
or O
TPI O
alone O
but O
not O
FTD O
alone O
. O
This O
may O
suggest O
the O
possibility O
of O
a O
decrease O
in O
antitumor O
effect O
. O
However O
, O
our O
study O
indicated O
that O
the O
therapeutic O
index O
was O
clearly O
increased O
by O
FTD O
combined O
with O
TPI O
, O
compared O
with O
FTD O
alone O
, O
suggesting O
FTD-induced O
toxicity O
to O
sensitive O
host O
tissue O
can O
be O
selectively O
reversed O
with O
dThd O
. O
In O
conclusion O
, O
TK O
and O
TPI O
effects O
on O
TP O
play O
important O
roles O
in O
the O
cytotoxic O
action O
of O
TAS-102 O
, O
and O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
more O
precisely O
individual O
resistance O
or O
sensitivity O
. O

PSE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pseudoephedrine O
inhibits O
T-cell O
activation O
by O
targeting O
NF-kappaB O
, O
NFAT O
and O
AP-1 O
signaling O
pathways.Pseudoephedrine O
(PSE) O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 O
(IL-2) O
and O
tumor B
necrosis I
factor I
(TNF) I
alpha- I
gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
diseases O
. O

doxycycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Dose-response O
effect O
of O
tetracyclines O
on O
cerebral O
matrix O
metalloproteinase-9 O
after O
vascular O
endothelial O
growth O
factor O
hyperstimulation.Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder O
. O
Matrix O
metalloproteinase O
(MMP)-9 O
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens O
. O
Doxycycline O
was O
shown O
to O
decrease O
cerebral O
MMP-9 O
activities O
and O
angiogenesis O
induced O
by O
vascular O
endothelial O
growth O
factor O
(VEGF) O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline O
and O
minocycline O
on O
cerebral O
MMP-9 O
using O
our O
mouse O
model O
with O
VEGF O
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O
brain O
. O
Mice O
were O
treated O
with O
doxycycline O
or O
minocycline O
, O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 B
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 O
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O
effect O
at O
a O
lower O
dose O
, O
1 O
mg/kg/day O
(P<0.02) O
. O
The O
inhibition O
of O
cerebral O
MMP-9 O
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue O
. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O
in O
vitro O
to O
elucidate O
the O
mechanisms O
underlying O
the O
MMP-9 O
inhibition O
by O
tetracyclines O
. O
In O
vitro O
, O
minocycline O
, O
but O
not O
doxycycline O
, O
inhibits O
MMP-9 O
, O
at O
least O
in O
part O
, O
via O
the O
extracellular O
signaling-related O
kinase O
1/2 O
(ERK1/2)-mediated O
pathway O
. O
This O
study O
provided O
the O
evidence O
that O
the O
tetracyclines O
inhibit O
stimulated O
cerebral O
MMP-9 O
at O
multiple O
levels O
and O
are O
effective O
at O
very O
low O
doses O
, O
offering O
great O
potential O
for O
therapeutic O
use O
. O

sulindac O
sulfide O
acts O
as O
NOT O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 B
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

glipizide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sitagliptin.Sitagliptin O
, O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O
glipizide O
. O
Sitagliptin O
had O
a O
generally O
neutral O
effect O
on O
bodyweight O
. O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 O
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 B
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt- B
dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

Cobalt O
chloride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cross-talk O
between O
constitutive O
androstane O
receptor O
and O
hypoxia-inducible O
factor O
in O
the O
regulation O
of O
gene O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR- B
target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O
in O
the O
liver O
of O
untreated O
mice O
and O
that O
the O
complex O
dissociates O
upon O
PB O
treatment O
. O
Taken O
together O
these O
results O
suggest O
that O
CAR O
and O
HIF-α O
interact O
and O
reciprocally O
modulate O
the O
functions O
of O
each O
other O
. O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
crocin O
on O
diazinon O
induced O
cardiotoxicity O
in O
rats O
in O
subchronic O
exposure.This O
study O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
crocin O
, O
main O
component O
of O
Crocus O
sativus O
L O
. O
(Saffron) O
against O
subchronic O
diazinon O
(DZN) O
induced O
cardiotoxicity O
in O
rats O
. O
METHODS O
: O
Rats O
were O
divided O
into O
7 O
groups; O
control O
(corn O
oil O
, O
gavage) O
, O
DZN O
(15mg/kg/day O
, O
gavage,) O
, O
crocin O
(12.5 O
, O
25 O
or O
50mg/kg/day O
, O
i.p) O
plus O
DZN O
, O
vitamin O
E O
(200IU/kg O
, O
i.p O
, O
three O
times O
per O
week) O
plus O
DZN O
and O
crocin O
(50mg/kg/day O
, O
i.p) O
groups O
. O
Treatments O
were O
continued O
for O
4weeks O
. O
Creatine O
phosphokinase O
MB O
(CK-MB) O
, O
malondealdehyde O
(MDA) O
and O
glutathione O
(GSH) O
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments O
. O
Levels O
of O
apoptotic O
proteins O
(Bax O
, O
Bcl2 O
, O
caspase O
3) O
and O
cytosolic O
cytochrome O
c O
were O
analyzed O
by O
Western O
blotting O
. O
Transcript O
levels O
of O
Bax O
and O
Bcl2 O
were O
also O
determined O
using O
qRT O
PCR O
. O
RESULTS O
: O
DZN O
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB B
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras O
/ O
mTOR B
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

Caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE B
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
leflunomide O
in O
rheumatoid O
arthritis.Leflunomide O
, O
a O
novel O
drug O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
: O
inhibition O
of O
dihydroorotate O
dehydrogenase O
( O
DHODH) B
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH O
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine O
kinases O
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O
the O
S O
phase O
. O
Increased O
levels O
of O
ribonucleotides O
can O
only O
be O
met O
by O
de O
novo O
ribonucleotide O
synthesis O
. O
At O
low O
levels O
of O
ribonucleotides O
, O
p53 O
, O
a O
"sensor" O
molecule O
, O
gets O
activated O
and O
prevents O
progression O
through O
the O
cell O
cycle O
. O
Therefore O
, O
an O
inhibitor O
of O
de O
novo O
uridine O
monophosphate O
synthesis O
would O
predictably O
arrest O
stimulated O
cells O
at O
the O
G1 O
phase O
. O
In O
support O
of O
this O
mechanism O
of O
action O
, O
in O
vitro O
mitogen O
stimulated O
human O
peripheral O
blood O
lymphocytes O
treated O
with O
A77 O
1726 O
undergo O
arrest O
at O
the O
G1 O
phase; O
this O
inhibition O
is O
reversed O
by O
uridine O
. O

memantine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
neuropharmacological O
basis O
for O
the O
use O
of O
memantine O
in O
the O
treatment O
of O
Alzheimer's O
disease.Memantine O
has O
been O
demonstrated O
to O
be O
safe O
and O
effective O
in O
the O
symptomatic O
treatment O
of O
Alzheimer's O
disease O
(AD) O
. O
While O
the O
neurobiological O
basis O
for O
the O
therapeutic O
activity O
of O
memantine O
is O
not O
fully O
understood O
, O
the O
drug O
is O
not O
a O
cholinesterase O
inhibitor O
and O
, O
therefore O
, O
acts O
differently O
from O
current O
AD O
therapies O
. O
Memantine O
can O
interact O
with O
a O
variety O
of O
ligand-gated O
ion O
channels O
. O
However O
, O
NMDA B
receptors I
appear O
to O
be O
a O
key O
target O
of O
memantine O
at O
therapeutic O
concentrations O
. O
Memantine O
is O
an O
uncompetitive O
(channel O
blocking) O
NMDA O
receptor O
antagonist O
. O
Like O
other O
NMDA O
receptor O
antagonists O
, O
memantine O
at O
high O
concentrations O
can O
inhibit O
mechanisms O
of O
synaptic O
plasticity O
that O
are O
believed O
to O
underlie O
learning O
and O
memory O
. O
However O
, O
at O
lower O
, O
clinically O
relevant O
concentrations O
memantine O
can O
under O
some O
circumstances O
promote O
synaptic O
plasticity O
and O
preserve O
or O
enhance O
memory O
in O
animal O
models O
of O
AD O
. O
In O
addition O
, O
memantine O
can O
protect O
against O
the O
excitotoxic O
destruction O
of O
cholinergic O
neurons O
. O
Blockade O
of O
NMDA O
receptors O
by O
memantine O
could O
theoretically O
confer O
disease-modifying O
activity O
in O
AD O
by O
inhibiting O
the O
"weak" O
NMDA O
receptor-dependent O
excitotoxicity O
that O
has O
been O
hypothesized O
to O
play O
a O
role O
in O
the O
progressive O
neuronal O
loss O
that O
underlies O
the O
evolving O
dementia O
. O
Moreover O
, O
recent O
in O
vitro O
studies O
suggest O
that O
memantine O
abrogates O
beta-amyloid O
(Abeta) O
toxicity O
and O
possibly O
inhibits O
Abeta O
production O
. O
Considerable O
attention O
has O
focused O
on O
the O
investigation O
of O
theories O
to O
explain O
the O
better O
tolerability O
of O
memantine O
over O
other O
NMDA O
receptor O
antagonists O
, O
particularly O
those O
that O
act O
by O
a O
similar O
channel O
blocking O
mechanism O
such O
as O
dissociative O
anesthetic-like O
agents O
(phencyclidine O
, O
ketamine O
, O
MK-801) O
. O
A O
variety O
of O
channel-level O
factors O
could O
be O
relevant O
, O
including O
fast O
channel-blocking O
kinetics O
and O
strong O
voltage-dependence O
(allowing O
rapid O
relief O
of O
block O
during O
synaptic O
activity) O
, O
as O
well O
as O
reduced O
trapping O
(permitting O
egress O
from O
closed O
channels) O
. O
These O
factors O
may O
allow O
memantine O
to O
block O
channel O
activity O
induced O
by O
low O
, O
tonic O
levels O
of O
glutamate--an O
action O
that O
might O
contribute O
to O
symptomatic O
improvement O
and O
could O
theoretically O
protect O
against O
weak O
excitotoxicity--while O
sparing O
synaptic O
responses O
required O
for O
normal O
behavioral O
functioning O
, O
cognition O
and O
memory O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O
His-tagged O
human B
adenine I
phosphoribosyltransferase I
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O
spectrophotometric-based O
enzyme-coupled O
assay O
system O
and O
a O
radiometric O
ionic O
capture O
scintillation O
proximity O
bead O
assay O
format O
. O
Ultimately O
, O
the O
scintillation O
proximity O
assay O
format O
was O
chosen O
because O
of O
automated O
screening O
compatibility O
limitations O
of O
the O
coupled O
assay O
. O
We O
describe O
here O
the O
biochemical O
characterization O
of O
adenine O
phosphoribosyltransferase O
and O
the O
development O
of O
a O
robust O
, O
homogeneous O
, O
384-well O
assay O
suitable O
for O
high O
throughput O
screening O
. O

formoterol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Systemic O
administration O
of O
beta2-adrenoceptor O
agonists O
, O
formoterol O
and O
salmeterol O
, O
elicit O
skeletal O
muscle O
hypertrophy O
in O
rats O
at O
micromolar O
doses.beta(2)-Adrenoceptor O
agonists O
provide O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness O
, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart O
, O
mediated O
in O
part O
, O
by O
beta(1)-adrenoceptor O
activation O
. O
Two O
beta(2)-agonists O
, O
formoterol O
and O
salmeterol O
, O
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O
safety O
, O
associated O
with O
greater O
beta(2)-adrenoceptor B
selectivity O
. O
The O
pharmacological O
profiles O
of O
formoterol O
and O
salmeterol O
and O
their O
effects O
on O
skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old O
, O
male O
F344 O
rats O
. O
Formoterol O
and O
salmeterol O
were O
each O
administered O
via O
daily O
i.p O
. O
injection O
at O
one O
of O
seven O
doses O
(ranging O
from O
1 O
to O
2,000 O
microg O
kg(-1) O
day(-1)) O
, O
for O
4 O
weeks O
. O
Rats O
were O
anaesthetised O
and O
the O
EDL O
and O
soleus O
muscles O
and O
the O
heart O
were O
excised O
and O
weighed O
. O
Dose-response O
curves O
were O
constructed O
based O
on O
skeletal O
and O
cardiac O
muscle O
hypertrophy O
. O
Formoterol O
was O
more O
potent O
than O
salmeterol O
, O
with O
a O
significantly O
lower O
ED(50) O
in O
EDL O
muscles O
(1 O
and O
130 O
microg O
kg(-1) O
day(-1) O
, O
P O
<0.05) O
, O
whereas O
salmeterol O
had O
greater O
intrinsic O
activity O
than O
formoterol O
in O
both O
EDL O
and O
soleus O
muscles O
(12% O
greater O
hypertrophy O
than O
formoterol) O
. O
The O
drugs O
had O
similar O
potency O
and O
intrinsic O
activity O
in O
the O
heart O
, O
with O
a O
smaller O
leftward O
shift O
for O
formoterol O
than O
seen O
in O
skeletal O
muscle O
. O
A O
dose O
of O
25 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
elicited O
greater O
EDL O
and O
soleus O
hypertrophy O
than O
salmeterol O
, O
but O
resulted O
in O
similar O
beta-adrenoceptor O
downregulation O
. O
These O
results O
show O
that O
doses O
as O
low O
as O
1 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
can O
elicit O
significant O
muscle O
hypertrophy O
with O
minimal O
cardiac O
hypertrophy O
and O
provide O
important O
information O
regarding O
the O
potential O
therapeutic O
use O
of O
formoterol O
and O
salmeterol O
for O
muscle O
wasting O
. O

IB-MECA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
The O
effects O
of O
the O
adenosine B
A3 I
receptor I
agonist O
IB-MECA O
on O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis.The O
role O
of O
adenosine O
A3 O
receptors O
and O
their O
distribution O
in O
the O
gastrointestinal O
tract O
have O
been O
widely O
investigated O
. O
Most O
of O
the O
reports O
discuss O
their O
role O
in O
intestinal O
inflammations O
. O
However O
, O
the O
role O
of O
adenosine O
A3 O
receptor O
agonist O
in O
pancreatitis O
has O
not O
been O
well O
established O
. O
The O
aim O
of O
this O
study O
is O
(Ed O
note O
: O
Purpose O
statements O
should O
be O
in O
present O
tense) O
to O
evaluate O
the O
effects O
of O
the O
adenosine O
A3 O
receptor O
agonist O
on O
the O
course O
of O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis O
(EAP) O
. O
The O
experiments O
were O
performed O
on O
80 O
male O
Wistar O
rats O
, O
58 O
of O
which O
survived O
, O
subdivided O
into O
3 O
groups O
: O
C-control O
rats O
, O
I-EAP O
group O
, O
and O
II-EAP O
group O
treated O
with O
the O
adenosine O
A3 O
receptor O
agonist O
IB-MECA O
(1-deoxy-1-6[[(3-iodophenyl) O
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide O
at O
a O
dose O
of O
0.75 O
mg/kg O
b.w O
. O
i.p O
. O
at O
48 O
, O
24 O
, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium O
taurocholate O
solution O
into O
the O
biliary-pancreatic O
duct O
. O
Serum O
for O
α-amylase O
and O
lipase O
determinations O
and O
tissue O
samples O
for O
morphological O
examinations O
were O
collected O
at O
2 O
, O
6 O
, O
and O
24 O
h O
of O
the O
experiment O
. O
In O
the O
IB-MECA O
group O
, O
α-amylase O
activity O
was O
decreased O
with O
statistically O
high O
significance O
compared O
to O
group O
I O
. O
The O
activity O
of O
lipase O
was O
not O
significantly O
different O
among O
the O
experimental O
groups O
but O
higher O
than O
in O
the O
control O
group O
. O
The O
administration O
of O
IB-MECA O
attenuated O
the O
histological O
parameters O
of O
inflammation O
as O
compared O
to O
untreated O
animals O
. O
The O
use O
of O
A3 O
receptor O
agonist O
IB-MECA O
attenuates O
EAP O
. O
Our O
findings O
suggest O
that O
stimulation O
of O
adenosine O
A3 O
receptors O
plays O
a O
positive O
role O
in O
the O
sodium O
taurocholate-induced O
EAP O
in O
rats O
. O

etomidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Activation O
of O
alpha O
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidate.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor O
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O
intraperitoneal O
injection O
of O
etomidate O
in O
wild-type O
and O
in O
alpha2A-receptor- B
deficient O
mice O
, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate O
in O
mice O
does O
not O
require O
the O
alpha2A-receptor O
subtype O
. O
Intravenous O
injection O
of O
etomidate O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors O
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O
. O

Vegfrecine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vegfrecine O
, O
an O
Inhibitor O
of O
VEGF B
Receptor I
Tyrosine I
Kinases I
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp.A O
new O
inhibitor O
of O
VEGF O
receptor O
tyrosine O
kinases O
, O
vegfrecine O
(1) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp O
. O
MK931-CF8 O
. O
The O
molecular O
structure O
of O
1 O
was O
determined O
by O
NMR O
and O
MS O
analysis O
combined O
with O
synthesis O
. O
Compound O
1 O
showed O
potent O
inhibitory O
activity O
against O
vascular O
endothelial O
growth O
factor O
receptor O
(VEGFR) O
tyrosine O
kinases O
in O
in O
vitro O
enzyme O
assays O
, O
but O
platelet-derived O
growth O
factor O
receptors O
(PDGFRs) O
, O
fibroblast O
growth O
factor O
receptor O
(FGFR) O
, O
and O
epidermal O
growth O
factor O
receptor O
(EGFR) O
responded O
only O
weakly O
. O
Compound O
1 O
is O
a O
promising O
new O
selective O
VEGFR O
inhibitor O
for O
investigating O
new O
treatments O
of O
cancer O
and O
inflammatory O
diseases O
. O

(+)-Tamsulosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha O
1 O
adrenoceptor O
antagonists O
at O
prostatic O
alpha O
1 O
adrenoceptors O
: O
binding O
, O
functional O
and O
in O
vivo O
studies.1 O
. O
The O
profile O
of O
a O
range O
of O
alpha O
1 O
adrenoceptor O
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human O
alpha O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human B
alpha I
1D I
adrenoceptors I
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O
17053 O
= O
SNAP O
1069 O
. O
4 O
. O
(-)-Tamsulosin O
was O
a O
very O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity O
, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O
this O
model O
. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha O
1 O
adrenoceptor O
mediating O
noradrenaline-induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O
1 O
adrenoceptors O
, O
particularly O
over O
the O
alpha O
1D O
subtype O
, O
appear O
to O
inhibit O
phenylephrine-induced O
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure O
. O

I3A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC B
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC O
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

naloxone O
estrone O
azine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
naloxone-steroid O
hybrid O
azine O
with O
selective O
and O
long-acting O
opioid O
antagonism O
at O
delta O
receptors O
in O
vitro.The O
interaction O
of O
naloxone O
estrone O
azine O
(N-EH) O
with O
various O
opioid B
receptor I
types O
was O
studied O
in O
vitro O
. O
Its O
potency O
as O
an O
antagonist O
of O
opioid O
effects O
was O
compared O
to O
that O
of O
naloxone O
on O
the O
electrically O
evoked O
contractions O
of O
mouse O
vas O
deferens O
(Mvd) O
and O
guinea O
pig O
ileum O
myenteric O
plexus O
longitudinal O
muscle O
(Gpi) O
preparations O
. O
N-EH O
was O
found O
to O
be O
9-fold O
more O
potent O
than O
naloxone O
in O
antagonizing O
the O
effects O
of O
D-Ala2-Leu5-enkephalin O
in O
the O
Mvd O
and O
22-fold O
less O
potent O
in O
antagonizing O
normorphine O
in O
the O
Gpi O
. O
In O
the O
Mvd O
, O
the O
recovery O
half-time O
for O
N-EH O
was O
longer O
than O
1000 O
min O
. O
Neither O
compound O
showed O
agonism O
. O
The O
two O
compounds O
were O
also O
compared O
for O
their O
capacity O
to O
displace O
the O
binding O
of O
3H-D-Ala2-Leu5-enkephalin O
, O
3H-dihydromorphine O
, O
and O
3H-ethylketocyclazocine O
to O
rat O
brain O
membranes O
under O
conditions O
where O
delta O
, O
mu O
, O
and O
kappa O
sites O
were O
labeled O
. O
The O
relative O
affinities O
were O
0.70 O
, O
0.16 O
, O
and O
0.14 O
for O
N-EH O
and O
0.05 O
, O
0.87 O
, O
and O
0.08 O
for O
naloxone O
, O
respectively O
. O
Thus O
, O
compared O
to O
naloxone O
, O
which O
is O
mu O
selective O
, O
N-EH O
is O
a O
delta-selective O
antagonist O
. O

Phillyrin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Phillyrin O
attenuates O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
through O
the O
activation O
of O
LKB1/AMP-activated O
protein O
kinase-dependent O
signalling.Phillyrin O
, O
an O
active O
constituent O
found O
in O
many O
medicinal O
plants O
and O
certain O
functional O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol B
regulatory I
element-binding I
protein-1c I
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

thiazolidinedione O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cytosolic O
aspartate O
aminotransferase O
, O
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedione.We O
show O
that O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT O
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
 O
, O
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedione.We O
show O
that O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT O
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

SC-51089 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandins O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
( O
EP1 B
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

All-trans O
retinoic O
acid O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
All-trans O
retinoic O
acid O
protects O
hepatocellular O
carcinoma O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
upregulating O
collagen B
8A2 I
.As O
a O
therapeutic O
or O
chemopreventative O
agent O
for O
various O
cancers O
, O
all-trans O
retinoic O
acid O
(atRA) O
has O
been O
reported O
to O
inhibit O
growth O
, O
induce O
apoptosis O
or O
cause O
differentiation O
. O
It O
was O
found O
that O
atRA O
could O
protect O
hepatocellular O
carcinoma O
(HCC) O
cells O
against O
cell O
death O
induced O
by O
serum O
starvation O
. O
Furthermore O
, O
it O
was O
found O
that O
atRA O
could O
enhance O
cell O
adhesion O
, O
but O
had O
no O
effect O
on O
the O
cell O
cycle O
and O
apoptosis O
. O
Using O
an O
Illumina O
Human O
HT-12 O
v4 O
expression O
microarray O
, O
207 O
upregulated O
and O
173 O
downregulated O
genes O
were O
identified O
in O
HepG2 O
cells O
treated O
with O
atRA O
. O
The O
most O
upregulated O
genes O
are O
cytochrome O
P450 O
family O
26 O
subfamily O
A O
polypeptide O
1 O
(CYP26A1) O
, O
histidine O
triad O
nucleotide O
binding O
protein O
3 O
(HINT3) O
, O
miR-1282 O
and O
cytochrome O
P450 O
family O
26 O
subfamily O
B O
polypeptide O
1 O
(CYP26B1) O
, O
which O
showed O
more O
than O
fivefold O
greater O
expression O
. O
Using O
Gene O
Ontology O
analysis O
, O
the O
greatest O
significance O
was O
found O
in O
extracellular-matrix-related O
molecular O
functions O
and O
the O
cellular O
component O
in O
upregulated O
genes O
. O
The O
upregulation O
of O
collagen O
8A2 O
(COL8A2) O
was O
further O
confirmed O
using O
quantitative O
RT-PCR O
and O
western O
blotting O
. O
Knockdown O
of O
COL8A2 O
blocked O
enhancement O
in O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA O
treatment O
. O
Re-expression O
of O
COL8A2 O
in O
COL8A2-knocked-down O
HCC O
cells O
reversed O
the O
effect O
of O
small O
interfering O
RNA-COL8A2 O
. O
In O
addition O
, O
COL8A2 O
could O
increase O
HCC O
cell O
migration O
and O
invasion O
. O
Thus O
, O
COL8A2 O
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA O
under O
serum-free O
conditions O
. O
In O
conclusion O
, O
atRA O
protects O
HCC O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
enhancing O
cell O
adhesion O
, O
and O
COL8A2 O
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion O
. O

choline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT B
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Plerixafor O
, O
a O
CXCR4 O
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells.Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 B
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O
combination O
of O
plerixafor O
and O
G-CSF O
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF O
mobilization O
alone O
. O

Sphingosine-1-phosphate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sphingosine-1-phosphate O
promotes O
the O
nuclear O
translocation O
of O
β-catenin B
and O
thereby O
induces O
osteoprotegerin O
gene O
expression O
in O
osteoblast-like O
cell O
lines.Sphingosine-1-phosphate O
(S1P) O
is O
a O
well-known O
signaling O
sphingolipid O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O
of O
β-catenin O
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin O
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

CGP O
12177A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor B
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs/cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

2-oxobutyrate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Crystal O
structure O
of O
the O
pyridoxal-5'-phosphate-dependent O
serine O
dehydratase O
from O
human O
liver.L-serine O
dehydratase O
( O
SDH) B
 O
, O
a O
member O
of O
the O
beta-family O
of O
pyridoxal O
phosphate-dependent O
(PLP) O
enzymes O
, O
catalyzes O
the O
deamination O
of O
L-serine O
and O
L-threonine O
to O
yield O
pyruvate O
or O
2-oxobutyrate O
. O
The O
crystal O
structure O
of O
L-serine O
dehydratase O
from O
human O
liver O
(hSDH) O
has O
been O
solved O
at O
2.5 O
A-resolution O
by O
molecular O
replacement O
. O
The O
structure O
is O
a O
homodimer O
and O
reveals O
a O
fold O
typical O
for O
beta-family O
PLP-dependent O
enzymes O
. O
Each O
monomer O
serves O
as O
an O
active O
unit O
and O
is O
subdivided O
into O
two O
distinct O
domains O
: O
a O
small O
domain O
and O
a O
PLP-binding O
domain O
that O
covalently O
anchors O
the O
cofactor O
. O
Both O
domains O
show O
the O
typical O
open O
alpha/beta O
architecture O
of O
PLP O
enzymes O
. O
Comparison O
with O
the O
rSDH-(PLP-OMS) O
holo-enzyme O
reveals O
a O
large O
structural O
difference O
in O
active O
sites O
caused O
by O
the O
artifical O
O-methylserine O
. O
Furthermore O
, O
the O
activity O
of O
hSDH-PLP O
was O
assayed O
and O
it O
proved O
to O
show O
catalytic O
activity O
. O
That O
suggests O
that O
the O
structure O
of O
hSDH-PLP O
is O
the O
first O
structure O
of O
the O
active O
natural O
holo-SDH O
. O

compound O
C O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

diclofenac O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
inhibitory O
effects O
of O
meloxicam O
and O
diclofenac O
on O
human O
thromboxane O
biosynthesis O
after O
single O
doses O
and O
at O
steady O
state.OBJECTIVE O
: O
To O
evaluate O
the O
extent O
of O
human O
cyclooxygenase-1 O
(COX-1) O
inhibition O
by O
meloxicam O
, O
which O
has O
been O
reported O
to O
preferentially O
inhibit O
cyclooxygenase-2 O
(COX-2) O
. O
The O
effects O
of O
meloxicam O
were O
compared O
with O
those O
of O
diclofenac O
, O
a O
nonselective O
COX B
inhibitor O
. O
METHODS O
: O
COX-1 O
inhibition O
was O
determined O
by O
measuring O
thromboxane O
B2 O
(TXB2)-generation O
from O
clotting O
whole O
blood O
ex O
vivo O
after O
single O
oral O
doses O
of O
7.5 O
and O
15 O
mg O
meloxicam O
and O
75 O
mg O
diclofenac O
and O
at O
steady O
state O
(15 O
mg O
meloxicam O
daily O
and O
150 O
mg O
diclofenac O
daily) O
. O
The O
effect O
was O
expressed O
as O
percentage O
inhibition O
of O
serum O
TXB2 O
generation O
and O
was O
directly O
related O
to O
the O
serum O
drug O
concentration O
with O
use O
of O
a O
standard O
sigmoidal O
E(max) O
model O
. O
RESULTS O
: O
In O
terms O
of O
inhibition O
of O
TXB2 O
generation O
, O
diclofenac O
was O
about O
1 O
order O
of O
magnitude O
more O
potent O
than O
meloxicam O
, O
indicated O
by O
a O
diclofenac O
EC50 O
(concentration O
of O
drug O
required O
to O
cause O
50% O
of O
maximum O
effect) O
that O
was O
about O
10 O
times O
lower O
than O
that O
of O
meloxicam O
(EC50 O
diclofenac O
single O
doses O
: O
37.50+/-29.64; O
EC50 O
meloxicam O
single O
doses O
: O
677.50+/-189.08) O
. O
However O
, O
serum O
concentrations O
of O
meloxicam O
after O
administration O
of O
15 O
mg O
were O
approximately O
10-fold O
higher O
than O
those O
of O
diclofenac O
. O
Therefore O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
area O
under O
the O
effect O
time O
curve O
(P O
= O
.115) O
and O
the O
mean O
effect O
(P O
= O
.424) O
between O
meloxicam O
and O
diclofenac O
. O
The O
EC50 O
of O
both O
drugs O
was O
significantly O
higher O
at O
steady O
state O
(diclofenac O
steady O
state O
: O
87.07+/-55.24 O
ng/mL; O
meloxicam O
steady O
state O
: O
1850.12+/-829.93 O
ng/mL) O
than O
after O
a O
single O
dose O
(P O
< O
.001) O
. O
CONCLUSION O
: O
These O
data O
show O
that O
meloxicam O
inhibits O
TXB2 O
generation O
at O
clinically O
relevant O
doses O
, O
although O
less O
potently O
than O
diclofenac O
. O
Thus O
our O
data O
suggest O
that O
the O
COX-2 O
preference O
of O
meloxicam O
observed O
in O
vitro O
may O
not O
result O
in O
clinical O
advantages O
when O
the O
higher O
dose O
of O
15 O
mg O
is O
needed O
. O
Because O
of O
the O
increase O
in O
EC50 O
at O
steady O
state O
, O
COX-1 O
is O
relatively O
spared O
when O
the O
lower O
dose O
of O
7.5 O
mg O
is O
administered O
. O

MXF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 B
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

25-OHD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Decreased O
serum O
concentrations O
of O
25-hydroxycholecalciferol O
are O
associated O
with O
increased O
risk O
of O
progression O
to O
impaired O
fasting O
glucose O
and O
diabetes.OBJECTIVE O
To O
study O
the O
association O
between O
vitamin O
D O
status O
and O
the O
risk O
of O
incident O
impaired O
fasting O
glucose O
(IFG) O
and O
diabetes O
in O
a O
population-based O
cohort O
of O
diabetes-free O
subjects O
. O
RESEARCH O
DESIGN O
AND O
METHODS O
In O
a O
historical O
prospective O
cohort O
study O
of O
subjects O
from O
the O
Clalit O
Health O
Services O
database O
, O
which O
includes O
information O
on O
nearly O
4 O
million O
people O
, O
diabetes-free O
subjects O
aged O
40-70 O
years O
with O
serum O
25-hydroxycholecalciferol O
(25-OHD) O
measurements O
available O
were O
followed O
for O
2 O
years O
to O
assess O
the O
development O
of O
IFG O
and O
diabetes O
in O
five O
25-OHD O
subgroups O
: O
≥25 O
, O
25.1-37.5 O
, O
37.6-50 O
, O
50.1-75 O
, O
and O
>75 O
nmol/L O
. O
RESULTS O
The O
baseline O
cohort O
included O
117,960 O
adults O
: O
83,526 O
normoglycemic O
subjects O
and O
34,434 O
subjects O
with O
IFG O
. O
During O
follow-up O
, O
8,629 O
subjects O
(10.3% O
of O
the O
normoglycemic O
group) O
developed O
IFG O
, O
and O
2,162 O
subjects O
(1.8% O
of O
the O
total O
cohort) O
progressed O
to O
diabetes O
. O
A O
multivariable O
model O
adjusted O
for O
age O
, O
sex O
, O
population O
group O
, O
immigrant O
status O
, O
BMI O
, O
season O
of O
vitamin O
D O
measurement O
, O
LDL O
and O
HDL B
cholesterol O
, O
triglycerides O
, O
estimated O
glomerular O
filtration O
rate O
, O
history O
of O
hypertension O
or O
cardiovascular O
disease O
, O
Charlson O
comorbidity O
index O
, O
smoking O
, O
and O
socioeconomic O
status O
revealed O
an O
inverse O
association O
between O
25-OHD O
and O
the O
risk O
of O
progression O
to O
IFG O
and O
diabetes O
. O
The O
odds O
of O
transitioning O
from O
normoglycemia O
to O
IFG O
, O
from O
normoglycemia O
to O
diabetes O
, O
and O
from O
IFG O
to O
diabetes O
in O
subjects O
with O
a O
25-OHD O
level O
≤25 O
nmol/L O
were O
greater O
than O
those O
of O
subjects O
with O
a O
25-OHD O
level O
>75 O
nmol/L O
[odds O
ratio O
1.13 O
(95% O
CI O
1.03-1.24) O
, O
1.77 O
(1.11-2.83) O
, O
and O
1.43 O
(1.16-1.76) O
, O
respectively] O
. O
CONCLUSIONS O
Vitamin O
D O
deficiency O
appears O
to O
be O
an O
independent O
risk O
factor O
for O
the O
development O
of O
IFG O
and O
diabetes O
. O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
( O
COX-2) B
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O
apoptosis O
via O
the O
PPARdelta/14-3-3epsilon O
transcriptional O
pathway O
. O
These O
results O
suggest O
that O
14-3-3epsilon O
is O
a O
target O
for O
the O
prevention O
and O
therapy O
of O
colorectal O
cancer O
. O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O
current O
study O
, O
SHR O
, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT O
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT B
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

paraoxon O
acts O
as O
NOT O
for O
what O
entity O
? O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon.Using O
paraoxon O
as O
a O
reference O
acetylcholinesterase O
(AChE) O
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O
and O
AChE O
activity O
increased O
in O
a O
stage-dependent O
manner O
following O
segmentation O
. O
We O
then O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon O
(31.2-500 O
nM) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage- O
and O
concentration-dependent O
AChE O
inhibition O
, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water O
. O
However O
, O
even O
in O
the O
presence O
of O
significant O
AChE B
inhibition O
, O
exposure O
to O
non-teratogenic O
paraoxon O
concentrations O
(≤250 O
nM) O
did O
not O
adversely O
impact O
secondary O
motoneuron O
development O
at O
96 O
hpf O
. O
Therefore O
, O
we O
investigated O
the O
potential O
effects O
of O
paraoxon O
exposure O
on O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE O
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O
this O
study O
highlights O
the O
potential O
challenges O
in O
developing O
quantitative O
AOPs O
to O
support O
chemical O
screening O
and O
prioritization O
strategies O
. O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Effect O
of O
sinapic O
acid O
against O
dimethylnitrosamine-induced O
hepatic O
fibrosis O
in O
rats.Sinapic O
acid O
is O
a O
member O
of O
the O
phenylpropanoid O
family O
and O
is O
abundant O
in O
cereals O
, O
nuts O
, O
oil O
seeds O
, O
and O
berries O
. O
It O
exhibits O
a O
wide O
range O
of O
pharmacological O
properties O
. O
In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic O
acid O
on O
dimethylnitrosamine O
(DMN)-induced O
chronic O
liver O
injury O
in O
rats O
. O
Sinapic O
acid O
remarkably O
prevented O
DMN-induced O
loss O
of O
body O
weight O
. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
liver O
malondialdehyde O
content O
. O
Furthermore O
, O
sinapic O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming B
growth I
factor-β1 I
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
. O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 O
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O
that O
sinapic O
acid O
is O
a O
potentially O
useful O
agent O
for O
the O
protection O
against O
liver O
fibrosis O
and O
cirrhosis O
. O

nitric O
oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
( O
NOS) B
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

dihydropyridine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC B
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

pyridoxal O
5-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Serine O
racemases O
from O
barley O
, O
Hordeum O
vulgare O
L. O
, O
and O
other O
plant O
species O
represent O
a O
distinct O
eukaryotic O
group O
: O
gene O
cloning O
and O
recombinant O
protein O
characterization.Several O
d-amino O
acids O
have O
been O
identified O
in O
plants O
. O
However O
, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine O
racemases O
. O
This O
suggests O
that O
plant O
serine O
racemases O
represent O
a O
distinct O
group O
in O
the O
eukaryotic O
serine O
racemase O
family O
and O
can O
be O
clustered O
into O
monocot O
and O
dicot O
types O
. O

risperidone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha B
1-adrenoceptors I
.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO B
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Identification O
of O
aldo-keto O
reductases O
as O
NRF2-target O
marker O
genes O
in O
human O
cells.Transcription O
factor O
NF-E2-related O
factor O
2 O
(NRF2) O
plays O
a O
crucial O
role O
in O
the O
cellular O
defense O
against O
oxidative/electrophilic O
stress O
by O
up-regulating O
multiple O
antioxidant O
genes O
. O
Numerous O
studies O
with O
genetically O
modified O
animals O
have O
demonstrated O
that O
Nrf2 O
is O
a O
sensitivity O
determining O
factor O
upon O
the O
exposure O
to O
environmental O
chemicals O
including O
carcinogens O
. O
Moreover O
, O
recent O
studies O
have O
demonstrated O
that O
polymorphism O
in O
the O
human O
NRF2 O
promoter O
is O
associated O
with O
higher O
risks O
for O
developing O
acute O
lung O
injury O
, O
gastric O
mucosal O
inflammation O
, O
and O
nephritis O
. O
Therefore O
, O
the O
identification O
of O
reliable O
and O
effective O
human O
target O
genes O
of O
NRF2 O
may O
allow O
the O
monitoring O
of O
NRF2 O
activity O
and O
to O
predict O
individual O
sensitivity O
to O
environmental O
stress-induced O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 O
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 B
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O
and O
NRF2 O
dependency O
shown O
in O
renal O
epithelial O
cells O
as O
well O
as O
in O
peripherally O
available O
blood O
cells O
, O
current O
findings O
suggest O
that O
AKRs O
can O
be O
utilized O
as O
a O
marker O
of O
NRF2 O
activity O
in O
human O
cells O
. O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras B
/ O
MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

anthranilic O
acid O
sulfonamides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
of O
anthranilic O
acid O
sulfonamides O
as O
inhibitors O
of O
methionine B
aminopeptidase-2 I
 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human O
MetAP2 O
were O
identified O
using O
affinity O
selection O
by O
mass O
spectrometry O
(ASMS) O
screening O
. O
These O
micromolar O
hits O
were O
rapidly O
improved O
to O
nanomolar O
leads O
on O
the O
basis O
of O
insights O
from O
protein O
crystallography; O
however O
, O
the O
compounds O
displayed O
extensive O
binding O
to O
human O
serum O
albumin O
and O
had O
limited O
activity O
in O
cellular O
assays O
. O
Modifications O
based O
on O
structural O
information O
on O
the O
binding O
of O
lead O
compounds O
to O
both O
MetAP2 O
and O
domain O
III O
of O
albumin O
allowed O
the O
identification O
of O
compounds O
with O
significant O
improvements O
in O
both O
parameters O
, O
which O
showed O
good O
cellular O
activity O
in O
both O
proliferation O
and O
methionine O
processing O
assays O
. O

6-aryl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 B
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O
bronchoconstriction O
in O
vivo O
and O
exhibit O
promising O
anti-inflammatory O
activity O
via O
intratracheal O
administration O
. O

ginseng O
saponins O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
ginseng O
saponins O
on O
the O
stress-induced O
plasma O
interleukin-6 B
level O
in O
mice.The O
effect O
of O
ginseng O
saponins O
on O
plasma O
interleukin-6 O
(IL-6) O
in O
non-stressed O
and O
immobilization-stressed O
mice O
were O
investigated O
. O
Ginseng O
total O
saponins O
, O
ginsenosides O
Rb2 O
, O
Rg1 O
and O
Rd O
administered O
intraperitoneally O
attenuated O
the O
immobilization O
stress-induced O
increase O
in O
plasma O
IL-6 O
level O
. O
But O
, O
intracerebroventricular O
injection O
of O
each O
ginsenoside O
did O
not O
affect O
plasma O
IL-6 O
level O
induced O
by O
immobilization O
stress O
. O
Ginsenosides O
Rb2 O
, O
Rd O
and O
Rg1 O
significantly O
decreased O
norepinephrine O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
cell O
line O
(RAW O
264.7) O
. O
Thus O
, O
it O
can O
be O
suggested O
that O
the O
inhibitory O
action O
of O
ginseng O
saponins O
against O
the O
immobilization O
stress-induced O
increase O
of O
plasma O
IL-6 O
level O
would O
be O
in O
periphery; O
at O
least O
in O
part O
, O
mediated O
by O
blocking O
norepinephrine- O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
rather O
than O
in O
the O
brain O
. O
Ginseng O
saponins O
might O
be O
proposed O
as O
a O
possible O
candidate O
in O
the O
research O
or O
therapeutic O
modulation O
of O
stress-related O
disorders O
. O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
p38 O
Mitogen O
Activated O
Protein O
Kinase O
Regulates O
the O
Nuclear O
Receptor O
CAR O
to O
Activate O
the O
CYP2B6 O
Gene.The O
constitutive O
active/androstane O
receptor O
(CAR) O
regulates O
hepatic O
drug O
metabolism O
by O
activating O
genes O
such O
as O
cytochrome O
P450 O
(CYP) O
and O
certain O
transferases O
. O
p38 O
mitogen O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 B
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O
understood O
by O
ligand O
binding O
alone O
because O
the O
specificity O
and O
magnitude O
of O
induction O
are O
co-determined O
by O
a O
given O
cell O
signaling O
such O
as O
p38 O
MAPK; O
both O
physiological O
and O
pathophysiological O
states O
of O
cell O
signaling O
may O
have O
a O
strong O
impact O
in O
hepatic O
drug O
metabolizing O
capability O
during O
therapeutic O
treatments O
. O

DHEAS O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 B
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

R-(alpha)-methyl-histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Influence O
of O
the O
novel O
histamine O
H3 O
receptor O
antagonist O
ST1283 O
on O
voluntary O
alcohol O
consumption O
and O
ethanol-induced O
place O
preference O
in O
mice.RATIONALE O
: O
Growing O
evidence O
supports O
a O
role O
for O
the O
central O
histaminergic O
system O
to O
have O
a O
modulatory O
influence O
on O
drug O
addiction O
in O
general O
and O
alcohol-use O
disorders O
in O
particular O
through O
histamine O
H3 O
receptors O
(H3R) O
. O
OBJECTIVE O
: O
In O
the O
present O
study O
, O
the O
effects O
of O
systemic O
injection O
of O
the O
newly O
synthesized O
H3R O
antagonist O
ST1283 O
on O
ethanol O
(EtOH) O
voluntary O
intake O
and O
EtOH-conditioned O
reward O
in O
mice O
have O
been O
investigated O
. O
METHODS O
: O
Oral O
EtOH O
, O
saccharin O
, O
and O
quinine O
intake O
was O
assessed O
in O
a O
two-bottle O
choice O
paradigm O
using O
escalating O
concentrations O
of O
alcohol O
or O
tastant O
solutions O
. O
EtOH-induced O
place O
preference O
(CPP) O
, O
EtOH-induced O
locomotor O
activity O
, O
and O
blood O
ethanol O
concentration O
(BEC) O
were O
also O
measured O
. O
RESULTS O
: O
Following O
administration O
of O
the O
H3R O
antagonist O
(2.5 O
, O
5 O
, O
and O
10 O
mg/kg O
, O
i.p.) O
, O
there O
was O
a O
significant O
dose-dependent O
decrease O
in O
alcohol O
consumption O
and O
preference O
. O
Importantly O
, O
vehicle- O
and O
ST1283 O
(5 O
mg/kg)-treated O
mice O
showed O
similar O
consumption O
and O
preference O
to O
increasing O
concentration O
of O
both O
sweet O
and O
bitter O
tastes O
. O
More O
interestingly O
, O
systemic O
administration O
of O
ST1283 O
inhibited O
EtOH-CPP O
and O
EtOH-enhanced O
locomotion O
. O
This O
inhibition O
was O
blocked O
when O
mice O
were O
pretreated O
with O
the O
selective O
H3R B
agonist O
R-(alpha)-methyl-histamine O
(10 O
mg/kg) O
. O
Finally O
, O
vehicle- O
and O
ST1283-treated O
mice O
had O
similar O
BECs O
. O
CONCLUSION O
: O
Our O
results O
show O
that O
ST1283 O
may O
decrease O
voluntary O
EtOH O
consumption O
and O
EtOH-CPP O
by O
altering O
its O
reinforcing O
effects O
, O
suggesting O
a O
novel O
role O
for O
histamine O
signaling O
in O
regulation O
of O
alcoholism O
. O
Lastly O
, O
the O
results O
add O
to O
the O
growing O
literature O
on O
H3R O
modulation O
in O
the O
pharmacotherapy O
of O
EtOH O
addiction O
. O

GS-6-DHSG O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Glutathione O
conjugation O
attenuates O
biological O
activities O
of O
6-dehydroshogaol O
from O
ginger.6-Dehydroshogaol O
(6-DHSG) O
is O
a O
bioactive O
α,β-unsaturated O
carbonyl O
compound O
isolated O
from O
fresh O
ginger O
with O
anti-inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O
Here O
we O
describe O
the O
glutathione O
(GSH)-dependent O
metabolism O
and O
the O
effect O
of O
this O
metabolic O
transformation O
on O
the O
biological O
activities O
of O
6-DHSG O
. O
Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6-gingerol O
and O
6-shogaol O
, O
6-DHSG O
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
(GS-6-DHSG) O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase B
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG O
and O
other O
α,β-unsaturated O
carbonyl O
compounds O
. O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 B
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

arginine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Chromosomal O
localization O
, O
gene O
structure O
, O
and O
expression O
pattern O
of O
DDAH1 O
: O
comparison O
with O
DDAH2 O
and O
implications O
for O
evolutionary O
origins.Endogenously O
produced O
asymmetrically O
methylated O
arginine O
residues O
are O
competitive O
inhibitors O
of O
all O
three O
isoforms O
of O
nitric O
oxide O
synthase O
( O
NOS) B
 O
. O
The O
enzyme O
dimethylarginine O
dimethylaminohydrolase O
(DDAH) O
specifically O
hydrolyzes O
these O
asymmetrically O
methylated O
arginine O
residues O
to O
citrulline O
and O
methylamines O
. O
Previously O
we O
have O
proposed O
that O
regulation O
of O
asymmetric O
methylarginine O
concentration O
by O
DDAH O
may O
provide O
a O
novel O
mechanism O
for O
the O
regulation O
of O
NOS O
activity O
in O
vivo O
. O
Recently O
we O
reported O
the O
cloning O
of O
human O
DDAH O
and O
identified O
a O
novel O
human O
DDAH O
isoform O
(DDAH O
I O
and O
DDAH O
II O
, O
respectively) O
. O
Here O
we O
report O
that O
the O
DDAH1 O
gene O
maps O
to O
chromosome O
1p22 O
and O
confirm O
that O
DDAH2 O
maps O
to O
the O
MHC O
III O
region O
of O
chromosome O
6p21.3 O
. O
Extensive O
analysis O
of O
the O
distribution O
of O
DDAH1 O
and O
DDAH2 O
mRNA O
in O
50 O
human O
tissues O
indicates O
differential O
expression O
of O
DDAH O
isoforms O
in O
brain O
regions O
, O
in O
immune O
cells O
, O
and O
during O
development O
. O
DDAH2 O
expression O
predominates O
in O
highly O
vascularized O
tissues O
that O
express O
the O
endothelial O
NOS O
isoform O
and O
in O
immune O
tissues O
that O
can O
express O
iNOS O
. O
Whereas O
DDAH2 O
is O
expressed O
at O
relatively O
high O
levels O
in O
all O
fetal O
tissues O
examined O
, O
DDAH1 O
expression O
varies O
little O
between O
fetal O
and O
adult O
tissues O
. O
The O
chromosomal O
localization O
of O
the O
DDAHs O
is O
consistent O
with O
gene O
duplication O
, O
and O
consistent O
with O
this O
, O
comparison O
of O
the O
gene O
structures O
indicates O
that O
the O
intron/exon O
organization O
is O
highly O
conserved O
. O
Phylogenetic O
analysis O
of O
DDAH O
sequences O
from O
diverse O
species O
suggests O
that O
DDAH O
gene O
duplication O
occurred O
prior O
to O
the O
emergence O
of O
bony O
fish O
some O
400 O
million O
years O
ago O
. O
Overall O
the O
data O
suggest O
that O
DDAH2 O
may O
be O
the O
more O
ancient O
of O
the O
two O
genes O
. O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

Zolmitriptan O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D O
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine B
(5HT)1B/1D I
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D O
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O
ability O
to O
inhibit O
trigeminovascular O
activation O
centrally O
as O
well O
as O
peripherally O
in O
preclinical O
studies O
. O
Consistent O
with O
its O
selectivity O
for O
5HT1B/1D O
receptors O
, O
zolmitriptan O
produces O
constriction O
of O
various O
isolated O
blood O
vessels O
, O
most O
notably O
cranial O
arteries O
. O
In O
anaesthetized O
animals O
, O
these O
vascular O
effects O
manifest O
as O
a O
selective O
constriction O
of O
cranial O
arterio-venous O
anastomoses O
resulting O
in O
a O
redistribution O
of O
carotid O
arterial O
blood O
flow O
. O
This O
effect O
is O
produced O
without O
significant O
effects O
on O
heart O
rate O
, O
blood O
pressure O
or O
blood O
flow O
to O
the O
brain O
, O
heart O
or O
lungs O
. O
Zolmitriptan O
also O
inhibits O
trigeminal-evoked O
increases O
in O
cerebral O
blood O
flow O
in O
anaesthetized O
cats O
and O
blocks O
trigeminal-evoked O
plasma O
protein O
extravasation O
in O
the O
dura O
of O
guinea-pigs O
. O
These O
actions O
are O
consistent O
with O
a O
pre-junctional O
inhibition O
of O
neuropeptide O
release O
from O
perivascular O
afferents O
of O
the O
trigeminal O
nerve O
, O
as O
confirmed O
by O
independent O
studies O
showing O
that O
zolmitriptan O
blocks O
elevations O
of O
calcitonin-gene-related O
peptide O
in O
jugular O
venous O
blood O
during O
electrical O
stimulation O
of O
the O
trigeminal O
ganglion O
. O
In O
all O
of O
these O
effects O
, O
zolmitriptan O
is O
three O
to O
four O
times O
more O
potent O
than O
sumatriptan O
, O
but O
produces O
the O
same O
maximum O
response O
. O
Zolmitriptan O
crosses O
the O
intact O
blood-brain O
barrier O
to O
inhibit O
trigeminovascular O
activation O
in O
the O
brainstem O
. O
This O
was O
shown O
initially O
by O
the O
ability O
of O
the O
drug O
to O
block O
a O
brainstem O
reflex O
provoking O
vasoactive O
intestinal O
peptide O
release O
from O
the O
VIIth O
cranial O
(facial) O
nerve O
during O
trigeminal O
stimulation O
. O
Subsequent O
ex O
vivo O
autoradiography O
confirmed O
that O
intravenously O
injected O
[3H]zolmitriptan O
labels O
a O
discrete O
population O
of O
cells O
in O
the O
trigeminal O
nucleus O
caudalis O
(TNC) O
and O
nucleus O
tractus O
solitarius O
. O
Direct O
evidence O
for O
a O
central O
neuromodulatory O
effect O
of O
zolmitriptan O
was O
provided O
by O
electrophysiological O
experiments O
which O
clearly O
demonstrated O
that O
the O
drug O
inhibits O
the O
excitability O
of O
cells O
in O
the O
TNC O
after O
systemic O
administration O
. O
This O
novel O
pre-clinical O
profile O
not O
only O
distinguishes O
zolmitriptan O
from O
sumatriptan O
, O
but O
raises O
intriguing O
questions O
about O
the O
clinical O
relevance O
of O
a O
dual O
action O
. O
Studies O
to O
date O
show O
that O
zolmitriptan O
indeed O
modulates O
cranial O
sensory O
processing O
in O
humans O
, O
yet O
central O
side-effects O
are O
no O
different O
from O
sumatriptan O
. O
This O
property O
may O
account O
for O
the O
remarkable O
consistency O
in O
clinical O
efficacy O
observed O
in O
clinical O
trials O
. O

bromfenac O
sodium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
( O
COX) B
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

desoxypeganine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase B
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor O
antagonism O
. O
H1-receptor B
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O
anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O
on O
mast O
cell O
function O
. O
In O
low O
concentrations O
in O
vitro O
, O
antihistamines O
have O
been O
found O
to O
inhibit O
immunologically O
stimulated O
mast O
cell O
mediator O
release O
, O
with O
the O
IC50 O
in O
the O
nanomolar O
to O
micromolar O
range O
, O
while O
at O
higher O
concentrations O
they O
induce O
histamine O
release O
. O
The O
potency O
of O
these O
drugs O
in O
producing O
such O
effects O
is O
unrelated O
to O
their O
H1-receptor O
blocking O
activity O
. O
Furthermore O
the O
sedative O
effects O
of O
these O
therapeutic O
agents O
limit O
the O
tolerable O
administrable O
dose O
and O
thus O
the O
degree O
of O
H1-receptor O
blockade O
achievable O
within O
the O
airways O
. O
The O
recent O
development O
of O
H1-receptor O
antagonists O
devoid O
of O
clinical O
sedative O
effects O
has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines O
which O
achieve O
a O
greater O
degree O
of O
H1-receptor O
blockade O
within O
the O
airways O
, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine O
in O
this O
condition O
. O
Furthermore O
, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
cetirizine O
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin O
activity O
of O
clinical O
relevance O
. O
However O
, O
of O
these O
agents O
both O
loratadine O
and O
cetirizine O
possess O
additional O
actions O
likely O
to O
be O
of O
relevance O
to O
asthma O
. O
Pretreatment O
with O
loratadine O
has O
been O
shown O
to O
reduce O
the O
recovery O
of O
both O
histamine O
and O
prostaglandin O
D2 O
(PGD2) O
in O
nasal O
lavage O
fluid O
following O
nasal O
allergen O
challenge O
, O
a O
finding O
interpreted O
as O
indicative O
of O
in O
vivo O
mast O
cell O
stabilization O
, O
and O
cetirizine O
has O
been O
shown O
in O
vivo O
at O
therapeutic O
doses O
to O
inhibit O
allergen-induced O
eosinophil O
chemotaxis O
. O
Thus O
while O
both O
these O
agents O
offer O
the O
potential O
of O
an O
oral O
therapy O
for O
asthma O
based O
on O
an O
H1-receptor O
antagonist O
, O
their O
additional O
actions O
do O
not O
make O
them O
ideally O
suited O
to O
the O
exploration O
of O
the O
role O
of O
histamine O
in O
asthma.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles.Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast B
mitochondrial I
LeuRS I
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast O
mitochondrial O
LeuRS O
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C-terminal O
domain O
. O

salmeterol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Systemic O
administration O
of O
beta2-adrenoceptor O
agonists O
, O
formoterol O
and O
salmeterol O
, O
elicit O
skeletal O
muscle O
hypertrophy O
in O
rats O
at O
micromolar O
doses.beta(2)-Adrenoceptor O
agonists O
provide O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness O
, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart O
, O
mediated O
in O
part O
, O
by O
beta(1)-adrenoceptor O
activation O
. O
Two O
beta(2)-agonists O
, O
formoterol O
and O
salmeterol O
, O
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O
safety O
, O
associated O
with O
greater O
beta(2)-adrenoceptor O
selectivity O
. O
The O
pharmacological O
profiles O
of O
formoterol O
and O
salmeterol O
and O
their O
effects O
on O
skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old O
, O
male O
F344 O
rats O
. O
Formoterol O
and O
salmeterol O
were O
each O
administered O
via O
daily O
i.p O
. O
injection O
at O
one O
of O
seven O
doses O
(ranging O
from O
1 O
to O
2,000 O
microg O
kg(-1) O
day(-1)) O
, O
for O
4 O
weeks O
. O
Rats O
were O
anaesthetised O
and O
the O
EDL O
and O
soleus O
muscles O
and O
the O
heart O
were O
excised O
and O
weighed O
. O
Dose-response O
curves O
were O
constructed O
based O
on O
skeletal O
and O
cardiac O
muscle O
hypertrophy O
. O
Formoterol O
was O
more O
potent O
than O
salmeterol O
, O
with O
a O
significantly O
lower O
ED(50) O
in O
EDL O
muscles O
(1 O
and O
130 O
microg O
kg(-1) O
day(-1) O
, O
P O
<0.05) O
, O
whereas O
salmeterol O
had O
greater O
intrinsic O
activity O
than O
formoterol O
in O
both O
EDL O
and O
soleus O
muscles O
(12% O
greater O
hypertrophy O
than O
formoterol) O
. O
The O
drugs O
had O
similar O
potency O
and O
intrinsic O
activity O
in O
the O
heart O
, O
with O
a O
smaller O
leftward O
shift O
for O
formoterol O
than O
seen O
in O
skeletal O
muscle O
. O
A O
dose O
of O
25 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
elicited O
greater O
EDL O
and O
soleus O
hypertrophy O
than O
salmeterol O
, O
but O
resulted O
in O
similar O
beta-adrenoceptor B
downregulation O
. O
These O
results O
show O
that O
doses O
as O
low O
as O
1 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
can O
elicit O
significant O
muscle O
hypertrophy O
with O
minimal O
cardiac O
hypertrophy O
and O
provide O
important O
information O
regarding O
the O
potential O
therapeutic O
use O
of O
formoterol O
and O
salmeterol O
for O
muscle O
wasting O
. O

4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
( O
AChE) B
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

Ca O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antithrombin O
binding O
of O
low O
molecular O
weight O
heparins O
and O
inhibition O
of O
factor O
Xa.Fluorescence O
and O
stopped O
flow O
methods O
were O
used O
to O
compare O
clinically O
used O
heparins O
with O
regard O
to O
their O
ability O
to O
bind O
to O
antithrombin O
and O
to O
accelerate O
the O
inactivation O
of O
factor O
Xa O
. O
Titration O
of O
antithrombin O
with O
both O
low O
molecular O
weight O
heparin O
(LMWH) O
(enoxaparin O
, O
fragmin O
and O
ardeparin) O
and O
unfractionated O
heparin O
(UFH) O
produced O
an O
equivalent O
fluorescence O
increase O
and O
indicates O
similar O
affinity O
of O
all O
heparin O
preparations O
to O
antithrombin O
. O
However O
, O
relative O
to O
UFH O
enoxaparin O
, O
the O
LMWH O
with O
the O
smallest O
average O
molecular O
mass O
, O
contained O
only O
12% O
material O
with O
high O
affinity O
for O
antithrombin O
. O
The O
rate O
of O
factor O
Xa O
inhibition O
by O
antithrombin O
increased O
with O
the O
concentration O
of O
the O
examined O
heparins O
to O
the O
same O
limiting O
value O
, O
but O
the O
concentration O
required O
for O
maximal O
acceleration O
depended O
on O
the O
preparation O
. O
According O
to O
these O
data O
the O
high O
affinity O
fraction O
of O
the O
heparin O
preparations O
increased O
the O
intrinsic O
fluorescence O
and O
inhibitory O
activity O
equally O
without O
additional O
effects O
by O
variations O
in O
chain O
length O
and O
chemical O
composition O
. O
In O
contrast O
, O
in O
the O
presence O
of O
Ca O
UFH O
accelerated O
the O
inhibition O
of O
factor O
Xa O
by O
antithrombin B
10-fold O
more O
efficiently O
than O
comparable O
concentrations O
of O
the O
high O
affinity O
fractions O
of O
enoxaparin O
and O
fragmin O
. O
The O
bell-shaped O
dependence O
of O
this O
accelerating O
effect O
suggests O
simultaneous O
binding O
of O
both O
proteins O
to O
heparin O
. O
In O
conclusion O
, O
under O
physiologic O
conditions O
the O
anti-factor O
Xa O
activity O
of O
heparin O
results O
from O
a O
composite O
effect O
of O
chain O
length O
and O
the O
content O
of O
material O
with O
high O
affinity O
to O
antithrombin O
. O
Thus O
, O
the O
reduced O
antithrombotic O
activity O
of O
LMWH O
relative O
to O
UFH O
results O
from O
a O
smaller O
content O
of O
high O
affinity O
material O
and O
the O
absence O
of O
a O
stimulating O
effect O
of O
calcium O
. O

clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nonadrenergic O
imidazoline O
binding O
sites O
on O
human O
platelets.Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity O
, O
imidazol(in)e-preferring O
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 O
adrenoceptors O
. O
These O
nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
of O
alpha-2 O
adrenoceptors O
. O
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan O
(IDX) O
binding O
vs O
. O
[125I]p-iodoclonidine O
(PIC) O
binding O
. O
Nonadrenergic O
[125I]PIC-labeled O
sites O
were O
enriched O
in O
platelet O
plasma O
membranes O
, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] O
IDX O
were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled O
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs O
. O
the O
[3H]IDX-labeled O
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes) O
. O
Furthermore O
, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human O
subtype-I1 O
imidazol(in)e O
receptor O
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 B
imidazol(in)e I
receptor I
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sphingosine-1-phosphate O
promotes O
the O
nuclear O
translocation O
of O
β-catenin O
and O
thereby O
induces O
osteoprotegerin O
gene O
expression O
in O
osteoblast-like O
cell O
lines.Sphingosine-1-phosphate O
(S1P) O
is O
a O
well-known O
signaling O
sphingolipid O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O
of O
β-catenin B
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin O
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

okadaic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
serine/threonine O
protein O
phosphatase O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
serine/threonine O
protein O
phosphatase O
(PP) O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice O
, O
and O
on O
[3H]naloxone O
binding O
to O
the O
forebrain O
crude O
synaptosome O
fraction O
. O
Neither O
okadaic O
acid O
nor O
cantharidin O
(1-10000 O
nM) O
displaced O
[3H]naloxone O
from O
its O
specific O
binding O
sites O
, O
which O
indicates O
that O
they O
do O
not O
interact O
at O
the O
opioid O
receptor O
level O
. O
The O
i.c.v O
. O
administration O
of O
very O
low O
doses O
of O
okadaic O
acid O
(0.001-1 O
pg/mouse) O
and O
cantharidin O
(0.001-1 O
ng/mouse) O
, O
which O
inhibit O
PP2A B
, O
produced O
a O
dose-dependent O
antagonism O
of O
the O
antinociception O
induced O
by O
morphine O
(s.c.) O
. O
However O
, O
L-nor-okadaone O
(0.001 O
pg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
an O
analogue O
of O
okadaic O
acid O
lacking O
activity O
against O
protein O
phosphatases O
, O
did O
not O
affect O
the O
antinociceptive O
effect O
of O
morphine O
. O
On O
the O
other O
hand O
, O
high O
doses O
of O
okadaic O
acid O
(10 O
ng/mouse O
, O
i.c.v.) O
and O
cantharidin O
(1 O
microg/mouse O
, O
i.c.v.) O
, O
which O
also O
block O
PP1 O
, O
and O
calyculin-A O
(0.1 O
fg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
which O
inhibits O
equally O
both O
PP1 O
and O
PP2A O
, O
did O
not O
modify O
the O
morphine-induced O
antinociception O
. O
These O
results O
suggest O
that O
the O
activation O
of O
type O
2A O
serine/threonine O
protein O
phosphatases O
may O
play O
a O
role O
in O
the O
antinociceptive O
effect O
of O
morphine O
, O
and O
that O
PP1 O
might O
counterbalace O
this O
activity O
. O

BH(4) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Oral O
administration O
of O
tetrahydrobiopterin O
prevents O
endothelial O
dysfunction O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats.We O
have O
reported O
that O
a O
deficiency O
of O
tetrahydrobiopterin O
(BH(4)) O
, O
an O
active O
cofactor O
of O
endothelial B
NO I
synthase I
(eNOS) O
, O
contributes O
to O
the O
endothelial O
dysfunction O
through O
reduced O
eNOS O
activity O
and O
increased O
superoxide O
anion O
(O(2)(-)) O
generation O
in O
the O
insulin-resistant O
state O
. O
To O
further O
confirm O
this O
hypothesis O
, O
we O
investigated O
the O
effects O
of O
dietary O
treatment O
with O
BH(4) O
on O
endothelium-dependent O
arterial O
relaxation O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats O
. O
Oral O
supplementation O
of O
BH(4) O
(10 O
mg O
. O
kg(-1) O
. O
d(-1)) O
for O
8 O
weeks O
significantly O
increased O
the O
BH(4) O
content O
in O
cardiovascular O
tissues O
of O
rats O
fed O
high O
levels O
of O
fructose O
(fructose-fed O
rats) O
. O
Impairment O
of O
endothelium-dependent O
arterial O
relaxation O
in O
the O
aortic O
strips O
of O
the O
fructose-fed O
rats O
was O
reversed O
with O
BH(4) O
treatment O
. O
The O
BH(4) O
treatment O
was O
associated O
with O
a O
2-fold O
increase O
in O
eNOS O
activity O
as O
well O
as O
a O
70% O
reduction O
in O
endothelial O
O(2)(-) O
production O
compared O
with O
those O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
also O
partially O
improved O
the O
insulin O
sensitivity O
and O
blood O
pressure O
, O
as O
well O
as O
the O
serum O
triglyceride O
concentration O
, O
in O
the O
fructose-fed O
rats O
. O
Moreover O
, O
BH(4) O
treatment O
of O
the O
fructose-fed O
rats O
markedly O
reduced O
the O
lipid O
peroxide O
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O
the O
activation O
of O
2 O
redox-sensitive O
transcription O
factors O
, O
nuclear O
factor-kappaB O
and O
activating O
protein-1 O
, O
which O
were O
increased O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
of O
control O
rats O
did O
not O
have O
any O
significant O
effects O
on O
these O
parameters O
. O
These O
results O
indicate O
that O
BH(4) O
augmentation O
is O
essential O
for O
the O
restoration O
of O
eNOS O
function O
and O
the O
reduction O
of O
vascular O
oxidative O
stress O
in O
insulin-resistant O
rats O
. O

acetylcarnitine O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Redesign O
of O
carnitine O
acetyltransferase O
specificity O
by O
protein O
engineering.In O
eukaryotes O
, O
L-carnitine O
is O
involved O
in O
energy O
metabolism O
by O
facilitating O
beta-oxidation O
of O
fatty O
acids O
. O
Carnitine B
acetyltransferases I
(CrAT) O
catalyze O
the O
reversible O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O
mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
. O
Kinetic O
constants O
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O
to O
methionine O
in O
carnitine O
octanoyltransferase O
(COT) O
decreased O
activity O
toward O
its O
natural O
substrates O
, O
medium- O
and O
long-chain O
acyl-CoAs O
, O
and O
increased O
activity O
toward O
short-chain O
acyl-CoAs O
. O
Another O
CrAT O
mutant O
, O
M564A O
, O
was O
prepared O
and O
tested O
in O
the O
same O
way O
, O
with O
similar O
results O
. O
We O
conclude O
that O
Met564 O
blocks O
the O
entry O
of O
medium- O
and O
long-chain O
acyl-CoAs O
to O
the O
catalytic O
site O
of O
CrAT O
. O
Three-dimensional O
models O
of O
wild-type O
and O
mutated O
CrAT O
and O
COT O
support O
this O
hypothesis O
. O
We O
show O
for O
the O
first O
time O
that O
a O
single O
amino O
acid O
is O
able O
to O
determine O
the O
substrate O
specificity O
of O
CrAT O
and O
COT O
. O

palmitic O
and O
stearic O
acids O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt B
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
A O
genetically O
encoded O
and O
gate O
for O
cell-targeted O
metabolic O
labeling O
of O
proteins.We O
describe O
a O
genetic O
AND O
gate O
for O
cell-targeted O
metabolic O
labeling O
and O
proteomic O
analysis O
in O
complex O
cellular O
systems O
. O
The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA O
synthetase O
(MetRS) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine O
(Anl) O
to O
tRNA(Met) O
. O
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N- O
and O
C-terminal O
fragments O
of O
the O
bisected O
MetRS B
. O
Anl-labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed O
or O
strain-promoted O
azide-alkyne O
cycloaddition O
. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl O
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated O
. O
This O
method O
allows O
spatial O
and O
temporal O
control O
of O
proteomic O
labeling O
and O
identification O
of O
proteins O
made O
in O
specific O
cellular O
subpopulations O
. O
The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar-flow O
microfluidic O
channel O
, O
where O
they O
are O
exposed O
to O
overlapping O
, O
opposed O
gradients O
of O
inducers O
of O
the O
N- O
and O
C-terminal O
MetRS O
fragments O
. O
The O
observed O
labeling O
profile O
is O
predicted O
accurately O
from O
the O
strengths O
of O
the O
individual O
input O
signals O
. O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG B
synthase I
2 I
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O
or O
recombinant O
ovine O
IFNT O
and O
into O
the O
uterus O
from O
day O
10 O
to O
day O
14 O
after O
mating O
. O
Inhibition O
of O
HSD11B1 O
activity O
in O
utero O
prevented O
conceptus O
elongation O
, O
whereas O
IFNT O
rescued O
conceptus O
elongation O
in O
PF-infused O
ewes O
. O
These O
results O
suggest O
that O
HSD11B1-derived O
cortisol O
mediates O
, O
in O
part O
, O
actions O
of O
ovarian O
progesterone O
and O
the O
conceptus O
on O
endometrial O
function O
and O
support O
the O
hypothesis O
that O
IFNT O
, O
PG O
, O
and O
cortisol O
coordinately O
regulate O
endometrial O
functions O
important O
for O
conceptus O
elongation O
and O
implantation O
during O
early O
pregnancy O
in O
sheep O
. O

wogonoside O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II B
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Time-dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
( O
CYP3A) B
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses O
. O
5 O
. O
Some O
physiological O
compounds O
such O
as O
cytokines O
might O
be O
involved O
in O
decreasing O
the O
CYP3A O
activity O
to O
maintain O
homeostasis O
of O
the O
body O
. O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neoechinulin O
A O
suppresses O
amyloid-β O
oligomer-induced O
microglia O
activation O
and O
thereby O
protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis B
signal-regulating I
kinase I
1 I
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin O
A O
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
AD O
. O

formoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Systemic O
administration O
of O
beta2-adrenoceptor O
agonists O
, O
formoterol O
and O
salmeterol O
, O
elicit O
skeletal O
muscle O
hypertrophy O
in O
rats O
at O
micromolar O
doses.beta(2)-Adrenoceptor O
agonists O
provide O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness O
, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart O
, O
mediated O
in O
part O
, O
by O
beta(1)-adrenoceptor O
activation O
. O
Two O
beta(2)-agonists O
, O
formoterol O
and O
salmeterol O
, O
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O
safety O
, O
associated O
with O
greater O
beta(2)-adrenoceptor B
selectivity O
. O
The O
pharmacological O
profiles O
of O
formoterol O
and O
salmeterol O
and O
their O
effects O
on O
skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old O
, O
male O
F344 O
rats O
. O
Formoterol O
and O
salmeterol O
were O
each O
administered O
via O
daily O
i.p O
. O
injection O
at O
one O
of O
seven O
doses O
(ranging O
from O
1 O
to O
2,000 O
microg O
kg(-1) O
day(-1)) O
, O
for O
4 O
weeks O
. O
Rats O
were O
anaesthetised O
and O
the O
EDL O
and O
soleus O
muscles O
and O
the O
heart O
were O
excised O
and O
weighed O
. O
Dose-response O
curves O
were O
constructed O
based O
on O
skeletal O
and O
cardiac O
muscle O
hypertrophy O
. O
Formoterol O
was O
more O
potent O
than O
salmeterol O
, O
with O
a O
significantly O
lower O
ED(50) O
in O
EDL O
muscles O
(1 O
and O
130 O
microg O
kg(-1) O
day(-1) O
, O
P O
<0.05) O
, O
whereas O
salmeterol O
had O
greater O
intrinsic O
activity O
than O
formoterol O
in O
both O
EDL O
and O
soleus O
muscles O
(12% O
greater O
hypertrophy O
than O
formoterol) O
. O
The O
drugs O
had O
similar O
potency O
and O
intrinsic O
activity O
in O
the O
heart O
, O
with O
a O
smaller O
leftward O
shift O
for O
formoterol O
than O
seen O
in O
skeletal O
muscle O
. O
A O
dose O
of O
25 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
elicited O
greater O
EDL O
and O
soleus O
hypertrophy O
than O
salmeterol O
, O
but O
resulted O
in O
similar O
beta-adrenoceptor O
downregulation O
. O
These O
results O
show O
that O
doses O
as O
low O
as O
1 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
can O
elicit O
significant O
muscle O
hypertrophy O
with O
minimal O
cardiac O
hypertrophy O
and O
provide O
important O
information O
regarding O
the O
potential O
therapeutic O
use O
of O
formoterol O
and O
salmeterol O
for O
muscle O
wasting O
. O

cyanopindolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Serotonin O
transporter O
function O
in O
vivo O
: O
assessment O
by O
chronoamperometry.Local O
application O
of O
selective O
serotonin O
reuptake O
inhibitors O
, O
fluvoxamine O
and O
citalopram O
, O
prolonged O
the O
clearance O
of O
exogenously O
administered O
serotonin O
(5-HT) O
in O
both O
the O
dentate O
gyrus O
and O
CA3 O
region O
of O
the O
dorsal O
hippocampus O
, O
as O
measured O
using O
in O
vivo O
chronoamperometry O
. O
These O
effects O
were O
abolished O
in O
rats O
pretreated O
with O
5,7-dihydroxytryptamine O
. O
The O
NE O
uptake O
inhibitors O
, O
desipramine O
and O
protriptyline O
, O
did O
not O
alter O
the O
5-HT O
signal O
in O
the O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT O
and O
NET O
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin B
terminal I
autoreceptor I
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin O
autoreceptor O
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O
effect O
on O
the O
serotonin O
transporter O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin B
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

NH2 O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Catalytic O
properties O
of O
mouse O
carbonic O
anhydrase O
V.A O
cDNA O
encoding O
the O
mouse O
carbonic O
anhydrase O
V O
gene O
was O
isolated O
by O
reverse O
transcription O
and O
polymerase O
chain O
reaction O
from O
BALB/c O
mouse O
liver O
mRNA O
. O
Vectors O
containing O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic B
anhydrase I
(CA) I
V I
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
, O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA O
V O
are O
not O
due O
to O
the O
presence O
of O
tyrosine O
at O
position O
64 O
. O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
PET O
study O
of O
dopamine O
D2 O
and O
serotonin O
5-HT2 O
receptor O
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone.OBJECTIVE O
: O
Ziprasidone O
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin O
5-HT(2) O
receptors O
compared O
with O
dopamine O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O
in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) O
occupancy O
(using O
[(11)C]raclopride) O
and O
5-HT(2) O
occupancy O
(using O
[(18)F]setoperone) O
in O
brain O
regions O
of O
interest O
in O
16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40 O
, O
80 O
, O
120 O
, O
or O
160 O
mg/day O
of O
ziprasidone O
, O
which O
reflected O
the O
recommended O
dose O
range O
. O
PET O
scanning O
was O
done O
after O
3 O
weeks O
of O
administration O
and O
at O
trough O
plasma O
levels O
, O
i.e. O
, O
12-16 O
hours O
after O
the O
last O
dose O
. O
RESULTS O
: O
The O
mean O
5-HT(2) O
receptor O
occupancy O
was O
significantly O
higher O
than O
the O
mean O
D(2) O
receptor O
occupancy O
(mean=76% O
, O
SD=15% O
, O
and O
mean=56% O
, O
SD=18% O
, O
respectively) O
. O
The O
estimated O
plasma O
ziprasidone O
concentration O
associated O
with O
50% O
maximal O
5-HT(2) O
receptor O
occupancy O
was O
almost O
four O
times O
lower O
than O
that O
for O
D(2) O
receptor O
occupancy O
. O
CONCLUSIONS O
: O
These O
data O
affirm O
that O
ziprasidone O
is O
similar O
to O
other O
novel O
antipsychotics O
in O
having O
greater O
5-HT(2) O
than O
D(2) O
receptor O
occupancy O
at O
therapeutic O
doses O
and O
suggest O
that O
the O
optimal O
effective O
dose O
of O
ziprasidone O
is O
closer O
to O
120 O
mg/day O
than O
to O
the O
lower O
doses O
suggested O
by O
previous O
PET O
studies O
. O
The O
relatively O
high O
D(2) B
receptor I
occupancy O
, O
even O
at O
trough O
plasma O
levels O
, O
suggests O
that O
ziprasidone O
is O
more O
similar O
to O
risperidone O
and O
olanzapine O
in O
receptor O
occupancy O
profile O
than O
to O
clozapine O
and O
quetiapine O
. O
Since O
ziprasidone O
plasma O
levels O
show O
significant O
(more O
than O
twofold) O
variation O
within O
a O
single O
dose O
cycle O
, O
studies O
that O
are O
aimed O
at O
peak O
plasma O
levels O
(6 O
hours O
after O
the O
last O
dose) O
and O
that O
examine O
extrastriatal O
regions O
are O
required O
to O
fully O
characterize O
the O
in O
vivo O
occupancy O
profile O
of O
ziprasidone O
. O

SB224289 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
5-HT1B O
receptors O
, O
alpha2A/2C- O
and O
, O
to O
a O
lesser O
extent O
, O
alpha1-adrenoceptors O
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow O
. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v O
. O
bolus O
injection O
of O
, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control) O
, O
or O
the O
antagonists O
SB224289 O
(300 O
microg/kg; O
5-HT1B) B
 O
, O
BRL15572 O
(300 O
microg/kg; O
5-HT1D) O
, O
rauwolscine O
(300 O
microg/kg; O
alpha2) O
, O
SB224289 O
+ O
BRL15572 O
(300 O
microg/kg O
each) O
, O
SB224289 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
BRL15572 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg; O
alpha1) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
BRL44408 O
(1,000 O
microg/kg; O
alpha2A) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg)+ O
imiloxan O
(1,000 O
microg/kg; O
alpha2B) O
, O
or O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
MK912 O
(300 O
microg/kg; O
alpha2C) O
. O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine O
(0.56 O
, O
1 O
, O
1.8 O
, O
3.1 O
, O
5.6 O
, O
10 O
and O
18 O
microg/min) O
, O
following O
a O
cumulative O
schedule O
. O
In O
saline-pretreated O
animals O
, O
ergotamine O
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate O
. O
These O
control O
responses O
were O
: O
unaffected O
by O
SB224289 O
, O
BRL15572 O
, O
rauwolscine O
or O
the O
combinations O
of O
SB224289 O
+ O
BRL15572 O
, O
BRL15572 O
+ O
rauwolscine O
, O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
, O
or O
SB224289 O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors O
. O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Protective O
Effects O
of O
a O
Purified O
Saponin O
Mixture O
from O
Astragalus O
corniculatus O
Bieb. O
, O
in O
vivo O
Hepatotoxicity O
Models.In O
this O
study O
, O
the O
in O
vivo O
effects O
of O
a O
purified O
saponin O
mixture O
(PSM) O
, O
obtained O
from O
Astragalus O
corniculatus O
Bieb. O
, O
were O
investigated O
using O
two O
in O
vivo O
hepatotoxicity O
models O
based O
on O
liver O
damage O
caused O
by O
paracetamol O
(PC) O
and O
carbon O
tetrachloride O
(CCl4 O
) O
. O
The O
effects O
of O
PSM O
were O
compared O
with O
silymarin O
. O
Male O
Wistar O
rats O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate B
dehydrogenase I
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Lifelong O
exposure O
to O
bisphenol O
a O
alters O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
DNA O
methylation O
in O
adult O
mice.Bisphenol O
A O
(BPA) O
is O
an O
estrogenizing O
endocrine O
disruptor O
compound O
of O
concern O
. O
Our O
objective O
was O
to O
test O
whether O
lifelong O
BPA O
would O
impact O
cardiac O
structure/function O
, O
calcium O
homeostasis O
protein O
expression O
, O
and O
the O
DNA O
methylation O
of O
cardiac O
genes O
. O
We O
delivered O
0.5 O
and O
5.0 O
µg/kg/day O
BPA O
lifelong O
from O
gestation O
day O
11 O
or O
200 O
µg/kg/day O
from O
gestation O
day O
11 O
to O
postnatal O
day O
21 O
via O
the O
drinking O
water O
to O
C57bl/6n O
mice O
. O
BPA O
5.0 O
males O
and O
females O
had O
increased O
body O
weight O
, O
body O
mass O
index O
, O
body O
surface O
area O
, O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA B
methyltransferase I
3a I
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
epigenetic O
DNA O
methylation O
marks O
in O
males O
and O
females O
. O

leukotriene O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene B
receptor I
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids O
were O
studied O
. O
The O
patients' O
symptoms O
were O
evaluated O
by O
asthma O
diary O
and O
twice-daily O
peak O
flow O
monitoring O
. O
RESULTS O
: O
Of O
the O
206 O
patients O
enrolled O
, O
197 O
were O
eligible O
for O
analysis O
. O
The O
pranlukast O
group O
(n O
= O
98) O
showed O
statistically O
significant O
improvement O
in O
asthma O
symptoms O
, O
including O
asthma O
attack O
rate O
, O
daily O
living O
score O
, O
and O
morning O
and O
evening O
asthma O
scores O
. O
Pranlukast O
significantly O
reduced O
the O
consumption O
of O
beta2-agonist O
. O
Compared O
with O
the O
placebo O
group O
, O
forced O
vital O
capacity O
(FVC) O
and O
forced O
expiratory O
volume O
in O
1 O
s O
(FEV1) O
were O
not O
significantly O
higher O
in O
the O
pranlukast O
group O
. O
Morning O
and O
evening O
peak O
expiratory O
flow O
(PEF) O
were O
significantly O
increased O
after O
pranlukast O
treatment O
at O
weeks O
2 O
and O
4 O
(380.8 O
+/- O
10.1 O
L/min O
at O
baseline O
, O
394.5 O
+/- O
10.1 O
at O
week O
2 O
, O
396.3 O
+/- O
10.4 O
at O
week O
4) O
. O
There O
were O
no O
serious O
adverse O
reactions O
. O
CONCLUSION O
: O
Pranlukast O
, O
an O
oral O
leukotriene O
antagonist O
, O
was O
well O
tolerated O
and O
was O
effective O
for O
the O
management O
of O
mild-to-moderate O
asthma O
. O

TZD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase.Thiazolidinediones O
(TZDs) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase O
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase B
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism O
. O
Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O
or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
activity O
, O
and O
osteocalcin O
production O
were O
measured O
. O
TZDs O
inhibited O
estradiol O
production O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

lithium O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 B
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Carvedilol O
modulates O
the O
expression O
of O
hypoxia-inducible O
factor-1alpha O
and O
vascular O
endothelial O
growth O
factor O
in O
a O
rat O
model O
of O
volume-overload O
heart O
failure.BACKGROUND O
: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure O
. O
Hypoxia-inducible O
factor-1alpha O
(HIF-1alpha) O
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium O
. O
However O
, O
the O
expression O
of O
HIF-1alpha O
in O
chronic O
heart O
failure O
resulting O
from O
volume O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known O
. O
METHODS O
AND O
RESULTS O
: O
To O
test O
the O
hypothesis O
that O
HIF-1alpha O
plays O
a O
role O
in O
the O
failing O
myocardium O
because O
of O
volume O
overload O
, O
an O
aorta-caval O
shunt O
was O
created O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
volume-overload O
heart O
failure O
. O
Carvedilol O
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O
was O
given O
. O
The O
heart O
weight O
and O
body O
weight O
ratio O
increased O
from O
2.6 O
+/- O
0.3 O
in O
the O
sham O
group O
to O
3.9 O
+/- O
0.7 O
(P O
< O
.001) O
in O
the O
shunt O
group O
. O
Left O
ventricular O
end-diastolic O
dimension O
increased O
from O
6.5 O
+/- O
0.5 O
mm O
to O
8.7 O
+/- O
0.6 O
mm O
(P O
< O
.001) O
. O
Treatment O
with O
carvedilol O
in O
the O
shunt O
group O
reversed O
the O
heart O
weight O
and O
ventricular O
dimension O
to O
the O
baseline O
values O
. O
Western O
blot O
showed O
that O
HIF-1alpha O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
brain O
natriuretic O
peptide O
(BNP) O
proteins O
were O
upregulated O
and O
nerve O
growth O
factor-beta O
(NGF-beta) O
downregulated O
in O
the O
shunt O
group O
. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
increased O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha B
, O
VEGF O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O
. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha O
and O
VEGF O
in O
the O
failing O
ventricular O
myocardium O
. O

captopril O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase B
A I
(MMP-2) O
by O
batimastat O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril O
, O
on O
metalloproteinase O
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro O
, O
and O
on O
local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice O
. O
The O
effect O
of O
BB-94 O
and O
captopril O
on O
the O
survival O
of O
the O
3LL-tumor-bearing O
mice O
was O
also O
examined O
. O
Here O
we O
report O
that O
captopril O
treatment O
resulted O
in O
decreased O
transcription O
and O
protein O
levels O
of O
gelatinase O
A O
by O
3LL O
cells O
. O
Both O
BB-94 O
and O
captopril O
also O
prevented O
substrate O
degradation O
by O
gelatinase O
A O
and O
B O
released O
in O
conditioned O
medium O
by O
cultured O
cells O
. O
Treatment O
of O
tumor-bearing O
animals O
with O
BB-94 O
(i.p.) O
or O
captopril O
(in O
drinking O
water) O
resulted O
in O
significant O
inhibition O
of O
the O
mean O
tumor O
volume O
(25 O
and O
33% O
respectively) O
and O
of O
the O
mean O
lung O
metastasis O
number O
(26 O
and O
29% O
respectively) O
. O
When O
both O
agents O
were O
given O
, O
they O
acted O
in O
synergy O
, O
resulting O
in O
51 O
and O
80% O
inhibition O
of O
tumor O
growth O
and O
metastasis O
. O
The O
survival O
time O
of O
the O
mice O
treated O
with O
both O
BB-94 O
and O
captopril O
was O
also O
significantly O
longer O
compared O
with O
the O
groups O
treated O
with O
each O
agent O
alone O
or O
with O
the O
vehicle O
. O
Our O
data O
support O
the O
hypothesis O
of O
an O
essential O
role O
of O
metalloproteinase(s) O
in O
the O
metastatic O
process O
. O
Moreover O
, O
blockade O
of O
invasion O
, O
angiogenesis O
and O
other O
processes O
mediated O
by O
metalloproteinases O
may O
underlie O
the O
anti-tumor O
and O
anti-metastatic O
effect O
of O
BB-94 O
and O
captopril O
and O
their O
combination O
. O
It O
is O
conceivable O
that O
this O
combination O
could O
be O
tested O
in O
selected O
clinical O
conditions O
as O
an O
adjuvant O
modality O
to O
cytotoxic O
therapy O
. O

AH O
6809 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandins O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors I
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

epinastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like B
receptor I
, O
located O
to O
sensory O
nerves O
. O

DL-alpha-difluoromethylornithine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine B
decarboxylase I
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Felbamate O
block O
of O
recombinant O
N-methyl-D-aspartate O
receptors O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O
the O
specificity O
of O
felbamate O
block O
of O
recombinant O
NMDA B
receptors I
composed O
of O
the O
NR1a O
subunit O
and O
various O
NR2 O
subunits O
. O
Felbamate O
produced O
a O
rapid O
, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA O
and O
10 O
microM O
glycine O
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat O
NR1a O
subunit O
, O
and O
either O
the O
NR2A O
, O
NR2B O
or O
NR2C O
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6 O
, O
0.52 O
and O
2.4 O
mM O
, O
respectively O
(holding O
potential O
, O
- O
60 O
mV) O
. O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and O
, O
in O
kinetic O
analyses O
, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O
functions O
, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KIT O
D816V B
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Artemisinic O
acid O
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP O
α-dependent O
expression O
of O
HMG-CoA O
reductase O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG B
CoA I
reductase I
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
NF-kappa O
B O
by O
sodium O
salicylate O
and O
aspirin.The O
transcription O
factor O
nuclear O
factor-kappa O
B O
(NF-kappa O
B) O
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 O
(IL-1) O
, O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa B
B I
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig O
kappa O
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

anisomycin O
acts O
as O
NOT O
for O
what O
entity O
? O
p38 O
Mitogen O
Activated O
Protein O
Kinase O
Regulates O
the O
Nuclear O
Receptor O
CAR O
to O
Activate O
the O
CYP2B6 O
Gene.The O
constitutive O
active/androstane O
receptor O
(CAR) O
regulates O
hepatic O
drug O
metabolism O
by O
activating O
genes O
such O
as O
cytochrome O
P450 O
(CYP) O
and O
certain O
transferases O
. O
p38 O
mitogen O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 B
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O
understood O
by O
ligand O
binding O
alone O
because O
the O
specificity O
and O
magnitude O
of O
induction O
are O
co-determined O
by O
a O
given O
cell O
signaling O
such O
as O
p38 O
MAPK; O
both O
physiological O
and O
pathophysiological O
states O
of O
cell O
signaling O
may O
have O
a O
strong O
impact O
in O
hepatic O
drug O
metabolizing O
capability O
during O
therapeutic O
treatments O
. O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Methylphenidate O
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition O
, O
motivated O
behaviors O
, O
appetite O
, O
and O
stress.Thousands O
of O
children O
receive O
methylphenidate O
(MPH; O
Ritalin) O
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD) O
, O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH O
treatment O
are O
unknown O
. O
To O
mimic O
clinical O
Ritalin O
treatment O
in O
children O
, O
male O
rats O
were O
injected O
with O
MPH O
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural B
cell I
adhesion I
molecule) I
 O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O
involved O
in O
motivated O
behaviors O
, O
cognition O
, O
appetite O
, O
and O
stress O
. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time O
, O
chronic O
modulation O
of O
young O
brains O
with O
MPH O
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood O
. O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T B
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

prostaglandin O
E2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
essential O
oil O
and O
its O
constituents O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
through O
blocking O
JNK O
, O
ERK O
and O
NF-κB O
signaling O
pathways O
in O
LPS-activated O
RAW O
264.7 O
cells.We O
investigated O
the O
composition O
of O
essential O
oil O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase B
(COX)-2 I
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O
N-terminal O
kinase O
(JNK) O
and O
extracellular O
signal-regulated O
kinase O
(ERK) O
but O
not O
that O
of O
p38 O
mitogen-activated O
protein O
kinase O
. O
These O
results O
indicate O
that O
FCEO O
inhibits O
LPS-stimulated O
inflammation O
by O
blocking O
the O
NF-κB O
, O
JNK O
, O
and O
ERK O
pathways O
in O
macrophages O
, O
and O
demonstrate O
that O
FCEO O
possesses O
anti-inflammatory O
properties O
. O

naltrexone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
[Pharmacological O
effects O
of O
a O
mu-opioid B
receptor I
antagonist O
naltrexone O
on O
alcohol O
dependence].Alcohol O
is O
one O
of O
the O
most O
commonly O
abused O
substances O
, O
and O
its O
chronic O
intake O
leads O
to O
the O
development O
of O
ethanol O
dependence O
in O
both O
humans O
and O
laboratory O
animals O
. O
In O
many O
countries O
, O
a O
mu-opioid O
receptor O
antagonist O
naltrexone O
has O
been O
used O
in O
the O
treatment O
of O
alcohol O
dependence O
. O
The O
introduction O
of O
naltrexone O
for O
the O
treatment O
of O
alcohol O
dependence O
has O
been O
mainly O
based O
on O
behavioral O
animal O
models O
that O
provide O
evidence O
of O
the O
involvement O
of O
the O
endogenous O
opioid O
system O
in O
alcohol O
drinking O
and O
dependence O
. O
It O
has O
been O
well O
known O
that O
alcohol O
leads O
to O
the O
activation O
of O
the O
endogenous O
opioid O
system O
. O
The O
endogenous O
opioid O
agonists O
, O
such O
as O
beta-endorphin O
, O
increase O
the O
activity O
of O
the O
mesolimbic O
dopaminergic O
system O
through O
the O
inhibition O
of O
the O
gamma-aminobutyric O
acid O
(GABA)-containing O
inhibitory O
interneurons O
in O
the O
ventral O
tegmental O
area O
, O
resulting O
in O
the O
expression O
of O
alcohol O
reinforcement O
and/or O
rewarding O
effect O
. O
Therefore O
, O
naltrexone O
, O
which O
is O
useful O
for O
alcohol O
dependence O
therapy O
, O
may O
attenuate O
the O
rewarding O
effect O
of O
ethanol O
by O
interfering O
with O
the O
ethanol-induced O
stimulation O
of O
the O
mesolimbic O
dopaminergic O
system O
. O
The O
following O
review O
provides O
a O
summary O
of O
the O
interactions O
between O
endogenous O
opioid O
system O
and O
mesolimbic O
dopaminergic O
system O
in O
alcohol O
dependence O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt B
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

ammonium O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Influence O
of O
nitrogen O
supply O
on O
the O
production O
of O
higher O
alcohols/esters O
and O
expression O
of O
flavour-related O
genes O
in O
cachaça O
fermentation.This O
study O
provides O
the O
first O
attempt O
to O
analyse O
the O
influence O
of O
ammonium O
supplements O
on O
sugar-cane O
juice O
fermentation O
and O
the O
flavour O
profile O
in O
a O
cachaça O
industrial O
process O
. O
The O
objective O
was O
to O
find O
a O
relationship O
between O
higher O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich B
pathway I
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol O
acyl-transferase O
EEB1 O
and O
the O
acyl O
esterase O
IAH1 O
. O

tyrosine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Tissue-type O
plasminogen O
activator O
acts O
as O
a O
cytokine O
that O
triggers O
intracellular O
signal O
transduction O
and O
induces O
matrix O
metalloproteinase-9 O
gene O
expression.Tissue-type O
plasminogen O
activator O
(tPA) O
, O
a O
serine O
protease O
well O
known O
for O
generating O
plasmin O
, O
has O
been O
demonstrated O
to O
induce O
matrix O
metalloproteinase-9 O
(MMP-9) O
gene O
expression O
and O
protein O
secretion O
in O
renal O
interstitial O
fibroblasts O
. O
However O
, O
exactly O
how O
tPA O
transduces O
its O
signal O
into O
the O
nucleus O
to O
control O
gene O
expression O
is O
unknown O
. O
This O
study O
investigated O
the O
mechanism O
by O
which O
tPA O
induces O
MMP-9 O
gene O
expression O
. O
Both O
wild-type O
and O
non-enzymatic O
mutant O
tPA O
were O
found O
to O
induce O
MMP-9 O
expression O
in O
rat O
kidney O
interstitial O
fibroblasts O
(NRK-49F) O
, O
indicating O
that O
the O
actions O
of O
tPA O
are O
independent O
of O
its O
proteolytic O
activity O
. O
tPA O
bound O
to O
the O
low O
density O
lipoprotein O
receptor-related O
protein-1 O
(LRP-1) O
in O
NRK-49F O
cells O
, O
and O
this O
binding O
was O
competitively O
abrogated O
by O
the O
LRP-1 O
antagonist O
, O
the O
receptor-associated O
protein O
. O
In O
mouse O
embryonic O
fibroblasts O
(PEA-13) O
lacking O
LRP-1 O
, O
tPA O
failed O
to O
induce O
MMP-9 O
expression O
. O
Furthermore O
, O
tPA O
induced O
rapid O
tyrosine O
phosphorylation O
on O
the O
beta O
subunit O
of O
LRP-1 O
, O
which O
was O
followed O
by O
the O
activation O
of O
Mek1 O
and O
its O
downstream O
Erk-1 B
and I
-2 I
. O
Blockade O
of O
Erk-1/2 O
activation O
by O
the O
Mek1 O
inhibitor O
abolished O
MMP-9 O
induction O
by O
tPA O
in O
NRK-49F O
cells O
. O
Conversely O
, O
overexpression O
of O
constitutively O
activated O
Mek1 O
induced O
Erk-1/2 O
phosphorylation O
and O
MMP-9 O
expression O
. O
In O
mouse O
obstructed O
kidney O
, O
tPA O
, O
LRP-1 O
, O
and O
MMP-9 O
were O
concomitantly O
induced O
in O
the O
renal O
interstitium O
. O
Collectively O
, O
these O
results O
suggest O
that O
besides O
its O
classical O
proteolytic O
activity O
, O
tPA O
acts O
as O
a O
cytokine O
that O
binds O
to O
the O
cell O
membrane O
receptor O
LRP-1 O
, O
induces O
its O
tyrosine O
phosphorylation O
, O
and O
triggers O
intracellular O
signal O
transduction O
, O
thereby O
inducing O
specific O
gene O
expression O
in O
renal O
interstitial O
fibroblasts O
. O

lovastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Statins O
increase O
p21 O
through O
inhibition O
of O
histone O
deacetylase O
activity O
and O
release O
of O
promoter-associated O
HDAC1/2.Statins O
are O
3-hydroxy-3-methylglutaryl-CoA O
reductase O
inhibitors O
broadly O
used O
for O
the O
control O
of O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 B
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O
protein O
binding O
assay O
and O
chromatin O
immunoprecipitation O
assay O
showed O
the O
dissociation O
of O
HDAC1/2 O
and O
association O
of O
CBP O
, O
leading O
to O
the O
histone-H3 O
acetylation O
on O
the O
Sp1 O
sites O
of O
p21 O
promoter O
. O
In O
vitro O
cell O
proliferation O
and O
in O
vivo O
tumor O
growth O
were O
both O
inhibited O
by O
statins O
. O
These O
results O
suggest O
a O
novel O
mechanism O
for O
statins O
through O
abrogation O
of O
the O
HDAC O
activity O
and O
promoter O
histone-H3 O
acetylation O
to O
regulate O
p21 O
expression O
. O
Therefore O
, O
statins O
might O
serve O
as O
novel O
HDAC O
inhibitors O
for O
cancer O
therapy O
and O
chemoprevention O
. O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK- B
mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
In O
vitro O
investigation O
of O
efficacy O
of O
new O
reactivators O
on O
OPC O
inhibited O
rat O
brain O
acetylcholinesterase.Organophosphorus O
compounds O
(OPC) O
were O
developed O
as O
warfare O
nerve O
agents O
. O
They O
are O
also O
widely O
used O
as O
pesticides O
. O
The O
drug O
therapy O
of O
intoxication O
with O
OPC O
includes O
mainly O
combination O
of O
cholinesterase O
(ChE) O
reactivators O
and O
cholinolytics O
. O
There O
is O
no O
single O
ChE O
reactivator O
having O
an O
ability O
to O
reactivate O
sufficiently O
the O
inhibited O
enzyme O
due O
to O
the O
high O
variability O
of O
chemical O
structure O
of O
the O
inhibitors O
. O
The O
difficulties O
in O
reactivation O
of O
ChE O
activity O
and O
slight O
antidote O
effect O
regarding O
intoxication O
with O
some O
OPC O
are O
some O
of O
the O
reasons O
for O
continuous O
efforts O
to O
obtain O
new O
reactivators O
of O
ChE O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
some O
ChE O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat O
brain O
AChE O
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

GCS O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 B
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

serotonin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
( O
SERT) B
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA-induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin O
, O
but O
may O
occur O
in O
response O
to O
some O
other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA O
. O

2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
a O
heme O
binding O
protein O
from O
the O
genome O
of O
Saccharomyces O
cerevisiae.The O
YLR205c O
gene O
of O
Saccharomyces O
cerevisiae O
does O
not O
show O
significant O
sequence O
identity O
to O
any O
known O
gene O
, O
except O
for O
heme O
oxygenase O
(22% O
to O
human O
HO-1) O
. O
The O
YLR205 O
ORF O
was O
cloned O
and O
overexpressed O
in O
both O
Escherichia O
coli O
and O
S O
. O
cerevisiae O
. O
Both O
expression O
systems O
yielded O
proteins O
that O
bound O
heme O
tightly O
. O
The O
isolated O
YLR205c O
protein O
underwent O
reduction O
in O
the O
presence O
of O
either O
NADPH-cytochrome O
P450 O
reductase O
or O
NADH-putidaredoxin-putidaredoxin O
reductase O
but O
did O
not O
exhibit O
heme O
oxygenase O
activity O
. O
The O
protein O
exhibited O
modest O
H(2)O(2)-dependent O
peroxidase B
activities O
with O
guaiacol O
, O
potassium O
iodide O
, O
and O
2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic O
acid O
(ABTS) O
. O
Thus O
, O
YLR205c O
codes O
for O
a O
hemoprotein O
of O
unknown O
physiological O
function O
that O
exhibits O
peroxidase O
activity O
. O

DHT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR B
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

N-ethylmaleimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acyl-CoA O
synthetase O
isoforms O
1 O
, O
4 O
, O
and O
5 O
are O
present O
in O
different O
subcellular O
membranes O
in O
rat O
liver O
and O
can O
be O
inhibited O
independently.Inhibition O
studies O
have O
suggested O
that O
acyl-CoA O
synthetase O
(ACS O
, O
EC O
) O
isoforms O
might O
regulate O
the O
use O
of O
acyl-CoAs O
by O
different O
metabolic O
pathways O
. O
In O
order O
to O
determine O
whether O
the O
subcellular O
locations O
differed O
for O
each O
of O
the O
three O
ACSs O
present O
in O
liver O
and O
whether O
these O
isoforms O
were O
regulated O
independently O
, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
. O
ACS1 O
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O
ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS O
isoforms O
in O
unique O
subcellular O
locations O
. O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Estimation O
of O
warfarin O
maintenance O
dose O
based O
on O
VKORC1 O
(-1639 O
G>A) O
and O
CYP2C9 O
genotypes.BACKGROUND O
: O
CYP2C9 O
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin O
clearance O
and O
lower O
maintenance O
dosage O
. O
Decreased O
expression O
of O
VKORC1 B
resulting O
from O
the O
-1639G>A O
substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin O
dose O
requirements O
. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O
allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O
were O
lowest O
in O
patients O
with O
the O
VKORC1 O
-1639AA O
genotype O
and O
demonstrated O
a O
positive O
association O
with O
the O
VKORC1 O
-1639G O
allele O
copy O
number O
(trend O
P O
= O
0.012) O
. O
A O
model O
including O
VKORC1 O
and O
CYP2C9 O
genotypes O
, O
age O
, O
sex O
, O
and O
body O
weight O
accounted O
for O
61% O
of O
the O
variance O
in O
warfarin O
daily O
maintenance O
dose O
. O
CONCLUSIONS O
: O
The O
VKORC1 O
-1639A O
allele O
accounts O
for O
low O
dosage O
requirements O
of O
most O
patients O
without O
a O
CYP2C9 O
variant O
. O
Higher O
plasma O
S-warfarin O
concentrations O
corresponding O
to O
increased O
warfarin O
maintenance O
dosages O
support O
a O
hypothesis O
for O
increased O
expression O
of O
the O
VKORC1 O
-1639G O
allele O
. O
VKORC1 O
and O
CYP2C9 O
genotypes O
, O
age O
, O
sex O
, O
and O
body O
weight O
account O
for O
the O
majority O
of O
variance O
in O
warfarin O
dose O
among O
our O
study O
population O
. O

ritonavir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
mechanisms O
responsible O
for O
garlic O
- O
drug O
interactions O
and O
their O
in O
vivo O
relevance.Garlic O
phytochemicals O
and O
garlic O
supplements O
influence O
the O
pharmacokinetic O
and O
pharmacodynamic O
behavior O
of O
concomitantly O
ingested O
drugs O
. O
In O
this O
paper O
we O
have O
summarized O
the O
mechanisms O
responsible O
for O
first-pass O
intestinal O
pharmacokinetic O
interactions O
by O
investigating O
the O
intestinal O
permeability O
of O
some O
cardiovascular O
, O
antiviral O
drugs O
, O
their O
transport O
with O
hepatic O
transporters O
and O
CYP3A4 O
metabolism O
. O
Transporter-enzyme O
interplay O
was O
studied O
with O
several O
in O
vitro O
models O
of O
varying O
complexity O
: O
rat O
small O
intestine O
and O
Caco-2 O
cell O
monolayers O
were O
used O
in O
studies O
of O
intestinal O
processes O
, O
and O
hepatic O
pharmacokinetics O
was O
monitored O
in O
HepG2 O
cells O
, O
isolated O
rat O
hepatocytes O
and O
rat O
liver O
slices O
. O
Garlic O
phytochemicals O
from O
aged O
garlic O
extract O
modified O
the O
activities O
of O
secretory O
and O
absorptive O
transporters O
in O
both O
intestine O
and O
liver O
and O
competitively O
inhibited O
CYP3A4 O
enzyme O
. O
The O
increased O
activities O
of O
the O
most O
important O
intestinal O
efflux O
(P-glycoprotein O
- O
Pgp O
, O
Multidrug O
Resistance O
Associated O
Protein O
2 O
- O
MRP-2 O
, O
Breast O
Cancer O
Resistance O
Protein O
- O
BCRP) O
and O
uptake O
(MonoCarboxylate O
Transporter O
1 O
- O
MCT1 O
, O
Organic O
Anion O
Transporting O
Polypeptide O
- O
OATP O
, O
Peptide O
transporter O
1 O
- O
PepT1) O
transporters O
were O
caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications O
. O
Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human B
immunodeficiency I
virus I
protease I
inhibitors O
saquinavir O
and O
ritonavir O
have O
already O
been O
performed O
, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first-pass O
intestinal O
metabolism O
changes O
. O
We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O
novel O
drug O
darunavir O
and O
other O
cardiovascular O
drugs O
. O
Finally O
, O
selected O
garlic O
phytochemicals O
were O
tested O
for O
their O
ability O
to O
influence O
P-glycoprotein O
and O
CYP3A4 O
activities O
. O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sphingosine-1-phosphate O
promotes O
the O
nuclear O
translocation O
of O
β-catenin O
and O
thereby O
induces O
osteoprotegerin O
gene O
expression O
in O
osteoblast-like O
cell O
lines.Sphingosine-1-phosphate O
(S1P) O
is O
a O
well-known O
signaling O
sphingolipid O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin O
/ O
T-cell B
factor I
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O
of O
β-catenin O
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin O
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

quinone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Quinone O
compounds O
regulate O
the O
level O
of O
ROS O
production O
by O
the O
NADPH O
oxidase O
Nox4.NADPH O
oxidase O
Nox4 O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
(Cys226 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
. O
Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones O
and O
Nox4 O
are O
implicated O
. O

VP-16 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 B
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

dimethocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
comparison O
of O
the O
reinforcing O
and O
dopamine O
transporter O
effects O
of O
local O
anesthetics O
in O
rhesus O
monkeys.Dopaminergic O
mechanisms O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
reinforcing O
effects O
of O
cocaine O
. O
Similar O
to O
cocaine O
, O
other O
local O
anesthetics O
bind O
to O
the O
dopamine O
transporter O
(DAT) O
and O
inhibit O
DA O
uptake O
in O
rodent O
and O
monkey O
brain O
. O
Additionally O
, O
local O
anesthetics O
are O
self-administered O
in O
rhesus O
monkeys O
, O
indicative O
of O
abuse O
liability O
. O
The O
present O
study O
examined O
the O
reinforcing O
and O
DAT O
effects O
of O
the O
local O
anesthetics O
dimethocaine O
, O
procaine O
and O
cocaine O
using O
in O
vivo O
techniques O
. O
Monkeys O
were O
trained O
to O
respond O
under O
a O
second-order O
schedule O
for O
i.v O
. O
cocaine O
administration O
(0.10 O
or O
0.30 O
mg/kg/infusion) O
. O
When O
responding O
was O
stable O
, O
dimethocaine O
(0.030-1.7 O
mg/kg O
/ O
infusion) O
or O
procaine O
(0.10-10 O
mg/kg O
/ O
infusion) O
was O
substituted O
for O
the O
cocaine O
training O
dose O
. O
Dimethocaine O
administration O
produced O
higher O
response O
rates O
compared O
with O
that O
of O
procaine O
, O
and O
was O
a O
more O
potent O
reinforcer O
. O
Drug O
effects O
on O
behavior O
were O
related O
to O
DAT O
occupancy O
in O
monkey O
striatum O
during O
neuroimaging O
with O
positron O
emission O
tomography O
(PET) O
. O
DAT O
occupancy O
was O
determined O
by O
displacement O
of O
8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane O
(FECNT) O
. O
DAT B
occupancy O
was O
between O
66 O
and O
82% O
and O
<10-41% O
for O
doses O
of O
dimethocaine O
and O
procaine O
that O
maintained O
maximum O
response O
rates O
, O
respectively O
. O
Finally O
, O
in O
vivo O
microdialysis O
in O
awake O
subjects O
determined O
drug-induced O
changes O
in O
extracellular O
DA O
in O
the O
caudate O
nucleus O
. O
There O
was O
close O
correspondence O
between O
peak O
increases O
in O
DA O
and O
DAT O
occupancy O
. O
Overall O
, O
reinforcing O
effects O
were O
consistent O
with O
DAT O
effects O
determined O
with O
in O
vivo O
techniques O
. O
The O
results O
further O
support O
a O
role O
for O
the O
DAT O
in O
the O
abuse O
liability O
of O
local O
anesthetics O
. O

2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
pharmacology O
at O
AMPA O
and O
kainate O
preferring O
glutamate O
receptors O
of O
4-heteroarylmethylidene O
glutamate O
analogues.2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O
potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O
kainic B
acid I
(KA) I
receptors I
, O
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 O
subtype O
of O
KA O
receptors O
and O
much O
lower O
affinity O
for O
the O
GluR2 O
subtype O
of O
AMPA O
receptors O
. O
As O
an O
attempt O
to O
develop O
new O
pharmacological O
tools O
for O
studies O
of O
GluR5 O
receptors O
, O
(S)-E-4-(2-thiazolylmethylene)glutamic O
acid O
(4a) O
was O
designed O
as O
a O
structural O
hybrid O
between O
1 O
and O
3 O
. O
4a O
was O
shown O
to O
be O
a O
potent O
GluR5 O
agonist O
and O
a O
high O
affinity O
ligand O
and O
to O
indiscriminately O
bind O
to O
the O
AMPA O
receptor O
subtypes O
GluR1-4 O
with O
lower O
affinities O
. O
Compounds O
4b-h O
, O
in O
which O
the O
2-thiazolyl O
substituent O
of O
4a O
was O
replaced O
by O
other O
heterocyclic O
rings O
, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA O
analogues O
, O
as O
exemplified O
by O
1 O
were O
also O
synthesized O
. O
Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 O
and O
GluR5 O
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA O
analogues O
as O
AMPA O
receptor O
agonists O
. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O
mapping O
of O
the O
GluR5 O
agonist O
binding O
site O
. O

clopidogrel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
P2Y12 O
, O
a O
new O
platelet O
ADP O
receptor O
, O
target O
of O
clopidogrel.Clopidogrel O
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced O
platelet O
aggregation O
. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel O
over O
aspirin O
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction O
, O
stroke O
, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease O
. O
The O
antiaggregating O
effect O
of O
clopidogrel O
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP O
binding O
to O
a O
purinergic O
receptor O
present O
at O
the O
platelet O
surface O
. O
Clopidogrel O
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O
ADP O
, O
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets O
. O
The O
binding O
of O
(33)P-2MeS-ADP O
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
with O
a O
potency O
that O
was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets O
. O
In O
these O
transfected O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet B
receptor I
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP O
on O
platelets O
. O

noradrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O
. O

methyleugenol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
vivo O
genotoxicity O
of O
methyleugenol O
in O
gpt B
delta O
transgenic O
rats O
following O
medium-term O
exposure.Methyleugenol O
(MEG) O
, O
which O
is O
commonly O
used O
as O
a O
fragrance O
and O
flavoring O
agent O
, O
has O
been O
shown O
to O
induce O
hepatocellular O
tumors O
in O
rodents O
. O
However O
, O
the O
role O
of O
genotoxicity O
as O
a O
possible O
mechanism O
of O
action O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O
metabolite O
of O
MEG O
has O
been O
identified O
. O
In O
this O
study O
, O
a O
gpt O
delta O
transgenic O
rat O
model O
was O
used O
to O
clarify O
whether O
genotoxic O
mechanisms O
are O
involved O
in O
MEG-induced O
hepatocarcinogenesis O
following O
medium-term O
exposure O
. O
F344 O
gpt O
delta O
rats O
were O
subjected O
to O
repeated O
oral O
administration O
of O
MEG O
at O
dosages O
of O
0 O
, O
10 O
, O
30 O
, O
or O
100mg/kg O
(a O
carcinogenic O
dose) O
for O
13 O
weeks O
. O
The O
relative O
weight O
of O
the O
liver O
of O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
and O
the O
absolute O
weight O
of O
the O
liver O
of O
the O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
(GST-P) O
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

tyrphostine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA B
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O
and O
of O
6.46-13.52 O
for O
inhibiting O
ScCA O
over O
hCA O
II O
. O
The O
model O
organism O
S O
. O
cerevisiae O
and O
this O
particular O
enzyme O
may O
be O
useful O
for O
detecting O
antifungals O
with O
a O
novel O
mechanism O
of O
action O
compared O
to O
the O
classical O
azole O
drugs O
to O
which O
significant O
drug O
resistance O
emerged O
. O
Indeed O
, O
some O
of O
these O
sulfonamides O
inhibited O
the O
growth O
of O
the O
yeast O
with O
CC50-s O
in O
the O
range O
of O
0.73-6.54μM O
. O

alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Endogenous O
opioid O
systems O
and O
alcohol O
addiction.Alcohol O
exerts O
numerous O
pharmacological O
effects O
through O
its O
interaction O
with O
various O
neurotransmitters O
and O
neuromodulators O
. O
Among O
the O
latter O
, O
the O
endogenous O
opioids O
play O
a O
key O
role O
in O
the O
rewarding O
(addictive) O
properties O
of O
ethanol O
. O
Three O
types O
of O
opioid O
receptors O
(mu O
, O
delta O
and O
kappa) O
represent O
the O
respective O
targets O
of O
the O
major O
opioid O
peptides O
(beta-endorphin O
, O
enkephalins O
and O
dynorphins O
, O
respectively) O
. O
The O
rewarding O
(reinforcing) O
properties O
of O
mu- O
and O
delta-receptor O
ligands O
are O
brought O
by O
activation O
of O
the O
mesolimbic O
dopamine O
system O
which O
ascends O
from O
the O
ventral O
tegmentum O
of O
the O
midbrain O
(VTA) O
to O
rostral O
structures; O
of O
these O
, O
the O
nucleus O
accumbens O
(NAC) O
is O
of O
particular O
importance O
in O
drug O
addiction O
. O
In O
contrast O
, O
dysphoria O
results O
from O
activation O
of O
kappa-receptors O
. O
The O
neurochemical O
manifestations O
of O
these O
opposing O
effects O
are O
, O
respectively O
, O
increases O
and O
decreases O
in O
dopamine O
release O
in O
the O
NAC O
. O
Several O
lines O
of O
evidence O
indicate O
that O
alcohol O
interferes O
with O
endogenous O
opioid O
mechanisms O
which O
are O
closely O
linked O
with O
dopamine O
transmission O
in O
the O
mesolimbic O
pathway O
. O
The O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid B
peptide I
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase O
, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease O
, O
alcohol O
consumption O
. O
Conversely O
, O
opioid O
antagonists O
such O
as O
naloxone O
and O
naltrexone O
(which O
bind O
to O
non-selectively O
opioid O
receptors) O
have O
been O
shown O
to O
decrease O
alcohol O
consumption O
under O
various O
experimental O
conditions O
. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- O
or O
delta-receptor O
antagonists O
are O
administered O
. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol O
also O
support O
the O
view O
that O
alcohol O
intake O
depends O
on O
the O
activity O
of O
the O
endogenous O
opioid O
reward O
system O
and O
that O
alcohol O
consumption O
may O
serve O
to O
compensate O
for O
inherent O
deficits O
in O
this O
system O
. O
One O
hypothetical O
model O
proposes O
that O
reward O
results O
from O
activation O
of O
mu-opioid O
receptors O
in O
the O
VTA O
and/or O
delta-receptor O
in O
the O
NAC; O
both O
these O
nuclei O
are O
targets O
of O
endogenous O
beta-endorphin O
. O
It O
is O
suggested O
that O
alcohol O
interferes O
with O
this O
reward O
pathway O
either O
directly O
or O
indirectly O
. O
The O
available O
experimental O
data O
accord O
well O
with O
those O
obtained O
from O
clinical O
studies O
which O
opioid O
antagonists O
have O
been O
used O
to O
prevent O
relapse O
in O
alcoholics O
. O
Conceptual O
considerations O
concerning O
communalities O
between O
various O
forms O
of O
addictions O
are O
also O
discussed O
in O
this O
review O
. O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
vascular O
protective O
properties O
of O
kinsenoside O
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose O
condition.Anoectochilus O
roxburghii O
is O
a O
traditional O
Chinese O
herb O
used O
for O
the O
treatment O
of O
diabetes O
and O
some O
other O
diseases O
. O
The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide B
dismutase I
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes-related O
changes O
in O
mice O
aortas O
after O
kinsenoside O
(20 O
and O
50μg/mL) O
treatment O
. O
These O
results O
indicated O
that O
kinsenoside O
might O
be O
a O
promising O
agent O
for O
the O
treatment O
of O
diabetic O
vascular O
disease O
. O

H4biopterin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Tyrosine O
hydroxylase O
binds O
tetrahydrobiopterin O
cofactor O
with O
negative O
cooperativity O
, O
as O
shown O
by O
kinetic O
analyses O
and O
surface O
plasmon O
resonance O
detection.Kinetic O
studies O
of O
tetrameric O
recombinant O
human O
tyrosine O
hydroxylase O
isoform O
1 O
(hTH1) O
have O
revealed O
properties O
so O
far O
not O
reported O
for O
this O
enzyme O
. O
Firstly O
, O
with O
the O
natural O
cofactor O
(6R)-Lerythro-5,6,7 O
, O
8-tetrahydrobiopterin O
(H4biopterin) O
a O
time-dependent O
change O
(burst) O
in O
enzyme O
activity O
was O
observed O
, O
with O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient O
. O
Secondly O
, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin O
with O
a O
pronounced O
negative O
cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM) O
. O
On O
phosphorylation O
of O
Ser40 O
by O
protein O
kinase O
A O
, O
the O
affinity O
for O
H4biopterin O
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O
negative O
cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03) O
. O
The O
dimeric O
C-terminal O
deletion O
mutant O
(Delta473-528) O
of O
hTH1 B
also O
showed O
negative O
cooperativity O
of O
H4biopterin O
binding O
(h O
= O
0.4) O
. O
Cooperativity O
was O
not O
observed O
with O
the O
cofactor O
analogues O
6-methyl-5,6,7,8-tetrahydropterin O
(h O
= O
0.9 O
+/- O
0.1; O
Km O
= O
62.7 O
+/- O
5.7 O
microM) O
and O
3-methyl-5,6,7 O
, O
8-tetrahydropterin O
(H43-methyl-pterin)(h O
= O
1.0 O
+/- O
0.1; O
Km O
= O
687 O
+/- O
50 O
microM) O
. O
In O
the O
presence O
of O
1 O
mM O
H43-methyl-pterin O
, O
used O
as O
a O
competitive O
cofactor O
analogue O
to O
BH4 O
, O
hyperbolic O
saturation O
curves O
were O
also O
found O
for O
H4biopterin O
(h O
= O
1.0) O
, O
thus O
confirming O
the O
genuine O
nature O
of O
the O
kinetic O
negative O
cooperativity O
. O
This O
cooperativity O
was O
confirmed O
by O
real-time O
biospecific O
interaction O
analysis O
by O
surface O
plasmon O
resonance O
detection O
. O
The O
equilibrium O
binding O
of O
H4biopterin O
to O
the O
immobilized O
iron-free O
apoenzyme O
results O
in O
a O
saturable O
positive O
resonance O
unit O
(DeltaRU) O
response O
with O
negative O
cooperativity O
(h O
= O
0.52-0.56) O
. O
Infrared O
spectroscopic O
studies O
revealed O
a O
reduced O
thermal O
stability O
both O
of O
the O
apo-and O
the O
holo-hTH1 O
on O
binding O
of O
H4biopterin O
and O
Lerythro-dihydrobiopterin O
(H2biopterin) O
. O
Moreover O
, O
the O
ligand-bound O
forms O
of O
the O
enzyme O
also O
showed O
a O
decreased O
resistance O
to O
limited O
tryptic O
proteolysis O
. O
These O
findings O
indicate O
that O
the O
binding O
of O
H4biopterin O
at O
the O
active O
site O
induces O
a O
destabilizing O
conformational O
change O
in O
the O
enzyme O
which O
could O
be O
related O
to O
the O
observed O
negative O
cooperativity O
. O
Thus O
, O
our O
studies O
provide O
new O
insight O
into O
the O
regulation O
of O
TH O
by O
the O
concentration O
of O
H4biopterin O
which O
may O
have O
significant O
implications O
for O
the O
physiological O
regulation O
of O
catecholamine O
biosynthesis O
in O
neuroendocrine O
cells O
. O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Lifelong O
exposure O
to O
bisphenol O
a O
alters O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
DNA O
methylation O
in O
adult O
mice.Bisphenol O
A O
(BPA) O
is O
an O
estrogenizing O
endocrine O
disruptor O
compound O
of O
concern O
. O
Our O
objective O
was O
to O
test O
whether O
lifelong O
BPA O
would O
impact O
cardiac O
structure/function O
, O
calcium O
homeostasis O
protein O
expression O
, O
and O
the O
DNA O
methylation O
of O
cardiac O
genes O
. O
We O
delivered O
0.5 O
and O
5.0 O
µg/kg/day O
BPA O
lifelong O
from O
gestation O
day O
11 O
or O
200 O
µg/kg/day O
from O
gestation O
day O
11 O
to O
postnatal O
day O
21 O
via O
the O
drinking O
water O
to O
C57bl/6n O
mice O
. O
BPA O
5.0 O
males O
and O
females O
had O
increased O
body O
weight O
, O
body O
mass O
index O
, O
body O
surface O
area O
, O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium B
calcium I
exchanger-1 I
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
epigenetic O
DNA O
methylation O
marks O
in O
males O
and O
females O
. O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt B
b5 I
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

pemetrexed O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Cellular O
and O
pharmacogenetics O
foundation O
of O
synergistic O
interaction O
of O
pemetrexed O
and O
gemcitabine O
in O
human O
non-small-cell O
lung O
cancer O
cells.Gemcitabine O
and O
pemetrexed O
are O
effective O
agents O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
(NSCLC) O
, O
and O
the O
present O
study O
investigates O
cellular O
and O
genetic O
aspects O
of O
their O
interaction O
against O
A549 O
, O
Calu-1 O
, O
and O
Calu-6 O
cells O
. O
Cells O
were O
treated O
with O
pemetrexed O
and O
gemcitabine O
, O
and O
their O
interaction O
was O
assessed O
using O
the O
combination O
index O
. O
The O
role O
of O
drug O
metabolism O
in O
gemcitabine O
cytotoxicity O
was O
examined O
with O
inhibitors O
of O
deoxycytidine O
kinase O
(dCK) O
, O
5'-nucleotidase O
, O
and O
cytidine O
deaminase O
, O
whereas O
the O
role O
of O
pemetrexed O
targets O
, O
thymidylate O
synthase O
(TS) O
, O
dihydrofolate O
reductase O
(DHFR) O
, O
and O
glycinamide O
ribonucleotide O
formyltransferase O
(GARFT) O
in O
drug O
chemosensitivity O
was O
analyzed O
in O
cytotoxicity O
rescue O
studies O
. O
The O
effect O
of O
gemcitabine O
and O
pemetrexed O
on O
Akt O
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay O
, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug O
. O
Synergistic O
cytotoxicity O
was O
demonstrated O
, O
and O
pemetrexed O
significantly O
decreased O
the O
amount O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK O
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O
of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O
. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt O
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O
genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed O
enhances O
dCK O
and O
hENT1 B
expression O
, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O
for O
rational O
development O
of O
chemotherapy O
combinations O
. O

4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase B
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol B
3-kinase I
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramide O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
' O
Rac B
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
( O
CSE) B
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) B
 O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O
cloned O
from O
a O
human O
brain O
library O
. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart O
, O
liver O
and O
lung O
. O
Within O
the O
brain O
, O
erg3 O
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal O
, O
parietal O
and O
occipital O
lobes O
. O
Transient O
expression O
of O
erg3 O
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) O
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 O
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs O
. O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine B
D(2) I
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O
1.3 O
mg/day) O
and O
haloperidol O
(HAL O
, O
n O
= O
11 O
, O
8.5 O
+/- O
5.5 O
mg/day) O
. O
MATERIALS O
AND O
METHODS O
: O
Each O
patient O
underwent O
two O
PET O
scans O
with O
3-N-[(11)C]methylspiperone O
(target O
: O
frontal O
5-HT(2A)) O
, O
[(11)C]SCH23390 O
(striatal O
D(1)) O
or O
[(11)C]raclopride O
(striatal O
D(2)) O
. O
RO O
was O
calculated O
as O
the O
percentage O
reduction O
of O
specific O
binding O
in O
comparison O
with O
healthy O
controls O
. O
RESULTS O
: O
D(2)-RO O
under O
FLX O
was O
between O
50% O
and O
70% O
, O
indicating O
an O
ED(50) O
of O
about O
0.7 O
ng/ml O
serum O
. O
5-HT(2A) O
and O
D(1)-RO O
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean O
, O
SEM) O
. O
Under O
HAL O
, O
D(1)-RO O
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero O
. O
CONCLUSIONS O
: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) O
and O
D(1) O
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol O
, O
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation O
. O
Therefore O
, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
, O
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism O
. O
However O
, O
these O
data O
suggest O
that O
mechanisms O
other O
than O
D(1) O
or O
5-HT(2A) O
antagonism O
may O
contribute O
to O
flupentixol's O
efficacy O
on O
negative O
symptoms O
. O

imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS B
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
investigation O
of O
efficacy O
of O
new O
reactivators O
on O
OPC O
inhibited O
rat O
brain O
acetylcholinesterase.Organophosphorus O
compounds O
(OPC) O
were O
developed O
as O
warfare O
nerve O
agents O
. O
They O
are O
also O
widely O
used O
as O
pesticides O
. O
The O
drug O
therapy O
of O
intoxication O
with O
OPC O
includes O
mainly O
combination O
of O
cholinesterase O
(ChE) O
reactivators O
and O
cholinolytics O
. O
There O
is O
no O
single O
ChE O
reactivator O
having O
an O
ability O
to O
reactivate O
sufficiently O
the O
inhibited O
enzyme O
due O
to O
the O
high O
variability O
of O
chemical O
structure O
of O
the O
inhibitors O
. O
The O
difficulties O
in O
reactivation O
of O
ChE O
activity O
and O
slight O
antidote O
effect O
regarding O
intoxication O
with O
some O
OPC O
are O
some O
of O
the O
reasons O
for O
continuous O
efforts O
to O
obtain O
new O
reactivators O
of O
ChE O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
some O
ChE O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

quinones O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Quinone O
compounds O
regulate O
the O
level O
of O
ROS O
production O
by O
the O
NADPH O
oxidase O
Nox4.NADPH O
oxidase O
Nox4 O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 O
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
(Cys226 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
. O
Such O
model O
of O
Nox4 B
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones O
and O
Nox4 O
are O
implicated O
. O

sulprostone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC B
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

sodium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Block O
of O
human B
NaV1.5 I
sodium O
channels O
by O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
phenytoin.Voltage-gated O
sodium O
(Na) O
channels O
are O
a O
critical O
component O
of O
electrically O
excitable O
cells O
. O
Phenytoin O
(diphenylhydantoin O
, O
DPH) O
is O
an O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O
examined O
including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
phenyl O
ring O
substitutions O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O
greater O
activity O
. O
In O
comparison O
to O
diphenylhydantoin O
, O
the O
novel O
chloro-substituted O
alpha-hydroxyphenylamide O
compounds O
produced O
as O
much O
as O
a O
20-fold O
greater O
tonic O
and O
frequency-dependent O
blockade O
of O
Na(V)1.5 O
channels O
with O
an O
IC(50) O
value O
of O
14.5 O
microM O
. O
In O
addition O
, O
the O
chloro-substitutions O
have O
position O
specific O
state O
dependent O
blocking O
properties O
. O
The O
ortho- O
, O
meta- O
and O
para-chloro O
substitutions O
have O
an O
8- O
, O
13- O
and O
3-fold O
increased O
affinity O
for O
the O
inactivated O
state O
, O
respectively O
. O
Molecular O
modeling O
suggests O
that O
these O
differences O
in O
affinity O
are O
due O
to O
a O
direct O
interaction O
with O
the O
receptor O
. O
Comparing O
models O
of O
diphenylhydantoin O
to O
the O
novel O
alpha-hydroxyphenlyamide O
compound O
suggests O
that O
the O
increased O
activity O
may O
be O
due O
to O
an O
optimized O
phenyl O
ring O
position O
and O
increased O
molecular O
volume O
. O
This O
information O
may O
be O
useful O
in O
the O
development O
of O
more O
potent O
sodium O
channel O
blockers O
. O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O
study O
, O
we O
used O
immunohistochemistry O
to O
investigate O
the O
expression O
of O
TK-1 O
and O
TS O
in O
various O
types O
of O
cancer O
. O
TK-1 O
and O
TS O
expression O
was O
markedly O
different O
between O
cancer O
types O
. O
High O
TK-1 O
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS B
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
. O
In O
non-small O
cell O
lung O
cancers O
, O
high O
TK-1 O
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas O
, O
but O
not O
in O
adenocarcinomas O
. O
This O
result O
suggests O
that O
TAS-102 O
efficacy O
and O
the O
pyrimidine O
synthetic O
pathway O
may O
differ O
depending O
on O
histological O
type O
. O
Our O
results O
indicate O
that O
administration O
of O
TAS-102 O
could O
be O
selected O
on O
the O
basis O
of O
the O
immunohistochemical O
evaluation O
of O
TK-1 O
and O
TS O
. O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Bimodal O
occurrence O
of O
aspartoacylase O
in O
myelin O
and O
cytosol O
of O
brain.The O
growing O
use O
of O
N-acetylaspartate O
as O
an O
indicator O
of O
neuronal O
viability O
has O
fostered O
interest O
in O
the O
biological O
function(s) O
of O
this O
unusual O
amino O
acid O
derivative O
. O
In O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
( O
ASPA) B
 O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O
method O
for O
the O
assay O
of O
ASPA O
. O
That O
observation O
, O
together O
with O
previous O
demonstrations O
of O
numerous O
lipid-synthesizing O
enzymes O
in O
myelin O
, O
suggests O
utilization O
of O
acetyl O
groups O
liberated O
by O
myelin-localized O
ASPA O
for O
lipid O
synthesis O
within O
the O
myelin O
sheath O
. O
Such O
synthesis O
might O
be O
selective O
and O
could O
explain O
the O
deficit O
of O
myelin O
lipids O
in O
animals O
lacking O
ASPA O
. O

Fluorescein O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescein O
Conjugates O
as O
GluN1 B
/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B O
. O
To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound O
, O
ifenprodil O
. O
We O
performed O
chemical O
modifications O
of O
ifenprodil O
at O
the O
benzylic O
position O
and O
on O
the O
phenol O
ring O
by O
introducing O
secondary O
amine O
or O
amide O
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary O
amide O
functions O
as O
spacers O
. O
The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O
the O
inhibition O
of O
NMDA-induced O
Ca(2+) O
influx O
by O
calcium O
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1-1A O
and O
GluN2B O
. O
Further O
investigations O
revealed O
that O
this O
probe O
had O
a O
neuroprotective O
effect O
equivalent O
to O
that O
of O
ifenprodil O
in O
a O
standard O
test O
for O
neurotoxicity O
. O
Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil O
, O
we O
demonstrated O
that O
they O
displaced O
[(3) O
H]ifenprodil O
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

Safrole-2',3'-oxide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Safrole-2',3'-oxide O
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein B
E I
-knockout O
mice.Safrole-2',3'-oxide O
(SFO) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole O
(4-allyl-1 O
, O
2-methylenedioxybenzene) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO-induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

(m)CpGs O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3- B
(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
( O
SP) B
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

ketone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Monocarboxylate O
transporters O
in O
the O
central O
nervous O
system O
: O
distribution O
, O
regulation O
and O
function O
. O
Monocarboxylate B
transporters I
(MCTs) O
are O
proton-linked O
membrane O
carriers O
involved O
in O
the O
transport O
of O
monocarboxylates O
such O
as O
lactate O
, O
pyruvate O
, O
as O
well O
as O
ketone O
bodies O
. O
They O
belong O
to O
a O
larger O
family O
of O
transporters O
composed O
of O
14 O
members O
in O
mammals O
based O
on O
sequence O
homologies O
. O
MCTs O
are O
found O
in O
various O
tissues O
including O
the O
brain O
where O
three O
isoforms O
, O
MCT1 O
, O
MCT2 O
and O
MCT4 O
, O
have O
been O
described O
. O
Each O
of O
these O
isoforms O
exhibits O
a O
distinct O
regional O
and O
cellular O
distribution O
in O
rodent O
brain O
. O
At O
the O
cellular O
level O
, O
MCT1 O
is O
expressed O
by O
endothelial O
cells O
of O
microvessels O
, O
by O
ependymocytes O
as O
well O
as O
by O
astrocytes O
. O
MCT4 O
expression O
appears O
to O
be O
specific O
for O
astrocytes O
. O
By O
contrast O
, O
the O
predominant O
neuronal O
monocarboxylate O
transporter O
is O
MCT2 O
. O
Interestingly O
, O
part O
of O
MCT2 O
immunoreactivity O
is O
located O
at O
postsynaptic O
sites O
, O
suggesting O
a O
particular O
role O
of O
monocarboxylates O
and O
their O
transporters O
in O
synaptic O
transmission O
. O
In O
addition O
to O
variation O
in O
expression O
during O
development O
and O
upon O
nutritional O
modifications O
, O
new O
data O
indicate O
that O
MCT O
expression O
is O
regulated O
at O
the O
translational O
level O
by O
neurotransmitters O
. O
Understanding O
how O
transport O
of O
monocarboxylates O
is O
regulated O
could O
be O
of O
particular O
importance O
not O
only O
for O
neuroenergetics O
but O
also O
for O
areas O
such O
as O
functional O
brain O
imaging O
, O
regulation O
of O
food O
intake O
and O
glucose O
homeostasis O
, O
or O
for O
central O
nervous O
system O
disorders O
such O
as O
ischaemia O
and O
neurodegenerative O
diseases O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6- B
catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

2-Arylpropionic O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
2-Arylpropionic O
CXC O
chemokine O
receptor O
1 O
(CXCR1) O
ligands O
as O
novel O
noncompetitive O
CXCL8 B
inhibitors.The O
CXC O
chemokine O
CXCL8/IL-8 O
plays O
a O
major O
role O
in O
the O
activation O
and O
recruitment O
of O
polymorphonuclear O
(PMN) O
cells O
at O
inflammatory O
sites O
. O
CXCL8 O
activates O
PMNs O
by O
binding O
the O
seven-transmembrane O
(7-TM) O
G-protein-coupled O
receptors O
CXC O
chemokine O
receptor O
1 O
(CXCR1) O
and O
CXC O
chemokine O
receptor O
2 O
(CXCR2) O
. O
(R)-Ketoprofen O
(1) O
was O
previously O
reported O
to O
be O
a O
potent O
and O
specific O
noncompetitive O
inhibitor O
of O
CXCL8-induced O
human O
PMNs O
chemotaxis O
. O
We O
report O
here O
molecular O
modeling O
studies O
showing O
a O
putative O
interaction O
site O
of O
1 O
in O
the O
TM O
region O
of O
CXCR1 O
. O
The O
binding O
model O
was O
confirmed O
by O
alanine O
scanning O
mutagenesis O
and O
photoaffinity O
labeling O
experiments O
. O
The O
molecular O
model O
driven O
medicinal O
chemistry O
optimization O
of O
1 O
led O
to O
a O
new O
class O
of O
potent O
and O
specific O
inhibitors O
of O
CXCL8 O
biological O
activity O
. O
Among O
these O
, O
repertaxin O
(13) O
was O
selected O
as O
a O
clinical O
candidate O
drug O
for O
prevention O
of O
post-ischemia O
reperfusion O
injury O
. O

RES O
701-1 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Threshold O
concentrations O
of O
endothelin-1 O
: O
the O
effects O
on O
contractions O
induced O
by O
5-hydroxytryptamine O
in O
isolated O
rat O
cerebral O
and O
mesenteric O
arteries.This O
study O
compares O
the O
effects O
of O
threshold O
concentrations O
of O
endothelin-1 O
in O
isolated O
rat O
basilar O
arteries O
with O
those O
in O
mesenteric O
arterial O
branches O
and O
investigates O
the O
mechanisms O
of O
inhibitory O
and O
potentiating O
endothelin-1-effects O
. O
In O
basilar O
arteries O
, O
endothelin-1 O
reduces O
the O
contractions O
induced O
by O
5-hydroxytryptamine O
(5-HT) O
, O
by O
the O
thromboxane O
A2 O
agonist O
U46619 O
, O
and O
by O
vasopressin O
. O
The O
inhibitory O
effect O
of O
endothelin-1 O
on O
the O
contraction O
induced O
by O
5-HT O
is O
abolished O
by O
deendothelialization O
, O
by O
the O
endothelin B
ET(B) I
receptor I
antagonist O
RES O
701-1 O
, O
by O
indomethacin O
, O
or O
by O
glibenclamide O
. O
In O
mesenteric O
arteries O
, O
endothelin-1 O
potentiates O
the O
contractile O
effects O
of O
5-HT O
, O
U46619 O
, O
and O
vasopressin O
. O
The O
potentiation O
of O
the O
contractile O
effect O
induced O
by O
5-HT O
is O
only O
somewhat O
modified O
by O
deendothelialization O
, O
but O
abolished O
by O
the O
thromboxane O
A2 O
receptor O
antagonists O
GR32191 O
and O
ridogrel O
. O
U46619 O
potentiates O
the O
5-HT-effect O
in O
mesenteric O
arteries O
. O
Thus O
, O
though O
the O
contractile O
endothelin O
ET(A) O
receptors O
were O
not O
blocked O
, O
threshold O
concentrations O
of O
endothelin-1 O
inhibited O
contractile O
effects O
in O
the O
rat O
basilar O
artery O
via O
activation O
of O
endothelial O
ET(B) O
receptors O
. O
Prostaglandins O
and O
ATP-sensitive O
K+ O
channels O
are O
involved O
in O
this O
inhibitory O
action O
. O
In O
contrast O
, O
endothelin-1 O
potentiates O
contractile O
actions O
in O
mesenteric O
arteries O
via O
the O
release O
of O
endogeneous O
thromboxane O
A2 O
from O
non-endothelial O
cells O
. O
The O
study O
points O
out O
the O
completely O
different O
role O
of O
the O
endothelium O
in O
combined O
effects O
of O
endothelin-1 O
between O
cerebral O
and O
mesenteric O
arteries O
. O

Pulsatilla O
saponin O
D O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SB365 O
, O
Pulsatilla O
saponin O
D O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT B
/mTOR O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer O
. O
We O
found O
that O
SB365 O
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis O
. O
Also O
, O
SB365 O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer O
. O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R B
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

(-)-tamsulosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha O
1 O
adrenoceptor O
antagonists O
at O
prostatic O
alpha O
1 O
adrenoceptors O
: O
binding O
, O
functional O
and O
in O
vivo O
studies.1 O
. O
The O
profile O
of O
a O
range O
of O
alpha O
1 O
adrenoceptor O
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human O
alpha O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human B
alpha I
1D I
adrenoceptors I
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O
17053 O
= O
SNAP O
1069 O
. O
4 O
. O
(-)-Tamsulosin O
was O
a O
very O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity O
, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O
this O
model O
. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha O
1 O
adrenoceptor O
mediating O
noradrenaline-induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O
1 O
adrenoceptors O
, O
particularly O
over O
the O
alpha O
1D O
subtype O
, O
appear O
to O
inhibit O
phenylephrine-induced O
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure O
. O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Fisetin O
averts O
oxidative O
stress O
in O
pancreatic O
tissues O
of O
streptozotocin-induced O
diabetic O
rats.Persistent O
hyperglycemia O
is O
associated O
with O
chronic O
oxidative O
stress O
which O
contributes O
to O
the O
development O
and O
progression O
of O
diabetes-associated O
complications O
. O
The O
sensitivity O
of O
pancreatic O
β-cells O
to O
oxidative O
stress O
has O
been O
attributed O
to O
their O
low O
content O
of O
antioxidants O
compared O
with O
other O
tissues O
. O
Bioactive O
compounds O
with O
potent O
antidiabetic O
properties O
have O
been O
shown O
to O
ameliorate O
hyperglycemia O
mediated O
oxidative O
stress O
. O
Recently O
, O
we O
have O
reported O
that O
oral O
administration O
of O
fisetin O
(10 O
mg/Kg O
b.w.) O
, O
a O
bioflavonoid O
found O
to O
be O
present O
in O
strawberries O
, O
persimmon O
, O
to O
STZ-induced O
experimental O
diabetic O
rats O
significantly O
improved O
normoglycemia O
. O
The O
present O
study O
was O
aimed O
to O
evaluate O
the O
antioxidant O
potential O
of O
fisetin O
in O
both O
in O
vitro O
and O
in O
vivo O
. O
Diabetes O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated B
hemoglobin I
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O
the O
antioxidant O
potential O
of O
fisetin O
. O
In O
addition O
, O
the O
results O
of O
DPPH O
and O
ABTS O
assays O
substantiate O
the O
free O
radical O
scavenging O
activity O
of O
fisetin O
. O
Histological O
studies O
of O
the O
pancreas O
also O
evidenced O
the O
tissue O
protective O
nature O
of O
fisetin O
. O
It O
is O
concluded O
that O
, O
fisetin O
possesses O
antioxidant O
and O
anti-inflammatory O
property O
and O
may O
be O
considered O
as O
an O
adjunct O
for O
the O
treatment O
of O
diabetes O
. O

eicosapentaenoic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
acid O
interact O
to O
modify O
iNOS O
mRNA O
levels O
through O
the O
PPARgamma B
/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O
alpha O
and O
gamma O
mRNA O
levels O
. O
In O
Expt O
. O
1 O
, O
macrophages O
were O
collected O
from O
broiler O
chicks O
fed O
3 O
or O
6% O
dietary O
fat O
(g/100 O
g) O
with O
0 O
, O
25 O
, O
and O
50 O
mg O
lutein/kg O
feed O
for O
23 O
d O
. O
In O
Expt O
. O
2 O
, O
using O
a O
3 O
x O
3 O
factorial O
, O
eicosapentaenoic O
acid O
(EPA) O
at O
0 O
, O
15 O
and O
50 O
micromol/L O
and O
lutein O
at O
0 O
, O
10 O
and O
100 O
micromol/L O
were O
applied O
to O
HD11 O
cell O
culture O
for O
24 O
h O
. O
In O
both O
experiments O
, O
cells O
were O
stimulated O
with O
lipopolysaccharide O
before O
RNA O
isolation O
. O
Lutein O
interacted O
with O
fat O
in O
Expt O
. O
1 O
and O
with O
EPA O
in O
Expt O
. O
2 O
to O
affect O
mRNA O
levels O
of O
iNOS O
, O
PPARgamma O
, O
and O
RXRalpha O
in O
chicken O
macrophages O
and O
HD11 O
cells O
, O
respectively O
(P O
< O
0.05) O
. O
At O
3% O
dietary O
fat O
or O
up O
to O
15 O
micromol/L O
EPA O
in O
the O
medium O
, O
increasing O
lutein O
increased O
the O
iNOS O
mRNA O
. O
However O
, O
at O
6% O
dietary O
fat O
or O
50 O
micromol/L O
EPA O
, O
lutein O
did O
not O
cause O
a O
rise O
in O
iNOS O
mRNA O
. O
Increasing O
lutein O
in O
the O
medium O
from O
0 O
to O
100 O
micromol/L O
decreased O
iNOS O
mRNA O
. O
Increasing O
lutein O
with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma O
and O
RXRalpha O
mRNA O
levels O
. O
Lutein O
increased O
PPARalpha O
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma O
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

[3H]RX821002 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Activation O
of O
alpha O
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidate.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor B
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O
intraperitoneal O
injection O
of O
etomidate O
in O
wild-type O
and O
in O
alpha2A-receptor-deficient O
mice O
, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate O
in O
mice O
does O
not O
require O
the O
alpha2A-receptor O
subtype O
. O
Intravenous O
injection O
of O
etomidate O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors O
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O
. O

toluene O
diisocyanate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

Rufinamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rufinamide O
attenuates O
mechanical O
allodynia O
in O
a O
model O
of O
neuropathic O
pain O
in O
the O
mouse O
and O
stabilizes O
voltage-gated B
sodium I
channel I
inactivated O
state.BACKGROUND O
: O
Voltage-gated O
sodium O
channels O
dysregulation O
is O
important O
for O
hyperexcitability O
leading O
to O
pain O
persistence O
. O
Sodium O
channel O
blockers O
currently O
used O
to O
treat O
neuropathic O
pain O
are O
poorly O
tolerated O
. O
Getting O
new O
molecules O
to O
clinical O
use O
is O
laborious O
. O
We O
here O
propose O
a O
drug O
already O
marketed O
as O
anticonvulsant O
, O
rufinamide O
. O
METHODS O
: O
We O
compared O
the O
behavioral O
effect O
of O
rufinamide O
to O
amitriptyline O
using O
the O
Spared O
Nerve O
Injury O
neuropathic O
pain O
model O
in O
mice O
. O
We O
compared O
the O
effect O
of O
rufinamide O
on O
sodium O
currents O
using O
in O
vitro O
patch O
clamp O
in O
cells O
expressing O
the O
voltage-gated O
sodium O
channel O
Nav1.7 O
isoform O
and O
on O
dissociated O
dorsal O
root O
ganglion O
neurons O
to O
amitriptyline O
and O
mexiletine O
. O
RESULTS O
: O
In O
naive O
mice O
, O
amitriptyline O
(20 O
mg/kg) O
increased O
withdrawal O
threshold O
to O
mechanical O
stimulation O
from O
1.3 O
(0.6-1.9) O
(median O
[95% O
CI]) O
to O
2.3 O
g O
(2.2-2.5) O
and O
latency O
of O
withdrawal O
to O
heat O
stimulation O
from O
13.1 O
(10.4-15.5) O
to O
30.0 O
s O
(21.8-31.9) O
, O
whereas O
rufinamide O
had O
no O
effect O
. O
Rufinamide O
and O
amitriptyline O
alleviated O
injury-induced O
mechanical O
allodynia O
for O
4 O
h O
(maximal O
effect O
: O
0.10 O
+/- O
0.03 O
g O
(mean O
+/- O
SD) O
to O
1.99 O
+/- O
0.26 O
g O
for O
rufinamide O
and O
0.25 O
+/- O
0.22 O
g O
to O
1.92 O
+/- O
0.85 O
g O
for O
amitriptyline) O
. O
All O
drugs O
reduced O
peak O
current O
and O
stabilized O
the O
inactivated O
state O
of O
voltage-gated O
sodium O
channel O
Nav1.7 O
, O
with O
similar O
effects O
in O
dorsal O
root O
ganglion O
neurons O
. O
CONCLUSIONS O
: O
At O
doses O
alleviating O
neuropathic O
pain O
, O
amitriptyline O
showed O
alteration O
of O
behavioral O
response O
possibly O
related O
to O
either O
alteration O
of O
basal O
pain O
sensitivity O
or O
sedative O
effect O
or O
both O
. O
Side-effects O
and O
drug O
tolerance/compliance O
are O
major O
problems O
with O
drugs O
such O
as O
amitriptyline O
. O
Rufinamide O
seems O
to O
have O
a O
better O
tolerability O
profile O
and O
could O
be O
a O
new O
alternative O
to O
explore O
for O
the O
treatment O
of O
neuropathic O
pain O
. O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTOR O
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR B
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O
activation O
of O
mTOR O
with O
increase O
in O
Nox4 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
small O
dose O
of O
rapamycin O
reduces O
podocyte O
apoptosis O
, O
attenuates O
glomerular O
injury O
and O
albuminuria O
. O
Our O
data O
provide O
evidence O
for O
a O
novel O
function O
of O
mTOR O
in O
Nox4-derived O
ROS O
generation O
and O
podocyte O
apoptosis O
that O
contributes O
to O
urinary O
albumin O
excretion O
in O
type O
1 O
diabetes O
. O
Thus O
mTOR O
and O
or O
NADPH O
oxidase O
inhibition O
may O
represent O
a O
therapeutic O
modality O
of O
diabetic O
kidney O
disease O
. O

veratridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Verapamil O
prevents O
torsade O
de O
pointes O
by O
reduction O
of O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
early O
afterdepolarizations O
in O
an O
intact O
heart O
model O
of O
LQT3.BACKGROUND O
: O
In O
long O
QT O
syndrome O
(LQTS) O
, O
prolongation O
of O
the O
QT-interval O
is O
associated O
with O
sudden O
cardiac O
death O
resulting O
from O
potentially O
life-threatening O
polymorphic O
tachycardia O
of O
the O
torsade O
de O
pointes O
(TdP) O
type O
. O
Experimental O
as O
well O
as O
clinical O
reports O
support O
the O
hypothesis O
that O
calcium O
channel O
blockers O
such O
as O
verapamil O
may O
be O
an O
appropriate O
therapeutic O
approach O
in O
LQTS O
. O
We O
investigated O
the O
electrophysiologic O
mechanism O
by O
which O
verapamil O
suppresses O
TdP O
, O
in O
a O
recently O
developed O
intact O
heart O
model O
of O
LQT3 O
. O
METHODS O
AND O
RESULTS O
: O
In O
8 O
Langendorff-perfused O
rabbit O
hearts O
, O
veratridine O
(0.1 O
microM) O
, O
an O
inhibitor O
of O
sodium B
channel I
inactivation O
, O
led O
to O
a O
marked O
increase O
in O
QT-interval O
and O
simultaneously O
recorded O
monophasic O
ventricular O
action O
potentials O
(MAPs) O
(p O
< O
0.05) O
thereby O
mimicking O
LQT3 O
. O
In O
bradycardic O
(AV-blocked) O
hearts O
, O
simultaneous O
recording O
of O
up O
to O
eight O
epi- O
and O
endocardial O
MAPs O
demonstrated O
a O
significant O
increase O
in O
total O
dispersion O
of O
repolarization O
(56% O
, O
p O
< O
0.05) O
and O
reverse O
frequency-dependence O
. O
After O
lowering O
potassium O
concentration O
, O
veratridine O
reproducibly O
led O
to O
early O
afterdepolarizations O
(EADs) O
and O
TdP O
in O
6 O
of O
8 O
(75%) O
hearts O
. O
Additional O
infusion O
of O
verapamil O
(0.75 O
microM) O
suppressed O
EADs O
and O
consecutively O
TdP O
in O
all O
hearts O
. O
Verapamil O
significantly O
shortened O
endocardial O
but O
not O
epicardial O
MAPs O
which O
resulted O
in O
significant O
reduction O
of O
ventricular O
transmural O
dispersion O
of O
repolarization O
. O
CONCLUSIONS O
: O
Verapamil O
is O
highly O
effective O
in O
preventing O
TdP O
via O
shortening O
of O
endocardial O
MAPs O
, O
reduction O
of O
left O
ventricular O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
EADs O
in O
an O
intact O
heart O
model O
of O
LQT3 O
. O
These O
data O
suggest O
a O
possible O
therapeutic O
role O
of O
verapamil O
in O
the O
treatment O
of O
LQT3 O
patients O
. O

Tomudex O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Cyclin O
E-cdk2 O
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate O
synthase O
inhibitor O
Tomudex.Tomudex O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O
p53 O
and O
p21(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 B
protein O
expression O
and O
kinase O
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O
cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O
Cyclin O
D1 O
, O
cyclin O
B O
, O
cdk4 O
, O
and O
cdc2 O
protein O
expression O
and O
kinase O
activities O
remain O
constant O
. O
Lack O
of O
activation O
of O
cyclin O
A- O
and O
B-cdc2 O
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases O
. O
Increased O
cyclin O
E-cdk2 O
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days O
. O
Tomudex O
treatment O
resulted O
in O
a O
time-dependent O
induction O
of O
the O
megabase O
DNA O
fragments O
, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation O
. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase O
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex O
are O
not O
p53 O
dependent O
. O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Alcohol O
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl B
CpG-binding I
proteins I
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
development O
. O

SB216763 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β B
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

β-ionone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved- O
caspase-3 B
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

ONO-8713 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O
E O
synthase-1 O
, O
and O
EP(1) O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) B
receptor I
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O
treated O
with O
COX O
inhibitors O
. O
This O
study O
suggests O
that O
PGE(2) O
is O
important O
for O
MB O
growth O
and O
that O
therapies O
targeting O
the O
prostanoid O
metabolic O
pathway O
are O
potentially O
beneficial O
and O
should O
be O
tested O
in O
clinical O
settings O
for O
treatment O
of O
children O
with O
MB O
. O

cAMP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
The O
microsomal/peroxidase O
antigen O
: O
modulation O
of O
its O
expression O
in O
thyroid O
cells.Evidence O
has O
accumulated O
in O
the O
last O
few O
years O
that O
the O
expression O
of O
the O
microsomal/peroxidase B
antigen I
(M/TPO-Ag) O
in O
thyroid O
cells O
is O
induced O
by O
TSH O
, O
through O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO O
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O
is O
due O
to O
a O
direct O
transcriptional O
regulation O
of O
the O
TPO O
gene O
, O
as O
shown O
in O
dog O
thyroid O
cells O
, O
or O
to O
posttranscriptional O
effects O
, O
as O
it O
would O
appear O
in O
FRTL-5 O
cells O
, O
remains O
to O
be O
clarified O
by O
future O
experiments O
. O
Thyroid O
stimulating O
antibody O
(TSAb) O
of O
Graves' O
disease O
also O
stimulates O
the O
expression O
of O
M/TPO-Ag O
. O
This O
finding O
gives O
further O
support O
to O
the O
relevance O
of O
TSAb O
in O
the O
pathogenesis O
of O
hyperthyroidism O
and O
explains O
the O
well O
known O
observation O
that O
the O
"microsomal" O
antigen O
is O
particularly O
abundant O
in O
glands O
of O
Graves' O
patients O
. O
The O
modulation O
of O
M/TPO-Ag O
surface O
expression O
by O
TSH O
can O
explain O
the O
decrease O
of O
circulating O
anti-MAb O
observed O
during O
L-thyroxine O
therapy O
in O
hypothyroid O
patients O
with O
Hashimoto's O
thyroiditis O
. O
Other O
agents O
, O
such O
as O
methimazole O
and O
sodium O
iodide O
, O
which O
influence O
thyroid O
cell O
function O
, O
do O
not O
directly O
interfere O
with O
the O
expression O
of O
M/TPO-Ag O
. O
Cytokines O
, O
such O
as O
gamma-interferon O
, O
interleukin-1 O
, O
and O
interleukin-6 O
have O
been O
shown O
to O
inhibit O
the O
TSH-induced O
increase O
of O
TPO O
mRNA O
, O
but O
further O
investigations O
are O
required O
to O
elucidate O
the O
exact O
role O
of O
cytokines O
in O
the O
regulation O
of O
M/TPO-Ag O
expression O
. O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Mechanisms O
of O
agonist-induced O
down-regulation O
of O
the O
human O
kappa-opioid O
receptor O
: O
internalization O
is O
required O
for O
down-regulation.Previously O
, O
we O
showed O
that O
the O
human O
kappa-opioid O
receptor O
(hkor) O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O
receptors O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynamin O
I-K44A O
significantly O
reduced O
U50,488H-induced O
down-regulation O
of O
the O
hkor B
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7-N125I O
blunted O
U50,488H-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O
down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes O
for O
degradation O
. O
Thus O
, O
U50,488H-induced O
internalization O
and O
down-regulation O
of O
the O
hkor O
share O
initial O
common O
mechanisms O
. O
To O
the O
best O
of O
our O
knowledge O
, O
these O
results O
represent O
the O
first O
report O
on O
the O
involvement O
of O
both O
rab5 O
and O
rab7 O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O
In O
addition O
, O
this O
study O
is O
among O
the O
first O
to O
show O
the O
involvement O
of O
proteasomes O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O

oxysterols O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Absence O
of O
correlation O
between O
oxysterol O
accumulation O
in O
lipid O
raft O
microdomains O
, O
calcium O
increase O
, O
and O
apoptosis O
induction O
on O
158N O
murine O
oligodendrocytes.There O
is O
some O
evidence O
that O
oxidized O
derivatives O
of O
cholesterol O
, O
7-ketocholesterol O
(7KC) O
and O
7β-hydroxycholesterol O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O
found O
with O
the O
different O
oxysterols O
, O
whereas O
strong O
signals O
were O
detected O
with O
ionomycin O
used O
as O
positive O
control O
. O
At O
concentrations O
which O
induced O
apoptosis O
, O
7KC O
but O
not O
7βOHC O
accumulated O
in O
lipid O
rafts O
. O
Although O
not O
cytotoxic O
, O
27OHC O
was O
mainly O
detected O
in O
lipid O
rafts O
. O
It O
is O
noteworthy O
that O
α-tocopherol O
(but O
not O
ellagic O
acid O
and O
resveratrol) O
was O
able O
to O
counteract O
7KC- O
and O
7βOHC-induced O
apoptosis O
and O
to O
decrease O
the O
accumulation O
of O
7KC O
and O
27OHC O
in O
lipid O
rafts O
. O
Thus O
, O
in O
158N O
cells O
, O
the O
ability O
of O
oxysterols O
to O
trigger O
a O
mode O
of O
cell O
death O
by O
apoptosis O
involving O
GSK-3 O
and O
caspase-3 B
activation O
is O
independent O
of O
the O
increase O
in O
the O
Ca(2+) O
level O
and O
of O
their O
accumulation O
in O
lipid O
raft O
microdomains O
. O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR B
/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

glucose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
G6PC2 O
: O
A O
Negative O
Regulator O
of O
Basal O
Glucose-Stimulated O
Insulin O
Secretion.Elevated O
fasting O
blood O
glucose O
(FBG) O
is O
associated O
with O
increased O
risk O
for O
the O
development O
of O
type O
2 O
diabetes O
and O
cardiovascular-associated O
mortality O
. O
Genome-wide O
association O
studies O
(GWAS) O
have O
linked O
polymorphisms O
in O
G6PC2 O
with O
variations O
in O
FBG O
and O
body O
fat O
, O
although O
not O
insulin O
sensitivity O
or O
glucose O
tolerance O
. O
G6PC2 O
encodes O
an O
islet-specific O
, O
endoplasmic O
reticulum-resident O
glucose-6-phosphatase O
catalytic O
subunit O
. O
A O
combination O
of O
in O
situ O
perfused O
pancreas O
, O
in O
vitro O
isolated O
islet O
, O
and O
in O
vivo O
analyses O
were O
used O
to O
explore O
the O
function O
of O
G6pc2 O
in O
mice O
. O
G6pc2 O
deletion O
had O
little O
effect O
on O
insulin O
sensitivity O
and O
glucose O
tolerance O
, O
whereas O
body O
fat O
was O
reduced O
in O
female O
G6pc2 O
knockout O
(KO) O
mice O
on O
both O
a O
chow O
and O
high-fat O
diet O
, O
observations O
that O
are O
all O
consistent O
with O
human O
GWAS O
data O
. O
G6pc2 O
deletion O
resulted O
in O
a O
leftward O
shift O
in O
the O
dose-response O
curve O
for O
glucose-stimulated O
insulin B
secretion O
(GSIS) O
. O
As O
a O
consequence O
, O
under O
fasting O
conditions O
in O
which O
plasma O
insulin O
levels O
were O
identical O
, O
blood O
glucose O
levels O
were O
reduced O
in O
G6pc2 O
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O
mice O
. O
These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose-6-phosphate O
, O
thereby O
reducing O
glycolytic O
flux O
. O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 B
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1 O
/ O
CIP1) B
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

OMT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Neuroprotective O
effects O
of O
oxymatrine O
against O
excitotoxicity O
partially O
through O
down-regulation O
of O
NR2B-containing O
NMDA O
receptors.Oxymatrine O
(OMT) O
is O
a O
major O
bioactive O
component O
derived O
from O
Sophora O
flavescens O
Ait O
(kushen) O
, O
which O
is O
widely O
used O
in O
Chinese O
medicine O
. O
Recent O
studies O
have O
shown O
that O
it O
has O
neuroprotective O
effects; O
however O
, O
its O
underlying O
mechanisms O
remain O
unclear O
. O
We O
focus O
on O
the O
mechanisms O
of O
pharmacologic O
action O
in O
OMT O
by O
detecting O
its O
pharmacological O
properties O
against O
focal O
cerebral O
ischemia O
in O
vivo O
and O
NMDA-induced O
neurotoxicity O
in O
vitro O
. O
OMT O
prevented O
cerebral O
ischemic O
injury O
in O
mice O
induced O
via O
a O
2 O
h O
middle O
cerebral O
artery O
occlusion O
and O
a O
24 O
h O
reperfusion O
, O
in O
vivo O
. O
In O
vitro O
cultured O
neurons O
challenged O
with O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA B
receptors I
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

As(III) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Arsenic O
activates O
endothelin-1 O
Gi O
protein-coupled O
receptor O
signaling O
to O
inhibit O
stem O
cell O
differentiation O
in O
adipogenesis.Dysfunctional O
lipid O
and O
glucose O
metabolism O
contribute O
to O
metabolic O
syndrome-a O
major O
public O
health O
concern O
that O
enhances O
cardiovascular O
disease O
risk O
. O
Arsenic O
(As(III)) O
exposure O
may O
increase O
metabolic O
syndrome O
and O
cardiovascular O
disease O
risk O
by O
impairing O
adipose O
tissue O
differentiation O
, O
function O
, O
and O
insulin O
sensitivity O
through O
pathogenic O
mechanisms O
that O
remain O
unclear O
. O
We O
hypothesized O
that O
As(III) O
signals O
through O
the O
Pertussis O
toxin O
(Ptx) O
sensitive O
, O
Gi O
protein-coupled O
receptor O
(GPCR) O
to O
impair O
adipogenesis O
, O
as O
previously O
demonstrated O
for O
its O
stimulation O
of O
vascular O
oxidant O
generation O
, O
angiogenesis O
, O
and O
remodeling O
. O
Because O
both O
As(III) O
and O
GPCR O
ligands O
inhibit O
progenitor O
cell O
differentiation O
into O
adipocytes O
, O
we O
investigated O
the O
hypothesis O
in O
a O
model O
of O
low-passage O
human O
mesenchymal O
stem O
cells O
(hMSC) O
. O
As(III) O
(0.1-1.0 O
µM) O
suppressed O
dexamethasone/insulin-induced O
hMSC O
adipogenesis O
, O
as O
indicated O
by O
decreased O
transcriptional O
promoters O
of O
differentiation O
, O
decreased O
fat O
droplet O
formation O
, O
and O
decreased O
expression O
of O
differentiated O
adipocyte O
markers O
, O
such O
as O
adiponectin O
and O
perilipin O
. O
Preincubating O
hMSC O
with O
Ptx O
prevented O
90% O
of O
the O
suppressive O
effect O
of O
As(III) O
. O
Selective O
competitive O
antagonists O
of O
Gi-coupled O
endothelin-1 O
type O
A O
and O
B O
receptors O
were O
~60% O
effective O
in O
blocking O
As(III) O
inhibition O
and O
combination O
of O
antagonists O
to O
both O
receptors O
were O
85% O
effective O
. O
In O
contrast O
, O
antagonists O
to O
the O
sphingosine-1-phosphate O
type O
1 O
receptor O
(previously O
shown O
to O
mediate O
As(III) O
vascular O
effects) O
or O
the O
angiotensin O
II O
type O
1 O
receptor O
were O
ineffective O
in O
blocking O
As(III) O
effects O
. O
These O
studies O
suggest O
a O
majority O
of O
arsenic-inhibited O
adipocyte O
differentiation O
, O
and O
metabolism O
requires O
endothelin-1 O
GPCRs O
and O
that O
As(III) O
effects O
on O
GPCR B
signaling O
are O
tissue O
and O
context O
specific O
. O
This O
may O
represent O
a O
significant O
mechanism O
for O
the O
contribution O
of O
arsenic O
exposure O
to O
increased O
metabolic O
and O
cardiovascular O
diseases O
. O

o-quinones O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index O
. O
Aldo-keto B
reductases I
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

gallic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

CDCA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Bile O
acids O
induce O
cdx2 O
expression O
through O
the O
farnesoid O
x O
receptor O
in O
gastric O
epithelial O
cells.Clinical O
and O
experimental O
studies O
showed O
that O
the O
reflux O
of O
bile O
into O
the O
stomach O
contributes O
to O
the O
induction O
of O
intestinal O
metaplasia O
of O
the O
stomach O
and O
gastric O
carcinogenesis O
. O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 B
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

Amitriptyline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA- B
TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis.Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 B
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2 O
, O
rofecoxib O
. O
We O
also O
assessed O
the O
antithrombotic O
effect O
of O
licofelone O
in O
rabbit O
platelet-rich O
plasma O
. O
For O
this O
purpose O
, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SIRT1 O
inhibits O
NADPH O
oxidase O
activation O
and O
protects O
endothelial O
function O
in O
the O
rat O
aorta O
: O
Implications O
for O
vascular O
aging.Vascular O
aging O
is O
characterized O
by O
up-regulation O
of O
NADPH O
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 B
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC-1α O
acetylation O
and O
the O
subsequent O
PPARα O
activation O
, O
resulting O
in O
both O
decreased O
NADPH O
oxidase-driven O
ROS O
production O
and O
NO O
inactivation O
. O

[3H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat B
alpha I
1D-adrenoceptors I
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O
and O
7.8 O
respectively) O
. O
The O
selective O
alpha O
1D O
antagonist O
BMY O
7378 O
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors O
. O
5 O
. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha O
1D-adrenoceptors O
(r O
= O
0.96) O
, O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O
1B O
(r O
= O
0.46) O
subtypes O
. O
6 O
. O
Noradrenaline-mediated O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

glutamic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Probing O
for O
a O
hydrophobic O
a O
binding O
register O
in O
prostate-specific O
membrane O
antigen O
with O
phenylalkylphosphonamidates.To O
explore O
for O
the O
existence O
of O
an O
auxiliary O
hydrophobic O
binding O
register O
remote O
from O
the O
active O
site O
of O
PSMA O
a O
series O
of O
phenylalkylphosphonamidate O
derivatives O
of O
glutamic O
acid O
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
potencies O
against O
PSMA B
. O
Both O
the O
phenyl- O
and O
benzylphosphonamidates O
(1a O
and O
1b) O
exhibited O
only O
modest O
inhibitory O
potency O
against O
. O
The O
phenethyl O
analog O
1c O
was O
intermediate O
in O
inhibitory O
potency O
while O
inhibitors O
possessing O
a O
longer O
alkyl O
tether O
from O
the O
phenyl O
ring O
, O
resulted O
in O
markedly O
improved O
K(i) O
values O
. O
The O
greatest O
inhibitory O
potency O
was O
obtained O
for O
the O
inhibitors O
in O
which O
the O
phenyl O
ring O
was O
extended O
furthest O
from O
the O
central O
phosphorus O
(1f O
, O
n=5 O
and O
1g O
, O
n=6) O
. O
The O
slightly O
serrated O
pattern O
that O
emerged O
as O
the O
alkyl O
tether O
increased O
from O
three O
to O
six O
methylene O
units O
suggests O
that O
inhibitory O
potency O
is O
not O
simply O
correlated O
to O
increased O
hydrophobicity O
imparted O
by O
the O
phenylalkyl O
chain O
, O
but O
rather O
that O
one O
or O
more O
hydrophobic O
binding O
registers O
may O
exist O
remote O
from O
the O
substrate O
recognition O
architecture O
in O
the O
active O
site O
of O
PSMA O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Down-regulation O
of O
LRRK2 O
in O
control O
and O
DAT O
transfected O
HEK O
cells O
increases O
manganese-induced O
oxidative O
stress O
and O
cell O
toxicity.The O
extra-pyramidal O
symptoms O
associated O
with O
manganism O
often O
overlap O
with O
that O
seen O
in O
Parkinsonism O
suggesting O
a O
common O
link O
between O
the O
two O
disorders O
. O
Since O
wide O
deviations O
are O
observed O
in O
susceptibility O
and O
characteristics O
of O
the O
symptoms O
observed O
in O
manganism O
, O
these O
differences O
may O
be O
due O
to O
underlying O
genetic O
variability O
. O
Genes O
linked O
to O
early O
onset O
of O
Parkinsonism O
which O
includes O
ATP13A2 O
and O
parkin O
have O
already O
been O
suggested O
to O
promote O
development O
of O
Mn O
toxicity O
. O
Of O
the O
other O
Parkinson-linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT B
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK O
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 O
plays O
a O
role O
in O
the O
phosphorylation O
of O
p38 O
, O
our O
results O
similarly O
demonstrate O
a O
decrease O
in O
p38 O
activation O
in O
LRRK2 O
knock-down O
cells O
. O
Our O
findings O
suggest O
that O
null O
mutations O
in O
LRRK2 O
which O
cause O
Parkinsonism O
potentiate O
Mn O
toxicity O
and O
increase O
susceptibility O
to O
develop O
manganism O
. O

15d-PGJ2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cyclopentenone O
prostaglandins O
suppress O
activation O
of O
microglia O
: O
down-regulation O
of O
inducible O
nitric-oxide O
synthase O
by O
15-deoxy-Delta12,14-prostaglandin O
J2.Mechanisms O
leading O
to O
down-regulation O
of O
activated O
microglia O
and O
astrocytes O
are O
poorly O
understood O
, O
in O
spite O
of O
the O
potentially O
detrimental O
role O
of O
activated O
glia O
in O
neurodegeneration O
. O
Prostaglandins O
, O
produced O
both O
by O
neurons O
and O
glia O
, O
may O
serve O
as O
mediators O
of O
glial O
and O
neuronal O
functions O
. O
We O
examined O
the O
influence O
of O
cyclopentenone O
prostaglandins O
and O
their O
precursors O
on O
activated O
glia O
. O
As O
models O
of O
glial O
activation O
, O
production O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
was O
studied O
in O
lipopolysaccharide-stimulated O
rat O
microglia O
, O
a O
murine O
microglial O
cell O
line O
BV-2 O
, O
and O
IL-1beta-stimulated O
rat O
astrocytes O
. O
Cyclopentenone O
prostaglandins O
were O
potent O
inhibitors O
of O
iNOS O
induction O
and O
were O
more O
effective O
than O
their O
precursors O
, O
prostaglandins O
E2 O
and O
D2 O
. O
15-Deoxy-Delta12,14-prostaglandin O
J2 O
(15d-PGJ2) O
was O
the O
most O
potent O
prostaglandin O
among O
those O
tested O
. O
In O
activated O
microglia O
, O
15d-PGJ2 O
suppressed O
iNOS O
promoter O
activity O
, O
iNOS O
mRNA O
, O
and O
protein O
levels O
. O
The O
action O
of O
15d-PGJ2 O
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O
because O
troglitazone O
, O
a O
specific O
ligand O
of O
PPARgamma O
, O
was O
unable O
to O
inhibit O
iNOS O
induction O
, O
and O
neither O
troglitazone O
nor O
15d-PGJ2 O
could O
stimulate O
the O
activity O
of O
a O
PPAR-dependent O
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma O
. O
15d-PGJ2 O
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O
transcription O
factor O
NFkappaB O
, O
but O
it O
did O
inhibit O
the O
activity O
of O
an O
NFkappaB O
reporter O
construct O
, O
suggesting O
that O
the O
mechanism O
of O
suppression O
of O
microglial O
iNOS B
by O
15d-PGJ2 O
may O
involve O
interference O
with O
NFkappaB O
transcriptional O
activity O
in O
the O
nucleus O
. O
Thus O
, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
mediated O
by O
cyclopentenone O
prostaglandins O
, O
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O
glial O
responses O
in O
the O
brain O
. O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Warfarin O
dose O
and O
the O
pharmacogenomics O
of O
CYP2C9 O
and O
VKORC1 O
- O
rationale O
and O
perspectives.Warfarin O
is O
the O
most O
widely O
prescribed O
oral O
anticoagulant O
, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 B
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O
VKORC1) O
, O
demographic O
, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin O
dosage O
, O
could O
potentially O
minimize O
the O
risk O
of O
over O
dose O
during O
warfarin O
induction O
. O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon B
kinase I
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

isatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
( O
MAO) B
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO O
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Gene O
expression O
signature O
of O
parathion-transformed O
human O
breast O
epithelial O
cells.Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers O
. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous O
pesticides O
. O
Parathion O
is O
a O
cholinesterase O
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline O
esters O
, O
including O
acetylcholine O
at O
cholinergic O
synapses O
. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O
acetylcholinesterase O
at O
the O
synaptic O
junction O
. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O
antidote O
to O
acetylcholinesterase O
inhibitors O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
parathion O
and O
atropine O
on O
cell O
transformation O
of O
human O
breast O
epithelial O
cells O
in O
vitro O
. O
These O
studies O
showed O
that O
parathion O
alone O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 B
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion-treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O
MCM2 O
and O
MCM3 O
. O
It O
is O
suggested O
that O
parathion O
influences O
human O
breast O
epithelial O
cell O
transformation O
and O
is O
an O
initiator O
factor O
in O
the O
transformation O
process O
in O
breast O
cancer O
. O

BPB O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 B
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase B
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
5-Lipoxygenase O
inhibitors O
: O
a O
review O
of O
recent O
patents O
(2010 O
- O
2012).Introduction O
: O
5-Lipoxygenase B
(5-LO) O
is O
a O
crucial O
enzyme O
of O
the O
arachidonic O
acid O
(AA) O
cascade O
and O
catalyzes O
the O
formation O
of O
bioactive O
leukotrienes O
(LTs) O
with O
the O
help O
of O
FLAP O
, O
the O
5-LO-activating O
protein O
. O
LTs O
are O
inflammatory O
mediators O
playing O
a O
pathophysiological O
role O
in O
different O
diseases O
like O
asthma O
, O
allergic O
rhinitis O
as O
well O
as O
cardiovascular O
diseases O
and O
certain O
types O
of O
cancer O
. O
With O
the O
rising O
number O
of O
indications O
for O
anti-LT O
therapy O
, O
5-LO O
inhibitor O
drug O
development O
becomes O
increasingly O
important O
. O
Areas O
covered O
: O
Here O
, O
both O
recent O
findings O
regarding O
the O
pathophysiological O
role O
of O
5-LO O
and O
the O
patents O
claimed O
for O
5-LO O
inhibitors O
are O
discussed O
. O
Focusing O
on O
direct O
inhibitors O
, O
several O
patents O
disclosing O
FLAP O
antagonists O
are O
also O
subject O
of O
this O
review O
. O
Novel O
compounds O
include O
1,5-diarylpyrazoles O
, O
indolizines O
and O
indoles O
and O
several O
natural O
product O
extracts O
. O
Expert O
opinion O
: O
Evaluation O
of O
the O
patent O
activities O
revealed O
only O
quite O
moderate O
action O
. O
Nevertheless O
, O
several O
auspicious O
drug-like O
molecules O
were O
disclosed O
. O
It O
seems O
that O
in O
the O
near O
future O
, O
FLAP O
inhibitors O
can O
be O
expected O
to O
enter O
the O
market O
for O
the O
treatment O
of O
asthma O
. O
With O
the O
resolved O
structure O
of O
5-LO O
, O
structure-based O
drug O
design O
is O
now O
applicable O
. O
Together O
with O
the O
identification O
of O
downstream O
enzyme O
inhibitors O
and O
dual-targeting O
drugs O
within O
the O
AA O
cascade O
, O
several O
tools O
are O
at O
hand O
to O
cope O
with O
5-LOs O
increasing O
pathophysiological O
roles O
. O

Fc11a-2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
novel O
benzo[d]imidazole O
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 O
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
, O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
, O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase B
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Amitriptyline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA B
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

M6P O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O
to O
assess O
the O
relevance O
of O
the O
different O
ligand-binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O
this O
cellular O
system O
. O
The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P/IGF2R O
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin-like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells O
. O
In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R O
and O
M6P-modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P O
/ O
IGF2R B
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P-binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding O
domains O
of O
the O
receptor O
. O

catalpol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Catalpol O
suppresses O
advanced O
glycation O
end-products-induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen O
species O
in O
human O
monocytic O
THP-1 O
cells.Advanced O
glycation O
end-products O
(AGEs) O
play O
a O
pivotal O
role O
in O
the O
development O
of O
diabetic O
complications O
by O
inducing O
inflammation O
. O
We O
previously O
reported O
that O
the O
fresh O
roots O
of O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH B
oxidase I
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB O
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications O
. O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Rasagiline O
protects O
against O
alpha-synuclein O
induced O
sensitivity O
to O
oxidative O
stress O
in O
dopaminergic O
cells.Rasagiline O
is O
a O
propargylamine O
and O
irreversible O
monoamine O
oxidase O
(MAO) O
B O
inhibitor O
used O
for O
the O
treatment O
of O
Parkinson's O
disease O
(PD) O
. O
It O
has O
demonstrated O
neuroprotective O
properties O
in O
laboratory O
studies O
. O
Current O
concepts O
of O
PD O
aetiopathogenesis O
include O
the O
role O
of O
alpha-synuclein O
, O
protein O
aggregation O
, O
free O
radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death O
. O
We O
have O
used O
a O
combination O
of O
alpha-synuclein O
and O
free O
radical O
mediated O
toxicity O
in O
a O
dopaminergic O
cell O
line O
to O
provide O
a O
model O
of O
nigral O
toxicity O
in O
order O
to O
investigate O
the O
potential O
molecular O
mechanisms O
that O
mediate O
rasagiline O
protection O
. O
We O
demonstrate O
that O
rasagiline O
protects O
against O
cell O
death O
induced O
by O
the O
combination O
of O
free O
radicals O
generated O
by O
paraquat O
and O
either O
wild-type O
or O
A53T B
mutant O
alpha-synuclein O
over-expression O
. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase O
3 O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O
Rasagiline O
induced O
an O
increase O
in O
cellular O
glutathione O
levels O
. O
The O
results O
support O
a O
role O
for O
rasagiline O
in O
protecting O
dopaminergic O
cells O
against O
free O
radical O
mediated O
damage O
and O
apoptosis O
in O
the O
presence O
of O
alpha-synuclein O
over-expression O
. O
The O
data O
are O
of O
relevance O
to O
the O
interpretation O
of O
the O
potential O
mechanisms O
of O
action O
of O
rasagiline O
in O
explaining O
the O
results O
of O
disease O
modification O
trials O
in O
PD O
. O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Phase O
1 O
and O
phase O
2 O
drug O
metabolism O
and O
bile O
acid O
production O
of O
HepaRG O
cells O
in O
a O
bioartificial O
liver O
in O
absence O
of O
dimethyl O
sulfoxide.The O
human O
liver O
cell O
line O
HepaRG O
has O
been O
recognized O
as O
a O
promising O
source O
for O
in O
vitro O
testing O
of O
metabolism O
and O
toxicity O
of O
compounds O
. O
However O
, O
currently O
the O
hepatic O
differentiation O
of O
these O
cells O
relies O
on O
exposure O
to O
dimethylsulfoxide O
(DMSO) O
, O
which O
, O
as O
a O
side O
effect O
, O
has O
a O
cytotoxic O
effect O
and O
represses O
an O
all-round O
hepatic O
functionality O
. O
The O
AMC-bioartificial O
liver O
(AMC-BAL) O
is O
a O
three-dimensional O
bioreactor O
that O
has O
previously O
been O
shown O
to O
upregulate O
various O
liver O
functions O
of O
cultured O
cells O
. O
We O
therefore O
cultured O
HepaRG O
cells O
in O
the O
AMC-BAL O
without O
DMSO O
and O
characterized O
the O
drug O
metabolism O
. O
Within O
14 O
days O
of O
culture O
, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 O
activity O
could O
be O
induced O
2-fold O
by O
rifampicin O
, O
whereas O
CYP2C9 B
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O
DMSO O
addition O
superfluous O
for O
the O
promotion O
of O
drug O
metabolism O
. O
Therefore O
, O
AMC-BAL O
culturing O
makes O
the O
HepaRG O
cells O
more O
suitable O
for O
testing O
metabolism O
and O
toxicity O
of O
drugs O
. O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR B
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat B
GnRHR) I
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

dihydroquinolinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PF-04859989 O
as O
a O
template O
for O
structure-based O
drug O
design O
: O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT B
II I
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole O
analogs O
, O
with O
a O
k(inact)/K(i) O
value O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O
8.53 O
. O
The O
X-ray O
crystal O
structure O
of O
20 O
with O
KAT O
II O
demonstrates O
key O
features O
that O
contribute O
to O
this O
remarkable O
potency O
and O
binding O
efficiency O
. O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Energy O
depletion O
of O
bovine O
mammary O
epithelial O
cells O
activates O
AMPK O
and O
suppresses O
protein O
synthesis O
through O
inhibition O
of O
mTORC1 O
signaling.The O
molecular O
mechanisms O
by O
which O
cellular O
energy O
status O
regulates O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK B
at O
Thr172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O
associated O
with O
a O
marked O
increase O
in O
Ser792 O
phosphorylation O
on O
raptor O
. O
Collectively O
, O
the O
results O
suggest O
that O
activation O
of O
AMPK O
represses O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
through O
inhibition O
of O
mTORC1 O
signaling O
. O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
nicotinamide O
derivative O
as O
anti-angiogenic O
agents.Previously O
, O
we O
have O
found O
that O
BRN-103 O
, O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
(VEGF)-mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine B
kinase I
activity O
of O
VEGF O
receptor O
2 O
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin B
receptor I
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Selective O
Bisubstrate O
Inhibitors O
with O
Sub-nanomolar O
Affinity O
for O
Protein O
Kinase O
Pim-1.Potent O
and O
selective O
: O
The O
unique O
nature O
of O
the O
ATP O
binding O
pocket O
structure O
of O
Pim O
family O
protein O
kinases O
( O
PKs) B
was O
used O
for O
the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub-nanomolar O
affinity O
. O
Conjugates O
of O
arginine-rich O
peptides O
with O
two O
ATP O
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim-1 O
. O
Against O
a O
panel O
of O
124 O
protein O
kinases O
, O
a O
novel O
ARC-PIM O
conjugate O
selectively O
inhibited O
PKs O
of O
the O
Pim O
family O
. O

IDX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nonadrenergic O
imidazoline O
binding O
sites O
on O
human O
platelets.Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity O
, O
imidazol(in)e-preferring O
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 O
adrenoceptors O
. O
These O
nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
of O
alpha-2 O
adrenoceptors O
. O
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan O
(IDX) O
binding O
vs O
. O
[125I]p-iodoclonidine O
(PIC) O
binding O
. O
Nonadrenergic O
[125I]PIC-labeled O
sites O
were O
enriched O
in O
platelet O
plasma O
membranes O
, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] O
IDX O
were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled O
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs O
. O
the O
[3H]IDX-labeled O
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes) O
. O
Furthermore O
, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ O
affinity O
of O
cardiac O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) O
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase O
inhibition) O
. O
Three O
mutants O
(S37G O
, O
V44Q O
, O
and O
L48Q) O
were O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) O
sensitivity O
, O
partial O
loss O
of O
ATPase O
inhibition O
, O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac O
(c)TnCs O
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC B
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

DEX O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 B
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 B
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

LY139037 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidine O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
(LY139037) O
, O
a O
selective O
histamine B
H2-receptor I
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O
bullfrog O
. O
Nizatidine O
was O
8.9 O
times O
as O
active O
as O
cimetidine O
on O
basal O
acid O
secretion O
of O
the O
chronic O
gastric O
fistula O
rats O
after O
s.c O
. O
administration O
. O
Against O
acid O
secretion O
from O
the O
vagally O
innervated O
gastric O
fistula O
and O
Heidenhain O
pouch O
of O
dogs O
stimulated O
with O
submaximal O
doses O
of O
histamine O
, O
methacholine O
and O
gastrin O
, O
nizatidine O
was O
, O
respectively O
, O
6.5 O
, O
5 O
and O
4.7 O
times O
as O
active O
as O
cimetidine O
by O
i.v O
. O
administration O
. O
Nizatidine O
was O
very O
well O
absorbed O
from O
the O
gut O
and O
was O
5 O
to O
10 O
times O
as O
active O
as O
cimetidine O
on O
gastric O
acid O
secretion O
of O
dogs O
induced O
by O
submaximal O
and O
maximal O
doses O
of O
histamine O
when O
given O
p.o O
. O
Equal O
molar O
doses O
of O
nizatidine O
showed O
equal O
peak O
effects O
when O
given O
i.v. O
, O
s.c O
. O
or O
i.m O
. O
Pharmacological O
data O
indicate O
that O
nizatidine O
is O
safe O
and O
effective O
as O
an O
agent O
for O
the O
control O
of O
excessive O
gastric O
acid O
secretion O
. O

kurarinol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol B
acyltransferase I
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT O
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Add-on O
therapy O
with O
the O
DPP-4 O
inhibitor O
sitagliptin O
improves O
glycemic O
control O
in O
insulin-treated O
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus.The O
effect O
of O
add-on O
therapy O
with O
sitagliptin O
on O
glycemic O
control O
was O
prospectively O
investigated O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
receiving O
insulin O
alone O
or O
insulin O
combined O
with O
oral O
antidiabetic O
drugs O
. O
Seventy-one O
patients O
were O
evaluated O
(38 O
men O
and O
33 O
women O
aged O
63.9±10.2 O
years) O
. O
They O
were O
divided O
into O
three O
groups O
, O
which O
were O
45 O
patients O
receiving O
premixed O
insulin O
twice O
daily O
, O
15 O
patients O
receiving O
multiple O
daily O
insulin O
injections O
, O
and O
11 O
patients O
receiving O
basal O
insulin O
with O
oral O
antidiabetic O
drugs O
(basal O
insulin O
therapy) O
. O
Concomitant O
oral O
drugs O
included O
sulfonylureas O
, O
α-glucosidase O
inhibitors O
and O
metformin O
. O
The O
hemoglobin O
A1c O
(HbA1c) O
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O
sitagliptin O
(p<0.01) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c B
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin O
. O
These O
findings O
suggest O
that O
add-on O
therapy O
with O
sitagliptin O
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient's O
demographic O
profile O
. O
Stratified O
analysis O
based O
on O
the O
insulin O
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin O
when O
it O
was O
added O
to O
basal O
insulin O
therapy O
. O
The O
results O
of O
this O
investigation O
confirmed O
that O
add-on O
therapy O
with O
sitagliptin O
to O
various O
insulin O
regimens O
could O
improve O
glycemic O
control O
without O
severe O
hypoglycemia O
and/or O
weight O
gain O
. O

MET O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR B
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

Nor-NOHA O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS B
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

DRF O
2655 O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
DRF O
2655 O
: O
a O
unique O
molecule O
that O
reduces O
body O
weight O
and O
ameliorates O
metabolic O
abnormalities.OBJECTIVE O
: O
Preclinical O
evaluation O
of O
DRF O
2655 O
, O
a O
peroxisome O
proliferator-activated O
receptor O
alpha O
(PPARalpha) O
and O
PPARgamma O
agonist O
, O
as O
a O
body-weight O
lowering O
, O
hypolipidemic O
and O
euglycemic O
agent O
. O
RESEARCH O
METHODS O
AND O
PROCEDURES O
: O
DRF O
2655 O
was O
studied O
in O
different O
genetic O
, O
normal O
, O
and O
hyperlipidemic O
animal O
models O
. O
HEK O
293 O
cells O
were O
used O
to O
conduct O
the O
reporter-based O
transactivation O
of O
PPARalpha O
and O
PPARgamma O
. O
To O
understand O
the O
biochemical O
mechanism O
of O
lipid- O
, O
body-weight- O
, O
and O
glucose-lowering O
effects O
, O
activities O
of O
key O
beta-oxidation O
and O
lipid O
catabolism O
enzymes O
and O
gluconeogenic O
enzymes O
were O
studied O
in O
db/db O
mice O
treated O
with O
DRF O
2655 O
. O
3T3L1 O
cells O
were O
used O
for O
adipogenesis O
study O
, O
and O
HepG2 O
cells O
were O
used O
to O
study O
the O
effect O
of O
DRF O
2655 O
on O
total O
cholesterol O
and O
triglyceride O
synthesis O
using O
[(14)C]acetate O
and O
[(3)H]glycerol O
. O
RESULTS O
: O
DRF O
2655 O
showed O
concentration-dependent O
transactivation O
of O
PPARalpha O
and O
PPARgamma B
. O
In O
the O
3T3L1 O
cell-differentiation O
study O
, O
DRF O
2655 O
and O
rosiglitazone O
showed O
369% O
and O
471% O
increases O
, O
respectively O
, O
in O
triglyceride O
accumulation O
. O
DRF O
2655 O
showed O
body-weight O
lowering O
and O
euglycemic O
and O
hypolipidemic O
effects O
in O
various O
animal O
models O
. O
db/db O
mice O
treated O
with O
DRF O
2655 O
showed O
5- O
and O
3.6-fold O
inhibition O
in O
phosphoenolpyruvate O
carboxykinase O
and O
glucose O
6-phosphatase O
activity O
and O
651% O
and O
77% O
increases O
in O
the O
beta-oxidation O
enzymes O
carnitine O
palmitoyltransferase O
and O
carnitine O
acetyltransferase O
, O
respectively O
. O
HepG2 O
cells O
treated O
with O
DRF O
2655 O
showed O
significant O
reduction O
in O
lipid O
synthesis O
. O
DISCUSSION O
: O
DRF O
2655 O
showed O
excellent O
euglycemic O
and O
hypolipidemic O
activities O
in O
different O
animal O
models O
. O
An O
exciting O
finding O
is O
its O
body-weight O
lowering O
effect O
in O
these O
models O
, O
which O
might O
be O
mediated O
by O
the O
induction O
of O
target O
enzymes O
involved O
in O
hepatic O
lipid O
catabolism O
through O
PPARalpha O
activation O
. O

alcohol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Narirutin O
fraction O
from O
citrus O
peels O
attenuates O
alcoholic O
liver O
disease O
in O
mice.This O
study O
aimed O
to O
demonstrate O
protective O
activities O
of O
the O
narirutin O
fraction O
from O
peels O
of O
Citrus O
unshiu O
against O
ethanol-induced O
hepatic O
damage O
through O
an O
animal O
study O
. O
Citrus O
narirutin O
fraction O
(CNF) O
, O
contained O
75% O
of O
narirutin O
, O
was O
obtained O
by O
an O
ultra-sonicated O
extraction O
and O
further O
purification O
. O
ICR O
mice O
were O
divided O
into O
four O
groups; O
normaldiet O
control O
, O
ethanol O
control O
(6.5g O
ethanol/kg) O
, O
low-CNF O
(ethanol+150mg O
CNF/kg) O
and O
high-CNF O
(ethanol+300mg O
CNF/kg) O
groups O
. O
Consumption O
of O
alcohol O
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate O
transaminase O
, O
alanine O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH O
and O
malondialdehyde O
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O
Chronic O
consumption O
of O
alcohol O
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear O
factor O
(NF)-κB O
, O
tumor B
necrosis I
factor I
(TNF)-α I
and O
interleukin O
(IL)-1β O
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose-dependently O
. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol O
can O
alleviate O
alcohol O
induced O
liver O
damage O
through O
preventing O
lipid O
formation O
, O
protecting O
antioxidant O
system O
and O
suppressing O
productions O
of O
pro-inflammatory O
cytokines O
. O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK B
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; B
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Vitamin O
K2 O
covalently O
binds O
to O
Bak O
and O
induces O
Bak-mediated O
apoptosis.Vitamin O
K2 O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome B
c I
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

amino O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 O
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
, O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 B
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 O
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

quercetin O
glycosides O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs B
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

timolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
, O
reduces O
Na(+) O
influx O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) O
channels O
: O
comparison O
with O
other O
beta-adrenoceptor O
antagonists.Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
used O
for O
the O
treatment O
of O
glaucoma O
, O
is O
known O
to O
be O
neuroprotective O
in O
paradigms O
of O
ischaemia/excitotoxicity O
. O
In O
this O
study O
, O
we O
examined O
whether O
betaxolol O
and O
other O
beta-adrenoceptor O
antagonists O
interact O
directly O
with O
neurotoxin O
binding O
to O
sites O
1 O
and O
2 O
of O
the O
voltage-sensitive O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM O
. O
Comparison O
of O
all O
the O
beta-adrenoceptor B
antagonists O
tested O
revealed O
a O
potency O
order O
of O
propranolol>betaxolol O
approximately O
levobetaxolol>levobunolol O
approximately O
carteolol>/=timolol>atenolol O
. O
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin O
binding O
to O
neurotoxin O
receptor O
site O
1 O
, O
even O
at O
concentrations O
as O
high O
as O
250 O
microM O
. O
Saturation O
experiments O
showed O
that O
betaxolol O
increased O
the O
K(D) O
of O
[(3)H]-BTX-B O
binding O
but O
had O
no O
effect O
on O
the O
B(max) O
. O
The O
association O
kinetics O
of O
[(3)H]-BTX-B O
were O
unaffected O
by O
betaxolol O
, O
but O
the O
drug O
significantly O
accelerated O
the O
dissociation O
rate O
of O
the O
radioligand O
. O
These O
findings O
argue O
for O
a O
competitive O
, O
indirect O
, O
allosteric O
mode O
of O
inhibition O
of O
[(3)H]-BTX-B O
binding O
by O
betaxolol O
. O
Betaxolol O
inhibited O
veratridine-stimulated O
Na(+) O
influx O
in O
rat O
cortical O
synaptosomes O
with O
an O
IC(50) O
value O
of O
28 O
. O
3 O
microM O
. O
Carteolol O
, O
levobunolol O
, O
timolol O
and O
atenolol O
were O
significantly O
less O
effective O
than O
betaxolol O
at O
reducing O
veratridine-evoked O
Na(+) O
influx O
. O
The O
ability O
of O
betaxolol O
to O
interact O
with O
neurotoxin O
site O
2 O
of O
the O
Na(+) O
channel O
and O
inhibit O
Na(+) O
influx O
may O
have O
a O
role O
in O
its O
neuroprotective O
action O
in O
paradigms O
of O
excitotoxicity/ischaemia O
and O
in O
its O
therapeutic O
effect O
in O
glaucoma O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST-4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 B
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
rat B
brain I
aldosterone I
receptors I
reveals O
high O
affinity O
for O
corticosterone.The O
two O
[3H]aldosterone-binding O
proteins O
of O
rat O
brain O
cytosol O
were O
characterized O
by O
a O
dextran-coated O
charcoal O
method O
. O
With O
molybdate O
present O
to O
stabilize O
receptors O
, O
the O
affinities O
of O
the O
two O
sites O
for O
[3H]aldosterone O
in O
adrenalectomized O
perfused O
rat O
brain O
cytosols O
were O
0.28 O
and O
18.0 O
nM O
at O
4 O
C O
. O
High O
affinity O
sites O
comprised O
15% O
of O
the O
total O
receptor O
number O
. O
A O
small O
contamination O
of O
perfused O
brain O
cytosol O
preparations O
with O
corticosteroid-binding O
globulin O
(CBG) O
was O
found O
. O
However O
, O
due O
to O
the O
very O
high O
affinity O
of O
CBG O
for O
corticosterone O
at O
4 O
C O
, O
this O
slight O
contamination O
resulted O
in O
significant O
alterations O
in O
the O
apparent O
affinity O
of O
steroids O
competing O
for O
aldosterone-binding O
sites O
. O
Selective O
precipitation O
of O
cytosol O
receptors O
with O
36% O
(NH4)2SO4 O
reduced O
CBG O
concentrations O
to O
negligible O
levels O
. O
After O
blockade O
of O
low O
affinity O
sites O
with O
a O
highly O
selective O
glucocorticoid O
(RU O
26988) O
, O
the O
order O
of O
steroids O
in O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid O
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid O
receptor O
(aldosterone O
greater O
than O
desoxycorticosterone O
greater O
than O
corticosterone) O
. O
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined O
. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus O
. O
The O
high O
affinity O
site O
was O
at O
greatest O
density O
in O
limbic O
regions O
, O
whereas O
the O
low O
affinity O
receptor O
, O
apparently O
identical O
to O
the O
glucocorticoid O
type O
II O
receptor O
, O
was O
at O
greatest O
density O
in O
cortex O
and O
cerebellum O
. O
It O
is O
concluded O
that O
the O
high O
affinity O
aldosterone O
receptor O
of O
rat O
brain O
, O
which O
had O
been O
identified O
in O
preliminary O
studies O
as O
a O
mineralocorticoid O
receptor O
, O
may O
bind O
either O
corticosterone O
or O
aldosterone O
in O
vivo O
. O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

sodium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Preferential O
block O
of O
late O
sodium O
current O
in O
the O
LQT3 O
DeltaKPQ O
mutant O
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide.Flecainide O
block O
of O
Na(+) O
current O
(I(Na)) O
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long B
QT I
syndrome I
3 I
(LQT3) I
sodium I
channel I
alpha I
subunit O
mutation O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ O
I(Na) O
was O
more O
sensitive O
to O
flecainide O
, O
and O
flecainide O
preferentially O
inhibited O
late O
I(Na) O
(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
80 O
+/- O
9 O
and O
19 O
+/- O
2 O
microM O
(n O
= O
31) O
respectively O
. O
UDB O
of O
peak O
I(Na) O
was O
greater O
and O
developed O
more O
slowly O
during O
pulse O
trains O
for O
DeltaKPQ O
than O
for O
WT O
. O
The O
IC(50) O
value O
for O
UDB O
of O
peak O
I(Na) O
for O
WT O
was O
29 O
+/- O
4 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
11 O
+/- O
1 O
microM O
(n O
= O
26) O
. O
For O
DeltaKPQ O
, O
UDB O
of O
late O
I(Na) O
was O
greater O
than O
for O
peak O
I(Na) O
. O
Recovery O
from O
block O
was O
slower O
for O
DeltaKPQ O
than O
for O
WT O
. O
We O
conclude O
that O
DeltaKPQ O
interacts O
differently O
with O
flecainide O
than O
with O
WT O
, O
leading O
to O
increased O
block O
and O
slowed O
recovery O
, O
especially O
for O
late O
I(Na) O
. O
These O
data O
provide O
insights O
into O
mechanisms O
for O
flecainide O
block O
and O
provide O
a O
rationale O
at O
the O
cellular O
and O
molecular O
level O
that O
open O
channel O
block O
may O
be O
a O
useful O
pharmacological O
property O
for O
treatment O
of O
LQT3 O
. O

Astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Astemizole O
, O
a O
potent O
histamine B
H1-receptor I
antagonist O
: O
effect O
in O
allergic O
rhinoconjunctivitis O
, O
on O
antigen O
and O
histamine O
induced O
skin O
weal O
responses O
and O
relationship O
to O
serum O
levels.The O
efficacy O
of O
astemizole O
, O
a O
new O
, O
long O
acting O
, O
oral O
histamine O
H1-receptor O
antagonist O
was O
compared O
to O
placebo O
for O
the O
treatment O
of O
allergic O
rhinitis O
and O
conjunctivitis O
during O
the O
grass O
pollen O
season O
of O
1982 O
. O
Sixty-three O
patients O
with O
a O
positive O
skin O
prick O
test O
to O
grass O
pollen O
and O
current O
symptoms O
participated O
in O
an O
8 O
week O
, O
double-blind O
, O
randomized O
study O
. O
Astemizole O
, O
10 O
mg O
, O
was O
significantly O
better O
than O
placebo O
in O
alleviating O
both O
nose O
(P O
less O
than O
0.05) O
and O
eye O
(P O
less O
than O
0.01) O
symptoms O
despite O
significantly O
greater O
use O
of O
the O
reserve O
medication O
, O
clemastine O
, O
by O
the O
placebo O
group O
(P O
less O
than O
0.003) O
. O
There O
was O
a O
lag O
period O
of O
5 O
days O
after O
initiation O
of O
therapy O
before O
treatment O
benefit O
became O
manifest O
. O
Subdivision O
of O
nasal O
symptoms O
indicated O
significant O
improvement O
compared O
to O
placebo O
over O
the O
8 O
weeks O
for O
sneezing O
(P O
less O
than O
0.05) O
and O
runny O
nose O
(P O
less O
than O
0.05) O
but O
not O
blocked O
nose O
. O
The O
absence O
of O
effect O
on O
nasal O
blockage O
was O
confirmed O
by O
parallel O
measurement O
of O
nasal O
calibre O
by O
body O
plethysmography O
. O
The O
antihistaminic O
potency O
of O
astemizole O
was O
indicated O
by O
an O
80% O
inhibition O
of O
the O
histamine O
induced O
skin O
weal O
response O
after O
8 O
weeks O
therapy O
. O
A O
positive O
correlation O
was O
found O
between O
serum O
drug O
levels O
and O
% O
inhibition O
of O
histamine O
skin O
weal O
(r O
= O
0.64 O
, O
P O
less O
than O
0.001) O
. O
Astemizole O
was O
free O
from O
adverse O
sedative O
or O
anticholinergic O
effects O
but O
did O
cause O
a O
mean O
increase O
in O
weight O
of O
1.3 O
kg O
(P O
less O
than O
0.01) O
after O
8 O
weeks O
therapy O
, O
not O
found O
with O
placebo O
. O

arachidonyl O
trifluoromethyl O
ketone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 B
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

oleate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Mechanism O
of O
the O
haemostatic O
effect O
of O
ethanolamine O
oleate O
in O
the O
injection O
sclerotherapy O
for O
oesophageal O
varices.Changes O
in O
coagulation O
and O
fibrinolysis O
were O
investigated O
in O
20 O
patients O
with O
oesophageal O
varices O
, O
who O
underwent O
endoscopic O
injection O
sclerotherapy O
(EIS) O
with O
5 O
per O
cent O
ethanolamine O
oleate O
(EO) O
, O
by O
means O
of O
serial O
determination O
of O
plasma O
fibrinopeptide O
A O
(FPA) O
and O
fibrinopeptide O
B O
beta O
15-42 O
(B O
beta O
15-42) O
. O
One O
hour O
after O
the O
completion O
of O
EIS O
, O
the O
value O
of O
FPA O
was O
significantly O
increased O
to O
38.1 O
+/- O
11.1 O
ng/ml O
(mean O
+/- O
s.e.m.) O
from O
a O
pre-EIS O
value O
of O
7.1 O
+/- O
1.4 O
ng/ml O
(P O
less O
than O
0.01) O
and O
it O
gradually O
returned O
to O
normal O
range O
by O
48 O
h O
after O
EIS O
. O
A O
very O
similar O
change O
was O
observed O
in O
the O
value O
of O
B O
beta O
15-42 O
(P O
less O
than O
0.01) O
. O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis O
. O
In O
vitro O
studies O
, O
however O
, O
revealed O
that O
EO O
inhibits O
fibrin O
clot O
formation O
because O
of O
the O
Ca2+-chelating O
ability O
of O
its O
constituent O
ethanolamine O
, O
although O
oleate O
or O
benzyl O
alcohol O
exhibited O
procoagulant O
activity O
in O
FPA B
formation O
in O
vitro O
. O
Nevertheless O
, O
an O
external O
application O
of O
EO O
or O
oleate O
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO O
, O
which O
exerts O
an O
inhibitory O
effect O
on O
coagulation O
in O
vitro O
, O
activates O
the O
local O
coagulation O
system O
. O
The O
activation O
may O
be O
accelerated O
by O
an O
acute O
inflammatory O
process O
provoked O
by O
oleate O
, O
which O
is O
supported O
by O
such O
clinical O
manifestations O
as O
mild O
fever O
, O
retrosternal O
pain O
leukocytosis O
and O
an O
increase O
in O
plasma O
fibrinogen O
level O
which O
was O
observed O
in O
all O
during O
the O
period O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs B
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

DL-alpha-difluoromethylornithine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine O
decarboxylase O
( O
ODC) B
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Phenothiazines O
inhibit O
S100A4 O
function O
by O
inducing O
protein O
oligomerization.S100A4 O
, O
a O
member O
of O
the O
S100 O
family O
of O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 B
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase B
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

AlCl3 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Possible O
Therapeutic O
Uses O
of O
Salvia O
triloba O
and O
Piper O
nigrum O
in O
Alzheimer's O
Disease-Induced O
Rats.Abstract O
This O
study O
aimed O
to O
investigate O
the O
role O
of O
Salvia O
triloba O
L O
. O
and O
Piper O
nigrum O
extracts O
in O
ameliorating O
neuroinflammatory O
insults O
characteristic O
of O
Alzheimer's O
disease O
(AD) O
in O
an O
experimentally O
induced O
rat O
model O
. O
Adult O
male O
Sprague-Dawley O
rats O
were O
classified O
into O
Group O
1 O
(n=10) O
: O
normal O
healthy O
animals O
serving O
as O
the O
negative O
control O
group; O
Group O
2 O
(n=60) O
: O
the O
AD-induced O
group O
. O
After O
AD O
induction O
, O
animals O
in O
the O
AD-induced O
group O
were O
divided O
randomly O
and O
equally O
into O
6 O
subgroups O
. O
The O
first O
subgroup O
served O
as O
AD O
control; O
the O
second O
one O
, O
which O
served O
as O
positive O
control O
, O
was O
treated O
orally O
with O
the O
conventional O
therapy O
for O
AD O
(rivastigmine) O
at O
a O
dose O
of O
0.3 O
mg/kg O
body O
weight O
(b.w.) O
daily O
for O
3 O
months O
. O
The O
third O
and O
fourth O
subgroups O
were O
, O
respectively O
, O
treated O
orally O
with O
the O
S O
. O
triloba O
extract O
at O
a O
dose O
of O
750 O
and O
375 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
The O
fifth O
and O
sixth O
subgroups O
were O
, O
respectively O
, O
treated O
orally O
with O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE O
activity O
, O
CRP O
, O
NF-κB B
, O
and O
MCP-1 O
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O
P O
. O
nigrum O
methanolic O
extracts O
have O
potent O
anti-inflammatory O
effects O
against O
neuroinflammation O
characterizing O
AD O
. O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 B
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR- B
dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

acarbose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
changeover O
from O
voglibose O
to O
acarbose O
on O
postprandial O
triglycerides O
in O
type O
2 O
diabetes O
mellitus O
patients.INTRODUCTION O
: O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
alpha-glucosidase B
inhibitors O
acarbose O
and O
voglibose O
on O
postprandial O
plasma O
glucose O
and O
serum O
triglyceride O
levels O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
METHODS O
: O
Twenty-one O
Japanese O
patients O
with O
type O
2 O
diabetes O
were O
enrolled O
in O
this O
study O
. O
Subjects O
had O
been O
treated O
with O
voglibose O
for O
at O
least O
3 O
months O
. O
They O
underwent O
a O
400 O
kcal O
balanced O
food O
meal O
tolerance O
test O
before O
and O
8 O
weeks O
after O
the O
changeover O
from O
voglibose O
to O
acarbose O
. O
Subjects O
were O
divided O
into O
two O
groups O
: O
the O
first O
group O
(low-dose O
group; O
n=11) O
was O
changed O
over O
from O
0.6 O
mg/day O
voglibose O
to O
150 O
mg/day O
acarbose O
, O
and O
the O
other O
(high-dose O
group; O
n=10) O
from O
0.9 O
mg/day O
voglibose O
to O
300 O
mg/day O
acarbose O
. O
RESULTS O
: O
The O
increment O
rate O
of O
postprandial O
plasma O
glucose O
([plasma O
glucose O
2 O
hours O
after O
test O
meal O
- O
fasting O
glucose]/fasting O
glucose) O
decreased O
from O
34.7%+/-23.9% O
to O
25.0%+/-24.6% O
(P=0.13) O
in O
the O
low-dose O
group O
, O
and O
decreased O
significantly O
from O
56.1%+/-53.1% O
to O
31.5%+/-36.0% O
(P=0.03) O
in O
the O
high-dose O
group O
after O
changeover O
. O
However O
, O
there O
were O
no O
significant O
changes O
in O
blood O
glycated O
hemoglobin O
(HbA(1c)) O
levels O
before O
and O
after O
changeover O
in O
either O
group O
. O
The O
increment O
rate O
of O
postprandial O
serum O
triglyceride O
(TG) O
([serum O
TG O
2 O
hours O
after O
test O
meal O
- O
fasting O
TG]/fasting O
TG) O
decreased O
significantly O
only O
in O
the O
high-dose O
group O
(52.4%+/-60.0% O
to O
24.3%+/-16.6%) O
(P=0.05) O
. O
No O
significant O
changes O
in O
serum O
high-density O
lipoprotein O
cholesterol O
levels O
were O
observed O
in O
either O
group O
, O
whereas O
serum O
low-density O
lipoprotein O
cholesterol O
levels O
decreased O
significantly O
from O
3.20+/-0.25 O
to O
2.65+/-0.18 O
mmol/L O
(P=0.04) O
, O
only O
in O
the O
high-dose O
group O
. O
CONCLUSIONS O
: O
In O
patients O
with O
type O
2 O
diabetes O
our O
findings O
suggest O
that O
acarbose O
300 O
mg/day O
is O
superior O
to O
voglibose O
0.9 O
mg/day O
in O
improving O
postprandial O
hyperglycemia O
and O
hypertriglyceridemia O
. O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Iron O
and O
zinc O
bioavailability O
in O
Caco-2 O
cells O
: O
influence O
of O
caseinophosphopeptides.A O
study O
has O
been O
made O
of O
the O
influence O
of O
two O
pools O
of O
caseinophosphopeptides O
(CPPs) O
obtained O
from O
α(s)- O
and O
β-casein O
(CN) O
fractions O
, O
and O
of O
three O
specific O
CPPs O
(β-CN(1-25)4P O
, O
α(s1)-CN(64-74)4P O
and O
α(s2)-CN(1-19)4P) O
, O
on O
iron O
bioavailability O
(ferritin O
synthesis) O
and O
zinc O
bioavailability O
(retention O
, O
transport O
and O
uptake O
of O
zinc) O
in O
Caco-2 O
cells O
. O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN( B
64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

ethoxzolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Catalytic O
properties O
of O
mouse O
carbonic O
anhydrase O
V.A O
cDNA O
encoding O
the O
mouse O
carbonic O
anhydrase O
V O
gene O
was O
isolated O
by O
reverse O
transcription O
and O
polymerase O
chain O
reaction O
from O
BALB/c O
mouse O
liver O
mRNA O
. O
Vectors O
containing O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic O
anhydrase O
(CA) O
V O
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
, O
and O
cyanate O
, O
CA B
V I
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA O
V O
are O
not O
due O
to O
the O
presence O
of O
tyrosine O
at O
position O
64 O
. O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 B
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
of O
inhibition O
of O
calmodulin-stimulated O
cyclic O
nucleotide O
phosphodiesterase O
by O
dihydropyridine O
calcium O
antagonists.Calmodulin-dependent O
cyclic O
nucleotide O
phosphodiesterase O
(CaMPDE) O
is O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
complex O
interaction O
between O
the O
cyclic O
nucleotide O
and O
Ca2+ O
second-messenger O
systems O
. O
CaMPDE O
exists O
as O
tissue-specific O
isozymes O
, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass O
. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
( O
PDE B
1B1) I
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel O
blockers O
. O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cucurbitacin O
I O
inhibits O
rac1 O
activation O
in O
breast O
cancer O
cells O
by O
a O
reactive O
oxygen O
species-mediated O
mechanism O
and O
independently O
of O
janus O
tyrosine O
kinase O
2 O
and O
p-rex1.The O
small O
GTPase O
Rac1 O
has O
been O
widely O
implicated O
in O
mammary O
tumorigenesis O
and O
metastasis O
. O
Previous O
studies O
established O
that O
stimulation O
of O
ErbB O
receptors O
in O
breast O
cancer O
cells O
activates O
Rac1 O
and O
enhances O
motility O
via O
the O
Rac-guanine O
nucleotide O
exchange O
factor O
P-Rex1 O
. O
As O
the O
Janus O
tyrosine O
kinase O
2 O
(Jak2)/signal O
transducer O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho O
and O
Rac O
. O

metformin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Metformin O
and O
Sulfonylureas O
in O
Relation O
to O
Cancer O
Risk O
in O
Type O
II O
Diabetes O
Patients O
: O
A O
Meta-analysis O
using O
primary O
data O
of O
published O
studies.INTRODUCTION O
: O
Accumulating O
evidence O
suggests O
that O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
hyperinsulinemia O
are O
at O
increased O
risk O
for O
developing O
malignancies O
. O
It O
remains O
to O
be O
fully O
elucidated O
whether O
use O
of O
metformin O
, O
an O
insulin B
sensitizer O
, O
and/or O
sulfonylureas O
, O
insulin O
secretagogues O
, O
affect O
cancer O
incidence O
in O
subjects O
with O
T2DM O
. O
MATERIAL O
& O
METHODS O
: O
We O
performed O
a O
meta-analysis O
using O
PubMed O
, O
of O
randomized O
control O
trials O
(RCTs) O
, O
cohorts O
, O
and O
case-control O
studies O
published O
through O
July O
2012 O
that O
assess O
effects O
of O
metformin O
and/or O
sulfonylurea O
sulfonylureas O
on O
cancer O
risk O
at O
any O
site O
, O
in O
subjects O
with O
T2DM O
. O
Fixed O
and O
random O
effects O
meta-analysis O
models O
were O
used O
, O
and O
the O
effect O
size O
was O
summarized O
as O
relative O
risk O
(RR) O
for O
RCTs/cohorts O
and O
as O
odds O
ratio O
(OR) O
for O
the O
case-control O
studies O
. O
RESULTS O
: O
Analysis O
of O
24 O
metformin O
studies O
in O
subjects O
with O
T2DM O
showed O
that O
metformin O
use O
is O
associated O
with O
reduced O
risk O
for O
the O
development O
of O
cancer O
, O
in O
both O
cohort O
(RR=0.70 O
[95% O
CI=0.67-0.73]) O
and O
case-control O
studies O
(OR=0.90 O
[95% O
CI=0.84-0.98]) O
, O
but O
this O
finding O
was O
not O
supported O
by O
RCTs O
(RR=1.01[95% O
CI=0.81-1.26]) O
. O
Data O
from O
18 O
sulfonylurea O
studies O
in O
subjects O
with O
T2DM O
showed O
that O
sulfonylurea O
use O
is O
associated O
with O
an O
increase O
in O
all-cancer O
risk O
, O
in O
cohort O
studies O
(RR=1.55 O
[95% O
CI=1.48 O
-1.63]) O
, O
though O
data O
from O
RCTs O
(RR=1.17 O
[95% O
CI=0.95-1.45]) O
and O
case-control O
studies O
(OR=1.02 O
[95% O
CI=0.93-1.13]) O
failed O
to O
demonstrate O
a O
statistically O
significant O
effect O
. O
CONCLUSIONS O
: O
This O
analysis O
using O
pooled O
primary O
data O
demonstrates O
that O
metformin O
use O
reduces O
, O
while O
sulfonylurea O
use O
may O
be O
associated O
with O
an O
increased O
cancer O
risk O
in O
subjects O
with O
T2DM O
. O
These O
findings O
need O
to O
be O
confirmed O
in O
large-scale O
RCTs O
before O
they O
are O
translated O
into O
clinical O
practice O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB B
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

TPI O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Thymidine O
kinase O
and O
thymidine O
phosphorylase O
level O
as O
the O
main O
predictive O
parameter O
for O
sensitivity O
to O
TAS-102 O
in O
a O
mouse O
model.TAS-102 O
is O
a O
new O
oral O
anti-cancer O
drug O
preparation O
, O
composed O
of O
a O
1:0.5 O
mixture O
(on O
a O
molar O
basis) O
of O
alpha,alpha,alpha-trifluorothymidine O
(FTD) O
and O
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione O
hydrochloride O
(TPI) O
. O
TAS-102 O
currently O
undergoing O
clinical O
trials O
, O
has O
been O
demonstrated O
to O
have O
at O
least O
two O
mechanisms O
, O
inhibition O
of O
TS O
and O
incorporation O
into O
DNA O
. O
We O
hypothesized O
that O
the O
thymidine O
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O
activity O
of O
TAS-102 O
. O
In O
the O
present O
study O
, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine O
phosphorylase O
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O
, O
tumor O
growth O
and O
TS O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O
TP O
ratio O
. O
There O
was O
a O
significant O
correlation O
(p=0.04) O
between O
tumor O
growth O
inhibition O
and O
this O
ratio O
. O
These O
results O
suggested O
that O
the O
activation O
and O
degradation O
pattern O
of O
FTD O
plays O
an O
important O
role O
in O
the O
efficacy O
of O
TAS-102 O
and O
that O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
response O
to O
TAS-102 O
therapy O
. O
We O
also O
studied O
the O
influence O
of O
TPI O
on O
the O
capacity O
of O
exogenous O
dThd O
to O
reverse O
FTD-dependent O
growth O
inhibition O
. O
Thymidine O
(dThd) O
levels O
rescued O
the O
effect O
of O
FTD O
in O
vitro O
and O
significantly O
increased O
in O
serum O
after O
administration O
of O
TAS-102 O
or O
TPI O
alone O
but O
not O
FTD O
alone O
. O
This O
may O
suggest O
the O
possibility O
of O
a O
decrease O
in O
antitumor O
effect O
. O
However O
, O
our O
study O
indicated O
that O
the O
therapeutic O
index O
was O
clearly O
increased O
by O
FTD O
combined O
with O
TPI O
, O
compared O
with O
FTD O
alone O
, O
suggesting O
FTD-induced O
toxicity O
to O
sensitive O
host O
tissue O
can O
be O
selectively O
reversed O
with O
dThd O
. O
In O
conclusion O
, O
TK O
and O
TPI O
effects O
on O
TP B
play O
important O
roles O
in O
the O
cytotoxic O
action O
of O
TAS-102 O
, O
and O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
more O
precisely O
individual O
resistance O
or O
sensitivity O
. O

GBR O
12909 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurotoxicity O
of O
"ecstasy" O
and O
its O
metabolites O
in O
human O
dopaminergic O
differentiated O
SH-SY5Y O
cells.Ecstasy O
(3,4-methylenedioxymethamphetamine O
or O
MDMA) O
is O
a O
widely O
abused O
recreational O
drug O
, O
reported O
to O
produce O
neurotoxic O
effects O
, O
both O
in O
laboratory O
animals O
and O
in O
humans O
. O
MDMA O
metabolites O
can O
be O
major O
contributors O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MDMA O
catechol O
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
do O
pamine B
(DA) I
transporter I
, O
G I
BR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O
N-Me-α-MeDA-induced O
neurotoxicity O
, O
but O
only O
slightly O
affected O
NAC O
neuroprotection O
. O
In O
conclusion O
, O
MDMA O
catechol O
metabolites O
promote O
differential O
toxic O
effects O
to O
differentiated O
dopaminergic O
human O
SH-SY5Y O
cells O
. O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
( O
BHMT) B
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

Sar O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Long O
range O
effect O
of O
mutations O
on O
specific O
conformational O
changes O
in O
the O
extracellular O
loop O
2 O
of O
angiotensin O
II O
type O
1 O
receptor.The O
topology O
of O
the O
second O
extracellular O
loop O
(ECL2) O
and O
its O
interaction O
with O
ligands O
is O
unique O
in O
each O
G O
protein-coupled O
receptor O
. O
When O
the O
orthosteric O
ligand O
pocket O
located O
in O
the O
transmembrane O
(TM) O
domain O
is O
occupied O
, O
ligand-specific O
conformational O
changes O
occur O
in O
the O
ECL2 O
. O
In O
more O
than O
90% O
of O
G O
protein-coupled O
receptors O
, O
ECL2 O
is O
tethered O
to O
the O
third O
TM O
helix O
via O
a O
disulfide O
bond O
. O
Therefore O
, O
understanding O
the O
extent O
to O
which O
the O
TM O
domain O
and O
ECL2 O
conformations O
are O
coupled O
is O
useful O
. O
To O
investigate O
this O
, O
we O
examined O
conformational O
changes O
in O
ECL2 O
of O
the O
angiotensin O
II O
type O
1 O
receptor O
(AT1R) O
by O
introducing O
mutations O
in O
distant O
sites O
that O
alter O
the O
activation O
state O
equilibrium O
of O
the O
AT1R O
. O
Differential O
accessibility O
of O
reporter O
cysteines O
introduced O
at O
four O
conformation-sensitive O
sites O
in O
ECL2 O
of O
these O
mutants O
was O
measured O
. O
Binding O
of O
the O
agonist O
angiotensin O
II O
(AngII) O
and O
inverse O
agonist O
losartan O
in O
wild-type O
AT1R O
changed O
the O
accessibility O
of O
reporter O
cysteines O
, O
and O
the O
pattern O
was O
consistent O
with O
ligand-specific O
"lid" O
conformations O
of O
ECL2 O
. O
Without O
agonist O
stimulation O
, O
the O
ECL2 O
in O
the O
gain O
of O
function O
mutant O
N111G O
assumed O
a O
lid O
conformation O
similar O
to O
AngII-bound O
wild-type O
AT1R O
. O
In O
the O
presence O
of O
inverse O
agonists O
, O
the O
conformation O
of O
ECL2 O
in O
the O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2),Ile(8)] O
AngII B
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F B
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

calyculin-A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
serine/threonine O
protein O
phosphatase O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
serine/threonine O
protein O
phosphatase O
(PP) O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice O
, O
and O
on O
[3H]naloxone O
binding O
to O
the O
forebrain O
crude O
synaptosome O
fraction O
. O
Neither O
okadaic O
acid O
nor O
cantharidin O
(1-10000 O
nM) O
displaced O
[3H]naloxone O
from O
its O
specific O
binding O
sites O
, O
which O
indicates O
that O
they O
do O
not O
interact O
at O
the O
opioid O
receptor O
level O
. O
The O
i.c.v O
. O
administration O
of O
very O
low O
doses O
of O
okadaic O
acid O
(0.001-1 O
pg/mouse) O
and O
cantharidin O
(0.001-1 O
ng/mouse) O
, O
which O
inhibit O
PP2A O
, O
produced O
a O
dose-dependent O
antagonism O
of O
the O
antinociception O
induced O
by O
morphine O
(s.c.) O
. O
However O
, O
L-nor-okadaone O
(0.001 O
pg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
an O
analogue O
of O
okadaic O
acid O
lacking O
activity O
against O
protein O
phosphatases O
, O
did O
not O
affect O
the O
antinociceptive O
effect O
of O
morphine O
. O
On O
the O
other O
hand O
, O
high O
doses O
of O
okadaic O
acid O
(10 O
ng/mouse O
, O
i.c.v.) O
and O
cantharidin O
(1 O
microg/mouse O
, O
i.c.v.) O
, O
which O
also O
block O
PP1 O
, O
and O
calyculin-A O
(0.1 O
fg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
which O
inhibits O
equally O
both O
PP1 B
and O
PP2A O
, O
did O
not O
modify O
the O
morphine-induced O
antinociception O
. O
These O
results O
suggest O
that O
the O
activation O
of O
type O
2A O
serine/threonine O
protein O
phosphatases O
may O
play O
a O
role O
in O
the O
antinociceptive O
effect O
of O
morphine O
, O
and O
that O
PP1 O
might O
counterbalace O
this O
activity O
. O

(m)CpG O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3- B
(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramide O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE B
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

L-serine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mouse O
brain O
serine O
racemase O
catalyzes O
specific O
elimination O
of O
L-serine O
to O
pyruvate.D-Serine O
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' O
site O
of O
the O
N-methyl-D-aspartate O
(NMDA)-type O
receptors O
. O
Racemization O
of O
serine O
is O
catalyzed O
by O
serine O
racemase O
, O
a O
pyridoxal O
5'-phosphate-dependent O
enzyme O
expressed O
mainly O
in O
brain O
and O
liver O
. O
NMDA O
receptor O
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine O
racemase O
are O
thus O
potentially O
interesting O
targets O
for O
therapy O
. O
We O
expressed O
recombinant O
mouse O
serine O
racemase O
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity O
. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+) O
, O
Ca(2+) O
or O
Mn(2+) O
for O
activity O
but O
not O
for O
dimerization O
. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O
of O
L-Ser O
to O
pyruvate O
. O
D-Serine O
is O
eliminated O
much O
less O
efficiently O
. O
Both O
L-serine O
racemization O
and O
elimination O
activities O
of O
serine O
racemase O
are O
of O
comparable O
magnitude O
, O
display O
alkaline O
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5 O
catalyzes O
specific O
elimination O
of O
L-serine O
to O
pyruvate.D-Serine O
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' O
site O
of O
the O
N-methyl-D-aspartate O
(NMDA)-type O
receptors O
. O
Racemization O
of O
serine O
is O
catalyzed O
by O
serine O
racemase O
, O
a O
pyridoxal O
5'-phosphate-dependent O
enzyme O
expressed O
mainly O
in O
brain O
and O
liver O
. O
NMDA O
receptor O
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine O
racemase O
are O
thus O
potentially O
interesting O
targets O
for O
therapy O
. O
We O
expressed O
recombinant O
mouse O
serine O
racemase O
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity O
. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+) O
, O
Ca(2+) O
or O
Mn(2+) O
for O
activity O
but O
not O
for O
dimerization O
. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O
of O
L-Ser O
to O
pyruvate O
. O
D-Serine O
is O
eliminated O
much O
less O
efficiently O
. O
Both O
L-serine O
racemization O
and O
elimination O
activities O
of O
serine O
racemase O
are O
of O
comparable O
magnitude O
, O
display O
alkaline O
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5 O
. O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
( O
hCES1) B
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

M6P O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate) O
/ O
IGF2R B
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O
to O
assess O
the O
relevance O
of O
the O
different O
ligand-binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O
this O
cellular O
system O
. O
The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P/IGF2R O
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin-like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells O
. O
In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R O
and O
M6P-modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R O
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P-binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding O
domains O
of O
the O
receptor O
. O

cortisol O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 O
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes O
. O
Type B
2 I
11β-hydroxysteroid I
dehydrogenase I
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
, O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O
for O
a O
highly O
polymorphic O
CA-repeat O
polymorphism O
in O
the O
first O
intron O
of O
HSD11B2 O
. O
Allele O
and O
genotype O
frequencies O
differed O
between O
normal O
and O
impaired O
glucose O
tolerance O
(P O
= O
0.0014 O
and O
0.0407 O
, O
respectively; O
4DF) O
or O
type O
2 O
diabetes O
(P O
= O
0.0053 O
and O
0.0078) O
, O
with O
significant O
linear O
trends O
between O
the O
repeat O
length O
and O
the O
phenotype O
fraction O
. O
In O
normal O
subjects O
, O
total O
CA-repeat O
length O
was O
negatively O
correlated O
with O
fasting O
insulin O
and O
HOMA-β O
. O
Thus O
, O
subjects O
having O
more O
CA O
repeats O
are O
susceptible O
to O
developing O
abnormal O
glucose O
tolerance O
, O
whereas O
normal O
subjects O
carrying O
more O
CA O
repeats O
appeared O
to O
have O
frugal O
characteristics O
in O
insulin O
secretion O
. O

carvedilol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Serum O
carvedilol O
concentration O
and O
its O
relation O
to O
change O
in O
plasma O
brain O
natriuretic O
peptide O
level O
in O
the O
treatment O
of O
heart O
failure O
: O
a O
preliminary O
study.OBJECTIVE O
: O
To O
examine O
the O
influence O
of O
carvedilol O
dose O
and O
concentration O
in O
serum O
on O
plasma O
brain O
natriuretic O
peptide O
( O
BNP) B
 O
, O
a O
measure O
of O
heart O
failure O
progression O
. O
METHODS O
: O
12 O
patients O
with O
New O
York O
Heart O
Association O
(NYHA) O
functional O
class O
II-III O
chronic O
heart O
failure O
were O
enrolled O
in O
the O
study O
. O
They O
received O
carvedilol O
at O
daily O
doses O
of O
1-20 O
mg O
with O
a O
1-2 O
weekly O
adjustment O
. O
Serum O
carvedilol O
trough O
concentrations O
were O
measured O
in O
steady-state O
using O
a O
specific O
fluorescence O
HPLC O
method O
. O
The O
degree O
of O
improvement O
in O
heart O
failure O
was O
assessed O
from O
the O
ratio O
of O
change O
in O
the O
plasma O
BNP O
concentration O
, O
2 O
weeks O
, O
1 O
month O
and O
3 O
months O
after O
the O
commencement O
of O
carvedilol O
administration O
. O
RESULTS O
: O
From O
the O
pharmacokinetic O
aspect O
, O
there O
was O
no O
valid O
correlation O
between O
the O
trough O
serum O
carvedilol O
concentration O
(Cmin) O
and O
daily O
dose O
per O
body O
weight O
(Dd/BW) O
, O
indicating O
that O
there O
was O
a O
wide O
difference O
in O
the O
carvedilol O
elimination O
capacity O
among O
individuals O
. O
A O
significant O
decrease O
in O
the O
BNP O
was O
observed O
at O
the O
3rd O
month O
in O
patients O
treated O
with O
the O
high O
dose O
(> O
750 O
mg/3 O
months) O
. O
On O
the O
other O
hand O
, O
in O
patients O
with O
a O
mean O
serum O
carvedilol O
level O
(Cmin) O
of O
less O
than O
2.5 O
nmol/l O
up O
to O
2 O
weeks O
after O
the O
start O
ofcarvedilol O
therapy O
, O
the O
degree O
of O
reduction O
in O
the O
BNP O
value O
after O
the O
3rd O
month O
was O
significantly O
larger O
, O
relative O
to O
the O
patient O
group O
with O
Cmin O
over O
2.5 O
nmol/l O
. O
CONCLUSIONS O
: O
The O
total O
carvedilol O
dose O
was O
confirmed O
to O
be O
one O
of O
the O
determinants O
for O
improvement O
in O
heart O
failure O
, O
and O
it O
was O
suggested O
that O
the O
initial O
serum O
level O
also O
plays O
an O
important O
role O
in O
therapeutic O
outcome O
. O
Therefore O
, O
it O
may O
be O
important O
to O
monitor O
the O
serum O
carvedilol O
level O
at O
the O
introductory O
period O
to O
determine O
the O
daily O
dose O
requirements O
because O
of O
the O
wide O
inter-individual O
variability O
in O
its O
metabolic O
clearance O
. O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KIT B
D816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

MXF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF B
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR- B
dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

clopidogrel-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 B
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

cefadroxil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanisms O
of O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
: O
studies O
in O
wild-type O
and O
PEPT2 O
knockout O
mice.The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil O
was O
studied O
in O
peptide O
transporter O
2 O
(PEPT2) O
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature O
, O
transport O
inhibitors O
, O
pH O
, O
and O
saturability O
. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C) O
, O
the O
uptake O
of O
1 O
microM O
cefadroxil O
was O
reduced O
by O
83% O
in O
PEPT2(-/-) O
mice O
as O
compared O
with O
PEPT2(+/+) O
mice O
(p O
< O
0.001) O
. O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C O
, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil O
or O
p-aminohippurate O
(p O
< O
0.05) O
. O
Glycylsarcosine O
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil O
in O
PEPT2(+/+) O
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) O
mice O
. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil O
was O
demonstrated O
in O
PEPT2(+/+) O
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01) O
, O
no O
pH O
dependence O
was O
observed O
in O
PEPT2( B
-/-) O
mice O
. O
Kinetic O
parameters O
for O
cefadroxil O
(without O
p-aminohippurate) O
in O
wild-type O
mice O
were O
: O
V(max) O
= O
5.4 O
pmol/mg/min O
, O
K(m) O
= O
34 O
microM O
, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
the O
parameters O
were O
: O
V(max) O
= O
4.1 O
pmol/mg/min O
, O
K(m) O
= O
27 O
microM O
, O
and O
K(d) O
= O
0.0064 O
microl/mg/min O
. O
In O
null O
animals O
, O
the O
kinetic O
parameters O
of O
cefadroxil O
(without O
p-aminohippurate) O
were O
: O
V(max) O
= O
2.7 O
pmol/mg/min O
, O
K(m) O
= O
110 O
microM O
, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed O
. O
Based O
on O
kinetic O
and O
inhibitor O
analyses O
, O
it O
was O
determined O
that O
(under O
linear O
conditions) O
, O
80 O
to O
85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2 O
, O
10 O
to O
15% O
by O
organic O
anion O
transporter(s) O
, O
and O
5% O
by O
nonspecific O
mechanisms O
. O
These O
findings O
demonstrate O
that O
PEPT2 O
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
. O
Moreover O
, O
the O
data O
suggest O
a O
role O
for O
PEPT2 O
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid O
. O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D B
and O
CYP3A O
activities O
. O

benzyloxyphenyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) O
exchanger O
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX B
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

ziprasidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
PET O
study O
of O
dopamine O
D2 O
and O
serotonin O
5-HT2 O
receptor O
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone.OBJECTIVE O
: O
Ziprasidone O
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin O
5-HT(2) O
receptors O
compared O
with O
dopamine O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O
in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) O
occupancy O
(using O
[(11)C]raclopride) O
and O
5-HT(2) O
occupancy O
(using O
[(18)F]setoperone) O
in O
brain O
regions O
of O
interest O
in O
16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40 O
, O
80 O
, O
120 O
, O
or O
160 O
mg/day O
of O
ziprasidone O
, O
which O
reflected O
the O
recommended O
dose O
range O
. O
PET O
scanning O
was O
done O
after O
3 O
weeks O
of O
administration O
and O
at O
trough O
plasma O
levels O
, O
i.e. O
, O
12-16 O
hours O
after O
the O
last O
dose O
. O
RESULTS O
: O
The O
mean O
5-HT(2) O
receptor O
occupancy O
was O
significantly O
higher O
than O
the O
mean O
D(2) O
receptor O
occupancy O
(mean=76% O
, O
SD=15% O
, O
and O
mean=56% O
, O
SD=18% O
, O
respectively) O
. O
The O
estimated O
plasma O
ziprasidone O
concentration O
associated O
with O
50% O
maximal O
5-HT(2) B
receptor O
occupancy O
was O
almost O
four O
times O
lower O
than O
that O
for O
D(2) O
receptor O
occupancy O
. O
CONCLUSIONS O
: O
These O
data O
affirm O
that O
ziprasidone O
is O
similar O
to O
other O
novel O
antipsychotics O
in O
having O
greater O
5-HT(2) O
than O
D(2) O
receptor O
occupancy O
at O
therapeutic O
doses O
and O
suggest O
that O
the O
optimal O
effective O
dose O
of O
ziprasidone O
is O
closer O
to O
120 O
mg/day O
than O
to O
the O
lower O
doses O
suggested O
by O
previous O
PET O
studies O
. O
The O
relatively O
high O
D(2) O
receptor O
occupancy O
, O
even O
at O
trough O
plasma O
levels O
, O
suggests O
that O
ziprasidone O
is O
more O
similar O
to O
risperidone O
and O
olanzapine O
in O
receptor O
occupancy O
profile O
than O
to O
clozapine O
and O
quetiapine O
. O
Since O
ziprasidone O
plasma O
levels O
show O
significant O
(more O
than O
twofold) O
variation O
within O
a O
single O
dose O
cycle O
, O
studies O
that O
are O
aimed O
at O
peak O
plasma O
levels O
(6 O
hours O
after O
the O
last O
dose) O
and O
that O
examine O
extrastriatal O
regions O
are O
required O
to O
fully O
characterize O
the O
in O
vivo O
occupancy O
profile O
of O
ziprasidone O
. O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
( O
CSE) B
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

mitiglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 B
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

phosphatidylinositol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
tyrosine O
kinase O
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol B
3-kinase I
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

clopidogrel O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
P2Y12 O
, O
a O
new O
platelet O
ADP B
receptor I
 O
, O
target O
of O
clopidogrel.Clopidogrel O
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced O
platelet O
aggregation O
. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel O
over O
aspirin O
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction O
, O
stroke O
, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease O
. O
The O
antiaggregating O
effect O
of O
clopidogrel O
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP O
binding O
to O
a O
purinergic O
receptor O
present O
at O
the O
platelet O
surface O
. O
Clopidogrel O
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O
ADP O
, O
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets O
. O
The O
binding O
of O
(33)P-2MeS-ADP O
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
with O
a O
potency O
that O
was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets O
. O
In O
these O
transfected O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet O
receptor O
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP O
on O
platelets O
. O

TAK-375 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 B
receptor I
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O

Rofecoxib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis.Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2 O
, O
rofecoxib O
. O
We O
also O
assessed O
the O
antithrombotic O
effect O
of O
licofelone O
in O
rabbit O
platelet-rich O
plasma O
. O
For O
this O
purpose O
, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 B
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

pioglitazone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pioglitazone O
protects O
against O
cisplatin O
induced O
nephrotoxicity O
in O
rats O
and O
potentiates O
its O
anticancer O
activity O
against O
human O
renal O
adenocarcinoma O
cell O
lines.Cisplatin-induced O
nephrotoxicity O
is O
a O
serious O
problem O
that O
limits O
its O
use O
in O
cancer O
treatment O
. O
The O
present O
study O
aimed O
to O
investigate O
the O
renal O
protective O
capacity O
of O
pioglitazone O
to O
reduce O
the O
cisplatin- O
induced O
nephrotoxicity O
. O
The O
underlying O
suggested O
mechanism(s) O
and O
whether O
this O
nephroprotective O
effect O
(if O
any) O
interferes O
with O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
cancer O
cells O
were O
also O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O
these O
results O
suggested O
that O
pioglitazone O
protected O
against O
cisplatin- O
induced O
nephrotoxicity O
through O
its O
interaction O
with O
PPAR-γ B
receptors O
and O
antioxidant O
effects O
. O
Furthermore O
, O
pioglitazone O
did O
not O
interfere O
but O
rather O
potentiated O
the O
cytotoxic O
effects O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
. O

berberine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Development O
of O
a O
cell-based O
high-throughput O
peroxisome O
proliferator-activated O
receptors O
(PPARs) O
screening O
model O
and O
its O
application O
for O
evaluation O
of O
the O
extracts O
from O
Rhizoma O
Coptis.To O
date O
, O
peroxisome O
proliferator-activated O
receptors O
(PPARs) O
are O
becoming O
the O
new O
therapeutic O
targets O
for O
the O
treatment O
of O
metabolic O
diseases O
, O
such O
as O
Type O
2 O
diabetes O
, O
obesity O
, O
and O
cardiovascular O
disease O
. O
In O
this O
study O
, O
a O
cell-based O
high-throughput O
PPARs O
(PPARα/β/γ) O
model O
was O
developed O
for O
the O
screening O
of O
PPARs O
agonists O
. O
The O
screening O
conditions O
were O
evaluated O
through O
analyzing O
the O
expression O
value O
of O
luciferase O
. O
Finally O
, O
24 O
h O
of O
drug O
acting O
time O
, O
5 O
times O
of O
the O
dilution O
factor O
of O
luciferase O
zymolyte O
, O
and O
about O
2 O
× O
10(4) O
cells O
/ O
well O
on O
HeLa O
cells O
in O
96-well O
plates O
were O
used O
, O
respectively O
. O
Furthermore O
, O
the O
quality O
of O
high-throughput O
screening O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs B
besides O
berberine O
. O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O
. O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD B
816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

carvedilol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Serum O
carvedilol O
concentration O
and O
its O
relation O
to O
change O
in O
plasma O
brain O
natriuretic O
peptide O
level O
in O
the O
treatment O
of O
heart O
failure O
: O
a O
preliminary O
study.OBJECTIVE O
: O
To O
examine O
the O
influence O
of O
carvedilol O
dose O
and O
concentration O
in O
serum O
on O
plasma O
brain O
natriuretic O
peptide O
(BNP) O
, O
a O
measure O
of O
heart O
failure O
progression O
. O
METHODS O
: O
12 O
patients O
with O
New O
York O
Heart O
Association O
(NYHA) O
functional O
class O
II-III O
chronic O
heart O
failure O
were O
enrolled O
in O
the O
study O
. O
They O
received O
carvedilol O
at O
daily O
doses O
of O
1-20 O
mg O
with O
a O
1-2 O
weekly O
adjustment O
. O
Serum O
carvedilol O
trough O
concentrations O
were O
measured O
in O
steady-state O
using O
a O
specific O
fluorescence O
HPLC O
method O
. O
The O
degree O
of O
improvement O
in O
heart O
failure O
was O
assessed O
from O
the O
ratio O
of O
change O
in O
the O
plasma O
BNP O
concentration O
, O
2 O
weeks O
, O
1 O
month O
and O
3 O
months O
after O
the O
commencement O
of O
carvedilol O
administration O
. O
RESULTS O
: O
From O
the O
pharmacokinetic O
aspect O
, O
there O
was O
no O
valid O
correlation O
between O
the O
trough O
serum O
carvedilol O
concentration O
(Cmin) O
and O
daily O
dose O
per O
body O
weight O
(Dd/BW) O
, O
indicating O
that O
there O
was O
a O
wide O
difference O
in O
the O
carvedilol O
elimination O
capacity O
among O
individuals O
. O
A O
significant O
decrease O
in O
the O
BNP O
was O
observed O
at O
the O
3rd O
month O
in O
patients O
treated O
with O
the O
high O
dose O
(> O
750 O
mg/3 O
months) O
. O
On O
the O
other O
hand O
, O
in O
patients O
with O
a O
mean O
serum O
carvedilol O
level O
(Cmin) O
of O
less O
than O
2.5 O
nmol/l O
up O
to O
2 O
weeks O
after O
the O
start O
ofcarvedilol O
therapy O
, O
the O
degree O
of O
reduction O
in O
the O
BNP B
value O
after O
the O
3rd O
month O
was O
significantly O
larger O
, O
relative O
to O
the O
patient O
group O
with O
Cmin O
over O
2.5 O
nmol/l O
. O
CONCLUSIONS O
: O
The O
total O
carvedilol O
dose O
was O
confirmed O
to O
be O
one O
of O
the O
determinants O
for O
improvement O
in O
heart O
failure O
, O
and O
it O
was O
suggested O
that O
the O
initial O
serum O
level O
also O
plays O
an O
important O
role O
in O
therapeutic O
outcome O
. O
Therefore O
, O
it O
may O
be O
important O
to O
monitor O
the O
serum O
carvedilol O
level O
at O
the O
introductory O
period O
to O
determine O
the O
daily O
dose O
requirements O
because O
of O
the O
wide O
inter-individual O
variability O
in O
its O
metabolic O
clearance O
. O

lisuride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Re-evaluation O
of O
lisuride O
pharmacology O
: O
5-hydroxytryptamine1A O
receptor-mediated O
behavioral O
effects O
overlap O
its O
other O
properties O
in O
rats.RATIONALE O
: O
There O
is O
substantial O
evidence O
that O
lisuride O
can O
produce O
effects O
linked O
to O
5-HT(1A) O
receptor O
occupancy O
. O
Nevertheless O
, O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride O
, O
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine B
receptors I
in O
considering O
its O
antiparkinsonian O
effects O
, O
or O
an O
exclusive O
role O
of O
5-HT(2A/2C) O
receptor O
activation O
in O
hallucinogenesis O
. O
These O
conclusions O
are O
surprising O
when O
one O
considers O
that O
the O
potent O
interaction O
of O
lisuride O
with O
5-HT(1A) O
receptors O
has O
been O
demonstrated O
in O
several O
different O
laboratories O
and O
that O
activation O
of O
5-HT(1A) O
and O
5-HT(1B) O
receptors O
can O
modulate O
dopaminergically O
mediated O
responses O
. O
OBJECTIVE O
: O
The O
lack O
of O
full O
substitution O
of O
lisuride O
for O
lysergic O
acid O
diethylamide O
(LSD) O
in O
drug O
discrimination O
experiments O
and O
induction O
of O
a O
pronounced O
5-HT O
syndrome O
by O
this O
compound O
at O
relatively O
low O
doses O
convinced O
us O
to O
execute O
two O
series O
of O
experiments O
that O
might O
explain O
the O
primary O
mechanism O
responsible O
for O
lisuride-mediated O
biological O
effects O
and O
its O
paradoxical O
classification O
as O
a O
dopamine O
agonist O
in O
the O
literature O
. O
RESULTS O
: O
In O
drug O
discrimination O
studies O
, O
lisuride O
fully O
mimicked O
the O
5-HT(1A) O
agonist O
LY O
293284 O
, O
only O
partially O
substituted O
for O
LSD O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O
(+)-amphetamine O
. O
Lisuride O
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O
, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O
Only O
pMPPI O
[4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride] O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O
effective O
in O
inhibiting O
all O
5-HT O
syndrome O
behaviors O
produced O
by O
lisuride O
, O
whereas O
pMPPI O
was O
without O
effect O
on O
any O
behavior O
induced O
by O
LSD O
. O
Lisuride O
dose O
dependently O
decreased O
body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O
of O
the O
selective O
5-HT(1A) O
agonist O
LY O
293284 O
. O
The O
hypothermic O
effect O
of O
lisuride O
was O
prevented O
by O
pre-injection O
of O
pMPPI O
, O
but O
not O
by O
ketanserin O
or O
haloperidol O
. O
CONCLUSION O
: O
We O
have O
demonstrated O
that O
the O
behavioral O
effects O
of O
low O
doses O
of O
lisuride O
are O
clearly O
mediated O
by O
stimulation O
of O
5-HT(1A) O
receptors O
. O

betamethasone O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Species-specific O
differences O
in O
the O
glucocorticoid O
receptor O
transactivation O
function O
upon O
binding O
with O
betamethasone-esters.Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases O
. O
A O
number O
of O
adverse O
side O
effects O
, O
however O
, O
limit O
chronic O
treatment O
with O
GCs O
. O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human B
or I
rat I
GR I
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O
involution O
and O
body O
weight O
loss O
, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats O
. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM O
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O
in O
receptor O
binding O
. O

bromfenac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
glycogen B
synthase I
kinase-3β I
/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagin-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O
that O
cinobufagin O
potently O
inhibited O
the O
proliferation O
of O
U2OS O
, O
MG63 O
and O
SaOS-2 O
cells O
. O
Significant O
increases O
in O
G2/M O
cell-cycle O
arrest O
and O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Gene O
expression O
signature O
of O
parathion-transformed O
human O
breast O
epithelial O
cells.Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers O
. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous O
pesticides O
. O
Parathion O
is O
a O
cholinesterase O
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline O
esters O
, O
including O
acetylcholine O
at O
cholinergic O
synapses O
. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O
acetylcholinesterase O
at O
the O
synaptic O
junction O
. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O
antidote O
to O
acetylcholinesterase O
inhibitors O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
parathion O
and O
atropine O
on O
cell O
transformation O
of O
human O
breast O
epithelial O
cells O
in O
vitro O
. O
These O
studies O
showed O
that O
parathion O
alone O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit B
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion-treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O
MCM2 O
and O
MCM3 O
. O
It O
is O
suggested O
that O
parathion O
influences O
human O
breast O
epithelial O
cell O
transformation O
and O
is O
an O
initiator O
factor O
in O
the O
transformation O
process O
in O
breast O
cancer O
. O

heterocyclic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt B
b5 I
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

formoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Systemic O
administration O
of O
beta2-adrenoceptor B
agonists O
, O
formoterol O
and O
salmeterol O
, O
elicit O
skeletal O
muscle O
hypertrophy O
in O
rats O
at O
micromolar O
doses.beta(2)-Adrenoceptor O
agonists O
provide O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness O
, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart O
, O
mediated O
in O
part O
, O
by O
beta(1)-adrenoceptor O
activation O
. O
Two O
beta(2)-agonists O
, O
formoterol O
and O
salmeterol O
, O
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O
safety O
, O
associated O
with O
greater O
beta(2)-adrenoceptor O
selectivity O
. O
The O
pharmacological O
profiles O
of O
formoterol O
and O
salmeterol O
and O
their O
effects O
on O
skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old O
, O
male O
F344 O
rats O
. O
Formoterol O
and O
salmeterol O
were O
each O
administered O
via O
daily O
i.p O
. O
injection O
at O
one O
of O
seven O
doses O
(ranging O
from O
1 O
to O
2,000 O
microg O
kg(-1) O
day(-1)) O
, O
for O
4 O
weeks O
. O
Rats O
were O
anaesthetised O
and O
the O
EDL O
and O
soleus O
muscles O
and O
the O
heart O
were O
excised O
and O
weighed O
. O
Dose-response O
curves O
were O
constructed O
based O
on O
skeletal O
and O
cardiac O
muscle O
hypertrophy O
. O
Formoterol O
was O
more O
potent O
than O
salmeterol O
, O
with O
a O
significantly O
lower O
ED(50) O
in O
EDL O
muscles O
(1 O
and O
130 O
microg O
kg(-1) O
day(-1) O
, O
P O
<0.05) O
, O
whereas O
salmeterol O
had O
greater O
intrinsic O
activity O
than O
formoterol O
in O
both O
EDL O
and O
soleus O
muscles O
(12% O
greater O
hypertrophy O
than O
formoterol) O
. O
The O
drugs O
had O
similar O
potency O
and O
intrinsic O
activity O
in O
the O
heart O
, O
with O
a O
smaller O
leftward O
shift O
for O
formoterol O
than O
seen O
in O
skeletal O
muscle O
. O
A O
dose O
of O
25 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
elicited O
greater O
EDL O
and O
soleus O
hypertrophy O
than O
salmeterol O
, O
but O
resulted O
in O
similar O
beta-adrenoceptor O
downregulation O
. O
These O
results O
show O
that O
doses O
as O
low O
as O
1 O
microg O
kg(-1) O
day(-1) O
of O
formoterol O
can O
elicit O
significant O
muscle O
hypertrophy O
with O
minimal O
cardiac O
hypertrophy O
and O
provide O
important O
information O
regarding O
the O
potential O
therapeutic O
use O
of O
formoterol O
and O
salmeterol O
for O
muscle O
wasting O
. O

LY117018 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
the O
uterotropic O
activity O
of O
estrogens O
and O
antiestrogens O
by O
the O
short O
acting O
antiestrogen O
LY117018.The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
the O
dihydroxylated O
antiestrogen O
LY117018 O
, O
with O
a O
high O
affinity O
for O
the O
estrogen O
receptor O
and O
low O
intrinsic O
estrogenic O
activity O
, O
could O
inhibit O
the O
uterotropic O
actions O
of O
steroidal O
[estradiol-17 O
beta O
(E2)] O
and O
nonsteroidal O
[ICI O
3188 O
and O
trianisylchloroethylene O
(TACE)] O
estrogens O
in O
immature O
rats O
and O
also O
the O
uterotropic O
actions O
of O
tamoxifen O
and O
monohydroxytamoxifen O
in O
the O
ovariectomized O
mouse O
and O
immature O
rat O
. O
In O
the O
first O
series O
of O
experiments O
, O
LY117018 O
was O
compared O
with O
monohydroxytamoxifen O
. O
Both O
antiestrogens O
inhibited O
the O
uterotropic O
actions O
of O
E2 O
(0.32 O
micrograms O
daily) O
, O
ICI O
3188 O
(5 O
micrograms O
daily) O
, O
and O
TACE O
(40 O
and O
160 O
micrograms O
daily) O
in O
a O
dose-related O
manner O
(0.32-82 O
micrograms O
daily) O
. O
The O
potency O
of O
the O
antiestrogens O
against O
E2 O
and O
ICI O
3188 O
was O
similar O
, O
however O
, O
at O
higher O
doses O
(20.48 O
and O
82 O
micrograms O
daily) O
LY117018 O
reduced O
uterine O
weights O
to O
below O
the O
lowest O
level O
achieved O
by O
monohydroxytamoxifen O
. O
In O
contrast O
, O
LY117018 O
was O
less O
effective O
against O
the O
long O
acting O
estrogen O
TACE O
. O
The O
competitive O
interaction O
of O
LY117018 O
with O
tamoxifen O
and O
monohydroxytamoxifen O
was O
compared O
in O
3-day O
ovariectomized O
mouse O
and O
immature O
rat O
uterine O
weight O
tests O
. O
Tamoxifen O
and O
monohydroxytamoxifen O
were O
fully O
estrogenic O
in O
the O
mouse O
(5 O
micrograms O
daily) O
and O
partially O
estrogenic O
in O
the O
rat O
(1.5-20 O
micrograms O
daily) O
. O
LY117018 O
was O
a O
partial O
estrogen O
in O
the O
mouse O
and O
a O
weekly O
active O
partial O
estrogen O
in O
the O
rat O
(2.5-120 O
micrograms O
daily) O
. O
LY117018 O
produced O
dose-related O
decreases O
in O
the O
uterine O
weight O
increases O
induced O
by O
tamoxifen O
and O
monohydroxytamoxifen O
in O
both O
species O
. O
However O
, O
in O
the O
rat O
, O
LY117018 O
was O
more O
effective O
against O
the O
less O
potent O
compound O
tamoxifen O
, O
at O
a O
6:1 O
dosage O
ratio O
compared O
with O
a O
24:1 O
dosage O
ratio O
required O
for O
the O
potent O
compound O
monohydroxytamoxifen O
. O
LY117018 O
had O
a O
short O
duration O
of O
action O
as O
an O
antiestrogen O
when O
compared O
with O
monohydroxytamoxifen O
. O
LY117018 O
(120 O
micrograms) O
was O
only O
completely O
effective O
as O
an O
antiestrogen O
if O
administered O
repeatedly O
with O
E2 O
whereas O
a O
single O
injection O
of O
monohydroxytamoxifen O
(120 O
micrograms) O
was O
sufficient O
to O
inhibit O
fully O
E2 O
action O
in O
the O
uterus O
for O
up O
to O
4 O
days O
. O
Because O
LY117018 O
has O
a O
shorter O
duration O
of O
action O
than O
monohydroxytamoxifen O
, O
a O
high O
dosage O
ratio O
of O
LY117018 O
over O
monohydroxytamoxifen O
is O
required O
to O
maintain O
effective O
competitive O
antagonism O
in O
the O
uterus O
. O
Overall O
, O
these O
findings O
suggest O
that O
monohydroxytamoxifen O
and O
LY117018 O
probably O
act O
through O
the O
same O
mechanism O
of O
action O
via O
the O
estrogen B
receptor I
. O

phosphatidylinositol-4,5-bisphosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cis-silencing O
of O
PIP5K1B O
evidenced O
in O
Friedreich's O
ataxia O
patient O
cells O
results O
in O
cytoskeleton O
anomalies.Friedreich's O
ataxia O
(FRDA) O
is O
a O
progressive O
neurodegenerative O
disease O
characterized O
by O
ataxia O
, O
variously O
associating O
heart O
disease O
, O
diabetes O
mellitus O
and/or O
glucose O
intolerance O
. O
It O
results O
from O
intronic O
expansion O
of O
GAA O
triplet O
repeats O
at O
the O
FXN O
locus O
. O
Homozygous O
expansions O
cause O
silencing O
of O
the O
FXN O
gene O
and O
subsequent O
decreased O
expression O
of O
the O
encoded O
mitochondrial O
frataxin O
. O
Detailed O
analyses O
in O
fibroblasts O
and O
neuronal O
tissues O
from O
FRDA O
patients O
have O
revealed O
profound O
cytoskeleton O
anomalies O
. O
So O
far O
, O
however O
, O
the O
molecular O
mechanism O
underlying O
these O
cytoskeleton O
defects O
remains O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B B
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O
suppressed O
this O
phenotype O
in O
FRDA O
cells O
. O
In O
addition O
to O
provide O
new O
insights O
into O
the O
consequences O
of O
the O
FXN O
gene O
expansion O
, O
these O
findings O
raise O
the O
question O
whether O
PIP5K1B O
silencing O
may O
contribute O
to O
the O
variable O
manifestation O
of O
this O
complex O
disease O
. O

sulindac O
sulfide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 B
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

AuF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Thioredoxin-mimetic O
peptides O
(TXM) O
reverse O
auranofin O
induced O
apoptosis O
and O
restore O
insulin O
secretion O
in O
insulinoma O
cells.The O
thioredoxin O
reductase/thioredoxin O
system O
(TrxR/Trx1) O
plays O
a O
major O
role O
in O
protecting O
cells O
from O
oxidative O
stress O
. O
Disruption O
of O
the O
TrxR-Trx1 O
system O
keeps O
Trx1 O
in O
the O
oxidized O
state O
leading O
to O
cell O
death O
through O
activation O
of O
the O
ASK1-Trx1 O
apoptotic O
pathway O
. O
The O
potential O
mechanism O
and O
ability O
of O
tri- O
and O
tetra-oligopeptides O
derived O
from O
the O
canonical O
-CxxC- O
motif O
of O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 B
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O
NAC O
, O
AD4 O
, O
or O
ascorbic O
acid O
. O
Unable O
to O
reverse O
ERK1/2 O
phosphorylation O
, O
TXM-CB3 O
(NAc-Cys-Pro-Cys O
amide) O
appeared O
to O
function O
in O
part O
, O
through O
inhibiting O
ASK1-Trx O
dissociation O
. O
These O
highly O
effective O
anti-apoptotic O
effects O
of O
Trx1 O
mimetic O
peptides O
exhibited O
in O
INS O
832/13 O
cells O
could O
become O
valuable O
in O
treating O
adverse O
oxidative-stress O
related O
disorders O
such O
as O
diabetes O
. O

Streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Clock O
Gene O
Expression O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O
followed O
by O
real-time O
polymerase O
chain O
reaction O
. O
Diabetic O
STZ O
and O
Iddm O
rats O
, O
as O
well O
as O
insulin-substituted O
Iddm O
rats O
, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock O
genes O
as O
determined O
by O
Cosinor O
analysis; O
however O
, O
the O
MESOR O
(midline O
estimating O
statistic O
of O
rhythm) O
of O
Bmal1 O
, O
Per2 O
, O
and O
Clock O
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin-substituted O
Iddm O
rats O
. O
The O
hepatic O
expression O
of O
the O
CCGs O
Dbp O
and O
RevErbα O
revealed O
a O
diurnal O
rhythm O
in O
all O
investigated O
groups O
. O
Insulin O
administration O
to O
Iddm O
rats O
normalized O
the O
enhanced O
MESOR O
in O
the O
expression O
of O
Dbp O
, O
RevErbα O
, O
and O
E4bp4 O
to O
the O
levels O
of O
normoglycemic O
controls O
. O
Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O
Pparγ O
expression O
in O
the O
livers O
of O
diabetic O
STZ O
or O
Iddm O
rats O
or O
in O
those O
of O
insulin-substituted O
Iddm O
rats O
. O
Also O
, O
insulin O
substitution O
could O
not O
reverse O
the O
decreased O
MESOR O
of O
Pparγ O
expression O
in O
Iddm O
rats O
. O
In O
consequence O
of O
the O
diabetic O
disease O
, O
changes O
in O
the O
expression O
of O
clock O
genes O
and O
CCGs O
suggest O
alterations O
in O
the O
hepatic O
peripheral O
clock O
mechanism O
Gene O
Expression O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O
followed O
by O
real-time O
polymerase O
chain O
reaction O
. O
Diabetic O
STZ O
and O
Iddm O
rats O
, O
as O
well O
as O
insulin-substituted O
Iddm O
rats O
, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock O
genes O
as O
determined O
by O
Cosinor O
analysis; O
however O
, O
the O
MESOR O
(midline O
estimating O
statistic O
of O
rhythm) O
of O
Bmal1 O
, O
Per2 O
, O
and O
Clock O
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin-substituted O
Iddm O
rats O
. O
The O
hepatic O
expression O
of O
the O
CCGs O
Dbp O
and O
RevErbα O
revealed O
a O
diurnal O
rhythm O
in O
all O
investigated O
groups O
. O
Insulin O
administration O
to O
Iddm O
rats O
normalized O
the O
enhanced O
MESOR O
in O
the O
expression O
of O
Dbp O
, O
RevErbα O
, O
and O
E4bp4 O
to O
the O
levels O
of O
normoglycemic O
controls O
. O
Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O
Pparγ O
expression O
in O
the O
livers O
of O
diabetic O
STZ O
or O
Iddm O
rats O
or O
in O
those O
of O
insulin-substituted O
Iddm O
rats O
. O
Also O
, O
insulin O
substitution O
could O
not O
reverse O
the O
decreased O
MESOR O
of O
Pparγ O
expression O
in O
Iddm O
rats O
. O
In O
consequence O
of O
the O
diabetic O
disease O
, O
changes O
in O
the O
expression O
of O
clock O
genes O
and O
CCGs O
suggest O
alterations O
in O
the O
hepatic O
peripheral O
clock O
mechanism O
. O

prenylflavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol B
acyltransferase I
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol O
acyltransferase O
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT O
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

SC-51089 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandins O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase B
beta I
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

CT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
In O
vitro O
simulation O
of O
therapeutic O
plasmatic O
fibrinolysis.One O
type O
of O
therapy O
for O
thromboembolism O
is O
plasmatic O
thrombolysis O
. O
Several O
plasminogen O
activators O
(PA) O
are O
clinically O
available O
, O
including O
urokinase O
(u-PA) O
, O
tissue O
plasminogen O
activator O
(t-PA) O
, O
streptokinase O
(SK) O
, O
plasminogen-streptokinase-activator-complex O
(PSAC) O
, O
or O
mutants O
of O
t-PA O
such O
as O
reteplase O
(RP) O
or O
tenecteplase O
(TP) O
. O
Therapeutic O
plasmatic O
fibrinolysis O
was O
simulated O
, O
using O
the O
PA O
at O
relevant O
plasma O
concentrations O
, O
and O
plasmin O
(Pli) O
and O
PA O
activities O
were O
determined O
. O
Normal O
citrated O
plasma O
was O
supplemented O
with O
31 O
to O
1,000 O
IU/mL O
u-PA O
, O
0.31 O
to O
20 O
microg/mL O
t-PA O
, O
125 O
to O
4,000 O
IU/mL O
SK O
, O
12.5 O
to O
400 O
U/mL O
PSAC O
, O
125 O
to O
4,000 O
U/mL O
RP O
, O
or O
0.31 O
to O
10 O
microg/mL O
TP O
. O
Ten O
IU/mL O
urokinase O
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O
patients O
, O
that O
was O
previously O
oxidized O
with O
the O
singlet O
oxygen O
(1O2) O
donor O
chloramine O
T O
(CT) O
, O
to O
destroy O
plasmatic O
PAI-1 O
and O
alpha2-anti O
plasmin B
. O
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C) O
, O
50-microL O
samples O
were O
withdrawn O
and O
added O
to O
100 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT O
. O
For O
determination O
of O
plasmin O
activity O
, O
10 O
microL O
thereof O
was O
incubated O
with O
150 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
100 O
microL O
20 O
mM O
CT O
preoxidized O
(15 O
minutes O
37 O
degrees O
C) O
pooled O
normal O
citrate O
buffered O
EDTA-plasma O
for O
30 O
minutes O
(37 O
degrees O
C) O
. O
For O
determination O
of O
[PA+Pli]-activity O
, O
arginine O
was O
added O
after O
this O
incubation O
. O
25-microL O
6 O
mM O
Val-Leu-Lys-pNA O
were O
added O
and O
deltaA/h O
at O
room O
temperature O
(RT) O
was O
monitored O
, O
using O
a O
microtiterplate O
reader O
. O
[PA+Pli]-Pli O
= O
PA O
. O
The O
PA O
concentration O
required O
to O
induce O
25% O
[ED25] O
of O
the O
maximally O
inducible O
Pli-activity O
in O
plasma O
(= O
1 O
U/mL O
= O
45 O
mg/L O
= O
0.53 O
micromol/L O
active O
Pli; O
deltaA O
= O
363 O
+/- O
8 O
mA/h O
RT) O
after O
10 O
minutes O
(37 O
degrees O
C) O
were O
320 O
IU/mL O
u-PA O
, O
8 O
microg/mL O
t-PA O
, O
140 O
U/mL O
PSAC O
, O
6,000 O
IU/mL O
SK O
, O
720 O
U/mL O
RP O
, O
and O
approximately O
150 O
microg/mL O
TP O
. O
The O
approximate O
activity O
half-lives O
of O
the O
PA O
in O
plasma O
were O
30 O
minutes O
for O
u-PA O
, O
30 O
minutes O
for O
t-PA O
, O
greater O
than O
80 O
minutes O
for O
SK O
, O
greater O
than O
80 O
minutes O
for O
PSAC O
, O
50 O
minutes O
for O
RP O
, O
and O
80 O
minutes O
for O
TP O
. O
The O
present O
study O
shows--for O
the O
first O
time--a O
combined O
kinetic O
in O
vitro O
simulation O
of O
the O
plasmatic O
activity O
of O
six O
different O
PAs O
. O
At O
clinically O
used O
concentrations O
, O
RP O
induces O
the O
highest O
plasmatic O
Pli O
activity O
. O
Due O
to O
unselective O
generation O
of O
plasmin O
in O
plasma O
, O
all O
PA O
are O
of O
some O
danger O
in O
inducing O
severe O
hemorrhagias O
. O
Clinical O
thrombolysis O
might O
be O
improved O
by O
usage O
of O
more O
physiologic O
activators O
of O
thrombolysis O
, O
such O
as O
activators O
of O
polymorphonuclear O
neutrophils O
. O

NO O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 B
activity O
. O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs B
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

HED O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Stereospecific O
inhibition O
of O
monoamine O
uptake O
transporters O
by O
meta-hydroxyephedrine O
isomers.Meta-hydroxyephedrine O
(HED) O
comprises O
four O
stereoisomers O
consisting O
of O
two O
enantiomeric O
pairs O
related O
to O
ephedrine O
and O
pseudoephedrine O
. O
HED O
is O
transported O
into O
adrenergic O
neurons O
and O
radiolabeled O
HED O
has O
been O
employed O
in O
positron O
emission O
tomography O
(PET) O
to O
image O
adrenergic O
neurons O
in O
vivo O
. O
To O
extend O
structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine O
transporters O
and O
to O
determine O
which O
stereoisomer O
displayed O
the O
best O
selectivity O
for O
PET O
imaging O
applications O
, O
we O
tested O
the O
HED O
compounds O
for O
their O
abilities O
to O
inhibit O
[(3)H]neurotransmitter O
uptake O
into O
platelets O
, O
transfected O
cells O
, O
and O
chromaffin O
vesicles O
. O
We O
hypothesized O
that O
the O
HED O
compounds O
would O
be O
most O
potent O
at O
the O
norepinephrine O
transporter O
( O
NET) B
compared O
to O
the O
serotonin O
or O
dopamine O
transporters O
and O
that O
the O
1R O
diastereomers O
would O
be O
more O
effective O
than O
1S O
diastereomers O
. O
Supporting O
the O
hypotheses O
, O
all O
stereoisomers O
were O
most O
potent O
at O
the O
NET O
and O
the O
1R,2S O
stereoisomer O
was O
the O
most O
potent O
inhibitor O
overall O
. O
However O
, O
the O
1S,2R O
isomer O
may O
be O
preferred O
for O
PET O
applications O
because O
of O
better O
selectivity O
among O
the O
transporters O
and O
reduced O
neuronal O
recycling O
. O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
( O
ERK) B
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

dipyridamole O
acts O
as O
NOT O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 B
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome B
P450 I
(CYP) I
2B6 I
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data O
. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 O
and O
CYP3A4 O
, O
respectively O
. O
The O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 O
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme-ketamine O
binding O
and O
catalytic O
activity O
. O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos B
 O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pseudoephedrine O
inhibits O
T-cell O
activation O
by O
targeting O
NF-kappaB O
, O
NFAT O
and O
AP-1 O
signaling O
pathways.Pseudoephedrine O
(PSE) O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 O
(IL-2) O
and O
tumor O
necrosis O
factor O
(TNF) O
alpha-gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 B
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
diseases O
. O

CP[c]Ph O
acts O
as O
NOT O
for O
what O
entity O
? O
Cyclopenta[c]phenanthrenes O
- O
Chemistry O
and O
biological O
activity.Despite O
cyclopenta-fused O
polycyclic O
aromatic O
hydrocarbons O
(CP-PAHs) O
having O
been O
detected O
in O
the O
environment O
, O
the O
ability O
of O
these O
compounds O
to O
induce O
cellular O
and O
tissue O
responses O
remains O
poorly O
characterized O
. O
In O
this O
review O
, O
we O
look O
at O
the O
chemistry O
and O
biological O
activity O
of O
the O
cyclopenta[c]phenanthrenes O
(CP[c]Ph) O
as O
potential O
chemicals O
of O
concern O
in O
the O
process O
of O
risk O
assessment O
. O
The O
first O
part O
of O
the O
review O
deals O
with O
the O
environmental O
occurrence O
and O
chemistry O
of O
CP-PAHs O
, O
focusing O
on O
available O
methods O
of O
CP[c]Ph O
chemical O
synthesis O
. O
The O
most O
interesting O
structural O
feature O
of O
the O
CP[c]Ph O
is O
the O
presence O
of O
a O
pseudo O
fjord-region O
constructed O
by O
the O
cyclopentane O
ring O
. O
This O
compound O
can O
be O
treated O
either O
as O
a O
structurally O
similar O
one O
to O
B[c]Ph O
, O
or O
as O
a O
phenanthrene O
skeleton O
with O
an O
electrodonating O
alkyl O
substituent O
in O
the O
bay-region O
of O
the O
molecule O
. O
The O
second O
thread O
, O
providing O
available O
data O
on O
the O
adverse O
effects O
of O
CP[c]Ph O
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A O
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα B
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay O
. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs O
are O
chemicals O
of O
concern O
for O
which O
potential O
pathways O
of O
exposure O
should O
be O
further O
identified O
. O

TDCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
In O
ovo O
effects O
of O
two O
organophosphate O
flame O
retardants O
, O
TCPP O
and O
TDCPP O
, O
on O
pipping O
success O
, O
development O
, O
mRNA O
expression O
and O
thyroid O
hormone O
levels O
in O
chicken O
embryos.Tris(1-chloro-2-propyl) O
phosphate O
(TCPP) O
and O
tris(1,3-dichloro-2-propyl) O
phosphate O
(TDCPP) O
are O
organic O
flame O
retardants O
detected O
in O
the O
environment O
and O
biota O
for O
which O
toxicological O
data O
for O
avian O
species O
are O
limited O
. O
In O
this O
study O
, O
domestic O
chicken O
eggs O
were O
injected O
with O
TCPP O
or O
TDCPP O
(maximum O
dose O
= O
51600 O
and O
45000 O
ng/g O
egg O
, O
respectively) O
to O
determine O
dose-dependent O
effects O
on O
pipping O
success O
, O
development O
, O
hepatic O
messenger O
RNA O
(mRNA) O
expression O
levels O
of O
genes O
associated O
with O
xenobiotic O
metabolism O
and O
the O
thyroid O
hormone O
(TH) O
pathway O
, O
and O
TH O
levels O
following O
20-22 O
days O
of O
incubation O
. O
Neither O
compound O
reduced O
pipping O
success; O
however O
, O
TCPP O
significantly O
delayed O
pipping O
at O
9240 O
and O
51600 O
ng/g O
and O
reduced O
tarsus O
length O
at O
51600 O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
, O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 B
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O
and O
TDCPP O
exposure O
may O
be O
associated O
with O
disruption O
of O
the O
TH-axis O
, O
which O
is O
critical O
for O
normal O
growth O
and O
development O
in O
birds O
. O
The O
effects O
of O
TDCPP O
on O
the O
gallbladder O
indicate O
that O
the O
disturbance O
of O
lipid O
metabolism O
is O
a O
likely O
target O
in O
its O
mechanism O
of O
toxicity O
. O

atenolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Beta1 O
adrenergic O
receptor-mediated O
enhancement O
of O
hippocampal O
CA3 O
network O
activity.Norepinephrine O
is O
an O
endogenous O
neurotransmitter O
distributed O
throughout O
the O
mammalian O
brain O
. O
In O
higher O
cortical O
structures O
such O
as O
the O
hippocampus O
, O
norepinephrine O
, O
via O
beta O
adrenergic O
receptor O
(AR) O
activation O
, O
has O
been O
shown O
to O
reinforce O
the O
cognitive O
processes O
of O
attention O
and O
memory O
. O
In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
beta1AR O
activation O
on O
hippocampal O
cornu O
ammonis O
3 O
(CA3) O
network O
activity O
. O
AR O
expression O
was O
first O
determined O
using O
immunocytochemistry O
with O
antibodies O
against O
beta1ARs O
, O
which O
were O
found O
to O
be O
exceptionally O
dense O
in O
hippocampal O
CA3 O
pyramidal O
neurons O
. O
CA3 O
network O
activity O
was O
then O
examined O
in O
vitro O
using O
field O
potential O
recordings O
in O
rat O
brain O
slices O
. O
The O
selective O
betaAR O
agonist O
isoproterenol O
caused O
an O
enhancement O
of O
hippocampal O
CA3 O
network O
activity O
, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region O
. O
In O
the O
presence O
of O
alphaAR O
blockade O
, O
concentration-response O
curves O
for O
isoproterenol O
, O
norepinephrine O
, O
and O
epinephrine O
suggested O
that O
a O
beta1AR O
was O
involved O
in O
this O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR B
antagonists O
atenolol O
and O
metoprolol O
blocked O
isoproterenol-induced O
enhancement O
, O
with O
apparent O
K(b) O
values O
of O
85 O
+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM O
, O
respectively O
. O
In O
contrast O
, O
the O
selective O
beta2AR O
antagonists O
ICI-118,551 O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM O
, O
respectively) O
. O
Together O
, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR O
antagonists O
indicates O
that O
in O
this O
model O
, O
beta1AR O
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
yeast O
cap O
binding O
complex O
modulates O
transcription O
factor O
recruitment O
and O
establishes O
proper O
histone O
H3K36 O
trimethylation O
during O
active O
transcription.Recent O
studies O
have O
revealed O
a O
close O
relationship O
between O
transcription O
, O
histone O
modification O
, O
and O
RNA O
processing O
. O
In O
fact O
, O
genome-wide O
analyses O
that O
correlate O
histone O
marks O
with O
RNA O
processing O
signals O
raise O
the O
possibility O
that O
specific O
RNA O
processing O
factors O
may O
modulate O
transcription O
and O
help O
to O
"write" O
chromatin O
marks O
. O
Here O
we O
show O
that O
the O
nuclear O
cap O
binding O
complex O
(CBC) O
directs O
recruitment O
of O
transcription O
elongation O
factors O
and O
establishes O
proper O
histone O
marks O
during O
active O
transcription O
. O
A O
directed O
genetic O
screen O
revealed O
that O
deletion O
of O
either O
subunit O
of O
the O
CBC O
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 O
or O
Bur2 O
, O
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb O
. O
The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser-2 O
of O
the O
C-terminal O
domain O
(CTD) O
of O
RNA B
polymerase I
II I
. O
To O
understand O
how O
these O
interactions O
influence O
downstream O
events O
, O
histone O
H3K36me3 O
was O
examined O
, O
and O
we O
demonstrate O
that O
CBCΔ O
affects O
proper O
Set2-dependent O
H3K36me3 O
. O
Consistent O
with O
this O
, O
the O
CBC O
and O
Set2 O
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O
activated O
gene O
expression O
, O
and O
these O
effects O
are O
distinct O
from O
other O
histone O
methyltransferases O
. O
This O
work O
provides O
evidence O
for O
an O
emerging O
model O
that O
RNA O
processing O
factors O
can O
modulate O
the O
recruitment O
of O
transcription O
factors O
and O
influence O
histone O
modification O
during O
elongation O
. O

CDB-4124 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vitro O
antiprogestational/antiglucocorticoid O
activity O
and O
progestin O
and O
glucocorticoid O
receptor O
binding O
of O
the O
putative O
metabolites O
and O
synthetic O
derivatives O
of O
CDB-2914 O
, O
CDB-4124 O
, O
and O
mifepristone.In O
determining O
the O
biological O
profiles O
of O
various O
antiprogestins O
, O
it O
is O
important O
to O
assess O
the O
hormonal O
and O
antihormonal O
activity O
, O
selectivity O
, O
and O
potency O
of O
their O
proximal O
metabolites O
. O
The O
early O
metabolism O
of O
mifepristone O
is O
characterized O
by O
rapid O
demethylation O
and O
hydroxylation O
. O
Similar O
initial O
metabolic O
pathways O
have O
been O
proposed O
for O
CDB-2914 O
(CDB O
: O
Contraceptive O
Development O
Branch O
of O
NICHD) O
and O
CDB-4124 O
, O
and O
their O
putative O
metabolites O
have O
been O
synthesized O
. O
We O
have O
examined O
the O
functional O
activities O
and O
potencies O
, O
in O
various O
cell-based O
assays O
, O
and O
relative O
binding O
affinities O
(RBAs) O
for O
progesterone O
receptors O
(PR) O
and O
glucocorticoid O
receptors O
(GR) O
of O
the O
putative O
mono- O
and O
didemethylated O
metabolites O
of O
CDB-2914 O
, O
CDB-4124 O
, O
and O
mifepristone O
and O
of O
the O
17alpha-hydroxy O
and O
aromatic O
A-ring O
derivatives O
of O
CDB-2914 O
and O
CDB-4124 O
. O
The O
binding O
affinities O
of O
the O
monodemethylated O
metabolites O
for O
rabbit O
uterine O
PR O
and O
human O
PR-A O
and O
PR-B O
were O
similar O
to O
those O
of O
the O
parent O
compounds O
. O
Monodemethylated O
mifepristone O
bound O
to O
rabbit B
thymic I
GR I
with O
higher O
affinity O
than O
monodemethylated O
CDB-2914 O
or O
CDB-4124 O
. O
T47D-CO O
cells O
were O
used O
to O
assess O
inhibition O
of O
R5020-stimulated O
endogenous O
alkaline O
phosphatase O
activity O
and O
transactivation O
of O
the O
PRE(2)-thymidine O
kinase O
(tk)-luciferase O
(LUC) O
reporter O
plasmid O
in O
transient O
transfections O
. O
The O
antiprogestational O
potency O
was O
as O
follows O
: O
mifepristone/CDB-2914/CDB-4124/monodemethylated O
metabolites O
(IC(50)'s O
approximately O
10(-9)M) O
> O
aromatic O
A-ring O
derivatives O
(IC(50)'s O
approximately O
10(-8)M) O
> O
didemethylated/17alpha-hydroxy O
derivatives O
(IC(50)'s O
approximately O
10(-7)M) O
. O
Antiglucocorticoid O
activity O
was O
determined O
by O
inhibition O
of O
dexamethasone-stimulated O
transcriptional O
activity O
in O
HepG2 O
cells O
. O
The O
mono- O
and O
didemethylated O
metabolites O
of O
CDB-2914 O
and O
CDB-4124 O
had O
less O
antiglucocorticoid O
activity O
(IC(50)'s O
approximately O
10(-6)M) O
than O
monodemethylated O
mifepristone O
(IC(50) O
approximately O
10(-8)M) O
or O
the O
other O
test O
compounds O
. O
At O
10(-6)M O
in O
transcription O
assays O
, O
none O
of O
these O
compounds O
showed O
progestin O
agonist O
activity O
, O
whereas O
mifepristone O
and O
its O
monodemethylated O
metabolite O
manifested O
slight O
glucocorticoid O
agonist O
activity O
. O
The O
reduced O
antiglucocorticoid O
activity O
of O
monodemethylated O
CDB-2914 O
and O
CDB-4124 O
was O
confirmed O
in O
vivo O
by O
the O
thymus O
involution O
assay O
in O
adrenalectomized O
male O
rats O
. O
The O
aromatic O
A-ring O
derivatives-stimulated O
transcription O
of O
an O
estrogen-responsive O
reporter O
plasmid O
in O
MCF-7 O
and O
T47D-CO O
human O
breast O
cancer O
cells O
but O
were O
much O
less O
potent O
than O
estradiol O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
the O
proximal O
metabolites O
of O
mifepristone O
, O
CDB-2914 O
, O
and O
CDB-4124 O
contribute O
significantly O
to O
the O
antiprogestational O
activity O
of O
the O
parent O
compounds O
in O
vivo O
. O
Furthermore O
, O
the O
reduced O
antiglucocorticoid O
activity O
of O
CDB-2914 O
and O
CDB-4124 O
compared O
to O
mifepristone O
in O
vivo O
may O
be O
due O
in O
part O
to O
decreased O
activity O
of O
their O
putative O
proximal O
metabolites O
. O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antitumor O
activity O
of O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 O
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 B
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
. O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
IFNα O
converts O
IL-22 O
into O
a O
cytokine O
efficiently O
activating O
STAT1 O
and O
its O
downstream O
targets.Besides O
their O
antiviral O
activity O
, O
type O
I O
Interferons O
(IFN) O
display O
context-specific O
immunomodulation O
. O
In O
contrast O
to O
long-known O
IFNα/β O
, O
Interleukin O
(IL)-22 O
is O
an O
anti-bacterial O
, O
largely O
tissue O
protective O
cytokine O
that O
recently O
gained O
attention O
. O
Herein O
, O
cellular O
IFNα/IL-22 O
interactions O
are O
investigated O
. O
We O
report O
that O
pre-conditioning O
of O
epithelial O
cells O
with O
IFNα O
initiated O
dramatic O
changes O
in O
IL-22 O
signaling O
normally O
dominated O
by O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT)-3 O
. O
Specifically O
, O
by O
using O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 B
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O
characteristics O
of O
IFNα/β O
in O
clinical O
therapy O
and O
expose O
margins O
of O
tissue O
protection O
by O
IL-22 O
application O
. O

mifepristone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
[Effect O
of O
mifepristone O
on O
the O
expression O
of O
progesterone O
receptor O
messenger O
RNA O
and O
protein O
in O
uterine O
leiomyomata].OBJECTIVE O
: O
To O
determine O
the O
expression O
of O
progesterone O
receptor O
(PR) O
mRNA O
and O
PR O
protein O
levels O
in O
the O
myometrium O
and O
leiomyomata O
from O
untreated O
and O
mifepristone O
pretreated O
women O
with O
leiomyoma O
and O
to O
examine O
the O
mechanism O
of O
mifepristone O
treatment O
on O
uterine O
leiomyomata O
. O
METHODS O
: O
Expression O
of O
PR B
mRNA I
and O
PR O
protein O
were O
determined O
by O
Northern O
blot O
and O
HAP O
of O
single-dose O
saturated O
analysis O
in O
myometrium O
and O
leiomyomata O
(center O
and O
marginal O
area) O
from O
27 O
untreated O
and O
6 O
mifepristone O
pretreated O
women O
with O
leiomyomata O
. O
RESULTS O
: O
PR O
mRNA O
abundance O
and O
PR O
protein O
levels O
in O
both O
myomatous O
center O
and O
marginal O
area O
were O
significantly O
greater O
than O
those O
in O
corporal O
myometrium O
(P O
< O
0.01) O
in O
both O
follicular O
and O
luteal O
phases O
, O
but O
similar O
between O
myomatous O
center O
and O
marginal O
area O
(P O
> O
0.05) O
. O
6 O
cases O
pretreated O
with O
mifepristone O
25 O
mg/day O
for O
3 O
months O
were O
operated O
, O
all O
but O
one O
patient O
displayed O
a O
decrease O
in O
leiomyomata O
volume O
. O
PR O
mRNA O
abundance O
in O
both O
myometruim O
and O
leiomyomata O
(center O
and O
marginal O
area) O
was O
significantly O
decreased O
in O
4 O
patients O
continuing O
mifepristone O
treatment O
before O
the O
operation O
but O
not O
in O
the O
other O
2 O
patients O
stopping O
RU486 O
1 O
month O
before O
operation O
. O
PR O
protein O
levels O
in O
these O
tissues O
showed O
significant O
decrease O
in O
all O
6 O
cases O
. O
CONCLUSION O
: O
There O
are O
overexpression O
of O
PRmRNA O
and O
PR O
protein O
in O
leiomyomata O
. O
One O
of O
the O
mechanism O
of O
mifepristone O
action O
on O
decreasing O
leiomyomata O
volume O
may O
be O
related O
to O
suppression O
on O
expression O
of O
PR O
gene O
. O
It O
seems O
that O
suppression O
on O
transcription O
of O
PR O
gene O
is O
reversible O
, O
but O
on O
translation O
of O
PR O
gene O
may O
maintain O
in O
a O
relatively O
longer O
period O
. O

PEC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
for O
controlled O
drug O
release O
. O
Cholesterol B
esterase I
(CE) O
induced O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
(PEC) O
and O
drug O
release O
from O
PEC O
under O
mild O
physiological O
environment O
was O
investigated O
. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films O
. O
During O
the O
whole O
period O
of O
degradation O
, O
MW O
of O
PEC O
was O
unchanged O
. O
Water O
uptake O
of O
the O
polymer O
was O
only O
2.8 O
and O
0.2% O
for O
PEC O
with O
the O
MW O
of O
200 O
kDa O
(PEC200) O
and O
PEC O
with O
the O
MW O
of O
41 O
kDa O
(PEC41) O
, O
respectively O
. O
Degradation O
of O
less O
hydrophilic O
PEC41 O
with O
higher O
density O
was O
slower O
than O
that O
of O
PEC200 O
. O
By O
this O
mechanism O
, O
CE-responsive O
drug O
in O
vitro O
release O
from O
PEC O
in O
situ O
forming O
depots O
(ISFD) O
was O
conducted O
successfully O
. O
As O
expected O
, O
less O
bovine O
serum O
albumin O
(BSA) O
was O
released O
from O
PEC41 O
compared O
with O
that O
of O
PEC200 O
in O
the O
same O
time O
period O
. O
In O
conclusion O
, O
this O
work O
enabled O
the O
in O
vitro O
drug O
release O
evaluation O
of O
existing O
PEC O
devices O
and O
implied O
a O
new O
candidate O
for O
the O
development O
of O
enzyme-responsive O
systems O
. O

4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
( O
BuChE) B
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

gemfibrozil O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS B
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles.Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast B
mitochondrial I
LeuRS I
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C-terminal O
domain O
. O

CP O
55,940 O
acts O
as O
NOT O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O
in O
the O
recognition O
of O
SR O
141716A O
. O
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 B
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

cefadroxil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanisms O
of O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
: O
studies O
in O
wild-type O
and O
PEPT2 O
knockout O
mice.The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil O
was O
studied O
in O
peptide O
transporter O
2 O
(PEPT2) O
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature O
, O
transport O
inhibitors O
, O
pH O
, O
and O
saturability O
. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C) O
, O
the O
uptake O
of O
1 O
microM O
cefadroxil O
was O
reduced O
by O
83% O
in O
PEPT2(-/-) O
mice O
as O
compared O
with O
PEPT2(+/+) O
mice O
(p O
< O
0.001) O
. O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C O
, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil O
or O
p-aminohippurate O
(p O
< O
0.05) O
. O
Glycylsarcosine O
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil O
in O
PEPT2(+/+) O
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) O
mice O
. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil O
was O
demonstrated O
in O
PEPT2(+/+) O
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01) O
, O
no O
pH O
dependence O
was O
observed O
in O
PEPT2(-/-) O
mice O
. O
Kinetic O
parameters O
for O
cefadroxil O
(without O
p-aminohippurate) O
in O
wild-type O
mice O
were O
: O
V(max) O
= O
5.4 O
pmol/mg/min O
, O
K(m) O
= O
34 O
microM O
, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
the O
parameters O
were O
: O
V(max) O
= O
4.1 O
pmol/mg/min O
, O
K(m) O
= O
27 O
microM O
, O
and O
K(d) O
= O
0.0064 O
microl/mg/min O
. O
In O
null O
animals O
, O
the O
kinetic O
parameters O
of O
cefadroxil O
(without O
p-aminohippurate) O
were O
: O
V(max) O
= O
2.7 O
pmol/mg/min O
, O
K(m) O
= O
110 O
microM O
, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed O
. O
Based O
on O
kinetic O
and O
inhibitor O
analyses O
, O
it O
was O
determined O
that O
(under O
linear O
conditions) O
, O
80 O
to O
85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2 O
, O
10 O
to O
15% O
by O
organic O
anion O
transporter(s) O
, O
and O
5% O
by O
nonspecific O
mechanisms O
. O
These O
findings O
demonstrate O
that O
PEPT2 B
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
. O
Moreover O
, O
the O
data O
suggest O
a O
role O
for O
PEPT2 O
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid O
. O

pyrrole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O
compounds O
proved O
to O
be O
very O
potent O
and O
selective O
COX-2 O
inhibitors O
in O
in O
vitro O
experimental O
models O
. O
Further O
in O
vivo O
studies O
on O
compounds O
9a,c O
and O
17a O
highlighted O
good O
anti-inflammatory O
and O
antinociceptive O
activities O
. O
Compound O
9c O
was O
able O
to O
inhibit O
glycosaminoglycan O
(GAG) O
release O
induced O
by O
interleukin-1β O
(IL-1β) O
, O
showing O
cartilage O
protective O
properties O
. O
Finally O
, O
molecular O
modeling O
and O
(1)H- O
and O
(13)C-NMR O
studies O
performed O
on O
compounds O
6c,d O
, O
9c O
, O
and O
10b O
allowed O
the O
right O
conformation O
of O
nitrooxyalkyl O
ester O
and O
ether O
side O
chain O
of O
these O
molecules O
within O
the O
COX-2 O
active O
site O
to O
be O
assessed O
. O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain B
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
effect O
of O
rofecoxib O
(a O
cyclooxygenase B
2 I
inhibitor) O
, O
ibuprofen O
, O
and O
placebo O
on O
the O
gastroduodenal O
mucosa O
of O
patients O
with O
osteoarthritis O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
The O
Rofecoxib O
Osteoarthritis O
Endoscopy O
Multinational O
Study O
Group.OBJECTIVE O
: O
This O
randomized O
, O
double-blind O
study O
tested O
the O
hypothesis O
that O
rofecoxib O
, O
a O
drug O
that O
specifically O
inhibits O
cyclooxygenase O
2 O
, O
would O
cause O
fewer O
gastroduodenal O
ulcers O
than O
ibuprofen O
(in O
a O
multicenter O
trial) O
, O
and O
its O
side O
effects O
would O
be O
equivalent O
to O
those O
of O
placebo O
(in O
a O
prespecified O
analysis O
combining O
the O
results O
with O
another O
trial O
of O
identical O
design) O
. O
METHODS O
: O
Seven O
hundred O
seventy-five O
patients O
with O
osteoarthritis O
were O
randomized O
to O
receive O
rofecoxib O
at O
a O
dosage O
of O
25 O
mg O
or O
50 O
mg O
once O
daily O
, O
ibuprofen O
800 O
mg O
3 O
times O
daily O
, O
or O
placebo O
. O
Gastroduodenal O
ulceration O
was O
assessed O
by O
endoscopy O
at O
6 O
, O
12 O
, O
and O
(for O
active O
treatment) O
24 O
weeks O
. O
The O
primary O
and O
secondary O
end O
points O
were O
the O
incidence O
of O
gastroduodenal O
ulcers O
at O
12 O
and O
24 O
weeks O
, O
respectively O
. O
RESULTS O
: O
Ulcers O
were O
significantly O
less O
common O
(P O
< O
0.001) O
following O
treatment O
with O
rofecoxib O
(25 O
mg O
or O
50 O
mg) O
than O
with O
ibuprofen O
after O
12 O
weeks O
(5.3% O
and O
8.8% O
versus O
29.2% O
, O
respectively) O
or O
24 O
weeks O
(9.9% O
and O
12.4% O
versus O
46.8% O
, O
respectively) O
. O
In O
the O
combined O
analysis O
, O
the O
12-week O
ulcer O
incidence O
with O
25 O
mg O
rofecoxib O
(4.7%) O
and O
with O
placebo O
(7.3%) O
satisfied O
prespecified O
criteria O
for O
equivalence O
. O
CONCLUSION O
: O
At O
2-4 O
times O
the O
therapeutically O
effective O
dose O
, O
rofecoxib O
caused O
fewer O
endoscopically O
detected O
ulcers O
than O
did O
ibuprofen O
. O
Rofecoxib O
at O
a O
dose O
of O
25 O
mg O
(the O
highest O
dose O
recommended O
for O
osteoarthritis) O
satisfied O
prespecified O
criteria O
for O
equivalence O
to O
placebo O
. O

methimazole O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
microsomal/peroxidase O
antigen O
: O
modulation O
of O
its O
expression O
in O
thyroid O
cells.Evidence O
has O
accumulated O
in O
the O
last O
few O
years O
that O
the O
expression O
of O
the O
microsomal/peroxidase O
antigen O
(M/TPO-Ag) O
in O
thyroid O
cells O
is O
induced O
by O
TSH O
, O
through O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO O
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O
is O
due O
to O
a O
direct O
transcriptional O
regulation O
of O
the O
TPO O
gene O
, O
as O
shown O
in O
dog O
thyroid O
cells O
, O
or O
to O
posttranscriptional O
effects O
, O
as O
it O
would O
appear O
in O
FRTL-5 O
cells O
, O
remains O
to O
be O
clarified O
by O
future O
experiments O
. O
Thyroid O
stimulating O
antibody O
(TSAb) O
of O
Graves' O
disease O
also O
stimulates O
the O
expression O
of O
M/TPO-Ag O
. O
This O
finding O
gives O
further O
support O
to O
the O
relevance O
of O
TSAb O
in O
the O
pathogenesis O
of O
hyperthyroidism O
and O
explains O
the O
well O
known O
observation O
that O
the O
"microsomal" O
antigen O
is O
particularly O
abundant O
in O
glands O
of O
Graves' O
patients O
. O
The O
modulation O
of O
M/TPO-Ag O
surface O
expression O
by O
TSH O
can O
explain O
the O
decrease O
of O
circulating O
anti-MAb O
observed O
during O
L-thyroxine O
therapy O
in O
hypothyroid O
patients O
with O
Hashimoto's O
thyroiditis O
. O
Other O
agents O
, O
such O
as O
methimazole O
and O
sodium O
iodide O
, O
which O
influence O
thyroid O
cell O
function O
, O
do O
not O
directly O
interfere O
with O
the O
expression O
of O
M/TPO-Ag B
. O
Cytokines O
, O
such O
as O
gamma-interferon O
, O
interleukin-1 O
, O
and O
interleukin-6 O
have O
been O
shown O
to O
inhibit O
the O
TSH-induced O
increase O
of O
TPO O
mRNA O
, O
but O
further O
investigations O
are O
required O
to O
elucidate O
the O
exact O
role O
of O
cytokines O
in O
the O
regulation O
of O
M/TPO-Ag O
expression O
. O

[3H]EBOB O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl O
GABA O
receptor O
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride O
channel O
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
 O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl O
GABA O
receptor O
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride O
channel O
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
. O

isobutylmethylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue O
factor O
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue B
factor I
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
No O
influence O
of O
moderate O
hepatic O
impairment O
on O
the O
pharmacokinetics O
of O
lumiracoxib O
, O
an O
oral O
COX-2 B
selective O
inhibitor.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
hepatic O
impairment O
on O
the O
pharmacokinetics O
(PK) O
of O
the O
novel O
cyclooxygenase-2 O
(COX-2) O
selective O
inhibitor O
lumiracoxib O
(Prexige) O
, O
so O
that O
dose O
recommendations O
for O
clinical O
use O
can O
be O
provided O
. O
This O
was O
an O
open-label O
, O
single O
dose O
, O
case-controlled O
study O
in O
which O
eight O
subjects O
with O
liver O
cirrhosis O
classed O
as O
moderate O
hepatic O
impairment O
(Child-Pugh O
score O
: O
7-9) O
and O
eight O
demographically-matched O
healthy O
subjects O
received O
a O
single O
oral O
400 O
mg O
dose O
of O
lumiracoxib O
. O
Routine O
safety O
assessments O
were O
made O
and O
blood O
samples O
were O
taken O
for O
determination O
of O
lumiracoxib O
concentrations O
for O
96 O
h O
post O
dose O
. O
The O
ex O
vivo O
binding O
of O
lumiracoxib O
to O
plasma O
proteins O
was O
determined O
pre O
dose O
and O
at O
2 O
and O
12 O
h O
post O
dose O
. O
An O
analysis O
of O
variance O
was O
used O
to O
detect O
differences O
in O
PK O
parameters O
(AUC O
, O
Cmax O
and O
Tmax) O
between O
the O
treatment O
groups O
. O
There O
were O
no O
significant O
differences O
between O
subjects O
with O
moderate O
hepatic O
insufficiency O
and O
healthy O
subjects O
in O
the O
area O
under O
the O
lumiracoxib O
plasma O
concentration-time O
curves O
(AUC(0-infinity)) O
: O
29.2 O
+/- O
6.7 O
microg O
h O
ml(-1) O
versus O
28.7 O
+/- O
6.3 O
mircrog O
h O
ml(-1) O
. O
The O
rate O
of O
absorption O
of O
lumiracoxib O
was O
not O
significantly O
altered O
by O
hepatic O
impairment O
based O
on O
Cmax O
and O
Tmax O
. O
The O
protein-bound O
fraction O
of O
lumiracoxib O
exceeded O
98% O
both O
in O
healthy O
control O
subjects O
and O
in O
those O
with O
moderate O
hepatic O
insufficiency O
. O
A O
single O
dose O
of O
400 O
mg O
lumiracoxib O
was O
well O
tolerated O
. O
In O
conclusion O
, O
no O
dose O
adjustments O
appear O
to O
be O
required O
when O
lumiracoxib O
is O
administered O
to O
patients O
with O
either O
mild O
or O
moderate O
hepatic O
impairment O
. O

GW572016 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Truncated O
ErbB2 O
receptor O
(p95ErbB2) O
is O
regulated O
by O
heregulin O
through O
heterodimer O
formation O
with O
ErbB3 O
yet O
remains O
sensitive O
to O
the O
dual O
EGFR/ErbB2 O
kinase O
inhibitor O
GW572016.The O
expression O
of O
the O
NH2 O
terminally O
truncated O
ErbB2 O
receptor O
(p95ErbB2) O
in O
breast O
cancer O
correlates O
with O
metastatic O
disease O
progression O
compared O
with O
the O
expression O
of O
full-length O
p185ErbB2 O
. O
We O
now O
show O
that O
heregulin O
(HRG) O
, O
but O
not O
EGF O
, O
stimulates O
p95ErbB2 O
phosphorylation O
in O
BT474 O
breast O
cancer O
cells O
. O
Furthermore O
, O
phospho-p95ErbB2 O
forms O
heterodimers O
with O
ErbB3 O
, O
but O
not O
EGFR O
, O
while O
p185ErbB2 O
heterodimerizes O
with O
both O
EGFR O
and O
ErbB3 O
. O
The O
predilection O
of O
p95ErbB2 O
to O
heterodimerize O
with O
ErbB3 O
provides O
an O
explanation O
for O
its O
regulation O
by O
HRG O
, O
an O
ErbB3 O
ligand O
. O
GW572016 O
, O
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR O
and O
ErbB2 O
tyrosine O
kinases O
, O
inhibits O
baseline O
p95ErbB2 O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O
GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
and O
cyclin B
D I
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O
in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
or O
cyclin O
D O
. O
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O
by O
the O
selection O
of O
p95ErbB2-expressing O
breast O
cancer O
cells O
capable O
of O
exerting O
potent O
growth O
and O
prosurvival O
signals O
through O
p95ErbB2-ErbB3 O
heterodimers O
. O
Thus O
, O
p95ErbB2 O
represents O
a O
target O
for O
therapeutic O
intervention O
, O
and O
one O
that O
is O
sensitive O
to O
GW572016 O
therapy O
. O

Rapamycin O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome B
.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O
proteasome O
. O
These O
protein O
complexes O
are O
known O
to O
bind O
to O
specific O
grooves O
on O
the O
α O
face O
region O
of O
the O
20S O
core O
. O
A O
treatment O
with O
rapamycin O
affects O
conformational O
dynamics O
of O
the O
proteasomal O
gate O
, O
a O
centrally O
positioned O
within O
the O
α O
face O
and O
allosterically O
regulated O
element O
responsible O
for O
the O
intake O
of O
substrates O
. O
Interestingly O
, O
we O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two-domain O
, O
closed-ring O
analogs O
(rapalogs) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome O
function O
. O
The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin O
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome O
are O
discussed O
. O

WB-4101 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Alpha-2 O
adrenoceptor O
subtype O
causing O
nitric O
oxide-mediated O
vascular O
relaxation O
in O
rats.The O
alpha-2 O
adrenoceptor O
subtype O
and O
its O
signal O
transduction O
pathway O
mediating O
vascular O
relaxation O
in O
rats O
were O
studied O
in O
vitro O
using O
rings O
of O
superior O
mesenteric O
arteries O
. O
Removal O
of O
endothelium O
or O
incubation O
with O
NG-nitro-L-arginine O
completely O
blocked O
relaxant O
responses O
to O
UK14,304 O
, O
suggesting O
endothelium-derived O
nitric O
oxide O
mediates O
relaxation O
. O
The O
order O
of O
potency O
for O
full O
(F) O
or O
partial O
(P) O
agonists O
causing O
relaxation O
was O
guanabenz O
(P) O
> O
UK14,304 O
(F) O
> O
clonidine O
(P) O
> O
epinephrine O
(F) O
> O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D O
adrenoceptor O
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A B
adrenoceptor I
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O
cAMP O
formation O
in O
endothelium O
. O
Forskolin O
did O
not O
affect O
the O
relaxant O
response O
to O
UK14,304 O
, O
suggesting O
that O
cAMP O
is O
not O
involved O
in O
the O
coupling O
of O
alpha-2 O
adrenoceptors O
to O
nitric O
oxide-induced O
vascular O
relaxation O
. O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pioglitazone O
protects O
against O
cisplatin O
induced O
nephrotoxicity O
in O
rats O
and O
potentiates O
its O
anticancer O
activity O
against O
human O
renal O
adenocarcinoma O
cell O
lines.Cisplatin-induced O
nephrotoxicity O
is O
a O
serious O
problem O
that O
limits O
its O
use O
in O
cancer O
treatment O
. O
The O
present O
study O
aimed O
to O
investigate O
the O
renal O
protective O
capacity O
of O
pioglitazone O
to O
reduce O
the O
cisplatin- O
induced O
nephrotoxicity O
. O
The O
underlying O
suggested O
mechanism(s) O
and O
whether O
this O
nephroprotective O
effect O
(if O
any) O
interferes O
with O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
cancer O
cells O
were O
also O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
( O
TNF-α) B
 O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O
these O
results O
suggested O
that O
pioglitazone O
protected O
against O
cisplatin- O
induced O
nephrotoxicity O
through O
its O
interaction O
with O
PPAR-γ O
receptors O
and O
antioxidant O
effects O
. O
Furthermore O
, O
pioglitazone O
did O
not O
interfere O
but O
rather O
potentiated O
the O
cytotoxic O
effects O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
. O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB B
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 B
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

octreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Acromegaly O
: O
molecular O
expression O
of O
somatostatin O
receptor O
subtypes O
and O
treatment O
outcome.About O
a O
third O
of O
acromegalic O
patients O
are O
resistant O
to O
the O
currently O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 O
and O
SSTR5 O
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 B
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O
mainly O
for O
SSTR5 O
, O
of O
a O
SSTR2-SSTR5 O
bispecific O
compound O
, O
and O
of O
a O
"universal" O
analog O
with O
high O
affinity O
to O
SSTR1 O
, O
2 O
, O
3 O
, O
and O
5 O
showed O
preliminary O
, O
albeit O
promising O
results O
for O
the O
treatment O
of O
resistant O
somatotropic O
adenomas O
. O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 B
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
pharmacology O
at O
AMPA O
and O
kainate O
preferring O
glutamate O
receptors O
of O
4-heteroarylmethylidene O
glutamate O
analogues.2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O
potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O
kainic O
acid O
(KA) O
receptors O
, O
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 B
subtype O
of O
KA O
receptors O
and O
much O
lower O
affinity O
for O
the O
GluR2 O
subtype O
of O
AMPA O
receptors O
. O
As O
an O
attempt O
to O
develop O
new O
pharmacological O
tools O
for O
studies O
of O
GluR5 O
receptors O
, O
(S)-E-4-(2-thiazolylmethylene)glutamic O
acid O
(4a) O
was O
designed O
as O
a O
structural O
hybrid O
between O
1 O
and O
3 O
. O
4a O
was O
shown O
to O
be O
a O
potent O
GluR5 O
agonist O
and O
a O
high O
affinity O
ligand O
and O
to O
indiscriminately O
bind O
to O
the O
AMPA O
receptor O
subtypes O
GluR1-4 O
with O
lower O
affinities O
. O
Compounds O
4b-h O
, O
in O
which O
the O
2-thiazolyl O
substituent O
of O
4a O
was O
replaced O
by O
other O
heterocyclic O
rings O
, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA O
analogues O
, O
as O
exemplified O
by O
1 O
were O
also O
synthesized O
. O
Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 O
and O
GluR5 O
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA O
analogues O
as O
AMPA O
receptor O
agonists O
. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O
mapping O
of O
the O
GluR5 O
agonist O
binding O
site O
. O

calcium O
acts O
as O
NOT O
for O
what O
entity O
? O
Robust O
autoactivation O
, O
chymotrypsin O
C O
independence O
and O
diminished O
secretion O
define O
a O
subset O
of O
hereditary O
pancreatitis O
associated O
cationic O
trypsinogen O
mutants.Mutations O
in O
human O
cationic O
trypsinogen O
cause O
hereditary O
pancreatitis O
by O
altering O
its O
proteolytic O
regulation O
of O
activation O
and O
degradation O
by O
chymotrypsin O
C O
(CTRC) O
. O
CTRC O
stimulates O
trypsinogen O
autoactivation O
by O
processing O
the O
activation O
peptide O
to O
a O
shorter O
form O
but O
also O
promotes O
degradation O
by O
cleaving O
the O
calcium O
binding O
loop O
in O
trypsinogen O
. O
Mutations O
render O
trypsinogen O
resistant O
to O
CTRC-mediated O
degradation O
and/or O
increase O
processing O
of O
the O
activation O
peptide O
by O
CTRC O
. O
Here O
we O
demonstrate O
that O
activation O
peptide O
mutations O
D19A O
, O
D22G O
, O
K23R O
and O
K23_I24insIDK O
robustly O
increased O
the O
rate O
of O
trypsinogen O
autoactivation O
, O
both O
in O
the O
presence O
and O
absence O
of O
CTRC O
. O
Degradation O
of O
the O
mutants O
by O
CTRC O
was O
unchanged O
and O
processing O
of O
the O
activation O
peptide O
was O
increased O
only O
in O
the O
D19A O
mutant O
by O
4-fold O
. O
Surprisingly O
, O
however O
, O
this O
increased O
processing O
had O
only O
a O
minimal O
effect O
on O
autoactivation O
. O
The O
tetra-aspartate O
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G B
and O
K23_I24insIDK O
was O
not O
stimulated O
by O
calcium O
. O
Finally O
, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells O
, O
and O
secreted O
trypsinogen O
levels O
were O
inversely O
proportional O
with O
autoactivation O
rates O
. O
We O
conclude O
that O
D19A O
, O
D22G O
, O
K23R O
and O
K23_I24insIDK O
form O
a O
mechanistically O
distinct O
subset O
of O
hereditary O
pancreatitis O
associated O
mutations O
, O
which O
exert O
their O
effect O
primarily O
through O
direct O
stimulation O
of O
autoactivation O
, O
independently O
of O
CTRC O
. O
The O
potentially O
severe O
clinical O
impact O
of O
the O
markedly O
increased O
autoactivation O
is O
offset O
by O
diminished O
secretion O
, O
resulting O
in O
a O
clinical O
phenotype O
indistinguishable O
from O
typical O
hereditary O
pancreatitis O
. O
This O
article O
is O
protected O
by O
copyright O
. O
All O
rights O
reserved O
. O

MPTP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Cyperi O
Rhizoma O
inhibits O
the O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced O
reduction O
in O
nigrostriatal O
dopaminergenic O
neurons O
in O
estrogen-deprived O
mice.ETHNOPHARMACOLOGICAL O
RELEVANCE O
: O
Cyperi O
Rhizoma O
has O
commonly O
been O
used O
for O
the O
treatment O
of O
gynecological O
and O
neuropsychiatric O
disorders O
in O
traditional O
medicine O
. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
estrogenic O
properties O
and O
neuroprotective O
effects O
of O
Cyperi O
Rhizoma O
under O
estrogen-deprived O
condition O
in O
female O
mice O
. O
MATERIALS O
AND O
METHODS O
: O
To O
determine O
the O
estrogen-like O
effect O
of O
Cyperi O
Rhizoma O
extract O
(CRE) O
, O
we O
measured O
luciferase O
expression O
after O
transfection O
of O
a O
promoter O
construct O
containing O
an O
estrogen O
response O
element O
(ERE) O
and O
treatment O
of O
CRE O
. O
To O
evaluate O
the O
neuroprotective O
effect O
of O
CRE O
, O
we O
measured O
striatal O
dopamine O
, O
movement O
ability O
, O
tyrosine O
hydroxylase O
(TH) O
immunoreactivity O
, O
and O
apoptosis-related O
protein O
expression O
levels O
after O
treatment O
of O
CRE O
either O
with O
or O
without O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O
(MPTP) O
in O
ovariectomized O
female O
mice O
. O
RESULTS O
: O
CRE O
significantly O
induced O
the O
luciferase O
expression O
driven O
by O
an O
ERE O
in O
PC12 O
cells O
, O
a O
dopaminergic O
cell O
line O
, O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved- O
caspase-3 B
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like O
and O
neuroprotective O
effects O
on O
dopaminergic O
neurons O
in O
estrogen-deprived O
mice O
treated O
with O
MPTP-toxin O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Structure O
of O
acetylcholinesterase O
complexed O
with O
(-)-galanthamine O
at O
2.3 O
A O
resolution.(-)-Galanthamine O
(GAL) O
, O
an O
alkaloid O
from O
the O
flower O
, O
the O
common O
snowdrop O
(Galanthus O
nivalis) O
, O
shows O
anticholinesterase O
activity O
. O
This O
property O
has O
made O
GAL O
the O
target O
of O
research O
as O
to O
its O
effectiveness O
in O
the O
treatment O
of O
Alzheimer's O
disease O
. O
We O
have O
solved O
the O
X-ray O
crystal O
structure O
of O
GAL O
bound O
in O
the O
active O
site O
of O
Torpedo O
californica O
acetylcholinesterase O
(TcAChE) O
to O
2.3 O
A O
resolution O
. O
The O
inhibitor O
binds O
at O
the O
base O
of O
the O
active O
site O
gorge O
of O
TcAChE B
, O
interacting O
with O
both O
the O
choline-binding O
site O
(Trp-84) O
and O
the O
acyl-binding O
pocket O
(Phe-288 O
, O
Phe-290) O
. O
The O
tertiary O
amine O
group O
of O
GAL O
does O
not O
interact O
closely O
with O
Trp-84; O
rather O
, O
the O
double O
bond O
of O
its O
cyclohexene O
ring O
stacks O
against O
the O
indole O
ring O
. O
The O
tertiary O
amine O
appears O
to O
make O
a O
non-conventional O
hydrogen O
bond O
, O
via O
its O
N-methyl O
group O
, O
to O
Asp-72 O
, O
near O
the O
top O
of O
the O
gorge O
. O
The O
hydroxyl O
group O
of O
the O
inhibitor O
makes O
a O
strong O
hydrogen O
bond O
(2.7 O
A) O
with O
Glu-199 O
. O
The O
relatively O
tight O
binding O
of O
GAL O
to O
TcAChE O
appears O
to O
arise O
from O
a O
number O
of O
moderate O
to O
weak O
interactions O
with O
the O
protein O
, O
coupled O
to O
a O
low O
entropy O
cost O
for O
binding O
due O
to O
the O
rigid O
nature O
of O
the O
inhibitor O
. O

Lu O
AF21934 O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ B
receptor.Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor-selective O
orthosteric O
agonist O
, O
LSP1-2111 O
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration O
. O
Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
, O
and O
brain-penetrant O
positive O
allosteric O
modulator O
(PAM) O
of O
the O
mGlu(4) O
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH) O
, O
four-plate O
, O
marble-burying O
and O
Vogel's O
conflict O
tests O
. O
In O
all O
models O
, O
except O
Vogel's O
conflict O
test O
, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine O
receptor O
antagonist O
flumazenil O
(10 O
mg/kg) O
and O
was O
not O
serotonin-dependent O
, O
as O
it O
persisted O
in O
serotonin-deficient O
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) O
receptors O
by O
WAY100635 O
, O
or O
5-HT(2A/2C) O
receptors O
by O
ritanserin O
. O
These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu O
AF21934 O
in O
rodents O
. O
Lu O
AF21934 O
did O
not O
produce O
antidepressant-like O
effects O
in O
the O
tail O
suspension O
test O
(TST) O
in O
mice; O
however O
, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O
mice O
that O
were O
not O
habituated O
to O
activity O
cages O
. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic O
Glutamate O
Receptors' O
. O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 B
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

rifampicin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ B
fibril O
aggregation O
inhibition O
activity O
with O
a O
nearly O
similar O
potential O
as O
the O
reference O
compound O
rifampicin O
, O
which O
makes O
them O
promising O
anti-Alzheimer O
drug O
candidates O
. O
Docking O
experiments O
were O
carried O
out O
with O
the O
aim O
to O
understand O
the O
interactions O
of O
the O
most O
active O
compounds O
with O
the O
active O
site O
of O
the O
cholinesterase O
enzymes O
. O

BH4 O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Tryptophan O
hydroxylase O
mRNA O
levels O
are O
elevated O
by O
repeated O
immobilization O
stress O
in O
rat O
raphe O
nuclei O
but O
not O
in O
pineal O
gland.Repeated O
stress O
triggers O
a O
wide O
range O
of O
adaptive O
changes O
in O
the O
central O
nervous O
system O
including O
the O
elevation O
of O
serotonin O
(5-HT) O
metabolism O
and O
an O
increased O
susceptibility O
to O
affective O
disorders O
. O
To O
begin O
to O
examine O
whether O
these O
changes O
are O
mediated O
by O
alterations O
in O
gene O
expression O
for O
tryptophan O
hydroxylase O
(TPH) O
, O
the O
rate-limiting O
enzyme O
in O
5-HT O
biosynthesis O
, O
we O
quantitated O
its O
mRNA O
levels O
by O
competitive O
reverse O
transcription-polymerase O
chain O
reaction O
(RT-PCR) O
. O
Repeated O
immobilization O
stress O
(2 O
h O
, O
7 O
days) O
elicited O
a O
six- O
or O
ten-fold O
rise O
in O
TPH O
mRNA O
in O
median O
raphe O
nucleus O
(MRN) O
and O
dorsal O
raphe O
nucleus O
(DRN) O
, O
respectively O
, O
without O
significantly O
altering O
TPH O
mRNA O
levels O
in O
the O
pineal O
gland O
. O
In O
contrast O
, O
there O
was O
little O
change O
in O
mRNA O
levels O
for O
GTP O
cyclohydrolase O
I O
(GTPCH) O
, O
the O
rate O
limiting O
enzyme O
in O
synthesis O
of O
the O
tetrahydrobiopterin O
(BH4) O
, O
the O
obligate O
cofactor O
for O
TPH B
. O
This O
is O
the O
first O
study O
to O
reveal O
stress-elicited O
activation O
of O
TPH O
gene O
expression O
. O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O
in O
the O
recognition O
of O
SR O
141716A O
. O
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 B
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

p-bromophenacyl O
bromide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
( O
IL-2) B
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST-4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

rapamycin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mTOR O
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 B
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O
activation O
of O
mTOR O
with O
increase O
in O
Nox4 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
small O
dose O
of O
rapamycin O
reduces O
podocyte O
apoptosis O
, O
attenuates O
glomerular O
injury O
and O
albuminuria O
. O
Our O
data O
provide O
evidence O
for O
a O
novel O
function O
of O
mTOR O
in O
Nox4-derived O
ROS O
generation O
and O
podocyte O
apoptosis O
that O
contributes O
to O
urinary O
albumin O
excretion O
in O
type O
1 O
diabetes O
. O
Thus O
mTOR O
and O
or O
NADPH O
oxidase O
inhibition O
may O
represent O
a O
therapeutic O
modality O
of O
diabetic O
kidney O
disease O
. O

Mg2+ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
( O
AdSS) B
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O
ordered O
C O
kinetic O
mechanism O
for O
the O
MjAdSS O
catalyzed O
reaction O
. O
AdSS O
are O
known O
to O
exhibit O
monomer-dimer O
equilibrium O
with O
the O
dimer O
being O
implicated O
in O
catalysis O
. O
In O
contrast O
, O
our O
studies O
show O
that O
MjAdSS O
is O
an O
equilibrium O
mixture O
of O
dimers O
and O
tetramers O
with O
the O
tetramer O
being O
the O
catalytically O
active O
form O
. O
The O
tetramer O
dissociates O
into O
dimers O
with O
a O
minor O
increase O
in O
ionic O
strength O
of O
the O
buffer O
, O
while O
the O
dimer O
is O
extremely O
stable O
and O
does O
not O
dissociate O
even O
at O
1.2 O
M O
NaCl O
. O
Phosphate O
, O
a O
product O
of O
the O
reaction O
, O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
MjAdSS O
showing O
biphasic O
inhibition O
of O
enzyme O
activity O
. O
The O
inhibition O
was O
competitive O
with O
IMP O
and O
noncompetitive O
with O
GTP O
. O
MjAdSS O
, O
like O
the O
mouse O
acidic O
isozyme O
, O
exhibits O
substrate O
inhibition O
, O
with O
IMP O
inhibiting O
enzyme O
activity O
at O
subsaturating O
GTP O
concentrations O
. O
Regulation O
of O
enzyme O
activity O
by O
the O
glycolytic O
intermediate O
, O
fructose O
1,6 O
bisphosphate O
, O
was O
also O
observed O
with O
the O
inhibition O
being O
competitive O
with O
IMP O
and O
noncompetitive O
against O
GTP O
. O

fluoropyrimidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O
study O
, O
we O
used O
immunohistochemistry O
to O
investigate O
the O
expression O
of O
TK-1 O
and O
TS O
in O
various O
types O
of O
cancer O
. O
TK-1 O
and O
TS O
expression O
was O
markedly O
different O
between O
cancer O
types O
. O
High O
TK-1 O
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS O
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS B
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
. O
In O
non-small O
cell O
lung O
cancers O
, O
high O
TK-1 O
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas O
, O
but O
not O
in O
adenocarcinomas O
. O
This O
result O
suggests O
that O
TAS-102 O
efficacy O
and O
the O
pyrimidine O
synthetic O
pathway O
may O
differ O
depending O
on O
histological O
type O
. O
Our O
results O
indicate O
that O
administration O
of O
TAS-102 O
could O
be O
selected O
on O
the O
basis O
of O
the O
immunohistochemical O
evaluation O
of O
TK-1 O
and O
TS O
. O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
characterization O
of O
a O
novel O
human O
phosphodiesterase O
that O
hydrolyzes O
both O
cAMP O
and O
cGMP O
(PDE10A).cDNA O
encoding O
a O
novel O
phosphodiesterase O
(PDE) O
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A O
. O
The O
deduced O
amino O
acid O
sequence O
contains O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O
the O
amino-terminal O
portion O
of O
the O
molecule O
and O
a O
catalytic O
domain O
that O
is O
16-47% O
identical O
in O
amino O
acid O
sequence O
to O
those O
of O
other O
PDE O
families O
. O
Recombinant O
PDE10A B
transfected O
and O
expressed O
in O
COS-7 O
cells O
hydrolyzed O
cAMP O
and O
cGMP O
with O
Km O
values O
of O
0.26 O
and O
7.2 O
microM O
, O
respectively O
, O
and O
Vmax O
with O
cGMP O
was O
almost O
twice O
that O
with O
cAMP O
. O
Of O
the O
PDE O
inhibitors O
tested O
, O
dipyridamole O
was O
most O
effective O
, O
with O
IC50 O
values O
of O
1.2 O
and O
0.45 O
microM O
for O
inhibition O
of O
cAMP O
and O
cGMP O
hydrolysis O
, O
respectively O
. O
cGMP O
inhibited O
hydrolysis O
of O
cAMP O
, O
and O
cAMP O
inhibited O
cGMP O
hydrolysis O
with O
IC50 O
values O
of O
14 O
and O
0.39 O
microM O
, O
respectively O
. O
Thus O
, O
PDE10A O
exhibited O
properties O
of O
a O
cAMP O
PDE O
and O
a O
cAMP-inhibited O
cGMP O
PDE O
. O
PDE10A O
transcripts O
were O
particularly O
abundant O
in O
the O
putamen O
and O
caudate O
nucleus O
regions O
of O
brain O
and O
in O
thyroid O
and O
testis O
, O
and O
in O
much O
lower O
amounts O
in O
other O
tissues O
. O
The O
PDE10A O
gene O
was O
located O
on O
chromosome O
6q26 O
by O
fluorescent O
in O
situ O
hybridization O
analysis O
. O
PDE10A O
represents O
a O
new O
member O
of O
the O
PDE O
superfamily O
, O
exhibiting O
unique O
kinetic O
properties O
and O
inhibitor O
sensitivity O
. O

RU486 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
to O
ginsenoside O
Rg1 O
protection O
against O
β-amyloid O
peptide-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
( O
GR) B
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
4 O
inhibitors O
delay O
human O
eosinophil O
and O
neutrophil O
apoptosis O
in O
the O
absence O
and O
presence O
of O
salbutamol.In O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
(COPD) O
, O
the O
number O
of O
eosinophils O
and O
neutrophils O
in O
the O
lung O
is O
increased O
. O
One O
described O
mechanism O
leading O
to O
the O
impaired O
clearance O
of O
these O
cells O
from O
the O
lung O
is O
the O
delay O
in O
their O
programmed O
cell O
death O
(apoptosis) O
. O
Selective O
inhibitors O
of O
phosphodiesterases O
(PDEs) O
are O
under O
development O
for O
the O
treatment O
of O
lung O
diseases O
because O
of O
their O
anti-inflammatory O
and O
bronchodilator O
activity O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
establish O
whether O
inhibitors O
of O
PDE3 O
, O
PDE4 O
and O
PDE5 O
modulate O
human O
eosinophil O
or O
neutrophil O
apoptosis O
or O
beta O
2-adrenoceptor O
agonist- O
or O
cytokine-afforded O
survival O
. O
We O
also O
evaluated O
whether O
a O
PDE4 O
inhibitor O
could O
modulate O
the O
effect O
of O
a O
corticosteroid O
on O
eosinophil O
and O
neutrophil O
apoptosis O
. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding O
. O
Inhibitors O
of O
PDE4 O
(rolipram; O
0.1-10 O
microM) O
and O
PDE3 O
(cilostazol; O
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15% O
, O
respectively O
. O
A O
combination O
of O
a O
PDE4 O
or O
PDE3 O
inhibitor O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13% O
. O
The O
combination O
of O
rolipram O
(10 O
microM) O
and O
salbutamol O
(100 O
nM) O
produced O
a O
27% O
inhibition O
of O
neutrophil O
apoptosis O
. O
Inhibitor O
of O
cGMP-specific B
PDE5 I
(zaprinast; O
0.1-10 O
microM) O
did O
not O
affect O
eosinophil O
apoptosis O
and O
only O
slightly O
increased O
spontaneous O
neutrophil O
apoptosis O
. O
The O
effect O
of O
budesonide O
on O
apoptosis O
was O
not O
significantly O
modulated O
by O
a O
PDE4 O
inhibitor O
in O
eosinophils O
or O
neutrophils O
. O
The O
present O
results O
show O
that O
selective O
inhibitors O
of O
cAMP-hydrolyzing O
PDEs O
(PDE3 O
and O
PDE4) O
delay O
eosinophil O
apoptosis O
and O
, O
thus O
, O
increase O
their O
survival O
in O
vitro O
. O
Furthermore O
, O
beta O
2-adrenoceptor O
agonists O
enhance O
the O
anti-apoptotic O
effects O
of O
PDE3 O
and O
PDE4 O
inhibitors O
, O
suggesting O
that O
such O
drug O
combinations O
may O
prolong O
eosinophil O
and O
neutrophil O
longevity O
in O
the O
lung O
. O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
( O
AChE) B
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; O
the O
respective O
dissociation O
constants O
and O
the O
type O
of O
inhibition O
exhibited O
considerable O
differences O
. O
The O
affinities O
to O
both O
the O
active O
and O
the O
allosteric O
site O
were O
considerably O
higher O
for O
suxamethonium O
(Kii O
81.3 O
microM; O
Ki O
15.9 O
microM) O
and O
decamethonium O
(Kii O
15.4 O
microM; O
Ki O
4.4 O
microM) O
than O
for O
TMA O
(Kii O
1 O
mM; O
Ki O
289.6 O
microM) O
and O
hexamethonium O
(Kii O
4.5 O
mM; O
Ki O
331.8 O
microM) O
. O
The O
reactivation O
experiments O
were O
performed O
in O
a O
four-step O
procedure O
(soman-inhibition O
at O
0 O
degree O
and O
pH O
10 O
, O
aging O
at O
37 O
degrees O
and O
pH O
7.3 O
, O
reactivation O
by O
the O
oxime O
HI O
6 O
at O
37 O
degrees O
and O
pH O
7.3 O
followed O
by O
AChE O
assay) O
. O
After O
these O
four O
steps O
(total O
duration O
55 O
min) O
, O
AChE O
was O
inhibited O
by O
soman O
to O
95-100% O
. O
HI O
6 O
could O
reactivate O
about O
20% O
of O
the O
inhibited O
enzyme O
. O
All O
effectors O
increased O
the O
AChE O
reactivatability O
by O
HI O
6 O
when O
added O
before O
aging O
was O
started O
. O
The O
maximal O
increase O
in O
reactivatability O
was O
higher O
in O
the O
presence O
of O
1.6 O
mM O
suxamethonium O
(+35.8%) O
and O
150 O
microM O
decamethonium O
(+40%) O
than O
of O
22 O
mM O
TMA O
(+22.5%) O
and O
8.3 O
mM O
hexamethonium O
(+19.2%) O
. O
If O
the O
effectors O
were O
added O
after O
5 O
min O
of O
aging O
they O
increased O
the O
activity O
of O
soman-inhibited O
AChE O
, O
but O
to O
a O
considerably O
smaller O
extent O
than O
HI O
6 O
. O
A O
good O
correlation O
of O
the O
respective O
Kii O
values O
and O
the O
effective O
concentrations O
of O
these O
drugs O
was O
observed O
, O
indicating O
that O
an O
allosteric O
binding O
site O
of O
AChE O
might O
be O
involved O
in O
the O
protective O
effect O
of O
these O
drugs O
. O

5-(N,N-dimethyl)-amiloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 B
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
property O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
is O
mediated O
through O
the O
expression O
of O
Glut-4 O
in O
L6 O
myotubes.Tinospora O
cordifolia O
is O
a O
well O
reported O
plant O
possessing O
numerous O
medicinal O
values O
including O
anti-diabetic O
property O
. O
Aim O
of O
the O
present O
study O
is O
to O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin B
pathway O
. O

Sb(III) O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reduction O
of O
dimethylarsinic O
acid O
to O
the O
highly O
toxic O
dimethylarsinous O
acid O
by O
rats O
and O
rat O
liver O
cytosol.Dimethylarsinic O
acid O
(DMAs(V)) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
(DMAs(III)) O
, O
is O
highly O
toxic O
. O
Although O
glutathione O
S-transferase O
omega O
1 O
(GSTO1) O
and O
arsenic O
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) O
reduction O
, O
their O
role O
in O
DMAs(V) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O
Therefore O
, O
the O
reduction O
of O
DMAs(V) O
to O
DMAs(III) O
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O
To O
assess O
DMAs(V) O
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O
the O
accumulation O
of O
red O
blood O
cell O
(RBC)-bound O
dimethylarsenic O
(DMAs) O
, O
which O
represents O
DMAs(III) O
, O
in O
the O
blood O
of O
DMAs(V)-injected O
anesthetized O
rats O
. O
These O
studies O
indicated O
that O
rats O
reduced O
DMAs(V) O
to O
DMAs(III) O
to O
a O
significant O
extent O
, O
as O
in O
90 O
min O
31% O
of O
the O
injected O
50 O
μmol/kg O
DMAs(V) O
dose O
was O
converted O
to O
DMAs(III) O
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes O
. O
Pretreatment O
of O
rats O
with O
glutathione O
(GSH) O
depletors O
(phorone O
or O
BSO) O
delayed O
the O
elimination O
of O
DMAs(V) O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
( O
TRR) B
inhibitors O
(aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O
also O
suggested O
that O
the O
reducing O
enzyme O
was O
larger O
than O
100 O
kDa O
and O
was O
not O
GSTO1 O
. O
In O
summary O
, O
reduction O
of O
DMAs(V) O
to O
the O
highly O
toxic O
DMAs(III) O
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH-dependent O
enzymatic O
process O
, O
yet O
its O
mechanism O
remains O
uncertain O
. O

Ambrisentan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effect O
of O
ketoconazole O
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan.Ambrisentan O
is O
an O
endothelin B
type I
A I
(ET(A))-selective I
receptor I
antagonist O
that O
is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4 O
. O
The O
potential O
for O
ketoconazole O
, O
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4 O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
and O
its O
oxidative O
metabolite O
, O
4-hydroxymethyl O
ambrisentan O
, O
was O
assessed O
in O
an O
open-label O
, O
nonrandomized O
, O
2-period O
, O
single-sequence O
study O
in O
16 O
healthy O
men O
. O
Participants O
received O
a O
single O
dose O
of O
ambrisentan O
10 O
mg O
alone O
and O
after O
4 O
days O
of O
ketoconazole O
400 O
mg O
administered O
once O
daily O
. O
In O
the O
presence O
of O
multiple O
doses O
of O
ketoconazole O
, O
single-dose O
ambrisentan O
AUC(0-infinity) O
estimate O
was O
increased O
by O
35.3% O
, O
whereas O
C(max) O
was O
increased O
by O
20.0% O
. O
For O
the O
4-hydroxymethyl O
ambrisentan O
metabolite O
, O
AUC(0-infinity) O
estimate O
was O
decreased O
by O
4.0% O
, O
whereas O
C(max) O
was O
decreased O
by O
16.5% O
. O
Concomitant O
administration O
of O
ambrisentan O
and O
ketoconazole O
was O
well O
tolerated O
. O
In O
summary O
, O
ketoconazole O
had O
no O
clinically O
significant O
effect O
on O
the O
pharmacokinetics O
or O
safety O
profile O
of O
ambrisentan; O
therefore O
, O
no O
changes O
in O
ambrisentan O
dose O
should O
be O
necessary O
when O
the O
drug O
is O
administered O
concomitantly O
with O
known O
CYP3A4 O
inhibitors O
. O

IB-MECA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
The O
effects O
of O
the O
adenosine O
A3 O
receptor O
agonist O
IB-MECA O
on O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis.The O
role O
of O
adenosine O
A3 O
receptors O
and O
their O
distribution O
in O
the O
gastrointestinal O
tract O
have O
been O
widely O
investigated O
. O
Most O
of O
the O
reports O
discuss O
their O
role O
in O
intestinal O
inflammations O
. O
However O
, O
the O
role O
of O
adenosine O
A3 O
receptor O
agonist O
in O
pancreatitis O
has O
not O
been O
well O
established O
. O
The O
aim O
of O
this O
study O
is O
(Ed O
note O
: O
Purpose O
statements O
should O
be O
in O
present O
tense) O
to O
evaluate O
the O
effects O
of O
the O
adenosine O
A3 O
receptor O
agonist O
on O
the O
course O
of O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis O
(EAP) O
. O
The O
experiments O
were O
performed O
on O
80 O
male O
Wistar O
rats O
, O
58 O
of O
which O
survived O
, O
subdivided O
into O
3 O
groups O
: O
C-control O
rats O
, O
I-EAP O
group O
, O
and O
II-EAP O
group O
treated O
with O
the O
adenosine B
A3 I
receptor I
agonist O
IB-MECA O
(1-deoxy-1-6[[(3-iodophenyl) O
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide O
at O
a O
dose O
of O
0.75 O
mg/kg O
b.w O
. O
i.p O
. O
at O
48 O
, O
24 O
, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium O
taurocholate O
solution O
into O
the O
biliary-pancreatic O
duct O
. O
Serum O
for O
α-amylase O
and O
lipase O
determinations O
and O
tissue O
samples O
for O
morphological O
examinations O
were O
collected O
at O
2 O
, O
6 O
, O
and O
24 O
h O
of O
the O
experiment O
. O
In O
the O
IB-MECA O
group O
, O
α-amylase O
activity O
was O
decreased O
with O
statistically O
high O
significance O
compared O
to O
group O
I O
. O
The O
activity O
of O
lipase O
was O
not O
significantly O
different O
among O
the O
experimental O
groups O
but O
higher O
than O
in O
the O
control O
group O
. O
The O
administration O
of O
IB-MECA O
attenuated O
the O
histological O
parameters O
of O
inflammation O
as O
compared O
to O
untreated O
animals O
. O
The O
use O
of O
A3 O
receptor O
agonist O
IB-MECA O
attenuates O
EAP O
. O
Our O
findings O
suggest O
that O
stimulation O
of O
adenosine O
A3 O
receptors O
plays O
a O
positive O
role O
in O
the O
sodium O
taurocholate-induced O
EAP O
in O
rats O
. O

4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
( O
AChE) B
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

Tomudex O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cyclin O
E-cdk2 O
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate O
synthase O
inhibitor O
Tomudex.Tomudex O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O
p53 O
and O
p21(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 O
protein O
expression O
and O
kinase O
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O
cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O
Cyclin O
D1 O
, O
cyclin O
B O
, O
cdk4 O
, O
and O
cdc2 O
protein O
expression O
and O
kinase O
activities O
remain O
constant O
. O
Lack O
of O
activation O
of O
cyclin O
A- O
and O
B-cdc2 O
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases O
. O
Increased O
cyclin O
E-cdk2 O
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days O
. O
Tomudex O
treatment O
resulted O
in O
a O
time-dependent O
induction O
of O
the O
megabase O
DNA O
fragments O
, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation O
. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate B
synthase I
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase O
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex O
are O
not O
p53 O
dependent O
. O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
vascular O
protective O
properties O
of O
kinsenoside O
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose O
condition.Anoectochilus O
roxburghii O
is O
a O
traditional O
Chinese O
herb O
used O
for O
the O
treatment O
of O
diabetes O
and O
some O
other O
diseases O
. O
The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
( O
NF-κB) B
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes-related O
changes O
in O
mice O
aortas O
after O
kinsenoside O
(20 O
and O
50μg/mL) O
treatment O
. O
These O
results O
indicated O
that O
kinsenoside O
might O
be O
a O
promising O
agent O
for O
the O
treatment O
of O
diabetic O
vascular O
disease O
. O

barbiturates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
( O
L-VGCCs) B
 O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

formate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF B
synthase I
/ O
SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

steroid O
hormone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
( O
FDX1; B
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O
bind O
to O
the O
FDX1 O
promoter O
in O
differentiated O
hMSCs O
. O
Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 O
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O
ovarian O
granulosa O
cells O
. O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Long-term O
use O
of O
sildenafil.The O
treatment O
of O
erectile O
dysfunction O
(ED) O
has O
been O
revolutionised O
by O
new O
agents O
to O
inhibit O
the O
enzyme O
PDE5 O
. O
The O
scientific O
basis O
of O
this O
treatment O
of O
ED O
includes O
relaxation O
of O
the O
corpus O
cavernosum O
smooth O
muscle O
tissue O
by O
inhibition O
of O
PDE5 O
that O
breaks O
down O
cGMP O
, O
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
(PDE6) O
, O
which O
produces O
visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O
irrespective O
of O
aetiology O
. O
The O
aetiology O
of O
ED O
, O
also O
, O
does O
not O
appear O
to O
effect O
the O
function O
of O
sildenafil O
in O
relaxing O
corpus O
cavernosum O
smooth O
muscle O
tissue O
. O
Adverse O
events O
are O
usually O
associated O
with O
the O
vascular O
changes O
from O
PDE5 O
inhibition O
. O
These O
include O
headache O
and O
flushing O
. O
Each O
of O
these O
adverse O
events O
, O
however O
, O
declines O
with O
medication O
use O
. O
With O
the O
use O
of O
sildenafil O
, O
it O
has O
been O
clearly O
, O
clinically O
demonstrated O
that O
the O
selective O
inhibition O
of O
PDE5 B
is O
an O
appropriate O
, O
effective O
, O
safe O
method O
for O
the O
treatment O
of O
ED O
of O
all O
aetiologies O
and O
severities O
. O

adenosine O
acts O
as O
NOT O
for O
what O
entity O
? O
Impaired O
function O
of O
prejunctional O
adenosine O
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt O
hypertensive O
rats.Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone O
acetate O
(DOCA)-salt O
hypertension O
in O
rats O
. O
ATP O
and O
norepinephrine O
(NE) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O
NE O
acts O
at O
prejunctional O
α2-adrenergic O
receptors O
(α2ARs) O
to O
inhibit O
NE O
release O
, O
and O
α2AR O
function O
is O
impaired O
in O
DOCA-salt O
rats O
. O
Adenosine O
, O
an O
enzymatic O
ATP O
degradation O
product O
, O
acts O
at O
prejunctional O
A1 O
adenosine O
receptors O
(A1Rs) O
to O
inhibit O
NE O
release O
. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt O
rats O
. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs B
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

fructose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Oral O
administration O
of O
tetrahydrobiopterin O
prevents O
endothelial O
dysfunction O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats.We O
have O
reported O
that O
a O
deficiency O
of O
tetrahydrobiopterin O
(BH(4)) O
, O
an O
active O
cofactor O
of O
endothelial O
NO O
synthase O
(eNOS) O
, O
contributes O
to O
the O
endothelial O
dysfunction O
through O
reduced O
eNOS O
activity O
and O
increased O
superoxide O
anion O
(O(2)(-)) O
generation O
in O
the O
insulin-resistant O
state O
. O
To O
further O
confirm O
this O
hypothesis O
, O
we O
investigated O
the O
effects O
of O
dietary O
treatment O
with O
BH(4) O
on O
endothelium-dependent O
arterial O
relaxation O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats O
. O
Oral O
supplementation O
of O
BH(4) O
(10 O
mg O
. O
kg(-1) O
. O
d(-1)) O
for O
8 O
weeks O
significantly O
increased O
the O
BH(4) O
content O
in O
cardiovascular O
tissues O
of O
rats O
fed O
high O
levels O
of O
fructose O
(fructose-fed O
rats) O
. O
Impairment O
of O
endothelium-dependent O
arterial O
relaxation O
in O
the O
aortic O
strips O
of O
the O
fructose-fed O
rats O
was O
reversed O
with O
BH(4) O
treatment O
. O
The O
BH(4) O
treatment O
was O
associated O
with O
a O
2-fold O
increase O
in O
eNOS O
activity O
as O
well O
as O
a O
70% O
reduction O
in O
endothelial O
O(2)(-) O
production O
compared O
with O
those O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
also O
partially O
improved O
the O
insulin O
sensitivity O
and O
blood O
pressure O
, O
as O
well O
as O
the O
serum O
triglyceride O
concentration O
, O
in O
the O
fructose-fed O
rats O
. O
Moreover O
, O
BH(4) O
treatment O
of O
the O
fructose-fed O
rats O
markedly O
reduced O
the O
lipid O
peroxide O
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O
the O
activation O
of O
2 O
redox-sensitive O
transcription O
factors O
, O
nuclear O
factor-kappaB O
and O
activating B
protein-1 I
, O
which O
were O
increased O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
of O
control O
rats O
did O
not O
have O
any O
significant O
effects O
on O
these O
parameters O
. O
These O
results O
indicate O
that O
BH(4) O
augmentation O
is O
essential O
for O
the O
restoration O
of O
eNOS O
function O
and O
the O
reduction O
of O
vascular O
oxidative O
stress O
in O
insulin-resistant O
rats O
. O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Methylphenidate O
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition O
, O
motivated O
behaviors O
, O
appetite O
, O
and O
stress.Thousands O
of O
children O
receive O
methylphenidate O
(MPH; O
Ritalin) O
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD) O
, O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH O
treatment O
are O
unknown O
. O
To O
mimic O
clinical O
Ritalin O
treatment O
in O
children O
, O
male O
rats O
were O
injected O
with O
MPH O
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine B
transporter I
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O
involved O
in O
motivated O
behaviors O
, O
cognition O
, O
appetite O
, O
and O
stress O
. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time O
, O
chronic O
modulation O
of O
young O
brains O
with O
MPH O
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood O
. O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha O
1A-adrenoceptor O
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha B
1B-adrenoceptors I
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

ethanol O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Withdrawal O
from O
free-choice O
ethanol O
consumption O
results O
in O
increased O
packing O
density O
of O
glutamine B
synthetase I
-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O
interruption O
of O
ethanol O
drinking O
, O
subjected O
to O
a O
3-day O
withdrawal O
period O
at O
the O
end O
of O
2 O
months O
, O
or O
subjected O
to O
three O
3-day O
withdrawal O
periods O
along O
6 O
months O
. O
At O
2 O
months O
, O
P O
rats O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS O
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS O
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

felbamate O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Felbamate O
block O
of O
recombinant O
N-methyl-D-aspartate O
receptors O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA B
receptor I
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O
the O
specificity O
of O
felbamate O
block O
of O
recombinant O
NMDA O
receptors O
composed O
of O
the O
NR1a O
subunit O
and O
various O
NR2 O
subunits O
. O
Felbamate O
produced O
a O
rapid O
, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA O
and O
10 O
microM O
glycine O
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat O
NR1a O
subunit O
, O
and O
either O
the O
NR2A O
, O
NR2B O
or O
NR2C O
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6 O
, O
0.52 O
and O
2.4 O
mM O
, O
respectively O
(holding O
potential O
, O
- O
60 O
mV) O
. O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and O
, O
in O
kinetic O
analyses O
, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O
functions O
, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Add-on O
therapy O
with O
the O
DPP-4 B
inhibitor O
sitagliptin O
improves O
glycemic O
control O
in O
insulin-treated O
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus.The O
effect O
of O
add-on O
therapy O
with O
sitagliptin O
on O
glycemic O
control O
was O
prospectively O
investigated O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
receiving O
insulin O
alone O
or O
insulin O
combined O
with O
oral O
antidiabetic O
drugs O
. O
Seventy-one O
patients O
were O
evaluated O
(38 O
men O
and O
33 O
women O
aged O
63.9±10.2 O
years) O
. O
They O
were O
divided O
into O
three O
groups O
, O
which O
were O
45 O
patients O
receiving O
premixed O
insulin O
twice O
daily O
, O
15 O
patients O
receiving O
multiple O
daily O
insulin O
injections O
, O
and O
11 O
patients O
receiving O
basal O
insulin O
with O
oral O
antidiabetic O
drugs O
(basal O
insulin O
therapy) O
. O
Concomitant O
oral O
drugs O
included O
sulfonylureas O
, O
α-glucosidase O
inhibitors O
and O
metformin O
. O
The O
hemoglobin O
A1c O
(HbA1c) O
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O
sitagliptin O
(p<0.01) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c O
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin O
. O
These O
findings O
suggest O
that O
add-on O
therapy O
with O
sitagliptin O
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient's O
demographic O
profile O
. O
Stratified O
analysis O
based O
on O
the O
insulin O
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin O
when O
it O
was O
added O
to O
basal O
insulin O
therapy O
. O
The O
results O
of O
this O
investigation O
confirmed O
that O
add-on O
therapy O
with O
sitagliptin O
to O
various O
insulin O
regimens O
could O
improve O
glycemic O
control O
without O
severe O
hypoglycemia O
and/or O
weight O
gain O
. O

sinapic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
sinapic O
acid O
against O
dimethylnitrosamine-induced O
hepatic O
fibrosis O
in O
rats.Sinapic O
acid O
is O
a O
member O
of O
the O
phenylpropanoid O
family O
and O
is O
abundant O
in O
cereals O
, O
nuts O
, O
oil O
seeds O
, O
and O
berries O
. O
It O
exhibits O
a O
wide O
range O
of O
pharmacological O
properties O
. O
In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic O
acid O
on O
dimethylnitrosamine O
(DMN)-induced O
chronic O
liver O
injury O
in O
rats O
. O
Sinapic O
acid O
remarkably O
prevented O
DMN-induced O
loss O
of O
body O
weight O
. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
liver O
malondialdehyde O
content O
. O
Furthermore O
, O
sinapic O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen B
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
. O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 O
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O
that O
sinapic O
acid O
is O
a O
potentially O
useful O
agent O
for O
the O
protection O
against O
liver O
fibrosis O
and O
cirrhosis O
. O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
( O
MAO) B
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O
MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS O
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O
doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B
enzymes I
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
( O
GABA-T) B
 O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

all-trans-13,14-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 O
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat O
A O
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 B
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O
which O
could O
have O
signaling O
functions O
. O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
crocin O
on O
diazinon O
induced O
cardiotoxicity O
in O
rats O
in O
subchronic O
exposure.This O
study O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
crocin O
, O
main O
component O
of O
Crocus O
sativus O
L O
. O
(Saffron) O
against O
subchronic O
diazinon O
(DZN) O
induced O
cardiotoxicity O
in O
rats O
. O
METHODS O
: O
Rats O
were O
divided O
into O
7 O
groups; O
control O
(corn O
oil O
, O
gavage) O
, O
DZN O
(15mg/kg/day O
, O
gavage,) O
, O
crocin O
(12.5 O
, O
25 O
or O
50mg/kg/day O
, O
i.p) O
plus O
DZN O
, O
vitamin O
E O
(200IU/kg O
, O
i.p O
, O
three O
times O
per O
week) O
plus O
DZN O
and O
crocin O
(50mg/kg/day O
, O
i.p) O
groups O
. O
Treatments O
were O
continued O
for O
4weeks O
. O
Creatine O
phosphokinase O
MB O
(CK-MB) O
, O
malondealdehyde O
(MDA) O
and O
glutathione O
(GSH) O
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments O
. O
Levels O
of O
apoptotic O
proteins O
(Bax O
, O
Bcl2 O
, O
caspase O
3) O
and O
cytosolic O
cytochrome O
c O
were O
analyzed O
by O
Western O
blotting O
. O
Transcript O
levels O
of O
Bax O
and O
Bcl2 O
were O
also O
determined O
using O
qRT O
PCR O
. O
RESULTS O
: O
DZN O
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax O
/ O
Bcl2 B
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR B
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

ketanserin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 B
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

Histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
( O
HDC) B
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

adamantyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
: O
aromatic O
and O
heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
with O
strong O
anticonvulsant O
activity.A O
series O
of O
aromatic/heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic O
aminosulfonamides O
with O
the O
acyl O
chlorides O
derived O
from O
adamantyl-1-carboxylic O
acid O
and O
1-adamantyl-acetic O
acid O
. O
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides O
with O
adamantyl O
isocyanate O
and O
adamantyl O
isothiocyanate O
, O
respectively O
. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human O
CA O
isozymes O
involved O
in O
important O
physiological O
processes O
, O
CA O
I O
, O
and O
CA O
II O
, O
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide O
and O
methazolamide O
. O
The O
lipophilicity O
of O
the O
best O
CA O
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value O
. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35) O
. O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA O
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice O
. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)) O
, O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O
(> O
90%) O
. O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1) O
, O
respectively O
inhibitors O
: O
aromatic O
and O
heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
with O
strong O
anticonvulsant O
activity.A O
series O
of O
aromatic/heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic O
aminosulfonamides O
with O
the O
acyl O
chlorides O
derived O
from O
adamantyl-1-carboxylic O
acid O
and O
1-adamantyl-acetic O
acid O
. O
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides O
with O
adamantyl O
isocyanate O
and O
adamantyl O
isothiocyanate O
, O
respectively O
. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human O
CA O
isozymes O
involved O
in O
important O
physiological O
processes O
, O
CA O
I O
, O
and O
CA O
II O
, O
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide O
and O
methazolamide O
. O
The O
lipophilicity O
of O
the O
best O
CA O
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value O
. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35) O
. O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA O
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice O
. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)) O
, O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O
(> O
90%) O
. O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1) O
, O
respectively O
. O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
: O
aromatic O
and O
heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
with O
strong O
anticonvulsant O
activity.A O
series O
of O
aromatic/heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic O
aminosulfonamides O
with O
the O
acyl O
chlorides O
derived O
from O
adamantyl-1-carboxylic O
acid O
and O
1-adamantyl-acetic O
acid O
. O
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides O
with O
adamantyl O
isocyanate O
and O
adamantyl O
isothiocyanate O
, O
respectively O
. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human O
CA O
isozymes O
involved O
in O
important O
physiological O
processes O
, O
CA O
I O
, O
and O
CA B
II I
, O
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide O
and O
methazolamide O
. O
The O
lipophilicity O
of O
the O
best O
CA O
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value O
. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35) O
. O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA O
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice O
. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)) O
, O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O
(> O
90%) O
. O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1) O
, O
respectively O
. O

NDP-MSH O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
MELANOTAN O
, O
[Nle(4) O
, O
D-Phe(7)]-alpha-MSH O
, O
on O
melanin O
synthesis O
in O
humans O
with O
MC1R O
variant O
alleles.MELANOTAN O
(NDP-MSH) O
binds O
the O
MC1 B
receptor I
to O
significantly O
increase O
the O
eumelanin O
content O
of O
human O
skin O
cells O
. O
In O
this O
study O
of O
77 O
Caucasian O
individuals O
, O
we O
investigated O
the O
effects O
of O
MELANOTAN O
in O
individuals O
with O
variant O
MC1R O
genotypes O
, O
as O
it O
has O
been O
suggested O
through O
in O
vitro O
studies O
that O
variant O
alleles O
decrease O
MELANOTAN O
binding O
efficacy O
, O
which O
would O
subsequently O
affect O
the O
synthesis O
of O
melanin O
. O
Administration O
of O
MELANOTAN O
produced O
a O
significant O
(p<0.001) O
increase O
in O
melanin O
density O
in O
treated O
, O
compared O
to O
placebo O
, O
individuals O
. O
Importantly O
, O
MELANOTAN O
increased O
the O
melanin O
density O
to O
a O
greater O
extent O
in O
individuals O
carrying O
the O
variant O
alleles O
Val60Leu O
, O
Asp84Glu O
, O
Val92Met O
, O
Arg142His O
, O
Arg151Cys O
, O
and O
Arg160Trp O
than O
in O
individuals O
with O
no O
variant O
alleles O
. O
This O
study O
demonstrates O
that O
MELANOTAN O
effectively O
increases O
the O
melanin O
content O
of O
skin O
in O
those O
individuals O
with O
MC1R O
variant O
alleles O
and O
therefore O
, O
those O
most O
in O
need O
of O
photoprotection O
. O

MNU O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
A O
New O
Proposed O
Rodent O
Model O
of O
Chemically O
Induced O
Prostate O
Carcinogenesis O
: O
Distinct O
Time-Course O
Prostate O
Cancer O
Progression O
in O
the O
Dorsolateral O
and O
Ventral O
Lobes.BACKGROUND O
: O
Characterization O
of O
novel O
rodent O
models O
for O
prostate O
cancer O
studies O
requires O
evaluation O
of O
either O
spontaneous O
and O
carcinogen-induced O
tumors O
as O
well O
as O
tumor O
incidence O
in O
different O
prostatic O
lobes O
. O
We O
propose O
a O
new O
short-term O
rodent O
model O
of O
chemically O
induced O
prostate O
carcinogenesis O
in O
which O
prostate O
cancer O
progression O
occurs O
differentially O
in O
the O
dorsolateral O
and O
ventral O
lobes O
. O
METHODS O
: O
Adult O
gerbils O
were O
treated O
with O
MNU O
alone O
or O
associated O
with O
testosterone O
for O
3 O
or O
6 O
months O
of O
treatment O
. O
Tumor O
incidence O
, O
latency O
, O
localization O
, O
and O
immunohistochemistry O
(AR O
, O
PCNA O
, O
smooth O
muscle O
α-actin O
, O
p63 O
, O
MGMT O
, O
and O
E-cadherin) O
were O
studied O
in O
both O
lobes O
. O
RESULTS O
: O
Comparisons O
between O
both O
lobes O
revealed O
that O
lesions O
developed O
first O
in O
the O
DL O
while O
the O
VL O
presented O
longer O
tumor O
latency O
. O
However O
, O
after O
6 O
months O
, O
there O
was O
a O
dramatic O
increase O
in O
tumor O
multiplicity O
in O
the O
VL O
, O
mainly O
in O
MNU-treated O
groups O
. O
Lesions O
clearly O
progressed O
from O
a O
premalignant O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU O
+ O
testosterone O
administration O
. O
Three-dimensional O
reconstruction O
of O
the O
prostatic O
complex O
showed O
that O
the O
DL O
developed O
tumors O
exclusively O
in O
the O
periurethral O
area O
and O
showed O
intense O
AR O
, O
PCNA O
, O
and O
MGMT O
immunostaining O
. O
Moreover O
, O
VL O
lesions O
emerged O
throughout O
the O
entire O
lobe O
. O
MNU-induced O
lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype O
: O
lack O
of O
basal O
cells O
, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer O
, O
loss O
of O
E-cadherin B
, O
and O
high O
MGMT O
staining O
. O
CONCLUSIONS O
: O
There O
are O
distinct O
pathways O
involved O
in O
tumor O
progression O
in O
gerbil O
prostate O
lobes O
. O
This O
animal O
provides O
a O
good O
model O
for O
prostate O
cancer O
since O
it O
allows O
the O
investigation O
of O
advanced O
steps O
of O
carcinogenesis O
with O
shorter O
latency O
periods O
in O
both O
lobes O
. O
Prostate O
© O
2013 O
Wiley O
Periodicals O
, O
Inc O
. O

Pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O
cloned O
from O
a O
human O
brain O
library O
. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart O
, O
liver O
and O
lung O
. O
Within O
the O
brain O
, O
erg3 O
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal O
, O
parietal O
and O
occipital O
lobes O
. O
Transient O
expression O
of O
erg3 O
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) O
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 O
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 B
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs O
. O

sodium O
acts O
as O
NOT O
for O
what O
entity O
? O
Preferential O
block O
of O
late O
sodium O
current O
in O
the O
LQT3 B
DeltaKPQ I
mutant I
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide.Flecainide O
block O
of O
Na(+) O
current O
(I(Na)) O
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long O
QT O
syndrome O
3 O
(LQT3) O
sodium O
channel O
alpha O
subunit O
mutation O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ O
I(Na) O
was O
more O
sensitive O
to O
flecainide O
, O
and O
flecainide O
preferentially O
inhibited O
late O
I(Na) O
(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
80 O
+/- O
9 O
and O
19 O
+/- O
2 O
microM O
(n O
= O
31) O
respectively O
. O
UDB O
of O
peak O
I(Na) O
was O
greater O
and O
developed O
more O
slowly O
during O
pulse O
trains O
for O
DeltaKPQ O
than O
for O
WT O
. O
The O
IC(50) O
value O
for O
UDB O
of O
peak O
I(Na) O
for O
WT O
was O
29 O
+/- O
4 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
11 O
+/- O
1 O
microM O
(n O
= O
26) O
. O
For O
DeltaKPQ O
, O
UDB O
of O
late O
I(Na) O
was O
greater O
than O
for O
peak O
I(Na) O
. O
Recovery O
from O
block O
was O
slower O
for O
DeltaKPQ O
than O
for O
WT O
. O
We O
conclude O
that O
DeltaKPQ O
interacts O
differently O
with O
flecainide O
than O
with O
WT O
, O
leading O
to O
increased O
block O
and O
slowed O
recovery O
, O
especially O
for O
late O
I(Na) O
. O
These O
data O
provide O
insights O
into O
mechanisms O
for O
flecainide O
block O
and O
provide O
a O
rationale O
at O
the O
cellular O
and O
molecular O
level O
that O
open O
channel O
block O
may O
be O
a O
useful O
pharmacological O
property O
for O
treatment O
of O
LQT3 O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg- O
CYP2D6 B
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

serotonin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Identification O
of O
an O
Allosteric O
Modulator O
of O
Serotonin O
Transporter O
with O
Novel O
Mechanism O
of O
Action.Serotonin O
transporters O
(SERT) O
play O
an O
essential O
role O
in O
the O
termination O
and O
regulation O
of O
serotonin O
signaling O
in O
the O
brain O
. O
SERT O
is O
also O
the O
target O
of O
antidepressants O
and O
psychostimulants O
. O
Molecules O
with O
novel O
activities O
and O
modes O
of O
interaction O
with O
regard O
to O
SERT O
function O
are O
of O
great O
scientific O
and O
clinical O
interest O
. O
We O
explored O
structural O
regions O
outside O
the O
putative O
serotonin O
translocation O
pathway O
to O
identify O
potential O
binding O
sites O
for O
allosteric O
transporter O
modulators O
(ATMs) O
. O
Mutational O
studies O
revealed O
a O
pocket O
of O
amino O
acids O
outside O
the O
orthosteric O
substrate O
binding O
sites O
located O
in O
the O
interface O
between O
extracellular O
loops O
1 O
and O
3 O
that O
when O
mutated O
affect O
transporter O
function O
. O
Using O
the O
structure O
of O
the O
bacterial O
transporter O
homologue O
leucine O
transporter O
as O
a O
template O
, O
we O
developed O
a O
structural O
model O
of O
SERT O
. O
We O
performed O
molecular O
dynamics O
simulations O
to O
further O
characterize O
the O
allosteric O
pocket O
that O
was O
identified O
by O
site-directed O
mutagenesis O
studies O
and O
employed O
this O
pocket O
in O
a O
virtual O
screen O
for O
small-molecule O
modulators O
of O
SERT O
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
, O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT B
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
(MDMA O
, O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O
an O
outward-facing O
conformation O
of O
SERT O
. O
Taken O
together O
these O
observations O
demonstrate O
that O
ATM7 O
acts O
through O
a O
novel O
mechanism O
that O
involves O
allosteric O
modulation O
of O
SERT O
function O
. O

ATP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
SUR-dependent O
modulation O
of O
KATP O
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N- O
and O
C-terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O
(P(O(max))) O
and O
attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O
did O
not O
affect O
significantly O
the O
mean O
open O
or O
"fast," O
K(+) O
driving O
force-dependent O
, O
intraburst O
closed O
times O
, O
verifying O
that O
Ntp O
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times O
. O
Ctp O
and O
Rnp O
, O
a O
randomized O
Ntp O
, O
had O
no O
effect O
, O
indicating O
that O
the O
effects O
of O
Ntp O
are O
structure O
specific O
. O
Ntp O
opened O
K(IR)6.1/SUR1 O
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) O
and O
attenuated O
the O
coupling O
of O
high-affinity O
sulfonylurea O
binding O
with O
K(ATP) O
pore O
closure O
. O
These O
effects O
resemble O
those O
seen O
with O
N-terminal O
deletions O
(DeltaN) O
of O
K(IR)6.0 O
, O
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) B
channels I
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP O
in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O
the O
channel O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O
core O
of O
SUR O
with O
the O
K(IR) O
pore O
. O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
glycogen O
synthase O
kinase-3β/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagin-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O
that O
cinobufagin O
potently O
inhibited O
the O
proliferation O
of O
U2OS O
, O
MG63 O
and O
SaOS-2 O
cells O
. O
Significant O
increases O
in O
G2/M O
cell-cycle O
arrest O
and O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β O
/ O
NF-κB B
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

[(3)H]dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 O
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

Reboxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Reboxetine O
versus O
fluvoxamine O
in O
the O
treatment O
of O
motor O
vehicle O
accident-related O
posttraumatic O
stress O
disorder O
: O
a O
double-blind O
, O
fixed-dosage O
, O
controlled O
trial.BACKGROUND O
: O
Motor O
vehicle O
accidents O
(MVAs) O
are O
a O
leading O
cause O
of O
posttraumatic O
stress O
disorder O
(PTSD) O
in O
the O
general O
population O
. O
Alterations O
in O
norepinephrine O
and O
serotonin O
systems O
have O
been O
proposed O
as O
mechanisms O
involved O
in O
the O
pathophysiology O
of O
the O
condition O
, O
with O
treatment O
directed O
at O
these O
neurotransmitter O
systems O
. O
Reboxetine O
, O
a O
selective O
norepinephrine O
reuptake O
inhibitor O
, O
exhibits O
high O
affinity O
and O
selectivity O
for O
the O
human B
norepinephrine I
transporter I
. O
Inasmuch O
as O
PTSD O
may O
be O
associated O
with O
dysregulation O
of O
noradrenergic O
activity O
, O
the O
present O
double-blind O
randomized O
clinical O
trial O
intended O
to O
evaluate O
reboxetine's O
efficacy O
in O
the O
management O
of O
MVA-related O
PTSD O
and O
to O
compare O
its O
efficacy O
with O
a O
medication O
commonly O
used O
in O
PTSD O
, O
the O
selective O
serotonin O
reuptake O
inhibitor O
fluvoxamine O
. O
METHODS O
: O
Forty O
patients O
with O
MVA-related O
PTSD O
attending O
a O
local O
community O
mental O
health O
outpatient O
clinic O
were O
randomized O
to O
receive O
a O
fixed O
dose O
of O
either O
reboxetine O
(8 O
mg/d) O
or O
fluvoxamine O
(150 O
mg/d) O
in O
a O
double-blind O
fashion O
for O
a O
period O
of O
8 O
weeks O
. O
RESULTS O
: O
At O
baseline O
and O
at O
study O
end O
point O
, O
the O
2 O
subgroups O
demonstrated O
no O
statistical O
differences O
in O
scores O
on O
PTSD O
, O
depression O
, O
and O
anxiety O
rating O
scales O
. O
Both O
medications O
led O
to O
significant O
improvements O
in O
all O
clinical O
scales O
measured O
. O
Nine O
patients O
receiving O
reboxetine O
and O
3 O
receiving O
fluvoxamine O
withdrew O
from O
the O
study O
because O
of O
side O
effects O
. O
CONCLUSIONS O
: O
Study O
observations O
indicate O
comparable O
efficacy O
of O
reboxetine O
and O
fluvoxamine O
in O
the O
management O
of O
MVA-related O
PTSD O
despite O
reboxetine's O
selective O
noradrenergic O
activity O
. O
Reboxetine O
appears O
to O
be O
at O
least O
as O
effective O
as O
fluvoxamine O
and O
may O
offer O
an O
alternative O
management O
option O
in O
this O
often O
difficult-to-treat O
and O
disabling O
condition O
. O
A O
lower O
and O
flexible O
reboxetine O
dosing O
schedule O
will O
be O
recommended O
for O
future O
research O
to O
improve O
its O
tolerability O
in O
PTSD O
patients O
. O

AMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase B
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

venlafaxine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Affinities O
of O
venlafaxine O
and O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
and O
norepinephrine O
transporters.In O
vitro O
radioligand O
binding O
studies O
were O
carried O
out O
in O
rat O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
(5-hydroxytryptamine O
, O
5-HT) O
and O
the O
norepinephrine O
transporters O
using O
the O
selective O
ligands O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
, O
respectively O
. O
The O
selective O
5-HT O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
only O
a O
moderate O
affinity O
for O
the O
5-HT B
transporter I
(Ki O
= O
74 O
nM) O
and O
a O
very O
low O
affinity O
for O
the O
norepinephrine O
transporter O
(Ki O
= O
1.26 O
microM) O
. O
The O
relatively O
low O
affinities O
of O
venlafaxine O
contrast O
with O
its O
potent O
in O
vivo O
5-HT O
and O
norepinephrine O
reuptake O
blocking O
properties O
. O
These O
results O
raise O
the O
possibility O
that O
the O
in O
vivo O
effects O
on O
the O
5-HT O
and O
norepinephrine O
reuptake O
observed O
with O
venlafaxine O
may O
not O
be O
mediated O
solely O
by O
its O
binding O
to O
the O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
binding O
sites O
. O

Vitamin O
K2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Vitamin O
K2 O
covalently O
binds O
to O
Bak B
and O
induces O
Bak-mediated O
apoptosis.Vitamin O
K2 O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
( O
COX-2) B
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O
apoptosis O
via O
the O
PPARdelta/14-3-3epsilon O
transcriptional O
pathway O
. O
These O
results O
suggest O
that O
14-3-3epsilon O
is O
a O
target O
for O
the O
prevention O
and O
therapy O
of O
colorectal O
cancer O
. O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 B
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data O
. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 O
and O
CYP3A4 O
, O
respectively O
. O
The O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 O
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme-ketamine O
binding O
and O
catalytic O
activity O
. O

Carbohydrate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
Effects O
of O
Carbohydrate O
, O
Unsaturated O
Fat O
, O
and O
Protein O
Intake O
on O
Measures O
of O
Insulin B
Sensitivity O
: O
Results O
from O
the O
OmniHeart O
Trial.OBJECTIVE O
Impaired O
insulin O
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease O
. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin O
sensitivity O
, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin O
sensitivity O
are O
uncertain O
. O
The O
purpose O
of O
this O
study O
is O
to O
determine O
the O
effects O
on O
insulin O
sensitivity O
of O
a O
carbohydrate-rich O
diet O
(CARB; O
similar O
to O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
[DASH] O
diet) O
, O
a O
protein-rich O
diet O
(PROT; O
protein O
predominantly O
from O
plant O
sources) O
, O
and O
an O
unsaturated O
fat-rich O
diet O
(UNSAT; O
predominantly O
monounsaturated) O
. O
RESEARCH O
DESIGN O
AND O
METHODS O
This O
study O
was O
a O
randomized O
, O
controlled O
, O
three-period O
, O
crossover O
feeding O
study O
. O
The O
study O
participants O
were O
164 O
individuals O
with O
prehypertension O
or O
stage O
1 O
hypertension O
without O
diabetes O
. O
Diets O
were O
administered O
for O
6 O
weeks O
each O
, O
with O
a O
washout O
period O
between O
diets O
of O
2-4 O
weeks O
. O
Weight O
was O
held O
constant O
throughout O
the O
study O
. O
For O
our O
primary O
outcome O
, O
we O
calculated O
the O
quantitative O
insulin O
sensitivity O
check O
index O
(QUICKI) O
using O
the O
end-of-period O
fasting O
serum O
glucose O
and O
insulin O
. O
QUICKI O
is O
a O
validated O
measure O
of O
insulin O
sensitivity O
. O
The O
primary O
analyses O
used O
generalized O
estimating O
equations O
. O
RESULTS O
At O
baseline O
, O
mean O
(SD) O
BMI O
was O
30.2 O
(6.1) O
kg/m(2) O
, O
and O
mean O
(SD) O
QUICKI O
was O
0.35 O
(0.04) O
. O
The O
UNSAT O
diet O
increased O
QUICKI O
by O
0.005 O
, O
more O
than O
the O
CARB O
diet O
(P O
= O
0.04) O
. O
PROT O
had O
no O
significant O
effect O
compared O
with O
CARB O
. O
CONCLUSIONS O
A O
diet O
that O
partially O
replaces O
carbohydrate O
with O
unsaturated O
fat O
may O
improve O
insulin O
sensitivity O
in O
a O
population O
at O
risk O
for O
cardiovascular O
disease O
. O
Given O
the O
well-recognized O
challenges O
of O
sustaining O
weight O
loss O
, O
our O
results O
suggest O
an O
alternative O
approach O
for O
improving O
insulin O
sensitivity O
. O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin O
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine-induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O
chromatography O
(IMAC) O
, O
with O
two-dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN-/- O
, O
MK-/- O
and O
wild O
type O
(WT) O
mice O
treated O
with O
amphetamine O
. O
We O
identified O
13 O
differentially O
expressed O
phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN O
and O
MK B
against O
amphetamine-induced O
neurotoxicity O
. O
It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins O
, O
annexin O
A7 O
(ANXA7) O
, O
COP9 O
signalosome O
subunit O
5 O
(COPS5) O
, O
aldehyde O
dehydrogenase O
family O
1 O
member O
A1 O
(ALDH1A1) O
and O
creatine O
kinase O
U-type O
(CKMT1) O
, O
are O
known O
to O
be O
involved O
in O
Parkinson's O
disease O
, O
a O
result O
of O
significant O
importance O
since O
PTN O
and O
MK O
have O
been O
also O
demonstrated O
to O
limit O
Parkinson's O
disease O
(PD) O
progress O
and O
have O
been O
suggested O
to O
be O
among O
the O
important O
genetic O
factors O
possibly O
preventing O
the O
development O
of O
PD O
in O
methamphetamine O
abusers O
. O
The O
data O
identify O
phosphoproteins O
differentially O
regulated O
by O
amphetamine O
treatment O
and/or O
the O
presence O
of O
endogenous O
PTN/MK O
which O
may O
be O
relevant O
mediators O
of O
PTN/MK O
neuroprotective O
effects O
against O
amphetamine-induced O
neurotoxicity O
. O
The O
data O
support O
further O
studies O
to O
validate O
the O
phosphoproteins O
here O
identified O
as O
possible O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain B
and O
AIF O
levels O
. O

BB-94 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase O
A O
(MMP-2) O
by O
batimastat O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril O
, O
on O
metalloproteinase B
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro O
, O
and O
on O
local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice O
. O
The O
effect O
of O
BB-94 O
and O
captopril O
on O
the O
survival O
of O
the O
3LL-tumor-bearing O
mice O
was O
also O
examined O
. O
Here O
we O
report O
that O
captopril O
treatment O
resulted O
in O
decreased O
transcription O
and O
protein O
levels O
of O
gelatinase O
A O
by O
3LL O
cells O
. O
Both O
BB-94 O
and O
captopril O
also O
prevented O
substrate O
degradation O
by O
gelatinase O
A O
and O
B O
released O
in O
conditioned O
medium O
by O
cultured O
cells O
. O
Treatment O
of O
tumor-bearing O
animals O
with O
BB-94 O
(i.p.) O
or O
captopril O
(in O
drinking O
water) O
resulted O
in O
significant O
inhibition O
of O
the O
mean O
tumor O
volume O
(25 O
and O
33% O
respectively) O
and O
of O
the O
mean O
lung O
metastasis O
number O
(26 O
and O
29% O
respectively) O
. O
When O
both O
agents O
were O
given O
, O
they O
acted O
in O
synergy O
, O
resulting O
in O
51 O
and O
80% O
inhibition O
of O
tumor O
growth O
and O
metastasis O
. O
The O
survival O
time O
of O
the O
mice O
treated O
with O
both O
BB-94 O
and O
captopril O
was O
also O
significantly O
longer O
compared O
with O
the O
groups O
treated O
with O
each O
agent O
alone O
or O
with O
the O
vehicle O
. O
Our O
data O
support O
the O
hypothesis O
of O
an O
essential O
role O
of O
metalloproteinase(s) O
in O
the O
metastatic O
process O
. O
Moreover O
, O
blockade O
of O
invasion O
, O
angiogenesis O
and O
other O
processes O
mediated O
by O
metalloproteinases O
may O
underlie O
the O
anti-tumor O
and O
anti-metastatic O
effect O
of O
BB-94 O
and O
captopril O
and O
their O
combination O
. O
It O
is O
conceivable O
that O
this O
combination O
could O
be O
tested O
in O
selected O
clinical O
conditions O
as O
an O
adjuvant O
modality O
to O
cytotoxic O
therapy O
. O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii O
. O
Adenylosuccinate B
synthetase I
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O
ordered O
C O
kinetic O
mechanism O
for O
the O
MjAdSS O
catalyzed O
reaction O
. O
AdSS O
are O
known O
to O
exhibit O
monomer-dimer O
equilibrium O
with O
the O
dimer O
being O
implicated O
in O
catalysis O
. O
In O
contrast O
, O
our O
studies O
show O
that O
MjAdSS O
is O
an O
equilibrium O
mixture O
of O
dimers O
and O
tetramers O
with O
the O
tetramer O
being O
the O
catalytically O
active O
form O
. O
The O
tetramer O
dissociates O
into O
dimers O
with O
a O
minor O
increase O
in O
ionic O
strength O
of O
the O
buffer O
, O
while O
the O
dimer O
is O
extremely O
stable O
and O
does O
not O
dissociate O
even O
at O
1.2 O
M O
NaCl O
. O
Phosphate O
, O
a O
product O
of O
the O
reaction O
, O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
MjAdSS O
showing O
biphasic O
inhibition O
of O
enzyme O
activity O
. O
The O
inhibition O
was O
competitive O
with O
IMP O
and O
noncompetitive O
with O
GTP O
. O
MjAdSS O
, O
like O
the O
mouse O
acidic O
isozyme O
, O
exhibits O
substrate O
inhibition O
, O
with O
IMP O
inhibiting O
enzyme O
activity O
at O
subsaturating O
GTP O
concentrations O
. O
Regulation O
of O
enzyme O
activity O
by O
the O
glycolytic O
intermediate O
, O
fructose O
1,6 O
bisphosphate O
, O
was O
also O
observed O
with O
the O
inhibition O
being O
competitive O
with O
IMP O
and O
noncompetitive O
against O
GTP O
. O

Tetrahydrobiopterin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Contrasting O
effects O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric B
oxide I
synthases I
(EC O
1.14.13.39) O
. O
Here O
we O
compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine O
reductase O
(EC O
1.6.99.7) O
and O
phenylalanine O
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O
Substitution O
at O
N(5) O
occurs O
at O
a O
position O
critical O
to O
the O
redox O
cycle O
of O
the O
cofactor O
in O
phenylalanine O
hydroxylase/dihydropteridine O
reductase O
. O
We O
also O
included O
N(2)'-methyl O
H(4)biopterin O
, O
a O
derivative O
substituted O
at O
a O
position O
not O
directly O
involved O
in O
redox O
cycling O
, O
as O
a O
control O
. O
As O
compared O
with O
N(5)-methyl O
H(4)biopterin O
, O
N(5)-formyl O
H(4)biopterin O
bound O
with O
twice O
the O
capacity O
but O
stimulated O
nitric O
oxide O
synthase O
to O
a O
lesser O
extent O
. O
Depending O
on O
the O
substituent O
used O
, O
N(5)-substituted O
derivatives O
were O
redox-active O
: O
N(5)-methyl- O
and O
N(5)-hydroxyl O
methyl O
H(4)biopterin O
, O
but O
not O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
, O
reduced O
2,6-dichlorophenol O
indophenol O
. O
N(5)-Substituted O
H(4)biopterin O
derivatives O
were O
not O
oxidized O
to O
products O
serving O
as O
substrates O
for O
dihydropteridine O
reductase O
and,depending O
on O
the O
substituent O
, O
were O
competitive O
inhibitors O
of O
phenylalanine O
hydroxylase O
: O
N(5)-methyl- O
and O
N(5)-hydroxymethyl O
H(4)biopterin O
inhibited O
phenylalanine O
hydroxylase O
, O
whereas O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
had O
no O
effect O
. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine O
hydroxylase O
and O
nitric O
oxide O
synthase O
by O
H(4)biopterin O
. O
They O
are O
compatible O
with O
a O
novel O
, O
non-classical O
, O
redox-active O
contribution O
of O
H(4)biopterin O
to O
the O
catalysis O
of O
the O
nitric O
oxide O
synthase O
reaction O
. O

BDZs O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) B
receptors I
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Astemizole O
, O
a O
potent O
histamine O
H1-receptor O
antagonist O
: O
effect O
in O
allergic O
rhinoconjunctivitis O
, O
on O
antigen O
and O
histamine O
induced O
skin O
weal O
responses O
and O
relationship O
to O
serum O
levels.The O
efficacy O
of O
astemizole O
, O
a O
new O
, O
long O
acting O
, O
oral O
histamine B
H1-receptor I
antagonist O
was O
compared O
to O
placebo O
for O
the O
treatment O
of O
allergic O
rhinitis O
and O
conjunctivitis O
during O
the O
grass O
pollen O
season O
of O
1982 O
. O
Sixty-three O
patients O
with O
a O
positive O
skin O
prick O
test O
to O
grass O
pollen O
and O
current O
symptoms O
participated O
in O
an O
8 O
week O
, O
double-blind O
, O
randomized O
study O
. O
Astemizole O
, O
10 O
mg O
, O
was O
significantly O
better O
than O
placebo O
in O
alleviating O
both O
nose O
(P O
less O
than O
0.05) O
and O
eye O
(P O
less O
than O
0.01) O
symptoms O
despite O
significantly O
greater O
use O
of O
the O
reserve O
medication O
, O
clemastine O
, O
by O
the O
placebo O
group O
(P O
less O
than O
0.003) O
. O
There O
was O
a O
lag O
period O
of O
5 O
days O
after O
initiation O
of O
therapy O
before O
treatment O
benefit O
became O
manifest O
. O
Subdivision O
of O
nasal O
symptoms O
indicated O
significant O
improvement O
compared O
to O
placebo O
over O
the O
8 O
weeks O
for O
sneezing O
(P O
less O
than O
0.05) O
and O
runny O
nose O
(P O
less O
than O
0.05) O
but O
not O
blocked O
nose O
. O
The O
absence O
of O
effect O
on O
nasal O
blockage O
was O
confirmed O
by O
parallel O
measurement O
of O
nasal O
calibre O
by O
body O
plethysmography O
. O
The O
antihistaminic O
potency O
of O
astemizole O
was O
indicated O
by O
an O
80% O
inhibition O
of O
the O
histamine O
induced O
skin O
weal O
response O
after O
8 O
weeks O
therapy O
. O
A O
positive O
correlation O
was O
found O
between O
serum O
drug O
levels O
and O
% O
inhibition O
of O
histamine O
skin O
weal O
(r O
= O
0.64 O
, O
P O
less O
than O
0.001) O
. O
Astemizole O
was O
free O
from O
adverse O
sedative O
or O
anticholinergic O
effects O
but O
did O
cause O
a O
mean O
increase O
in O
weight O
of O
1.3 O
kg O
(P O
less O
than O
0.01) O
after O
8 O
weeks O
therapy O
, O
not O
found O
with O
placebo O
. O

mannose O
6-phosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Purification O
and O
multimeric O
structure O
of O
bovine O
N-acetylglucosamine-1-phosphodiester O
alpha-N-acetylglucosaminidase O
. O
N-Acetylglucosamine-1-phosphodiester B
alpha-N-Acetylglucosaminidase I
(EC O
3.1.4.45; O
phosphodiester O
alpha-GlcNAcase) O
catalyzes O
the O
second O
step O
in O
the O
synthesis O
of O
the O
mannose O
6-phosphate O
determinant O
required O
for O
efficient O
intracellular O
targeting O
of O
newly O
synthesized O
lysosomal O
hydrolases O
to O
the O
lysosome O
. O
A O
partially O
purified O
preparation O
of O
phosphodiester O
alpha-GlcNAcase O
from O
bovine O
pancreas O
was O
used O
to O
generate O
a O
panel O
of O
murine O
monoclonal O
antibodies O
. O
The O
anti-phosphodiester O
alpha-GlcNAcase O
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O
immunopurify O
the O
bovine O
liver O
enzyme O
670,000-fold O
in O
two O
steps O
to O
apparent O
homogeneity O
with O
an O
overall O
yield O
of O
14% O
. O
The O
purified O
phosphodiester O
alpha-GlcNAcase O
has O
a O
specific O
activity O
of O
498 O
micromol O
of O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
cleaved O
per O
h O
per O
mg O
of O
protein O
using O
0.5 O
mM O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
as O
substrate O
. O
The O
subunit O
structure O
of O
the O
enzyme O
was O
determined O
using O
a O
combination O
of O
analytical O
gel O
filtration O
chromatography O
, O
SDS-polyacrylamide O
gel O
electrophoresis O
, O
and O
amino-terminal O
sequencing O
. O
The O
data O
indicate O
that O
bovine O
phosphodiester O
alpha-GlcNAcase O
is O
a O
272,000-Da O
complex O
of O
four O
identical O
68,000-Da O
glycoprotein O
subunits O
arranged O
as O
two O
disulfide-linked O
homodimers O
. O
A O
soluble O
form O
of O
the O
enzyme O
, O
isolated O
from O
fetal O
bovine O
serum O
, O
showed O
the O
same O
subunit O
structure O
. O
Both O
forms O
of O
the O
enzyme O
reacted O
with O
a O
rabbit O
antibody O
raised O
to O
the O
amino-terminal O
peptide O
of O
the O
liver O
enzyme O
, O
suggesting O
that O
phosphodiester O
alpha-GlcNAcase O
is O
a O
type O
I O
membrane-spanning O
glycoprotein O
with O
its O
amino O
terminus O
in O
the O
lumen O
of O
the O
Golgi O
apparatus O
. O

methacholine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effect O
of O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
on O
contractile O
receptor O
function O
in O
airway O
smooth O
muscle.In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
on O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
bovine O
tracheal O
smooth O
muscle O
contractions O
. O
Bovine O
tracheal O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O
various O
periods O
of O
time O
(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O
C) O
, O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic B
receptor I
agonist O
methacholine O
, O
the O
partial O
muscarinic O
receptor O
agonist O
4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
(McN-A-343) O
and O
histamine O
. O
Fenoterol O
treatment O
significantly O
reduced O
the O
sensitivity O
(pEC(50)) O
to O
methacholine O
in O
a O
time-dependent O
manner O
, O
without O
affecting O
maximal O
contraction O
(E(max)) O
. O
Fenoterol O
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 O
and O
histamine; O
however O
, O
E(max) O
values O
were O
also O
reduced O
, O
to O
approximately O
70% O
of O
control O
after O
18-h O
treatment O
. O
The O
inverse O
agonist O
timolol O
, O
having O
no O
effect O
on O
control O
preparations O
, O
consistently O
restored O
the O
reduced O
pEC(50) O
and O
E(max) O
values O
of O
the O
contractile O
agonists O
. O
Remarkably O
, O
in O
the O
presence O
of O
timolol O
the O
pEC(50) O
values O
of O
McN-A-343 O
and O
histamine O
in O
fenoterol-treated O
airways O
were O
significantly O
enhanced O
compared O
to O
controls O
. O
In O
conclusion O
, O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
reduces O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
contractions O
of O
bovine O
tracheal O
smooth O
muscle O
, O
which O
can O
be O
reversed O
by O
the O
inverse O
agonist O
timolol O
. O
Moreover O
, O
after O
beta(2)-adrenoceptor O
agonist O
treatment O
, O
inverse O
agonism O
by O
beta-adrenoceptor O
antagonists O
may O
cause O
enhanced O
airway O
reactivity O
to O
contractile O
mediators O
. O

diphenidol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
antagonistic O
activity O
at O
muscarinic O
receptor O
subtypes O
of O
some O
2-carbonyl O
derivatives O
of O
diphenidol.A O
series O
of O
2-carbonyl O
analogues O
of O
the O
muscarinic O
antagonist O
diphenidol O
bearing O
1-substituents O
of O
different O
lipophilic O
, O
electronic O
, O
and O
steric O
properties O
was O
synthesized O
and O
their O
affinity O
for O
the O
M2 B
and I
M3 I
muscarinic I
receptor I
subtypes O
was O
evaluated O
by O
functional O
tests O
. O
Two O
derivatives O
(2g O
and O
2d) O
showed O
an O
M2-selective O
profile O
which O
was O
confirmed O
by O
functional O
tests O
on O
the O
M1 O
and O
M4 O
receptors O
. O
A O
possible O
relationship O
between O
M2 O
selectivity O
and O
lipophilicity O
of O
the O
1-substituent O
was O
suggested O
by O
structure-activity O
analysis O
. O
This O
work O
showed O
that O
appropriate O
structural O
modification O
of O
diphenidol O
can O
lead O
to O
M2-selective O
muscarinic O
antagonists O
of O
possible O
interest O
in O
the O
field O
of O
Alzheimer's O
disease O
. O

GCS O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R B
alpha I
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

Caprelsa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal B
growth-factor I
receptors I
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O
benefits O
in O
advanced O
MTC O
, O
and O
it O
has O
recently O
been O
approved O
for O
locally O
advanced O
or O
metastatic O
MTC O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
(April O
2011) O
and O
the O
European O
Medicines O
Agency O
(February O
2012) O
. O
This O
review O
, O
starting O
from O
the O
phases O
II O
and O
III O
efficacy O
and O
safety O
data O
that O
led O
to O
these O
approvals O
, O
explores O
important O
issues O
related O
to O
dosing O
, O
patient O
selection O
, O
and O
strategies O
for O
managing O
the O
substantial O
risk O
of O
toxicity O
associated O
with O
the O
drug O
(including O
life-threatening O
cardiac O
events O
that O
are O
the O
subject O
of O
a O
black-box O
warning O
in O
the O
United O
States) O
. O
All O
these O
issues O
still O
remain O
to O
be O
defined O
. O
Vandetanib O
is O
becoming O
a O
standard O
of O
care O
for O
symptomatic O
, O
progressive O
, O
metastatic O
MTCs O
, O
to O
be O
used O
selectively O
in O
those O
patients O
who O
are O
likely O
to O
benefit O
from O
it O
. O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 O
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
, O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 O
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent B
amino I
acid I
transporter I
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

progestins O
acts O
as O
NOT O
for O
what O
entity O
? O
Medroxyprogesterone O
acetate O
but O
not O
drospirenone O
ablates O
the O
protective O
function O
of O
17 O
beta-estradiol O
in O
aldosterone O
salt-treated O
rats.Controversial O
results O
obtained O
from O
human O
and O
animal O
studies O
on O
the O
prevention O
of O
heart O
disease O
by O
estrogens O
and O
progestins O
warrant O
a O
better O
understanding O
of O
nuclear O
hormone O
receptor O
function O
and O
interaction O
. O
To O
address O
this O
issue O
and O
taking O
into O
account O
that O
effects O
of O
synthetic O
progestins O
are O
not O
only O
referable O
to O
action O
through O
the O
progesterone B
receptor I
but O
may O
also O
be O
mediated O
by O
other O
steroid O
receptors O
, O
we O
characterized O
cardiovascular O
function O
and O
inflammatory O
gene O
expression O
in O
aldosterone O
salt-treated O
rats O
on O
long-term O
administration O
of O
17beta-estradiol O
, O
medroxyprogesterone O
acetate O
, O
and O
drospirenone O
, O
a O
new O
progestogen O
exhibiting O
antimineralocorticoid O
activity O
. O
The O
complex O
pattern O
of O
cardiovascular O
injury O
in O
ovariectomized O
Wistar O
rats O
induced O
by O
chronic O
aldosterone O
infusion O
plus O
a O
high-salt O
diet O
was O
significantly O
attenuated O
in O
sham-ovariectomized O
rats O
and O
by O
coadministration O
of O
17beta-estradiol O
in O
ovariectomized O
animals O
after O
8 O
weeks O
of O
continuous O
treatment O
. O
The O
beneficial O
role O
of O
17beta-estradiol O
on O
blood O
pressure O
, O
cardiac O
hypertrophy O
, O
vascular O
osteopontin O
expression O
, O
perivascular O
fibrosis O
, O
and O
impaired O
NO-dependent O
relaxation O
of O
isolated O
aortic O
rings O
was O
completely O
abrogated O
by O
coadministration O
of O
medroxyprogesterone O
acetate O
. O
In O
contrast O
, O
drospirenone O
was O
either O
neutral O
or O
additive O
to O
17beta-estradiol O
in O
protecting O
against O
aldosterone O
salt-induced O
cardiovascular O
injury O
and O
inflammation O
. O
The O
current O
results O
support O
the O
hypothesis O
of O
complex O
interactions O
among O
estrogen O
, O
progesterone O
, O
glucocorticoid O
, O
androgen O
, O
and O
mineralocorticoid O
receptor O
signaling O
in O
cardiovascular O
injury O
and O
inflammation O
. O
Novel O
progestins O
, O
such O
as O
drospirenone O
, O
confer O
superior O
effects O
compared O
with O
medroxyprogesterone O
acetate O
in O
a O
model O
of O
aldosterone-induced O
heart O
disease O
because O
of O
its O
antimineralocorticoid O
properties O
. O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
apoptosis O
in O
association O
with O
activation O
of O
peroxisome O
proliferator-activated O
receptor O
gamma O
in O
rheumatoid O
synovial O
cells.Nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
have O
been O
reported O
to O
induce O
apoptosis O
in O
a O
variety O
of O
cell O
lines O
. O
In O
this O
study O
, O
we O
examined O
the O
effect O
of O
NSAIDs O
on O
the O
growth O
and O
apoptosis O
of O
synovial O
cells O
from O
patients O
with O
rheumatoid O
arthritis O
and O
analyzed O
the O
activation O
of O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O
as O
a O
possible O
mechanism O
of O
action O
of O
NSAIDs O
. O
Cell O
proliferation O
and O
viability O
were O
assessed O
from O
5-bromo-2'-deoxyuridine O
incorporation O
and O
by O
4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene O
disulfonate O
(WST-1) O
assay O
, O
respectively O
. O
The O
apoptosis O
of O
synovial O
cells O
was O
identified O
by O
DNA O
fragmentation O
assay O
and O
terminal O
deoxynucleotidyl O
transferase-mediated O
dUTP O
nick-end O
labeling O
assay O
. O
Indometacin O
, O
diclofenac O
, O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O
selective O
cyclooxygenase-2 B
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O
apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O
, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O
of O
NSAIDs O
and O
PPARgamma O
ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma O
correlated O
with O
their O
ability O
to O
decrease O
cell O
viability(r O
= O
0.92 O
, O
p O
< O
0.01) O
and O
ability O
to O
induce O
DNA O
fragmentation O
(r O
= O
0.97 O
, O
p O
< O
0.001) O
in O
synovial O
cells O
. O
These O
results O
suggest O
that O
PPARgamma O
is O
an O
attractive O
target O
for O
induction O
of O
apoptosis O
in O
rheumatoid O
synovial O
cells O
and O
that O
the O
activation O
of O
the O
PPARgamma O
pathway O
is O
associated O
with O
the O
apoptotic O
action O
of O
NSAIDs O
. O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human B
carboxylesterases I
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

chalcone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol B
acyltransferase I
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT O
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A B
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

Benzodiazepines O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) B
receptors I
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
p38 O
Mitogen O
Activated O
Protein O
Kinase O
Regulates O
the O
Nuclear O
Receptor O
CAR O
to O
Activate O
the O
CYP2B6 O
Gene.The O
constitutive O
active/androstane O
receptor O
(CAR) O
regulates O
hepatic O
drug O
metabolism O
by O
activating O
genes O
such O
as O
cytochrome O
P450 O
(CYP) O
and O
certain O
transferases O
. O
p38 O
mitogen O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK B
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O
understood O
by O
ligand O
binding O
alone O
because O
the O
specificity O
and O
magnitude O
of O
induction O
are O
co-determined O
by O
a O
given O
cell O
signaling O
such O
as O
p38 O
MAPK; O
both O
physiological O
and O
pathophysiological O
states O
of O
cell O
signaling O
may O
have O
a O
strong O
impact O
in O
hepatic O
drug O
metabolizing O
capability O
during O
therapeutic O
treatments O
. O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
In O
vivo O
genotoxicity O
of O
methyleugenol O
in O
gpt O
delta O
transgenic O
rats O
following O
medium-term O
exposure.Methyleugenol O
(MEG) O
, O
which O
is O
commonly O
used O
as O
a O
fragrance O
and O
flavoring O
agent O
, O
has O
been O
shown O
to O
induce O
hepatocellular O
tumors O
in O
rodents O
. O
However O
, O
the O
role O
of O
genotoxicity O
as O
a O
possible O
mechanism O
of O
action O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O
metabolite O
of O
MEG O
has O
been O
identified O
. O
In O
this O
study O
, O
a O
gpt O
delta O
transgenic O
rat O
model O
was O
used O
to O
clarify O
whether O
genotoxic O
mechanisms O
are O
involved O
in O
MEG-induced O
hepatocarcinogenesis O
following O
medium-term O
exposure O
. O
F344 O
gpt O
delta O
rats O
were O
subjected O
to O
repeated O
oral O
administration O
of O
MEG O
at O
dosages O
of O
0 O
, O
10 O
, O
30 O
, O
or O
100mg/kg O
(a O
carcinogenic O
dose) O
for O
13 O
weeks O
. O
The O
relative O
weight O
of O
the O
liver O
of O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
and O
the O
absolute O
weight O
of O
the O
liver O
of O
the O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
(GST-P) O
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
( O
PCNA) B
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA B
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

threonine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Xanthurenic O
aciduria O
due O
to O
a O
mutation O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase O
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase B
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine-to-alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

amitriptyline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA B
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

Epinastine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic B
receptors I
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

dexamethasone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

MDA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
MDA O
and O
MDMA O
on O
phosphatidyl O
inositol O
turnover O
in O
cultured O
cells O
expressing O
5-HT2A O
or O
5-HT2C O
receptors.The O
effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
3,4-methylenedioxyamphetamine O
(MDA) O
and O
its O
N-methyl O
analog O
3,4-methylenedioxymethamphetamine O
(MDMA) O
on O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A O
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C B
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

ATP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuroprotective O
role O
of O
ATP-sensitive O
potassium O
channels O
in O
cerebral O
ischemia.ATP-sensitive O
potassium O
(K(ATP)) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O
An O
increase O
in O
the O
ADP/ATP O
ratio O
opens O
K(ATP) B
channels I
, O
leading O
to O
membrane O
hyperpolarization O
. O
K(ATP) O
channels O
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O
hippocampus O
and O
cortex O
. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons O
. O
In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6.2 O
subunit O
of O
the O
K(ATP) O
channels O
increases O
ischemic O
infarction O
, O
and O
overexpression O
of O
the O
Kir6.2 O
subunit O
reduces O
neuronal O
injury O
from O
ischemic O
insults O
. O
These O
findings O
provide O
the O
basis O
for O
a O
practical O
strategy O
whereby O
activation O
of O
endogenous O
K(ATP) O
channels O
reduces O
cellular O
damage O
resulting O
from O
cerebral O
ischemic O
stroke O
. O
K(ATP) O
channel O
modulators O
may O
prove O
to O
be O
clinically O
useful O
as O
part O
of O
a O
combination O
therapy O
for O
stroke O
management O
in O
the O
future O
. O

[-]-Huperzine O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
combination O
of O
[+] O
and O
[-]-Huperzine O
A O
improves O
protection O
against O
soman O
toxicity O
compared O
to O
[+]-Huperzine O
A O
in O
guinea O
pigs.The O
neuropathologic O
mechanisms O
after O
exposure O
to O
lethal O
doses O
of O
nerve O
agent O
are O
complex O
and O
involve O
multiple O
biochemical O
pathways O
. O
Effective O
treatment O
requires O
drugs O
that O
can O
simultaneously O
protect O
by O
reversible O
binding O
to O
the O
acetylcholinesterase O
(AChE) O
and O
blocking O
cascades O
of O
seizure O
related O
brain O
damage O
, O
inflammation O
, O
neuronal O
degeneration O
as O
well O
as O
promoting O
induction O
of O
neuroregeneration O
. O
[-]-Huperzine O
A O
([-]-Hup O
A) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE B
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier O
. O
It O
also O
has O
several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid O
peptide O
, O
reduction O
of O
oxidative O
stress O
, O
anti-inflammatory O
, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve O
growth O
factor O
. O
Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[-]-Hup O
A O
for O
treatment O
. O
The O
synthetic O
stereoisomer O
, O
[+]-Hup O
A O
, O
is O
less O
toxic O
due O
to O
poor O
AChE O
inhibition O
and O
is O
suitable O
for O
both O
pre-/post-exposure O
treatments O
of O
nerve O
agent O
toxicity O
. O
[+]-Hup O
A O
block O
the O
N-methyl-d-aspartate O
(NMDA)-induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino O
acid O
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O
Unique O
combinations O
of O
two O
stereo-isomers O
of O
Hup O
A O
may O
provide O
an O
excellent O
pre/post-treatment O
drug O
for O
the O
nerve O
agent O
induced O
seizure/status O
epilepticus O
. O
We O
investigated O
a O
combination O
of O
[+]-Hup O
A O
with O
a O
small O
dose O
of O
[-]-Hup O
A O
([+] O
and O
[-]-Hup O
A) O
against O
soman O
toxicity O
. O
Our O
data O
showed O
that O
pretreatment O
with O
a O
combination O
[+] O
and O
[-]-Hup O
A O
significantly O
increased O
the O
survival O
rate O
and O
reduced O
behavioral O
abnormalities O
after O
exposure O
to O
1.2×LD50 O
soman O
compared O
to O
[+]-Hup O
A O
in O
guinea O
pigs O
. O
In O
addition O
, O
[+] O
and O
[-]-Hup O
A O
pretreatment O
inhibited O
the O
development O
of O
high O
power O
of O
EEG O
better O
than O
[+]-Hup O
A O
pretreatment O
alone O
. O
These O
data O
suggest O
that O
a O
combination O
of O
[+] O
and O
[-]-Hup O
A O
offers O
better O
protection O
than O
[+]-Hup O
A O
and O
serves O
as O
a O
potent O
medical O
countermeasure O
against O
lethal O
dose O
nerve O
agent O
toxicity O
in O
guinea O
pigs O
. O

sodium O
salicylate O
acts O
as O
NOT O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O
trilisate) O
pre-treatment O
on O
ASA-induced O
adverse O
reactions O
in O
nine O
patients O
. O
Pulmonary O
function O
tests O
, O
nasal O
symptoms O
score O
, O
PNIF O
and O
serum O
salicylate O
levels O
were O
monitored O
following O
challenges O
with O
threshold O
doses O
of O
ASA O
. O
Trilisate O
administered O
at O
a O
dose O
of O
3000 O
mg O
daily O
for O
3 O
days O
, O
offered O
a O
moderate O
protection O
against O
ASA-induced O
symptoms; O
it O
diminished O
the O
severity O
and/or O
delayed O
the O
appearance O
of O
FEV1 O
fall O
. O
Maximal O
decreases O
in O
FEV1 O
as O
well O
as O
reaction O
intensity O
indexes O
were O
significantly O
lower O
(P O
less O
than O
0.02 O
and O
P O
less O
than O
0.002 O
, O
respectively) O
after O
trilisate O
pre-treatment O
as O
compared O
to O
placebo O
. O
Trilisate O
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients O
. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate O
is O
unknown O
, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate O
and O
ASA O
on O
cyclo-oxygenase O
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant O
patients O
. O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O
apoptosis O
via O
the O
PPARdelta/14-3-3epsilon O
transcriptional O
pathway O
. O
These O
results O
suggest O
that O
14-3-3epsilon O
is O
a O
target O
for O
the O
prevention O
and O
therapy O
of O
colorectal O
cancer O
. O

Tomudex O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Cyclin O
E-cdk2 O
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate O
synthase O
inhibitor O
Tomudex.Tomudex O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O
p53 O
and O
p21(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 O
protein O
expression O
and O
kinase O
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O
cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O
Cyclin O
D1 O
, O
cyclin O
B O
, O
cdk4 O
, O
and O
cdc2 O
protein O
expression O
and O
kinase O
activities O
remain O
constant O
. O
Lack O
of O
activation O
of O
cyclin O
A- O
and O
B-cdc2 O
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases O
. O
Increased O
cyclin O
E-cdk2 O
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days O
. O
Tomudex O
treatment O
resulted O
in O
a O
time-dependent O
induction O
of O
the O
megabase O
DNA O
fragments O
, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation O
. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase B
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex O
are O
not O
p53 O
dependent O
. O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces B
cerevisiae I
β-carbonic I
anhydrase I
.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O
and O
of O
6.46-13.52 O
for O
inhibiting O
ScCA O
over O
hCA O
II O
. O
The O
model O
organism O
S O
. O
cerevisiae O
and O
this O
particular O
enzyme O
may O
be O
useful O
for O
detecting O
antifungals O
with O
a O
novel O
mechanism O
of O
action O
compared O
to O
the O
classical O
azole O
drugs O
to O
which O
significant O
drug O
resistance O
emerged O
. O
Indeed O
, O
some O
of O
these O
sulfonamides O
inhibited O
the O
growth O
of O
the O
yeast O
with O
CC50-s O
in O
the O
range O
of O
0.73-6.54μM O
. O

troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 B
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

GW572016 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Truncated O
ErbB2 O
receptor O
(p95ErbB2) O
is O
regulated O
by O
heregulin O
through O
heterodimer O
formation O
with O
ErbB3 O
yet O
remains O
sensitive O
to O
the O
dual O
EGFR/ErbB2 O
kinase O
inhibitor O
GW572016.The O
expression O
of O
the O
NH2 O
terminally O
truncated O
ErbB2 O
receptor O
(p95ErbB2) O
in O
breast O
cancer O
correlates O
with O
metastatic O
disease O
progression O
compared O
with O
the O
expression O
of O
full-length O
p185ErbB2 O
. O
We O
now O
show O
that O
heregulin O
(HRG) O
, O
but O
not O
EGF O
, O
stimulates O
p95ErbB2 O
phosphorylation O
in O
BT474 O
breast O
cancer O
cells O
. O
Furthermore O
, O
phospho-p95ErbB2 O
forms O
heterodimers O
with O
ErbB3 O
, O
but O
not O
EGFR O
, O
while O
p185ErbB2 O
heterodimerizes O
with O
both O
EGFR O
and O
ErbB3 O
. O
The O
predilection O
of O
p95ErbB2 O
to O
heterodimerize O
with O
ErbB3 O
provides O
an O
explanation O
for O
its O
regulation O
by O
HRG O
, O
an O
ErbB3 O
ligand O
. O
GW572016 O
, O
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR O
and O
ErbB2 O
tyrosine O
kinases O
, O
inhibits O
baseline O
p95ErbB2 O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O
GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
and O
cyclin O
D O
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O
in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
or O
cyclin O
D O
. O
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O
by O
the O
selection O
of O
p95ErbB2-expressing O
breast O
cancer O
cells O
capable O
of O
exerting O
potent O
growth O
and O
prosurvival O
signals O
through O
p95ErbB2-ErbB3 O
heterodimers O
. O
Thus O
, O
p95ErbB2 B
represents O
a O
target O
for O
therapeutic O
intervention O
, O
and O
one O
that O
is O
sensitive O
to O
GW572016 O
therapy O
. O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin B
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

PGE2 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type B
Ca2+ I
channels I
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 B
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
( O
FDX1; B
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O
bind O
to O
the O
FDX1 O
promoter O
in O
differentiated O
hMSCs O
. O
Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 O
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O
ovarian O
granulosa O
cells O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
A O
genetically O
encoded O
and O
gate O
for O
cell-targeted O
metabolic O
labeling O
of O
proteins.We O
describe O
a O
genetic O
AND O
gate O
for O
cell-targeted O
metabolic O
labeling O
and O
proteomic O
analysis O
in O
complex O
cellular O
systems O
. O
The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA O
synthetase O
(MetRS) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine O
(Anl) O
to O
tRNA(Met) O
. O
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N- O
and O
C-terminal O
fragments O
of O
the O
bisected O
MetRS O
. O
Anl-labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed O
or O
strain-promoted O
azide-alkyne O
cycloaddition O
. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl O
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated O
. O
This O
method O
allows O
spatial O
and O
temporal O
control O
of O
proteomic O
labeling O
and O
identification O
of O
proteins O
made O
in O
specific O
cellular O
subpopulations O
. O
The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar-flow O
microfluidic O
channel O
, O
where O
they O
are O
exposed O
to O
overlapping O
, O
opposed O
gradients O
of O
inducers O
of O
the O
N- O
and O
C-terminal O
MetRS B
fragments O
. O
The O
observed O
labeling O
profile O
is O
predicted O
accurately O
from O
the O
strengths O
of O
the O
individual O
input O
signals O
. O

dopamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 B
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

amiloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
inhibition O
of O
urokinase-type O
plasminogen O
activator O
(u-PA) O
by O
amiloride O
in O
the O
cornea O
and O
tear O
fluid O
of O
eyes O
irradiated O
with O
UVB.The O
purpose O
of O
the O
present O
study O
was O
to O
test O
our O
hypothesis O
that O
amiloride O
, O
a O
specific O
u-PA O
inhibitor O
, O
effectively O
decreases O
u-PA O
activity O
in O
cornea O
as O
well O
as O
in O
tear O
fluid O
and O
favourably O
affects O
corneal O
healing O
. O
Therefore O
, O
comparative O
histochemical O
and O
biochemical O
studies O
of O
u-PA O
and O
the O
effects O
of O
amiloride O
were O
performed O
on O
rabbit O
corneas O
and O
tear O
fluid O
using O
the O
sensitive O
fluorogenic O
substrate O
Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin O
. O
Rabbit O
eyes O
were O
repeatedly O
irradiated O
with O
UVB O
for O
9 O
days O
and O
during O
the O
irradiation O
topically O
treated O
with O
amiloride O
(1 O
mg/ml O
saline) O
or O
placebo O
(saline) O
(dropwise O
, O
5 O
times O
daily) O
. O
Results O
show O
that O
in O
placebo-treated O
eyes O
, O
UVB O
evoked O
the O
appearance O
of O
u-PA O
activity O
in O
cornea O
and O
tear O
fluid O
in O
early O
stages O
of O
irradiation O
, O
and O
u-PA O
levels O
increased O
during O
irradiation O
. O
Corneal O
epithelium O
was O
gradually O
lost O
and O
remnants O
of O
the O
epithelium O
as O
well O
as O
keratocytes O
in O
the O
upper O
part O
of O
corneal O
stroma O
showed O
high O
u-PA O
activity O
. O
Finally O
, O
corneas O
lost O
their O
epithelium O
completely O
. O
In O
corneal O
stroma O
, O
numerous O
u-PA-containing O
inflammatory O
cells O
were O
present O
. O
Corneas O
were O
vascularized O
. O
When O
amiloride O
was O
dropped O
on O
the O
eye O
surface O
on O
the O
first O
day O
of O
irradiation O
and O
subsequently O
daily O
until O
the O
end O
of O
the O
experiment O
, O
u-PA O
activity O
in O
both O
cornea O
and O
tear O
fluid O
was O
strongly O
inhibited O
. O
Corneas O
were O
covered O
with O
a O
continuous O
epithelium O
until O
the O
end O
of O
the O
experiment O
. O
The O
number O
of O
inflammatory O
cells O
was O
significantly O
decreased O
. O
Corneal O
vascularization O
was O
reduced O
by O
50% O
. O
In O
conclusion O
, O
early O
application O
of O
amiloride O
inhibited O
u-PA B
activity O
in O
UVB-irradiated O
corneas O
as O
well O
as O
in O
tear O
fluid O
and O
diminished O
the O
development O
of O
corneal O
pathology O
. O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
( O
Dkk1 B
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6- B
catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

Cu(I) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Biosynthesis O
, O
assembly O
and O
secretion O
of O
coagulation O
factor O
VIII.Factor O
VIII O
is O
a O
large O
complex O
glycoprotein O
that O
is O
deficient O
in O
hemophilia O
A O
. O
It O
has O
a O
domain O
organization O
consisting O
of O
A1-A2-B-A3-C1-C2 O
where O
the O
B O
domain O
is O
a O
heavily O
glycosylated O
region O
that O
is O
dispensable O
for O
procoagulant O
activity O
. O
Factor O
VIII O
expression O
is O
10-to O
20-fold O
lower O
than O
the O
homologous O
coagulation O
factor O
V O
. O
Factor O
VIII O
expression O
is O
limited O
due O
to O
a O
low O
level O
of O
steady-state O
messenger O
RNA O
in O
the O
cytoplasm O
and O
inefficient O
transport O
of O
the O
primary O
translation O
product O
from O
the O
endoplasmic O
reticulum O
to O
the O
Golgi O
apparatus O
. O
Within O
the O
secretory O
pathway O
, O
factor O
VIII O
is O
processed O
to O
a O
heterodimer O
of O
the O
heavy O
chain O
(domains O
A1-A2-B) O
in O
a O
metal O
ion O
association O
with O
the O
light O
chain O
(domains O
A3-C1-C2) O
. O
Upon O
secretion O
from O
the O
cell O
, O
von O
Willebrand O
factor O
binds O
the O
light O
chain O
of O
factor O
VIII O
and O
stabilizes O
the O
factor O
, O
preventing O
degradation O
. O
Protein O
folding O
within O
the O
mammalian O
secretory O
pathway O
is O
facilitated O
by O
molecular O
chaperones O
. O
Within O
the O
endoplasmic O
reticulum O
, O
factor O
VIII O
exhibits O
stable O
interaction O
with O
protein O
chaperones O
identified O
as O
the O
immunoglobulin-binding O
protein O
(BiP) O
, O
calnexin O
and O
calreticulin O
. O
BiP O
is O
a O
peptide-dependent O
ATPase O
that O
interacts O
with O
exposed O
hydrophobic O
surfaces O
on O
unfolded O
proteins O
or O
unassembled O
protein O
subunits O
. O
A O
potential O
BiP O
binding O
site O
within O
factor O
VIII O
has O
been O
identified O
. O
Mutation O
of O
a O
single O
amino O
acid O
residue O
in O
the O
potential O
BiP O
binding O
site O
increased O
the O
secretion O
efficiency O
of O
factor O
VIII O
by O
threefold O
. O
Interestingly O
, O
the O
proposed O
BiP O
binding O
site O
is O
adjacent O
to O
a O
type-1 O
copper O
binding O
site O
within O
the O
A1 O
domain O
that O
is O
required O
for O
interaction O
between O
the O
factor O
VIII O
A1 O
domain O
and O
the O
A3 O
domain O
. O
We O
propose O
that O
Cu(I) O
binds O
the O
type-1 O
copper O
ion-binding O
site O
in O
the O
A1 B
domain I
and O
provides O
the O
essential O
requirement O
for O
a O
stable O
interaction O
between O
the O
heavy O
and O
light O
chains O
. O
Calnexin O
and O
calreticulin O
are O
transmembrane O
and O
lumenal O
proteins O
, O
respectively O
, O
localized O
to O
the O
endoplasmic O
reticulum O
, O
which O
associate O
transiently O
with O
many O
soluble O
and O
membrane O
glycoproteins O
during O
folding O
and O
subunit O
assembly O
. O
The O
calnexin O
and O
calreticulin O
interaction O
with O
factor O
VIII O
occurs O
primarily O
through O
amino-terminal O
linked O
oligosaccharides O
within O
the O
heavily O
glycosylated O
factor O
VIII O
B O
domain O
and O
this O
interaction O
appears O
to O
be O
required O
for O
factor O
VIII O
secretion O
. O
The O
findings O
suggest O
that O
factor O
VIII O
cycles O
through O
interactions O
with O
BiP O
, O
calnexin O
and O
calreticulin O
. O
Although O
the O
interaction O
with O
BiP O
does O
not O
appear O
to O
be O
required O
for O
factor O
VIII O
secretion O
, O
data O
suggest O
that O
the O
calnexin O
and/or O
calreticulin O
interaction O
is O
required O
for O
secretion O
. O
The O
observations O
suggest O
a O
unique O
requirement O
for O
carbohydrate O
processing O
and O
calnexin/calreticulin O
interaction O
that O
may O
limit O
the O
productive O
secretion O
of O
factor O
VIII O
and O
have O
implications O
for O
approaches O
towards O
somatic O
cell O
gene O
therapy O
for O
hemophilia O
A O
. O

3,4-methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
( O
VMAT2) B
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 O
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

H(2)O(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
a O
heme O
binding O
protein O
from O
the O
genome O
of O
Saccharomyces O
cerevisiae.The O
YLR205c O
gene O
of O
Saccharomyces O
cerevisiae O
does O
not O
show O
significant O
sequence O
identity O
to O
any O
known O
gene O
, O
except O
for O
heme O
oxygenase O
(22% O
to O
human O
HO-1) O
. O
The O
YLR205 O
ORF O
was O
cloned O
and O
overexpressed O
in O
both O
Escherichia O
coli O
and O
S O
. O
cerevisiae O
. O
Both O
expression O
systems O
yielded O
proteins O
that O
bound O
heme O
tightly O
. O
The O
isolated O
YLR205c O
protein O
underwent O
reduction O
in O
the O
presence O
of O
either O
NADPH-cytochrome O
P450 O
reductase O
or O
NADH-putidaredoxin-putidaredoxin O
reductase O
but O
did O
not O
exhibit O
heme O
oxygenase O
activity O
. O
The O
protein O
exhibited O
modest O
H(2)O(2)-dependent O
peroxidase B
activities O
with O
guaiacol O
, O
potassium O
iodide O
, O
and O
2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic O
acid O
(ABTS) O
. O
Thus O
, O
YLR205c O
codes O
for O
a O
hemoprotein O
of O
unknown O
physiological O
function O
that O
exhibits O
peroxidase O
activity O
. O

Co2+ O
Cbl O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Co-C O
bond O
activation O
in O
methylmalonyl-CoA O
mutase O
by O
stabilization O
of O
the O
post-homolysis O
product O
Co2+ O
cobalamin.Despite O
decades O
of O
research O
, O
the O
mechanism O
by O
which O
coenzyme O
B12 O
(adenosylcobalamin O
, O
AdoCbl)-dependent O
enzymes O
promote O
homolytic O
cleavage O
of O
the O
cofactor's O
Co-C O
bond O
to O
initiate O
catalysis O
has O
continued O
to O
elude O
researchers O
. O
In O
this O
work O
, O
we O
utilized O
magnetic O
circular O
dichroism O
spectroscopy O
to O
explore O
how O
the O
electronic O
structure O
of O
the O
reduced O
B12 O
cofactor O
(i.e. O
, O
the O
post-homolysis O
product O
Co2+ O
Cbl) O
is O
modulated O
by O
the O
enzyme O
methylmalonyl-CoA B
mutase I
. O
Our O
data O
reveal O
a O
fairly O
uniform O
stabilization O
of O
the O
Co O
3d O
orbitals O
relative O
to O
the O
corrin O
pi/pi*-based O
molecular O
orbitals O
when O
Co2+ O
Cbl O
is O
bound O
to O
the O
enzyme O
active O
site O
, O
particularly O
in O
the O
presence O
of O
substrate O
. O
Contrastingly O
, O
our O
previous O
studies O
(Brooks O
, O
A O
. O
J.; O
Vlasie O
, O
M.; O
Banerjee O
, O
R.; O
Brunold O
, O
T O
. O
C O
. O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
2004 O
, O
126 O
, O
8167-8180.) O
showed O
that O
when O
AdoCbl O
is O
bound O
to O
the O
MMCM O
active O
site O
, O
no O
enzymatic O
perturbation O
of O
the O
Co3+ O
Cbl O
electronic O
structure O
occurs O
, O
even O
in O
the O
presence O
of O
substrate O
(analogues) O
. O
Collectively O
, O
these O
observations O
provide O
direct O
evidence O
that O
enzymatic O
Co-C O
bond O
activation O
involves O
stabilization O
of O
the O
post-homolysis O
product O
, O
Co2+ O
Cbl O
, O
rather O
than O
destabilization O
of O
the O
Co3+ O
Cbl O
"ground" O
state O
. O

cefadroxil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanisms O
of O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
: O
studies O
in O
wild-type O
and O
PEPT2 B
knockout O
mice.The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil O
was O
studied O
in O
peptide O
transporter O
2 O
(PEPT2) O
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature O
, O
transport O
inhibitors O
, O
pH O
, O
and O
saturability O
. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C) O
, O
the O
uptake O
of O
1 O
microM O
cefadroxil O
was O
reduced O
by O
83% O
in O
PEPT2(-/-) O
mice O
as O
compared O
with O
PEPT2(+/+) O
mice O
(p O
< O
0.001) O
. O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C O
, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil O
or O
p-aminohippurate O
(p O
< O
0.05) O
. O
Glycylsarcosine O
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil O
in O
PEPT2(+/+) O
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) O
mice O
. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil O
was O
demonstrated O
in O
PEPT2(+/+) O
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01) O
, O
no O
pH O
dependence O
was O
observed O
in O
PEPT2(-/-) O
mice O
. O
Kinetic O
parameters O
for O
cefadroxil O
(without O
p-aminohippurate) O
in O
wild-type O
mice O
were O
: O
V(max) O
= O
5.4 O
pmol/mg/min O
, O
K(m) O
= O
34 O
microM O
, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
the O
parameters O
were O
: O
V(max) O
= O
4.1 O
pmol/mg/min O
, O
K(m) O
= O
27 O
microM O
, O
and O
K(d) O
= O
0.0064 O
microl/mg/min O
. O
In O
null O
animals O
, O
the O
kinetic O
parameters O
of O
cefadroxil O
(without O
p-aminohippurate) O
were O
: O
V(max) O
= O
2.7 O
pmol/mg/min O
, O
K(m) O
= O
110 O
microM O
, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed O
. O
Based O
on O
kinetic O
and O
inhibitor O
analyses O
, O
it O
was O
determined O
that O
(under O
linear O
conditions) O
, O
80 O
to O
85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2 O
, O
10 O
to O
15% O
by O
organic O
anion O
transporter(s) O
, O
and O
5% O
by O
nonspecific O
mechanisms O
. O
These O
findings O
demonstrate O
that O
PEPT2 O
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
. O
Moreover O
, O
the O
data O
suggest O
a O
role O
for O
PEPT2 O
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid O
. O

malvidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)- O
CYP1A1 B
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
the O
JAK/ERK/STAT O
signaling O
in O
melanocortin-induced O
inhibition O
of O
local O
and O
systemic O
responses O
to O
myocardial O
ischemia/reperfusion.The O
janus O
kinases O
(JAK) O
, O
extracellular O
signal-regulated O
kinases O
(ERK) O
and O
signal O
transducers O
and O
activators O
of O
transcription O
(STAT) O
pathways O
have O
been O
shown O
to O
play O
a O
cardioprotective O
role O
. O
We O
previously O
gave O
evidence O
that O
melanocortins O
afford O
cardioprotection O
in O
conditions O
of O
myocardial O
ischemia/reperfusion O
. O
Here O
we O
aimed O
to O
investigate O
the O
influence O
of O
melanocortins O
on O
the O
JAK/ERK/STAT O
signaling O
in O
cardiac O
and O
systemic O
responses O
to O
prolonged O
myocardial O
ischemia/reperfusion O
. O
Ischemia O
was O
produced O
in O
rats O
by O
ligature O
of O
the O
left O
anterior O
descending O
coronary O
artery O
for O
30min O
. O
At O
the O
end O
of O
the O
2-h O
reperfusion O
, O
western O
blot O
analysis O
of O
the O
cardioprotective O
transcription O
factors O
pJAK2 O
, O
pERK1/2 O
, O
pTyr-STAT3 O
and O
pSer-STAT3 O
, O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK B
and O
ERK O
pathways O
with O
AG490 O
and O
U0126 O
, O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O
(STAT O
unrelated) O
signaling O
pathway O
. O

sulprostone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase B
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA B
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

choline O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats O
. O
Choline B
dehydrogenase I
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

NEM O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Functional O
and O
molecular O
characterization O
of O
multiple O
K-Cl O
cotransporter O
isoforms O
in O
corneal O
epithelial O
cells.The O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC O
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC B
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O
a O
hypotonic O
challenge O
, O
KCC1 O
membrane O
content O
increased O
more O
rapidly O
in O
HCEC O
than O
in O
RCEC O
. O
Such O
a O
challenge O
induced O
a O
larger O
increase O
and O
more O
transient O
p44/42MAPK O
activation O
in O
HCEC O
than O
RCEC O
. O
On O
the O
other O
hand O
, O
HCEC O
and O
RCEC O
p38MAPK O
phosphorylation O
reached O
peak O
activations O
at O
2.5 O
and O
15 O
min O
, O
respectively O
. O
Only O
in O
HCEC O
, O
pharmacological O
manipulation O
of O
KCC O
activity O
modified O
the O
hypotonicity-induced O
activation O
of O
p44/42MAPK O
, O
whereas O
p38MAPK O
phosphorylation O
was O
insensitive O
to O
such O
procedures O
in O
both O
cell O
lines O
. O
Larger O
increases O
in O
HCEC O
KCC1 O
membrane O
protein O
content O
correlated O
with O
their O
ability O
to O
undergo O
faster O
and O
more O
complete O
RVD O
. O
Furthermore O
, O
pharmacological O
activation O
of O
KCC O
increased O
p44/42MAPK O
phosphorylation O
in O
HCEC O
but O
not O
in O
RCEC O
, O
presumably O
a O
reflection O
of O
low O
KCC1 O
membrane O
expression O
in O
RCEC O
. O
These O
findings O
suggest O
that O
KCC1 O
plays O
a O
role O
in O
(i) O
maintaining O
isotonic O
steady-state O
cell O
volume O
homeostasis O
, O
(ii) O
recovery O
of O
isotonic O
cell O
volume O
after O
a O
hypotonic O
challenge O
through O
RVD O
, O
and O
(iii) O
regulating O
hypotonicity-induced O
activation O
of O
the O
p44/42MAPK O
signaling O
pathway O
required O
for O
cell O
proliferation O
. O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data O
. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 O
and O
CYP3A4 O
, O
respectively O
. O
The O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1 B
/ O
*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 O
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme-ketamine O
binding O
and O
catalytic O
activity O
. O

salbutamol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
in O
man.The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
, O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta B
2-adrenoceptor I
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O
2-adrenoceptor O
stimulation O
, O
and O
this O
response O
was O
totally O
abolished O
by O
pretreatment O
with O
N20 O
. O
Significant O
increases O
in O
systolic O
blood O
pressure O
and O
Doppler O
stroke O
distance O
occurred O
with O
BRL O
and O
SAL O
which O
were O
unaffected O
by O
pretreatment O
with O
B5 O
and O
completely O
blocked O
by O
N20 O
, O
in O
keeping O
with O
beta O
2-mediated O
effects O
. O
BRL O
and O
SAL O
produced O
significant O
chronotropic O
and O
minute O
distance O
responses O
which O
were O
unaffected O
by O
beta O
1-adrenoceptor O
blockade O
. O
However O
, O
whereas O
N20 O
blocked O
these O
responses O
to O
SAL O
, O
a O
small O
but O
significant O
response O
occurred O
with O
BRL O
in O
comparison O
with O
placebo O
despite O
complete O
blockade O
of O
co-existing O
beta O
2-mediated O
effects O
. O
Compared O
with O
PL O
, O
the O
mean O
responses O
to O
N20/BRL O
, O
and O
the O
95% O
confidence O
interval O
for O
the O
differences O
between O
the O
means O
were O
7.4 O
beats O
min-1 O
[3.2 O
to O
11.6] O
(P O
= O
0.002) O
for O
heart O
rate O
, O
and O
208.8 O
cm O
[38.3 O
to O
379.3] O
(P O
= O
0.02) O
for O
minute O
distance O
responses.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

AH O
23848 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O
E O
synthase-1 O
, O
and O
EP(1) O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) B
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O
treated O
with O
COX O
inhibitors O
. O
This O
study O
suggests O
that O
PGE(2) O
is O
important O
for O
MB O
growth O
and O
that O
therapies O
targeting O
the O
prostanoid O
metabolic O
pathway O
are O
potentially O
beneficial O
and O
should O
be O
tested O
in O
clinical O
settings O
for O
treatment O
of O
children O
with O
MB O
. O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
( O
GPx) B
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

AMPA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA B
receptors I
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

2 O
, O
4-dioxo-5-acetamido-6-phenylhexanoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Kinetic O
and O
stereochemical O
studies O
on O
novel O
inactivators O
of O
C-terminal O
amidation.C-terminal O
amidation O
, O
a O
required O
post-translational O
modification O
for O
the O
bioactivation O
of O
many O
neuropeptides O
, O
entails O
sequential O
enzymic O
action O
by O
peptidylglycine O
alpha-mono-oxygenase O
(PAM O
, O
EC O
1.14.17.3) O
and O
peptidylamidoglycolate O
lyase O
(PGL O
, O
EC O
4.3.2.5) O
. O
Here O
we O
introduce O
novel O
compounds O
in O
which O
an O
olefinic O
functionality O
is O
incorporated O
into O
peptide O
analogues O
as O
the O
most O
potent O
turnover-dependent O
inactivators O
of O
PAM O
. O
Kinetic O
parameters O
for O
PAM O
inactivation O
by O
4-oxo-5-acetamido-6-phenyl-hex-2-enoic O
acid O
and O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
were O
obtained O
by O
using O
both O
the O
conventional O
dilution O
assay O
method O
and O
the O
more O
complex O
progress O
curve O
method O
. O
The O
results O
obtained O
from O
the O
progress O
curve O
method O
establish O
that O
these O
compounds O
exhibit O
the O
kinetic O
characteristics O
of O
pure O
competitive O
inactivators O
(i.e O
. O
no O
ESI O
complex O
forms O
during O
inactivation) O
. O
On O
the O
basis O
of O
k(inact)/K(i) O
values O
, O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
almost O
two O
orders O
of O
magnitude O
more O
potent O
than O
benzoylacrylate O
, O
a O
chemically O
analogous O
olefinic O
inactivator O
that O
lacks O
the O
peptide O
moiety O
. O
Stereochemical O
studies O
established O
that O
PAM O
inactivation O
by O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
stereospecific O
with O
respect O
to O
the O
moiety O
at O
the O
P(2) O
position O
, O
which O
is O
consistent O
with O
previous O
results O
with O
substrates O
and O
reversible O
inhibitors O
. O
In O
contrast O
, O
2 O
, O
4-dioxo-5-acetamido-6-phenylhexanoic O
acid O
, O
which O
is O
a O
competitive O
inhibitor O
with O
respect O
to O
ascorbate O
, O
exhibits O
a O
low O
degree O
of O
stereospecificity O
in O
binding O
to O
the O
ascorbate O
sites O
of O
both O
PAM O
and O
dopamine-beta-hydroxylase B
. O

methionine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Methionine O
synthase O
reductase O
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine O
synthase O
reductase O
( O
MTRR) B
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
. O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR O
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O
Although O
we O
did O
not O
detect O
any O
significant O
associations O
between O
MTRR O
polymorphisms O
and O
BMD O
or O
serum O
osteocalcin O
levels O
, O
we O
found O
that O
the O
66G/524C O
haplotype O
, O
which O
has O
reduced O
enzyme O
activity O
, O
was O
significantly O
associated O
with O
serum O
osteocalcin O
levels O
in O
a O
gene-dose O
dependent O
manner O
(P O
= O
0.002) O
. O
That O
is O
, O
the O
highest O
osteocalcin O
levels O
(34.5 O
+/- O
16.8 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
two O
copies O
, O
intermediate O
osteocalcin O
levels O
(32.6 O
+/- O
14.4 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
one O
copy O
, O
and O
the O
lowest O
levels O
of O
osteocalcin O
(28.8 O
+/- O
10.9 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
no O
copies O
. O
These O
results O
suggest O
that O
the O
66G/524C O
haplotype O
of O
the O
MTRR O
gene O
affect O
bone O
turn O
over O
rate O
. O

Leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles O
. O
Leucyl-tRNA B
synthetase I
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast O
mitochondrial O
LeuRS O
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C-terminal O
domain O
. O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E B
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

5-(N,N-dimethyl)-amiloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 B
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atypical O
neuroleptics O
have O
low O
affinity O
for O
dopamine O
D2 O
receptors O
or O
are O
selective O
for O
D4 O
receptors.This O
review O
examines O
the O
possible O
receptor O
basis O
of O
the O
atypical O
action O
of O
those O
atypical O
antipsychotic O
drugs O
that O
elicit O
low O
levels O
of O
Parkinsonism O
. O
Such O
an O
examination O
requires O
consistent O
and O
accurate O
dissociation O
constants O
for O
the O
antipsychotic O
drugs O
at O
the O
relevant O
dopamine O
and O
serotonin O
receptors O
. O
It O
has O
long O
been O
known O
, O
however O
, O
that O
the O
dissociation O
constant O
of O
a O
given O
antipsychotic O
drug O
at O
the O
dopamine O
D2 O
receptor O
varies O
between O
laboratories O
. O
Although O
such O
variation O
depends O
on O
several O
factors O
, O
it O
has O
recently O
been O
recognized O
that O
the O
radioligand O
used O
to O
measure O
the O
competition O
between O
the O
antipsychotic O
drug O
and O
the O
radioligand O
is O
an O
important O
variable O
. O
The O
present O
review O
summarizes O
information O
on O
this O
radioligand O
dependence O
. O
In O
general O
, O
a O
radioligand O
of O
low O
solubility O
in O
the O
membrane O
(i.e. O
, O
low O
tissue:buffer O
partition) O
results O
in O
a O
low O
value O
for O
the O
antipsychotic O
dissociation O
constant O
when O
the O
drug O
competes O
with O
the O
radioligand O
. O
Hence O
, O
by O
first O
obtaining O
the O
antipsychotic O
dissociation O
constants O
using O
different O
radioligands O
of O
different O
solubility O
in O
the O
membrane O
, O
one O
can O
then O
extrapolate O
the O
data O
to O
low O
or O
"zero" O
ligand O
solubility O
. O
The O
extrapolated O
value O
represents O
the O
radioligand-independent O
dissociation O
constant O
of O
the O
antipsychotic O
. O
These O
values O
are O
here O
given O
for O
dopamine O
D2 O
and O
D4 O
receptors O
, O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine B
D4 I
receptor I
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 O
receptor O
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O
dopamine O
D2 O
receptors O
, O
making O
them O
more O
resistant O
to O
displacement O
by O
endogenous O
dopamine O
. O
Finally O
, O
a O
relation O
was O
found O
between O
the O
neuroleptic O
doses O
for O
rat O
catalepsy O
and O
the O
D2:D4 O
ratio O
of O
the O
radioligand-independent O
K O
values O
for O
these O
two O
receptors O
. O
Thus O
, O
the O
atypical O
neuroleptics O
appear O
to O
fall O
into O
two O
groups O
, O
those O
that O
have O
a O
low O
affinity O
for O
dopamine O
D2 O
receptors O
and O
those O
that O
are O
selective O
for O
dopamine O
D4 O
receptors O
. O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Low-Dose O
Dexamethasone O
Treatment O
Promotes O
Pro-Survival O
Signalling O
Pathway O
In O
Adult O
Rat O
Prefrontal O
Cortex.Synthetic O
glucocorticoid O
dexamethasone O
(DEX) O
, O
a O
highly O
potent O
anti-inflammatory O
and O
immunosuppressive O
agent O
, O
is O
widely O
used O
in O
treatments O
of O
brain O
cancer O
, O
inflammatory O
and O
autoimmune O
diseases O
. O
The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low-dose O
subchronic O
DEX O
treatment O
(100 O
μg/kg O
for O
8 O
consecutive O
days) O
exerts O
long-term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O
prefrontal O
cortex O
(PFC) O
by O
examining O
the O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 O
protein O
and O
enhanced O
Bcl-2 O
/ O
Bax B
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX-treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O
change O
apoptotic O
markers O
in O
rat O
PFC O
. O
This O
mechanism O
might O
be O
relevant O
for O
DEX-induced O
apoptosis O
resistance O
observed O
during O
and O
after O
chemotherapy O
of O
patients O
with O
brain O
tumours O
. O
© O
2013 O
British O
Society O
for O
Neuroendocrinology O
. O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin B
light I
chain I
kinase) I
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

GW4064 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
FXR-dependent O
and O
-independent O
interaction O
of O
glucocorticoids O
with O
the O
regulatory O
pathways O
involved O
in O
the O
control O
of O
bile O
acid O
handling O
by O
the O
liver.Treatment O
with O
glucocorticoids O
(GCs) O
may O
cause O
adverse O
effects O
, O
including O
cholestasis O
. O
The O
ability O
of O
dexamethasone O
, O
prednisolone O
and O
budesonide O
to O
affect O
the O
liver O
handling O
of O
bile O
acids O
(BAs) O
has O
been O
investigated O
. O
In O
rats O
treated O
with O
GCs O
for O
4 O
days O
, O
altered O
serum O
and O
bile O
BA O
levels O
, O
changed O
conjugation O
pattern O
, O
and O
delayed O
and O
decreased O
ability O
to O
conjugate/secrete O
exogenously O
administered O
deoxycholate O
, O
were O
found O
using O
HPLC-MS/MS O
. O
RT-QPCR O
analyses O
revealed O
that O
GC O
treatment O
also O
induced O
a O
down-regulation O
of O
liver O
nuclear O
receptors O
(Fxr O
, O
Gr O
and O
Shp) O
, O
transporters O
(Ntcp O
, O
Mrp4 O
and O
Bcrp) O
and O
enzymes O
(Cyp7a1 O
and O
Baat) O
, O
whereas O
Bsep O
, O
Mrp2 O
and O
Cyp27a1 O
were O
up-regulated O
. O
Human O
HepG2 O
and O
Alexander O
cell O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP B
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O
Moreover O
, O
GCs O
have O
a O
synergistic O
effect O
on O
GW4064-induced O
FXR O
activation O
, O
whereas O
chenodeoxycholate O
and O
GW4064 O
have O
an O
additive O
effect O
. O
In O
conclusion O
, O
GCs O
are O
able O
to O
directly O
or O
indirectly O
activate O
FXR O
but O
they O
also O
antagonize O
, O
through O
FXR-independent O
mechanisms O
, O
the O
expression O
of O
FXR O
and O
FXR O
target O
genes O
involved O
in O
the O
hepatic O
handling O
of O
BAs O
. O

Theophylline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Changes O
in O
submaxillary O
gland O
gene O
expression O
in O
F344 O
rats O
by O
multiple O
dosing O
of O
theophylline.Multiple O
exposure O
to O
theophylline O
, O
a O
phosphodiesterase O
(PDE) O
inhibitor O
, O
induces O
acinar O
hypertrophy O
in O
the O
salivary O
gland O
. O
This O
study O
examined O
the O
effect O
of O
theophylline O
on O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases O
in O
the O
submaxillary O
gland O
. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline O
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days O
. O
The O
gene O
expressions O
for O
the O
secretory O
protein O
, O
cystatin O
S O
(CysS) O
, O
and O
PDE O
subfamilies O
3A O
and O
4D O
in O
the O
submaxillary O
gland O
were O
quantified O
using O
RT-PCR O
. O
Theophylline O
exposure O
resulted O
in O
a O
sustained O
increase O
in O
mRNA O
expression O
for O
CysS O
and O
PDE3A B
, O
but O
PDE4D O
gene O
expression O
was O
unchanged O
. O
Our O
results O
suggest O
that O
submaxillary O
hypertrophy O
is O
primarily O
caused O
by O
the O
enhanced O
transcription O
of O
CysS O
, O
and O
that O
the O
transcription O
of O
each O
PDE O
subfamily O
gene O
is O
regulated O
differently O
. O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acetaminophen O
(paracetamol) O
is O
a O
selective O
cyclooxygenase-2 O
inhibitor O
in O
man.For O
more O
than O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) B
 O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 O
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O
gastrointestinal O
safety O
profile O
compared O
with O
NSAIDs O
. O
In O
view O
of O
its O
substantial O
COX-2 O
inhibition O
, O
recently O
defined O
cardiovascular O
warnings O
for O
use O
of O
COX-2 O
inhibitors O
should O
also O
be O
considered O
for O
acetaminophen O
. O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC B
4.2.1.1) I
 O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

phentolamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha B
1A I
and I
alpha I
1D I
adrenoceptors I
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O
and O
7.8 O
respectively) O
. O
The O
selective O
alpha O
1D O
antagonist O
BMY O
7378 O
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors O
. O
5 O
. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha O
1D-adrenoceptors O
(r O
= O
0.96) O
, O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O
1B O
(r O
= O
0.46) O
subtypes O
. O
6 O
. O
Noradrenaline-mediated O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

RAD001 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR B
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine O
kinase O
inhibitors O
sunitinib O
and/or O
sorafenib O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O
life O
, O
disease-related O
symptoms O
, O
and O
overall O
survival O
despite O
crossover O
of O
the O
majority O
of O
patients O
assigned O
to O
placebo O
. O
In O
2009 O
, O
everolimus O
was O
approved O
in O
the O
US O
and O
Europe O
as O
the O
only O
validated O
option O
for O
this O
indication O
. O
Toxicities O
are O
usually O
mild O
to O
moderate O
and O
can O
be O
managed O
with O
dose O
reduction O
or O
interruption O
if O
necessary O
. O
Opportunistic O
infections O
and O
non-infectious O
pneumonitis O
are O
seen O
as O
a O
class O
effect O
. O
Management O
of O
common O
practical O
management O
issues O
are O
discussed O
. O
Clinical O
trials O
are O
in O
progress O
to O
examine O
additional O
roles O
for O
everolimus O
in O
renal O
cancer O
, O
alone O
and O
in O
combination O
with O
other O
agents O
. O

Pro O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 B
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

erlotinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Emerging O
role O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
therapy O
for O
advanced O
malignancy O
: O
focus O
on O
NSCLC.Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer O
. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based O
therapy O
vs O
. O
best O
supportive O
care O
, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate O
. O
Just O
as O
importantly O
, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O
life O
. O
Newer O
agents O
, O
including O
the O
taxanes O
, O
vinorelbine O
, O
gemcitabine O
, O
and O
irinotecan O
, O
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer O
. O
Despite O
their O
contributions O
, O
we O
have O
reached O
a O
therapeutic O
plateau O
, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40% O
. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal B
growth I
factor I
receptor I
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O
Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O
persist O
. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular O
, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds O
. O
Both O
gefitinib O
and O
erlotinib O
have O
shown O
clinical O
activity O
in O
pretreated O
, O
advanced O
non-small-cell O
lung O
cancer O
, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib O
in O
combination O
with O
standard O
cytotoxic O
therapy O
, O
to O
our O
chagrin O
, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone O
. O

gemcitabine O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Common O
resistance O
mechanisms O
to O
deoxynucleoside O
analogues O
in O
variants O
of O
the O
human O
erythroleukaemic O
line O
K562.Resistant O
variants O
of O
the O
human O
leukaemic O
line O
K562 O
were O
developed O
using O
selection O
with O
the O
deoxynucleoside O
analogues O
cytosine O
arabinoside O
, O
2-chlorodeoxyadenosine O
, O
fludarabine O
and O
gemcitabine O
. O
The O
resistant O
lines O
displayed O
a O
high O
degree O
of O
cross O
resistance O
to O
all O
deoxynucleoside O
analogues O
, O
with O
little O
or O
no O
cross O
resistance O
to O
other O
agents O
. O
There O
was O
a O
profound O
accumulation O
defect O
of O
all O
nucleoside O
analogues O
in O
the O
resistant O
variants O
but O
no O
significant O
defect O
in O
nucleoside O
transport O
in O
any O
of O
the O
variants O
. O
5' O
nucleotidase O
activity O
was O
strongly O
increased O
and O
deoxycytidine O
kinase O
activity O
was O
moderately O
reduced O
in O
all O
of O
the O
resistant O
variants O
, O
resulting O
in O
reduced O
accumulation O
of O
triphosphate O
analogues O
. O
In O
addition O
a O
deletion O
in O
one O
of O
the O
alleles O
of O
the O
deoxycytidine O
kinase O
was O
detected O
in O
the O
fludarabine-resistant O
line O
. O
Ribonucleotide B
reductase I
activity O
was O
found O
to O
be O
strongly O
increased O
in O
the O
gemcitabine-selected O
line O
and O
purine O
nucleoside O
phosphorylase O
was O
increased O
in O
the O
2-chlorodeoxyadenosine-selected O
line O
. O
Free O
nucleotide O
pools O
were O
increased O
in O
the O
2-chlorodeoxyadenosine-selected O
line O
. O
There O
was O
no O
expression O
of O
the O
mdr1 O
gene O
by O
the O
resistant O
lines O
. O
Karyotypic O
analysis O
and O
FISH O
experiments O
using O
a O
6q21 O
specific O
probe O
showed O
alterations O
in O
the O
6(q16-q22) O
region O
which O
contains O
the O
5'-nucleotidase O
gene O
. O
Early O
events O
in O
the O
activation O
and O
degradation O
of O
deoxynucleoside O
analogues O
appear O
to O
constitute O
common O
mechanisms O
of O
resistance O
to O
these O
compounds O
. O

olanzapine O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
effects O
of O
adulthood O
olanzapine O
treatment O
on O
cognitive O
performance O
and O
neurotrophic O
factor O
content O
in O
male O
and O
female O
rats O
neonatally O
treated O
with O
quinpirole.Male O
and O
female O
Sprague-Dawley O
rats O
were O
administered O
quinpirole O
(1 O
mg/kg O
, O
i.p.) O
or O
saline O
once O
daily O
from O
postnatal O
day O
(P)1 O
to O
P21 O
. O
This O
drug O
treatment O
has O
been O
shown O
to O
produce O
long-term O
priming O
of O
the O
D2 O
receptor O
. O
Beginning O
on O
P62 O
, O
rats O
were O
administered O
the O
atypical O
antipsychotic O
olanzapine O
(2.5 O
mg/kg) O
or O
saline O
twice O
daily O
(i.p.) O
for O
28 O
days O
. O
One O
day O
after O
olanzapine O
treatment O
ceased O
, O
rats O
were O
tested O
on O
the O
place O
and O
match-to-place O
versions O
of O
the O
Morris O
water O
maze O
(MWM) O
for O
seven O
consecutive O
days O
. O
Dopamine O
D2 O
receptor O
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test O
, O
a O
D2 O
receptor-mediated O
event O
, O
before O
olanzapine O
was O
administered O
as O
well O
as O
after O
olanzapine O
treatment O
and O
behavioural O
testing O
were O
complete O
. O
Results O
showed O
that O
neonatal O
quinpirole O
treatment O
induced O
D2 O
priming O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
On O
the O
MWM O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF B
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

GSK2251052 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Disposition O
and O
Metabolism O
of O
GSK2251052 O
in O
Humans O
: O
A O
Novel O
Boron-Containing O
Antibiotic.(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole O
(GSK2251052) O
is O
a O
novel O
boron-containing O
antibiotic O
that O
inhibits O
bacterial B
leucyl I
tRNA I
synthetase I
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram-negative O
infections O
. O
In O
this O
study O
, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i.v O
. O
dose O
of O
[(14)C]GSK2251052 O
, O
1500 O
mg O
infused O
over O
1 O
hour O
. O
Blood O
, O
urine O
, O
and O
feces O
were O
collected O
over O
an O
extended O
period O
of O
14 O
days O
, O
and O
accelerator O
mass O
spectrometry O
was O
used O
to O
quantify O
low O
levels O
of O
radioactivity O
in O
plasma O
at O
later O
time O
points O
to O
supplement O
the O
less-sensitive O
liquid O
scintillation O
counting O
technique O
. O
An O
excellent O
mass O
balance O
recovery O
was O
achieved O
representing O
a O
mean O
total O
of O
98.2% O
of O
the O
dose O
, O
including O
90.5% O
recovered O
in O
the O
urine O
. O
Pharmacokinetic O
analysis O
demonstrated O
that O
radioactivity O
was O
moderately O
associated O
with O
the O
blood O
cellular O
components O
, O
and O
together O
with O
GSK2251052 O
, O
both O
were O
highly O
distributed O
into O
tissues O
. O
The O
parent O
compound O
had O
a O
much O
shorter O
half-life O
than O
total O
radioactivity O
in O
plasma O
, O
approximately O
11.6 O
hours O
compared O
with O
96 O
hours O
. O
GSK2251052 O
and O
its O
major O
metabolite O
M3 O
, O
which O
resulted O
from O
oxidation O
of O
the O
propanol O
side O
chain O
to O
the O
corresponding O
carboxylic O
acid O
, O
comprised O
the O
majority O
of O
the O
plasma O
radioactivity O
, O
37 O
and O
53% O
of O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity O
, O
respectively O
. O
Additionally O
, O
M3 O
was O
eliminated O
renally O
, O
and O
was O
demonstrated O
to O
be O
responsible O
for O
the O
long O
plasma O
radioactivity O
elimination O
half-life O
. O
A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4-methylpyrazole O
provided O
strong O
evidence O
that O
alcohol O
dehydrogenase O
, O
potentially O
in O
association O
with O
aldehyde O
dehydrogenase O
, O
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
p300-mediated O
acetylation O
of O
TRF2 O
is O
required O
for O
maintaining O
functional O
telomeres.The O
human O
telomeric O
protein O
TRF2 O
is O
required O
to O
protect O
chromosome O
ends O
by O
facilitating O
their O
organization O
into O
the O
protective O
capping O
structure O
. O
Post-translational O
modifications O
of O
TRF2 O
such O
as O
phosphorylation O
, O
ubiquitination O
, O
SUMOylation O
, O
methylation O
and O
poly(ADP-ribosyl)ation O
have O
been O
shown O
to O
play O
important O
roles O
in O
telomere O
function O
. O
Here O
we O
show O
that O
TRF2 O
specifically O
interacts O
with O
the O
histone O
acetyltransferase O
p300 O
, O
and O
that O
p300 O
acetylates O
the O
lysine O
residue O
at O
position O
293 O
of O
TRF2 B
. O
We O
also O
report O
that O
p300-mediated O
acetylation O
stabilizes O
the O
TRF2 O
protein O
by O
inhibiting O
its O
ubiquitin-dependent O
proteolysis O
and O
is O
required O
for O
efficient O
telomere O
binding O
of O
TRF2 O
. O
Furthermore O
, O
overexpression O
of O
the O
acetylation-deficient O
mutant O
, O
K293R O
, O
induces O
DNA-damage O
response O
foci O
at O
telomeres O
, O
thereby O
leading O
to O
induction O
of O
impaired O
cell O
growth O
, O
cellular O
senescence O
and O
altered O
cell O
cycle O
distribution O
. O
A O
small O
but O
significant O
number O
of O
metaphase O
chromosomes O
show O
no O
telomeric O
signals O
at O
chromatid O
ends O
, O
suggesting O
an O
aberrant O
telomere O
structure O
. O
These O
findings O
demonstrate O
that O
acetylation O
of O
TRF2 O
by O
p300 O
plays O
a O
crucial O
role O
in O
the O
maintenance O
of O
functional O
telomeres O
as O
well O
as O
in O
the O
regulation O
of O
the O
telomere-associated O
DNA-damage O
response O
, O
thus O
providing O
a O
new O
route O
for O
modulating O
telomere O
protection O
function O
. O

carbamazepine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Genetic O
predictors O
of O
the O
maximum O
doses O
patients O
receive O
during O
clinical O
use O
of O
the O
anti-epileptic O
drugs O
carbamazepine O
and O
phenytoin.Phenytoin O
and O
carbamazepine O
are O
effective O
and O
inexpensive O
anti-epileptic O
drugs O
(AEDs) O
. O
As O
with O
many O
AEDs O
, O
a O
broad O
range O
of O
doses O
is O
used O
, O
with O
the O
final O
"maintenance" O
dose O
normally O
determined O
by O
trial O
and O
error O
. O
Although O
many O
genes O
could O
influence O
response O
to O
these O
medicines O
, O
there O
are O
obvious O
candidates O
. O
Both O
drugs O
target O
the O
alpha-subunit O
of O
the O
sodium O
channel O
, O
encoded O
by O
the O
SCN O
family O
of O
genes O
. O
Phenytoin O
is O
principally O
metabolized O
by O
CYP2C9 O
, O
and O
both O
are O
probable O
substrates O
of O
the O
drug O
transporter O
P-glycoprotein O
. O
We O
therefore O
assessed O
whether O
variation O
in O
these O
genes O
associates O
with O
the O
clinical O
use O
of O
carbamazepine O
and O
phenytoin O
in O
cohorts O
of O
425 O
and O
281 O
patients O
, O
respectively O
. O
We O
report O
that O
a O
known O
functional O
polymorphism O
in O
CYP2C9 O
is O
highly O
associated O
with O
the O
maximum O
dose O
of O
phenytoin O
(P O
= O
0.0066) O
. O
We O
also O
show O
that O
an O
intronic O
polymorphism O
in O
the O
SCN1A B
gene O
shows O
significant O
association O
with O
maximum O
doses O
in O
regular O
usage O
of O
both O
carbamazepine O
and O
phenytoin O
(P O
= O
0.0051 O
and O
P O
= O
0.014 O
, O
respectively) O
. O
This O
polymorphism O
disrupts O
the O
consensus O
sequence O
of O
the O
5' O
splice O
donor O
site O
of O
a O
highly O
conserved O
alternative O
exon O
(5N) O
, O
and O
it O
significantly O
affects O
the O
proportions O
of O
the O
alternative O
transcripts O
in O
individuals O
with O
a O
history O
of O
epilepsy O
. O
These O
results O
provide O
evidence O
of O
a O
drug O
target O
polymorphism O
associated O
with O
the O
clinical O
use O
of O
AEDs O
and O
set O
the O
stage O
for O
a O
prospective O
evaluation O
of O
how O
pharmacogenetic O
diagnostics O
can O
be O
used O
to O
improve O
dosing O
decisions O
in O
the O
use O
of O
phenytoin O
and O
carbamazepine O
. O
Although O
the O
case O
made O
here O
is O
compelling O
, O
our O
results O
cannot O
be O
considered O
definitive O
or O
ready O
for O
clinical O
application O
until O
they O
are O
confirmed O
by O
independent O
replication O
. O

17864 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase B
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles O
. O
17864-L(x) O
loaded O
EGa1-PEG O
nanoparticles O
were O
internalized O
by O
clathrin-mediated O
endocytosis O
and O
ultimately O
digested O
in O
lysosomes O
. O
The O
intracellular O
routing O
of O
EGa1 O
targeted O
nanoparticles O
leads O
to O
a O
successful O
release O
of O
the O
kinase O
inhibitor O
in O
the O
cell O
and O
inhibition O
of O
proliferation O
whereas O
the O
non-targeted O
formulations O
had O
no O
antiproliferative O
effects O
on O
14C O
cells O
. O
The O
drug O
loaded O
targeted O
nanoparticles O
were O
as O
effective O
as O
the O
free O
drug O
in O
vitro O
. O
These O
results O
demonstrate O
that O
multikinase O
inhibitor O
loaded O
nanoparticles O
are O
interesting O
nanomedicines O
for O
the O
treatment O
of O
EGFR-positive O
cancers O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Influence O
of O
developmental O
lead O
exposure O
on O
expression O
of O
DNA O
methyltransferases O
and O
methyl O
cytosine-binding O
proteins O
in O
hippocampus.Developmental O
exposure O
to O
lead O
(Pb) O
has O
adverse O
effects O
on O
cognitive O
functioning O
and O
behavior O
that O
can O
persist O
into O
adulthood O
. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status O
. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl O
cytosine-binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O
Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb O
acetate O
(0 O
, O
150 O
, O
375 O
, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 B
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine B
oxidase-A I
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O
noradrenaline O
(NA) O
, O
3,4-dihydroxyphenylglycol O
(DHPG) O
, O
homovanillic O
acid O
(HVA) O
and O
5-hydroxyindolacetic O
acid O
(5-HIAA) O
. O
Urine O
was O
collected O
for O
measurements O
of O
normetanephrine O
and O
3-methoxytyramine O
excretion O
. O
Psychometric O
performance O
(short- O
and O
long-term O
memory O
, O
critical O
flicker O
fusion O
frequency O
, O
choice O
reaction O
time) O
and O
subjective O
feelings O
were O
assessed O
before O
each O
drug O
intake O
(in O
the O
morning O
, O
at O
noon O
, O
in O
the O
evening) O
. O
3 O
. O
Compared O
with O
placebo O
, O
both O
reversible O
monoamine O
oxidase O
inhibitors O
decreased O
the O
plasma O
concentration O
of O
DHPG O
and O
HVA O
. O
The O
overall O
fall O
in O
DHPG O
(AUC O
from O
0 O
to O
24 O
h) O
was O
44% O
during O
moclobemide O
and O
12% O
during O
toloxatone O
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A O
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
. O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O
and O
to O
a O
lesser O
extent O
on O
toloxatone O
. O
The O
urinary O
excretion O
of O
3-methoxytyramine O
was O
significantly O
raised O
by O
moclobemide O
but O
not O
by O
toloxatone O
. O
7 O
. O
Neither O
moclobemide O
nor O
toloxatone O
altered O
memory O
function O
, O
vigilance O
, O
subjective O
feelings O
or O
sleep O
characteristics O
of O
the O
subjects O
. O

[1,8]naphthyridines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase B
(AChE) O
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 B
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

Butein O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Butein O
protects O
human O
dental O
pulp O
cells O
from O
hydrogen O
peroxide-induced O
oxidative O
toxicity O
via O
Nrf2 O
pathway-dependent O
heme B
oxygenase-1 I
expressions.Rhus O
verniciflua O
Stokes O
is O
a O
plant O
that O
is O
native O
to O
East O
Asian O
countries O
, O
such O
as O
Korea O
, O
China O
, O
and O
Japan O
. O
Butein O
, O
a O
plant O
polyphenol O
, O
is O
one O
of O
the O
major O
active O
components O
of O
R O
. O
verniciflua O
. O
Reactive O
oxygen O
species O
(ROS) O
, O
produced O
via O
dental O
adhesive O
bleaching O
agents O
and O
pulpal O
disease O
, O
can O
cause O
oxidative O
stress O
. O
Here O
, O
we O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Gene O
expression O
signature O
of O
parathion-transformed O
human O
breast O
epithelial O
cells.Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers O
. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous O
pesticides O
. O
Parathion O
is O
a O
cholinesterase O
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline O
esters O
, O
including O
acetylcholine O
at O
cholinergic O
synapses O
. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O
acetylcholinesterase O
at O
the O
synaptic O
junction O
. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O
antidote O
to O
acetylcholinesterase O
inhibitors O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
parathion O
and O
atropine O
on O
cell O
transformation O
of O
human O
breast O
epithelial O
cells O
in O
vitro O
. O
These O
studies O
showed O
that O
parathion O
alone O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin B
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion-treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O
MCM2 O
and O
MCM3 O
. O
It O
is O
suggested O
that O
parathion O
influences O
human O
breast O
epithelial O
cell O
transformation O
and O
is O
an O
initiator O
factor O
in O
the O
transformation O
process O
in O
breast O
cancer O
. O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O
(K(p)) O
of O
dabrafenib O
after O
an O
i.v O
. O
dose O
(2.5 O
mg/kg) O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
, O
another O
BRAF( B
V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme B
oxygenase-1 I
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

UDP-Glc O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 B
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A B
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
monoamine O
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia O
. O

ANE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR B
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

Adenosine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Impaired O
function O
of O
prejunctional O
adenosine O
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt O
hypertensive O
rats.Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone O
acetate O
(DOCA)-salt O
hypertension O
in O
rats O
. O
ATP O
and O
norepinephrine O
(NE) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O
NE O
acts O
at O
prejunctional O
α2-adrenergic O
receptors O
(α2ARs) O
to O
inhibit O
NE O
release O
, O
and O
α2AR O
function O
is O
impaired O
in O
DOCA-salt O
rats O
. O
Adenosine O
, O
an O
enzymatic O
ATP O
degradation O
product O
, O
acts O
at O
prejunctional O
A1 B
adenosine I
receptors I
(A1Rs) O
to O
inhibit O
NE O
release O
. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt O
rats O
. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs O
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

putrescine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine B
decarboxylase I
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

N-propargyl-1R(+)-aminoindan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
( O
MAO) B
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O
MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS O
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O
doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis.Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2 O
, O
rofecoxib O
. O
We O
also O
assessed O
the O
antithrombotic O
effect O
of O
licofelone O
in O
rabbit O
platelet-rich O
plasma O
. O
For O
this O
purpose O
, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX B
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

benzyl O
alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Mechanism O
of O
the O
haemostatic O
effect O
of O
ethanolamine O
oleate O
in O
the O
injection O
sclerotherapy O
for O
oesophageal O
varices.Changes O
in O
coagulation O
and O
fibrinolysis O
were O
investigated O
in O
20 O
patients O
with O
oesophageal O
varices O
, O
who O
underwent O
endoscopic O
injection O
sclerotherapy O
(EIS) O
with O
5 O
per O
cent O
ethanolamine O
oleate O
(EO) O
, O
by O
means O
of O
serial O
determination O
of O
plasma O
fibrinopeptide O
A O
(FPA) O
and O
fibrinopeptide O
B O
beta O
15-42 O
(B O
beta O
15-42) O
. O
One O
hour O
after O
the O
completion O
of O
EIS O
, O
the O
value O
of O
FPA O
was O
significantly O
increased O
to O
38.1 O
+/- O
11.1 O
ng/ml O
(mean O
+/- O
s.e.m.) O
from O
a O
pre-EIS O
value O
of O
7.1 O
+/- O
1.4 O
ng/ml O
(P O
less O
than O
0.01) O
and O
it O
gradually O
returned O
to O
normal O
range O
by O
48 O
h O
after O
EIS O
. O
A O
very O
similar O
change O
was O
observed O
in O
the O
value O
of O
B O
beta O
15-42 O
(P O
less O
than O
0.01) O
. O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis O
. O
In O
vitro O
studies O
, O
however O
, O
revealed O
that O
EO O
inhibits O
fibrin O
clot O
formation O
because O
of O
the O
Ca2+-chelating O
ability O
of O
its O
constituent O
ethanolamine O
, O
although O
oleate O
or O
benzyl O
alcohol O
exhibited O
procoagulant O
activity O
in O
FPA B
formation O
in O
vitro O
. O
Nevertheless O
, O
an O
external O
application O
of O
EO O
or O
oleate O
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO O
, O
which O
exerts O
an O
inhibitory O
effect O
on O
coagulation O
in O
vitro O
, O
activates O
the O
local O
coagulation O
system O
. O
The O
activation O
may O
be O
accelerated O
by O
an O
acute O
inflammatory O
process O
provoked O
by O
oleate O
, O
which O
is O
supported O
by O
such O
clinical O
manifestations O
as O
mild O
fever O
, O
retrosternal O
pain O
leukocytosis O
and O
an O
increase O
in O
plasma O
fibrinogen O
level O
which O
was O
observed O
in O
all O
during O
the O
period O
. O

galanthamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase B
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

candoxatril O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effectiveness O
of O
endopeptidase O
inhibition O
(candoxatril) O
in O
congestive O
heart O
failure.Candoxatril O
is O
a O
novel O
, O
orally O
active O
inhibitor O
of O
neutral O
endopeptidase O
EC O
3.4.24.11 O
, O
the O
enzyme O
that O
degrades O
atrial O
natriuretic O
peptide O
(ANP) O
. O
The O
acute O
and O
chronic O
(10 O
days O
treatment) O
hemodynamic O
and O
hormonal O
effects O
of O
candoxatril O
(150 O
mg O
twice O
daily) O
in O
12 O
patients O
with O
moderately O
severe O
congestive O
heart O
failure O
were O
investigated O
in O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
study O
. O
On O
study O
day O
1 O
, O
candoxatril O
acutely O
increased O
plasma O
ANP B
levels O
, O
suppressed O
aldosterone O
and O
decreased O
right O
atrial O
and O
pulmonary O
capillary O
wedge O
pressures O
. O
After O
10 O
days O
of O
treatment O
, O
basal O
ANP O
was O
increased O
and O
basal O
aldosterone O
was O
decreased O
. O
Body O
weight O
was O
reduced O
, O
most O
likely O
reflecting O
chronic O
natriuretic O
or O
diuretic O
effects O
, O
or O
both O
, O
and O
there O
was O
a O
trend O
toward O
increased O
cardiac O
index O
and O
reduced O
preload O
values O
. O
On O
study O
day O
10 O
, O
the O
acute O
effects O
of O
candoxatril O
were O
similar O
to O
those O
on O
day O
1 O
(i.e. O
, O
ANP O
was O
further O
increased O
, O
aldosterone O
was O
suppressed O
, O
and O
right O
and O
left O
ventricular O
filling O
pressures O
were O
decreased) O
. O
Thus O
, O
candoxatril O
may O
offer O
a O
new O
and O
effective O
therapeutic O
approach O
in O
the O
treatment O
of O
heart O
failure O
. O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Emerging O
role O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
therapy O
for O
advanced O
malignancy O
: O
focus O
on O
NSCLC.Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer O
. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based O
therapy O
vs O
. O
best O
supportive O
care O
, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate O
. O
Just O
as O
importantly O
, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O
life O
. O
Newer O
agents O
, O
including O
the O
taxanes O
, O
vinorelbine O
, O
gemcitabine O
, O
and O
irinotecan O
, O
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer O
. O
Despite O
their O
contributions O
, O
we O
have O
reached O
a O
therapeutic O
plateau O
, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40% O
. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal B
growth I
factor I
receptor I
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O
Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O
persist O
. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular O
, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds O
. O
Both O
gefitinib O
and O
erlotinib O
have O
shown O
clinical O
activity O
in O
pretreated O
, O
advanced O
non-small-cell O
lung O
cancer O
, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib O
in O
combination O
with O
standard O
cytotoxic O
therapy O
, O
to O
our O
chagrin O
, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone O
. O

β-Lapachone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 O
( O
NQO1) B
 O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O
in O
an O
optimal O
random O
methylated-β-cyclodextrin/poloxamer O
407 O
mixture O
(i.e. O
, O
β-Lap O
ternary O
system) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF-7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti-tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O
This O
ternary O
system O
is O
fluid O
at O
room O
temperature O
, O
gels O
over O
29°C O
, O
and O
provides O
a O
significant O
amount O
of O
drug O
, O
thus O
facilitating O
intratumoral O
delivery O
, O
in O
situ O
gelation O
, O
and O
the O
formation O
of O
a O
depot O
for O
time-release O
. O
Administration O
of O
β-Lap O
ternary O
system O
to O
MCF-7 O
cells O
induces O
an O
increase O
in O
apoptosis O
and O
DNA O
damage O
, O
while O
producing O
no O
changes O
in O
cell O
cycle O
. O
Moreover O
, O
in O
a O
mouse O
xenograft O
tumor O
model O
, O
intratumoral O
injection O
of O
the O
system O
significantly O
reduces O
tumor O
volume O
, O
while O
increasing O
apoptosis O
and O
DNA O
damage O
without O
visible O
toxicity O
to O
liver O
or O
kidney O
. O
These O
anti-tumoral O
effects O
and O
lack O
of O
visible O
toxicity O
make O
this O
system O
a O
promising O
new O
therapeutic O
agent O
for O
breast O
cancer O
treatment O
. O

Catalpol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Catalpol O
suppresses O
advanced O
glycation O
end-products-induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen O
species O
in O
human O
monocytic O
THP-1 O
cells.Advanced O
glycation O
end-products O
(AGEs) O
play O
a O
pivotal O
role O
in O
the O
development O
of O
diabetic O
complications O
by O
inducing O
inflammation O
. O
We O
previously O
reported O
that O
the O
fresh O
roots O
of O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen B
activated I
protein I
(MAP) I
kinases I
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB O
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications O
. O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
NF-kappa O
B O
by O
sodium O
salicylate O
and O
aspirin.The O
transcription O
factor O
nuclear O
factor-kappa O
B O
(NF-kappa O
B) O
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 O
(IL-1) O
, O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig B
kappa I
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

polyamine O
acts O
as O
NOT O
for O
what O
entity O
? O
Properties O
of O
purified O
recombinant O
human O
polyamine O
oxidase O
, O
PAOh1/SMO.The O
discovery O
of O
an O
inducible O
oxidase O
whose O
apparent O
substrate O
preference O
is O
spermine O
indicates O
that O
polyamine O
catabolism O
is O
more O
complex O
than O
that O
originally O
proposed O
. O
To O
facilitate O
the O
study O
of O
this O
enzyme O
, O
the O
purification O
and O
characterization O
of O
the O
recombinant O
human O
PAOh1/SMO O
polyamine O
oxidase O
are O
reported O
. O
Purified O
PAOh1/SMO O
oxidizes O
both O
spermine O
(K(m)=1.6 O
microM) O
and O
N(1)-acetylspermine O
(K(m)=51 O
microM) O
, O
but O
does O
not O
oxidize O
spermidine O
. O
The O
purified O
human O
enzyme O
also O
does O
not O
oxidize O
eight O
representative O
antitumor O
polyamine O
analogues; O
however O
, O
specific O
oligamine O
analogues O
were O
found O
to O
be O
potent O
inhibitors O
of O
the O
oxidation O
of O
spermine O
by O
PAOh1 B
/ O
SMO O
. O
The O
results O
of O
these O
studies O
are O
consistent O
with O
the O
hypothesis O
that O
PAOh1/SMO O
represents O
a O
new O
addition O
to O
the O
polyamine O
metabolic O
pathway O
that O
may O
represent O
a O
new O
target O
for O
antineoplastic O
drug O
development O
. O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
( O
GST) B
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST-4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Linking O
GABA(A) O
receptor O
subunits O
to O
alcohol-induced O
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol O
intoxication.GABA O
type O
A O
receptors O
( O
GABA(A)-R) B
are O
important O
for O
ethanol O
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol O
behaviors O
. O
We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA(A)-R O
subunits O
(α1 O
, O
α2 O
, O
α3 O
, O
α4 O
, O
α5 O
and O
δ) O
. O
Only O
mice O
lacking O
the O
α2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
(CTA) O
to O
ethanol O
. O
These O
results O
are O
in O
agreement O
with O
data O
from O
knock-in O
mice O
with O
mutation O
of O
the O
ethanol-sensitive O
site O
in O
the O
α2-subunit O
(Blednov O
et O
al. O
, O
2011) O
. O
All O
together O
, O
they O
indicate O
that O
aversive O
property O
of O
ethanol O
is O
dependent O
on O
ethanol O
action O
on O
α2-containing O
GABA(A)-R O
. O
Deletion O
of O
the O
α2-subunit O
led O
to O
faster O
recovery O
whereas O
absence O
of O
the O
α3-subunit O
slowed O
recovery O
from O
ethanol-induced O
incoordination O
(rotarod) O
. O
Deletion O
of O
the O
other O
four O
subunits O
did O
not O
affect O
this O
behavior O
. O
Similar O
changes O
in O
this O
behavior O
for O
the O
α2 O
and O
α3 O
null O
mutants O
were O
found O
for O
flurazepam O
motor O
incoordination O
. O
However O
, O
no O
differences O
in O
recovery O
were O
found O
in O
motor-incoordinating O
effects O
of O
an O
α1-selective O
modulator O
(zolpidem) O
or O
an O
α4-selective O
agonist O
(gaboxadol) O
. O
Therefore O
, O
recovery O
of O
rotarod O
incoordination O
is O
under O
control O
of O
two O
GABA(A)-R O
subunits O
: O
α2 O
and O
α3 O
. O
For O
motor O
activity O
, O
α3 O
null O
mice O
demonstrated O
higher O
activation O
by O
ethanol O
(1 O
g/kg) O
whereas O
both O
α2 O
(-/-) O
and O
α3 O
(-/Y) O
knockout O
mice O
were O
less O
sensitive O
to O
ethanol-induced O
reduction O
of O
motor O
activity O
(1.5 O
g/kg) O
. O
These O
studies O
demonstrate O
that O
the O
effects O
of O
ethanol O
at O
GABAergic O
synapses O
containing O
α2 O
subunit O
are O
important O
for O
specific O
behavioral O
effects O
of O
ethanol O
which O
may O
be O
relevant O
to O
the O
genetic O
linkage O
of O
the O
α2 O
subunit O
with O
human O
alcoholism O
. O

Benzodiazepines O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
( O
GABA(A)R) B
 O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

GMC O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Apolipoprotein O
E3 O
(apoE3) O
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 O
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density O
lipoprotein O
(LDL) O
receptor O
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1-dependent O
glucose O
transport O
in O
pig O
proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O
model O
of O
gentamicin O
C O
(GMC)-induced O
reduction O
in O
SGLT1 O
activity O
, O
we O
examined O
whether O
ligands O
for O
megalin O
protect O
LLC-PK1 O
cells O
from O
the O
GMC-induced O
reduction O
in O
SGLT1 B
activity O
. O
We O
employed O
apolipoprotein O
E3 O
(apoE3) O
and O
lactoferrin O
as O
ligands O
for O
megalin O
. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3 O
, O
lactoferrin O
and O
bovine O
serum O
albumin O
with O
or O
without O
100 O
microg/ml O
of O
GMC O
, O
and O
the O
SGLT1-dependent O
methyl O
alpha-D-glucopyranoside O
(AMG) O
uptake O
and O
levels O
of O
SGLT1 O
expression O
were O
determined O
. O
As O
a O
result O
, O
we O
demonstrated O
that O
the O
apoE3 O
significantly O
protects O
these O
cells O
from O
GMC-induced O
reduction O
in O
AMG O
uptake O
, O
but O
neither O
lactoferrin O
nor O
albumin O
does O
. O
In O
accord O
with O
a O
rise O
in O
AMG O
uptake O
activity O
, O
the O
mRNA O
and O
protein O
levels O
of O
SGLT1 O
were O
apparently O
up-regulated O
in O
the O
presence O
of O
apoE3 O
. O
Furthermore O
, O
we O
found O
that O
the O
uptake O
of O
[3H] O
gentamicin O
is O
decreased O
by O
apoE3 O
, O
and O
that O
apoE3 O
showed O
obvious O
protection O
against O
the O
GMC-dependent O
N-acetyl-beta-D-glucosamidase O
(NAG) O
release O
from O
LLC-PK1 O
cells O
. O
Thus O
, O
these O
results O
indicate O
that O
apoE3 O
could O
be O
a O
valuable O
tool O
for O
the O
prevention O
of O
aminoglycoside O
nephrotoxicity O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cloning O
, O
functional O
expression O
and O
brain O
localization O
of O
a O
novel O
unconventional O
outward O
rectifier O
K+ O
channel.Human O
TWIK-1 O
, O
which O
has O
been O
cloned O
recently O
, O
is O
a O
new O
structural O
type O
of O
weak O
inward O
rectifier O
K+ O
channel O
. O
Here O
we O
report O
the O
structural O
and O
functional O
properties O
of O
TREK-1 O
, O
a O
mammalian O
TWIK-1-related O
K+ O
channel O
. O
Despite O
a O
low O
amino O
acid O
identity O
between O
TWIK-1 O
and O
TREK-1 B
(approximately O
28%) O
, O
both O
channel O
proteins O
share O
the O
same O
overall O
structural O
arrangement O
consisting O
of O
two O
pore-forming O
domains O
and O
four O
transmembrane O
segments O
(TMS) O
. O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 O
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O
been O
studied O
by O
in O
situ O
hybridization O
. O
TREK-1 O
expression O
is O
high O
in O
the O
olfactory O
bulb O
, O
hippocampus O
and O
cerebellum O
. O
These O
results O
provide O
the O
first O
evidence O
for O
the O
existence O
of O
a O
K+ O
channel O
family O
with O
four O
TMS O
and O
two O
pore O
domains O
in O
the O
nervous O
system O
of O
mammals O
. O
They O
also O
show O
that O
different O
members O
in O
this O
structural O
family O
can O
have O
totally O
different O
functional O
properties O
. O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Norethisterone O
metabolites O
modulate O
the O
uteroglobin O
and O
progesterone O
receptor O
gene O
expression O
in O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
( O
PR) B
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

cholesterol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1- B
mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI O
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

sodium O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
A O
novel O
SCN5A O
arrhythmia O
mutation O
, O
M1766L O
, O
with O
expression O
defect O
rescued O
by O
mexiletine.OBJECTIVE O
: O
Mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
, O
SCN5A O
, O
cause O
congenital O
long O
QT O
syndrome O
(LQT3) O
, O
Brugada O
syndrome O
, O
idiopathic O
ventricular O
fibrillation O
, O
and O
conduction O
disease O
by O
distinct O
cellular O
and O
clinical O
electrophysiological O
phenotypes O
. O
METHODS O
: O
Postmortem O
molecular O
analysis O
of O
SCN5A O
was O
conducted O
on O
an O
infant O
who O
presented O
shortly O
after O
birth O
with O
self-terminating O
torsades O
de O
pointes O
. O
The O
infant O
was O
treated O
with O
lidocaine O
, O
propranolol O
, O
and O
mexiletine O
and O
was O
stable O
for O
16 O
months O
manifesting O
only O
a O
prolonged O
QT O
interval O
. O
The O
infant O
collapsed O
suddenly O
following O
presumed O
viral O
gastroenteritis O
, O
was O
found O
in O
2:1 O
AV O
block O
, O
and O
was O
subsequently O
declared O
brain O
dead O
. O
Genomic O
DNA O
was O
subjected O
to O
SCN5A O
mutational O
analyses O
and O
DNA O
sequencing O
revealing O
a O
novel O
, O
spontaneous O
germline O
missense O
mutation O
, O
M1766L O
. O
The O
M1766L O
mutation O
was O
engineered O
into O
the O
hH1a O
clone O
by O
site-directed O
mutagenesis O
, O
transfected O
into O
embryonic O
kidney O
cells O
(HEK-293) O
, O
and O
studied O
by O
voltage O
clamp O
. O
RESULTS O
: O
The O
M1766L O
mutation O
caused O
a O
significant O
decrease O
in O
the O
sodium O
channel O
expression O
. O
Co-expression O
with O
beta1 O
subunit O
, O
incubation O
at O
low O
temperature O
, O
and O
most O
effectively O
incubation O
with O
mexiletine O
partially O
'rescued' O
the O
defective O
expression O
. O
In O
addition O
to O
this O
pronounced O
loss O
of O
function O
, O
M1766L B
also O
showed O
a O
10-fold O
increase O
in O
the O
persistent O
late O
sodium O
current O
. O
CONCLUSIONS O
: O
These O
findings O
suggest O
that O
M1766L-SCN5A O
channel O
dysfunction O
may O
contribute O
to O
the O
basis O
of O
lethal O
arrhythmias O
, O
displays O
an O
overlapping O
electrophysiological O
phenotype O
, O
and O
represents O
the O
first O
sodium O
channelopathy O
rescued O
by O
drug O
. O

aniracetam O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA B
receptors I
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

4'-(9-acridinylamino)methanesulfon-m-anisidide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 B
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic B
fibrosis I
transmembrane I
conductor I
regulator I
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
( O
CBS) B
 O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Mechanisms O
of O
agonist-induced O
down-regulation O
of O
the O
human O
kappa-opioid O
receptor O
: O
internalization O
is O
required O
for O
down-regulation.Previously O
, O
we O
showed O
that O
the O
human O
kappa-opioid O
receptor O
(hkor) O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O
receptors O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynamin O
I-K44A O
significantly O
reduced O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7- B
N125I O
blunted O
U50,488H-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O
down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes O
for O
degradation O
. O
Thus O
, O
U50,488H-induced O
internalization O
and O
down-regulation O
of O
the O
hkor O
share O
initial O
common O
mechanisms O
. O
To O
the O
best O
of O
our O
knowledge O
, O
these O
results O
represent O
the O
first O
report O
on O
the O
involvement O
of O
both O
rab5 O
and O
rab7 O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O
In O
addition O
, O
this O
study O
is O
among O
the O
first O
to O
show O
the O
involvement O
of O
proteasomes O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O

cirazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nonadrenergic O
imidazoline O
binding O
sites O
on O
human O
platelets.Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity O
, O
imidazol(in)e-preferring O
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 O
adrenoceptors O
. O
These O
nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
of O
alpha-2 O
adrenoceptors O
. O
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan O
(IDX) O
binding O
vs O
. O
[125I]p-iodoclonidine O
(PIC) O
binding O
. O
Nonadrenergic O
[125I]PIC-labeled O
sites O
were O
enriched O
in O
platelet O
plasma O
membranes O
, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] O
IDX O
were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled O
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs O
. O
the O
[3H]IDX-labeled O
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes) O
. O
Furthermore O
, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A B
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Carvedilol O
modulates O
the O
expression O
of O
hypoxia-inducible O
factor-1alpha O
and O
vascular O
endothelial O
growth O
factor O
in O
a O
rat O
model O
of O
volume-overload O
heart O
failure.BACKGROUND O
: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure O
. O
Hypoxia-inducible O
factor-1alpha O
(HIF-1alpha) O
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium O
. O
However O
, O
the O
expression O
of O
HIF-1alpha O
in O
chronic O
heart O
failure O
resulting O
from O
volume O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known O
. O
METHODS O
AND O
RESULTS O
: O
To O
test O
the O
hypothesis O
that O
HIF-1alpha O
plays O
a O
role O
in O
the O
failing O
myocardium O
because O
of O
volume O
overload O
, O
an O
aorta-caval O
shunt O
was O
created O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
volume-overload O
heart O
failure O
. O
Carvedilol O
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O
was O
given O
. O
The O
heart O
weight O
and O
body O
weight O
ratio O
increased O
from O
2.6 O
+/- O
0.3 O
in O
the O
sham O
group O
to O
3.9 O
+/- O
0.7 O
(P O
< O
.001) O
in O
the O
shunt O
group O
. O
Left O
ventricular O
end-diastolic O
dimension O
increased O
from O
6.5 O
+/- O
0.5 O
mm O
to O
8.7 O
+/- O
0.6 O
mm O
(P O
< O
.001) O
. O
Treatment O
with O
carvedilol O
in O
the O
shunt O
group O
reversed O
the O
heart O
weight O
and O
ventricular O
dimension O
to O
the O
baseline O
values O
. O
Western O
blot O
showed O
that O
HIF-1alpha O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
brain O
natriuretic O
peptide O
(BNP) O
proteins O
were O
upregulated O
and O
nerve O
growth O
factor-beta O
(NGF-beta) O
downregulated O
in O
the O
shunt O
group O
. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
increased O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O
. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha B
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha O
and O
VEGF O
in O
the O
failing O
ventricular O
myocardium O
. O

catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Catalpol O
suppresses O
advanced O
glycation O
end-products-induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen O
species O
in O
human O
monocytic O
THP-1 O
cells.Advanced O
glycation O
end-products O
(AGEs) O
play O
a O
pivotal O
role O
in O
the O
development O
of O
diabetic O
complications O
by O
inducing O
inflammation O
. O
We O
previously O
reported O
that O
the O
fresh O
roots O
of O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB B
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB O
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications O
. O

Probenecid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
potassium O
channel O
subunit O
Kvbeta3 O
interacts O
with O
pannexin O
1 O
and O
attenuates O
its O
sensitivity O
to O
changes O
in O
redox O
potentials.Pannexin O
1 O
(Panx1) O
, O
a O
member O
of O
the O
second O
gap O
junction O
protein O
family O
identified O
in O
vertebrates O
, O
appears O
to O
preferentially O
form O
non-junctional O
membrane O
channels O
. O
A O
candidate O
regulatory O
protein O
of O
Panx1 O
is O
the O
potassium O
channel O
subunit O
Kvbeta3 O
, O
previously O
identified O
by O
bacterial O
two-hybrid O
strategies O
. O
Here O
, O
we O
report O
on O
the O
physical O
association O
of O
Panx1 O
with O
Kvbeta3 O
by O
immunoprecipitation O
when O
co-expressed O
in O
a O
neuroblastoma O
cell O
line O
(Neuro2A) O
. O
Furthermore O
, O
in O
vivo O
co-expression O
of O
Panx1 O
and O
Kvbeta3 O
was O
shown O
to O
occur O
in O
murine O
hippocampus O
and O
cerebellum O
. O
Kvbeta3 O
is O
known O
to O
accelerate O
inactivation O
of O
otherwise O
slowly O
inactivating O
potassium O
channels O
under O
reducing O
conditions O
. O
We O
subsequently O
found O
that O
Panx1 O
channel O
currents O
exhibit O
a O
significant O
reduction O
when O
exposed O
to O
reducing O
agents O
, O
and O
that O
this O
effect O
is O
attenuated O
in O
the O
presence O
of O
Kvbeta3 O
. O
Apparently O
, O
Kvbeta3 O
is O
involved O
in O
regulating O
the O
susceptibility O
of O
Panx1 O
channels O
to O
redox O
potential O
. O
Furthermore O
, O
the O
Panx1 B
channel O
blockers O
carbenoxolone O
and O
Probenecid O
were O
less O
effective O
in O
inhibiting O
Panx1 O
currents O
when O
Kvbeta3 O
was O
co-expressed O
. O
The O
influence O
of O
Kvbeta3 O
on O
Panx1 O
is O
the O
first O
example O
of O
modulation O
of O
Panx1 O
channel O
function(s) O
by O
interacting O
proteins O
, O
and O
suggests O
the O
physiological O
importance O
of O
sensing O
changes O
in O
redox O
potentials O
. O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA B
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O
in O
the O
recognition O
of O
SR O
141716A O
. O
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 B
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 O
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2 B
/ O
STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

Diethylcarbamazine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Diethylcarbamazine O
activity O
against O
Brugia O
malayi O
microfilariae O
is O
dependent O
on O
inducible O
nitric-oxide O
synthase O
and O
the O
cyclooxygenase B
pathway.BACKGROUND O
: O
Diethylcarbamazine O
(DEC) O
has O
been O
used O
for O
many O
years O
in O
the O
treatment O
of O
human O
lymphatic O
filariasis O
. O
Its O
mode O
of O
action O
is O
not O
well O
understood O
, O
but O
it O
is O
known O
to O
interact O
with O
the O
arachidonic O
acid O
pathway O
. O
Here O
we O
have O
investigated O
the O
contribution O
of O
the O
nitric O
oxide O
and O
cyclooxygenase O
(COX) O
pathways O
to O
the O
activity O
of O
DEC O
against O
B O
. O
malayi O
microfilariae O
in O
mice O
. O
METHODS O
: O
B O
. O
malayi O
microfilariae O
were O
injected O
intravenously O
into O
mice O
and O
parasitaemia O
was O
measured O
24 O
hours O
later O
. O
DEC O
was O
then O
administered O
to O
BALB/c O
mice O
with O
and O
without O
pre-treatment O
with O
indomethacin O
or O
dexamethasone O
and O
the O
parasitaemia O
monitored O
. O
To O
investigate O
a O
role O
for O
inducible O
nitric O
oxide O
in O
DEC's O
activity O
, O
DEC O
and O
ivermectin O
were O
administered O
to O
microfilaraemic O
iNOS-/- O
mice O
and O
their O
background O
strain O
(129/SV) O
. O
Western O
blot O
analysis O
was O
used O
to O
determine O
any O
effect O
of O
DEC O
on O
the O
production O
of O
COX O
and O
inducible O
nitric-oxide O
synthase O
(iNOS) O
proteins O
. O
RESULTS O
: O
DEC O
administered O
alone O
to O
BALB/c O
mice O
resulted O
in O
a O
rapid O
and O
profound O
reduction O
in O
circulating O
microfilariae O
within O
five O
minutes O
of O
treatment O
. O
Microfilarial O
levels O
began O
to O
recover O
after O
24 O
hours O
and O
returned O
to O
near O
pre-treatment O
levels O
two O
weeks O
later O
, O
suggesting O
that O
the O
sequestration O
of O
microfilariae O
occurs O
independently O
of O
parasite O
killing O
. O
Pre-treatment O
of O
animals O
with O
dexamethasone O
or O
indomethacin O
reduced O
DEC's O
efficacy O
by O
almost O
90% O
or O
56% O
, O
respectively O
, O
supporting O
a O
role O
for O
the O
arachidonic O
acid O
and O
cyclooxygenase O
pathways O
in O
vivo O
. O
Furthermore O
, O
experiments O
showed O
that O
treatment O
with O
DEC O
results O
in O
a O
reduction O
in O
the O
amount O
of O
COX-1 O
protein O
in O
peritoneal O
exudate O
cells O
. O
Additionally O
, O
in O
iNOS-/- O
mice O
infected O
with O
B O
. O
malayi O
microfilariae O
, O
DEC O
showed O
no O
activity O
, O
whereas O
the O
efficacy O
of O
another O
antifilarial O
drug O
, O
ivermectin O
, O
was O
unaffected O
. O
CONCLUSION O
: O
These O
results O
confirm O
the O
important O
role O
of O
the O
arachidonic O
acid O
metabolic O
pathway O
in O
DEC's O
mechanism O
of O
action O
in O
vivo O
and O
show O
that O
in O
addition O
to O
its O
effects O
on O
the O
5-lipoxygenase O
pathway O
, O
it O
targets O
the O
cyclooxygenase O
pathway O
and O
COX-1 O
. O
Moreover O
, O
we O
show O
for O
the O
first O
time O
that O
inducible O
nitric O
oxide O
is O
essential O
for O
the O
rapid O
sequestration O
of O
microfilariae O
by O
DEC O
. O

pindolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
The O
role O
of O
5-HT(1A) O
and O
5-HT(1B/1D) O
receptors O
on O
the O
modulation O
of O
acute O
fluoxetine-induced O
changes O
in O
extracellular O
5-HT O
: O
the O
mechanism O
of O
action O
of O
(+/-)pindolol.Some O
clinical O
evidence O
has O
suggested O
that O
(+/-)pindolol O
can O
be O
effective O
at O
producing O
a O
shortened O
time O
to O
onset O
of O
antidepressant O
activity O
when O
co-administered O
with O
a O
serotonin O
specific O
reuptake O
inhibitor O
(SSRI) O
. O
This O
effect O
has O
been O
attributed O
to O
the O
antagonist O
effects O
of O
pindolol O
at O
the O
5-HT(1A) B
receptor O
. O
In O
the O
present O
study O
, O
we O
compared O
the O
pharmacology O
of O
(+/-)pindolol O
, O
WAY-100635 O
(a O
5-HT(1A) O
antagonist) O
, O
GR127935 O
(a O
5-HT(1B/1D) O
antagonist) O
, O
and O
isamoltane O
(a O
5-HT(1B) O
antagonist) O
, O
when O
given O
acutely O
in O
combination O
with O
fluoxetine O
, O
using O
in O
vivo O
microdialysis O
in O
the O
frontal O
cortex O
of O
the O
freely O
moving O
rat O
. O
We O
have O
determined O
that O
the O
acute O
fluoxetine-induced O
increases O
in O
extracellular O
5-HT O
can O
be O
augmented O
by O
(+/-)pindolol O
, O
WAY100635 O
, O
GR127935 O
and O
isamoltane O
with O
maximum O
increases O
of O
216+/-32% O
, O
235+/-49% O
, O
240+/-18% O
and O
171+/-47% O
of O
preinjection O
control O
levels O
, O
respectively O
. O
Combination O
of O
both O
5-HT(1A) O
and O
5-HT(1B/1D) O
autoreceptor O
antagonists O
with O
fluoxetine O
produced O
additive O
increases O
in O
extracellular O
5-HT O
(i.e O
. O
WAY100635+GR127935+fluoxetine O
and O
WAY100635+isamoltane+fluoxetine O
produced O
a O
four- O
and O
five-fold O
potentiation O
, O
respectively) O
, O
suggesting O
that O
this O
strategy O
may O
be O
useful O
in O
further O
augmenting O
the O
action O
of O
a O
SSRI O
in O
the O
treatment O
of O
depression O
. O
In O
addition O
, O
by O
comparing O
the O
combined O
administration O
of O
(+/-)pindolol O
with O
either O
WAY100635 O
, O
GR127935 O
or O
isamoltane O
, O
we O
have O
determined O
that O
(+/-)pindolol O
produces O
much O
of O
its O
acute O
potentiation O
of O
fluoxetine-induced O
increases O
in O
extracellular O
5-HT O
via O
its O
action O
at O
the O
5-HT(1B/D) O
receptor O
in O
addition O
to O
any O
activity O
it O
has O
at O
the O
presynaptic O
5-HT(1A) O
receptor O
. O

moclobemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O
noradrenaline O
(NA) O
, O
3,4-dihydroxyphenylglycol O
(DHPG) O
, O
homovanillic O
acid O
(HVA) O
and O
5-hydroxyindolacetic O
acid O
(5-HIAA) O
. O
Urine O
was O
collected O
for O
measurements O
of O
normetanephrine O
and O
3-methoxytyramine O
excretion O
. O
Psychometric O
performance O
(short- O
and O
long-term O
memory O
, O
critical O
flicker O
fusion O
frequency O
, O
choice O
reaction O
time) O
and O
subjective O
feelings O
were O
assessed O
before O
each O
drug O
intake O
(in O
the O
morning O
, O
at O
noon O
, O
in O
the O
evening) O
. O
3 O
. O
Compared O
with O
placebo O
, O
both O
reversible O
monoamine O
oxidase O
inhibitors O
decreased O
the O
plasma O
concentration O
of O
DHPG O
and O
HVA O
. O
The O
overall O
fall O
in O
DHPG O
(AUC O
from O
0 O
to O
24 O
h) O
was O
44% O
during O
moclobemide O
and O
12% O
during O
toloxatone O
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A B
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
. O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O
and O
to O
a O
lesser O
extent O
on O
toloxatone O
. O
The O
urinary O
excretion O
of O
3-methoxytyramine O
was O
significantly O
raised O
by O
moclobemide O
but O
not O
by O
toloxatone O
. O
7 O
. O
Neither O
moclobemide O
nor O
toloxatone O
altered O
memory O
function O
, O
vigilance O
, O
subjective O
feelings O
or O
sleep O
characteristics O
of O
the O
subjects O
. O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Sex O
differences O
in O
the O
antidepressant-like O
effects O
of O
ketamine.Current O
medications O
for O
major O
depression O
suffer O
from O
numerous O
limitations O
. O
Once O
the O
right O
drug O
for O
treatment O
has O
been O
determined O
, O
it O
still O
takes O
several O
weeks O
for O
it O
to O
take O
effect O
and O
improve O
mood O
. O
This O
time O
lag O
is O
a O
serious O
concern O
for O
the O
healthcare O
community O
when O
dealing O
with O
patients O
with O
suicidal O
thoughts O
. O
However O
, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low-dose O
injection O
of O
ketamine O
, O
an O
N-methyl O
d-aspartate O
receptor O
(NMDAR) O
antagonist O
, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting O
. O
Although O
major O
depression O
affects O
twice O
as O
many O
women O
as O
men O
, O
all O
studies O
examining O
the O
rapid O
antidepressant O
effects O
of O
ketamine O
have O
focused O
on O
male O
subjects O
. O
Thus O
, O
we O
have O
investigated O
the O
behavioral O
and O
molecular O
effects O
of O
ketamine O
in O
both O
male O
and O
female O
rats O
and O
demonstrated O
greater O
sensitivity O
in O
female O
rats O
at O
a O
low O
dose O
of O
ketamine O
, O
a O
dose O
does O
not O
have O
antidepressant-like O
effects O
in O
male O
rats O
. O
The O
antidepressant-like O
effects O
of O
this O
low O
dose O
of O
ketamine O
were O
completely O
abolished O
when O
female O
rats O
were O
ovariectomized O
(OVX) O
, O
and O
restored O
when O
physiological O
levels O
of O
estrogen O
and O
progesterone O
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin O
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic B
elongation I
factor I
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine's O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

ceramides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B B
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

spermidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine O
decarboxylase O
( O
ODC) B
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

[3H]prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
antidepressant O
drugs O
in O
mice O
lacking O
the O
norepinephrine O
transporter.One O
of O
the O
main O
theories O
concerning O
the O
mechanism O
of O
action O
of O
antidepressant O
drugs O
(ADs) O
is O
based O
on O
the O
notion O
that O
the O
neurochemical O
background O
of O
depression O
involves O
an O
impairment O
of O
central O
noradrenergic O
transmission O
with O
a O
concomitant O
decrease O
of O
the O
norepinephrine O
(NE) O
in O
the O
synaptic O
gap O
. O
Many O
ADs O
increase O
synaptic O
NE O
availability O
by O
inhibition O
of O
the O
reuptake O
of O
NE O
. O
Using O
mice O
lacking O
NE O
transporter O
(NET-/-) O
we O
examined O
their O
baseline O
phenotype O
as O
well O
as O
the O
response O
in O
the O
forced O
swim O
test O
(FST) O
and O
in O
the O
tail O
suspension O
test O
(TST) O
upon O
treatment O
with O
ADs O
that O
display O
different O
pharmacological O
profiles O
. O
In O
both O
tests O
, O
the O
NET-/- O
mice O
behaved O
like O
wild-type O
(WT) O
mice O
acutely O
treated O
with O
ADs O
. O
Autoradiographic O
studies O
showed O
decreased O
binding O
of O
the O
beta-adrenergic O
ligand O
[3H]CGP12177 O
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
, O
indicating O
the O
changes O
at O
the O
level O
of O
beta-adrenergic O
receptors O
similar O
to O
those O
obtained O
with O
ADs O
treatment O
. O
The O
binding O
of O
[3H]prazosin O
to O
alpha1-adrenergic B
receptors I
in O
the O
cerebral O
cortex O
of O
NET-/- O
mice O
was O
also O
decreased O
, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET O
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
, O
desipramine O
, O
and O
imipramine O
. O
Citalopram O
, O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- O
mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET O
knockout O
itself O
(ca O
25%); O
however O
, O
antidepressant-like O
action O
of O
repeatedly O
(7 O
days) O
administered O
desipramine O
was O
observed O
in O
NET-/- O
mice O
, O
indicating O
that O
the O
chronic O
presence O
of O
this O
drug O
may O
also O
affect O
other O
neurochemical O
targets O
involved O
in O
the O
behavioral O
reactions O
monitored O
by O
this O
test O
. O
From O
the O
present O
study O
, O
it O
may O
be O
concluded O
that O
mice O
lacking O
the O
NET O
may O
represent O
a O
good O
model O
of O
some O
aspects O
of O
depression-resistant O
behavior O
, O
paralleled O
with O
alterations O
in O
the O
expression O
of O
adrenergic O
receptors O
, O
which O
result O
as O
an O
adaptation O
to O
elevated O
levels O
of O
extracellular O
NE O
. O

Topotecan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Glioma O
cell O
sensitivity O
to O
topotecan O
: O
the O
role O
of O
p53 O
and O
topotecan-induced O
DNA O
damage.Topotecan O
is O
a O
topoisomerase B
I I
inhibitor O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 O
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 O
status O
, O
were O
associated O
with O
increased O
topotecan-induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

hydroxy O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol O
acyltransferase O
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT B
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antitumor O
activity O
of O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 O
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular B
signal-regulated I
kinase1/2 I
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
. O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A B
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Rosmarinic O
acid O
ameliorates O
acute O
liver O
damage O
and O
fibrogenesis O
in O
carbon O
tetrachloride-intoxicated O
mice.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
therapeutic O
potential O
of O
rosmarinic O
acid O
(RA) O
, O
a O
natural O
phenolic O
, O
in O
the O
treatment O
of O
acute O
liver O
toxicity O
. O
RA O
at O
10 O
, O
25 O
and O
50mg/kg O
was O
administered O
by O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 B
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O
growth O
factor-beta1 O
(TGF-β1) O
and O
alpha-smooth O
muscle O
actin O
(α-SMA) O
expression O
, O
suggesting O
suppression O
of O
profibrotic O
response O
. O
Furthermore O
, O
RA O
significantly O
inhibited O
the O
CCl(4)-induced O
apoptosis O
, O
which O
was O
evident O
from O
decreased O
cleavage O
of O
caspase-3 O
. O
The O
hepatoprotective O
activity O
of O
RA O
coincided O
with O
enhanced O
NF-E2-related O
factor O
2 O
(Nrf2) O
and O
heme O
oxygenase-1 O
(HO-1) O
expression O
. O
The O
results O
of O
this O
study O
indicates O
that O
RA O
possesses O
antioxidant O
, O
anti-inflammatory O
, O
antiapoptotic O
and O
antifibrotic O
activity O
against O
acute O
liver O
toxicity O
. O

vitamin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB O
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
, O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB O
activation O
that O
involves O
degradation O
of O
I-κBε O
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O
DNA O
by O
EMSA O
in O
alveolar O
epithelial O
A549 O
cells O
. O
We O
also O
examined O
the O
level O
of O
I-κBε O
and O
sub-cellular O
distribution O
of O
c-Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin O
C O
pretreatment O
. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB O
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
. O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB B
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS-induced O
inflammatory O
diseases O
. O

propranolol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor O
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs B
/ O
cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) B
 O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

chlorethylclonidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha O
1A-adrenoceptor O
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha B
1B-adrenoceptors I
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

Cl- O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O
5HT O
transporters O
. O
Two-electrode O
voltage-clamp O
analysis O
demonstrated O
5HT-induced O
, O
voltage-dependent O
currents O
. O
Cloning O
and O
characterization O
of O
dSERT1 O
adds O
significantly O
to O
our O
knowledge O
of O
the O
diversity O
of O
5HT O
transporters O
with O
regard O
to O
primary O
sequence O
, O
pharmacological O
profile O
, O
and O
permeation O
properties O
. O

Tamoxifen O
acts O
as O
NOT O
for O
what O
entity O
? O
Chemoprevention O
for O
high-risk O
women O
: O
tamoxifen O
and O
beyond.The O
demonstration O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
Project O
(NSABP) O
that O
5 O
years O
of O
tamoxifen O
therapy O
is O
associated O
with O
an O
approximate O
50% O
reduction O
in O
breast O
cancer O
incidence O
in O
high-risk O
women O
was O
a O
milestone O
in O
breast O
cancer O
prevention O
. O
Because O
tamoxifen O
is O
associated O
with O
increased O
risk O
of O
side-effects O
such O
as O
hot O
flashes O
, O
menstrual O
abnormalities O
, O
uterine O
cancer O
, O
and O
thromboembolic O
phenomena O
, O
its O
use O
will O
not O
be O
advisable O
or O
acceptable O
for O
all O
high-risk O
women O
. O
Women O
over O
50 O
years O
of O
age O
appear O
to O
be O
at O
highest O
risk O
for O
serious O
adverse O
events O
, O
such O
as O
uterine O
cancer O
and O
thromboembolic O
phenomena O
. O
Individuals O
in O
whom O
tamoxifen-associated O
breast O
cancer O
risk O
reduction O
appears O
to O
outweigh O
risk O
of O
serious O
side-effects O
include O
women O
with O
prior O
in O
situ O
or O
estrogen O
receptor O
(ER)-positive O
invasive O
cancer O
, O
atypical O
hyperplasia O
, O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7% O
, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 O
mutations O
, O
although O
preliminary O
evidence O
favors O
benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER O
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER- B
positive O
cancers O
. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O
specific O
classes O
of O
preventive O
agents O
, O
(c) O
drugs O
with O
fewer O
side-effects O
and/or O
effective O
in O
ER-negative O
or O
ER-positive O
tamoxifen-resistant O
precancerous O
disease O
, O
and O
(d) O
efficient O
clinical O
trial O
models O
to O
assess O
new O
agent O
efficacy O
. O
Breast O
intraepithelial O
neoplasia O
(IEN) O
may O
be O
sampled O
by O
minimally O
invasive O
techniques O
and O
is O
an O
attractive O
short-term O
risk O
biomarker O
. O
Molecular O
abnormalities O
observed O
in O
IEN O
may O
be O
used O
to O
select O
potential O
agents O
for O
testing/therapy O
, O
and O
modulation O
of O
these O
abnormalities O
may O
be O
used O
in O
phase O
I O
trials O
to O
select O
appropriate O
doses O
and O
in O
phase O
II O
trials O
to O
assess O
response O
. O
Breast O
density O
volume O
and O
certain O
serum O
markers O
such O
as O
insulin-like O
growth O
factor-1 O
are O
also O
being O
studied O
as O
potential O
risk O
and O
response O
biomarkers O
. O
Reversal O
or O
prevention O
of O
advanced O
IEN O
as O
well O
as O
modulation O
of O
other O
risk O
biomarkers O
in O
randomized O
phase O
II O
and O
phase O
III O
trials O
is O
being O
evaluated O
as O
a O
means O
of O
more O
efficiently O
evaluating O
prevention O
drugs O
in O
the O
future O
. O
A O
number O
of O
agents O
are O
being O
developed O
that O
target O
molecular O
abnormalities O
in O
IEN O
, O
have O
fewer O
or O
different O
side O
effects O
than O
tamoxifen O
, O
and O
may O
be O
effective O
in O
ER-negative O
or O
tamoxifen-resistant O
disease O
. O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 B
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ O
channels O
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun B
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

sulfates O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
binding O
of O
fibroblast O
growth O
factor-2 O
and O
-7 O
to O
basement O
membrane O
heparan O
sulfate O
: O
comparison O
of O
normal O
and O
abnormal O
human O
tissues.Fibroblast O
growth O
factors O
(FGFs) O
play O
multiple O
roles O
during O
development O
and O
in O
adult O
tissues O
as O
paracrine O
regulators O
of O
growth O
and O
differentiation O
. O
FGFs O
signal O
through O
transmembrane O
receptor O
tyrosine O
kinases O
, O
but O
heparan O
sulfate O
is O
also O
required O
for O
signaling O
by O
members O
of O
the O
FGF O
family O
. O
In O
addition O
, O
heparan O
sulfate O
may O
be O
involved O
in O
determining O
tissue O
distribution O
of O
FGFs O
. O
Using O
biotinylated O
FGF-2 O
and O
FGF-7 O
(KGF) O
as O
probes O
, O
we O
have O
identified O
specific O
interactions O
between O
FGFs O
and O
heparan O
sulfates O
in O
human O
tissues O
. O
Both O
FGF O
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes O
. O
Binding O
to O
basement O
membrane O
heparan O
sulfate O
is O
tissue O
source O
dependent O
and O
specific O
. O
Although O
FGF-2 O
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate O
in O
skin O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 O
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate O
in O
most O
locations O
. O
However O
, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma O
, O
strong O
FGF-7 O
binding O
is O
seen O
. O
In O
summary O
, O
distinct O
and O
specific O
affinities O
of O
heparan O
sulfates O
for O
different O
FGFs B
were O
identified O
that O
may O
affect O
growth O
factor O
activation O
and O
local O
distribution O
. O
Heparan O
sulfate O
may O
have O
a O
gatekeeper O
function O
to O
either O
restrict O
or O
permit O
diffusion O
of O
heparin-binding O
growth O
factors O
across O
the O
basement O
membrane O
. O

phenothiazines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Phenothiazines O
inhibit O
S100A4 O
function O
by O
inducing O
protein O
oligomerization.S100A4 O
, O
a O
member O
of O
the O
S100 O
family O
of O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 B
via O
small O
molecule-induced O
oligomerization O
. O

UDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumarin O
by O
recombinant O
human O
UDP-glucuronosyltransferases O
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
(HFC) O
for O
several O
UGTs O
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs B
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT B
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
5-HT1B O
receptors O
, O
alpha2A/2C- O
and O
, O
to O
a O
lesser O
extent O
, O
alpha1-adrenoceptors O
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors B
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow O
. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v O
. O
bolus O
injection O
of O
, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control) O
, O
or O
the O
antagonists O
SB224289 O
(300 O
microg/kg; O
5-HT1B) O
, O
BRL15572 O
(300 O
microg/kg; O
5-HT1D) O
, O
rauwolscine O
(300 O
microg/kg; O
alpha2) O
, O
SB224289 O
+ O
BRL15572 O
(300 O
microg/kg O
each) O
, O
SB224289 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
BRL15572 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg; O
alpha1) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
BRL44408 O
(1,000 O
microg/kg; O
alpha2A) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg)+ O
imiloxan O
(1,000 O
microg/kg; O
alpha2B) O
, O
or O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
MK912 O
(300 O
microg/kg; O
alpha2C) O
. O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine O
(0.56 O
, O
1 O
, O
1.8 O
, O
3.1 O
, O
5.6 O
, O
10 O
and O
18 O
microg/min) O
, O
following O
a O
cumulative O
schedule O
. O
In O
saline-pretreated O
animals O
, O
ergotamine O
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate O
. O
These O
control O
responses O
were O
: O
unaffected O
by O
SB224289 O
, O
BRL15572 O
, O
rauwolscine O
or O
the O
combinations O
of O
SB224289 O
+ O
BRL15572 O
, O
BRL15572 O
+ O
rauwolscine O
, O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
, O
or O
SB224289 O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors O
. O

2,5-thiophene O
amides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structural O
optimization O
of O
2,5-thiophene O
amides O
as O
highly O
potent O
and O
selective O
17β-hydroxysteroid B
dehydrogenase I
type I
2 I
inhibitors O
for O
the O
treatment O
of O
osteoporosis.Inhibition O
of O
17β-HSD2 O
is O
an O
attractive O
mechanism O
for O
the O
treatment O
of O
osteoporosis O
. O
We O
report O
here O
the O
optimization O
of O
human O
17β-HSD2 O
inhibitors O
in O
the O
2,5-thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O
0 O
and O
2) O
between O
the O
amide O
moiety O
and O
the O
phenyl O
group O
. O
While O
none O
of O
the O
phenethylamides O
(n O
= O
2) O
were O
active O
, O
most O
of O
the O
anilides O
(n O
= O
0) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17β-HSD2 O
. O
The O
four O
most O
active O
compounds O
showed O
an O
IC₅₀ O
of O
around O
60 O
nM O
and O
a O
very O
good O
selectivity O
toward O
17β-HSD1 O
, O
17β-HSD4 O
, O
17β-HSD5 O
, O
11β-HSD1 O
, O
11β-HSD2 O
and O
the O
estrogen O
receptors O
α O
and O
β O
. O
The O
investigated O
compounds O
inhibited O
monkey O
17β-HSD2 O
moderately O
, O
and O
one O
of O
them O
showed O
good O
inhibitory O
activity O
on O
mouse O
17β-HSD2 O
. O
SAR O
studies O
allowed O
a O
first O
characterization O
of O
the O
human O
17β-HSD2 O
active O
site O
, O
which O
is O
predicted O
to O
be O
considerably O
larger O
than O
that O
of O
17β-HSD1 O
. O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR B
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 B
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O
and O
structures O
were O
highly O
conserved O
, O
including O
residues O
previously O
shown O
to O
be O
involved O
in O
catalysis O
and O
coenzyme O
binding O
for O
human O
ALDH2 O
. O
Studies O
of O
ALDH1B1 O
sequences O
supported O
the O
hypothesis O
that O
the O
ALDH1B1 O
gene O
originated O
in O
early O
vertebrates O
from O
a O
retrotransposition O
of O
the O
vertebrate O
ALDH2 O
gene O
. O
Given O
the O
high O
degree O
of O
similarity O
between O
ALDH2 O
and O
ALDH1B1 O
, O
it O
is O
surprising O
that O
individuals O
with O
an O
inactivating O
mutation O
in O
ALDH2 O
(ALDH2*2) O
do O
not O
exhibit O
a O
compensatory O
increase O
in O
ALDH1B1 O
activity O
. O
We O
hypothesized O
that O
the O
similarity O
between O
the O
two O
ALDHs O
would O
allow O
for O
dominant O
negative O
heterotetramerization O
between O
the O
inactive O
ALDH2 O
mutants O
and O
ALDH1B1 O
. O
Computational-based O
molecular O
modeling O
studies O
examining O
predicted O
protein-protein O
interactions O
indicated O
that O
heterotetramerization O
between O
ALDH2 O
and O
ALDH1B1 O
subunits O
was O
highly O
probable O
and O
may O
partially O
explain O
a O
lack O
of O
compensation O
by O
ALDH1B1 O
in O
ALDH2(∗)2 O
individuals O
. O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha B
1-adrenoceptor I
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine O
oxidase O
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine B
oxidase-A I
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O
noradrenaline O
(NA) O
, O
3,4-dihydroxyphenylglycol O
(DHPG) O
, O
homovanillic O
acid O
(HVA) O
and O
5-hydroxyindolacetic O
acid O
(5-HIAA) O
. O
Urine O
was O
collected O
for O
measurements O
of O
normetanephrine O
and O
3-methoxytyramine O
excretion O
. O
Psychometric O
performance O
(short- O
and O
long-term O
memory O
, O
critical O
flicker O
fusion O
frequency O
, O
choice O
reaction O
time) O
and O
subjective O
feelings O
were O
assessed O
before O
each O
drug O
intake O
(in O
the O
morning O
, O
at O
noon O
, O
in O
the O
evening) O
. O
3 O
. O
Compared O
with O
placebo O
, O
both O
reversible O
monoamine O
oxidase O
inhibitors O
decreased O
the O
plasma O
concentration O
of O
DHPG O
and O
HVA O
. O
The O
overall O
fall O
in O
DHPG O
(AUC O
from O
0 O
to O
24 O
h) O
was O
44% O
during O
moclobemide O
and O
12% O
during O
toloxatone O
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A O
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
. O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O
and O
to O
a O
lesser O
extent O
on O
toloxatone O
. O
The O
urinary O
excretion O
of O
3-methoxytyramine O
was O
significantly O
raised O
by O
moclobemide O
but O
not O
by O
toloxatone O
. O
7 O
. O
Neither O
moclobemide O
nor O
toloxatone O
altered O
memory O
function O
, O
vigilance O
, O
subjective O
feelings O
or O
sleep O
characteristics O
of O
the O
subjects O
. O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B
catalytic I
domain I
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Purification O
and O
structural O
characterisation O
of O
phospholipase O
A1 O
(Vespapase O
, O
Ves O
a O
1) O
from O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
venom.The O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
is O
one O
of O
the O
most O
dangerous O
vespid O
species O
in O
Southeast O
Asia O
, O
and O
stinging O
accidents O
involving O
this O
species O
still O
cause O
fatalities O
. O
In O
the O
present O
study O
, O
four O
forms O
of O
V O
. O
affinis O
phospholipase O
A(1) O
were O
identified O
through O
a O
proteomics O
approach O
. O
Two O
of O
these O
enzymes O
were O
purified O
by O
reverse-phase O
chromatography O
, O
and O
their O
biochemical O
properties O
were O
characterised O
. O
These O
enzymes O
, O
designated O
Ves O
a O
1s O
, O
are O
not O
glycoproteins O
and O
exist O
as O
33441.5 O
and O
33474.4 O
Da O
proteins O
, O
which O
corresponded O
with O
the O
34-kDa O
band O
observed O
via O
SDS-PAGE O
. O
The O
thermal O
stabilities O
of O
these O
enzymes O
were O
stronger O
than O
snake O
venom O
. O
Using O
an O
in O
vivo O
assay O
, O
no O
difference O
was O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves O
a O
1s O
revealed O
that O
the O
Ves O
a O
1 O
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves B
a I
1 I
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
. O

2-hydroxy-3-methylanthraquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
2-Hydroxy-3-methylanthraquinone O
from O
Hedyotis O
diffusa O
Willd O
induces O
apoptosis O
in O
human O
leukemic O
U937 O
cells O
through O
modulation O
of O
MAPK O
pathways.The O
herb O
of O
Hedyotis O
diffusa O
Willd O
(H O
. O
diffusa O
Willd) O
, O
an O
annual O
herb O
distributed O
in O
northeastern O
Asia O
, O
has O
been O
known O
as O
a O
traditional O
oriental O
medicine O
for O
the O
treatment O
of O
cancer O
. O
Recently O
, O
Chinese O
researchers O
have O
discovered O
that O
two O
anthraquinones O
isolated O
from O
a O
water O
extract O
of O
H O
. O
diffusa O
Willd O
showed O
apoptosis-inducing O
effects O
against O
cancer O
cells O
. O
However O
, O
the O
cellular O
and O
molecular O
mechanisms O
responsible O
for O
this O
phenomenon O
are O
poorly O
understood O
. O
The O
current O
study O
determines O
the O
role O
of O
mitogen-activated O
protein O
kinases O
(MAPK) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone O
from O
H O
. O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK B
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 O
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O
Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2-hydroxy-3-methylanthraquinone O
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O
in O
part O
, O
through O
activation O
of O
p-p38MAPK O
and O
downregulation O
of O
p-ERK1/2 O
. O
Moreover O
, O
the O
triggering O
of O
caspase-3 O
activation O
mediated O
apoptotic O
induction O
. O

lactate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hypoxia O
and O
lactate O
production O
in O
trophoblast O
cells.The O
etiology O
of O
preeclampsia O
is O
unknown O
but O
is O
thought O
to O
be O
related O
to O
hypoxia O
in O
the O
placenta O
. O
We O
previously O
reported O
that O
the O
enzyme O
lactate O
dehydrogenase O
(LDH) O
has O
increased O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O
for O
preeclampsia O
. O
Primary O
trophoblast O
cells O
and O
JEG3 O
cells O
were O
cultured O
under O
1% O
oxygen O
. O
At O
6 O
, O
12 O
and O
24h O
, O
cells O
were O
analyzed O
for O
LDHA O
and O
LDHB O
isozyme O
activities O
, O
mRNA O
and O
protein O
expression O
compared O
to O
standard O
culture O
conditions O
. O
Lactate O
was O
measured O
from O
cell O
medium O
. O
The O
hypoxia O
inducible O
transcription O
factor O
(HIF-1alpha) O
protein O
expression O
was O
confirmed O
by O
western O
blot O
. O
Two O
lactate O
transporters O
(MCT1 O
and O
MCT4) O
mRNA O
and O
protein O
expression O
were O
also O
studied O
under O
hypoxia O
. O
Finally O
, O
lactate O
was O
measured O
in O
plasma O
obtained O
from O
patients O
with O
severe O
preeclampsia O
. O
Under O
hypoxic O
conditions O
, O
LDHA O
mRNA O
is O
increased O
in O
primary O
trophoblast O
cells O
and O
JEG3 O
cells O
. O
The O
HIF-1alpha O
protein O
expression O
is O
higher O
in O
hypoxia-treated O
JEG3 O
cells O
than O
control O
. O
LDHA O
isozyme O
activity O
and O
its O
protein O
expression O
are O
increased O
most O
significantly O
at O
24h O
of O
culture O
under O
hypoxia O
. O
However O
, O
LDHB O
protein O
is O
unchanged O
while O
its O
mRNA O
is O
decreased O
. O
Lactate O
secretion O
from O
JEG3 O
cells O
under O
hypoxia O
is O
increased O
, O
as O
is O
the O
lactate O
levels O
in O
the O
plasma O
from O
preeclampsia O
patients O
. O
Of O
the O
two O
lactate O
transporters O
studied O
, O
MCT4 O
mRNA O
and O
protein O
level O
are O
increased O
under O
hypoxia O
. O
Our O
findings O
support O
the O
role O
of O
hypoxia O
in O
inducing O
HIF-1alpha O
activity O
in O
trophoblasts O
and O
increasing O
LDH O
transcription O
as O
well O
as O
its O
activity O
. O
Higher O
levels O
of O
lactate O
are O
produced O
and O
secreted O
which O
may O
contribute O
to O
the O
higher O
lactate O
levels O
in O
plasma O
of O
preeclamptic O
patients O
. O
These O
mechanisms O
may O
be O
important O
in O
the O
pathophysiology O
of O
preeclampsia O
. O

olanzapine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
adulthood O
olanzapine O
treatment O
on O
cognitive O
performance O
and O
neurotrophic O
factor O
content O
in O
male O
and O
female O
rats O
neonatally O
treated O
with O
quinpirole.Male O
and O
female O
Sprague-Dawley O
rats O
were O
administered O
quinpirole O
(1 O
mg/kg O
, O
i.p.) O
or O
saline O
once O
daily O
from O
postnatal O
day O
(P)1 O
to O
P21 O
. O
This O
drug O
treatment O
has O
been O
shown O
to O
produce O
long-term O
priming O
of O
the O
D2 O
receptor O
. O
Beginning O
on O
P62 O
, O
rats O
were O
administered O
the O
atypical O
antipsychotic O
olanzapine O
(2.5 O
mg/kg) O
or O
saline O
twice O
daily O
(i.p.) O
for O
28 O
days O
. O
One O
day O
after O
olanzapine O
treatment O
ceased O
, O
rats O
were O
tested O
on O
the O
place O
and O
match-to-place O
versions O
of O
the O
Morris O
water O
maze O
(MWM) O
for O
seven O
consecutive O
days O
. O
Dopamine O
D2 O
receptor O
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test O
, O
a O
D2 O
receptor-mediated O
event O
, O
before O
olanzapine O
was O
administered O
as O
well O
as O
after O
olanzapine O
treatment O
and O
behavioural O
testing O
were O
complete O
. O
Results O
showed O
that O
neonatal O
quinpirole O
treatment O
induced O
D2 B
priming O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
On O
the O
MWM O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O
but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 B
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Leukotriene O
D4 O
induces O
cognitive O
impairment O
through O
enhancement O
of O
CysLT₁ O
R-mediated O
amyloid-β O
generation O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 B
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O
such O
as O
AD O
. O

BDZs O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
( O
GABA(A)R) B
 O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig B
and I
mouse I
splenic I
alpha I
1B-adrenoceptors I
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hypoxia O
and O
lactate O
production O
in O
trophoblast O
cells.The O
etiology O
of O
preeclampsia O
is O
unknown O
but O
is O
thought O
to O
be O
related O
to O
hypoxia O
in O
the O
placenta O
. O
We O
previously O
reported O
that O
the O
enzyme O
lactate O
dehydrogenase O
(LDH) O
has O
increased O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O
for O
preeclampsia O
. O
Primary O
trophoblast O
cells O
and O
JEG3 O
cells O
were O
cultured O
under O
1% O
oxygen O
. O
At O
6 O
, O
12 O
and O
24h O
, O
cells O
were O
analyzed O
for O
LDHA O
and O
LDHB O
isozyme O
activities O
, O
mRNA O
and O
protein O
expression O
compared O
to O
standard O
culture O
conditions O
. O
Lactate O
was O
measured O
from O
cell O
medium O
. O
The O
hypoxia O
inducible O
transcription O
factor O
(HIF-1alpha) O
protein O
expression O
was O
confirmed O
by O
western O
blot O
. O
Two O
lactate O
transporters O
(MCT1 O
and O
MCT4) O
mRNA O
and O
protein O
expression O
were O
also O
studied O
under O
hypoxia O
. O
Finally O
, O
lactate O
was O
measured O
in O
plasma O
obtained O
from O
patients O
with O
severe O
preeclampsia O
. O
Under O
hypoxic O
conditions O
, O
LDHA O
mRNA O
is O
increased O
in O
primary O
trophoblast O
cells O
and O
JEG3 O
cells O
. O
The O
HIF-1alpha O
protein O
expression O
is O
higher O
in O
hypoxia-treated O
JEG3 O
cells O
than O
control O
. O
LDHA O
isozyme O
activity O
and O
its O
protein O
expression O
are O
increased O
most O
significantly O
at O
24h O
of O
culture O
under O
hypoxia O
. O
However O
, O
LDHB O
protein O
is O
unchanged O
while O
its O
mRNA O
is O
decreased O
. O
Lactate O
secretion O
from O
JEG3 O
cells O
under O
hypoxia O
is O
increased O
, O
as O
is O
the O
lactate O
levels O
in O
the O
plasma O
from O
preeclampsia O
patients O
. O
Of O
the O
two O
lactate O
transporters O
studied O
, O
MCT4 O
mRNA O
and O
protein O
level O
are O
increased O
under O
hypoxia O
. O
Our O
findings O
support O
the O
role O
of O
hypoxia O
in O
inducing O
HIF-1alpha O
activity O
in O
trophoblasts O
and O
increasing O
LDH O
transcription O
as O
well O
as O
its O
activity O
. O
Higher O
levels O
of O
lactate O
are O
produced O
and O
secreted O
which O
may O
contribute O
to O
the O
higher O
lactate O
levels O
in O
plasma O
of O
preeclamptic O
patients O
. O
These O
mechanisms O
may O
be O
important O
in O
the O
pathophysiology O
of O
preeclampsia O
. O

cefadroxil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanisms O
of O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
: O
studies O
in O
wild-type O
and O
PEPT2 O
knockout O
mice.The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil O
was O
studied O
in O
peptide O
transporter O
2 O
(PEPT2) O
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature O
, O
transport O
inhibitors O
, O
pH O
, O
and O
saturability O
. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C) O
, O
the O
uptake O
of O
1 O
microM O
cefadroxil O
was O
reduced O
by O
83% O
in O
PEPT2(-/-) O
mice O
as O
compared O
with O
PEPT2(+/+) O
mice O
(p O
< O
0.001) O
. O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C O
, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil O
or O
p-aminohippurate O
(p O
< O
0.05) O
. O
Glycylsarcosine O
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil O
in O
PEPT2(+/+) O
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) O
mice O
. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil O
was O
demonstrated O
in O
PEPT2( B
+/+) O
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01) O
, O
no O
pH O
dependence O
was O
observed O
in O
PEPT2(-/-) O
mice O
. O
Kinetic O
parameters O
for O
cefadroxil O
(without O
p-aminohippurate) O
in O
wild-type O
mice O
were O
: O
V(max) O
= O
5.4 O
pmol/mg/min O
, O
K(m) O
= O
34 O
microM O
, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
the O
parameters O
were O
: O
V(max) O
= O
4.1 O
pmol/mg/min O
, O
K(m) O
= O
27 O
microM O
, O
and O
K(d) O
= O
0.0064 O
microl/mg/min O
. O
In O
null O
animals O
, O
the O
kinetic O
parameters O
of O
cefadroxil O
(without O
p-aminohippurate) O
were O
: O
V(max) O
= O
2.7 O
pmol/mg/min O
, O
K(m) O
= O
110 O
microM O
, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed O
. O
Based O
on O
kinetic O
and O
inhibitor O
analyses O
, O
it O
was O
determined O
that O
(under O
linear O
conditions) O
, O
80 O
to O
85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2 O
, O
10 O
to O
15% O
by O
organic O
anion O
transporter(s) O
, O
and O
5% O
by O
nonspecific O
mechanisms O
. O
These O
findings O
demonstrate O
that O
PEPT2 O
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
. O
Moreover O
, O
the O
data O
suggest O
a O
role O
for O
PEPT2 O
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid O
. O

estrogen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
pure O
antiandrogen O
RU O
23908 O
(Anandron) O
, O
a O
candidate O
of O
choice O
for O
the O
combined O
antihormonal O
treatment O
of O
prostatic O
cancer O
: O
a O
review.The O
nonsteroidal O
antiandrogen O
RU O
23908 O
( O
Anandron O
) O
weakly O
interacts O
with O
the O
prostatic O
cytosolic O
androgen O
receptor O
and O
shows O
a O
fast O
dissociation O
rate O
. O
When O
administered O
to O
immature O
castrated O
rats O
up O
to O
the O
daily O
dose O
of O
100 O
mg/kg O
, O
it O
is O
devoid O
of O
any O
androgenic O
activity O
but O
efficiently O
blocks O
the O
growth-promoting O
activity O
of O
androgens O
on O
ventral O
prostate O
and O
seminal O
vesicle O
weight O
, O
thus O
showing O
the O
characteristics O
of O
a O
pure O
antiandrogen O
. O
In O
intact O
animals O
, O
on O
the O
other O
hand O
, O
the O
antiandrogen O
administered O
alone O
exerts O
only O
a O
partial O
inhibition O
of O
prostate O
and O
seminal O
vesicle O
weight O
. O
This O
is O
due O
to O
the O
property O
of O
the O
pure O
antiandrogen O
to O
neutralize O
the O
inhibitory O
feedback O
effect O
of O
androgens O
at O
the O
pituitary O
level O
on O
the O
LH O
responsiveness O
to O
LHRH O
, O
as O
illustrated O
in O
vitro O
in O
rat O
anterior O
pituitary O
cells O
in O
culture O
as O
well O
as O
in O
vivo O
in O
intact O
and O
castrated O
animals O
. O
In O
intact O
animals O
, O
neutralization O
of O
the O
inhibitory O
feedback O
action O
of O
endogenous O
androgens O
leads O
to O
an O
increased O
LH O
and O
testosterone O
secretion O
, O
which O
partly O
overcomes O
the O
direct O
action O
of O
the O
antiandrogen O
at O
the O
level O
of O
the O
prostate O
and O
seminal O
vesicles O
. O
In O
fact O
, O
the O
plasma O
testosterone O
concentration O
is O
more O
than O
doubled O
6 O
hr O
after O
the O
administration O
of O
10 O
mg O
of O
RU O
23908 O
while O
plasma O
LH O
and O
testosterone O
levels O
are O
increased O
by O
7- O
and O
17-fold O
, O
respectively O
, O
after O
14 O
days O
of O
similar O
daily O
treatment O
. O
Efficient O
neutralization O
of O
the O
androgenic O
action O
at O
the O
prostatic O
level O
in O
intact O
animals O
thus O
requires O
prevention O
of O
this O
escape O
phenomenon O
through O
inhibition O
of O
LH O
secretion O
. O
Although O
inhibition O
of O
LH B
release O
can O
be O
achieved O
by O
estrogen O
and O
progestins O
, O
an O
optimal O
inhibitory O
effect O
on O
the O
prostate O
is O
obtained O
by O
the O
combined O
administration O
of O
the O
antiandrogen O
with O
an O
LHRH O
agonist O
that O
causes O
a O
specific O
blockage O
of O
testicular O
androgen O
biosynthesis O
as O
well O
as O
an O
inhibition O
of O
the O
LH O
responsiveness O
to O
LHRH O
. O

amitriptyline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB B
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
: O
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response.The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O
to O
response O
. O
Thirty-eight O
examinations O
with O
(123)I-IBZM O
single O
photon O
emission O
computed O
tomography O
were O
performed O
on O
22 O
patients O
with O
schizophrenia O
, O
at O
diagnosis O
, O
48 O
h O
after O
starting O
risperidone O
treatment O
and O
at O
a O
stable O
dose O
. O
Risperidone O
plasma O
levels O
were O
determined O
and O
psychopathologic O
evaluations O
(Brief O
Psychiatric O
Rating O
Scale O
, O
Positive O
and O
Negative O
Syndrome O
Scale) O
were O
carried O
out O
. O
No O
differences O
in O
the O
striatal/occipital O
(S/O) O
ratio O
or O
plasma O
levels O
were O
found O
between O
examinations O
at O
the O
48-h O
time O
point O
and O
when O
a O
stable O
dose O
level O
had O
been O
established O
, O
so O
these O
parameters O
could O
not O
account O
for O
the O
latency O
period O
required O
for O
clinical O
response O
. O
D2 O
receptor O
occupancy O
at O
48 O
h O
correlated O
positively O
with O
clinical O
improvement O
after O
2 O
weeks O
of O
treatment O
. O
Therefore O
, O
if O
these O
results O
are O
confirmed O
, O
D2 B
receptor I
occupancy O
at O
the O
beginning O
of O
treatment O
with O
risperidone O
may O
be O
a O
predictor O
of O
subsequent O
clinical O
response O
. O

isoproterenol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Beta1 O
adrenergic O
receptor-mediated O
enhancement O
of O
hippocampal O
CA3 O
network O
activity.Norepinephrine O
is O
an O
endogenous O
neurotransmitter O
distributed O
throughout O
the O
mammalian O
brain O
. O
In O
higher O
cortical O
structures O
such O
as O
the O
hippocampus O
, O
norepinephrine O
, O
via O
beta O
adrenergic O
receptor O
(AR) O
activation O
, O
has O
been O
shown O
to O
reinforce O
the O
cognitive O
processes O
of O
attention O
and O
memory O
. O
In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
beta1AR O
activation O
on O
hippocampal O
cornu O
ammonis O
3 O
(CA3) O
network O
activity O
. O
AR O
expression O
was O
first O
determined O
using O
immunocytochemistry O
with O
antibodies O
against O
beta1ARs O
, O
which O
were O
found O
to O
be O
exceptionally O
dense O
in O
hippocampal O
CA3 O
pyramidal O
neurons O
. O
CA3 O
network O
activity O
was O
then O
examined O
in O
vitro O
using O
field O
potential O
recordings O
in O
rat O
brain O
slices O
. O
The O
selective O
betaAR O
agonist O
isoproterenol O
caused O
an O
enhancement O
of O
hippocampal O
CA3 O
network O
activity O
, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region O
. O
In O
the O
presence O
of O
alphaAR O
blockade O
, O
concentration-response O
curves O
for O
isoproterenol O
, O
norepinephrine O
, O
and O
epinephrine O
suggested O
that O
a O
beta1AR B
was O
involved O
in O
this O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR O
antagonists O
atenolol O
and O
metoprolol O
blocked O
isoproterenol-induced O
enhancement O
, O
with O
apparent O
K(b) O
values O
of O
85 O
+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM O
, O
respectively O
. O
In O
contrast O
, O
the O
selective O
beta2AR O
antagonists O
ICI-118,551 O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM O
, O
respectively) O
. O
Together O
, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR O
antagonists O
indicates O
that O
in O
this O
model O
, O
beta1AR O
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol O
. O

GnRH O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
kisspeptin O
in O
human O
reproductive O
function O
- O
therapeutic O
implications.Kisspeptin O
is O
a O
54-amino O
acid O
peptide O
which O
is O
encoded O
by O
the O
KiSS-1 O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
(GnRH) O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O
(FSH) O
and O
testosterone O
without O
side O
effects O
in O
both O
males O
and O
in O
females O
particularly O
in O
the O
preovulatatory O
phase O
of O
the O
menstrual O
cycle O
. O
In O
infertility O
due O
to O
hypothalamic O
amenorrhoea O
acute O
administration O
of O
kisspeptin O
results O
in O
stimulation O
of O
reproductive O
hormones O
. O
The O
kisspeptin/GPR54 O
system O
therefore O
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
reproduction O
in O
humans O
. O
Hence O
kisspeptin O
has O
potential O
as O
a O
novel O
tool O
for O
the O
manipulation O
of O
the O
HPG O
axis O
and O
treatment O
of O
infertility O
in O
humans O
. O
This O
review O
discusses O
the O
evidence O
highlighting O
kisspeptin's O
key O
role O
in O
human O
reproduction O
. O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cytosolic O
aspartate O
aminotransferase O
, O
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedione.We O
show O
that O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT O
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT B
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

UDP-Gal O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T B
reaction O
. O

E217βG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Chalcogenopyrylium O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP B
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP O
modulators O
and O
also O
show O
that O
within O
this O
core O
structure O
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2 O
. O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Plerixafor O
, O
a O
CXCR4 O
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells.Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal B
cell-derived I
factor-1 I
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O
combination O
of O
plerixafor O
and O
G-CSF O
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF O
mobilization O
alone O
. O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

sodium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Block O
of O
human O
NaV1.5 O
sodium B
channels I
by O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
phenytoin.Voltage-gated O
sodium O
(Na) O
channels O
are O
a O
critical O
component O
of O
electrically O
excitable O
cells O
. O
Phenytoin O
(diphenylhydantoin O
, O
DPH) O
is O
an O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O
examined O
including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
phenyl O
ring O
substitutions O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O
greater O
activity O
. O
In O
comparison O
to O
diphenylhydantoin O
, O
the O
novel O
chloro-substituted O
alpha-hydroxyphenylamide O
compounds O
produced O
as O
much O
as O
a O
20-fold O
greater O
tonic O
and O
frequency-dependent O
blockade O
of O
Na(V)1.5 O
channels O
with O
an O
IC(50) O
value O
of O
14.5 O
microM O
. O
In O
addition O
, O
the O
chloro-substitutions O
have O
position O
specific O
state O
dependent O
blocking O
properties O
. O
The O
ortho- O
, O
meta- O
and O
para-chloro O
substitutions O
have O
an O
8- O
, O
13- O
and O
3-fold O
increased O
affinity O
for O
the O
inactivated O
state O
, O
respectively O
. O
Molecular O
modeling O
suggests O
that O
these O
differences O
in O
affinity O
are O
due O
to O
a O
direct O
interaction O
with O
the O
receptor O
. O
Comparing O
models O
of O
diphenylhydantoin O
to O
the O
novel O
alpha-hydroxyphenlyamide O
compound O
suggests O
that O
the O
increased O
activity O
may O
be O
due O
to O
an O
optimized O
phenyl O
ring O
position O
and O
increased O
molecular O
volume O
. O
This O
information O
may O
be O
useful O
in O
the O
development O
of O
more O
potent O
sodium O
channel O
blockers O
. O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
is O
a O
target O
for O
modification O
by O
lipid O
electrophiles.Oxidation O
of O
membrane O
phospholipids O
is O
associated O
with O
inflammation O
, O
neurodegenerative O
disease O
, O
and O
cancer O
. O
Oxyradical O
damage O
to O
phospholipids O
results O
in O
the O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation O
. O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Juglone O
, O
isolated O
from O
Juglans O
mandshurica O
Maxim O
, O
induces O
apoptosis O
via O
down-regulation O
of O
AR O
expression O
in O
human O
prostate O
cancer O
LNCaP O
cells.Juglone O
is O
a O
natural O
compound O
which O
has O
been O
isolated O
from O
Juglans O
mandshurica O
Maxim O
. O
Recent O
studies O
have O
shown O
that O
juglone O
had O
various O
pharmacological O
effects O
such O
as O
anti-viral O
, O
anti-bacterial O
and O
anti-cancer O
. O
However O
, O
its O
anti-cancer O
activity O
on O
human O
prostate O
cancer O
LNCaP O
cell O
has O
not O
been O
examined O
. O
Thus O
, O
the O
current O
study O
was O
designed O
to O
elucidate O
the O
molecular O
mechanism O
of O
apoptosis O
induced O
by O
juglone O
in O
androgen-sensitive O
prostate O
cancer O
LNCaP O
cells O
. O
MTT O
assay O
was O
performed O
to O
examine O
the O
anti-proliferative O
effect O
of O
juglone O
. O
Occurrence O
of O
apoptosis O
was O
detected O
by O
Hoechst O
33342 O
staining O
and O
flow O
cytometry O
in O
LNCaP O
cells O
treated O
with O
juglone O
for O
24h O
. O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR B
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR O
expression O
. O
Therefore O
, O
our O
results O
indicated O
that O
juglone O
may O
be O
a O
potential O
candidate O
of O
drug O
for O
androgen-sensitive O
prostate O
cancer O
. O

Doxycycline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dose-response O
effect O
of O
tetracyclines O
on O
cerebral O
matrix O
metalloproteinase-9 O
after O
vascular O
endothelial O
growth O
factor O
hyperstimulation.Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder O
. O
Matrix O
metalloproteinase O
(MMP)-9 O
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens O
. O
Doxycycline O
was O
shown O
to O
decrease O
cerebral O
MMP-9 O
activities O
and O
angiogenesis O
induced O
by O
vascular O
endothelial O
growth O
factor O
( O
VEGF) B
 O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline O
and O
minocycline O
on O
cerebral O
MMP-9 O
using O
our O
mouse O
model O
with O
VEGF O
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O
brain O
. O
Mice O
were O
treated O
with O
doxycycline O
or O
minocycline O
, O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 O
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 O
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O
effect O
at O
a O
lower O
dose O
, O
1 O
mg/kg/day O
(P<0.02) O
. O
The O
inhibition O
of O
cerebral O
MMP-9 O
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue O
. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O
in O
vitro O
to O
elucidate O
the O
mechanisms O
underlying O
the O
MMP-9 O
inhibition O
by O
tetracyclines O
. O
In O
vitro O
, O
minocycline O
, O
but O
not O
doxycycline O
, O
inhibits O
MMP-9 O
, O
at O
least O
in O
part O
, O
via O
the O
extracellular O
signaling-related O
kinase O
1/2 O
(ERK1/2)-mediated O
pathway O
. O
This O
study O
provided O
the O
evidence O
that O
the O
tetracyclines O
inhibit O
stimulated O
cerebral O
MMP-9 O
at O
multiple O
levels O
and O
are O
effective O
at O
very O
low O
doses O
, O
offering O
great O
potential O
for O
therapeutic O
use O
. O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
5-HT1B O
receptors O
, O
alpha2A/2C- O
and O
, O
to O
a O
lesser O
extent O
, O
alpha1-adrenoceptors B
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow O
. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v O
. O
bolus O
injection O
of O
, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control) O
, O
or O
the O
antagonists O
SB224289 O
(300 O
microg/kg; O
5-HT1B) O
, O
BRL15572 O
(300 O
microg/kg; O
5-HT1D) O
, O
rauwolscine O
(300 O
microg/kg; O
alpha2) O
, O
SB224289 O
+ O
BRL15572 O
(300 O
microg/kg O
each) O
, O
SB224289 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
BRL15572 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg; O
alpha1) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
BRL44408 O
(1,000 O
microg/kg; O
alpha2A) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg)+ O
imiloxan O
(1,000 O
microg/kg; O
alpha2B) O
, O
or O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
MK912 O
(300 O
microg/kg; O
alpha2C) O
. O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine O
(0.56 O
, O
1 O
, O
1.8 O
, O
3.1 O
, O
5.6 O
, O
10 O
and O
18 O
microg/min) O
, O
following O
a O
cumulative O
schedule O
. O
In O
saline-pretreated O
animals O
, O
ergotamine O
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate O
. O
These O
control O
responses O
were O
: O
unaffected O
by O
SB224289 O
, O
BRL15572 O
, O
rauwolscine O
or O
the O
combinations O
of O
SB224289 O
+ O
BRL15572 O
, O
BRL15572 O
+ O
rauwolscine O
, O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
, O
or O
SB224289 O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors O
. O

arachidonyl O
trifluoromethyl O
ketone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

acetazolamide O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic O
anhydrase O
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
(PGs) O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA O
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O
we O
studied O
in O
vitro O
and O
in O
vivo O
the O
effects O
of O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
on O
CA O
I O
and O
CA O
II O
. O
We O
also O
followed O
in O
vitro O
the O
effects O
on O
these O
isozymes O
of O
NSAIDs O
associated O
to O
histamine O
, O
Ca O
, O
PGE2 O
and O
acetazolamide O
. O
The O
results O
show O
that O
the O
NSAIDs O
used O
here O
, O
which O
reduce O
the O
activity O
of O
cyclooxygenase O
and O
PG O
production O
, O
activated O
CA O
I O
and O
CA O
II O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA B
I I
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O
inhibition O
occurs O
"via O
CA," O
with O
the O
pH O
variations O
it O
brings O
about O
. O

DMA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE B
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

Imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF- B
induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

procaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
comparison O
of O
the O
reinforcing O
and O
dopamine O
transporter O
effects O
of O
local O
anesthetics O
in O
rhesus O
monkeys.Dopaminergic O
mechanisms O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
reinforcing O
effects O
of O
cocaine O
. O
Similar O
to O
cocaine O
, O
other O
local O
anesthetics O
bind O
to O
the O
dopamine O
transporter O
(DAT) O
and O
inhibit O
DA O
uptake O
in O
rodent O
and O
monkey O
brain O
. O
Additionally O
, O
local O
anesthetics O
are O
self-administered O
in O
rhesus O
monkeys O
, O
indicative O
of O
abuse O
liability O
. O
The O
present O
study O
examined O
the O
reinforcing O
and O
DAT O
effects O
of O
the O
local O
anesthetics O
dimethocaine O
, O
procaine O
and O
cocaine O
using O
in O
vivo O
techniques O
. O
Monkeys O
were O
trained O
to O
respond O
under O
a O
second-order O
schedule O
for O
i.v O
. O
cocaine O
administration O
(0.10 O
or O
0.30 O
mg/kg/infusion) O
. O
When O
responding O
was O
stable O
, O
dimethocaine O
(0.030-1.7 O
mg/kg O
/ O
infusion) O
or O
procaine O
(0.10-10 O
mg/kg O
/ O
infusion) O
was O
substituted O
for O
the O
cocaine O
training O
dose O
. O
Dimethocaine O
administration O
produced O
higher O
response O
rates O
compared O
with O
that O
of O
procaine O
, O
and O
was O
a O
more O
potent O
reinforcer O
. O
Drug O
effects O
on O
behavior O
were O
related O
to O
DAT O
occupancy O
in O
monkey O
striatum O
during O
neuroimaging O
with O
positron O
emission O
tomography O
(PET) O
. O
DAT O
occupancy O
was O
determined O
by O
displacement O
of O
8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane O
(FECNT) O
. O
DAT B
occupancy O
was O
between O
66 O
and O
82% O
and O
<10-41% O
for O
doses O
of O
dimethocaine O
and O
procaine O
that O
maintained O
maximum O
response O
rates O
, O
respectively O
. O
Finally O
, O
in O
vivo O
microdialysis O
in O
awake O
subjects O
determined O
drug-induced O
changes O
in O
extracellular O
DA O
in O
the O
caudate O
nucleus O
. O
There O
was O
close O
correspondence O
between O
peak O
increases O
in O
DA O
and O
DAT O
occupancy O
. O
Overall O
, O
reinforcing O
effects O
were O
consistent O
with O
DAT O
effects O
determined O
with O
in O
vivo O
techniques O
. O
The O
results O
further O
support O
a O
role O
for O
the O
DAT O
in O
the O
abuse O
liability O
of O
local O
anesthetics O
. O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
( O
DAT B
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O
current O
study O
, O
SHR O
, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT O
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

ZnSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Artificial O
sweeteners O
and O
salts O
producing O
a O
metallic O
taste O
sensation O
activate O
TRPV1 O
receptors.Throughout O
the O
world O
many O
people O
use O
artificial O
sweeteners O
(AS) O
for O
the O
purpose O
of O
reducing O
caloric O
intake O
. O
The O
most O
prominently O
used O
of O
these O
molecules O
include O
saccharin O
, O
aspartame O
(Nutrasweet) O
, O
acesulfame-K O
, O
and O
cyclamate O
. O
Despite O
the O
caloric O
advantage O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R O
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
. O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O
taste O
receptor O
cells O
and O
in O
nerve O
terminals O
throughout O
the O
oral O
cavity O
. O
Hence O
, O
TRPV1 O
activation O
could O
be O
involved O
in O
the O
AS O
aftertaste O
or O
even O
contribute O
to O
the O
poorly O
understood O
metallic O
taste O
sensation O
. O
Using O
Ca(2+) O
imaging O
on O
TRPV1 O
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 B
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
, O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

Mn O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Down-regulation O
of O
LRRK2 O
in O
control O
and O
DAT O
transfected O
HEK O
cells O
increases O
manganese-induced O
oxidative O
stress O
and O
cell O
toxicity.The O
extra-pyramidal O
symptoms O
associated O
with O
manganism O
often O
overlap O
with O
that O
seen O
in O
Parkinsonism O
suggesting O
a O
common O
link O
between O
the O
two O
disorders O
. O
Since O
wide O
deviations O
are O
observed O
in O
susceptibility O
and O
characteristics O
of O
the O
symptoms O
observed O
in O
manganism O
, O
these O
differences O
may O
be O
due O
to O
underlying O
genetic O
variability O
. O
Genes O
linked O
to O
early O
onset O
of O
Parkinsonism O
which O
includes O
ATP13A2 O
and O
parkin O
have O
already O
been O
suggested O
to O
promote O
development O
of O
Mn O
toxicity O
. O
Of O
the O
other O
Parkinson-linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT O
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK B
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 O
plays O
a O
role O
in O
the O
phosphorylation O
of O
p38 O
, O
our O
results O
similarly O
demonstrate O
a O
decrease O
in O
p38 O
activation O
in O
LRRK2 O
knock-down O
cells O
. O
Our O
findings O
suggest O
that O
null O
mutations O
in O
LRRK2 O
which O
cause O
Parkinsonism O
potentiate O
Mn O
toxicity O
and O
increase O
susceptibility O
to O
develop O
manganism O
. O

AlCl3 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Possible O
Therapeutic O
Uses O
of O
Salvia O
triloba O
and O
Piper O
nigrum O
in O
Alzheimer's O
Disease-Induced O
Rats.Abstract O
This O
study O
aimed O
to O
investigate O
the O
role O
of O
Salvia O
triloba O
L O
. O
and O
Piper O
nigrum O
extracts O
in O
ameliorating O
neuroinflammatory O
insults O
characteristic O
of O
Alzheimer's O
disease O
(AD) O
in O
an O
experimentally O
induced O
rat O
model O
. O
Adult O
male O
Sprague-Dawley O
rats O
were O
classified O
into O
Group O
1 O
(n=10) O
: O
normal O
healthy O
animals O
serving O
as O
the O
negative O
control O
group; O
Group O
2 O
(n=60) O
: O
the O
AD-induced O
group O
. O
After O
AD O
induction O
, O
animals O
in O
the O
AD-induced O
group O
were O
divided O
randomly O
and O
equally O
into O
6 O
subgroups O
. O
The O
first O
subgroup O
served O
as O
AD O
control; O
the O
second O
one O
, O
which O
served O
as O
positive O
control O
, O
was O
treated O
orally O
with O
the O
conventional O
therapy O
for O
AD O
(rivastigmine) O
at O
a O
dose O
of O
0.3 O
mg/kg O
body O
weight O
(b.w.) O
daily O
for O
3 O
months O
. O
The O
third O
and O
fourth O
subgroups O
were O
, O
respectively O
, O
treated O
orally O
with O
the O
S O
. O
triloba O
extract O
at O
a O
dose O
of O
750 O
and O
375 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
The O
fifth O
and O
sixth O
subgroups O
were O
, O
respectively O
, O
treated O
orally O
with O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE O
activity O
, O
CRP O
, O
NF-κB O
, O
and O
MCP-1 B
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O
P O
. O
nigrum O
methanolic O
extracts O
have O
potent O
anti-inflammatory O
effects O
against O
neuroinflammation O
characterizing O
AD O
. O

Atomoxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atomoxetine O
increases O
extracellular O
levels O
of O
norepinephrine O
and O
dopamine O
in O
prefrontal O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine O
(NE) O
transporter O
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O
NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O
transporters O
with O
dissociation O
constants O
(K(i)) O
values O
of O
5 O
, O
77 O
and O
1451 O
nM O
, O
respectively O
, O
demonstrating O
selectivity O
for O
NE B
transporters I
. O
In O
microdialysis O
studies O
, O
atomoxetine O
increased O
extracellular O
(EX) O
levels O
of O
NE O
in O
prefrontal O
cortex O
(PFC) O
3-fold O
, O
but O
did O
not O
alter O
5-HT(EX) O
levels O
. O
Atomoxetine O
also O
increased O
DA(EX) O
concentrations O
in O
PFC O
3-fold O
, O
but O
did O
not O
alter O
DA(EX) O
in O
striatum O
or O
nucleus O
accumbens O
. O
In O
contrast O
, O
the O
psychostimulant O
methylphenidate O
, O
which O
is O
used O
in O
ADHD O
therapy O
, O
increased O
NE(EX) O
and O
DA(EX) O
equally O
in O
PFC O
, O
but O
also O
increased O
DA(EX) O
in O
the O
striatum O
and O
nucleus O
accumbens O
to O
the O
same O
level O
. O
The O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
was O
increased O
3.7-fold O
in O
PFC O
by O
atomoxetine O
administration O
, O
but O
was O
not O
increased O
in O
the O
striatum O
or O
nucleus O
accumbens O
, O
consistent O
with O
the O
regional O
distribution O
of O
increased O
DA(EX) O
. O
We O
hypothesize O
that O
the O
atomoxetine-induced O
increase O
of O
catecholamines O
in O
PFC O
, O
a O
region O
involved O
in O
attention O
and O
memory O
, O
mediates O
the O
therapeutic O
effects O
of O
atomoxetine O
in O
ADHD O
. O
In O
contrast O
to O
methylphenidate O
, O
atomoxetine O
did O
not O
increase O
DA O
in O
striatum O
or O
nucleus O
accumbens O
, O
suggesting O
it O
would O
not O
have O
motoric O
or O
drug O
abuse O
liabilities O
. O

cilazapril O
acts O
as O
NOT O
for O
what O
entity O
? O
Angiotensin-converting O
enzyme O
inhibition O
and O
AT1 O
receptor O
blockade O
modify O
the O
pressure-natriuresis O
relationship O
by O
additive O
mechanisms O
in O
rats O
with O
human O
renin O
and O
angiotensinogen O
genes.The O
intrarenal O
factors O
responsible O
for O
hypertension O
in O
double-transgenic O
rats O
(dTGR) O
harboring O
human O
renin O
and O
human O
angiotensinogen O
genes O
are O
unclear O
. O
The O
pressure-natriuresis O
and O
-diuresis O
relationships O
in O
response O
to O
chronic O
angiotensin-converting O
enzyme O
(ACE) O
inhibition O
and O
AT1 O
receptor O
blockade O
were O
evaluated O
. O
Renal O
renin-angiotensin O
and O
nitric O
oxide O
(NO) O
system O
gene O
expression O
was O
also O
investigated O
. O
Six-week-old O
dTGR O
were O
treated O
for O
3 O
wk O
with O
submaximal O
doses O
of O
cilazapril O
(10 O
mg/kg O
, O
orally) O
or O
losartan O
(10 O
mg/kg O
, O
orally) O
or O
with O
the O
drug O
combination O
. O
In O
untreated O
dTGR O
, O
pressure-natriuresis O
relationships O
were O
maximally O
shifted O
rightward O
by O
approximately O
70 O
to O
80 O
mmHg O
, O
and O
both O
renal O
blood O
flow O
(RBF) O
and O
GFR O
were O
markedly O
decreased O
. O
Submaximal O
cilazapril O
and O
losartan O
dosages O
both O
decreased O
systolic O
BP O
by O
30 O
mmHg O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
by O
25 O
to O
30 O
mmHg O
. O
Cilazapril O
increased O
RBF O
and O
GFR O
to O
values O
observed O
in O
normotensive O
control O
animals O
but O
did O
not O
significantly O
affect O
fractional O
sodium O
excretion O
(FENa) O
or O
fractional O
water O
excretion O
(FEH2O) O
curves O
. O
In O
contrast O
, O
losartan O
had O
no O
significant O
effect O
on O
RBF O
or O
GFR O
but O
shifted O
the O
FENa O
and O
FEH2O O
curves O
leftward O
. O
The O
cilazapril O
and O
losartan O
combination O
completely O
normalized O
BP O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
more O
than O
did O
either O
drug O
alone O
. O
When O
cilazapril O
and O
losartan O
were O
administered O
at O
higher O
doses O
(30 O
mg/kg O
, O
orally) O
, O
the O
two O
drugs O
equally O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
, O
by O
50 O
mmHg O
. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however O
, O
only O
losartan O
shifted O
FENa O
and O
FEH2O O
curves O
leftward O
. O
Human O
and O
rat O
renin O
and O
angiotensinogen O
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan O
and O
cilazapril O
treatments O
, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat O
ACE O
and O
AT1A B
receptor O
genes O
were O
observed O
. O
Endothelial O
NO O
synthase O
expression O
was O
increased O
by O
cilazapril O
but O
not O
by O
losartan O
. O
Neither O
inducible O
NO O
synthase O
nor O
neural O
NO O
synthase O
gene O
expression O
was O
affected O
by O
drug O
treatments O
. O
Therefore O
, O
submaximal O
ACE O
inhibition O
enhanced O
sodium O
excretion O
mainly O
by O
increasing O
RBF O
and O
GFR O
, O
whereas O
submaximal O
AT1 O
receptor O
blockade O
decreased O
tubular O
sodium O
and O
water O
reabsorption O
. O
The O
combination O
of O
the O
two O
drugs O
produced O
an O
additive O
effect O
. O
The O
ACE O
inhibitor O
effects O
may O
involve O
increased O
endothelial O
NO O
synthase O
expression O
, O
perhaps O
related O
to O
the O
inhibition O
of O
bradykinin O
degradation O
. O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat B
GnRHR) I
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

amines O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides O
. O
Carboxylesterases B
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

formate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate B
dehydrogenase I
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) B
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain B
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

diclofenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Meclofenamic O
acid O
and O
diclofenac O
, O
novel O
templates O
of O
KCNQ2/Q3 B
potassium O
channel O
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O
voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current O
. O
Furthermore O
, O
the O
KCNQ2 O
and O
KCNQ3 O
channel O
alpha O
subunits O
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 O
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics O
. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O
KCNQ2 O
than O
on O
KCNQ3 O
channel O
alpha O
subunits O
. O
In O
contrast O
, O
they O
did O
not O
enhance O
KCNQ1 O
K(+) O
currents O
. O
Both O
openers O
increased O
KCNQ2/Q3 O
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential O
. O
In O
cultured O
cortical O
neurons O
, O
meclofenamate O
and O
diclofenac O
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials O
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pain O
. O

mifepristone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
[Effect O
of O
mifepristone O
on O
the O
expression O
of O
progesterone O
receptor O
messenger O
RNA O
and O
protein O
in O
uterine O
leiomyomata].OBJECTIVE O
: O
To O
determine O
the O
expression O
of O
progesterone O
receptor O
(PR) O
mRNA O
and O
PR O
protein O
levels O
in O
the O
myometrium O
and O
leiomyomata O
from O
untreated O
and O
mifepristone O
pretreated O
women O
with O
leiomyoma O
and O
to O
examine O
the O
mechanism O
of O
mifepristone O
treatment O
on O
uterine O
leiomyomata O
. O
METHODS O
: O
Expression O
of O
PR O
mRNA O
and O
PR O
protein O
were O
determined O
by O
Northern O
blot O
and O
HAP O
of O
single-dose O
saturated O
analysis O
in O
myometrium O
and O
leiomyomata O
(center O
and O
marginal O
area) O
from O
27 O
untreated O
and O
6 O
mifepristone O
pretreated O
women O
with O
leiomyomata O
. O
RESULTS O
: O
PR O
mRNA O
abundance O
and O
PR O
protein O
levels O
in O
both O
myomatous O
center O
and O
marginal O
area O
were O
significantly O
greater O
than O
those O
in O
corporal O
myometrium O
(P O
< O
0.01) O
in O
both O
follicular O
and O
luteal O
phases O
, O
but O
similar O
between O
myomatous O
center O
and O
marginal O
area O
(P O
> O
0.05) O
. O
6 O
cases O
pretreated O
with O
mifepristone O
25 O
mg/day O
for O
3 O
months O
were O
operated O
, O
all O
but O
one O
patient O
displayed O
a O
decrease O
in O
leiomyomata O
volume O
. O
PR B
mRNA I
abundance O
in O
both O
myometruim O
and O
leiomyomata O
(center O
and O
marginal O
area) O
was O
significantly O
decreased O
in O
4 O
patients O
continuing O
mifepristone O
treatment O
before O
the O
operation O
but O
not O
in O
the O
other O
2 O
patients O
stopping O
RU486 O
1 O
month O
before O
operation O
. O
PR O
protein O
levels O
in O
these O
tissues O
showed O
significant O
decrease O
in O
all O
6 O
cases O
. O
CONCLUSION O
: O
There O
are O
overexpression O
of O
PRmRNA O
and O
PR O
protein O
in O
leiomyomata O
. O
One O
of O
the O
mechanism O
of O
mifepristone O
action O
on O
decreasing O
leiomyomata O
volume O
may O
be O
related O
to O
suppression O
on O
expression O
of O
PR O
gene O
. O
It O
seems O
that O
suppression O
on O
transcription O
of O
PR O
gene O
is O
reversible O
, O
but O
on O
translation O
of O
PR O
gene O
may O
maintain O
in O
a O
relatively O
longer O
period O
. O

EETs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O
delivery O
led O
to O
an O
abundant O
aortic O
CYP2J2 O
expression O
and O
increased O
EETs O
generation O
. O
It O
was O
shown O
that O
CYP2J2 O
overexpression O
attenuated O
matrix O
metalloproteinase O
expression O
and O
activity O
, O
elastin O
degradation O
, O
and O
AAA O
formation O
, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration O
. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
, O
rAAV-mediated O
CYP2J2 O
overexpression O
and O
EETs O
markedly O
suppressed O
Ang O
II-induced O
inflammatory O
cytokine O
expression O
. O
Moreover O
, O
overexpressed O
CYP2J2 O
and O
EETs O
inhibited O
Ang B
II- I
induced O
macrophage O
migration O
in O
a O
VSMC-macrophage O
coculture O
system O
. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
(PPAR)γ O
activation O
. O
Taken O
together O
, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 O
overexpression O
prevents O
AAA O
development O
which O
is O
likely O
via O
PPARγ O
activation O
and O
anti-inflammatory O
action O
, O
suggesting O
that O
increasing O
EETs O
levels O
could O
be O
considered O
as O
a O
potential O
strategy O
to O
prevent O
and O
treat O
AAA O
. O

glutamic O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
( O
BRAF( B
V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O
(K(p)) O
of O
dabrafenib O
after O
an O
i.v O
. O
dose O
(2.5 O
mg/kg) O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
, O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

KA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tissue O
expression O
and O
translational O
control O
of O
rat O
kynurenine O
aminotransferase/glutamine O
transaminase O
K O
mRNAs.Kynurenic O
acid O
(KA) O
is O
an O
endogenous O
glutamate O
receptor O
antagonist O
at O
the O
level O
of O
the O
different O
ionotropic O
glutamate O
receptors O
. O
One O
of O
the O
enzymes O
responsible O
for O
the O
production O
of O
KA O
, O
kynurenine O
aminotransferase O
I O
( O
KATI) B
 O
, O
also O
catalyses O
the O
reversible O
transamination O
of O
glutamine O
to O
oxoglutaramic O
acid O
(GTK O
, O
EC O
2.6.1.15) O
. O
The O
enzyme O
exists O
in O
a O
cytosolic O
and O
in O
a O
mitochondrial O
form O
because O
of O
the O
presence O
of O
two O
different O
KATI O
mRNAs O
coding O
for O
a O
protein O
respectively O
with O
and O
without O
leader O
sequence O
targeting O
the O
protein O
into O
mitochondria O
. O
We O
have O
cloned O
from O
a O
phage O
library O
of O
rat O
kidney O
cDNA O
four O
new O
KATI O
cDNAs O
containing O
different O
5' O
untranslated O
regions O
(UTRs) O
. O
One O
of O
the O
transcripts O
(+14KATI O
cDNA) O
contains O
an O
alternative O
site O
of O
initiation O
of O
translation O
. O
The O
tissue O
distribution O
of O
the O
different O
transcripts O
was O
studied O
by O
RT-PCR O
. O
The O
study O
demonstrated O
that O
several O
KATI O
mRNAs O
are O
constitutively O
expressed O
in O
ubiquitous O
manner O
, O
while O
+14KATI O
mRNA O
is O
present O
only O
in O
kidney O
. O
The O
translational O
efficiency O
of O
the O
different O
transcripts O
was O
studied O
in O
vitro O
and O
enzymatic O
activities O
were O
measured O
in O
transiently O
transfected O
Cos-1 O
cells O
. O
Each O
KATI O
mRNA O
exhibits O
a O
different O
in O
vitro O
translational O
efficiency O
, O
which O
corresponds O
to O
different O
levels O
of O
KAT O
enzymatic O
activity O
in O
transfected O
cells O
. O
Both O
findings O
correlate O
with O
the O
predicted O
accessibility O
of O
the O
ribosomal O
binding O
sites O
of O
the O
different O
mRNAs O
. O
The O
structure O
of O
the O
rat O
KATI/GTK O
gene O
was O
also O
studied O
. O
The O
expression O
of O
several O
KATI O
mRNAs O
with O
different O
5'UTRs O
represents O
an O
interesting O
example O
of O
transcriptional/translational O
control O
on O
the O
expression O
of O
pyridoxal O
phosphate O
(PLP)-dependent O
aminotransferases O
. O

Histamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine B
decarboxylase I
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

saquinavir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
mechanisms O
responsible O
for O
garlic O
- O
drug O
interactions O
and O
their O
in O
vivo O
relevance.Garlic O
phytochemicals O
and O
garlic O
supplements O
influence O
the O
pharmacokinetic O
and O
pharmacodynamic O
behavior O
of O
concomitantly O
ingested O
drugs O
. O
In O
this O
paper O
we O
have O
summarized O
the O
mechanisms O
responsible O
for O
first-pass O
intestinal O
pharmacokinetic O
interactions O
by O
investigating O
the O
intestinal O
permeability O
of O
some O
cardiovascular O
, O
antiviral O
drugs O
, O
their O
transport O
with O
hepatic O
transporters O
and O
CYP3A4 O
metabolism O
. O
Transporter-enzyme O
interplay O
was O
studied O
with O
several O
in O
vitro O
models O
of O
varying O
complexity O
: O
rat O
small O
intestine O
and O
Caco-2 O
cell O
monolayers O
were O
used O
in O
studies O
of O
intestinal O
processes O
, O
and O
hepatic O
pharmacokinetics O
was O
monitored O
in O
HepG2 O
cells O
, O
isolated O
rat O
hepatocytes O
and O
rat O
liver O
slices O
. O
Garlic O
phytochemicals O
from O
aged O
garlic O
extract O
modified O
the O
activities O
of O
secretory O
and O
absorptive O
transporters O
in O
both O
intestine O
and O
liver O
and O
competitively O
inhibited O
CYP3A4 O
enzyme O
. O
The O
increased O
activities O
of O
the O
most O
important O
intestinal O
efflux O
(P-glycoprotein O
- O
Pgp O
, O
Multidrug O
Resistance O
Associated O
Protein O
2 O
- O
MRP-2 O
, O
Breast O
Cancer O
Resistance O
Protein O
- O
BCRP) O
and O
uptake O
(MonoCarboxylate O
Transporter O
1 O
- O
MCT1 O
, O
Organic O
Anion O
Transporting O
Polypeptide O
- O
OATP O
, O
Peptide O
transporter O
1 O
- O
PepT1) O
transporters O
were O
caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications O
. O
Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human B
immunodeficiency I
virus I
protease I
inhibitors O
saquinavir O
and O
ritonavir O
have O
already O
been O
performed O
, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first-pass O
intestinal O
metabolism O
changes O
. O
We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O
novel O
drug O
darunavir O
and O
other O
cardiovascular O
drugs O
. O
Finally O
, O
selected O
garlic O
phytochemicals O
were O
tested O
for O
their O
ability O
to O
influence O
P-glycoprotein O
and O
CYP3A4 O
activities O
. O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase O
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
, O
leading O
to O
the O
formation O
of O
prostaglandins O
. O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O
utilizing O
a O
baculovirus O
expression O
system O
. O
hCOX-1 O
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 B
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
( O
PTGS2) B
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O
or O
recombinant O
ovine O
IFNT O
and O
into O
the O
uterus O
from O
day O
10 O
to O
day O
14 O
after O
mating O
. O
Inhibition O
of O
HSD11B1 O
activity O
in O
utero O
prevented O
conceptus O
elongation O
, O
whereas O
IFNT O
rescued O
conceptus O
elongation O
in O
PF-infused O
ewes O
. O
These O
results O
suggest O
that O
HSD11B1-derived O
cortisol O
mediates O
, O
in O
part O
, O
actions O
of O
ovarian O
progesterone O
and O
the O
conceptus O
on O
endometrial O
function O
and O
support O
the O
hypothesis O
that O
IFNT O
, O
PG O
, O
and O
cortisol O
coordinately O
regulate O
endometrial O
functions O
important O
for O
conceptus O
elongation O
and O
implantation O
during O
early O
pregnancy O
in O
sheep O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase B
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

Wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK B
-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

nodularins O
acts O
as O
NOT O
for O
what O
entity O
? O
Crystal O
structures O
of O
protein O
phosphatase-1 O
bound O
to O
motuporin O
and O
dihydromicrocystin-LA O
: O
elucidation O
of O
the O
mechanism O
of O
enzyme O
inhibition O
by O
cyanobacterial O
toxins.The O
microcystins O
and O
nodularins O
are O
tumour O
promoting O
hepatotoxins O
that O
are O
responsible O
for O
global O
adverse O
human O
health O
effects O
and O
wildlife O
fatalities O
in O
countries O
where O
drinking O
water O
supplies O
contain O
cyanobacteria O
. O
The O
toxins O
function O
by O
inhibiting O
broad O
specificity O
Ser/Thr O
protein O
phosphatases O
in O
the O
host O
cells O
, O
thereby O
disrupting O
signal O
transduction O
pathways O
. O
A O
previous O
crystal O
structure O
of O
a O
microcystin O
bound O
to O
the O
catalytic O
subunit O
of O
protein O
phosphatase-1 O
(PP-1c) O
showed O
distinct O
changes O
in O
the O
active O
site O
region O
when O
compared O
with O
protein O
phosphatase-1 O
structures O
bound O
to O
other O
toxins O
. O
We O
have O
elucidated O
the O
crystal O
structures O
of O
the O
cyanotoxins O
, O
motuporin O
(nodularin-V) O
and O
dihydromicrocystin-LA O
bound O
to O
human O
protein O
phosphatase-1c O
(gamma O
isoform) O
. O
The O
atomic O
structures O
of O
these O
complexes O
reveal O
the O
structural O
basis O
for O
inhibition O
of O
protein O
phosphatases O
by O
these O
toxins O
. O
Comparisons O
of O
the O
structures O
of O
the O
cyanobacterial O
toxin:phosphatase O
complexes O
explain O
the O
biochemical O
mechanism O
by O
which O
microcystins O
but O
not O
nodularins O
permanently O
modify O
their O
protein B
phosphatase I
targets O
by O
covalent O
addition O
to O
an O
active O
site O
cysteine O
residue O
. O

SB365 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SB365 O
, O
Pulsatilla O
saponin O
D O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT O
/mTOR B
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer O
. O
We O
found O
that O
SB365 O
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis O
. O
Also O
, O
SB365 O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer O
. O

cilazapril O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Altered O
vasoreactivity O
to O
angiotensin O
II O
in O
experimental O
diabetic O
neuropathy O
: O
role O
of O
nitric O
oxide.We O
evaluated O
the O
effects O
of O
angiotensin O
II O
and O
an O
angiotensin-converting B
enzyme I
inhibitor O
(cilazapril) O
on O
nerve O
blood O
flow O
(NBF) O
and O
electrophysiology O
in O
control O
and O
diabetic O
rats O
. O
When O
applied O
locally O
to O
the O
sciatic O
nerve O
, O
the O
dose-response O
curve O
of O
angiotensin O
II O
was O
more O
potent O
in O
experimental O
diabetic O
neuropathy O
(EDN) O
than O
control O
rats O
. O
No O
difference O
existed O
in O
plasma O
angiotensin O
II O
levels O
between O
EDN O
and O
controls O
. O
The O
rats O
were O
given O
typical O
rat O
pellets O
or O
pellets O
treated O
with O
10 O
mg/kg O
per O
day O
cilazapril O
for O
4 O
weeks O
. O
Diabetes O
caused O
a O
significant O
reduction O
in O
NBF O
, O
nerve O
conduction O
velocity O
, O
and O
compound O
muscle O
action O
potential O
(CMAP) O
amplitudes O
. O
NBF O
was O
significantly O
increased O
in O
diabetic O
rats O
supplemented O
with O
cilazapril O
diet O
, O
and O
nerve O
conduction O
velocity O
and O
amplitudes O
of O
the O
CMAP O
were O
also O
improved O
after O
4 O
weeks O
on O
this O
diet O
. O
Direct O
application O
10(-3) O
mol/L O
cilazapril O
on O
sciatic O
nerve O
did O
not O
increase O
NBF O
in O
normal O
and O
EDN O
rats O
. O
We O
topically O
applied O
the O
nitric O
oxide O
synthase O
(NOS) O
inhibitor O
, O
NG-nitro-L-arginine O
, O
on O
sciatic O
nerve O
and O
observed O
reduced O
inhibition O
of O
NBF O
in O
EDN O
, O
which O
was O
correctable O
with O
a O
cilazapril O
diet O
. O
These O
results O
suggest O
that O
diabetic O
neuropathy O
may O
have O
an O
increasing O
vasopressor O
action O
with O
angiotensin O
II O
and O
this O
is O
likely O
to O
be O
the O
mechanism O
of O
NOS O
inhibition O
. O
Angiotensin O
II-converting O
enzyme O
inhibitors O
may O
have O
potential O
in O
the O
treatment O
of O
diabetic O
neuropathy O
. O

CPT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Topoisomerase O
IIβ O
deficiency O
enhances O
camptothecin-induced O
apoptosis.Camptothecin O
(CPT) O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild-type O
MEFs O
, O
whereas O
RNAP O
LS O
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 O
protein O
level O
was O
greatly O
induced O
. O
Interestingly O
, O
RNAP O
LS O
depletion O
has O
been O
well O
documented O
to O
lead O
to O
p53-dependent O
apoptosis O
. O
Altogether O
, O
our O
findings O
support O
a O
model O
in O
which O
Top2β O
deficiency O
promotes O
CPT-induced O
apoptosis O
in O
quiescent O
non-S-phase O
cells O
, O
possibly O
due O
to O
RNAP B
LS I
depletion O
and O
p53 O
accumulation O
. O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
characteristics O
of O
genistin-induced O
inhibitory O
effects O
on O
intestinal O
motility.Genistin O
belongs O
to O
isoflavones O
. O
Based O
on O
the O
facts O
that O
genistin O
exerts O
inhibitory O
effects O
on O
the O
contractility O
of O
vascular O
smooth O
muscle,the O
present O
study O
was O
designed O
to O
characterize O
the O
effects O
of O
genistin O
on O
intestinal O
contractility O
and O
evaluate O
its O
potential O
clinical O
implication O
. O
Ex O
vivo O
[isolated O
jejunal O
segment O
(IJS) O
of O
rat] O
, O
in O
vitro O
, O
and O
in O
vivo O
assays O
were O
used O
in O
the O
study O
. O
The O
results O
indicated O
that O
genistin O
(5-80 O
μmol/L) O
inhibited O
the O
contraction O
of O
IJS O
in O
a O
dose-dependent O
manner O
and O
inhibited O
the O
increased-contractility O
of O
IJS O
induced O
by O
acetylcholine O
(ACh) O
, O
histamine O
, O
high O
Ca(2+) O
, O
and O
erythromycin O
, O
respectively O
. O
The O
inhibitory O
effects O
of O
genistin O
were O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
( O
MLCK) B
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin O
in O
relieving O
intestinal O
hypercontractility O
. O

2-oxobutyrate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Crystal O
structure O
of O
the O
pyridoxal-5'-phosphate-dependent O
serine O
dehydratase O
from O
human O
liver O
. O
L-serine B
dehydratase I
(SDH) O
, O
a O
member O
of O
the O
beta-family O
of O
pyridoxal O
phosphate-dependent O
(PLP) O
enzymes O
, O
catalyzes O
the O
deamination O
of O
L-serine O
and O
L-threonine O
to O
yield O
pyruvate O
or O
2-oxobutyrate O
. O
The O
crystal O
structure O
of O
L-serine O
dehydratase O
from O
human O
liver O
(hSDH) O
has O
been O
solved O
at O
2.5 O
A-resolution O
by O
molecular O
replacement O
. O
The O
structure O
is O
a O
homodimer O
and O
reveals O
a O
fold O
typical O
for O
beta-family O
PLP-dependent O
enzymes O
. O
Each O
monomer O
serves O
as O
an O
active O
unit O
and O
is O
subdivided O
into O
two O
distinct O
domains O
: O
a O
small O
domain O
and O
a O
PLP-binding O
domain O
that O
covalently O
anchors O
the O
cofactor O
. O
Both O
domains O
show O
the O
typical O
open O
alpha/beta O
architecture O
of O
PLP O
enzymes O
. O
Comparison O
with O
the O
rSDH-(PLP-OMS) O
holo-enzyme O
reveals O
a O
large O
structural O
difference O
in O
active O
sites O
caused O
by O
the O
artifical O
O-methylserine O
. O
Furthermore O
, O
the O
activity O
of O
hSDH-PLP O
was O
assayed O
and O
it O
proved O
to O
show O
catalytic O
activity O
. O
That O
suggests O
that O
the O
structure O
of O
hSDH-PLP O
is O
the O
first O
structure O
of O
the O
active O
natural O
holo-SDH O
. O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine B
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O
species O
of O
Pro42Ala O
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step O
. O

MSG O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
( O
pIRS-1) B
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

monoamines O
acts O
as O
NOT O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O
5HT O
transporters O
. O
Two-electrode O
voltage-clamp O
analysis O
demonstrated O
5HT-induced O
, O
voltage-dependent O
currents O
. O
Cloning O
and O
characterization O
of O
dSERT1 O
adds O
significantly O
to O
our O
knowledge O
of O
the O
diversity O
of O
5HT O
transporters O
with O
regard O
to O
primary O
sequence O
, O
pharmacological O
profile O
, O
and O
permeation O
properties O
. O

prostacyclin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue O
factor O
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin B
receptor I
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue O
factor O
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK-441 O
for O
the O
inhibition O
of O
Gli1 B
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor-associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog O
inhibition O
. O
To O
this O
end O
, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK-441 O
plasma O
to O
the O
responses O
of O
Gli1 O
mRNA O
in O
the O
tumor O
(target) O
and O
skin O
(surrogate) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04) O
. O
The O
responses O
of O
Gli1 O
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model O
, O
respectively O
. O
The O
IC50 O
values O
for O
Gli1 O
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK-441 O
were O
estimated O
to O
be O
0.0457 O
and O
0.113 O
μg/ml O
, O
respectively O
. O
The O
IC90 O
value O
for O
tumor O
growth O
inhibition O
was O
estimated O
to O
be O
0.68 O
μg/ml O
. O
These O
results O
suggest O
that O
a O
>83% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
skin O
or O
a O
>94% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
tumor O
would O
be O
required O
to O
sufficiently O
inhibit O
(>90%) O
hedgehog-related O
tumor O
growth O
in O
the O
xenografted O
model O
mice O
. O
We O
conclude O
that O
Gli1 O
mRNA O
expression O
in O
the O
tumor O
and O
skin O
could O
be O
a O
useful O
biomarker O
for O
predicting O
the O
antitumor O
effect O
of O
hedgehog O
inhibitors O
. O

DEX O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Species-specific O
differences O
in O
the O
glucocorticoid O
receptor O
transactivation O
function O
upon O
binding O
with O
betamethasone-esters.Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases O
. O
A O
number O
of O
adverse O
side O
effects O
, O
however O
, O
limit O
chronic O
treatment O
with O
GCs O
. O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human B
or I
rat I
GR I
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O
involution O
and O
body O
weight O
loss O
, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats O
. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM O
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O
in O
receptor O
binding O
. O

Dexmedetomidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced O
sympathetic O
activation O
and O
vasoconstriction O
in O
humans.OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 O
adrenergic O
receptor O
(AR) O
agonist O
(dexmedetomidine) O
. O
BACKGROUND O
: O
We O
recently O
showed O
that O
cocaine O
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA) O
, O
the O
neural O
stimulus O
to O
norepinephrine O
release O
. O
Thus O
, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin O
. O
METHODS O
: O
In O
22 O
healthy O
cocaine-naive O
humans O
, O
we O
measured O
skin O
SNA O
(microneurography) O
and O
skin O
blood O
flow O
(laser O
Doppler O
velocimetry) O
as O
well O
as O
heart O
rate O
and O
blood O
pressure O
before O
and O
after O
intranasal O
cocaine O
(2 O
mg/kg) O
alone O
and O
in O
combination O
with O
dexmedetomidine O
or O
saline O
. O
RESULTS O
: O
During O
intranasal O
cocaine O
alone O
, O
SNA O
increased O
by O
2-fold O
and O
skin O
vascular O
resistance O
increased O
from O
13.2 O
+/- O
2.3 O
to O
20.1 O
+/- O
2.2 O
resistance O
units O
while O
mean O
arterial O
pressure O
increased O
by O
14 O
+/- O
3 O
mm O
Hg O
and O
heart O
rate O
by O
18 O
+/- O
3 O
beats/min O
(p O
< O
0.01) O
. O
Dexmedetomidine O
abolished O
these O
increases O
, O
whereas O
intravenous O
saline O
was O
without O
effect O
. O
Dexmedetomidine O
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine O
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C B
AR I
, O
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks O
. O
CONCLUSIONS O
: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine O
constitutes O
a O
highly O
effective O
countermeasure O
for O
cocaine's O
sympathomimetic O
actions O
on O
the O
human O
cardiovascular O
system O
, O
even O
in O
individuals O
carrying O
the O
alpha2CDel322-325 O
polymorphism O
. O
(Study O
to O
Improve O
Scientific O
Understanding O
of O
the O
Cardiovascular O
Actions O
of O
Cocaine; O
http://clinicaltrials.gov/ct/show/NCT00338546?order=1; O
NCT00338546) O
. O

Thalidomide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Thalidomide O
inhibits O
growth O
of O
tumors O
through O
COX-2 O
degradation O
independent O
of O
antiangiogenesis.Thalidomide O
is O
an O
antiangiogenic O
drug O
and O
is O
clinically O
useful O
in O
a O
number O
of O
cancers O
. O
However O
, O
the O
molecular O
mechanism O
by O
which O
thalidomide O
exerts O
its O
antitumor O
effects O
is O
poorly O
understood O
. O
This O
study O
was O
designed O
to O
clarify O
the O
relationship O
between O
antiangiogenesis O
and O
antitumor O
effects O
of O
thalidomide O
and O
to O
explore O
the O
molecular O
mechanism O
for O
its O
antitumor O
activity O
. O
We O
evaluated O
the O
effects O
of O
thalidomide O
on O
the O
growth O
of O
human O
tumor O
cells O
expressing O
(MCF-7 O
and O
HL-60) O
or O
not O
expressing O
(HeLa O
and O
K562) O
COX-2 O
in O
vitro O
. O
We O
also O
studied O
the O
effects O
of O
thalidomide O
on O
COX-1 O
, O
COX-2 O
or O
bcl-2 O
expression O
, O
TNFalpha O
, O
VEGF O
, O
GSH O
and O
cytochrome O
c O
in O
these O
cells O
. O
Thalidomide O
could O
inhibit O
tumor O
growth O
in O
a O
concentration-dependent O
manner O
in O
MCF-7 O
and O
HL-60; O
its O
IC50s O
for O
them O
were O
18.36+/-2.34 O
and O
22.14+/-2.15 O
microM O
, O
respectively O
, O
while O
this O
effect O
was O
not O
observed O
in O
HeLa O
and O
K562 O
. O
Thalidomide O
reduced O
COX-2 O
expression O
accompanied O
by O
a O
decrease O
of O
bcl-2 O
protein O
, O
TNFalpha O
, O
VEGF O
, O
GSH O
and O
an O
increased O
cytochrome B
c I
, O
but O
had O
no O
effect O
on O
that O
of O
COX-1 O
, O
in O
MCF-7 O
and O
HL-60 O
. O
Moreover O
, O
cells O
not O
expressing O
COX-2 O
were O
insensitive O
to O
the O
growth-inhibitory O
and O
effects O
on O
cytokines O
of O
thalidomide O
. O
In O
our O
mouse O
xenograft O
model O
of O
OVCAR-3 O
and O
HCT-8 O
, O
we O
found O
that O
thalidomide O
could O
decrease O
intratumoral O
microvessel O
density O
in O
both O
tumors; O
it O
exerted O
antitumor O
effects O
only O
on O
OVCAR-3 O
expressing O
COX-2 O
but O
did O
not O
on O
HCT-8 O
not O
expressing O
COX-2 O
. O
Effect O
of O
thalidomide O
on O
COX-1 O
and O
COX-2 O
in O
vivo O
was O
consistent O
with O
that O
of O
in O
vitro O
. O
These O
results O
demonstrated O
that O
thalidomide O
might O
inhibit O
growth O
of O
tumors O
through O
COX-2 O
degradation O
independent O
of O
antiangiogenesis O
. O

methionine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Methionine O
synthase O
reductase O
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine B
synthase I
reductase I
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
. O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR O
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O
Although O
we O
did O
not O
detect O
any O
significant O
associations O
between O
MTRR O
polymorphisms O
and O
BMD O
or O
serum O
osteocalcin O
levels O
, O
we O
found O
that O
the O
66G/524C O
haplotype O
, O
which O
has O
reduced O
enzyme O
activity O
, O
was O
significantly O
associated O
with O
serum O
osteocalcin O
levels O
in O
a O
gene-dose O
dependent O
manner O
(P O
= O
0.002) O
. O
That O
is O
, O
the O
highest O
osteocalcin O
levels O
(34.5 O
+/- O
16.8 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
two O
copies O
, O
intermediate O
osteocalcin O
levels O
(32.6 O
+/- O
14.4 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
one O
copy O
, O
and O
the O
lowest O
levels O
of O
osteocalcin O
(28.8 O
+/- O
10.9 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
no O
copies O
. O
These O
results O
suggest O
that O
the O
66G/524C O
haplotype O
of O
the O
MTRR O
gene O
affect O
bone O
turn O
over O
rate O
. O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Catalpol O
suppresses O
advanced O
glycation O
end-products-induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen O
species O
in O
human O
monocytic O
THP-1 O
cells.Advanced O
glycation O
end-products O
(AGEs) O
play O
a O
pivotal O
role O
in O
the O
development O
of O
diabetic O
complications O
by O
inducing O
inflammation O
. O
We O
previously O
reported O
that O
the O
fresh O
roots O
of O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor B
for I
AGE I
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB O
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications O
. O

Ca O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic O
anhydrase O
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
(PGs) O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA O
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O
we O
studied O
in O
vitro O
and O
in O
vivo O
the O
effects O
of O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
on O
CA O
I O
and O
CA O
II O
. O
We O
also O
followed O
in O
vitro O
the O
effects O
on O
these O
isozymes O
of O
NSAIDs O
associated O
to O
histamine O
, O
Ca O
, O
PGE2 O
and O
acetazolamide O
. O
The O
results O
show O
that O
the O
NSAIDs O
used O
here O
, O
which O
reduce O
the O
activity O
of O
cyclooxygenase O
and O
PG O
production O
, O
activated O
CA O
I O
and O
CA O
II O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA B
II I
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O
inhibition O
occurs O
"via O
CA," O
with O
the O
pH O
variations O
it O
brings O
about O
. O

butaprost O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandins O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 B
receptors I
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O
. O

DEGBG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine O
decarboxylase O
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine B
decarboxylase I
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

estradiol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Norethisterone O
metabolites O
modulate O
the O
uteroglobin O
and O
progesterone O
receptor O
gene O
expression O
in O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG B
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 B
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

N-acetyl O
l-cysteine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Cucurbitacin O
I O
inhibits O
rac1 O
activation O
in O
breast O
cancer O
cells O
by O
a O
reactive O
oxygen O
species-mediated O
mechanism O
and O
independently O
of O
janus O
tyrosine O
kinase O
2 O
and O
p-rex1.The O
small O
GTPase O
Rac1 O
has O
been O
widely O
implicated O
in O
mammary O
tumorigenesis O
and O
metastasis O
. O
Previous O
studies O
established O
that O
stimulation O
of O
ErbB O
receptors O
in O
breast O
cancer O
cells O
activates O
Rac1 O
and O
enhances O
motility O
via O
the O
Rac-guanine O
nucleotide O
exchange O
factor O
P-Rex1 O
. O
As O
the O
Janus O
tyrosine O
kinase O
2 O
(Jak2)/signal O
transducer O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho O
and O
Rac O
. O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effects O
of O
ozone O
and O
fine O
particulate O
matter O
(PM(2.5)) O
on O
rat O
system O
inflammation O
and O
cardiac O
function.In O
order O
to O
understand O
the O
toxic O
mechanisms O
of O
cardiovascular O
system O
injuries O
induced O
by O
ambient O
PM(2.5) O
and/or O
ozone O
, O
a O
subacute O
toxicological O
animal O
experiment O
was O
designed O
with O
exposure O
twice O
a O
week O
for O
3 O
continuous O
weeks O
. O
Wistar O
rats O
were O
randomly O
categorized O
into O
8 O
groups O
(n=6) O
: O
1 O
control O
group O
, O
3 O
groups O
exposed O
to O
fine O
particulate O
matters O
(PM(2.5)) O
alone O
at O
3 O
doses O
(0.2 O
, O
0.8 O
, O
or O
3.2 O
mg/rat) O
, O
1 O
group O
to O
ozone O
(0.81 O
ppm) O
alone O
and O
3 O
groups O
to O
ozone O
plus O
PM(2.5) O
at O
3 O
doses O
(0.2 O
, O
0.8 O
, O
or O
3.2 O
mg/rat) O
. O
Heart O
rate O
(HR) O
and O
electrocardiogram O
(ECG) O
was O
monitored O
at O
approximately O
24-h O
both O
after O
the O
3rd O
exposure O
and O
the O
last O
(6th) O
exposure O
, O
and O
systolic O
blood O
pressure O
(SBP) O
was O
monitored O
at O
approximately O
24-h O
after O
the O
6th O
exposure O
. O
Biomarkers O
of O
systemic O
inflammation O
and O
injuries O
(CRP O
, O
IL-6 O
, O
LDH O
, O
CK) O
, O
heart O
oxidative O
stress O
(MDA O
, O
SOD) O
and O
endothelial O
function O
(ET-1 O
, O
VEGF) O
were O
analyzed O
after O
the O
6th O
exposure O
. O
Additionally O
, O
myocardial O
ultrastructural O
alterations O
were O
observed O
under O
transmission O
electron O
microscopy O
(TEM) O
for O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP B
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O
exposure O
could O
cause O
inflammation O
, O
endothelial O
function O
and O
ANS O
injuries O
, O
and O
ozone O
potentiated O
these O
effects O
induced O
by O
PM(2.5) O
. O

polyphenols O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Apple O
polyphenols O
suppress O
antigen O
presentation O
of O
ovalbumin B
by O
THP-1-derived O
dendritic O
cells.Apple O
polyphenol O
extract O
(AP) O
and O
procyanidin O
contained O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs) O
. O
The O
expression O
levels O
of O
HLA-DR O
(MHC O
class O
II) O
and O
CD86 O
(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O
in O
TDDCs O
. O
A O
significant O
decrease O
in O
HLA-DR O
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin-treated O
cells O
in O
the O
presence O
of O
ovalbumin O
(OVA) O
, O
but O
no O
effect O
on O
CD86 O
expression O
was O
observed O
. O
The O
uptake O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 O
and O
TNF-α O
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O
polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

glutamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Withdrawal O
from O
free-choice O
ethanol O
consumption O
results O
in O
increased O
packing O
density O
of O
glutamine O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
( O
GS) B
 O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O
interruption O
of O
ethanol O
drinking O
, O
subjected O
to O
a O
3-day O
withdrawal O
period O
at O
the O
end O
of O
2 O
months O
, O
or O
subjected O
to O
three O
3-day O
withdrawal O
periods O
along O
6 O
months O
. O
At O
2 O
months O
, O
P O
rats O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS O
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS O
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

procyanidin O
acts O
as O
NOT O
for O
what O
entity O
? O
Apple O
polyphenols O
suppress O
antigen O
presentation O
of O
ovalbumin O
by O
THP-1-derived O
dendritic O
cells.Apple O
polyphenol O
extract O
(AP) O
and O
procyanidin O
contained O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs) O
. O
The O
expression O
levels O
of O
HLA-DR O
(MHC O
class O
II) O
and O
CD86 O
(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O
in O
TDDCs O
. O
A O
significant O
decrease O
in O
HLA-DR O
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin-treated O
cells O
in O
the O
presence O
of O
ovalbumin O
(OVA) O
, O
but O
no O
effect O
on O
CD86 B
expression O
was O
observed O
. O
The O
uptake O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 O
and O
TNF-α O
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O
polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila B
serotonin I
transporter I
 O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 O
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O
5HT O
transporters O
. O
Two-electrode O
voltage-clamp O
analysis O
demonstrated O
5HT-induced O
, O
voltage-dependent O
currents O
. O
Cloning O
and O
characterization O
of O
dSERT1 O
adds O
significantly O
to O
our O
knowledge O
of O
the O
diversity O
of O
5HT O
transporters O
with O
regard O
to O
primary O
sequence O
, O
pharmacological O
profile O
, O
and O
permeation O
properties O
. O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced O
inflammatory O
activation O
is O
mediated O
by O
intracellular O
free O
calcium O
in O
microglial O
cells.2,3,7,8-Tetrachlorodibenzo-p-dioxin O
(TCDD) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O
However O
, O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
( O
cPLA2) B
 O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB O
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

sunitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR O
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine B
kinase I
inhibitors O
sunitinib O
and/or O
sorafenib O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O
life O
, O
disease-related O
symptoms O
, O
and O
overall O
survival O
despite O
crossover O
of O
the O
majority O
of O
patients O
assigned O
to O
placebo O
. O
In O
2009 O
, O
everolimus O
was O
approved O
in O
the O
US O
and O
Europe O
as O
the O
only O
validated O
option O
for O
this O
indication O
. O
Toxicities O
are O
usually O
mild O
to O
moderate O
and O
can O
be O
managed O
with O
dose O
reduction O
or O
interruption O
if O
necessary O
. O
Opportunistic O
infections O
and O
non-infectious O
pneumonitis O
are O
seen O
as O
a O
class O
effect O
. O
Management O
of O
common O
practical O
management O
issues O
are O
discussed O
. O
Clinical O
trials O
are O
in O
progress O
to O
examine O
additional O
roles O
for O
everolimus O
in O
renal O
cancer O
, O
alone O
and O
in O
combination O
with O
other O
agents O
. O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt B
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

rauwolscine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Alpha-2 O
adrenoceptor O
subtype O
causing O
nitric O
oxide-mediated O
vascular O
relaxation O
in O
rats.The O
alpha-2 O
adrenoceptor O
subtype O
and O
its O
signal O
transduction O
pathway O
mediating O
vascular O
relaxation O
in O
rats O
were O
studied O
in O
vitro O
using O
rings O
of O
superior O
mesenteric O
arteries O
. O
Removal O
of O
endothelium O
or O
incubation O
with O
NG-nitro-L-arginine O
completely O
blocked O
relaxant O
responses O
to O
UK14,304 O
, O
suggesting O
endothelium-derived O
nitric O
oxide O
mediates O
relaxation O
. O
The O
order O
of O
potency O
for O
full O
(F) O
or O
partial O
(P) O
agonists O
causing O
relaxation O
was O
guanabenz O
(P) O
> O
UK14,304 O
(F) O
> O
clonidine O
(P) O
> O
epinephrine O
(F) O
> O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O
cAMP O
formation O
in O
endothelium O
. O
Forskolin O
did O
not O
affect O
the O
relaxant O
response O
to O
UK14,304 O
, O
suggesting O
that O
cAMP O
is O
not O
involved O
in O
the O
coupling O
of O
alpha-2 O
adrenoceptors O
to O
nitric O
oxide-induced O
vascular O
relaxation O
. O

DZN O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
crocin O
on O
diazinon O
induced O
cardiotoxicity O
in O
rats O
in O
subchronic O
exposure.This O
study O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
crocin O
, O
main O
component O
of O
Crocus O
sativus O
L O
. O
(Saffron) O
against O
subchronic O
diazinon O
(DZN) O
induced O
cardiotoxicity O
in O
rats O
. O
METHODS O
: O
Rats O
were O
divided O
into O
7 O
groups; O
control O
(corn O
oil O
, O
gavage) O
, O
DZN O
(15mg/kg/day O
, O
gavage,) O
, O
crocin O
(12.5 O
, O
25 O
or O
50mg/kg/day O
, O
i.p) O
plus O
DZN O
, O
vitamin O
E O
(200IU/kg O
, O
i.p O
, O
three O
times O
per O
week) O
plus O
DZN O
and O
crocin O
(50mg/kg/day O
, O
i.p) O
groups O
. O
Treatments O
were O
continued O
for O
4weeks O
. O
Creatine O
phosphokinase O
MB O
(CK-MB) O
, O
malondealdehyde O
(MDA) O
and O
glutathione O
(GSH) O
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments O
. O
Levels O
of O
apoptotic O
proteins O
(Bax O
, O
Bcl2 O
, O
caspase O
3) O
and O
cytosolic O
cytochrome O
c O
were O
analyzed O
by O
Western O
blotting O
. O
Transcript O
levels O
of O
Bax O
and O
Bcl2 O
were O
also O
determined O
using O
qRT O
PCR O
. O
RESULTS O
: O
DZN O
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB B
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC B
4.1.1.15) I
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine B
kinase I
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
(RANKL)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Carvedilol O
modulates O
the O
expression O
of O
hypoxia-inducible O
factor-1alpha O
and O
vascular O
endothelial O
growth O
factor O
in O
a O
rat O
model O
of O
volume-overload O
heart O
failure.BACKGROUND O
: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure O
. O
Hypoxia-inducible O
factor-1alpha O
(HIF-1alpha) O
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium O
. O
However O
, O
the O
expression O
of O
HIF-1alpha O
in O
chronic O
heart O
failure O
resulting O
from O
volume O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known O
. O
METHODS O
AND O
RESULTS O
: O
To O
test O
the O
hypothesis O
that O
HIF-1alpha O
plays O
a O
role O
in O
the O
failing O
myocardium O
because O
of O
volume O
overload O
, O
an O
aorta-caval O
shunt O
was O
created O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
volume-overload O
heart O
failure O
. O
Carvedilol O
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O
was O
given O
. O
The O
heart O
weight O
and O
body O
weight O
ratio O
increased O
from O
2.6 O
+/- O
0.3 O
in O
the O
sham O
group O
to O
3.9 O
+/- O
0.7 O
(P O
< O
.001) O
in O
the O
shunt O
group O
. O
Left O
ventricular O
end-diastolic O
dimension O
increased O
from O
6.5 O
+/- O
0.5 O
mm O
to O
8.7 O
+/- O
0.6 O
mm O
(P O
< O
.001) O
. O
Treatment O
with O
carvedilol O
in O
the O
shunt O
group O
reversed O
the O
heart O
weight O
and O
ventricular O
dimension O
to O
the O
baseline O
values O
. O
Western O
blot O
showed O
that O
HIF-1alpha O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
brain O
natriuretic O
peptide O
(BNP) O
proteins O
were O
upregulated O
and O
nerve O
growth O
factor-beta O
(NGF-beta) O
downregulated O
in O
the O
shunt O
group O
. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
increased O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O
. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha B
and O
VEGF O
in O
the O
failing O
ventricular O
myocardium O
. O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
f O
ocal B
adhesion I
kinase I
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD B
816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

E O
4021 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 B
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

Angiotensin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Angiotensin-converting O
enzyme O
inhibition O
and O
AT1 O
receptor O
blockade O
modify O
the O
pressure-natriuresis O
relationship O
by O
additive O
mechanisms O
in O
rats O
with O
human B
renin I
and O
angiotensinogen O
genes.The O
intrarenal O
factors O
responsible O
for O
hypertension O
in O
double-transgenic O
rats O
(dTGR) O
harboring O
human O
renin O
and O
human O
angiotensinogen O
genes O
are O
unclear O
. O
The O
pressure-natriuresis O
and O
-diuresis O
relationships O
in O
response O
to O
chronic O
angiotensin-converting O
enzyme O
(ACE) O
inhibition O
and O
AT1 O
receptor O
blockade O
were O
evaluated O
. O
Renal O
renin-angiotensin O
and O
nitric O
oxide O
(NO) O
system O
gene O
expression O
was O
also O
investigated O
. O
Six-week-old O
dTGR O
were O
treated O
for O
3 O
wk O
with O
submaximal O
doses O
of O
cilazapril O
(10 O
mg/kg O
, O
orally) O
or O
losartan O
(10 O
mg/kg O
, O
orally) O
or O
with O
the O
drug O
combination O
. O
In O
untreated O
dTGR O
, O
pressure-natriuresis O
relationships O
were O
maximally O
shifted O
rightward O
by O
approximately O
70 O
to O
80 O
mmHg O
, O
and O
both O
renal O
blood O
flow O
(RBF) O
and O
GFR O
were O
markedly O
decreased O
. O
Submaximal O
cilazapril O
and O
losartan O
dosages O
both O
decreased O
systolic O
BP O
by O
30 O
mmHg O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
by O
25 O
to O
30 O
mmHg O
. O
Cilazapril O
increased O
RBF O
and O
GFR O
to O
values O
observed O
in O
normotensive O
control O
animals O
but O
did O
not O
significantly O
affect O
fractional O
sodium O
excretion O
(FENa) O
or O
fractional O
water O
excretion O
(FEH2O) O
curves O
. O
In O
contrast O
, O
losartan O
had O
no O
significant O
effect O
on O
RBF O
or O
GFR O
but O
shifted O
the O
FENa O
and O
FEH2O O
curves O
leftward O
. O
The O
cilazapril O
and O
losartan O
combination O
completely O
normalized O
BP O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
more O
than O
did O
either O
drug O
alone O
. O
When O
cilazapril O
and O
losartan O
were O
administered O
at O
higher O
doses O
(30 O
mg/kg O
, O
orally) O
, O
the O
two O
drugs O
equally O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
, O
by O
50 O
mmHg O
. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however O
, O
only O
losartan O
shifted O
FENa O
and O
FEH2O O
curves O
leftward O
. O
Human O
and O
rat O
renin O
and O
angiotensinogen O
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan O
and O
cilazapril O
treatments O
, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat O
ACE O
and O
AT1A O
receptor O
genes O
were O
observed O
. O
Endothelial O
NO O
synthase O
expression O
was O
increased O
by O
cilazapril O
but O
not O
by O
losartan O
. O
Neither O
inducible O
NO O
synthase O
nor O
neural O
NO O
synthase O
gene O
expression O
was O
affected O
by O
drug O
treatments O
. O
Therefore O
, O
submaximal O
ACE O
inhibition O
enhanced O
sodium O
excretion O
mainly O
by O
increasing O
RBF O
and O
GFR O
, O
whereas O
submaximal O
AT1 O
receptor O
blockade O
decreased O
tubular O
sodium O
and O
water O
reabsorption O
. O
The O
combination O
of O
the O
two O
drugs O
produced O
an O
additive O
effect O
. O
The O
ACE O
inhibitor O
effects O
may O
involve O
increased O
endothelial O
NO O
synthase O
expression O
, O
perhaps O
related O
to O
the O
inhibition O
of O
bradykinin O
degradation O
. O

mifepristone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
[Effect O
of O
mifepristone O
on O
the O
expression O
of O
progesterone O
receptor O
messenger O
RNA O
and O
protein O
in O
uterine O
leiomyomata].OBJECTIVE O
: O
To O
determine O
the O
expression O
of O
progesterone B
receptor I
(PR) O
mRNA O
and O
PR O
protein O
levels O
in O
the O
myometrium O
and O
leiomyomata O
from O
untreated O
and O
mifepristone O
pretreated O
women O
with O
leiomyoma O
and O
to O
examine O
the O
mechanism O
of O
mifepristone O
treatment O
on O
uterine O
leiomyomata O
. O
METHODS O
: O
Expression O
of O
PR O
mRNA O
and O
PR O
protein O
were O
determined O
by O
Northern O
blot O
and O
HAP O
of O
single-dose O
saturated O
analysis O
in O
myometrium O
and O
leiomyomata O
(center O
and O
marginal O
area) O
from O
27 O
untreated O
and O
6 O
mifepristone O
pretreated O
women O
with O
leiomyomata O
. O
RESULTS O
: O
PR O
mRNA O
abundance O
and O
PR O
protein O
levels O
in O
both O
myomatous O
center O
and O
marginal O
area O
were O
significantly O
greater O
than O
those O
in O
corporal O
myometrium O
(P O
< O
0.01) O
in O
both O
follicular O
and O
luteal O
phases O
, O
but O
similar O
between O
myomatous O
center O
and O
marginal O
area O
(P O
> O
0.05) O
. O
6 O
cases O
pretreated O
with O
mifepristone O
25 O
mg/day O
for O
3 O
months O
were O
operated O
, O
all O
but O
one O
patient O
displayed O
a O
decrease O
in O
leiomyomata O
volume O
. O
PR O
mRNA O
abundance O
in O
both O
myometruim O
and O
leiomyomata O
(center O
and O
marginal O
area) O
was O
significantly O
decreased O
in O
4 O
patients O
continuing O
mifepristone O
treatment O
before O
the O
operation O
but O
not O
in O
the O
other O
2 O
patients O
stopping O
RU486 O
1 O
month O
before O
operation O
. O
PR O
protein O
levels O
in O
these O
tissues O
showed O
significant O
decrease O
in O
all O
6 O
cases O
. O
CONCLUSION O
: O
There O
are O
overexpression O
of O
PRmRNA O
and O
PR O
protein O
in O
leiomyomata O
. O
One O
of O
the O
mechanism O
of O
mifepristone O
action O
on O
decreasing O
leiomyomata O
volume O
may O
be O
related O
to O
suppression O
on O
expression O
of O
PR O
gene O
. O
It O
seems O
that O
suppression O
on O
transcription O
of O
PR O
gene O
is O
reversible O
, O
but O
on O
translation O
of O
PR O
gene O
may O
maintain O
in O
a O
relatively O
longer O
period O
. O

Gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide B
synthase I
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Development O
and O
validation O
of O
a O
non-radioactive O
DNA O
polymerase O
assay O
for O
studying O
cytomegalovirus O
resistance O
to O
foscarnet.Phenotypic O
characterisation O
of O
the O
human O
cytomegalovirus O
(HCMV) O
pUL54 O
DNA O
polymerase O
is O
a O
useful O
tool O
for O
testing O
for O
mutations O
in O
the O
UL54 O
gene O
thought O
to O
render O
HCMV O
resistant O
to O
foscarnet O
. O
In O
this O
study O
, O
an O
in-house O
non-isotopic O
method O
for O
assessing O
polymerase O
enzymatic O
activity O
in O
the O
presence O
and O
absence O
of O
foscarnet O
was O
developed O
and O
its O
utility O
for O
HCMV O
polymerase O
phenotyping O
evaluated O
. O
Polymerase O
activity O
was O
assessed O
by O
monitoring O
the O
incorporation O
of O
digoxigenin-labelled O
nucleotides O
into O
the O
growing O
DNA O
chain O
and O
foscarnet O
concentrations O
inhibiting O
enzymatic O
activity O
by O
50% O
were O
determined O
. O
HCMV O
DNA O
polymerases O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) B
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

corticosteroid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapid O
glucocorticoid O
receptor-mediated O
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin B
releasing I
hormone I
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone O
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol O
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

Hcy O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methionine O
synthase O
reductase O
polymorphisms O
are O
associated O
with O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women.Homocysteine O
(Hcy) O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture O
. O
Methionine B
synthase I
reductase I
(MTRR) O
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy O
to O
methionine O
. O
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR O
leading O
to O
reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism O
. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G O
and O
C524T O
polymorphisms O
of O
the O
MTRR O
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin O
levels O
in O
postmenopausal O
women O
. O
Although O
we O
did O
not O
detect O
any O
significant O
associations O
between O
MTRR O
polymorphisms O
and O
BMD O
or O
serum O
osteocalcin O
levels O
, O
we O
found O
that O
the O
66G/524C O
haplotype O
, O
which O
has O
reduced O
enzyme O
activity O
, O
was O
significantly O
associated O
with O
serum O
osteocalcin O
levels O
in O
a O
gene-dose O
dependent O
manner O
(P O
= O
0.002) O
. O
That O
is O
, O
the O
highest O
osteocalcin O
levels O
(34.5 O
+/- O
16.8 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
two O
copies O
, O
intermediate O
osteocalcin O
levels O
(32.6 O
+/- O
14.4 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
one O
copy O
, O
and O
the O
lowest O
levels O
of O
osteocalcin O
(28.8 O
+/- O
10.9 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
no O
copies O
. O
These O
results O
suggest O
that O
the O
66G/524C O
haplotype O
of O
the O
MTRR O
gene O
affect O
bone O
turn O
over O
rate O
. O

VK2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Vitamin O
K2 O
covalently O
binds O
to O
Bak O
and O
induces O
Bak-mediated O
apoptosis.Vitamin O
K2 O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Plerixafor O
, O
a O
CXCR4 O
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells.Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
( O
SDF-1) B
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O
combination O
of O
plerixafor O
and O
G-CSF O
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF O
mobilization O
alone O
. O

gliclazide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase B
C I
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein B
kinase I
B-RaF I
(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O
(K(p)) O
of O
dabrafenib O
after O
an O
i.v O
. O
dose O
(2.5 O
mg/kg) O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
, O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

buthionine O
sulfoximine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurotoxicity O
of O
"ecstasy" O
and O
its O
metabolites O
in O
human O
dopaminergic O
differentiated O
SH-SY5Y O
cells.Ecstasy O
(3,4-methylenedioxymethamphetamine O
or O
MDMA) O
is O
a O
widely O
abused O
recreational O
drug O
, O
reported O
to O
produce O
neurotoxic O
effects O
, O
both O
in O
laboratory O
animals O
and O
in O
humans O
. O
MDMA O
metabolites O
can O
be O
major O
contributors O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MDMA O
catechol O
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ- O
GCS B
, O
p I
revented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O
N-Me-α-MeDA-induced O
neurotoxicity O
, O
but O
only O
slightly O
affected O
NAC O
neuroprotection O
. O
In O
conclusion O
, O
MDMA O
catechol O
metabolites O
promote O
differential O
toxic O
effects O
to O
differentiated O
dopaminergic O
human O
SH-SY5Y O
cells O
. O

choline O
acts O
as O
NOT O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine B
methyltransferase I
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

SB216763 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
( O
PDE5) B
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

Gly O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC B
2.1.1.10) I
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

thiols O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides O
. O
Carboxylesterases B
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

D,L-propargylglycine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Accumulation O
of O
cystathionine O
, O
cystathionine O
ketimine O
, O
and O
perhydro-1,4-thiazepine-3,5-dicarboxylic O
acid O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
of O
D O
, O
L-propargylglycine-treated O
rats.Experimental O
cystathioninuria O
was O
induced O
in O
rats O
by O
administration O
of O
the O
cystathionine B
gamma-lyase I
inhibitor O
, O
D,L-propargylglycine O
. O
The O
cystathionine O
metabolites O
, O
cystathionine O
ketimine O
(CK) O
and O
perhydro-1,4-thiazepine-3,5-dicarboxylic O
acid O
(PHTZDC) O
, O
were O
identified O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
in O
D,L-propargylglycine-treated O
rats O
. O
The O
concentration O
of O
CK O
and O
PHTZDC O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
increased O
gradually O
after O
administration O
of O
D,L-propargylglycine O
, O
and O
reached O
the O
highest O
value O
at O
about O
20 O
hours O
. O
CK O
and O
PHTZDC O
accumulated O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
in O
proportion O
to O
the O
amount O
of O
accumulated O
cystathionine O
after O
D,L-propargylglycine O
administration O
. O
The O
concentration O
of O
these O
compounds O
in O
the O
cerebellum O
was O
higher O
versus O
the O
other O
regions O
of O
the O
rat O
brain O
. O

clopidogrel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
P2Y12 O
, O
a O
new O
platelet O
ADP O
receptor O
, O
target O
of O
clopidogrel.Clopidogrel O
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced O
platelet O
aggregation O
. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel O
over O
aspirin O
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction O
, O
stroke O
, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease O
. O
The O
antiaggregating O
effect O
of O
clopidogrel O
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP O
binding O
to O
a O
purinergic B
receptor I
present O
at O
the O
platelet O
surface O
. O
Clopidogrel O
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O
ADP O
, O
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets O
. O
The O
binding O
of O
(33)P-2MeS-ADP O
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
with O
a O
potency O
that O
was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets O
. O
In O
these O
transfected O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet O
receptor O
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP O
on O
platelets O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
property O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
is O
mediated O
through O
the O
expression O
of O
Glut-4 O
in O
L6 O
myotubes.Tinospora O
cordifolia O
is O
a O
well O
reported O
plant O
possessing O
numerous O
medicinal O
values O
including O
anti-diabetic O
property O
. O
Aim O
of O
the O
present O
study O
is O
to O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
( O
Glut-4) B
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT O
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O
behavioral O
, O
neural O
and O
cognitive O
demand O
. O
In O
autoshaping O
task O
a O
dose-response O
curve O
for O
METH O
was O
determined O
. O
METH O
(1.0mg/kg) O
impaired O
short-term O
memory O
(STM; O
lasting O
less O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping O
, O
indicating O
that O
METH O
had O
long-lasting O
effects O
in O
the O
latter O
task O
. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT B
in O
autoshaping O
new O
untrained O
vs O
. O
trained O
treated O
(METH O
, O
FLX O
, O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT O
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH O
SERT O
binding O
in O
several O
areas O
including O
hippocampus O
and O
cortex O
decreased O
, O
more O
remarkably O
in O
the O
trained O
animals O
. O
In O
contrast O
, O
FLX O
improved O
memory O
, O
increased O
SERT O
binding O
, O
prevented O
the O
METH O
amnesic O
effect O
and O
re-established O
the O
SERT O
binding O
. O
In O
general O
, O
memory O
and O
amnesia O
seemed O
to O
make O
SERT O
more O
vulnerable O
to O
drugs O
effects O
. O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK- O
hDAT B
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

5-(p-toluenesulfonylamino)phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
new O
series O
of O
N2-substituted-5-(p-toluenesulfonylamino)phthalimide O
analogues O
as O
α-glucosidase O
inhibitors.Several O
members O
of O
a O
new O
family O
of O
non-sugar-type O
α-glycosidase O
inhibitors O
, O
bearing O
a O
5-(p-toluenesulfonylamino)phthalimide O
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O
The O
newly O
synthesized O
compounds O
displayed O
different O
inhibition O
profile O
towards O
yeast O
α-glycosidase O
and O
rat O
intestinal O
α-glycosidase O
. O
Almost O
all O
the O
compounds O
had O
strong O
inhibitory O
activities O
against O
yeast O
α-glycosidase O
. O
Regarding O
rat O
intestinal O
α-glycosidase O
, O
only O
analogs O
with O
N2-aromatic O
substituents O
displayed O
varying O
degrees O
of O
inhibitory O
activities O
on O
rat O
intestinal O
maltase O
and O
lactase O
and O
nearly O
all O
compounds O
showed O
no O
inhibition O
against O
rat O
intestinal O
α-amylase O
. O
Structure-activity O
relationship O
studies O
indicated O
that O
5-(p-toluenesulfonylamino)phthalimide O
moiety O
is O
a O
favorable O
scaffold O
to O
exert O
the O
α-glucosidase B
inhibitory O
activity O
and O
substituents O
at O
the O
N2 O
position O
have O
considerable O
influence O
on O
the O
efficacy O
of O
the O
inhibition O
activities O
. O

antofine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Antofine-induced O
connexin43 O
gap O
junction O
disassembly O
in O
rat O
astrocytes O
involves O
protein O
kinase O
Cβ.Antofine O
, O
a O
phenanthroindolizidine O
alkaloid O
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family O
, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O
In O
this O
study O
, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine O
induced O
dose-dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
(GJIC) O
, O
as O
assessed O
by O
scrape-loading O
6-carboxyfluorescein O
dye O
transfer O
. O
Levels O
of O
Cx43 O
protein O
were O
also O
decreased O
in O
a O
dose- O
and O
time-dependent O
manner O
following O
antofine O
treatment O
. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine O
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 O
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O
Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 O
, O
partially O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 B
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O
antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

dimethyldiguanide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
cinnamon O
polyphenols O
against O
STZ-diabetic O
mice O
fed O
high-sugar O
, O
high-fat O
diet O
and O
its O
underlying O
mechanism.This O
study O
was O
designed O
to O
investigate O
the O
potential O
effects O
of O
14days' O
intragastrically O
given O
of O
cinnamon O
polyphenols O
(CPS) O
in O
treating O
diabetic O
mice O
induced O
by O
intraperitoneal O
injection O
of O
streptozotocin O
(150mgkg(-1)) O
and O
fed O
high-sugar O
, O
high-fat O
diet O
. O
The O
diabetic O
mice O
model O
was O
successfully O
established O
through O
determining O
on O
fasting O
blood-glucose O
(FBG) O
test O
. O
As O
revealed O
by O
glucose O
oxidase O
(GOD) O
and O
radioimmunoassay O
(RIA) O
, O
both O
dimethyldiguanide O
(DC O
, O
0.6gkg(-1)d(-1)) O
and O
CPS O
(0.3 O
, O
0.6 O
, O
1.2gkg(-1)d(-1)) O
treatments O
significantly O
resulted O
in O
down-regulation O
of O
blood O
glucose O
and O
insulin B
levels O
in O
serum O
, O
while O
the O
levels O
of O
oxidative O
stress O
markers O
were O
markedly O
lowered O
through O
ELISA O
assay O
. O
Meanwhile O
, O
the O
pathological O
damage O
in O
islet O
with O
pancreatic O
beta O
cells O
was O
ameliorated O
by O
treatment O
of O
CPS O
at O
different O
doses O
, O
as O
shown O
in O
HE O
stain O
. O
At O
the O
same O
time O
, O
the O
treatments O
also O
caused O
notable O
reduction O
of O
iNOS O
, O
NF-κB O
expressions O
showing O
in O
Western O
blot O
analysis O
. O
These O
findings O
demonstrate O
that O
cinnamon O
polyphenols O
can O
exert O
the O
hypoglycemic O
and O
hypolipidemic O
effects O
through O
the O
mechanisms O
that O
may O
be O
associated O
with O
repairing O
pancreatic O
beta O
cells O
in O
diabetic O
mice O
and O
improving O
its O
anti-oxidative O
capacity O
, O
as O
well O
as O
attenuating O
cytotoxicity O
via O
inhibition O
of O
iNOS O
, O
NF-κB O
activation O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A B
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

barbiturates O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC B
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

isoproterenol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Beta1 O
adrenergic O
receptor-mediated O
enhancement O
of O
hippocampal O
CA3 O
network O
activity.Norepinephrine O
is O
an O
endogenous O
neurotransmitter O
distributed O
throughout O
the O
mammalian O
brain O
. O
In O
higher O
cortical O
structures O
such O
as O
the O
hippocampus O
, O
norepinephrine O
, O
via O
beta O
adrenergic O
receptor O
(AR) O
activation O
, O
has O
been O
shown O
to O
reinforce O
the O
cognitive O
processes O
of O
attention O
and O
memory O
. O
In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
beta1AR O
activation O
on O
hippocampal O
cornu O
ammonis O
3 O
(CA3) O
network O
activity O
. O
AR O
expression O
was O
first O
determined O
using O
immunocytochemistry O
with O
antibodies O
against O
beta1ARs O
, O
which O
were O
found O
to O
be O
exceptionally O
dense O
in O
hippocampal O
CA3 O
pyramidal O
neurons O
. O
CA3 O
network O
activity O
was O
then O
examined O
in O
vitro O
using O
field O
potential O
recordings O
in O
rat O
brain O
slices O
. O
The O
selective O
betaAR O
agonist O
isoproterenol O
caused O
an O
enhancement O
of O
hippocampal O
CA3 O
network O
activity O
, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region O
. O
In O
the O
presence O
of O
alphaAR O
blockade O
, O
concentration-response O
curves O
for O
isoproterenol O
, O
norepinephrine O
, O
and O
epinephrine O
suggested O
that O
a O
beta1AR O
was O
involved O
in O
this O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR B
antagonists O
atenolol O
and O
metoprolol O
blocked O
isoproterenol-induced O
enhancement O
, O
with O
apparent O
K(b) O
values O
of O
85 O
+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM O
, O
respectively O
. O
In O
contrast O
, O
the O
selective O
beta2AR O
antagonists O
ICI-118,551 O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM O
, O
respectively) O
. O
Together O
, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR O
antagonists O
indicates O
that O
in O
this O
model O
, O
beta1AR O
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol O
. O

petunidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)- O
CYP1A1 B
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
( O
hCES2) B
 O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

SR O
141716A O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 B
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O
in O
the O
recognition O
of O
SR O
141716A O
. O
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF B
/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)- O
AKT B
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

SL O
89,0591 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha O
1 O
adrenoceptor O
antagonists O
at O
prostatic O
alpha O
1 O
adrenoceptors O
: O
binding O
, O
functional O
and O
in O
vivo O
studies.1 O
. O
The O
profile O
of O
a O
range O
of O
alpha O
1 O
adrenoceptor O
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human O
alpha O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human B
alpha I
1D I
adrenoceptors I
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O
17053 O
= O
SNAP O
1069 O
. O
4 O
. O
(-)-Tamsulosin O
was O
a O
very O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity O
, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O
this O
model O
. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha O
1 O
adrenoceptor O
mediating O
noradrenaline-induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O
1 O
adrenoceptors O
, O
particularly O
over O
the O
alpha O
1D O
subtype O
, O
appear O
to O
inhibit O
phenylephrine-induced O
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure O
. O

polyamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Structures O
of O
wild-type O
and O
mutant O
human O
spermidine/spermine O
N1-acetyltransferase O
, O
a O
potential O
therapeutic O
drug O
target.Spermidine/spermine O
N1-acetyltransferase O
(SSAT) O
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine O
levels O
in O
human O
cells O
, O
as O
acetylation O
of O
spermidine O
and O
spermine O
triggers O
export O
or O
degradation O
. O
Increased O
intracellular O
polyamine O
levels O
accompany O
several O
types O
of O
cancers O
as O
well O
as O
other O
human O
diseases O
, O
and O
compounds O
that O
affect O
the O
expression O
, O
activity O
, O
or O
stability O
of O
SSAT O
are O
being O
explored O
as O
potential O
therapeutic O
drugs O
. O
We O
have O
expressed O
human O
SSAT O
from O
the O
cloned O
cDNA O
in O
Escherichia O
coli O
and O
have O
determined O
high-resolution O
structures O
of O
wild-type O
and O
mutant O
SSAT O
, O
as O
the O
free O
dimer O
and O
in O
binary O
and O
ternary O
complexes O
with O
CoA O
, O
acetyl-CoA O
(AcCoA) O
, O
spermine O
, O
and O
the O
inhibitor O
N1,N11bis-(ethyl)-norspermine O
(BE-3-3-3) O
. O
These O
structures O
show O
details O
of O
binding O
sites O
for O
cofactor O
, O
substrates O
, O
and O
inhibitor O
and O
provide O
a O
framework O
to O
understand O
enzymatic O
activity O
, O
mutations O
, O
and O
the O
action O
of O
potential O
drugs O
. O
Two O
dimer O
conformations O
were O
observed O
: O
a O
symmetric O
form O
with O
two O
open O
surface O
channels O
capable O
of O
binding O
substrate O
or O
cofactor O
, O
and O
an O
asymmetric O
form O
in O
which O
only O
one O
of O
the O
surface O
channels O
appears O
capable O
of O
binding O
and O
acetylating O
polyamines O
. O
SSAT O
was O
found O
to O
self-acetylate O
lysine-26 O
in O
the O
presence O
of O
AcCoA O
and O
absence O
of O
substrate O
, O
a O
reaction O
apparently O
catalzyed O
by O
AcCoA O
bound O
in O
the O
second O
channel O
of O
the O
asymmetric O
dimer O
. O
These O
unexpected O
and O
intriguing O
complexities O
seem O
likely O
to O
have O
some O
as O
yet O
undefined O
role O
in O
regulating O
SSAT B
activity O
or O
stability O
as O
a O
part O
of O
polyamine O
homeostasis O
. O
Sequence O
signatures O
group O
SSAT O
with O
proteins O
that O
appear O
to O
have O
thialysine O
Nepsilon-acetyltransferase O
activity O
. O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4 O
/ O
NF-κB B
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

choline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT B
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO B
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST-4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 B
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Leukotriene O
D4 O
induces O
cognitive O
impairment O
through O
enhancement O
of O
CysLT₁ O
R-mediated O
amyloid-β O
generation O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 B
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O
such O
as O
AD O
. O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Peroxynitrite O
mediates O
testosterone-induced O
vasodilation O
of O
microvascular O
resistance O
vessels.Our O
knowledge O
of O
how O
androgens O
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete O
, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens O
affect O
resistance O
vessels O
. O
Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone O
(TES) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES-induced O
vasodilation O
. O
Mesenteric O
microvessels O
were O
isolated O
from O
male O
Sprague-Dawley O
rats O
. O
Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration-dependent O
, O
vasodilatory O
response O
to O
TES O
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17β-estradiol O
. O
Dichlorofluorescein O
fluorescence O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine B
oxidase I
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

N-propargyl-1R(+)-aminoindan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine B
oxidase I
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O
MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS O
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O
doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

Cobalt O
chloride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cross-talk O
between O
constitutive O
androstane O
receptor O
and O
hypoxia-inducible O
factor O
in O
the O
regulation O
of O
gene O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive B
enhancer I
module- I
mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O
in O
the O
liver O
of O
untreated O
mice O
and O
that O
the O
complex O
dissociates O
upon O
PB O
treatment O
. O
Taken O
together O
these O
results O
suggest O
that O
CAR O
and O
HIF-α O
interact O
and O
reciprocally O
modulate O
the O
functions O
of O
each O
other O
. O

17-HDHA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Impaired O
local O
production O
of O
pro-resolving O
lipid O
mediators O
in O
obesity O
and O
17-HDHA O
as O
a O
potential O
treatment O
for O
obesity-associated O
inflammation.Obesity-induced O
chronic O
low-grade O
inflammation O
originates O
from O
adipose O
tissue O
and O
is O
crucial O
for O
obesity-driven O
metabolic O
deterioration O
including O
insulin O
resistance O
and O
type O
2 O
diabetes.Chronic O
inflammation O
may O
be O
a O
consequence O
of O
a O
failure O
to O
actively O
resolve O
inflammation,and O
could O
result O
from O
a O
lack O
of O
local O
specialized O
pro-resolving O
lipid O
mediators O
(SPM) O
such O
as O
resolvins O
and O
protectins O
, O
which O
derive O
from O
the O
n-3 O
polyunsaturated O
fatty O
acids O
eicosapentaenoic O
acid O
(EPA) O
and O
docosahexaenoic O
acid O
(DHA) O
. O
We O
assessed O
obesity-induced O
changes O
of O
n-3-derived O
SPM O
in O
adipose O
tissue O
and O
effects O
of O
dietary O
EPA/DHA O
thereon.Moreover O
, O
we O
treated O
obese O
mice O
with O
SPM O
precursors O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin O
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin O
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin B
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA O
as O
a O
novel O
treatment O
option O
for O
obesity-associated O
complications O
. O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Green O
tea O
extract O
alleviates O
arsenic-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats.The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin B
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O
also O
a O
significant O
increase O
in O
liver O
, O
kidney O
and O
testicular O
thiobarbituric O
acid O
reactive O
substances O
compared O
to O
control O
. O
However O
, O
the O
co-administration O
of O
GT O
was O
effective O
in O
reducing O
its O
level O
. O
To O
conclude O
, O
our O
data O
suggest O
that O
arsenic O
exposure O
enhanced O
an O
oxidative O
stress O
by O
disturbing O
the O
tissue O
antioxidant O
defense O
system O
, O
but O
the O
GT O
co-administration O
alleviates O
the O
toxicity O
induced O
by O
arsenic O
exposure O
. O

saccharin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Artificial O
sweeteners O
and O
salts O
producing O
a O
metallic O
taste O
sensation O
activate O
TRPV1 O
receptors.Throughout O
the O
world O
many O
people O
use O
artificial O
sweeteners O
(AS) O
for O
the O
purpose O
of O
reducing O
caloric O
intake O
. O
The O
most O
prominently O
used O
of O
these O
molecules O
include O
saccharin O
, O
aspartame O
(Nutrasweet) O
, O
acesulfame-K O
, O
and O
cyclamate O
. O
Despite O
the O
caloric O
advantage O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
. O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O
taste O
receptor O
cells O
and O
in O
nerve O
terminals O
throughout O
the O
oral O
cavity O
. O
Hence O
, O
TRPV1 O
activation O
could O
be O
involved O
in O
the O
AS O
aftertaste O
or O
even O
contribute O
to O
the O
poorly O
understood O
metallic O
taste O
sensation O
. O
Using O
Ca(2+) O
imaging O
on O
TRPV1 O
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
, O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro O
. O
Acetylcholinesterase B
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; O
the O
respective O
dissociation O
constants O
and O
the O
type O
of O
inhibition O
exhibited O
considerable O
differences O
. O
The O
affinities O
to O
both O
the O
active O
and O
the O
allosteric O
site O
were O
considerably O
higher O
for O
suxamethonium O
(Kii O
81.3 O
microM; O
Ki O
15.9 O
microM) O
and O
decamethonium O
(Kii O
15.4 O
microM; O
Ki O
4.4 O
microM) O
than O
for O
TMA O
(Kii O
1 O
mM; O
Ki O
289.6 O
microM) O
and O
hexamethonium O
(Kii O
4.5 O
mM; O
Ki O
331.8 O
microM) O
. O
The O
reactivation O
experiments O
were O
performed O
in O
a O
four-step O
procedure O
(soman-inhibition O
at O
0 O
degree O
and O
pH O
10 O
, O
aging O
at O
37 O
degrees O
and O
pH O
7.3 O
, O
reactivation O
by O
the O
oxime O
HI O
6 O
at O
37 O
degrees O
and O
pH O
7.3 O
followed O
by O
AChE O
assay) O
. O
After O
these O
four O
steps O
(total O
duration O
55 O
min) O
, O
AChE O
was O
inhibited O
by O
soman O
to O
95-100% O
. O
HI O
6 O
could O
reactivate O
about O
20% O
of O
the O
inhibited O
enzyme O
. O
All O
effectors O
increased O
the O
AChE O
reactivatability O
by O
HI O
6 O
when O
added O
before O
aging O
was O
started O
. O
The O
maximal O
increase O
in O
reactivatability O
was O
higher O
in O
the O
presence O
of O
1.6 O
mM O
suxamethonium O
(+35.8%) O
and O
150 O
microM O
decamethonium O
(+40%) O
than O
of O
22 O
mM O
TMA O
(+22.5%) O
and O
8.3 O
mM O
hexamethonium O
(+19.2%) O
. O
If O
the O
effectors O
were O
added O
after O
5 O
min O
of O
aging O
they O
increased O
the O
activity O
of O
soman-inhibited O
AChE O
, O
but O
to O
a O
considerably O
smaller O
extent O
than O
HI O
6 O
. O
A O
good O
correlation O
of O
the O
respective O
Kii O
values O
and O
the O
effective O
concentrations O
of O
these O
drugs O
was O
observed O
, O
indicating O
that O
an O
allosteric O
binding O
site O
of O
AChE O
might O
be O
involved O
in O
the O
protective O
effect O
of O
these O
drugs O
. O

PAG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE B
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nonadrenergic O
imidazoline O
binding O
sites O
on O
human O
platelets.Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity O
, O
imidazol(in)e-preferring O
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 O
adrenoceptors O
. O
These O
nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
of O
alpha-2 O
adrenoceptors O
. O
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan O
(IDX) O
binding O
vs O
. O
[125I]p-iodoclonidine O
(PIC) O
binding O
. O
Nonadrenergic O
[125I]PIC-labeled O
sites O
were O
enriched O
in O
platelet O
plasma O
membranes O
, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] O
IDX O
were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled O
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs O
. O
the O
[3H]IDX-labeled O
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes) O
. O
Furthermore O
, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

TES O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Peroxynitrite O
mediates O
testosterone-induced O
vasodilation O
of O
microvascular O
resistance O
vessels.Our O
knowledge O
of O
how O
androgens O
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete O
, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens O
affect O
resistance O
vessels O
. O
Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone O
(TES) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES-induced O
vasodilation O
. O
Mesenteric O
microvessels O
were O
isolated O
from O
male O
Sprague-Dawley O
rats O
. O
Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration-dependent O
, O
vasodilatory O
response O
to O
TES O
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17β-estradiol O
. O
Dichlorofluorescein O
fluorescence O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen B
receptor I
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Characterization O
of O
insulin-like O
growth O
factor-binding O
protein-related O
proteins O
(IGFBP-rPs) O
1 O
, O
2 O
, O
and O
3 O
in O
human O
prostate O
epithelial O
cells O
: O
potential O
roles O
for O
IGFBP-rP1 O
and O
2 O
in O
senescence O
of O
the O
prostatic O
epithelium.Insulin-like O
growth O
factor O
(IGF)-binding O
protein O
(IGFBP)-related O
proteins O
( O
IGFBP-rPs) B
are O
newly O
described O
cysteine-rich O
proteins O
that O
share O
significant O
aminoterminal O
structural O
similarity O
with O
the O
conventional O
IGFBPs O
and O
are O
involved O
in O
a O
diversity O
of O
biological O
functions O
, O
including O
growth O
regulation O
. O
IGFBP-rP1 O
(MAC25/Angiomodulin/prostacyclin-stimulating O
factor) O
is O
a O
potential O
tumor-suppressor O
gene O
that O
is O
differentially O
expressed O
in O
meningiomas O
, O
mammary O
and O
prostatic O
cancers O
, O
compared O
with O
their O
malignant O
counterparts O
. O
We O
have O
previously O
shown O
that O
IGFBP-rP1 O
is O
preferentially O
produced O
by O
primary O
cultures O
of O
human O
prostate O
epithelial O
cells O
(HPECs) O
and O
by O
poorly O
tumorigenic O
P69SV40T O
cells O
, O
compared O
with O
the O
cancerous O
prostatic O
LNCaP O
, O
DU145 O
, O
PC-3 O
, O
and O
M12 O
cells O
. O
We O
now O
show O
that O
IGFBP-rP1 O
increases O
during O
senescence O
of O
HPEC O
. O
IGFBP-rP2 O
(also O
known O
as O
connective O
tissue O
growth O
factor) O
, O
a O
downstream O
effector O
of O
transforming O
growth O
factor O
(TGF)-beta O
and O
modulator O
of O
growth O
for O
both O
fibroblasts O
and O
endothelial O
cells O
, O
was O
detected O
in O
most O
of O
the O
normal O
and O
malignant O
prostatic O
epithelial O
cells O
tested O
, O
with O
a O
marked O
up-regulation O
of O
IGFBP-rP2 O
during O
senescence O
of O
HPEC O
. O
Moreover O
, O
IGFBP-rP2 O
noticeably O
increased O
in O
response O
to O
TGF-beta1 O
and O
all-trans O
retinoic O
acid O
(atRA) O
in O
HPEC O
and O
PC-3 O
cells O
, O
and O
it O
decreased O
in O
response O
to O
IGF-I O
in O
HPEC O
. O
IGFBP-rP3 O
[nephroblastoma O
overexpressed O
(NOV)] O
, O
the O
protein O
product O
of O
the O
NOV O
protooncogene O
, O
was O
not O
detected O
in O
HPEC O
but O
was O
expressed O
in O
the O
tumorigenic O
DU145 O
and O
PC-3 O
cells O
. O
It O
was O
also O
synthesized O
by O
the O
SV40-T O
antigen-transformed O
P69 O
and O
malignant O
M12 O
cells O
, O
where O
it O
was O
down-regulated O
by O
atRA O
. O
These O
observations O
suggest O
biological O
roles O
of O
IGFBP-rPs O
in O
the O
human O
prostate O
. O
IGFBP-rP1 O
and O
IGFBP-rP2 O
are O
likely O
to O
negatively O
regulate O
growth O
, O
because O
they O
seem O
to O
increase O
during O
senescence O
of O
the O
prostate O
epithelium O
and O
in O
response O
to O
growth O
inhibitors O
(TGF-beta1 O
and O
atRA) O
. O
Although O
the O
data O
collected O
on O
IGFBP-rP3 O
in O
prostate O
are O
modest O
, O
its O
role O
as O
a O
growth O
stimulator O
and/or O
protooncogene O
is O
supported O
by O
its O
preferential O
expression O
in O
cancerous O
cells O
and O
its O
down-regulation O
by O
atRA O
. O

ziprasidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
PET O
study O
of O
dopamine O
D2 O
and O
serotonin O
5-HT2 O
receptor O
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone.OBJECTIVE O
: O
Ziprasidone O
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin O
5-HT(2) O
receptors O
compared O
with O
dopamine O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O
in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) O
occupancy O
(using O
[(11)C]raclopride) O
and O
5-HT(2) O
occupancy O
(using O
[(18)F]setoperone) O
in O
brain O
regions O
of O
interest O
in O
16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40 O
, O
80 O
, O
120 O
, O
or O
160 O
mg/day O
of O
ziprasidone O
, O
which O
reflected O
the O
recommended O
dose O
range O
. O
PET O
scanning O
was O
done O
after O
3 O
weeks O
of O
administration O
and O
at O
trough O
plasma O
levels O
, O
i.e. O
, O
12-16 O
hours O
after O
the O
last O
dose O
. O
RESULTS O
: O
The O
mean O
5-HT(2) O
receptor O
occupancy O
was O
significantly O
higher O
than O
the O
mean O
D(2) O
receptor O
occupancy O
(mean=76% O
, O
SD=15% O
, O
and O
mean=56% O
, O
SD=18% O
, O
respectively) O
. O
The O
estimated O
plasma O
ziprasidone O
concentration O
associated O
with O
50% O
maximal O
5-HT(2) O
receptor O
occupancy O
was O
almost O
four O
times O
lower O
than O
that O
for O
D(2) B
receptor I
occupancy O
. O
CONCLUSIONS O
: O
These O
data O
affirm O
that O
ziprasidone O
is O
similar O
to O
other O
novel O
antipsychotics O
in O
having O
greater O
5-HT(2) O
than O
D(2) O
receptor O
occupancy O
at O
therapeutic O
doses O
and O
suggest O
that O
the O
optimal O
effective O
dose O
of O
ziprasidone O
is O
closer O
to O
120 O
mg/day O
than O
to O
the O
lower O
doses O
suggested O
by O
previous O
PET O
studies O
. O
The O
relatively O
high O
D(2) O
receptor O
occupancy O
, O
even O
at O
trough O
plasma O
levels O
, O
suggests O
that O
ziprasidone O
is O
more O
similar O
to O
risperidone O
and O
olanzapine O
in O
receptor O
occupancy O
profile O
than O
to O
clozapine O
and O
quetiapine O
. O
Since O
ziprasidone O
plasma O
levels O
show O
significant O
(more O
than O
twofold) O
variation O
within O
a O
single O
dose O
cycle O
, O
studies O
that O
are O
aimed O
at O
peak O
plasma O
levels O
(6 O
hours O
after O
the O
last O
dose) O
and O
that O
examine O
extrastriatal O
regions O
are O
required O
to O
fully O
characterize O
the O
in O
vivo O
occupancy O
profile O
of O
ziprasidone O
. O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Serotonin O
transporter O
function O
in O
vivo O
: O
assessment O
by O
chronoamperometry.Local O
application O
of O
selective O
serotonin O
reuptake O
inhibitors O
, O
fluvoxamine O
and O
citalopram O
, O
prolonged O
the O
clearance O
of O
exogenously O
administered O
serotonin O
(5-HT) O
in O
both O
the O
dentate O
gyrus O
and O
CA3 O
region O
of O
the O
dorsal O
hippocampus O
, O
as O
measured O
using O
in O
vivo O
chronoamperometry O
. O
These O
effects O
were O
abolished O
in O
rats O
pretreated O
with O
5,7-dihydroxytryptamine O
. O
The O
NE O
uptake O
inhibitors O
, O
desipramine O
and O
protriptyline O
, O
did O
not O
alter O
the O
5-HT O
signal O
in O
the O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT O
and O
NET O
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin B
autoreceptor I
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O
effect O
on O
the O
serotonin O
transporter O
. O

Chalcogenopyrylium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Chalcogenopyrylium O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 B
 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP O
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP O
modulators O
and O
also O
show O
that O
within O
this O
core O
structure O
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2 O
. O

4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase B
(AChE) O
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O
(K(p)) O
of O
dabrafenib O
after O
an O
i.v O
. O
dose O
(2.5 O
mg/kg) O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
, O
another O
BRAF( O
V600E) B
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

metoprolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Beta1 O
adrenergic O
receptor-mediated O
enhancement O
of O
hippocampal O
CA3 O
network O
activity.Norepinephrine O
is O
an O
endogenous O
neurotransmitter O
distributed O
throughout O
the O
mammalian O
brain O
. O
In O
higher O
cortical O
structures O
such O
as O
the O
hippocampus O
, O
norepinephrine O
, O
via O
beta O
adrenergic O
receptor O
(AR) O
activation O
, O
has O
been O
shown O
to O
reinforce O
the O
cognitive O
processes O
of O
attention O
and O
memory O
. O
In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
beta1AR O
activation O
on O
hippocampal O
cornu O
ammonis O
3 O
(CA3) O
network O
activity O
. O
AR O
expression O
was O
first O
determined O
using O
immunocytochemistry O
with O
antibodies O
against O
beta1ARs O
, O
which O
were O
found O
to O
be O
exceptionally O
dense O
in O
hippocampal O
CA3 O
pyramidal O
neurons O
. O
CA3 O
network O
activity O
was O
then O
examined O
in O
vitro O
using O
field O
potential O
recordings O
in O
rat O
brain O
slices O
. O
The O
selective O
betaAR O
agonist O
isoproterenol O
caused O
an O
enhancement O
of O
hippocampal O
CA3 O
network O
activity O
, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region O
. O
In O
the O
presence O
of O
alphaAR O
blockade O
, O
concentration-response O
curves O
for O
isoproterenol O
, O
norepinephrine O
, O
and O
epinephrine O
suggested O
that O
a O
beta1AR O
was O
involved O
in O
this O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR B
antagonists O
atenolol O
and O
metoprolol O
blocked O
isoproterenol-induced O
enhancement O
, O
with O
apparent O
K(b) O
values O
of O
85 O
+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM O
, O
respectively O
. O
In O
contrast O
, O
the O
selective O
beta2AR O
antagonists O
ICI-118,551 O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM O
, O
respectively) O
. O
Together O
, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR O
antagonists O
indicates O
that O
in O
this O
model O
, O
beta1AR O
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol O
. O

alanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Xanthurenic O
aciduria O
due O
to O
a O
mutation O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase O
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase B
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine-to-alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

gonadotrophin O
releasing O
hormone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
kisspeptin O
in O
human O
reproductive O
function O
- O
therapeutic O
implications.Kisspeptin O
is O
a O
54-amino O
acid O
peptide O
which O
is O
encoded O
by O
the O
KiSS-1 O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
(GnRH) O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O
(FSH) O
and O
testosterone O
without O
side O
effects O
in O
both O
males O
and O
in O
females O
particularly O
in O
the O
preovulatatory O
phase O
of O
the O
menstrual O
cycle O
. O
In O
infertility O
due O
to O
hypothalamic O
amenorrhoea O
acute O
administration O
of O
kisspeptin O
results O
in O
stimulation O
of O
reproductive O
hormones O
. O
The O
kisspeptin/GPR54 O
system O
therefore O
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
reproduction O
in O
humans O
. O
Hence O
kisspeptin O
has O
potential O
as O
a O
novel O
tool O
for O
the O
manipulation O
of O
the O
HPG O
axis O
and O
treatment O
of O
infertility O
in O
humans O
. O
This O
review O
discusses O
the O
evidence O
highlighting O
kisspeptin's O
key O
role O
in O
human O
reproduction O
. O

troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
by O
troglitazone O
of O
the O
antigen-induced O
production O
of O
leukotrienes O
in O
immunoglobulin O
E-sensitized O
RBL-2H3 O
cells.1 O
. O
The O
effect O
of O
troglitazone O
, O
an O
anti-diabetic O
drug O
with O
insulin-sensitizing O
action O
, O
on O
antigen-induced O
production O
of O
leukotriene O
(LT) O
B(4) O
, O
C(4) O
and O
E(4) O
and O
prostaglandin O
D(2) O
(PGD(2)) O
was O
examined O
in O
dinitrophenol O
(DNP)-specific O
immunoglobulin O
E O
(IgE)-sensitized O
RBL-2H3 O
mast O
cells O
following O
stimulation O
by O
the O
antigen O
, O
DNP-conjugated O
human O
serum O
albumin O
. O
Levels O
of O
LTB(4) O
, O
C(4) O
and O
E(4) O
and O
PGD(2) O
in O
the O
conditioned O
medium O
were O
enzyme-immunoassayed O
. O
2 O
. O
Troglitazone O
inhibited O
the O
antigen-induced O
production O
of O
LTB(4) O
, O
C(4) O
and O
E(4) O
and O
the O
potency O
of O
the O
inhibition O
was O
comparable O
to O
that O
of O
zileuton O
, O
a O
specific O
inhibitor O
of O
5-lipoxygenase O
(5-LOX) O
and O
a O
clinically O
used O
anti-asthmatic O
drug O
. O
Neither O
troglitazone O
nor O
zileuton O
affected O
antigen-induced O
production O
of O
PGD(2) O
, O
arachidonic O
acid O
release O
from O
membrane O
phospholipids O
and O
degranulation O
. O
3 O
. O
Troglitazone O
inhibited O
LTB(4) O
production O
by O
the O
supernatant O
fraction O
of O
RBL-2H3 O
cell O
lysate O
with O
similar O
potency O
to O
zileuton O
, O
suggesting O
that O
troglitazone O
inhibits O
LT O
production O
by O
direct O
inhibition O
of O
5-LOX B
activity O
. O
4 O
. O
Furthermore O
, O
it O
was O
shown O
that O
troglitazone O
as O
well O
as O
zileuton O
inhibited O
LTB(4) O
production O
in O
A23187-stimulated O
rat O
peritoneal O
neutrophils O
. O
5 O
. O
These O
findings O
suggest O
that O
troglitazone O
inhibits O
antigen-induced O
LT O
production O
in O
the O
IgE-sensitized O
RBL-2H3 O
cells O
and O
A23187-stimulated O
rat O
peritoneal O
neutrophils O
by O
direct O
inhibition O
of O
5-LOX O
activity O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Histone O
deacetylase O
3 O
is O
required O
for O
maintenance O
of O
bone O
mass O
during O
aging.Histone O
deacetylase O
3 O
(Hdac3) O
is O
a O
nuclear O
enzyme O
that O
removes O
acetyl O
groups O
from O
lysine O
residues O
in O
histones B
and O
other O
proteins O
to O
epigenetically O
regulate O
gene O
expression O
. O
Hdac3 O
interacts O
with O
bone-related O
transcription O
factors O
and O
co-factors O
such O
as O
Runx2 O
and O
Zfp521 O
, O
and O
thus O
is O
poised O
to O
play O
a O
key O
role O
in O
the O
skeletal O
system O
. O
To O
understand O
the O
role O
of O
Hdac3 O
in O
osteoblasts O
and O
osteocytes O
, O
Hdac3 O
conditional O
knockout O
(CKO) O
mice O
were O
created O
with O
the O
osteocalcin O
(OCN) O
promoter O
driving O
Cre O
expression O
. O
Hdac3 O
CKO(OCN) O
mice O
were O
of O
normal O
size O
and O
weight O
, O
but O
progressively O
lost O
trabecular O
and O
cortical O
bone O
mass O
with O
age O
. O
The O
Hdac3 O
CKO(OCN) O
mice O
exhibited O
reduced O
cortical O
bone O
mineralization O
and O
material O
properties O
and O
suffered O
frequent O
fractures O
. O
Bone O
resorption O
was O
lower O
, O
not O
higher O
, O
in O
the O
Hdac3 O
CKO(OCN) O
mice O
, O
suggesting O
that O
primary O
defects O
in O
osteoblasts O
caused O
the O
reduced O
bone O
mass O
. O
Indeed O
, O
reductions O
in O
bone O
formation O
were O
observed O
. O
Osteoblasts O
and O
osteocytes O
from O
Hdac3 O
CKO(OCN) O
mice O
showed O
increased O
DNA O
damage O
and O
reduced O
functional O
activity O
in O
vivo O
and O
in O
vitro O
. O
Thus O
, O
Hdac3 O
expression O
in O
osteoblasts O
and O
osteocytes O
is O
essential O
for O
bone O
maintenance O
during O
aging O
. O

gefitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Emerging O
role O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
therapy O
for O
advanced O
malignancy O
: O
focus O
on O
NSCLC.Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer O
. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based O
therapy O
vs O
. O
best O
supportive O
care O
, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate O
. O
Just O
as O
importantly O
, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O
life O
. O
Newer O
agents O
, O
including O
the O
taxanes O
, O
vinorelbine O
, O
gemcitabine O
, O
and O
irinotecan O
, O
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer O
. O
Despite O
their O
contributions O
, O
we O
have O
reached O
a O
therapeutic O
plateau O
, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40% O
. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal B
growth I
factor I
receptor I
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O
Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O
persist O
. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular O
, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds O
. O
Both O
gefitinib O
and O
erlotinib O
have O
shown O
clinical O
activity O
in O
pretreated O
, O
advanced O
non-small-cell O
lung O
cancer O
, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib O
in O
combination O
with O
standard O
cytotoxic O
therapy O
, O
to O
our O
chagrin O
, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone O
. O

(S)-naproxen-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 B
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR B
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Hepatocytes O
display O
a O
compensatory O
survival O
response O
against O
cadmium O
toxicity O
by O
a O
mechanism O
mediated O
by O
EGFR O
and O
Src.Although O
the O
liver O
is O
a O
cadmium-target O
organ O
, O
hepatocyte O
response O
involved O
in O
its O
toxicity O
is O
not O
yet O
elucidated O
. O
A O
link O
between O
this O
heavy O
metal O
treatment O
and O
Stat3 O
signaling O
pathways O
was O
examined O
in O
primary O
mouse O
hepatocytes O
. O
We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH O
oxidase O
and O
Stat3 O
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1/2 O
. O
Cadmium O
activates O
NADPH O
oxidase O
. O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 B
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

Tomudex O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Cyclin O
E-cdk2 O
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate O
synthase O
inhibitor O
Tomudex.Tomudex O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O
p53 O
and O
p21(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 O
protein O
expression O
and O
kinase O
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O
cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O
Cyclin O
D1 O
, O
cyclin O
B O
, O
cdk4 O
, O
and O
cdc2 O
protein O
expression O
and O
kinase O
activities O
remain O
constant O
. O
Lack O
of O
activation O
of O
cyclin O
A- O
and O
B-cdc2 O
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases O
. O
Increased O
cyclin O
E-cdk2 O
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin B
E- I
cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days O
. O
Tomudex O
treatment O
resulted O
in O
a O
time-dependent O
induction O
of O
the O
megabase O
DNA O
fragments O
, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation O
. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase O
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex O
are O
not O
p53 O
dependent O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Vesicular O
monoamine O
transporter-1 O
(VMAT-1) O
mRNA O
and O
immunoreactive O
proteins O
in O
mouse O
brain.OBJECTIVE O
: O
Vesicular O
monoamine O
transporter O
1 O
(VMAT-1) O
mRNA O
and O
protein O
were O
examined O
(1) O
to O
determine O
whether O
adult O
mouse O
brain O
expresses O
full-length O
VMAT-1 O
mRNA O
that O
can O
be O
translated O
to O
functional O
transporter O
protein O
and O
(2) O
to O
compare O
immunoreactive O
VMAT-1 O
proteins O
in O
brain O
and O
adrenal O
. O
METHODS O
: O
VMAT-1 O
mRNA O
was O
detected O
in O
mouse O
brain O
with O
RT-PCR O
. O
The O
cDNA O
was O
sequenced O
, O
cloned O
into O
an O
expression O
vector O
, O
transfected O
into O
COS-1 O
cells O
, O
and O
cell O
protein O
was O
assayed O
for O
VMAT-1 O
activity O
. O
Immunoreactive O
proteins O
were O
examined O
on O
western O
blots O
probed O
with O
four O
different O
antibodies O
to O
VMAT-1 O
. O
RESULTS O
: O
Sequencing O
confirmed O
identity O
of O
the O
entire O
coding O
sequences O
of O
VMAT-1 O
cDNA O
from O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 B
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O
cells O
, O
which O
are O
positive O
controls O
for O
rodent O
VMAT-1 O
. O
CONCLUSIONS O
: O
These O
findings O
demonstrate O
that O
a O
functional O
VMAT-1 O
mRNA O
coding O
sequence O
is O
expressed O
in O
mouse O
brain O
and O
suggest O
processing O
of O
VMAT-1 O
protein O
differs O
in O
mouse O
adrenal O
and O
brain O
. O

nitroglycerin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
sodium O
nitroprusside O
on O
HIF-1 O
activation O
is O
not O
dependent O
on O
nitric O
oxide-soluble O
guanylyl O
cyclase O
pathway.Adaptation O
to O
hypoxia O
and O
maintenance O
of O
O(2) O
homeostasis O
involve O
a O
wide O
range O
of O
responses O
that O
occur O
at O
different O
organizational O
levels O
in O
the O
body O
. O
One O
of O
the O
most O
important O
transcription O
factors O
that O
activate O
the O
expression O
of O
O(2)-regulated O
genes O
is O
hypoxia-inducible O
factor O
1 O
(HIF-1) O
. O
Nitric O
oxide O
(NO) O
mediates O
a O
variety O
of O
biological O
effects O
including O
relaxation O
of O
blood O
vessels O
and O
cytotoxicity O
of O
activated O
macrophages O
. O
We O
investigated O
the O
effect O
of O
the O
clinically O
used O
nitrates O
nitroglycerin O
(NTG) O
, O
isosorbide O
dinitrate O
(ISDN) O
, O
and O
sodium O
nitroprusside O
(SNP) O
on O
HIF-1- B
mediated O
transcriptional O
responses O
to O
hypoxia O
. O
We O
demonstrate O
that O
among O
the O
three O
nitrates O
, O
only O
SNP O
inhibits O
HIF-1 O
activation O
in O
response O
to O
hypoxia O
. O
In O
contrast O
, O
NTG O
or O
ISDN O
does O
not O
affect O
HIF-1 O
activity O
. O
SNP O
inhibits O
the O
accumulation O
of O
HIF-1alpha O
, O
the O
regulatory O
subunit O
of O
HIF-1 O
, O
and O
the O
transcriptional O
activation O
of O
HIF-1alpha O
via O
a O
mechanism O
that O
is O
not O
dependent O
on O
either O
NO O
or O
soluble O
guanylate O
cyclase O
. O

pyrido-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
evaluation O
of O
N-Aryl O
pyrido-quinazolines O
derivatives O
as O
potent O
EGFR O
inhibitors.A O
series O
of O
pyrido-quinazolines O
have O
been O
synthesised O
, O
characterised O
and O
tested O
for O
their O
in O
vitro O
EGFR O
tyrosine B
kinase I
inhibitory O
activity O
. O
The O
compounds O
were O
prepared O
from O
Alkylideno/arylideno-bis-ureas O
. O
Their O
final O
structure O
of O
the O
compounds O
were O
elucidated O
on O
the O
basis O
of O
spectral O
studies O
(IR. O
, O
1H O
NMR O
, O
FT-IR O
and O
EI-MS) O
. O
The O
cellular O
EGFR O
internalization O
response O
of O
selected O
compounds O
was O
evaluated O
using O
HeLa O
cells O
. O
Most O
of O
the O
synthesized O
compounds O
displayed O
potent O
EGFR-TK O
inhibitory O
activity O
and O
structurally O
halogenated O
derivatives O
had O
a O
pronounced O
effect O
in O
inhibiting O
EGFR O
internalization O
. O
© O
2013 O
John O
Wiley O
& O
Sons O
A/S O
. O

acetylcholine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Success O
of O
pyridostigmine O
, O
physostigmine O
, O
eptastigmine O
and O
phosphotriesterase O
treatments O
in O
acute O
sarin O
intoxication.The O
acute O
toxicity O
of O
organophosphorus O
(OP) O
compounds O
in O
mammals O
is O
due O
to O
their O
irreversible O
inhibition O
of O
acetylcholinesterase B
(AChE) O
in O
the O
nervous O
system O
, O
which O
leads O
to O
increased O
synaptic O
acetylcholine O
levels O
. O
The O
protective O
actions O
of O
intravenously O
(i.v.) O
administered O
pyridostigmine O
, O
physostigmine O
, O
eptastigmine O
, O
and O
an O
organophosphate O
hydrolase O
, O
phosphotriesterase O
, O
in O
acute O
sarin O
intoxication O
were O
studied O
in O
mice O
. O
The O
acute O
intragastric O
(i.g.) O
toxicity O
(LD50) O
of O
sarin O
with O
and O
without O
the O
pretreatments O
was O
tested O
by O
the O
up-and-down O
method O
. O
The O
mice O
received O
pyridostigmine O
(0.06 O
mg/kg O
body O
weight) O
, O
physostigmine O
(0.09 O
mg/kg O
body O
weight) O
, O
the O
physostigmine O
derivative O
eptastigmine O
(0.90 O
mg/kg O
body O
weight) O
or O
phosphotriesterase O
(104 O
U/g O
, O
10.7 O
microg/g O
body O
weight) O
10 O
min O
prior O
to O
the O
i.g O
. O
administration O
of O
sarin O
. O
Physostigmine O
was O
also O
administered O
with O
phosphotriesterase O
. O
Phosphotriesterase O
was O
the O
most O
effective O
antidote O
in O
sarin O
intoxication O
. O
The O
LD50 O
value O
for O
sarin O
increased O
3.4-fold O
in O
mice O
receiving O
phosphotriesterase O
. O
Physostigmine O
was O
the O
most O
effective O
carbamate O
in O
sarin O
exposure O
. O
The O
protective O
ratios O
of O
physostigmine O
and O
pyridostigmine O
were O
1.5- O
and O
1.2-1.3-fold O
, O
respectively O
. O
Eptastigmine O
did O
not O
give O
any O
protection O
against O
sarin O
toxicity O
. O
Both O
the O
phosphotriesterase O
and O
physostigmine O
treatments O
protected O
the O
brain O
AChE O
activities O
measured O
24 O
h O
after O
sarin O
exposure O
. O
In O
phosphotriesterase O
and O
physostigmine-treated O
mice O
, O
a O
4- O
and O
2-fold O
higher O
sarin O
dose O
, O
respectively O
, O
was O
needed O
to O
cause O
a O
50% O
inhibition O
of O
brain O
AChE O
activity O
. O
Moreover O
, O
the O
combination O
of O
phosphotriesterase-physostigmine O
increased O
the O
LD50 O
value O
for O
sarin O
4.3-fold O
. O
The O
animals O
pretreated O
with O
phosphotriesterase-ephysostigmine O
tolerated O
four O
times O
the O
lethal O
dose O
in O
control O
animals O
, O
furthermore O
their O
survival O
time O
was O
2-3 O
h O
in O
comparison O
to O
20 O
min O
in O
controls O
. O
In O
conclusion O
, O
phosphotriesterase O
and O
physostigmine O
were O
the O
most O
effective O
treatments O
against O
sarin O
intoxication O
. O
However O
, O
eptastigmine O
did O
not O
provide O
any O
protection O
against O
sarin O
toxicity O
. O

FdUrd O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
(F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate O
synthase O
( O
TS) B
 O
. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O
and O
the O
mechanism O
of O
resistance O
to O
the O
drugs O
. O
When O
cells O
were O
incubated O
with O
the O
3 O
drugs O
for O
72 O
h O
, O
the O
resistance O
ratio O
to O
parental O
DLD-1 O
human O
colorectal O
tumor O
cells O
was O
65.2 O
for O
DLD-1/5-FU O
, O
9.7 O
for O
DLD-1/FdUrd O
and O
448.6 O
for O
DLD-1/F3(d)Thd O
cells O
. O
DLD-1/5-FU O
cells O
did O
not O
show O
any O
cross-resistance O
against O
FdUrd O
and O
F(3)dThd O
. O
However O
, O
DLD-1/FdUrd O
cells O
showed O
3- O
and O
9-fold O
increased O
resistance O
to O
5-FU O
and O
F3(d)Thd O
, O
respectively O
, O
and O
DLD-1/F3(d)Thd O
cells O
also O
showed O
about O
90-fold O
resistance O
to O
FdUrd O
. O
Analysis O
of O
enzyme O
activities O
and O
gene O
expression O
associated O
with O
pyrimidine O
metabolism O
indicated O
that O
a O
significant O
decrease O
in O
orotate O
phosphoribosyltransferase O
activity O
in O
DLD-1/5-FU O
cells O
, O
a O
7-fold O
increase O
of O
TS O
mRNA O
in O
DLD-1/FdUrd O
cells O
, O
and O
a O
37-fold O
decrease O
in O
thymidine O
kinase O
activity O
of O
DLD-1/F3(d)Thd O
cells O
were O
the O
major O
mechanisms O
of O
drug O
resistance O
. O
These O
findings O
were O
closely O
associated O
with O
the O
cytotoxicity O
of O
5-FU O
, O
FdUrd O
and O
F3(d)Thd O
against O
the O
established O
5-FU- O
, O
FdUrd- O
or O
F3(d)Thd-resistant O
cells O
. O
When O
DLD-1/FdUrd O
cells O
expressing O
increased O
TS O
mRNA O
were O
treated O
with O
FdUrd O
and O
F3(d)Thd O
for O
only O
4 O
h O
, O
the O
resistance O
ratios O
of O
DLD-1/FdUrd O
cells O
to O
parental O
DLD-1 O
cells O
were O
markedly O
different O
for O
FdUrd O
and O
F3(d)Thd O
, O
suggesting O
that O
the O
cytotoxicity O
with O
short-time O
exposure O
to O
F3(d)Thd O
is O
due O
to O
a O
mechanism O
other O
than O
TS O
inhibition O
, O
although O
the O
cytotoxicity O
of O
F3(d)Thd O
in O
the O
short-time O
is O
low O
compared O
to O
that O
of O
long-time O
exposure O
. O
In O
conclusion O
, O
F3(d)Thd O
, O
an O
antimetabolite O
that O
inhibits O
TS O
activity O
, O
may O
be O
effective O
against O
5-FU O
and/or O
FdUrd-resistance O
in O
colorectal O
cancer O
cells O
caused O
by O
amplification O
of O
TS O
and/or O
deletion O
of O
orotate O
phosphoribosyltransferase O
. O

Mibefradil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type B
Ca2+ I
channel I
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ O
channels O
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

saponins O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
ginseng O
saponins O
on O
the O
stress-induced O
plasma O
interleukin-6 O
level O
in O
mice.The O
effect O
of O
ginseng O
saponins O
on O
plasma O
interleukin-6 O
(IL-6) O
in O
non-stressed O
and O
immobilization-stressed O
mice O
were O
investigated O
. O
Ginseng O
total O
saponins O
, O
ginsenosides O
Rb2 O
, O
Rg1 O
and O
Rd O
administered O
intraperitoneally O
attenuated O
the O
immobilization O
stress-induced O
increase O
in O
plasma O
IL-6 B
level O
. O
But O
, O
intracerebroventricular O
injection O
of O
each O
ginsenoside O
did O
not O
affect O
plasma O
IL-6 O
level O
induced O
by O
immobilization O
stress O
. O
Ginsenosides O
Rb2 O
, O
Rd O
and O
Rg1 O
significantly O
decreased O
norepinephrine O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
cell O
line O
(RAW O
264.7) O
. O
Thus O
, O
it O
can O
be O
suggested O
that O
the O
inhibitory O
action O
of O
ginseng O
saponins O
against O
the O
immobilization O
stress-induced O
increase O
of O
plasma O
IL-6 O
level O
would O
be O
in O
periphery; O
at O
least O
in O
part O
, O
mediated O
by O
blocking O
norepinephrine- O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
rather O
than O
in O
the O
brain O
. O
Ginseng O
saponins O
might O
be O
proposed O
as O
a O
possible O
candidate O
in O
the O
research O
or O
therapeutic O
modulation O
of O
stress-related O
disorders O
. O

D-1997 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
2-(2-Aminoethyl)-quinoline O
(D-1997) O
: O
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like O
receptors O
in O
the O
canine O
basilar O
artery.This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline O
derivative O
, O
2-(2-aminoethyl)-quinoline O
(D-1997) O
, O
in O
the O
canine O
isolated O
basilar O
artery O
. O
For O
comparison O
, O
the O
effects O
of O
D-1997 O
were O
also O
evaluated O
on O
rat O
aorta O
. O
Canine O
basilar O
artery O
and O
rat O
aortic O
rings O
were O
prepared O
and O
mounted O
in O
organ O
baths O
to O
record O
isometric O
tension O
changes O
. O
The O
contractile O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
compared O
with O
those O
produced O
by O
5-hydroxytryptamine O
(5-HT) O
and O
the O
5-HT O
receptor O
agonist O
quipazine O
. O
Thus O
, O
4-HT O
(10(-10)-10(-6)M) O
, O
D-1997 O
(3.1 O
x O
10(-8)-10(-4) O
M) O
and O
quipazine O
(3.1 O
x O
10(-7)-10(-4) O
M) O
each O
caused O
concentration-dependent O
contractions O
of O
the O
canine O
basilar O
artery O
with O
a O
rank O
order O
of O
agonist O
potency O
of O
5-HT O
> O
D-1997 O
> O
quipazine O
. O
5-HT O
and O
D-1997 O
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 B
receptor I
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma B
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

fenofibrate O
acts O
as O
NOT O
for O
what O
entity O
? O
Effects O
of O
fenofibrate O
, O
a O
PPAR-α O
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII O
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion O
. O
The O
effects O
of O
PE O
and O
AII O
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated O
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O
for O
ET1 O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII O
and O
ET1 B
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

minocycline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dose-response O
effect O
of O
tetracyclines O
on O
cerebral O
matrix O
metalloproteinase-9 O
after O
vascular O
endothelial O
growth O
factor O
hyperstimulation.Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder O
. O
Matrix O
metalloproteinase O
(MMP)-9 O
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens O
. O
Doxycycline O
was O
shown O
to O
decrease O
cerebral O
MMP-9 O
activities O
and O
angiogenesis O
induced O
by O
vascular O
endothelial O
growth O
factor O
(VEGF) O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline O
and O
minocycline O
on O
cerebral O
MMP-9 O
using O
our O
mouse O
model O
with O
VEGF O
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O
brain O
. O
Mice O
were O
treated O
with O
doxycycline O
or O
minocycline O
, O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 O
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 B
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O
effect O
at O
a O
lower O
dose O
, O
1 O
mg/kg/day O
(P<0.02) O
. O
The O
inhibition O
of O
cerebral O
MMP-9 O
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue O
. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O
in O
vitro O
to O
elucidate O
the O
mechanisms O
underlying O
the O
MMP-9 O
inhibition O
by O
tetracyclines O
. O
In O
vitro O
, O
minocycline O
, O
but O
not O
doxycycline O
, O
inhibits O
MMP-9 O
, O
at O
least O
in O
part O
, O
via O
the O
extracellular O
signaling-related O
kinase O
1/2 O
(ERK1/2)-mediated O
pathway O
. O
This O
study O
provided O
the O
evidence O
that O
the O
tetracyclines O
inhibit O
stimulated O
cerebral O
MMP-9 O
at O
multiple O
levels O
and O
are O
effective O
at O
very O
low O
doses O
, O
offering O
great O
potential O
for O
therapeutic O
use O
. O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin B
A I
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha O
1 O
adrenoceptor O
antagonists O
at O
prostatic O
alpha O
1 O
adrenoceptors O
: O
binding O
, O
functional O
and O
in O
vivo O
studies.1 O
. O
The O
profile O
of O
a O
range O
of O
alpha O
1 O
adrenoceptor O
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human O
alpha O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha B
1A I
adrenoceptors I
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O
17053 O
= O
SNAP O
1069 O
. O
4 O
. O
(-)-Tamsulosin O
was O
a O
very O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity O
, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O
this O
model O
. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha O
1 O
adrenoceptor O
mediating O
noradrenaline-induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O
1 O
adrenoceptors O
, O
particularly O
over O
the O
alpha O
1D O
subtype O
, O
appear O
to O
inhibit O
phenylephrine-induced O
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure O
. O

clofarabine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Synergistic O
anti-cancer O
effects O
of O
resveratrol O
and O
chemotherapeutic O
agent O
clofarabine O
against O
human O
malignant O
mesothelioma O
MSTO-211H O
cells.Dietary O
phytochemicals O
as O
adjuvants O
have O
been O
suggested O
to O
play O
important O
roles O
in O
enhancing O
chemotherapeutic O
potential O
owing O
to O
multitargeted O
chemopreventive O
properties O
and O
lack O
of O
substantial O
toxicity O
. O
Here O
, O
we O
investigated O
the O
efficacy O
of O
the O
combined O
treatment O
of O
various O
phytochemicals O
with O
the O
anticancer O
drug O
clofarabine O
in O
malignant O
mesothelioma O
MSTO-211H O
cells O
and O
normal O
mesothelial O
MeT-5A O
cells O
. O
The O
combined O
treatment O
of O
resveratrol O
and O
clofarabine O
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells O
, O
but O
not O
in O
MeT-5A O
cells O
. O
In O
MSTO-211H O
cells O
, O
the O
nuclear O
accumulation O
of O
Sp1 O
and O
the O
levels O
of O
p-Akt O
, O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 B
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine B
hydroxylase I
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

Mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ B
channel I
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ O
channels O
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F B
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

prostaglandin O
E(2) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Dopamine O
D(2) O
receptor-induced O
COX-2 B
-mediated O
production O
of O
prostaglandin O
E(2) O
in O
D(2)-transfected O
Chinese O
hamster O
ovary O
cells O
without O
simultaneous O
administration O
of O
a O
Ca(2+)-mobilizing O
agent.We O
have O
earlier O
demonstrated O
that O
dopamine O
stimulates O
the O
liberation O
of O
the O
prostaglandin O
E(2) O
(PGE(2)) O
precursor O
, O
arachidonic O
acid O
, O
in O
Chinese O
hamster O
ovary O
cells O
transfected O
with O
the O
rat O
dopamine O
D(2) O
receptor O
(long O
isoform) O
, O
also O
without O
concomitant O
administration O
of O
a O
Ca(2+)-releasing O
agent O
[Nilsson O
et O
al. O
, O
Br O
J O
Pharmacol O
1998;124:1651-8] O
. O
In O
the O
present O
report O
, O
we O
show O
that O
dopamine O
, O
under O
the O
same O
conditions O
, O
also O
induces O
a O
concentration-dependent O
increase O
in O
the O
production O
of O
PGE(2) O
, O
with O
a O
maximal O
effect O
of O
235% O
at O
approximately O
100 O
microM O
, O
and O
with O
an O
EC(50) O
of O
794 O
nM O
. O
The O
effect O
was O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
, O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O
reinforce O
previous O
assumptions O
that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O
this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

wortmannin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol B
3-kinases I
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dioscin-induced O
autophagy O
mitigates O
cell O
apoptosis O
through O
modulation O
of O
PI3K O
/Akt B
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines.Our O
previous O
study O
has O
revealed O
that O
dioscin O
, O
a O
compound O
with O
anti-inflammatory O
, O
lipid-lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O
that O
is O
essential O
for O
cell O
survival O
and O
tissue O
homeostasis O
. O
In O
this O
study O
, O
the O
role O
of O
autophagy O
and O
related O
signaling O
pathways O
during O
dioscin-induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O
Results O
from O
4'-6-diamidino-2-phenylindole O
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- O
and O
caspase-8-dependent O
, O
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O
dioscin O
treatment O
. O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

methyltrienelone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR B
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

BRL-50481 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

SoRI-9804 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT B
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O
manner O
. O
SoRI-20041 O
, O
which O
does O
not O
alter O
DAT-mediated O
DA O
release O
measured O
with O
[(3)H]DA O
, O
reversed O
the O
effect O
of O
SoRI-20040 O
. O
SoRI-20040 O
and O
SoRI-9804 O
also O
partially O
inhibited O
DAT-mediated O
DA O
release O
induced O
by O
DA O
or O
(+/-)-3,4-methylenedioxyamphetamine O
, O
demonstrating O
that O
the O
observed O
partial O
inhibition O
is O
not O
specific O
for O
a O
particular O
DAT O
substrate O
. O
SoRI-9804 O
and O
SoRI-20040 O
did O
not O
attenuate O
D-amphetamine-induced O
release O
of O
[(3)H]5-hydroxytryptamine O
from O
serotonergic O
, O
or O
[(3)H]MPP(+) O
from O
noradrenergic O
, O
nerve O
terminals O
. O
Kinetic O
experiments O
demonstrated O
that O
SoRI-9804 O
, O
in O
contrast O
to O
cocaine O
, O
slowed O
D-amphetamine-induced O
release O
of O
[(3)H]MPP(+) O
from O
dopaminergic O
nerve O
terminals O
without O
altering O
the O
apparent O
rate O
constants O
. O
The O
two O
major O
findings O
of O
this O
study O
are O
1) O
the O
identification O
of O
both O
"agonist" O
(SoRI-9804 O
and O
SoRI-20040) O
and O
"antagonist" O
(SoRI-20041) O
allosteric O
modulators O
of O
D-amphetamine-induced O
DAT-mediated O
DA O
release O
and O
2) O
[(3)H]DA O
uptake O
and O
d-amphetamine-induced O
DAT-mediated O
efflux O
can O
be O
separately O
modulated O
. O
Such O
agents O
may O
have O
therapeutic O
potential O
for O
the O
treatment O
of O
stimulant O
addiction O
, O
Parkinson's O
disease O
, O
and O
other O
psychiatric O
disorders O
. O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 O
( O
COX-2) B
-derived O
prostaglandin O
E2 O
(PGE2) O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 O
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O
FLO O
EA O
cells O
. O
Pulsed O
acid O
treatment O
significantly O
increased O
mPGES1 O
mRNA O
and O
protein O
levels O
but O
had O
little O
or O
no O
effect O
on O
mPGES2 O
or O
cPGES O
mRNA O
. O
Knockdown O
of O
mPGES1 O
by O
mPGES1 O
small O
interfering O
RNA O
(siRNA) O
blocked O
acid-induced O
increase O
in O
PGE2 O
production O
and O
thymidine O
incorporation O
. O
Knockdown O
of O
NADPH O
oxidase O
, O
NOX5-S O
, O
a O
variant O
lacking O
calcium-binding O
domains O
, O
by O
NOX5 O
siRNA O
significantly O
inhibited O
acid-induced O
increase O
in O
mPGES1 O
expression O
, O
thymidine O
incorporation O
, O
and O
PGE2 O
production O
. O
Overexpression O
of O
NOX5-S O
significantly O
increased O
the O
luciferase O
activity O
in O
FLO O
cells O
transfected O
with O
a O
nuclear O
factor O
κB O
(NF-κB) O
in O
vivo O
activation O
reporter O
plasmid O
pNF-κB-Luc O
. O
Knockdown O
of O
NF-κB1 O
p50 O
by O
p50 O
siRNA O
significantly O
decreased O
acid-induced O
increase O
in O
mPGES1 O
expression O
, O
thymidine O
incorporation O
, O
and O
PGE2 O
production O
. O
Two O
novel O
NF-κB O
binding O
elements O
, O
GGAGTCTCCC O
and O
CGGGACACCC O
, O
were O
identified O
in O
the O
mPGES1 O
gene O
promoter O
. O
We O
conclude O
that O
mPGES1 O
mediates O
acid-induced O
increase O
in O
PGE2 O
production O
and O
cell O
proliferation O
. O
Acid-induced O
mPGES1 O
expression O
depends O
on O
activation O
of O
NOX5-S O
and O
NF-κB1 O
p50 O
. O
Microsomal O
PGES1 O
may O
be O
a O
potential O
target O
to O
prevent O
or O
treat O
EA O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 B
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

methazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
: O
aromatic O
and O
heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
with O
strong O
anticonvulsant O
activity.A O
series O
of O
aromatic/heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic O
aminosulfonamides O
with O
the O
acyl O
chlorides O
derived O
from O
adamantyl-1-carboxylic O
acid O
and O
1-adamantyl-acetic O
acid O
. O
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides O
with O
adamantyl O
isocyanate O
and O
adamantyl O
isothiocyanate O
, O
respectively O
. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human B
CA I
isozymes O
involved O
in O
important O
physiological O
processes O
, O
CA O
I O
, O
and O
CA O
II O
, O
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide O
and O
methazolamide O
. O
The O
lipophilicity O
of O
the O
best O
CA O
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value O
. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35) O
. O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA O
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice O
. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)) O
, O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O
(> O
90%) O
. O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1) O
, O
respectively O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A B
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

PGE2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
essential O
oil O
and O
its O
constituents O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
through O
blocking O
JNK O
, O
ERK O
and O
NF-κB O
signaling O
pathways O
in O
LPS-activated O
RAW O
264.7 O
cells.We O
investigated O
the O
composition O
of O
essential O
oil O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase B
(COX)-2 I
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O
N-terminal O
kinase O
(JNK) O
and O
extracellular O
signal-regulated O
kinase O
(ERK) O
but O
not O
that O
of O
p38 O
mitogen-activated O
protein O
kinase O
. O
These O
results O
indicate O
that O
FCEO O
inhibits O
LPS-stimulated O
inflammation O
by O
blocking O
the O
NF-κB O
, O
JNK O
, O
and O
ERK O
pathways O
in O
macrophages O
, O
and O
demonstrate O
that O
FCEO O
possesses O
anti-inflammatory O
properties O
. O

rolipram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Antipsychotic O
profile O
of O
rolipram O
: O
efficacy O
in O
rats O
and O
reduced O
sensitivity O
in O
mice O
deficient O
in O
the O
phosphodiesterase-4B O
(PDE4B) O
enzyme.RATIONALE O
: O
Recent O
studies O
provide O
evidence O
for O
reduced O
phosphodiesterase-4B O
(PDE4B) O
as O
a O
genetic O
susceptibility O
factor O
as O
well O
as O
suggesting O
an O
association O
of O
several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
PDE4B O
that O
are O
associated O
with O
an O
increased O
incidence O
of O
schizophrenia O
. O
OBJECTIVES O
: O
The O
aim O
of O
the O
current O
study O
was O
to O
assess O
the O
activity O
of O
rolipram O
, O
a O
nonsubtype-selective O
PDE4 O
inhibitor O
, O
in O
several O
animal O
models O
predictive O
of O
antipsychotic-like O
efficacy O
and O
side-effect O
liability O
and O
to O
use O
PDE4B O
wild-type O
and O
knockout O
mice O
to O
begin O
to O
understand O
the O
subtypes O
involved O
in O
the O
activity O
of O
rolipram O
. O
RESULTS O
: O
In O
rats O
, O
rolipram O
antagonized O
both O
phencyclidine O
hydrochloride- O
and O
D-amphetamine-induced O
hyperactivity O
and O
inhibited O
conditioned O
avoidance O
responding O
(CAR) O
. O
In O
PDE4B O
wild-type O
mice O
, O
rolipram O
dose-dependently O
suppressed O
CAR O
(ED(50) O
= O
2.4 O
mg/kg); O
however O
, O
in O
knockout O
mice O
, O
their O
sensitivity O
to O
rolipram O
at O
the O
higher O
doses O
(1.0 O
and O
3.2 O
mg/kg) O
was O
reduced O
, O
resulting O
in O
a O
threefold O
shift O
in O
the O
ED(50) O
(7.3 O
mg/kg) O
, O
suggesting O
PDE4B B
is O
involved O
, O
at O
least O
in O
part O
, O
with O
the O
activity O
of O
rolipram O
. O
Only O
the O
highest O
dose O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B O
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O
that O
the O
PDE4B-regulated O
cyclic O
adenosine O
monophosphate O
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O
psychosis O
. O

5'-AMN O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindole-derived O
ligands O
at O
the O
κ-opioid O
receptor.Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid O
receptor O
antagonists O
in O
the O
treatment O
of O
mood O
disorders O
. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action O
, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor B
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O
effects O
in O
mice O
, O
reducing O
the O
antinociceptive O
actions O
of O
U50,488 O
(10 O
mg/kg) O
at O
28 O
and O
21 O
days O
post-injection O
, O
respectively O
. O
Interestingly O
, O
while O
5'-AMN O
and O
5'-MABN O
were O
not O
κ-selective O
, O
both O
compounds O
did O
show O
significant O
antidepressant- O
and O
anxiolytic-like O
effects O
at O
7-14 O
days O
post-injection O
in O
mice O
. O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src O
/ O
extracellular B
signal-regulated I
kinase I
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

dfbp O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O
mechanism O
has O
been O
obscured O
by O
its O
instability O
. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

DMA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 B
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

calpeptin O
acts O
as O
NOT O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF B
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O
bronchoconstriction O
in O
vivo O
and O
exhibit O
promising O
anti-inflammatory O
activity O
via O
intratracheal O
administration O
. O

cefadroxil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanisms O
of O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
: O
studies O
in O
wild-type O
and O
PEPT2 O
knockout O
mice.The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil O
was O
studied O
in O
peptide O
transporter O
2 O
(PEPT2) O
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature O
, O
transport O
inhibitors O
, O
pH O
, O
and O
saturability O
. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C) O
, O
the O
uptake O
of O
1 O
microM O
cefadroxil O
was O
reduced O
by O
83% O
in O
PEPT2( B
-/-) O
mice O
as O
compared O
with O
PEPT2(+/+) O
mice O
(p O
< O
0.001) O
. O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C O
, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil O
or O
p-aminohippurate O
(p O
< O
0.05) O
. O
Glycylsarcosine O
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil O
in O
PEPT2(+/+) O
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) O
mice O
. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil O
was O
demonstrated O
in O
PEPT2(+/+) O
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01) O
, O
no O
pH O
dependence O
was O
observed O
in O
PEPT2(-/-) O
mice O
. O
Kinetic O
parameters O
for O
cefadroxil O
(without O
p-aminohippurate) O
in O
wild-type O
mice O
were O
: O
V(max) O
= O
5.4 O
pmol/mg/min O
, O
K(m) O
= O
34 O
microM O
, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
the O
parameters O
were O
: O
V(max) O
= O
4.1 O
pmol/mg/min O
, O
K(m) O
= O
27 O
microM O
, O
and O
K(d) O
= O
0.0064 O
microl/mg/min O
. O
In O
null O
animals O
, O
the O
kinetic O
parameters O
of O
cefadroxil O
(without O
p-aminohippurate) O
were O
: O
V(max) O
= O
2.7 O
pmol/mg/min O
, O
K(m) O
= O
110 O
microM O
, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate O
, O
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed O
. O
Based O
on O
kinetic O
and O
inhibitor O
analyses O
, O
it O
was O
determined O
that O
(under O
linear O
conditions) O
, O
80 O
to O
85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2 O
, O
10 O
to O
15% O
by O
organic O
anion O
transporter(s) O
, O
and O
5% O
by O
nonspecific O
mechanisms O
. O
These O
findings O
demonstrate O
that O
PEPT2 O
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil O
uptake O
in O
the O
choroid O
plexus O
. O
Moreover O
, O
the O
data O
suggest O
a O
role O
for O
PEPT2 O
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid O
. O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

repaglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 B
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
the O
liver O
and O
muscle O
isoforms O
of O
ovine O
carnitine O
palmitoyltransferase O
1 O
: O
residues O
within O
the O
N-terminus O
of O
the O
muscle O
isoform O
influence O
the O
kinetic O
properties O
of O
the O
enzyme.The O
nucleotide O
sequence O
data O
reported O
will O
appear O
in O
DDBJ O
, O
EMBL O
, O
GenBank(R) O
and O
GSDB O
Nucleotide O
Sequence O
Databases; O
the O
sequences O
of O
ovine O
CPT1A O
and O
CPT1B O
cDNAs O
have O
the O
accession O
numbers O
Y18387 O
and O
AJ272435 O
respectively O
and O
the O
partial O
adipose O
tissue O
and O
liver O
CPT1A O
clones O
have O
the O
accession O
numbers O
Y18830 O
and O
Y18829 O
respectively O
. O
Fatty O
acid O
and O
ketone O
body O
metabolism O
differ O
considerably O
between O
monogastric O
and O
ruminant O
species O
. O
The O
regulation O
of O
the O
key O
enzymes O
involved O
may O
differ O
accordingly O
. O
Carnitine O
palmitoyltransferase O
1 O
(CPT O
1) O
is O
the O
key O
locus O
for O
the O
control O
of O
long-chain O
fatty O
acid O
beta-oxidation O
and O
liver O
ketogenesis O
. O
Previously O
we O
showed O
that O
CPT O
1 O
kinetics O
in O
sheep O
and O
rat O
liver O
mitochondria O
differ O
. O
We O
cloned O
cDNAs O
for O
both O
isoforms O
[liver- O
(L-) O
and O
muscle- O
(M-)] O
of O
ovine O
CPT O
1 O
in O
order O
to O
elucidate O
the O
structural O
features O
of O
these O
proteins O
and O
their O
genes O
( O
CPT1A O
and O
CPT1B O
) O
. O
Their O
deduced O
amino O
acid O
sequences O
show O
a O
high O
degree O
of O
conservation O
compared O
with O
orthologues O
from O
other O
mammalian O
species O
, O
with O
the O
notable O
exception O
of O
the O
N-terminus O
of O
ovine B
M-CPT I
1 I
. O
These O
differences O
were O
also O
present O
in O
bovine O
M-CPT O
1 O
, O
whose O
N-terminal O
sequence O
we O
determined O
. O
In O
addition O
, O
the O
5'-end O
of O
the O
sheep O
CPT1B O
cDNA O
suggested O
a O
different O
promoter O
architecture O
when O
compared O
with O
previously O
characterized O
CPT1B O
genes O
. O
Northern O
blotting O
revealed O
differences O
in O
tissue O
distribution O
for O
both O
CPT1A O
and O
CPT1B O
transcripts O
compared O
with O
other O
species O
. O
In O
particular O
, O
ovine O
CPT1B O
mRNA O
was O
less O
tissue O
restricted O
, O
and O
the O
predominant O
transcript O
in O
the O
pancreas O
was O
CPT1B O
. O
Expression O
in O
yeast O
allowed O
kinetic O
characterization O
of O
the O
two O
native O
enzymes O
, O
and O
of O
a O
chimaera O
in O
which O
the O
distinctive O
N-terminal O
segment O
of O
ovine O
M-CPT O
1 O
was O
replaced O
with O
that O
from O
rat O
M-CPT O
1 O
. O
The O
ovine O
N-terminal O
segment O
influences O
the O
kinetics O
of O
the O
enzyme O
for O
both O
its O
substrates O
, O
such O
that O
the O
K O
(m) O
for O
palmitoyl-CoA O
is O
decreased O
and O
that O
for O
carnitine O
is O
increased O
for O
the O
chimaera O
, O
relative O
to O
the O
parental O
ovine O
M-CPT O
1 O
. O

PMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC O
isoform O
selectivity O
was O
observed O
. O
PKC B
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC O
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

aflatoxin O
B(1) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Antigenotoxic O
potencies O
of O
a O
lichen O
species O
, O
Evernia O
prunastri.In O
this O
article O
, O
the O
genotoxic O
and O
antigenotoxic O
effects O
of O
methanol O
extract O
of O
Evernia O
prunastri O
(Huds.) O
Willd O
. O
(MEP) O
were O
studied O
using O
WP2 O
, O
Ames O
(TA1535 O
and O
TA1537) O
and O
sister O
chromatid O
exchange O
(SCE) O
test O
systems O
. O
The O
results O
obtained O
from O
bacterial O
test O
systems O
demonstrated O
that O
MEP O
has O
strong O
antimutagenic O
potencies O
on O
TA1537 O
and O
WP2 O
strains O
. O
The O
highest O
inhibition O
rates O
for O
MEP O
on O
TA1537 O
and O
WP2 O
strains O
were O
37.70% O
and O
69.70% O
, O
respectively O
. O
According O
to O
the O
SCE O
test O
system O
, O
MEP O
reduced O
the O
genotoxic O
effects O
of O
aflatoxin O
. O
In O
order O
to O
clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP O
, O
the O
antioxidants O
were O
determined O
. O
Cotreatments O
of O
5 O
, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin O
B(1) O
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde O
level O
and O
increased O
amount O
of O
superoxide B
dismutase I
, O
glutathione O
and O
glutathione O
peroxidase O
which O
were O
decreased O
by O
aflatoxin O
. O
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O
to O
be O
partly O
due O
to O
the O
antioxidant O
activities O
and O
antioxidant O
inducing O
capability O
of O
MEP O
. O
This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O
N-methyl-N'-nitro-N-nitrosoguanidine O
, O
acridin O
and O
aflatoxin O
. O

Pelargonidin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Safrole-2',3'-oxide O
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein O
E-knockout O
mice.Safrole-2',3'-oxide O
(SFO) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole O
(4-allyl-1 O
, O
2-methylenedioxybenzene) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO-induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
( O
apoE( B
-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

sodium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Block O
of O
human O
NaV1.5 O
sodium O
channels O
by O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
phenytoin.Voltage-gated O
sodium O
(Na) O
channels O
are O
a O
critical O
component O
of O
electrically O
excitable O
cells O
. O
Phenytoin O
(diphenylhydantoin O
, O
DPH) O
is O
an O
established O
sodium B
channel I
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O
examined O
including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
phenyl O
ring O
substitutions O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O
greater O
activity O
. O
In O
comparison O
to O
diphenylhydantoin O
, O
the O
novel O
chloro-substituted O
alpha-hydroxyphenylamide O
compounds O
produced O
as O
much O
as O
a O
20-fold O
greater O
tonic O
and O
frequency-dependent O
blockade O
of O
Na(V)1.5 O
channels O
with O
an O
IC(50) O
value O
of O
14.5 O
microM O
. O
In O
addition O
, O
the O
chloro-substitutions O
have O
position O
specific O
state O
dependent O
blocking O
properties O
. O
The O
ortho- O
, O
meta- O
and O
para-chloro O
substitutions O
have O
an O
8- O
, O
13- O
and O
3-fold O
increased O
affinity O
for O
the O
inactivated O
state O
, O
respectively O
. O
Molecular O
modeling O
suggests O
that O
these O
differences O
in O
affinity O
are O
due O
to O
a O
direct O
interaction O
with O
the O
receptor O
. O
Comparing O
models O
of O
diphenylhydantoin O
to O
the O
novel O
alpha-hydroxyphenlyamide O
compound O
suggests O
that O
the O
increased O
activity O
may O
be O
due O
to O
an O
optimized O
phenyl O
ring O
position O
and O
increased O
molecular O
volume O
. O
This O
information O
may O
be O
useful O
in O
the O
development O
of O
more O
potent O
sodium O
channel O
blockers O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS B
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

IM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
A O
novel O
tyrosine O
kinase O
switch O
is O
a O
mechanism O
of O
imatinib O
resistance O
in O
gastrointestinal O
stromal O
tumors.KIT O
or O
alpha-platelet-derived O
growth O
factor O
receptor O
(alpha-PDGFR) O
activating O
mutations O
are O
the O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT B
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O
GIST-S O
and O
GIST-R O
cells O
confirmed O
the O
switch O
from O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

Aldosterone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells.Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
( O
PKD1) B
 O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O
network O
(TGN) O
through O
activation O
of O
phosphatidylinositol O
4-kinaseIIIβ O
(PI4KIIIβ) O
. O
We O
report O
rapid O
ENaCγ O
translocation O
to O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O
cortical O
collecting O
duct O
cells O
, O
which O
was O
significantly O
impaired O
in O
PKD1 O
shRNA-mediated O
knockdown O
cells O
. O
In O
PKD1-deficient O
cells O
, O
the O
ouabain-sensitive O
current O
was O
significantly O
reduced O
and O
Na(+)/K(+)-ATPase O
α O
and O
β O
subunits O
showed O
aberrant O
localization O
. O
PKD1 O
and O
PI4KIIIβ O
localize O
to O
the O
TGN O
, O
and O
aldosterone O
induced O
an O
interaction O
between O
PKD1 O
and O
PI4KIIIβ O
following O
aldosterone O
treatment O
. O
This O
study O
reveals O
a O
novel O
mechanism O
for O
rapid O
regulation O
of O
ENaC O
and O
the O
Na(+)/K(+)-ATPase O
, O
via O
directed O
trafficking O
through O
PKD1-PI4KIIIβ O
signalling O
at O
the O
level O
of O
the O
TGN O
. O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

C23H29N7O6.HCl.xH2O O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Impaired O
function O
of O
prejunctional O
adenosine O
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt O
hypertensive O
rats.Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone O
acetate O
(DOCA)-salt O
hypertension O
in O
rats O
. O
ATP O
and O
norepinephrine O
(NE) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O
NE O
acts O
at O
prejunctional O
α2-adrenergic O
receptors O
(α2ARs) O
to O
inhibit O
NE O
release O
, O
and O
α2AR O
function O
is O
impaired O
in O
DOCA-salt O
rats O
. O
Adenosine O
, O
an O
enzymatic O
ATP O
degradation O
product O
, O
acts O
at O
prejunctional O
A1 O
adenosine O
receptors O
(A1Rs) O
to O
inhibit O
NE O
release O
. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt O
rats O
. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A B
adenosine I
receptor I
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs O
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

CIQ O
acts O
as O
NOT O
for O
what O
entity O
? O
Contribution O
of O
the O
m1 O
transmembrane O
helix O
and O
pre-m1 O
region O
to O
positive O
allosteric O
modulation O
and O
gating O
of O
N-methyl-d-aspartate O
receptors.N-methyl-d-aspartate O
(NMDA) O
receptors O
are O
glutamate-gated O
ion O
channels O
whose O
function O
is O
critical O
for O
normal O
excitatory O
synaptic O
transmission O
in O
the O
brain O
and O
whose O
dysfunction O
has O
been O
implicated O
in O
several O
neurologic O
conditions O
. O
NMDA O
receptor O
function O
is O
subject O
to O
extensive O
allosteric O
regulation O
both O
by O
endogenous O
compounds O
and O
by O
exogenous O
small O
molecules O
. O
Elucidating O
the O
structural O
determinants O
and O
mechanism O
of O
action O
by O
which O
allosteric O
regulators O
control O
gating O
will O
enhance O
our O
understanding O
of O
NMDA O
receptor O
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics O
. O
Here O
, O
we O
investigated O
the O
structural O
determinants O
for O
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone O
(CIQ) O
, O
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator O
. O
We O
show O
that O
CIQ O
does O
not O
bind O
to O
the O
amino-terminal O
domain O
of O
the O
NMDA O
receptor O
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O
domain O
dimer O
interface O
or O
ion B
channel I
pore O
. O
Rather O
, O
we O
identified O
critical O
determinants O
of O
CIQ O
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D O
, O
including O
in O
a O
putative O
pre-M1 O
cuff O
helix O
that O
may O
influence O
channel O
gating O
. O
We O
also O
show O
that O
mutations O
within O
the O
GluN2D O
pre-M1 O
region O
alter O
open O
probability O
of O
the O
NMDA O
receptor O
. O
These O
results O
suggest O
a O
novel O
site O
of O
action O
for O
potentiation O
of O
NMDA O
receptors O
by O
small O
molecules O
and O
implicate O
the O
pre-M1 O
region O
in O
NMDA O
receptor O
gating O
. O

fenofibrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effects O
of O
fenofibrate O
, O
a O
PPAR-α O
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII B
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion O
. O
The O
effects O
of O
PE O
and O
AII O
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated O
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O
for O
ET1 O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII O
and O
ET1 O
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

atenolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
, O
reduces O
Na(+) O
influx O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) O
channels O
: O
comparison O
with O
other O
beta-adrenoceptor O
antagonists.Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
used O
for O
the O
treatment O
of O
glaucoma O
, O
is O
known O
to O
be O
neuroprotective O
in O
paradigms O
of O
ischaemia/excitotoxicity O
. O
In O
this O
study O
, O
we O
examined O
whether O
betaxolol O
and O
other O
beta-adrenoceptor O
antagonists O
interact O
directly O
with O
neurotoxin O
binding O
to O
sites O
1 O
and O
2 O
of O
the O
voltage-sensitive O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM O
. O
Comparison O
of O
all O
the O
beta-adrenoceptor B
antagonists O
tested O
revealed O
a O
potency O
order O
of O
propranolol>betaxolol O
approximately O
levobetaxolol>levobunolol O
approximately O
carteolol>/=timolol>atenolol O
. O
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin O
binding O
to O
neurotoxin O
receptor O
site O
1 O
, O
even O
at O
concentrations O
as O
high O
as O
250 O
microM O
. O
Saturation O
experiments O
showed O
that O
betaxolol O
increased O
the O
K(D) O
of O
[(3)H]-BTX-B O
binding O
but O
had O
no O
effect O
on O
the O
B(max) O
. O
The O
association O
kinetics O
of O
[(3)H]-BTX-B O
were O
unaffected O
by O
betaxolol O
, O
but O
the O
drug O
significantly O
accelerated O
the O
dissociation O
rate O
of O
the O
radioligand O
. O
These O
findings O
argue O
for O
a O
competitive O
, O
indirect O
, O
allosteric O
mode O
of O
inhibition O
of O
[(3)H]-BTX-B O
binding O
by O
betaxolol O
. O
Betaxolol O
inhibited O
veratridine-stimulated O
Na(+) O
influx O
in O
rat O
cortical O
synaptosomes O
with O
an O
IC(50) O
value O
of O
28 O
. O
3 O
microM O
. O
Carteolol O
, O
levobunolol O
, O
timolol O
and O
atenolol O
were O
significantly O
less O
effective O
than O
betaxolol O
at O
reducing O
veratridine-evoked O
Na(+) O
influx O
. O
The O
ability O
of O
betaxolol O
to O
interact O
with O
neurotoxin O
site O
2 O
of O
the O
Na(+) O
channel O
and O
inhibit O
Na(+) O
influx O
may O
have O
a O
role O
in O
its O
neuroprotective O
action O
in O
paradigms O
of O
excitotoxicity/ischaemia O
and O
in O
its O
therapeutic O
effect O
in O
glaucoma O
. O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
( O
iNOS) B
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

tolvaptan O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Tolvaptan O
and O
its O
potential O
in O
the O
treatment O
of O
hyponatremia.Tolvaptan O
is O
a O
selective O
arginine O
vasopressin O
(AVP) O
V(2) O
receptor O
blocker O
used O
to O
induce O
free O
water O
diuresis O
in O
the O
treatment O
of O
euvolemic O
or O
hypervolemic O
hyponatremia O
. O
Currently O
the O
orally O
active O
medication O
is O
in O
the O
final O
stages O
prior O
to O
approval O
by O
the O
FDA O
for O
outpatient O
therapy O
. O
It O
appears O
to O
be O
safe O
and O
effective O
at O
promoting O
aquaresis O
and O
raising O
serum O
sodium O
levels O
in O
both O
short- O
and O
long-term O
studies O
. O
Tolvaptan O
is O
also O
effective O
for O
treatment O
of O
congestive O
heart O
failure O
(CHF) O
exacerbation O
, O
but O
whether O
there O
are O
long O
standing O
beneficial O
effects O
on O
CHF O
is O
still O
controversial O
. O
Prolonged O
use O
of O
tolvaptan O
leads O
to O
increased O
endogenous O
levels O
of O
AVP O
and O
perhaps O
over-stimulation O
of O
V(1A) B
receptors I
. O
Theoretically O
this O
activation O
could O
lead O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis O
, O
causing O
progression O
of O
CHF O
. O
However O
, O
after O
52 O
weeks O
of O
tolvaptan O
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation O
. O
In O
addition O
, O
tolvaptan O
is O
metabolized O
by O
the O
CYP3A4 O
system; O
thus O
physicians O
should O
be O
aware O
of O
the O
potential O
for O
increased O
interactions O
with O
other O
medications O
. O
Tolvaptan O
is O
a O
breakthrough O
in O
the O
therapy O
of O
hyponatremia O
as O
it O
directly O
combats O
elevated O
AVP O
levels O
associated O
with O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
, O
congestive O
heart O
failure O
, O
and O
cirrhosis O
of O
the O
liver O
. O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon B
kinase I
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

BMY-7378 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Expressions O
and O
mechanical O
functions O
of O
alpha1-adrenoceptor O
subtypes O
in O
hamster O
ureter.We O
characterized O
the O
alpha(1)-adrenoceptor O
subtypes O
in O
hamster O
ureters O
according O
to O
gene O
and O
protein O
expressions O
and O
contractile O
function O
. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively O
, O
for O
alpha(1A)- O
, O
alpha(1B)- O
and O
alpha(1D)-adrenoceptors O
in O
hamster O
ureteral O
smooth O
muscle O
. O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O
for O
humans O
, O
alpha(1A)-adrenoceptor O
antagonists O
could O
become O
useful O
medication O
for O
stone O
passage O
in O
urolithiasis O
patients O
. O

carboxylic O
acids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides O
. O
Carboxylesterases B
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Multidrug O
resistance-associated O
proteins O
are O
involved O
in O
the O
transport O
of O
the O
glutathione O
conjugates O
of O
the O
ultimate O
carcinogen O
of O
benzo[a]pyrene O
in O
human O
Caco-2 O
cells.A O
wide O
variety O
of O
contaminants O
are O
ingested O
through O
food O
, O
among O
them O
the O
pro-carcinogenic O
polycyclic O
aromatic O
hydrocarbon O
benzo[a]pyrene O
(BP) O
that O
is O
resorbed O
and O
partially O
metabolized O
in O
the O
enterocytes O
of O
the O
small O
intestine O
. O
Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP O
phenols O
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates O
. O
This O
export O
is O
mediated O
by O
the O
breast O
cancer O
resistance O
protein O
(ABCG2) O
. O
The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O
anti-BP-7,8-dihydrodiol-9,10-epoxide O
(BPDE) O
can O
be O
detoxified O
by O
glutathione O
conjugate O
formation O
catalyzed O
by O
glutathione O
S-transferases O
. O
In O
the O
present O
study O
, O
differentiated O
human O
intestinal O
Caco-2 O
cells O
were O
used O
as O
a O
model O
for O
the O
human O
small O
intestine O
to O
investigate O
the O
detoxification O
of O
BPDE O
and O
excretion O
of O
stereoisomeric O
glutathione O
conjugates O
in O
the O
presence O
of O
an O
inhibitor O
of O
the O
glutathione-cleaving O
enzyme O
γ-glutamyl O
transpeptidase O
at O
the O
cell O
surface O
. O
The O
results O
indicate O
that O
the O
glutathione O
conjugates O
of O
BPDE O
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
( O
ABCCs) B
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation O
. O

nucleotide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Heteromtoxin O
(HmTx) O
, O
a O
novel O
heterodimeric O
phospholipase O
A(2) O
from O
Heterometrus O
laoticus O
scorpion O
venom.Heteromtoxin O
(HmTx) O
is O
a O
group O
III O
phospholipase O
A(2) O
produced O
in O
Heterometrus O
laoticus O
, O
in O
Thailand O
. O
In O
this O
study O
, O
HmTx O
was O
purified O
from O
venom O
by O
separation O
chromatography O
, O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx B
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1 O
/ O
5-HT2 B
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

DFMO O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine B
decarboxylase I
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

noradrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
( O
phenylalanine B
hydroxylase I
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β B
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

gentamicin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Apolipoprotein O
E3 O
(apoE3) O
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 B
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density O
lipoprotein O
(LDL) O
receptor O
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1-dependent O
glucose O
transport O
in O
pig O
proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O
model O
of O
gentamicin O
C O
(GMC)-induced O
reduction O
in O
SGLT1 O
activity O
, O
we O
examined O
whether O
ligands O
for O
megalin O
protect O
LLC-PK1 O
cells O
from O
the O
GMC-induced O
reduction O
in O
SGLT1 O
activity O
. O
We O
employed O
apolipoprotein O
E3 O
(apoE3) O
and O
lactoferrin O
as O
ligands O
for O
megalin O
. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3 O
, O
lactoferrin O
and O
bovine O
serum O
albumin O
with O
or O
without O
100 O
microg/ml O
of O
GMC O
, O
and O
the O
SGLT1-dependent O
methyl O
alpha-D-glucopyranoside O
(AMG) O
uptake O
and O
levels O
of O
SGLT1 O
expression O
were O
determined O
. O
As O
a O
result O
, O
we O
demonstrated O
that O
the O
apoE3 O
significantly O
protects O
these O
cells O
from O
GMC-induced O
reduction O
in O
AMG O
uptake O
, O
but O
neither O
lactoferrin O
nor O
albumin O
does O
. O
In O
accord O
with O
a O
rise O
in O
AMG O
uptake O
activity O
, O
the O
mRNA O
and O
protein O
levels O
of O
SGLT1 O
were O
apparently O
up-regulated O
in O
the O
presence O
of O
apoE3 O
. O
Furthermore O
, O
we O
found O
that O
the O
uptake O
of O
[3H] O
gentamicin O
is O
decreased O
by O
apoE3 O
, O
and O
that O
apoE3 O
showed O
obvious O
protection O
against O
the O
GMC-dependent O
N-acetyl-beta-D-glucosamidase O
(NAG) O
release O
from O
LLC-PK1 O
cells O
. O
Thus O
, O
these O
results O
indicate O
that O
apoE3 O
could O
be O
a O
valuable O
tool O
for O
the O
prevention O
of O
aminoglycoside O
nephrotoxicity O
. O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET B
/ O
DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

formate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC B
1.2.1.2) I
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

2-deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Energy O
depletion O
of O
bovine O
mammary O
epithelial O
cells O
activates O
AMPK O
and O
suppresses O
protein O
synthesis O
through O
inhibition O
of O
mTORC1 O
signaling.The O
molecular O
mechanisms O
by O
which O
cellular O
energy O
status O
regulates O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK B
at O
Thr172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O
associated O
with O
a O
marked O
increase O
in O
Ser792 O
phosphorylation O
on O
raptor O
. O
Collectively O
, O
the O
results O
suggest O
that O
activation O
of O
AMPK O
represses O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
through O
inhibition O
of O
mTORC1 O
signaling O
. O

eprosartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Introduction O
: O
The O
pharmacological O
profile O
of O
eprosartan--implications O
for O
cerebrovascular O
and O
cardiovascular O
risk O
reduction.Moderate O
elevations O
in O
blood O
pressure O
translate O
to O
significant O
increases O
in O
cardiovascular O
and O
cerebro O
vascular O
risk O
. O
Beneficially O
, O
this O
relationship O
allows O
small O
decreases O
in O
blood O
pressure O
to O
be O
associated O
with O
risk O
reduction O
. O
Both O
the O
renin-angiotensin O
system O
and O
the O
sympathetic O
nervous O
system O
are O
involved O
in O
hypertension O
, O
hence O
targeting O
these O
systems O
is O
likely O
to O
be O
of O
benefit O
in O
the O
treatment O
of O
hypertension O
. O
Angiotensin O
II O
type O
1 O
receptor O
blockers O
(ARBs) O
are O
used O
for O
controlling O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients O
, O
including O
those O
with O
diabetes O
and O
the O
elderly O
. O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin B
II I
type I
1 I
receptor I
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 O
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
. O
Eprosartan O
can O
also O
be O
differentiated O
from O
other O
ARBs O
due O
to O
its O
noradrenergic O
effects O
, O
which O
other O
ARBs O
used O
at O
therapeutic O
doses O
do O
not O
possess O
. O
Eprosartan O
, O
therefore O
, O
represents O
a O
useful O
therapeutic O
option O
in O
the O
management O
of O
patients O
with O
hypertension O
, O
including O
those O
with O
a O
history O
of O
stroke O
or O
with O
co-morbid O
type O
2 O
diabetes O
mellitus O
. O

Nitrogen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins B
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

GW572016 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Truncated O
ErbB2 O
receptor O
(p95ErbB2) O
is O
regulated O
by O
heregulin O
through O
heterodimer O
formation O
with O
ErbB3 O
yet O
remains O
sensitive O
to O
the O
dual O
EGFR/ErbB2 O
kinase O
inhibitor O
GW572016.The O
expression O
of O
the O
NH2 O
terminally O
truncated O
ErbB2 O
receptor O
(p95ErbB2) O
in O
breast O
cancer O
correlates O
with O
metastatic O
disease O
progression O
compared O
with O
the O
expression O
of O
full-length O
p185ErbB2 O
. O
We O
now O
show O
that O
heregulin O
(HRG) O
, O
but O
not O
EGF O
, O
stimulates O
p95ErbB2 O
phosphorylation O
in O
BT474 O
breast O
cancer O
cells O
. O
Furthermore O
, O
phospho-p95ErbB2 O
forms O
heterodimers O
with O
ErbB3 O
, O
but O
not O
EGFR O
, O
while O
p185ErbB2 O
heterodimerizes O
with O
both O
EGFR O
and O
ErbB3 O
. O
The O
predilection O
of O
p95ErbB2 O
to O
heterodimerize O
with O
ErbB3 O
provides O
an O
explanation O
for O
its O
regulation O
by O
HRG O
, O
an O
ErbB3 O
ligand O
. O
GW572016 O
, O
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR O
and O
ErbB2 B
tyrosine O
kinases O
, O
inhibits O
baseline O
p95ErbB2 O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O
GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
and O
cyclin O
D O
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O
in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
or O
cyclin O
D O
. O
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O
by O
the O
selection O
of O
p95ErbB2-expressing O
breast O
cancer O
cells O
capable O
of O
exerting O
potent O
growth O
and O
prosurvival O
signals O
through O
p95ErbB2-ErbB3 O
heterodimers O
. O
Thus O
, O
p95ErbB2 O
represents O
a O
target O
for O
therapeutic O
intervention O
, O
and O
one O
that O
is O
sensitive O
to O
GW572016 O
therapy O
. O

BPB O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 B
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

NCFP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
novel O
metabotropic O
glutamate O
receptor O
5 O
positive O
allosteric O
modulator O
acts O
at O
a O
unique O
site O
and O
confers O
stimulus O
bias O
to O
mGlu5 O
signaling.Metabotropic O
glutamate O
receptor O
5 O
(mGlu5) O
is O
a O
target O
for O
the O
treatment O
of O
central O
nervous O
system O
(CNS) O
disorders O
, O
such O
as O
schizophrenia O
and O
Alzheimer's O
disease O
. O
Furthermore O
, O
mGlu5 O
has O
been O
shown O
to O
play O
an O
important O
role O
in O
hippocampal O
synaptic O
plasticity O
, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 O
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 B
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O
PAMs O
may O
have O
similar O
responses O
in O
some O
systems O
, O
they O
can O
induce O
differential O
effects O
on O
mGlu5-mediated O
physiologic O
responses O
in O
the O
CNS O
. O
Such O
stimulus O
bias O
by O
mGlu5 O
PAMs O
may O
complicate O
drug O
discovery O
efforts O
but O
would O
also O
allow O
for O
specifically O
tailored O
therapies O
, O
if O
pharmacological O
biases O
can O
be O
attributed O
to O
different O
therapeutic O
outcomes O
. O

tricyclic O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
a O
novel O
serotonin B
receptor I
with O
high O
affinity O
for O
tricyclic O
psychotropic O
drugs.We O
have O
used O
the O
polymerase O
chain O
reaction O
technique O
to O
selectively O
amplify O
a O
guanine O
nucleotide-binding O
protein-coupled O
receptor O
cDNA O
sequence O
from O
rat O
striatal O
mRNA O
that O
exhibits O
high O
homology O
to O
previously O
cloned O
serotonin O
receptors O
. O
Sequencing O
of O
a O
full O
length O
clone O
isolated O
from O
a O
rat O
striatal O
cDNA O
library O
revealed O
an O
open O
reading O
frame O
of O
1311 O
base O
pairs O
, O
encoding O
a O
437-residue O
protein O
with O
seven O
hydrophobic O
regions O
. O
Within O
these O
hydrophobic O
regions O
, O
this O
receptor O
was O
found O
to O
be O
41-36% O
identical O
to O
the O
following O
serotonin O
[5-hydroxytryptamine O
(5-HT)] O
receptors O
: O
5-HT2 O
> O
5-HT1D O
> O
5-HT1C O
> O
5-HT1B O
> O
5-HT1A O
> O
5-HT1E O
. O
Northern O
blots O
revealed O
a O
approximately O
4.2-kilobase O
transcript O
localized O
in O
various O
brain O
regions O
, O
with O
the O
following O
rank O
order O
of O
abundance O
: O
striatum O
>> O
olfactory O
tubercle O
> O
cerebral O
cortex O
> O
hippocampus O
. O
Expression O
of O
this O
clone O
in O
COS-7 O
cells O
resulted O
in O
the O
appearance O
of O
high O
affinity O
, O
saturable O
binding O
of O
(+)-[2-125I] O
iodolysergic O
acid O
diethylamide O
([125I]LSD) O
with O
a O
Kd O
of O
1.26 O
nM O
. O
Among O
endogenous O
biogenic O
amines O
, O
only O
5-HT O
completely O
inhibited O
[125I]LSD O
binding O
(Ki O
= O
150 O
nM) O
. O
The O
inhibition O
of O
[125I]LSD O
binding O
by O
other O
serotonergic O
agonists O
and O
antagonists O
revealed O
a O
pharmacological O
profile O
that O
does O
not O
correlate O
with O
that O
of O
any O
previously O
described O
serotonin O
receptor O
subtype O
. O
In O
addition O
, O
this O
receptor O
exhibits O
high O
affinity O
for O
a O
number O
of O
tricyclic O
antipsychotic O
and O
antidepressant O
drugs O
, O
including O
clozapine O
, O
amoxipine O
, O
and O
amitriptyline O
. O
In O
HEK-293 O
cells O
stably O
transfected O
with O
this O
receptor O
, O
serotonin O
elicits O
a O
potent O
stimulation O
of O
adenylyl O
cyclase O
activity O
, O
which O
is O
blocked O
by O
antipsychotic O
and O
antidepressant O
drugs O
. O
The O
distinct O
structural O
and O
pharmacological O
properties O
of O
this O
receptor O
site O
indicate O
that O
it O
represents O
a O
completely O
novel O
subtype O
of O
serotonin O
receptor O
. O
Based O
on O
its O
affinity O
for O
tricyclic O
psychotropic O
drugs O
and O
its O
localization O
to O
limbic O
and O
cortical O
regions O
of O
the O
brain O
, O
it O
is O
likely O
that O
this O
receptor O
may O
play O
a O
role O
in O
several O
neuropsychiatric O
disorders O
that O
involve O
serotonergic O
systems O
. O

SB365 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
SB365 O
, O
Pulsatilla O
saponin O
D O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT/mTOR O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer O
. O
We O
found O
that O
SB365 O
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis O
. O
Also O
, O
SB365 O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT B
/ O
mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer O
. O

bile O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
LDL O
Cholesterol O
Goals O
in O
High-Risk O
Patients O
: O
How O
Low O
Do O
We O
Go O
and O
How O
Do O
We O
Get O
There?It O
is O
widely O
recognised O
that O
low-density O
lipoprotein O
cholesterol O
(LDL-C) O
is O
one O
of O
the O
most O
important O
and O
modifiable O
risk O
factors O
for O
cardiovascular O
disease O
(CVD) O
. O
Statins O
(HMG-CoA O
reductase O
inhibitors) O
have O
consistently O
been O
shown O
to O
decrease O
both O
LDL-C O
and O
CVD O
risk O
in O
almost O
all O
patient O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O
As O
a O
consequence O
, O
statins O
have O
become O
the O
cornerstone O
in O
current O
prevention O
guidelines O
. O
In O
patients O
who O
do O
not O
reach O
the O
LDL-C O
target O
, O
combination O
therapy O
with O
additional O
LDL- B
C O
lowering O
drugs O
(e.g O
. O
ezetimibe O
, O
bile O
acid O
sequestrants O
or O
fibrates) O
should O
be O
considered O
. O
Guidelines O
provide O
different O
LDL-C O
levels O
to O
strive O
for O
, O
depending O
on O
the O
CVD O
risk O
. O
In O
this O
review O
, O
we O
describe O
the O
rationale O
for O
these O
LDL-C O
targets O
and O
how O
these O
goals O
might O
be O
reached O
by O
current O
and O
future O
therapies O
. O

Wogonoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular B
signal-regulated I
kinase I
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

5-nitro-2,N,N-trimethylbenzenesulfonamide O
acts O
as O
NOT O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto- O
phosphodiesterase B
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS B
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

TDI O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC O
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC B
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

(125)I-Cyanopindolol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor O
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors B
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs/cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

Butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Butein O
protects O
human O
dental O
pulp O
cells O
from O
hydrogen O
peroxide-induced O
oxidative O
toxicity O
via O
Nrf2 O
pathway-dependent O
heme O
oxygenase-1 O
expressions.Rhus O
verniciflua O
Stokes O
is O
a O
plant O
that O
is O
native O
to O
East O
Asian O
countries O
, O
such O
as O
Korea O
, O
China O
, O
and O
Japan O
. O
Butein O
, O
a O
plant O
polyphenol O
, O
is O
one O
of O
the O
major O
active O
components O
of O
R O
. O
verniciflua O
. O
Reactive O
oxygen O
species O
(ROS) O
, O
produced O
via O
dental O
adhesive O
bleaching O
agents O
and O
pulpal O
disease O
, O
can O
cause O
oxidative O
stress O
. O
Here O
, O
we O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
( O
HO-1) B
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

donepezil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cholinesterase O
inhibitors O
for O
Alzheimer's O
disease.BACKGROUND O
: O
Since O
the O
introduction O
of O
the O
first O
cholinesterase O
inhibitor O
(ChEI) O
in O
1997 O
, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs O
, O
donepezil O
, O
galantamine O
and O
rivastigmine O
, O
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties O
, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine O
, O
an O
important O
neurotransmitter O
associated O
with O
memory O
, O
by O
blocking O
the O
enzyme O
acetylcholinesterase B
. O
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O
the O
manifestations O
of O
Alzheimer's O
disease O
. O
Cochrane O
reviews O
of O
each O
ChEI O
for O
Alzheimer's O
disease O
have O
been O
completed O
(Birks O
2005 O
, O
Birks O
2005b O
and O
Loy O
2005) O
. O
Despite O
the O
evidence O
from O
the O
clinical O
studies O
and O
the O
intervening O
clinical O
experience O
the O
debate O
on O
whether O
ChEIs O
are O
effective O
continues O
. O
OBJECTIVES O
: O
To O
assess O
the O
effects O
of O
donepezil O
, O
galantamine O
and O
rivastigmine O
in O
people O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
. O
SEARCH O
STRATEGY O
: O
The O
Cochrane O
Dementia O
and O
Cognitive O
Improvement O
Group's O
Specialized O
Register O
was O
searched O
using O
the O
terms O
'donepezil' O
, O
'E2020' O
 O
, O
'Aricept' O
 O
, O
galanthamin* O
galantamin* O
reminyl O
, O
rivastigmine O
, O
exelon O
, O
"ENA O
713" O
and O
ENA-713 O
on O
12 O
June O
2005 O
. O
This O
Register O
contains O
up-to-date O
records O
of O
all O
major O
health O
care O
databases O
and O
many O
ongoing O
trial O
databases O
. O
SELECTION O
CRITERIA O
: O
All O
unconfounded O
, O
blinded O
, O
randomized O
trials O
in O
which O
treatment O
with O
a O
ChEI O
was O
compared O
with O
placebo O
or O
another O
ChEI O
for O
patients O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
. O
DATA O
COLLECTION O
AND O
ANALYSIS O
: O
Data O
were O
extracted O
by O
one O
reviewer O
(JSB) O
, O
pooled O
where O
appropriate O
and O
possible O
, O
and O
the O
pooled O
treatment O
effects O
, O
or O
the O
risks O
and O
benefits O
of O
treatment O
estimated O
. O
MAIN O
RESULTS O
: O
The O
results O
of O
13 O
randomized O
, O
double O
blind O
, O
placebo O
controlled O
trials O
demonstrate O
that O
treatment O
for O
periods O
of O
6 O
months O
and O
one O
year O
, O
with O
donepezil O
, O
galantamine O
or O
rivastigmine O
at O
the O
recommended O
dose O
for O
people O
with O
mild O
, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
produced O
improvements O
in O
cognitive O
function O
, O
on O
average O
-2.7 O
points O
(95%CI O
-3.0 O
to O
-2.3) O
, O
in O
the O
midrange O
of O
the O
70 O
point O
ADAS-Cog O
Scale O
. O
Study O
clinicians O
blind O
to O
other O
measures O
rated O
global O
clinical O
state O
more O
positively O
in O
treated O
patients O
. O
Benefits O
of O
treatment O
were O
also O
seen O
on O
measures O
of O
activities O
of O
daily O
living O
and O
behaviour O
. O
None O
of O
these O
treatment O
effects O
are O
large O
. O
There O
is O
nothing O
to O
suggest O
the O
effects O
are O
less O
for O
patients O
with O
severe O
dementia O
or O
mild O
dementia O
, O
although O
there O
is O
very O
little O
evidence O
for O
other O
than O
mild O
to O
moderate O
dementia.More O
patients O
leave O
ChEI O
treatment O
groups O
, O
approximately O
29 O
% O
, O
on O
account O
of O
adverse O
events O
than O
leave O
the O
placebo O
groups O
(18%) O
. O
There O
is O
evidence O
of O
more O
adverse O
events O
in O
total O
in O
the O
patients O
treated O
with O
a O
ChEI O
than O
with O
placebo O
. O
Although O
many O
types O
of O
adverse O
event O
were O
reported O
, O
nausea O
, O
vomiting O
, O
diarrhoea O
, O
were O
significantly O
more O
frequent O
in O
the O
ChEI O
groups O
than O
in O
placebo O
. O
There O
are O
four O
studies O
, O
all O
supported O
by O
one O
of O
the O
pharmaceutical O
companies O
, O
in O
which O
two O
ChEIs O
were O
compared O
, O
two O
studies O
of O
donepezil O
compared O
with O
galantamine O
, O
and O
two O
of O
donepezil O
compared O
with O
rivastigmine O
. O
In O
three O
studies O
the O
patients O
were O
not O
blinded O
to O
treatment O
, O
only O
the O
fourth O
, O
DON O
vs O
RIV/Bullock O
is O
double O
blind O
. O
Two O
of O
the O
studies O
provide O
little O
evidence O
, O
they O
are O
of O
12 O
weeks O
duration O
, O
which O
is O
barely O
long O
enough O
to O
complete O
the O
drug O
titration O
. O
There O
is O
no O
evidence O
from O
DON O
vs O
GAL/Wilcock O
of O
a O
treatment O
difference O
between O
donepezil O
and O
galantamine O
at O
52 O
weeks O
for O
cognition O
, O
activities O
of O
daily O
living O
, O
the O
numbers O
who O
leave O
the O
trial O
before O
the O
end O
of O
treatment O
, O
the O
number O
who O
suffer O
any O
adverse O
event O
, O
or O
any O
specific O
adverse O
event O
. O
There O
is O
no O
evidence O
from O
DON O
vs O
RIV/Bullock O
of O
a O
difference O
between O
donepezil O
and O
rivastigmine O
for O
cognitive O
function O
, O
activities O
of O
daily O
living O
and O
behavioural O
disturbance O
at O
two O
years O
. O
Fewer O
patients O
suffer O
adverse O
events O
on O
donepezil O
than O
rivastigmine O
. O
AUTHORS' O
CONCLUSIONS O
: O
The O
three O
cholinesterase O
inhibitors O
are O
efficacious O
for O
mild O
to O
moderate O
Alzheimer's O
disease O
. O
It O
is O
not O
possible O
to O
identify O
those O
who O
will O
respond O
to O
treatment O
prior O
to O
treatment O
. O
There O
is O
no O
evidence O
that O
treatment O
with O
a O
ChEI O
is O
not O
cost O
effective O
. O
Despite O
the O
slight O
variations O
in O
the O
mode O
of O
action O
of O
the O
three O
cholinesterase O
inhibitors O
there O
is O
no O
evidence O
of O
any O
differences O
between O
them O
with O
respect O
to O
efficacy O
. O
There O
appears O
to O
be O
less O
adverse O
effects O
associated O
with O
donepezil O
compared O
with O
rivastigmine O
. O
It O
may O
be O
that O
galantamine O
and O
rivastigmine O
match O
donepezil O
in O
tolerability O
if O
a O
careful O
and O
gradual O
titration O
routine O
over O
more O
than O
three O
months O
is O
used O
. O
Titration O
with O
donepezil O
is O
more O
straightforward O
and O
the O
lower O
dose O
may O
be O
worth O
consideration O
. O

dasatinib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD B
816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Silencing O
α1,3-fucosyltransferases O
in O
human O
leukocytes O
reveals O
a O
role O
for O
FUT9 O
enzyme O
during O
E-selectin-mediated O
cell O
adhesion.Leukocyte O
adhesion O
during O
inflammation O
is O
initiated O
by O
the O
binding O
of O
sialofucosylated O
carbohydrates O
expressed O
on O
leukocytes O
to O
endothelial O
E/P-selectin O
. O
Although O
the O
glycosyltransferases O
(glycoTs) O
constructing O
selectin-ligands O
have O
largely O
been O
identified O
using O
knock-out O
mice O
, O
important O
differences O
may O
exist O
between O
humans O
and O
mice O
. O
To O
address O
this O
, O
we O
developed O
a O
systematic O
lentivirus-based O
shRNA O
delivery O
workflow O
to O
create O
human O
leukocytic O
HL-60 O
cell O
lines O
that O
lack O
up O
to O
three O
glycoTs O
. O
Using O
this O
, O
the O
contributions O
of O
all O
three O
myeloid O
α1,3-fucosyltransferases O
(FUT4 O
, O
FUT7 O
, O
and O
FUT9) O
to O
selectin-ligand O
biosynthesis O
were O
evaluated O
. O
The O
cell O
adhesion O
properties O
of O
these O
modified O
cells O
to O
L- O
, O
E- O
, O
and O
P-selectin O
under O
hydrodynamic O
shear O
were O
compared O
with O
bone O
marrow-derived O
neutrophils O
from O
Fut4(-/-)Fut7(-/-) O
dual O
knock-out O
mice O
. O
Results O
demonstrate O
that O
predominantly O
FUT7 O
, O
and O
to O
a O
lesser O
extent O
FUT4 O
, O
forms O
the O
selectin-ligand O
at O
the O
N O
terminus O
of O
leukocyte O
P-selectin B
glycoprotein I
ligand-1 I
(PSGL-1) O
in O
humans O
and O
mice O
. O
Here O
, O
85% O
reduction O
in O
leukocyte O
interaction O
was O
observed O
in O
human O
FUT4(-)7(-) O
dual O
knockdowns O
on O
P/L-selectin O
substrates O
. O
Unlike O
Fut4(-/-)Fut7(-/-) O
mouse O
neutrophils O
, O
however O
, O
human O
knockdowns O
lacking O
FUT4 O
and O
FUT7 O
only O
exhibited O
partial O
reduction O
in O
rolling O
interaction O
on O
E-selectin O
. O
In O
this O
case O
, O
the O
third O
α1,3-fucosyltransferase O
FUT9 O
played O
an O
important O
role O
because O
leukocyte O
adhesion O
was O
reduced O
by O
50-60% O
in O
FUT9-HL-60 O
, O
70-80% O
in O
dual O
knockdown O
FUT7(-)9(-) O
cells O
, O
and O
∼85% O
in O
FUT4(-)7(-)9(-) O
triple O
knockdowns O
. O
Gene O
silencing O
results O
are O
in O
agreement O
with O
gain-of-function O
experiments O
where O
all O
three O
fucosyltransferases O
conferred O
E-selectin-mediated O
rolling O
in O
HEK293T O
cells O
. O
This O
study O
advances O
new O
tools O
to O
study O
human O
glycoT O
function O
. O
It O
suggests O
a O
species-specific O
role O
for O
FUT9 O
during O
the O
biosynthesis O
of O
human O
E-selectin O
ligands O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
L-proline O
accumulation O
and O
freeze O
tolerance O
of O
Saccharomyces O
cerevisiae O
are O
caused O
by O
a O
mutation O
in O
the O
PRO1 O
gene O
encoding O
gamma-glutamyl O
kinase.We O
previously O
isolated O
a O
mutant O
which O
showed O
a O
high O
tolerance O
to O
freezing O
that O
correlated O
with O
higher O
levels O
of O
intracellular O
L-proline O
derived O
from O
L-proline O
analogue-resistant O
mutants O
. O
The O
mutation O
responsible O
for O
the O
analogue O
resistance O
and O
L-proline O
accumulation O
was O
a O
single O
nuclear O
dominant O
mutation O
. O
By O
introducing O
the O
mutant-derived O
genomic O
library O
into O
a O
non-L-proline-utilizing O
strain O
, O
the O
mutant O
was O
found O
to O
carry O
an O
allele O
of O
the O
wild-type O
PRO1 O
gene O
encoding O
gamma-glutamyl B
kinase I
, O
which O
resulted O
in O
a O
single O
amino O
acid O
replacement; O
Asp O
(GAC) O
at O
position O
154 O
was O
replaced O
by O
Asn O
(AAC) O
. O
Interestingly O
, O
the O
allele O
of O
PRO1 O
was O
shown O
to O
enhance O
the O
activities O
of O
gamma-glutamyl O
kinase O
and O
gamma-glutamyl O
phosphate O
reductase O
, O
both O
of O
which O
catalyze O
the O
first O
two O
steps O
of O
L-proline O
synthesis O
from O
L-glutamate O
and O
which O
together O
may O
form O
a O
complex O
in O
vivo O
. O
When O
cultured O
in O
liquid O
minimal O
medium O
, O
yeast O
cells O
expressing O
the O
mutated O
gamma-glutamyl O
kinase O
were O
found O
to O
accumulate O
intracellular O
L-proline O
and O
showed O
a O
prominent O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O
wild-type O
PRO1 O
gene O
. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl O
kinase O
results O
in O
stabilization O
of O
the O
complex O
or O
has O
an O
indirect O
effect O
on O
gamma-glutamyl O
phosphate O
reductase O
activity O
, O
which O
leads O
to O
an O
increase O
in O
L-proline O
production O
in O
Saccharomyces O
cerevisiae O
. O
The O
approach O
described O
in O
this O
paper O
could O
be O
a O
practical O
method O
for O
breeding O
novel O
freeze-tolerant O
yeast O
strains O
. O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP- B
expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Peroxynitrite O
mediates O
testosterone-induced O
vasodilation O
of O
microvascular O
resistance O
vessels.Our O
knowledge O
of O
how O
androgens O
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete O
, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens O
affect O
resistance O
vessels O
. O
Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone O
(TES) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES-induced O
vasodilation O
. O
Mesenteric O
microvessels O
were O
isolated O
from O
male O
Sprague-Dawley O
rats O
. O
Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration-dependent O
, O
vasodilatory O
response O
to O
TES O
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17β-estradiol O
. O
Dichlorofluorescein O
fluorescence O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine B
oxidase- I
generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Plerixafor O
, O
a O
CXCR4 O
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells.Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine B
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O
combination O
of O
plerixafor O
and O
G-CSF O
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF O
mobilization O
alone O
. O

moxonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nonadrenergic O
imidazoline O
binding O
sites O
on O
human O
platelets.Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity O
, O
imidazol(in)e-preferring O
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 O
adrenoceptors O
. O
These O
nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
of O
alpha-2 O
adrenoceptors O
. O
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan O
(IDX) O
binding O
vs O
. O
[125I]p-iodoclonidine O
(PIC) O
binding O
. O
Nonadrenergic O
[125I]PIC-labeled O
sites O
were O
enriched O
in O
platelet O
plasma O
membranes O
, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] O
IDX O
were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled O
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs O
. O
the O
[3H]IDX-labeled O
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes) O
. O
Furthermore O
, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

cetuximab O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Emerging O
role O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
therapy O
for O
advanced O
malignancy O
: O
focus O
on O
NSCLC.Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer O
. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based O
therapy O
vs O
. O
best O
supportive O
care O
, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate O
. O
Just O
as O
importantly O
, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O
life O
. O
Newer O
agents O
, O
including O
the O
taxanes O
, O
vinorelbine O
, O
gemcitabine O
, O
and O
irinotecan O
, O
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer O
. O
Despite O
their O
contributions O
, O
we O
have O
reached O
a O
therapeutic O
plateau O
, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40% O
. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal B
growth I
factor I
receptor I
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O
Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O
persist O
. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular O
, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds O
. O
Both O
gefitinib O
and O
erlotinib O
have O
shown O
clinical O
activity O
in O
pretreated O
, O
advanced O
non-small-cell O
lung O
cancer O
, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib O
in O
combination O
with O
standard O
cytotoxic O
therapy O
, O
to O
our O
chagrin O
, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone O
. O

glyburide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI O
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 B
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

quinoline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Kinetic O
mechanism O
of O
quinone O
oxidoreductase O
2 O
and O
its O
inhibition O
by O
the O
antimalarial O
quinolines O
. O
Quinone B
oxidoreductase I
2 I
(QR2) O
purified O
from O
human O
red O
blood O
cells O
was O
recently O
shown O
to O
be O
a O
potential O
target O
of O
the O
quinoline O
antimalarial O
compounds O
[Graves O
et O
al. O
, O
(2002) O
Mol O
. O
Pharmacol O
. O
62 O
, O
1364] O
. O
QR2 O
catalyzes O
the O
two-electron O
reduction O
of O
menadione O
via O
the O
oxidation O
of O
N-alkylated O
or O
N-ribosylated O
nicotinamides O
. O
To O
investigate O
the O
mechanism O
and O
consequences O
of O
inhibition O
of O
QR2 O
by O
the O
quinolines O
further O
, O
we O
have O
used O
steady-state O
and O
transient-state O
kinetics O
to O
define O
the O
mechanism O
of O
QR2 O
. O
Importantly O
, O
we O
have O
shown O
that O
QR2 O
when O
isolated O
from O
an O
overproducing O
strain O
of O
E O
. O
coli O
is O
kinetically O
equivalent O
to O
the O
enzyme O
from O
the O
native O
human O
red O
blood O
cell O
source O
. O
We O
observe O
ping-pong O
kinetics O
consistent O
with O
one O
substrate/inhibitor O
binding O
site O
that O
shows O
selectivity O
for O
the O
oxidation O
state O
of O
the O
FAD O
cofactor O
, O
suggesting O
that O
selective O
inhibition O
of O
the O
liver O
versus O
red O
blood O
cell O
forms O
of O
malaria O
may O
be O
possible O
. O
The O
reductant O
N-methyldihydronicotinamide O
and O
the O
inhibitor O
primaquine O
bind O
exclusively O
to O
the O
oxidized O
enzyme O
. O
In O
contrast O
, O
the O
inhibitors O
quinacrine O
and O
chloroquine O
bind O
exclusively O
to O
the O
reduced O
enzyme O
. O
The O
quinone O
substrate O
menadione O
, O
on O
the O
other O
hand O
, O
binds O
nonspecifically O
to O
both O
forms O
of O
the O
enzyme O
. O
Single-turnover O
kinetics O
of O
the O
reductive O
half-reaction O
are O
chemically O
and O
kinetically O
competent O
and O
confirm O
the O
inhibitor O
selectivity O
seen O
in O
the O
steady-state O
experiments O
. O
Our O
studies O
shed O
light O
on O
the O
possible O
in O
vivo O
potency O
of O
the O
quinolines O
and O
provide O
a O
foundation O
for O
future O
studies O
aimed O
at O
creating O
more O
potent O
QR2 O
inhibitors O
and O
at O
understanding O
the O
physiological O
significance O
of O
QR2 O
. O

Sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Long-term O
use O
of O
sildenafil.The O
treatment O
of O
erectile O
dysfunction O
(ED) O
has O
been O
revolutionised O
by O
new O
agents O
to O
inhibit O
the O
enzyme O
PDE5 O
. O
The O
scientific O
basis O
of O
this O
treatment O
of O
ED O
includes O
relaxation O
of O
the O
corpus O
cavernosum O
smooth O
muscle O
tissue O
by O
inhibition O
of O
PDE5 O
that O
breaks O
down O
cGMP O
, O
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE B
(PDE6) O
, O
which O
produces O
visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O
irrespective O
of O
aetiology O
. O
The O
aetiology O
of O
ED O
, O
also O
, O
does O
not O
appear O
to O
effect O
the O
function O
of O
sildenafil O
in O
relaxing O
corpus O
cavernosum O
smooth O
muscle O
tissue O
. O
Adverse O
events O
are O
usually O
associated O
with O
the O
vascular O
changes O
from O
PDE5 O
inhibition O
. O
These O
include O
headache O
and O
flushing O
. O
Each O
of O
these O
adverse O
events O
, O
however O
, O
declines O
with O
medication O
use O
. O
With O
the O
use O
of O
sildenafil O
, O
it O
has O
been O
clearly O
, O
clinically O
demonstrated O
that O
the O
selective O
inhibition O
of O
PDE5 O
is O
an O
appropriate O
, O
effective O
, O
safe O
method O
for O
the O
treatment O
of O
ED O
of O
all O
aetiologies O
and O
severities O
. O

SF1126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
substituted O
5-morpholino-7H-thieno[3,2-b]pyran-7-ones O
designed O
as O
next O
generation O
PI3K O
inhibitors.Dysregulation O
of O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K O
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O
the O
only O
PI3K B
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K O
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O
while O
simultaneously O
exhibiting O
an O
increased O
potency O
toward O
PI3K O
. O
This O
work O
resulted O
in O
the O
discovery O
of O
the O
5-morpholino-7H-thieno[3,2-b]pyran-7-one O
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O
inhibitors O
having O
improved O
potency O
toward O
PI3K O
. O
The O
synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
these O
compounds O
are O
reported O
herein O
. O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B B
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

Sumatriptan O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Both O
5-HT1B O
and O
5-HT1F O
receptors O
modulate O
c-fos O
expression O
within O
rat O
trigeminal O
nucleus O
caudalis.A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan O
is O
inhibition O
of O
the O
trigeminovascular O
pathway O
. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B O
, O
5-HT1D O
or O
5-HT1F O
receptors O
. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes O
, O
we O
compared O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F O
receptor O
agonist O
(LY O
344864) O
on O
c-fos O
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos- B
like O
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat O
5-HT1B O
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F O
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Effect O
of O
sinapic O
acid O
against O
dimethylnitrosamine-induced O
hepatic O
fibrosis O
in O
rats.Sinapic O
acid O
is O
a O
member O
of O
the O
phenylpropanoid O
family O
and O
is O
abundant O
in O
cereals O
, O
nuts O
, O
oil O
seeds O
, O
and O
berries O
. O
It O
exhibits O
a O
wide O
range O
of O
pharmacological O
properties O
. O
In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic O
acid O
on O
dimethylnitrosamine O
(DMN)-induced O
chronic O
liver O
injury O
in O
rats O
. O
Sinapic O
acid O
remarkably O
prevented O
DMN-induced O
loss O
of O
body O
weight O
. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
liver O
malondialdehyde O
content O
. O
Furthermore O
, O
sinapic O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
. O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 B
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O
that O
sinapic O
acid O
is O
a O
potentially O
useful O
agent O
for O
the O
protection O
against O
liver O
fibrosis O
and O
cirrhosis O
. O

Furanodiene O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Furanodiene O
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxel O
Via O
Altering O
Cell O
Cycle O
and O
Integrin B
Signaling O
in O
95-D O
Lung O
Cancer O
Cells.Furanodiene O
(FUR) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O
Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O
with O
paclitaxel O
(TAX) O
showed O
synergetic O
anti-proliferative O
activities O
in O
95-D O
lung O
cancer O
cells O
. O
Herein O
, O
we O
showed O
that O
FUR O
reduced O
the O
cell O
numbers O
distributed O
in O
mitosis O
phase O
induced O
by O
TAX O
while O
increased O
those O
in O
G1 O
phase O
. O
The O
protein O
levels O
of O
cyclin O
D1 O
, O
cyclin O
B1 O
, O
CDK6 O
and O
c-Myc O
were O
all O
down-regulated O
in O
the O
group O
of O
combined O
treatment O
. O
The O
dramatically O
down-regulated O
expression O
of O
integrin O
β4 O
, O
focal O
adhesion O
kinase O
and O
paxillin O
might O
partially O
contribute O
to O
the O
synergic O
effect O
. O
Though O
FUR O
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP O
and O
BIP O
was O
similar O
in O
FUR O
alone O
and O
combined O
treatment O
group O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O
mechanism O
has O
been O
obscured O
by O
its O
instability O
. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC O
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC B
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

CGP O
12177A O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor O
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs B
/ O
cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

spermine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Properties O
of O
purified O
recombinant O
human O
polyamine O
oxidase O
, O
PAOh1/SMO.The O
discovery O
of O
an O
inducible O
oxidase B
whose O
apparent O
substrate O
preference O
is O
spermine O
indicates O
that O
polyamine O
catabolism O
is O
more O
complex O
than O
that O
originally O
proposed O
. O
To O
facilitate O
the O
study O
of O
this O
enzyme O
, O
the O
purification O
and O
characterization O
of O
the O
recombinant O
human O
PAOh1/SMO O
polyamine O
oxidase O
are O
reported O
. O
Purified O
PAOh1/SMO O
oxidizes O
both O
spermine O
(K(m)=1.6 O
microM) O
and O
N(1)-acetylspermine O
(K(m)=51 O
microM) O
, O
but O
does O
not O
oxidize O
spermidine O
. O
The O
purified O
human O
enzyme O
also O
does O
not O
oxidize O
eight O
representative O
antitumor O
polyamine O
analogues; O
however O
, O
specific O
oligamine O
analogues O
were O
found O
to O
be O
potent O
inhibitors O
of O
the O
oxidation O
of O
spermine O
by O
PAOh1/SMO O
. O
The O
results O
of O
these O
studies O
are O
consistent O
with O
the O
hypothesis O
that O
PAOh1/SMO O
represents O
a O
new O
addition O
to O
the O
polyamine O
metabolic O
pathway O
that O
may O
represent O
a O
new O
target O
for O
antineoplastic O
drug O
development O
. O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Biophysical O
properties O
, O
pharmacology O
, O
and O
modulation O
of O
human O
, O
neuronal O
L-type O
(alpha(1D) O
, O
Ca(V)1.3) O
voltage-dependent O
calcium O
currents.Voltage-dependent O
calcium O
channels O
(VDCCs) O
are O
multimeric O
complexes O
composed O
of O
a O
pore-forming O
alpha(1) O
subunit O
together O
with O
several O
accessory O
subunits O
, O
including O
alpha(2)delta O
, O
beta O
, O
and O
, O
in O
some O
cases O
, O
gamma O
subunits O
. O
A O
family O
of O
VDCCs O
known O
as O
the O
L-type O
channels O
are O
formed O
specifically O
from O
alpha(1S) O
(skeletal O
muscle) O
, O
alpha(1C) O
(in O
heart O
and O
brain) O
, O
alpha(1D) O
(mainly O
in O
brain O
, O
heart O
, O
and O
endocrine O
tissue) O
, O
and O
alpha(1F) O
(retina) O
. O
Neuroendocrine O
L-type O
currents O
have O
a O
significant O
role O
in O
the O
control O
of O
neurosecretion O
and O
can O
be O
inhibited O
by O
GTP-binding O
(G-) O
proteins O
. O
However O
, O
the O
subunit O
composition O
of O
the O
VDCCs O
underlying O
these O
G-protein-regulated O
neuroendocrine O
L-type O
currents O
is O
unknown O
. O
To O
investigate O
the O
biophysical O
and O
pharmacological O
properties O
and O
role O
of O
G-protein O
modulation O
of O
alpha(1D) O
calcium O
channels O
, O
we O
have O
examined O
calcium O
channel O
currents O
formed O
by O
the O
human O
neuronal O
L-type O
alpha(1D) O
subunit O
, O
co-expressed O
with O
alpha(2)delta-1 O
and O
beta(3a) O
, O
stably O
expressed O
in O
a O
human O
embryonic O
kidney O
(HEK) O
293 O
cell O
line O
, O
using O
whole O
cell O
and O
perforated O
patch-clamp O
techniques O
. O
The O
alpha(1D)-expressing O
cell O
line O
exhibited O
L-type O
currents O
with O
typical O
characteristics O
. O
The O
currents O
were O
high-voltage O
activated O
(peak O
at O
+20 O
mV O
in O
20 O
mM O
Ba2+) O
and O
showed O
little O
inactivation O
in O
external O
Ba2+ O
, O
while O
displaying O
rapid O
inactivation O
kinetics O
in O
external O
Ca2+ O
. O
The O
L-type O
currents O
were O
inhibited O
by O
the O
1,4 O
dihydropyridine O
(DHP) O
antagonists O
nifedipine O
and O
nicardipine O
and O
were O
enhanced O
by O
the O
DHP O
agonist O
BayK O
S-(-)8644 O
. O
However O
, O
alpha(1D) O
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein O
pathways O
. O
Activation O
of O
endogenous O
somatostatin O
receptor O
subtype O
2 O
(sst2) O
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O
no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N-type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein- B
mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O
a O
glutathione-S-transferase O
(GST) O
fusion O
protein O
, O
did O
not O
bind O
Gbetagamma O
, O
unlike O
the O
alpha(1B) O
I-II O
loop O
fusion O
protein O
. O
These O
data O
show O
that O
the O
biophysical O
and O
pharmacological O
properties O
of O
recombinant O
human O
alpha(1D) O
L-type O
currents O
are O
similar O
to O
alpha(1C) O
currents O
, O
and O
these O
currents O
are O
also O
resistant O
to O
modulation O
by O
G(i/o)-linked O
G-protein-coupled O
receptors O
. O

H(4)biopterin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Contrasting O
effects O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric B
oxide I
synthases I
(EC O
1.14.13.39) O
. O
Here O
we O
compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine O
reductase O
(EC O
1.6.99.7) O
and O
phenylalanine O
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O
Substitution O
at O
N(5) O
occurs O
at O
a O
position O
critical O
to O
the O
redox O
cycle O
of O
the O
cofactor O
in O
phenylalanine O
hydroxylase/dihydropteridine O
reductase O
. O
We O
also O
included O
N(2)'-methyl O
H(4)biopterin O
, O
a O
derivative O
substituted O
at O
a O
position O
not O
directly O
involved O
in O
redox O
cycling O
, O
as O
a O
control O
. O
As O
compared O
with O
N(5)-methyl O
H(4)biopterin O
, O
N(5)-formyl O
H(4)biopterin O
bound O
with O
twice O
the O
capacity O
but O
stimulated O
nitric O
oxide O
synthase O
to O
a O
lesser O
extent O
. O
Depending O
on O
the O
substituent O
used O
, O
N(5)-substituted O
derivatives O
were O
redox-active O
: O
N(5)-methyl- O
and O
N(5)-hydroxyl O
methyl O
H(4)biopterin O
, O
but O
not O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
, O
reduced O
2,6-dichlorophenol O
indophenol O
. O
N(5)-Substituted O
H(4)biopterin O
derivatives O
were O
not O
oxidized O
to O
products O
serving O
as O
substrates O
for O
dihydropteridine O
reductase O
and,depending O
on O
the O
substituent O
, O
were O
competitive O
inhibitors O
of O
phenylalanine O
hydroxylase O
: O
N(5)-methyl- O
and O
N(5)-hydroxymethyl O
H(4)biopterin O
inhibited O
phenylalanine O
hydroxylase O
, O
whereas O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
had O
no O
effect O
. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine O
hydroxylase O
and O
nitric O
oxide O
synthase O
by O
H(4)biopterin O
. O
They O
are O
compatible O
with O
a O
novel O
, O
non-classical O
, O
redox-active O
contribution O
of O
H(4)biopterin O
to O
the O
catalysis O
of O
the O
nitric O
oxide O
synthase O
reaction O
. O

naloxone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
of O
cAMP B
response I
element I
binding I
protein I
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxone O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
(CREB) O
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v) O
, O
for O
one O
month O
. O
Changes O
in O
the O
levels O
of O
CREB O
and O
phospho-CREB O
(p-CREB) O
protein O
in O
the O
nucleus O
accumbens O
were O
measured O
by O
immunohistochemistry O
methods O
. O
RESULTS O
: O
Ethanol O
given O
to O
rats O
in O
drinking O
water O
decreased O
the O
level O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(-75 O
%) O
at O
the O
time O
of O
exposure O
to O
ethanol O
. O
The O
decrement O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
remained O
at O
24 O
h O
(-35 O
%) O
and O
72 O
h O
(-28 O
%) O
of O
ethanol O
withdrawal O
, O
which O
recovered O
toward O
control O
level O
after O
7 O
d O
of O
ethanol O
withdrawal O
. O
However O
, O
chronic O
ethanol O
, O
as O
well O
as O
ethanol O
withdrawal O
failed O
to O
produce O
any O
significant O
alteration O
in O
the O
level O
of O
CREB O
protein O
in O
the O
nucleus O
accumbens O
. O
Naloxone O
(alone) O
treatment O
of O
rats O
had O
no O
effect O
on O
the O
levels O
of O
CREB O
and O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
. O
However O
, O
when O
naloxone O
was O
administered O
concurrently O
with O
ethanol O
treatment O
, O
it O
antagonized O
the O
down-regulation O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(142 O
%) O
of O
rats O
exposed O
to O
ethanol O
. O
CONCLUSION O
: O
A O
long-term O
intake O
of O
ethanol O
solution O
down-regulates O
the O
phosphorylation O
of O
CREB O
in O
the O
nucleus O
accumbens O
, O
and O
those O
changes O
can O
be O
reversed O
by O
naloxone O
, O
which O
may O
be O
one O
kind O
of O
the O
molecular O
mechanisms O
associated O
with O
ethanol O
dependence O
. O

artemisinic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Artemisinic O
acid O
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP O
α-dependent O
expression O
of O
HMG-CoA O
reductase O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
( O
PKA) B
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

TAS-102 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Thymidine O
kinase O
and O
thymidine O
phosphorylase O
level O
as O
the O
main O
predictive O
parameter O
for O
sensitivity O
to O
TAS-102 O
in O
a O
mouse O
model.TAS-102 O
is O
a O
new O
oral O
anti-cancer O
drug O
preparation O
, O
composed O
of O
a O
1:0.5 O
mixture O
(on O
a O
molar O
basis) O
of O
alpha,alpha,alpha-trifluorothymidine O
(FTD) O
and O
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione O
hydrochloride O
(TPI) O
. O
TAS-102 O
currently O
undergoing O
clinical O
trials O
, O
has O
been O
demonstrated O
to O
have O
at O
least O
two O
mechanisms O
, O
inhibition O
of O
TS B
and O
incorporation O
into O
DNA O
. O
We O
hypothesized O
that O
the O
thymidine O
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O
activity O
of O
TAS-102 O
. O
In O
the O
present O
study O
, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine O
phosphorylase O
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O
, O
tumor O
growth O
and O
TS O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O
TP O
ratio O
. O
There O
was O
a O
significant O
correlation O
(p=0.04) O
between O
tumor O
growth O
inhibition O
and O
this O
ratio O
. O
These O
results O
suggested O
that O
the O
activation O
and O
degradation O
pattern O
of O
FTD O
plays O
an O
important O
role O
in O
the O
efficacy O
of O
TAS-102 O
and O
that O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
response O
to O
TAS-102 O
therapy O
. O
We O
also O
studied O
the O
influence O
of O
TPI O
on O
the O
capacity O
of O
exogenous O
dThd O
to O
reverse O
FTD-dependent O
growth O
inhibition O
. O
Thymidine O
(dThd) O
levels O
rescued O
the O
effect O
of O
FTD O
in O
vitro O
and O
significantly O
increased O
in O
serum O
after O
administration O
of O
TAS-102 O
or O
TPI O
alone O
but O
not O
FTD O
alone O
. O
This O
may O
suggest O
the O
possibility O
of O
a O
decrease O
in O
antitumor O
effect O
. O
However O
, O
our O
study O
indicated O
that O
the O
therapeutic O
index O
was O
clearly O
increased O
by O
FTD O
combined O
with O
TPI O
, O
compared O
with O
FTD O
alone O
, O
suggesting O
FTD-induced O
toxicity O
to O
sensitive O
host O
tissue O
can O
be O
selectively O
reversed O
with O
dThd O
. O
In O
conclusion O
, O
TK O
and O
TPI O
effects O
on O
TP O
play O
important O
roles O
in O
the O
cytotoxic O
action O
of O
TAS-102 O
, O
and O
it O
is O
possible O
to O
use O
the O
TK/TP O
ratio O
to O
predict O
more O
precisely O
individual O
resistance O
or O
sensitivity O
. O

TCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
In O
ovo O
effects O
of O
two O
organophosphate O
flame O
retardants O
, O
TCPP O
and O
TDCPP O
, O
on O
pipping O
success O
, O
development O
, O
mRNA O
expression O
and O
thyroid O
hormone O
levels O
in O
chicken O
embryos.Tris(1-chloro-2-propyl) O
phosphate O
(TCPP) O
and O
tris(1,3-dichloro-2-propyl) O
phosphate O
(TDCPP) O
are O
organic O
flame O
retardants O
detected O
in O
the O
environment O
and O
biota O
for O
which O
toxicological O
data O
for O
avian O
species O
are O
limited O
. O
In O
this O
study O
, O
domestic O
chicken O
eggs O
were O
injected O
with O
TCPP O
or O
TDCPP O
(maximum O
dose O
= O
51600 O
and O
45000 O
ng/g O
egg O
, O
respectively) O
to O
determine O
dose-dependent O
effects O
on O
pipping O
success O
, O
development O
, O
hepatic O
messenger O
RNA O
(mRNA) O
expression O
levels O
of O
genes O
associated O
with O
xenobiotic O
metabolism O
and O
the O
thyroid O
hormone O
(TH) O
pathway O
, O
and O
TH O
levels O
following O
20-22 O
days O
of O
incubation O
. O
Neither O
compound O
reduced O
pipping O
success; O
however O
, O
TCPP O
significantly O
delayed O
pipping O
at O
9240 O
and O
51600 O
ng/g O
and O
reduced O
tarsus O
length O
at O
51600 O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver B
fatty-acid I
binding I
protein I
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
, O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O
and O
TDCPP O
exposure O
may O
be O
associated O
with O
disruption O
of O
the O
TH-axis O
, O
which O
is O
critical O
for O
normal O
growth O
and O
development O
in O
birds O
. O
The O
effects O
of O
TDCPP O
on O
the O
gallbladder O
indicate O
that O
the O
disturbance O
of O
lipid O
metabolism O
is O
a O
likely O
target O
in O
its O
mechanism O
of O
toxicity O
. O

PMA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC O
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC O
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin B
6 I
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

bromfenac O
sodium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase B
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO B
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase B
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

moxonidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Species-specific O
pharmacological O
properties O
of O
human O
alpha(2A)-adrenoceptors.On O
the O
basis O
of O
data O
obtained O
in O
rabbits O
, O
the O
imidazoline O
receptor O
ligand O
rilmenidine O
has O
been O
suggested O
to O
decrease O
blood O
pressure O
in O
humans O
by O
activating O
central O
alpha(2A)-adrenoceptors O
. O
A O
prerequisite O
for O
this O
hypothesis O
was O
the O
unproved O
assumption O
that O
rabbit O
and O
human O
alpha(2A)-adrenoceptors O
are O
equally O
activated O
by O
rilmenidine O
. O
Because O
alpha(2A)-adrenoceptors O
in O
the O
brain O
and O
on O
cardiovascular O
sympathetic O
nerve O
terminals O
are O
identical O
, O
the O
latter O
were O
used O
as O
a O
model O
for O
the O
former O
to O
confirm O
or O
disprove O
this O
assumption O
. O
Human O
atrial O
appendages O
and O
rabbit O
pulmonary O
arteries O
were O
used O
to O
determine O
the O
potencies O
of O
alpha(2)-adrenoceptor O
agonists O
in O
inhibiting O
the O
electrically O
(2 O
Hz) O
evoked O
[(3)H]norepinephrine O
release O
and O
of O
antagonists O
in O
counteracting O
the O
alpha(2)-adrenoceptor- B
mediated O
inhibition O
induced O
by O
moxonidine O
. O
In O
the O
rabbit O
pulmonary O
artery O
, O
rilmenidine O
and O
oxymetazoline O
are O
potent O
full O
agonists O
, O
whereas O
in O
the O
human O
atrial O
appendages O
they O
are O
antagonists O
at O
the O
alpha(2)-autoreceptors O
, O
sharing O
this O
property O
with O
rauwolscine O
, O
phentolamine O
, O
and O
idazoxan O
. O
In O
contrast O
, O
prazosin O
is O
ineffective O
. O
In O
addition O
, O
a O
partial O
nucleotide O
and O
amino O
acid O
sequence O
of O
the O
rabbit O
alpha(2A)-adrenoceptor O
(a O
region O
known O
to O
substantially O
influence O
the O
pharmacological O
characteristics O
of O
the O
alpha(2)-adrenoceptor) O
revealed O
marked O
differences O
between O
the O
rabbit O
and O
the O
human O
alpha(2A)-adrenoceptor O
. O
The O
sympathetic O
nerves O
of O
both O
the O
human O
atrial O
appendages O
and O
rabbit O
pulmonary O
artery O
are O
endowed O
with O
alpha(2A)-autoreceptors O
, O
at O
which O
, O
however O
, O
both O
rilmenidine O
and O
oxymetazoline O
exhibit O
different O
properties O
(antagonism O
and O
agonism O
, O
respectively) O
. O
The O
antagonistic O
property O
of O
rilmenidine O
at O
human O
alpha(2A)-adrenoceptors O
indicates O
that O
in O
contrast O
to O
the O
suggestion O
based O
on O
rabbit O
data O
, O
the O
hypotensive O
property O
of O
the O
drug O
in O
humans O
is O
not O
due O
to O
activation O
of O
alpha(2A)-adrenoceptors O
but O
other O
, O
presumably O
I(1)-imidazoline O
receptors O
, O
are O
probably O
involved O
. O

DEC O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Diethylcarbamazine O
activity O
against O
Brugia O
malayi O
microfilariae O
is O
dependent O
on O
inducible O
nitric-oxide O
synthase O
and O
the O
cyclooxygenase O
pathway.BACKGROUND O
: O
Diethylcarbamazine O
(DEC) O
has O
been O
used O
for O
many O
years O
in O
the O
treatment O
of O
human O
lymphatic O
filariasis O
. O
Its O
mode O
of O
action O
is O
not O
well O
understood O
, O
but O
it O
is O
known O
to O
interact O
with O
the O
arachidonic O
acid O
pathway O
. O
Here O
we O
have O
investigated O
the O
contribution O
of O
the O
nitric O
oxide O
and O
cyclooxygenase O
(COX) O
pathways O
to O
the O
activity O
of O
DEC O
against O
B O
. O
malayi O
microfilariae O
in O
mice O
. O
METHODS O
: O
B O
. O
malayi O
microfilariae O
were O
injected O
intravenously O
into O
mice O
and O
parasitaemia O
was O
measured O
24 O
hours O
later O
. O
DEC O
was O
then O
administered O
to O
BALB/c O
mice O
with O
and O
without O
pre-treatment O
with O
indomethacin O
or O
dexamethasone O
and O
the O
parasitaemia O
monitored O
. O
To O
investigate O
a O
role O
for O
inducible O
nitric O
oxide O
in O
DEC's O
activity O
, O
DEC O
and O
ivermectin O
were O
administered O
to O
microfilaraemic O
iNOS-/- O
mice O
and O
their O
background O
strain O
(129/SV) O
. O
Western O
blot O
analysis O
was O
used O
to O
determine O
any O
effect O
of O
DEC O
on O
the O
production O
of O
COX O
and O
inducible O
nitric-oxide B
synthase I
(iNOS) O
proteins O
. O
RESULTS O
: O
DEC O
administered O
alone O
to O
BALB/c O
mice O
resulted O
in O
a O
rapid O
and O
profound O
reduction O
in O
circulating O
microfilariae O
within O
five O
minutes O
of O
treatment O
. O
Microfilarial O
levels O
began O
to O
recover O
after O
24 O
hours O
and O
returned O
to O
near O
pre-treatment O
levels O
two O
weeks O
later O
, O
suggesting O
that O
the O
sequestration O
of O
microfilariae O
occurs O
independently O
of O
parasite O
killing O
. O
Pre-treatment O
of O
animals O
with O
dexamethasone O
or O
indomethacin O
reduced O
DEC's O
efficacy O
by O
almost O
90% O
or O
56% O
, O
respectively O
, O
supporting O
a O
role O
for O
the O
arachidonic O
acid O
and O
cyclooxygenase O
pathways O
in O
vivo O
. O
Furthermore O
, O
experiments O
showed O
that O
treatment O
with O
DEC O
results O
in O
a O
reduction O
in O
the O
amount O
of O
COX-1 O
protein O
in O
peritoneal O
exudate O
cells O
. O
Additionally O
, O
in O
iNOS-/- O
mice O
infected O
with O
B O
. O
malayi O
microfilariae O
, O
DEC O
showed O
no O
activity O
, O
whereas O
the O
efficacy O
of O
another O
antifilarial O
drug O
, O
ivermectin O
, O
was O
unaffected O
. O
CONCLUSION O
: O
These O
results O
confirm O
the O
important O
role O
of O
the O
arachidonic O
acid O
metabolic O
pathway O
in O
DEC's O
mechanism O
of O
action O
in O
vivo O
and O
show O
that O
in O
addition O
to O
its O
effects O
on O
the O
5-lipoxygenase O
pathway O
, O
it O
targets O
the O
cyclooxygenase O
pathway O
and O
COX-1 O
. O
Moreover O
, O
we O
show O
for O
the O
first O
time O
that O
inducible O
nitric O
oxide O
is O
essential O
for O
the O
rapid O
sequestration O
of O
microfilariae O
by O
DEC O
. O

Pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene B
receptor I
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids O
were O
studied O
. O
The O
patients' O
symptoms O
were O
evaluated O
by O
asthma O
diary O
and O
twice-daily O
peak O
flow O
monitoring O
. O
RESULTS O
: O
Of O
the O
206 O
patients O
enrolled O
, O
197 O
were O
eligible O
for O
analysis O
. O
The O
pranlukast O
group O
(n O
= O
98) O
showed O
statistically O
significant O
improvement O
in O
asthma O
symptoms O
, O
including O
asthma O
attack O
rate O
, O
daily O
living O
score O
, O
and O
morning O
and O
evening O
asthma O
scores O
. O
Pranlukast O
significantly O
reduced O
the O
consumption O
of O
beta2-agonist O
. O
Compared O
with O
the O
placebo O
group O
, O
forced O
vital O
capacity O
(FVC) O
and O
forced O
expiratory O
volume O
in O
1 O
s O
(FEV1) O
were O
not O
significantly O
higher O
in O
the O
pranlukast O
group O
. O
Morning O
and O
evening O
peak O
expiratory O
flow O
(PEF) O
were O
significantly O
increased O
after O
pranlukast O
treatment O
at O
weeks O
2 O
and O
4 O
(380.8 O
+/- O
10.1 O
L/min O
at O
baseline O
, O
394.5 O
+/- O
10.1 O
at O
week O
2 O
, O
396.3 O
+/- O
10.4 O
at O
week O
4) O
. O
There O
were O
no O
serious O
adverse O
reactions O
. O
CONCLUSION O
: O
Pranlukast O
, O
an O
oral O
leukotriene O
antagonist O
, O
was O
well O
tolerated O
and O
was O
effective O
for O
the O
management O
of O
mild-to-moderate O
asthma O
. O

homomazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine B
transporter I
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

quinoxalines O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Discovery O
and O
structure-activity O
relationships O
of O
small O
molecules O
that O
block O
the O
human O
immunoglobulin O
G-human O
neonatal O
Fc O
receptor O
(hIgG-hFcRn) O
protein-protein O
interaction.The O
neonatal O
Fc O
receptor O
, O
FcRn O
, O
prolongs O
the O
half-life O
of O
IgG O
in O
the O
serum O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease O
. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human O
IgG-human O
FcRn O
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment O
. O
A O
novel O
class O
of O
quinoxalines O
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG O
: O
FcRn B
protein-protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand-based O
screen O
. O

Auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4 B
.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 B
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

all-trans-retinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 O
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O
which O
could O
have O
signaling O
functions O
. O

mannose O
6-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
( O
insulin-like B
growth I
factor I
II I
receptor) I
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O
to O
assess O
the O
relevance O
of O
the O
different O
ligand-binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O
this O
cellular O
system O
. O
The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P/IGF2R O
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin-like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells O
. O
In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R O
and O
M6P-modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R O
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P-binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding O
domains O
of O
the O
receptor O
. O

topiramate O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Selective O
antagonism O
of O
GluR5 B
kainate-receptor-mediated O
synaptic O
currents O
by O
topiramate O
in O
rat O
basolateral O
amygdala O
neurons.Topiramate O
is O
a O
widely O
used O
antiepileptic O
agent O
whose O
mechanism O
of O
action O
is O
poorly O
understood O
. O
The O
drug O
has O
been O
reported O
to O
interact O
with O
various O
ion O
channel O
types O
, O
including O
AMPA/kainate O
receptors O
. O
In O
whole-cell O
voltage-clamp O
recordings O
from O
principal O
neurons O
of O
the O
rat O
basolateral O
amygdala O
, O
topiramate O
at O
low O
concentrations O
(IC50 O
, O
approximately O
0.5 O
microm) O
selectively O
inhibited O
pharmacologically O
isolated O
excitatory O
synaptic O
currents O
mediated O
by O
kainate O
receptors O
containing O
the O
GluR5 O
subunit O
. O
Topiramate O
also O
partially O
depressed O
predominantly O
AMPA-receptor-mediated O
EPSCs O
, O
but O
with O
lower O
efficacy O
. O
Topiramate O
did O
not O
alter O
the O
degree O
of O
facilitation O
in O
paired-pulse O
experiments O
, O
and O
it O
reduced O
the O
amplitude O
of O
miniature O
EPSCs O
without O
affecting O
their O
frequency O
, O
demonstrating O
that O
the O
block O
of O
synaptic O
responses O
occurs O
postsynaptically O
. O
Inhibition O
of O
GluR5 O
kainate O
receptors O
could O
represent O
a O
key O
mechanism O
underlying O
the O
anticonvulsant O
activity O
of O
topiramate O
. O
Moreover O
, O
these O
results O
support O
the O
concept O
that O
GluR5 O
kainate O
receptors O
represent O
a O
novel O
target O
for O
antiepileptic O
drug O
development O
. O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Occupancy O
of O
dopamine O
D(1) O
, O
D O
(2) O
and O
serotonin O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) B
receptors I
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone O
(RIS O
, O
n O
= O
11 O
, O
3.6 O
+/- O
1.3 O
mg/day) O
and O
haloperidol O
(HAL O
, O
n O
= O
11 O
, O
8.5 O
+/- O
5.5 O
mg/day) O
. O
MATERIALS O
AND O
METHODS O
: O
Each O
patient O
underwent O
two O
PET O
scans O
with O
3-N-[(11)C]methylspiperone O
(target O
: O
frontal O
5-HT(2A)) O
, O
[(11)C]SCH23390 O
(striatal O
D(1)) O
or O
[(11)C]raclopride O
(striatal O
D(2)) O
. O
RO O
was O
calculated O
as O
the O
percentage O
reduction O
of O
specific O
binding O
in O
comparison O
with O
healthy O
controls O
. O
RESULTS O
: O
D(2)-RO O
under O
FLX O
was O
between O
50% O
and O
70% O
, O
indicating O
an O
ED(50) O
of O
about O
0.7 O
ng/ml O
serum O
. O
5-HT(2A) O
and O
D(1)-RO O
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean O
, O
SEM) O
. O
Under O
HAL O
, O
D(1)-RO O
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero O
. O
CONCLUSIONS O
: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) O
and O
D(1) O
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol O
, O
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation O
. O
Therefore O
, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
, O
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism O
. O
However O
, O
these O
data O
suggest O
that O
mechanisms O
other O
than O
D(1) O
or O
5-HT(2A) O
antagonism O
may O
contribute O
to O
flupentixol's O
efficacy O
on O
negative O
symptoms O
. O

cisapride O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
a O
serotonin O
5-HT(4) O
receptor O
antagonist O
SB-207266 O
on O
gastrointestinal O
motor O
and O
sensory O
function O
in O
humans.BACKGROUND O
: O
Serotonin O
5-HT(4) O
receptors O
are O
located O
on O
enteric O
cholinergic O
neurones O
and O
may O
regulate O
peristalsis O
. O
5-HT(4) O
receptors O
on O
primary O
afferent O
neurones O
have O
been O
postulated O
to O
modulate O
visceral O
sensation O
. O
While O
5-HT(4) O
agonists O
are O
used O
as O
prokinetic O
agents O
, O
the O
physiological O
role O
of O
5-HT(4) O
receptors O
in O
the O
human O
gut O
is O
unknown O
. O
AIMS O
: O
Our O
aim O
was O
to O
characterise O
the O
role O
of O
5-HT(4) O
receptors O
in O
regulating O
gastrointestinal O
motor O
and O
sensory O
function O
in O
healthy O
subjects O
under O
baseline O
and O
stimulated O
conditions O
with O
a O
5-HT(4) O
receptor O
antagonist O
. O
METHODS O
: O
Part O
A O
compared O
the O
effects O
of O
placebo O
to O
four O
doses O
of O
a O
5-HT(4) B
receptor O
antagonist O
(SB-207266) O
on O
the O
cisapride O
mediated O
increase O
in O
plasma O
aldosterone O
(a O
5-HT(4) O
mediated O
response) O
and O
orocaecal O
transit O
in O
18 O
subjects O
. O
In O
part O
B O
, O
52 O
healthy O
subjects O
received O
placebo O
, O
or O
0.05 O
, O
0.5 O
, O
or O
5 O
mg O
of O
SB-207266 O
for O
10-12 O
days; O
gastric O
, O
small O
bowel O
, O
and O
colonic O
transit O
were O
measured O
by O
scintigraphy O
on O
days O
7-9 O
, O
and O
fasting O
and O
postprandial O
colonic O
motor O
function O
, O
compliance O
, O
and O
sensation O
during O
distensions O
were O
assessed O
on O
day O
12 O
. O
RESULTS O
: O
Part O
A O
: O
0.5 O
, O
5 O
, O
and O
20 O
mg O
doses O
of O
SB-207266 O
had O
significant O
and O
quantitatively O
similar O
effects O
, O
antagonising O
the O
cisapride O
mediated O
increase O
in O
plasma O
aldosterone O
and O
acceleration O
of O
orocaecal O
transit O
. O
Part O
B O
: O
SB-207266 O
tended O
to O
delay O
colonic O
transit O
(geometric O
centre O
of O
isotope O
at O
24 O
(p=0.06) O
and O
48 O
hours O
(p=0.08)) O
, O
but O
did O
not O
have O
dose O
related O
effects O
on O
transit O
, O
fasting O
or O
postprandial O
colonic O
motor O
activity O
, O
compliance O
, O
or O
sensation O
. O
CONCLUSION O
: O
5-HT(4) O
receptors O
are O
involved O
in O
the O
regulation O
of O
cisapride O
stimulated O
orocaecal O
transit; O
SB O
207266 O
tends O
to O
modulate O
colonic O
transit O
but O
not O
sensory O
functions O
or O
compliance O
in O
healthy O
human O
subjects O
. O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
investigation O
of O
efficacy O
of O
new O
reactivators O
on O
OPC O
inhibited O
rat O
brain O
acetylcholinesterase.Organophosphorus O
compounds O
(OPC) O
were O
developed O
as O
warfare O
nerve O
agents O
. O
They O
are O
also O
widely O
used O
as O
pesticides O
. O
The O
drug O
therapy O
of O
intoxication O
with O
OPC O
includes O
mainly O
combination O
of O
cholinesterase O
(ChE) O
reactivators O
and O
cholinolytics O
. O
There O
is O
no O
single O
ChE O
reactivator O
having O
an O
ability O
to O
reactivate O
sufficiently O
the O
inhibited O
enzyme O
due O
to O
the O
high O
variability O
of O
chemical O
structure O
of O
the O
inhibitors O
. O
The O
difficulties O
in O
reactivation O
of O
ChE O
activity O
and O
slight O
antidote O
effect O
regarding O
intoxication O
with O
some O
OPC O
are O
some O
of O
the O
reasons O
for O
continuous O
efforts O
to O
obtain O
new O
reactivators O
of O
ChE O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
some O
ChE O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat O
brain O
AChE O
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE B
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

UDP-Gal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I O
. O
Beta-1,4-galactosyltransferase B
I I
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KI O
TD816V B
 O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
( O
GAD B
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

HSYA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Hydroxysafflor O
yellow O
a O
inhibits O
lipopolysaccharide-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells.Hydroxysafflor O
yellow O
A O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated B
protein I
kinase I
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

hydroxylamines O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B
b5R I
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

n-butanol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Lipoxygenase O
and O
urease O
inhibition O
of O
the O
aerial O
parts O
of O
the O
Polygonatum O
verticillatum.Over O
expression O
of O
lipoxygenase O
(LOX) O
and O
urease O
has O
already O
contributed O
to O
the O
pathology O
of O
different O
human O
disease O
. O
Targeting O
the O
inhibition O
of O
these O
enzymes O
has O
proved O
great O
clinical O
utility O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
scrutinised O
the O
inhibitory O
profile O
of O
the O
aerial O
parts O
of O
the O
Polygonatum O
verticillatum O
enzyme O
against O
LOX O
, O
urease O
, O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
(BChE) O
using O
standard O
experimental O
protocols O
. O
When O
checked O
against O
lipoxygenase O
, O
the O
extracts O
revealed O
significant O
attenuation O
. O
Of O
the O
tested O
extracts O
, O
the O
ethyl O
acetate O
fraction O
was O
the O
most O
potent O
(half-maximal O
inhibitory O
concentration O
(IC50) O
: O
97 O
µg/mL) O
followed O
by O
aqueous O
fraction O
IC50 O
: O
109 O
µg/mL) O
. O
Regarding O
urease B
inhibition O
, O
n-butanol O
was O
the O
most O
potent O
fraction O
(IC50 O
: O
97 O
µg/mL) O
. O
However O
, O
the O
extracts O
did O
not O
show O
significant O
inhibition O
on O
AChE O
and O
BChE O
. O
In O
the O
preliminary O
phytochemical O
tests O
, O
the O
aerial O
parts O
of O
the O
plant O
showed O
the O
presence O
of O
saponins O
, O
alkaloids O
, O
flavonoids O
, O
phenols O
, O
tannins O
and O
terpenoids O
. O
The O
current O
findings O
could O
be O
attributed O
to O
these O
groups O
of O
compounds O
. O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc B
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

Lys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Heteromtoxin O
(HmTx) O
, O
a O
novel O
heterodimeric O
phospholipase O
A(2) O
from O
Heterometrus O
laoticus O
scorpion O
venom.Heteromtoxin O
(HmTx) O
is O
a O
group O
III O
phospholipase O
A(2) O
produced O
in O
Heterometrus O
laoticus O
, O
in O
Thailand O
. O
In O
this O
study O
, O
HmTx O
was O
purified O
from O
venom O
by O
separation O
chromatography O
, O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx B
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

flutamide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Evaluation O
of O
flutamide O
genotoxicity O
in O
rats O
and O
in O
primary O
human O
hepatocytes.Flutamide O
, O
an O
effective O
competitive O
inhibitor O
of O
the O
androgen O
receptor O
used O
orally O
for O
palliative O
treatment O
of O
prostatic O
carcinoma O
and O
regulation O
of O
prostatic O
hyperplasia O
was O
evaluated O
for O
its O
genotoxic O
effects O
in O
the O
intact O
rat O
and O
in O
primary O
cultures O
of O
human O
hepatocytes O
. O
Negative O
responses O
were O
obtained O
in O
all O
the O
in O
vivo O
assays O
as O
well O
as O
in O
the O
in O
vitro O
assay O
. O
In O
rats O
given O
a O
single O
oral O
dose O
of O
500 O
mg/kg O
flutamide O
, O
fragmentation O
and O
repair O
of O
liver O
DNA O
were O
absent O
, O
and O
no O
increase O
was O
observed O
in O
the O
frequency O
of O
micronucleated O
hepatocytes O
. O
In O
the O
liver O
of O
rats O
given O
flutamide O
as O
initiating O
agent O
at O
the O
dose O
of O
500 O
mg/kg/week O
for O
6 O
successive O
weeks O
, O
gamma-glutamyltraspeptidase- B
positive O
foci O
were O
detected O
only O
in O
3 O
of O
10 O
rats O
. O
There O
was O
no O
evidence O
of O
a O
promoting O
effect O
on O
the O
development O
of O
aberrant O
crypt O
foci O
in O
rats O
given O
100 O
mg/kg O
flutamide O
on O
alternate O
days O
for O
8 O
successive O
weeks O
. O
In O
primary O
cultures O
of O
human O
hepatocytes O
from O
one O
male O
and O
one O
female O
donor O
DNA O
fragmentation O
as O
measured O
by O
the O
Comet O
assays O
, O
and O
DNA O
repair O
synthesis O
as O
revealed O
by O
quantitative O
autoradiography O
, O
were O
absent O
after O
a O
20 O
hr O
exposure O
to O
flutamide O
concentrations O
ranging O
from O
18 O
to O
56 O
microM O
. O
Taken O
as O
a O
whole O
, O
our O
results O
seem O
to O
indicate O
that O
flutamide O
is O
a O
non-genotoxic O
drug O
. O

SB216367 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
glycogen O
synthase O
kinase-3β/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagin-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O
that O
cinobufagin O
potently O
inhibited O
the O
proliferation O
of O
U2OS O
, O
MG63 O
and O
SaOS-2 O
cells O
. O
Significant O
increases O
in O
G2/M O
cell-cycle O
arrest O
and O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved- O
PARP B
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

Jaspamide O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
effects O
of O
jaspamide O
on O
human O
cardiomyocyte O
function O
and O
cardiac O
ion O
channel O
activity.Jaspamide O
(jasplakinolide; O
NSC-613009) O
is O
a O
cyclodepsipeptide O
that O
has O
antitumor O
activity O
. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
( O
hERG) B
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O
amplitude O
, O
putative O
measurements O
of O
cell O
viability O
and O
cardiac O
contractility O
, O
respectively O
. O
Concentration-dependent O
increases O
in O
rhythmic O
beating O
rate O
were O
noted O
at O
≤ O
6 O
h O
of O
treatment O
, O
followed O
by O
dose-dependent O
decreases O
after O
6 O
and O
72 O
h O
exposure O
. O
The O
toxic O
effects O
of O
jaspamide O
were O
compared O
with O
that O
of O
the O
known O
cardiotoxicant O
mitoxantrone O
, O
and O
confirmed O
by O
multiparameter O
fluorescence O
imaging O
analysis O
. O
These O
results O
support O
the O
hypothesis O
that O
the O
toxicity O
observed O
in O
rats O
and O
dogs O
is O
due O
to O
toxic O
effects O
of O
jaspamide O
on O
cardiomyocytes O
. O

[3H]NBMPR O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 B
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

ciprostene O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue O
factor O
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue B
factor I
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue O
factor O
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

GW9662 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
acid O
interact O
to O
modify O
iNOS O
mRNA O
levels O
through O
the O
PPARgamma/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O
alpha O
and O
gamma O
mRNA O
levels O
. O
In O
Expt O
. O
1 O
, O
macrophages O
were O
collected O
from O
broiler O
chicks O
fed O
3 O
or O
6% O
dietary O
fat O
(g/100 O
g) O
with O
0 O
, O
25 O
, O
and O
50 O
mg O
lutein/kg O
feed O
for O
23 O
d O
. O
In O
Expt O
. O
2 O
, O
using O
a O
3 O
x O
3 O
factorial O
, O
eicosapentaenoic O
acid O
(EPA) O
at O
0 O
, O
15 O
and O
50 O
micromol/L O
and O
lutein O
at O
0 O
, O
10 O
and O
100 O
micromol/L O
were O
applied O
to O
HD11 O
cell O
culture O
for O
24 O
h O
. O
In O
both O
experiments O
, O
cells O
were O
stimulated O
with O
lipopolysaccharide O
before O
RNA O
isolation O
. O
Lutein O
interacted O
with O
fat O
in O
Expt O
. O
1 O
and O
with O
EPA O
in O
Expt O
. O
2 O
to O
affect O
mRNA O
levels O
of O
iNOS O
, O
PPARgamma O
, O
and O
RXRalpha O
in O
chicken O
macrophages O
and O
HD11 O
cells O
, O
respectively O
(P O
< O
0.05) O
. O
At O
3% O
dietary O
fat O
or O
up O
to O
15 O
micromol/L O
EPA O
in O
the O
medium O
, O
increasing O
lutein O
increased O
the O
iNOS O
mRNA O
. O
However O
, O
at O
6% O
dietary O
fat O
or O
50 O
micromol/L O
EPA O
, O
lutein O
did O
not O
cause O
a O
rise O
in O
iNOS O
mRNA O
. O
Increasing O
lutein O
in O
the O
medium O
from O
0 O
to O
100 O
micromol/L O
decreased O
iNOS O
mRNA O
. O
Increasing O
lutein O
with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma O
and O
RXRalpha O
mRNA O
levels O
. O
Lutein O
increased O
PPARalpha O
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma O
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma B
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine B
hydroxylase I
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
DNA O
polymerase O
POLQ O
and O
cellular O
defense O
against O
DNA O
damage.In O
mammalian O
cells O
, O
POLQ O
(pol O
θ) O
is O
an O
unusual O
specialized O
DNA O
polymerase O
whose O
in O
vivo O
function O
is O
under O
active O
investigation O
. O
POLQ O
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability O
, O
in O
base O
excision O
repair O
, O
and O
in O
immunological O
diversification O
. O
The O
protein O
is O
formed O
by O
an O
N-terminal O
helicase-like O
domain O
, O
a O
C-terminal B
DNA I
polymerase I
domain I
, O
and O
a O
large O
central O
domain O
that O
spans O
between O
the O
two O
. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila O
Mus308 O
protein O
, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents O
. O
Homologs O
of O
POLQ O
and O
Mus308 O
are O
found O
in O
multicellular O
eukaryotes O
, O
including O
plants O
, O
but O
a O
comparison O
of O
phenotypes O
suggests O
that O
not O
all O
of O
these O
genes O
are O
functional O
orthologs O
. O
Flies O
defective O
in O
Mus308 O
are O
sensitive O
to O
DNA O
interstrand O
crosslinking O
agents O
, O
while O
mammalian O
cells O
defective O
in O
POLQ O
are O
primarily O
sensitive O
to O
DNA O
double-strand O
breaking O
agents O
. O
Cells O
from O
Polq(-/-) O
mice O
are O
hypersensitive O
to O
radiation O
and O
peripheral O
blood O
cells O
display O
increased O
spontaneous O
and O
ionizing O
radiation-induced O
levels O
of O
micronuclei O
(a O
hallmark O
of O
gross O
chromosomal O
aberrations) O
, O
though O
mice O
apparently O
develop O
normally O
. O
Loss O
of O
POLQ O
in O
human O
and O
mouse O
cells O
causes O
sensitivity O
to O
ionizing O
radiation O
and O
other O
double O
strand O
breaking O
agents O
and O
increased O
DNA O
damage O
signaling O
. O
Retrospective O
studies O
of O
clinical O
samples O
show O
that O
higher O
levels O
of O
POLQ O
gene O
expression O
in O
breast O
and O
colorectal O
cancer O
are O
correlated O
with O
poorer O
outcomes O
for O
patients O
. O
A O
clear O
understanding O
of O
the O
mechanism O
of O
action O
and O
physiologic O
function O
of O
POLQ O
in O
the O
cell O
is O
likely O
to O
bear O
clinical O
relevance O
. O

clopidogrel O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
P2Y12 O
, O
a O
new O
platelet O
ADP O
receptor O
, O
target O
of O
clopidogrel.Clopidogrel O
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced O
platelet O
aggregation O
. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel O
over O
aspirin O
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction O
, O
stroke O
, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease O
. O
The O
antiaggregating O
effect O
of O
clopidogrel O
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP O
binding O
to O
a O
purinergic O
receptor O
present O
at O
the O
platelet O
surface O
. O
Clopidogrel O
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O
ADP O
, O
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets O
. O
The O
binding O
of O
(33)P-2MeS-ADP O
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
with O
a O
potency O
that O
was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets O
. O
In O
these O
transfected O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet O
receptor O
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP O
on O
platelets O
 O
, O
a O
new O
platelet O
ADP O
receptor O
, O
target O
of O
clopidogrel.Clopidogrel O
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced O
platelet O
aggregation O
. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel O
over O
aspirin O
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction O
, O
stroke O
, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease O
. O
The O
antiaggregating O
effect O
of O
clopidogrel O
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP O
binding O
to O
a O
purinergic O
receptor O
present O
at O
the O
platelet O
surface O
. O
Clopidogrel O
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O
ADP O
, O
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets O
. O
The O
binding O
of O
(33)P-2MeS-ADP O
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
with O
a O
potency O
that O
was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets O
. O
In O
these O
transfected O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet O
receptor O
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP O
on O
platelets O
. O

tolbutamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB B
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

(m)CpG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA B
methyl I
transferase I
3a I
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

tryptophan O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Bovine O
and O
ovine O
gonadotropin-releasing O
hormone O
(GnRH)-II O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II O
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II B
decapeptide O
possessing O
arginine O
(codon O
: O
CGG) O
rather O
than O
tryptophan O
(TGG) O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O
We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O
not O
bind O
to O
mammalian O
GnRH O
receptors O
expressed O
in O
different O
types O
of O
cell O
nor O
did O
it O
exhibit O
agonist O
or O
antagonist O
properties O
on O
types O
I O
or O
II O
GnRH O
receptors O
expressed O
in O
COS-7 O
cells O
. O
Bovine O
primers O
facilitated O
cloning O
of O
ovine O
GnRH-II O
DNA O
. O
A O
premature O
stop O
codon O
(TGA) O
replaces O
the O
expected O
tryptophan O
codon O
at O
position O
seven O
of O
GnRH-II O
in O
sheep O
DNA O
. O
Thus O
, O
both O
species O
possess O
prepro-GnRH-II O
genes O
encoding O
inactive O
peptides O
, O
as O
previously O
described O
for O
chimpanzee O
GnRH-II O
. O
The O
updated O
bovine O
type O
II O
GnRH O
receptor O
gene O
sequence O
revealed O
inactivation O
by O
frame O
shifts O
, O
premature O
stop O
codons O
, O
and O
nucleotide O
changes O
specifying O
nonconservative O
replacement O
of O
amino O
acid O
residues O
, O
similar O
to O
inactivation O
of O
sheep O
type O
II O
GnRH O
receptor O
. O
Spliced O
RNA O
transcripts O
from O
the O
disrupted O
receptor O
gene O
were O
not O
detected O
in O
bovine O
pituitary O
. O
In O
contrast O
, O
bovine O
prepro-GnRH-I O
and O
type O
I O
GnRH O
receptor O
genes O
are O
intact O
, O
encoding O
well-conserved O
protein O
sequences O
. O
These O
findings O
, O
and O
previous O
descriptions O
of O
inactivation O
of O
the O
human O
type O
II O
GnRH O
receptor O
and O
deletions O
of O
prepro-GnRH-II O
and O
type O
II O
GnRH O
receptor O
in O
laboratory O
rodents O
, O
suggest O
the O
GnRH-II O
system O
has O
been O
replaced O
by O
the O
GnRH-I O
system O
or O
is O
redundant O
in O
certain O
mammals O
. O

vitamin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB O
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
, O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB B
activation O
that O
involves O
degradation O
of O
I-κBε O
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O
DNA O
by O
EMSA O
in O
alveolar O
epithelial O
A549 O
cells O
. O
We O
also O
examined O
the O
level O
of O
I-κBε O
and O
sub-cellular O
distribution O
of O
c-Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin O
C O
pretreatment O
. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB O
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
. O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB O
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS-induced O
inflammatory O
diseases O
. O

topotecan O
acts O
as O
NOT O
for O
what O
entity O
? O
Glioma O
cell O
sensitivity O
to O
topotecan O
: O
the O
role O
of O
p53 O
and O
topotecan-induced O
DNA O
damage.Topotecan O
is O
a O
topoisomerase O
I O
inhibitor O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 O
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 B
status O
, O
were O
associated O
with O
increased O
topotecan-induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
SPACRCAN O
, O
a O
novel O
human O
interphotoreceptor O
matrix O
hyaluronan-binding O
proteoglycan O
synthesized O
by O
photoreceptors O
and O
pinealocytes.The O
interphotoreceptor O
matrix O
is O
a O
unique O
extracellular O
complex O
occupying O
the O
interface O
between O
photoreceptors O
and O
the O
retinal O
pigment O
epithelium O
in O
the O
fundus O
of O
the O
eye O
. O
Because O
of O
the O
putative O
supportive O
role O
in O
photoreceptor O
maintenance O
, O
it O
is O
likely O
that O
constituent O
molecules O
play O
key O
roles O
in O
photoreceptor O
function O
and O
may O
be O
targets O
for O
inherited O
retinal O
disease O
. O
In O
this O
study O
we O
identify O
and O
characterize O
SPACRCAN O
, O
a O
novel O
chondroitin O
proteoglycan O
in O
this O
matrix O
. O
SPACRCAN O
was O
cloned O
from O
a O
human O
retinal O
cDNA O
library O
and O
the O
gene O
localized O
to O
chromosome O
3q11.2 O
. O
Analysis O
of O
SPACRCAN O
mRNA O
and O
protein O
revealed O
that O
SPACRCAN O
is O
expressed O
exclusively O
by O
photoreceptors O
and O
pinealocytes O
. O
SPACRCAN O
synthesized O
by O
photoreceptors O
is O
localized O
to O
the O
interphotoreceptor O
matrix O
where O
it O
surrounds O
both O
rods O
and O
cones O
. O
The O
functional O
protein O
contains O
1160 O
amino O
acids O
with O
a O
large O
central O
mucin B
domain I
, O
three O
consensus O
sites O
for O
glycosaminoglycan O
attachment O
, O
two O
epidermal O
growth O
factor-like O
repeats O
, O
a O
putative O
hyaluronan-binding O
motif O
, O
and O
a O
potential O
transmembrane O
domain O
near O
the O
C-terminal O
. O
Lectin O
and O
Western O
blotting O
indicate O
an O
M(r) O
around O
400,000 O
before O
and O
230,000 O
after O
chondroitinase O
ABC O
digestion O
. O
Removal O
of O
N- O
and O
O-linked O
oligosaccharides O
reduces O
the O
M(r) O
to O
approximately O
160,000 O
, O
suggesting O
that O
approximately O
60% O
of O
the O
mass O
of O
SPACRCAN O
is O
carbohydrate O
. O
Finally O
, O
we O
demonstrate O
that O
SPACRCAN O
binds O
hyaluronan O
and O
propose O
that O
associations O
between O
SPACRCAN O
and O
hyaluronan O
may O
be O
involved O
in O
organization O
of O
the O
insoluble O
interphotoreceptor O
matrix O
, O
particularly O
as O
SPACRCAN O
is O
the O
major O
proteoglycan O
present O
in O
this O
matrix O
. O

iloprost O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue O
factor O
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin B
receptor I
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue O
factor O
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

Adrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
pertussis O
toxin-sensitive O
G-proteins O
in O
the O
hormonal O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
in O
an O
insulin-secreting O
cell O
line O
(RINm5F).Adrenaline O
inhibits O
insulin O
secretion O
via O
pertussis O
toxin-sensitive O
mechanisms O
. O
Since O
voltage-dependent O
Ca2+ O
currents O
play O
a O
key O
role O
in O
insulin O
secretion O
, O
we O
examined O
whether O
adrenaline O
modulates O
voltage-dependent O
Ca2+ O
currents O
of O
the O
rat O
insulinoma O
cell O
line O
, O
RINm5F O
. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O
technique O
, O
dihydropyridine- O
but O
not O
omega-conotoxin-sensitive O
Ca2+ O
currents O
were O
identified O
. O
Adrenaline O
via O
alpha B
2-adrenoceptors I
inhibited O
the O
Ca2+ O
currents O
by O
about O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin O
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
, O
galanin O
, O
another O
inhibitor O
of O
insulin O
secretion O
, O
reduced O
Ca2+ O
currents O
by O
about O
40% O
in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O
and O
another O
Go O
subtype O
, O
most O
likely O
representing O
Go1 O
. O
In O
membranes O
of O
control O
but O
not O
of O
pertussis O
toxin-treated O
cells O
, O
adrenaline O
via O
alpha O
2-adrenoceptors O
stimulated O
incorporation O
of O
the O
photo-reactive O
GTP O
analog O
[alpha-32P]GTP O
azidoanilide O
into O
pertussis O
toxin O
substrates O
comigrating O
with O
the O
alpha-subunits O
of O
Gi2 O
, O
Go2 O
, O
and O
the O
not O
further O
identified O
Go O
subtype O
. O
The O
present O
findings O
indicate O
that O
activated O
alpha O
2-adrenoceptors O
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins O
, O
i.e O
. O
two O
forms O
of O
Go O
and O
with O
Gi2 O
. O
These O
G-proteins O
are O
likely O
to O
be O
involved O
in O
the O
adrenaline-induced O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
and O
in O
other O
signal O
transduction O
pathways O
contributing O
to O
the O
adrenaline-induced O
inhibition O
of O
insulin O
secretion O
. O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Roles O
of O
rifampicin O
in O
drug-drug O
interactions O
: O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear O
pregnane O
X O
receptor.Rifampicin O
, O
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis O
, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O
drug-drug O
interactions O
, O
creating O
serious O
problems O
. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment O
. O
The O
concomitantly O
administered O
effects O
of O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes B
P450 I
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

Acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA B
I I
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

palinurin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Evidence O
for O
a O
new O
binding O
mode O
to O
GSK-3 O
: O
allosteric O
regulation O
by O
the O
marine O
compound O
palinurin.Glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
is O
widely O
recognised O
as O
a O
relevant O
player O
in O
the O
pathogenesis O
of O
several O
highly O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease O
, O
mood O
disorders O
, O
diabetes O
and O
cancer O
. O
Therefore O
, O
this O
enzyme O
constitutes O
a O
highly O
attractive O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies O
. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene O
palinurin O
as O
a O
GSK-3β O
inhibitor O
. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β O
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O
mechanism O
by O
which O
binding O
of O
palinurin O
leads O
to O
GSK-3β B
inhibition O
. O
The O
inhibitory O
activities O
determined O
for O
a O
series O
of O
structurally O
related O
analogues O
support O
the O
proposed O
binding O
mode O
of O
palinurin O
, O
which O
is O
the O
first O
compound O
described O
to O
target O
this O
allosteric O
site O
. O
The O
results O
offer O
new O
opportunities O
for O
designing O
and O
developing O
selective O
inhibitors O
with O
novel O
mechanisms O
of O
action O
. O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma B
protein I
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

H4biopterin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Tyrosine O
hydroxylase O
binds O
tetrahydrobiopterin O
cofactor O
with O
negative O
cooperativity O
, O
as O
shown O
by O
kinetic O
analyses O
and O
surface O
plasmon O
resonance O
detection.Kinetic O
studies O
of O
tetrameric O
recombinant O
human O
tyrosine O
hydroxylase O
isoform O
1 O
(hTH1) O
have O
revealed O
properties O
so O
far O
not O
reported O
for O
this O
enzyme O
. O
Firstly O
, O
with O
the O
natural O
cofactor O
(6R)-Lerythro-5,6,7 O
, O
8-tetrahydrobiopterin O
(H4biopterin) O
a O
time-dependent O
change O
(burst) O
in O
enzyme O
activity O
was O
observed O
, O
with O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient O
. O
Secondly O
, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin O
with O
a O
pronounced O
negative O
cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM) O
. O
On O
phosphorylation O
of O
Ser40 O
by O
protein O
kinase O
A O
, O
the O
affinity O
for O
H4biopterin O
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O
negative O
cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03) O
. O
The O
dimeric O
C-terminal O
deletion O
mutant O
(Delta473-528) O
of O
hTH1 O
also O
showed O
negative O
cooperativity O
of O
H4biopterin O
binding O
(h O
= O
0.4) O
. O
Cooperativity O
was O
not O
observed O
with O
the O
cofactor O
analogues O
6-methyl-5,6,7,8-tetrahydropterin O
(h O
= O
0.9 O
+/- O
0.1; O
Km O
= O
62.7 O
+/- O
5.7 O
microM) O
and O
3-methyl-5,6,7 O
, O
8-tetrahydropterin O
(H43-methyl-pterin)(h O
= O
1.0 O
+/- O
0.1; O
Km O
= O
687 O
+/- O
50 O
microM) O
. O
In O
the O
presence O
of O
1 O
mM O
H43-methyl-pterin O
, O
used O
as O
a O
competitive O
cofactor O
analogue O
to O
BH4 O
, O
hyperbolic O
saturation O
curves O
were O
also O
found O
for O
H4biopterin O
(h O
= O
1.0) O
, O
thus O
confirming O
the O
genuine O
nature O
of O
the O
kinetic O
negative O
cooperativity O
. O
This O
cooperativity O
was O
confirmed O
by O
real-time O
biospecific O
interaction O
analysis O
by O
surface O
plasmon O
resonance O
detection O
. O
The O
equilibrium O
binding O
of O
H4biopterin O
to O
the O
immobilized O
iron-free O
apoenzyme O
results O
in O
a O
saturable O
positive O
resonance O
unit O
(DeltaRU) O
response O
with O
negative O
cooperativity O
(h O
= O
0.52-0.56) O
. O
Infrared O
spectroscopic O
studies O
revealed O
a O
reduced O
thermal O
stability O
both O
of O
the O
apo-and O
the O
holo- O
hTH1 B
on O
binding O
of O
H4biopterin O
and O
Lerythro-dihydrobiopterin O
(H2biopterin) O
. O
Moreover O
, O
the O
ligand-bound O
forms O
of O
the O
enzyme O
also O
showed O
a O
decreased O
resistance O
to O
limited O
tryptic O
proteolysis O
. O
These O
findings O
indicate O
that O
the O
binding O
of O
H4biopterin O
at O
the O
active O
site O
induces O
a O
destabilizing O
conformational O
change O
in O
the O
enzyme O
which O
could O
be O
related O
to O
the O
observed O
negative O
cooperativity O
. O
Thus O
, O
our O
studies O
provide O
new O
insight O
into O
the O
regulation O
of O
TH O
by O
the O
concentration O
of O
H4biopterin O
which O
may O
have O
significant O
implications O
for O
the O
physiological O
regulation O
of O
catecholamine O
biosynthesis O
in O
neuroendocrine O
cells O
. O

Genistin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
characteristics O
of O
genistin-induced O
inhibitory O
effects O
on O
intestinal O
motility.Genistin O
belongs O
to O
isoflavones O
. O
Based O
on O
the O
facts O
that O
genistin O
exerts O
inhibitory O
effects O
on O
the O
contractility O
of O
vascular O
smooth O
muscle,the O
present O
study O
was O
designed O
to O
characterize O
the O
effects O
of O
genistin O
on O
intestinal O
contractility O
and O
evaluate O
its O
potential O
clinical O
implication O
. O
Ex O
vivo O
[isolated O
jejunal O
segment O
(IJS) O
of O
rat] O
, O
in O
vitro O
, O
and O
in O
vivo O
assays O
were O
used O
in O
the O
study O
. O
The O
results O
indicated O
that O
genistin O
(5-80 O
μmol/L) O
inhibited O
the O
contraction O
of O
IJS O
in O
a O
dose-dependent O
manner O
and O
inhibited O
the O
increased-contractility O
of O
IJS O
induced O
by O
acetylcholine O
(ACh) O
, O
histamine O
, O
high O
Ca(2+) O
, O
and O
erythromycin O
, O
respectively O
. O
The O
inhibitory O
effects O
of O
genistin O
were O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)- O
ATPase B
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin O
in O
relieving O
intestinal O
hypercontractility O
. O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras O
homologous O
A O
protein O
(Rho O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 B
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatment O
. O

seroquel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atypical O
neuroleptics O
have O
low O
affinity O
for O
dopamine O
D2 O
receptors O
or O
are O
selective O
for O
D4 O
receptors.This O
review O
examines O
the O
possible O
receptor O
basis O
of O
the O
atypical O
action O
of O
those O
atypical O
antipsychotic O
drugs O
that O
elicit O
low O
levels O
of O
Parkinsonism O
. O
Such O
an O
examination O
requires O
consistent O
and O
accurate O
dissociation O
constants O
for O
the O
antipsychotic O
drugs O
at O
the O
relevant O
dopamine O
and O
serotonin O
receptors O
. O
It O
has O
long O
been O
known O
, O
however O
, O
that O
the O
dissociation O
constant O
of O
a O
given O
antipsychotic O
drug O
at O
the O
dopamine O
D2 O
receptor O
varies O
between O
laboratories O
. O
Although O
such O
variation O
depends O
on O
several O
factors O
, O
it O
has O
recently O
been O
recognized O
that O
the O
radioligand O
used O
to O
measure O
the O
competition O
between O
the O
antipsychotic O
drug O
and O
the O
radioligand O
is O
an O
important O
variable O
. O
The O
present O
review O
summarizes O
information O
on O
this O
radioligand O
dependence O
. O
In O
general O
, O
a O
radioligand O
of O
low O
solubility O
in O
the O
membrane O
(i.e. O
, O
low O
tissue:buffer O
partition) O
results O
in O
a O
low O
value O
for O
the O
antipsychotic O
dissociation O
constant O
when O
the O
drug O
competes O
with O
the O
radioligand O
. O
Hence O
, O
by O
first O
obtaining O
the O
antipsychotic O
dissociation O
constants O
using O
different O
radioligands O
of O
different O
solubility O
in O
the O
membrane O
, O
one O
can O
then O
extrapolate O
the O
data O
to O
low O
or O
"zero" O
ligand O
solubility O
. O
The O
extrapolated O
value O
represents O
the O
radioligand-independent O
dissociation O
constant O
of O
the O
antipsychotic O
. O
These O
values O
are O
here O
given O
for O
dopamine O
D2 O
and O
D4 O
receptors O
, O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O
dopamine O
D2 O
receptors O
, O
making O
them O
more O
resistant O
to O
displacement O
by O
endogenous O
dopamine O
. O
Finally O
, O
a O
relation O
was O
found O
between O
the O
neuroleptic O
doses O
for O
rat O
catalepsy O
and O
the O
D2:D4 O
ratio O
of O
the O
radioligand-independent O
K O
values O
for O
these O
two O
receptors O
. O
Thus O
, O
the O
atypical O
neuroleptics O
appear O
to O
fall O
into O
two O
groups O
, O
those O
that O
have O
a O
low O
affinity O
for O
dopamine O
D2 O
receptors O
and O
those O
that O
are O
selective O
for O
dopamine O
D4 O
receptors O
. O

aminoglycoside O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Apolipoprotein O
E3 O
(apoE3) O
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 O
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density B
lipoprotein I
(LDL) I
receptor I
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1-dependent O
glucose O
transport O
in O
pig O
proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O
model O
of O
gentamicin O
C O
(GMC)-induced O
reduction O
in O
SGLT1 O
activity O
, O
we O
examined O
whether O
ligands O
for O
megalin O
protect O
LLC-PK1 O
cells O
from O
the O
GMC-induced O
reduction O
in O
SGLT1 O
activity O
. O
We O
employed O
apolipoprotein O
E3 O
(apoE3) O
and O
lactoferrin O
as O
ligands O
for O
megalin O
. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3 O
, O
lactoferrin O
and O
bovine O
serum O
albumin O
with O
or O
without O
100 O
microg/ml O
of O
GMC O
, O
and O
the O
SGLT1-dependent O
methyl O
alpha-D-glucopyranoside O
(AMG) O
uptake O
and O
levels O
of O
SGLT1 O
expression O
were O
determined O
. O
As O
a O
result O
, O
we O
demonstrated O
that O
the O
apoE3 O
significantly O
protects O
these O
cells O
from O
GMC-induced O
reduction O
in O
AMG O
uptake O
, O
but O
neither O
lactoferrin O
nor O
albumin O
does O
. O
In O
accord O
with O
a O
rise O
in O
AMG O
uptake O
activity O
, O
the O
mRNA O
and O
protein O
levels O
of O
SGLT1 O
were O
apparently O
up-regulated O
in O
the O
presence O
of O
apoE3 O
. O
Furthermore O
, O
we O
found O
that O
the O
uptake O
of O
[3H] O
gentamicin O
is O
decreased O
by O
apoE3 O
, O
and O
that O
apoE3 O
showed O
obvious O
protection O
against O
the O
GMC-dependent O
N-acetyl-beta-D-glucosamidase O
(NAG) O
release O
from O
LLC-PK1 O
cells O
. O
Thus O
, O
these O
results O
indicate O
that O
apoE3 O
could O
be O
a O
valuable O
tool O
for O
the O
prevention O
of O
aminoglycoside O
nephrotoxicity O
. O

spermidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine B
decarboxylase I
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

EtOH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 O
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group O
, O
HbA1c O
level O
in O
EtOH+DM8W O
group O
was O
lower O
than O
in O
DM8W O
group O
. O
Compared O
with O
control O
group O
, O
there O
were O
no O
changes O
of O
LVDP O
, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group O
, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD B
and O
ALDH2 O
in O
EtOH+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX O
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O
trilisate) O
pre-treatment O
on O
ASA-induced O
adverse O
reactions O
in O
nine O
patients O
. O
Pulmonary O
function O
tests O
, O
nasal O
symptoms O
score O
, O
PNIF O
and O
serum O
salicylate O
levels O
were O
monitored O
following O
challenges O
with O
threshold O
doses O
of O
ASA O
. O
Trilisate O
administered O
at O
a O
dose O
of O
3000 O
mg O
daily O
for O
3 O
days O
, O
offered O
a O
moderate O
protection O
against O
ASA-induced O
symptoms; O
it O
diminished O
the O
severity O
and/or O
delayed O
the O
appearance O
of O
FEV1 O
fall O
. O
Maximal O
decreases O
in O
FEV1 O
as O
well O
as O
reaction O
intensity O
indexes O
were O
significantly O
lower O
(P O
less O
than O
0.02 O
and O
P O
less O
than O
0.002 O
, O
respectively) O
after O
trilisate O
pre-treatment O
as O
compared O
to O
placebo O
. O
Trilisate O
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients O
. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate O
is O
unknown O
, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate O
and O
ASA O
on O
cyclo-oxygenase B
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant O
patients O
. O

dilevalol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
The O
effects O
of O
labetalol O
and O
dilevalol O
on O
isolated O
cardiovascular O
preparations O
of O
the O
guinea-pig O
and O
rat.Differing O
effects O
of O
labetalol O
and O
dilevalol O
on O
cardiovascular O
preparations O
have O
been O
reported O
. O
I O
have O
studied O
the O
effects O
of O
labetalol O
and O
dilevalol O
on O
the O
contractile O
responses O
of O
the O
rat O
and O
guinea-pig O
left O
atria O
and O
rat O
portal O
vein O
. O
On O
the O
guinea-pig O
left O
atria O
low O
concentrations O
of O
labetalol O
(> O
or O
= O
10(-8) O
M) O
and O
of O
dilevalol O
(> O
or O
= O
10(-7) O
M) O
inhibited O
to O
a O
small O
extent O
the O
responses O
to O
electrical O
cardiac O
stimulation O
, O
which O
is O
indicative O
of O
membrane O
stabilizing O
activity O
. O
Labetalol O
(> O
or O
= O
3 O
x O
10(-8) O
M) O
and O
dilevalol O
(> O
or O
= O
10(-8) O
M) O
caused O
surmountable O
antagonism O
of O
the O
isoprenaline O
responses O
of O
the O
atria O
and O
the O
pA2 O
values O
were O
8.60 O
and O
8.98 O
at O
the O
beta O
1-adrenoceptors O
of O
the O
rat O
left O
atria O
and O
7.90 O
and O
8.31 O
, O
respectively O
, O
on O
the O
guinea-pig O
left O
atria O
which O
has O
functional O
beta O
1- O
and O
beta O
2-adrenoceptors O
. O
Labetalol O
and O
dilevalol O
(both O
at O
> O
or O
= O
10(-7) O
M) O
attenuated O
the O
spontaneous O
contractile O
activity O
of O
the O
rat O
portal O
vein O
and O
the O
attenuation O
to O
labetalol O
at O
10(-6) O
M O
was O
abolished O
by O
ICI O
118,551 O
which O
illustrates O
that O
the O
labetalol-induced O
attenuation O
is O
beta O
2-adrenoceptor O
mediated O
. O
The O
isoprenaline O
attenuation O
responses O
of O
the O
portal O
vein O
were O
inhibited O
by O
labetalol O
and O
dilevalol O
(both O
at O
> O
or O
= O
10(-7) O
M) O
and O
the O
pA2 O
value O
for O
the O
labetalol O
at O
beta O
2-adrenoceptors O
was O
7.59 O
. O
It O
is O
concluded O
that O
labetalol O
and O
dilevalol O
are O
beta B
1-adrenoceptor I
selective O
antagonists O
. O

PMA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC O
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC B
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

TAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin B
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

repaglinide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic B
receptors I
in O
rat O
brain O
. O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC O
/ O
ABL B
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMBT O
is O
mediated O
by O
downregulation O
of O
VEGF B
and O
MMP-9 O
through O
Akt O
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O
In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O
series O
of O
brartemicin O
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activity O
against O
invasion O
. O
Among O
the O
synthetic O
analogs O
tested O
, O
DMBT O
, O
6,6'-bis O
(2,3-dimethoxybenzoyl)-a,a-d-trehalose O
, O
was O
found O
to O
be O
the O
most O
potent O
anti-invasive O
agent O
. O
But O
the O
effects O
of O
DMBT O
on O
breast O
cancer O
cells O
were O
not O
known O
. O
In O
this O
study O
, O
the O
effects O
of O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Alcohol O
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
( O
MeCP-2 B
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
development O
. O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA B
transporter I
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

pyridoxal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Abnormally O
high O
plasma O
levels O
of O
vitamin O
B6 O
in O
children O
with O
autism O
not O
taking O
supplements O
compared O
to O
controls O
not O
taking O
supplements.BACKGROUND O
: O
There O
have O
been O
many O
studies O
of O
the O
effect O
of O
high-dose O
supplementation O
of O
vitamin O
B6 O
on O
children O
and O
adults O
with O
autism O
, O
with O
all O
but O
one O
reporting O
benefits O
. O
OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
biochemical O
basis O
for O
vitamin O
B6 O
therapy O
by O
measuring O
the O
level O
of O
total O
vitamin O
B6 O
in O
the O
plasma O
of O
unsupplemented O
children O
with O
autism O
spectrum O
disorder O
compared O
to O
unsupplemented O
control O
subjects O
. O
PARTICIPANTS O
: O
Children O
with O
autism O
spectrum O
disorders O
(n O
= O
35 O
, O
age O
3-9 O
years) O
and O
unrelated O
typical O
children O
(n O
= O
11 O
, O
age O
6-9 O
years) O
, O
all O
from O
Arizona O
, O
were O
studied O
. O
(This O
includes O
the O
data O
from O
24 O
children O
with O
autism O
from O
our O
previous O
study.) O
METHODOLOGY O
: O
A O
microbiologic O
assay O
was O
used O
to O
measure O
the O
level O
of O
total O
vitamin O
B6 O
(including O
phosphorylated O
and O
unphosphorylated O
forms) O
, O
in O
a O
blinded O
fashion O
. O
RESULTS O
: O
Children O
with O
autism O
had O
a O
75% O
higher O
level O
of O
total O
vitamin O
B6 O
than O
the O
controls O
(medians O
of O
56 O
versus O
32 O
ng/mL O
, O
respectively O
, O
p O
= O
0.00002) O
. O
Most O
of O
the O
autistic O
children O
(77%) O
had O
levels O
that O
were O
more O
than O
2 O
standard O
deviations O
above O
the O
median O
value O
of O
the O
controls O
. O
The O
autistic O
girls O
(n O
= O
5) O
also O
had O
elevated O
levels O
(mean O
of O
54.6 O
ng/mL O
, O
median O
of O
60 O
ng/mL) O
. O
DISCUSSION O
: O
These O
results O
are O
consistent O
with O
previous O
studies O
that O
found O
that O
: O
(1) O
pyridoxal O
kinase O
had O
a O
very O
low O
activity O
in O
children O
with O
autism O
and O
(2) O
pyridoxal O
5 O
phosphate O
(PLP) O
levels O
are O
unusually O
low O
in O
children O
with O
autism O
. O
Thus O
, O
it O
appears O
that O
the O
low O
conversion O
of O
pyridoxal O
and O
pyridoxine O
to O
PLP O
results O
in O
low O
levels O
of O
PLP O
, O
which O
is O
the O
active O
cofactor O
for O
113 O
known O
enzymatic O
reactions O
, O
including O
the O
formation O
of O
many O
key O
neurotransmitters O
. O
CONCLUSIONS O
: O
Total O
vitamin O
B6 O
is O
abnormally O
high O
in O
autism O
, O
consistent O
with O
previous O
reports O
of O
an O
impaired O
pyridoxal B
kinase I
for O
the O
conversion O
of O
pyridoxine O
and O
pyridoxal O
to O
PLP O
. O
This O
may O
explain O
the O
many O
published O
studies O
of O
benefits O
of O
high-dose O
vitamin O
B6 O
supplementation O
in O
some O
children O
and O
adults O
with O
autism O
. O

somatostatin-14 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Biophysical O
properties O
, O
pharmacology O
, O
and O
modulation O
of O
human O
, O
neuronal O
L-type O
(alpha(1D) O
, O
Ca(V)1.3) O
voltage-dependent O
calcium O
currents.Voltage-dependent O
calcium O
channels O
(VDCCs) O
are O
multimeric O
complexes O
composed O
of O
a O
pore-forming O
alpha(1) O
subunit O
together O
with O
several O
accessory O
subunits O
, O
including O
alpha(2)delta O
, O
beta O
, O
and O
, O
in O
some O
cases O
, O
gamma O
subunits O
. O
A O
family O
of O
VDCCs O
known O
as O
the O
L-type O
channels O
are O
formed O
specifically O
from O
alpha(1S) O
(skeletal O
muscle) O
, O
alpha(1C) O
(in O
heart O
and O
brain) O
, O
alpha(1D) O
(mainly O
in O
brain O
, O
heart O
, O
and O
endocrine O
tissue) O
, O
and O
alpha(1F) O
(retina) O
. O
Neuroendocrine O
L-type O
currents O
have O
a O
significant O
role O
in O
the O
control O
of O
neurosecretion O
and O
can O
be O
inhibited O
by O
GTP-binding O
(G-) O
proteins O
. O
However O
, O
the O
subunit O
composition O
of O
the O
VDCCs O
underlying O
these O
G-protein-regulated O
neuroendocrine O
L-type O
currents O
is O
unknown O
. O
To O
investigate O
the O
biophysical O
and O
pharmacological O
properties O
and O
role O
of O
G-protein O
modulation O
of O
alpha(1D) O
calcium O
channels O
, O
we O
have O
examined O
calcium O
channel O
currents O
formed O
by O
the O
human O
neuronal O
L-type O
alpha(1D) O
subunit O
, O
co-expressed O
with O
alpha(2)delta-1 O
and O
beta(3a) O
, O
stably O
expressed O
in O
a O
human O
embryonic O
kidney O
(HEK) O
293 O
cell O
line O
, O
using O
whole O
cell O
and O
perforated O
patch-clamp O
techniques O
. O
The O
alpha(1D)-expressing O
cell O
line O
exhibited O
L-type O
currents O
with O
typical O
characteristics O
. O
The O
currents O
were O
high-voltage O
activated O
(peak O
at O
+20 O
mV O
in O
20 O
mM O
Ba2+) O
and O
showed O
little O
inactivation O
in O
external O
Ba2+ O
, O
while O
displaying O
rapid O
inactivation O
kinetics O
in O
external O
Ca2+ O
. O
The O
L-type O
currents O
were O
inhibited O
by O
the O
1,4 O
dihydropyridine O
(DHP) O
antagonists O
nifedipine O
and O
nicardipine O
and O
were O
enhanced O
by O
the O
DHP O
agonist O
BayK O
S-(-)8644 O
. O
However O
, O
alpha(1D) O
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein O
pathways O
. O
Activation O
of O
endogenous O
somatostatin O
receptor O
subtype O
2 O
( O
sst2) B
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O
no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N-type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein-mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O
a O
glutathione-S-transferase O
(GST) O
fusion O
protein O
, O
did O
not O
bind O
Gbetagamma O
, O
unlike O
the O
alpha(1B) O
I-II O
loop O
fusion O
protein O
. O
These O
data O
show O
that O
the O
biophysical O
and O
pharmacological O
properties O
of O
recombinant O
human O
alpha(1D) O
L-type O
currents O
are O
similar O
to O
alpha(1C) O
currents O
, O
and O
these O
currents O
are O
also O
resistant O
to O
modulation O
by O
G(i/o)-linked O
G-protein-coupled O
receptors O
. O

somatostatin-14 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Biophysical O
properties O
, O
pharmacology O
, O
and O
modulation O
of O
human O
, O
neuronal O
L-type O
(alpha(1D) O
, O
Ca(V)1.3) O
voltage-dependent O
calcium O
currents.Voltage-dependent O
calcium O
channels O
(VDCCs) O
are O
multimeric O
complexes O
composed O
of O
a O
pore-forming O
alpha(1) O
subunit O
together O
with O
several O
accessory O
subunits O
, O
including O
alpha(2)delta O
, O
beta O
, O
and O
, O
in O
some O
cases O
, O
gamma O
subunits O
. O
A O
family O
of O
VDCCs O
known O
as O
the O
L-type O
channels O
are O
formed O
specifically O
from O
alpha(1S) O
(skeletal O
muscle) O
, O
alpha(1C) O
(in O
heart O
and O
brain) O
, O
alpha(1D) O
(mainly O
in O
brain O
, O
heart O
, O
and O
endocrine O
tissue) O
, O
and O
alpha(1F) O
(retina) O
. O
Neuroendocrine O
L-type O
currents O
have O
a O
significant O
role O
in O
the O
control O
of O
neurosecretion O
and O
can O
be O
inhibited O
by O
GTP-binding O
(G-) O
proteins O
. O
However O
, O
the O
subunit O
composition O
of O
the O
VDCCs O
underlying O
these O
G-protein-regulated O
neuroendocrine O
L-type O
currents O
is O
unknown O
. O
To O
investigate O
the O
biophysical O
and O
pharmacological O
properties O
and O
role O
of O
G-protein O
modulation O
of O
alpha(1D) O
calcium O
channels O
, O
we O
have O
examined O
calcium O
channel O
currents O
formed O
by O
the O
human O
neuronal O
L-type O
alpha(1D) O
subunit O
, O
co-expressed O
with O
alpha(2)delta-1 O
and O
beta(3a) O
, O
stably O
expressed O
in O
a O
human O
embryonic O
kidney O
(HEK) O
293 O
cell O
line O
, O
using O
whole O
cell O
and O
perforated O
patch-clamp O
techniques O
. O
The O
alpha(1D)-expressing O
cell O
line O
exhibited O
L-type O
currents O
with O
typical O
characteristics O
. O
The O
currents O
were O
high-voltage O
activated O
(peak O
at O
+20 O
mV O
in O
20 O
mM O
Ba2+) O
and O
showed O
little O
inactivation O
in O
external O
Ba2+ O
, O
while O
displaying O
rapid O
inactivation O
kinetics O
in O
external O
Ca2+ O
. O
The O
L-type O
currents O
were O
inhibited O
by O
the O
1,4 O
dihydropyridine O
(DHP) O
antagonists O
nifedipine O
and O
nicardipine O
and O
were O
enhanced O
by O
the O
DHP O
agonist O
BayK O
S-(-)8644 O
. O
However O
, O
alpha(1D) O
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein O
pathways O
. O
Activation O
of O
endogenous O
somatostatin B
receptor I
subtype I
2 I
(sst2) O
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O
no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N-type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein-mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O
a O
glutathione-S-transferase O
(GST) O
fusion O
protein O
, O
did O
not O
bind O
Gbetagamma O
, O
unlike O
the O
alpha(1B) O
I-II O
loop O
fusion O
protein O
. O
These O
data O
show O
that O
the O
biophysical O
and O
pharmacological O
properties O
of O
recombinant O
human O
alpha(1D) O
L-type O
currents O
are O
similar O
to O
alpha(1C) O
currents O
, O
and O
these O
currents O
are O
also O
resistant O
to O
modulation O
by O
G(i/o)-linked O
G-protein-coupled O
receptors O
. O

oxygen O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
mutation O
in O
the O
FAM36A O
gene O
, O
the O
human O
ortholog O
of O
COX20 O
, O
impairs O
cytochrome O
c O
oxidase O
assembly O
and O
is O
associated O
with O
ataxia O
and O
muscle O
hypotonia.The O
mitochondrial B
respiratory I
chain I
complex I
IV I
(cytochrome O
c O
oxidase) O
is O
a O
multi-subunit O
enzyme O
that O
transfers O
electrons O
from O
cytochrome O
c O
to O
molecular O
oxygen O
, O
yielding O
water O
. O
Its O
biogenesis O
requires O
concerted O
expression O
of O
mitochondria- O
and O
nuclear-encoded O
subunits O
and O
assembly O
factors O
. O
In O
this O
report O
, O
we O
describe O
a O
homozygous O
missense O
mutation O
in O
FAM36A O
from O
a O
patient O
who O
displays O
ataxia O
and O
muscle O
hypotonia O
. O
The O
FAM36A O
gene O
is O
a O
remote O
, O
putative O
ortholog O
of O
the O
fungal O
complex O
IV O
assembly O
factor O
COX20 O
. O
Messenger O
RNA O
(mRNA) O
and O
protein O
co-expression O
analyses O
support O
the O
involvement O
of O
FAM36A O
in O
complex O
IV O
function O
in O
mammals O
. O
The O
c.154A>C O
mutation O
in O
the O
FAM36A O
gene O
, O
a O
mutation O
that O
is O
absent O
in O
sequenced O
exomes O
, O
leads O
to O
a O
reduced O
activity O
and O
lower O
levels O
of O
complex O
IV O
and O
its O
protein O
subunits O
. O
The O
FAM36A O
protein O
is O
nearly O
absent O
in O
patient's O
fibroblasts O
. O
Cells O
affected O
by O
the O
mutation O
accumulate O
subassemblies O
of O
complex O
IV O
that O
contain O
COX1 O
but O
are O
almost O
devoid O
of O
COX2 O
protein O
. O
We O
observe O
co-purification O
of O
FAM36A O
and O
COX2 O
proteins O
, O
supporting O
that O
the O
FAM36A O
defect O
hampers O
the O
early O
step O
of O
complex O
IV O
assembly O
at O
the O
incorporation O
of O
the O
COX2 O
subunit O
. O
Lentiviral O
complementation O
of O
patient's O
fibroblasts O
with O
wild-type O
FAM36A O
increases O
the O
complex O
IV O
activity O
as O
well O
as O
the O
amount O
of O
holocomplex O
IV O
and O
of O
individual O
subunits O
. O
These O
results O
establish O
the O
function O
of O
the O
human O
gene O
FAM36A/COX20 O
in O
complex O
IV O
assembly O
and O
support O
a O
causal O
role O
of O
the O
gene O
in O
complex O
IV O
deficiency O
. O

dextrocetirizine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Compared O
pharmacological O
characteristics O
in O
humans O
of O
racemic O
cetirizine O
and O
levocetirizine O
, O
two O
histamine O
H1-receptor O
antagonists.The O
potent O
histamine B
H(1)-receptor I
antagonist O
cetirizine O
(Zyrtec) O
is O
a O
racemic O
mixture O
of O
levocetirizine O
(now O
available O
under O
the O
trademark O
Xyzal O
and O
dextrocetirizine O
. O
In O
this O
Commentary O
, O
we O
examine O
some O
biological O
properties O
of O
cetirizine O
and O
levocetirizine O
, O
namely O
enantioselectivity O
in O
pharmacological O
activity O
and O
pharmacokinetic O
properties O
, O
with O
emphasis O
on O
the O
possibility O
of O
racemization O
, O
the O
compared O
behavior O
of O
the O
two O
enantiomers O
, O
and O
the O
potential O
for O
interactions O
with O
other O
drugs O
. O
Recent O
data O
demonstrate O
that O
the O
antihistaminergic O
activity O
of O
the O
racemate O
is O
primarily O
due O
to O
levocetirizine O
. O
Levocetirizine O
is O
rapidly O
and O
extensively O
absorbed O
, O
poorly O
metabolized O
, O
and O
not O
subject O
to O
racemization O
. O
Its O
pharmacokinetic O
characteristics O
are O
comparable O
after O
administration O
alone O
or O
in O
the O
racemate O
. O
Its O
apparent O
volume O
of O
distribution O
is O
smaller O
than O
that O
of O
dextrocetirizine O
(0.41 O
L O
kg(-1) O
vs O
. O
0.60 O
L O
kg(-1)) O
. O
Moreover O
, O
the O
non-renal O
(mostly O
hepatic) O
clearance O
of O
levocetirizine O
is O
also O
significantly O
lower O
than O
that O
of O
dextrocetirizine O
(11.8 O
mL O
min(-1) O
vs O
. O
29.2 O
mL O
min(-1)) O
. O
Our O
conclusion O
is O
that O
levocetirizine O
is O
indeed O
the O
eutomer O
of O
cetirizine O
. O
The O
evidence O
reviewed O
here O
confirms O
preclinical O
findings O
and O
offers O
a O
rationale O
for O
the O
chiral O
switch O
from O
the O
racemate O
to O
levocetirizine O
. O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Purification O
and O
structural O
characterisation O
of O
phospholipase O
A1 O
(Vespapase O
, O
Ves O
a O
1) O
from O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
venom.The O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
is O
one O
of O
the O
most O
dangerous O
vespid O
species O
in O
Southeast O
Asia O
, O
and O
stinging O
accidents O
involving O
this O
species O
still O
cause O
fatalities O
. O
In O
the O
present O
study O
, O
four O
forms O
of O
V O
. O
affinis O
phospholipase O
A(1) O
were O
identified O
through O
a O
proteomics O
approach O
. O
Two O
of O
these O
enzymes O
were O
purified O
by O
reverse-phase O
chromatography O
, O
and O
their O
biochemical O
properties O
were O
characterised O
. O
These O
enzymes O
, O
designated O
Ves O
a O
1s O
, O
are O
not O
glycoproteins O
and O
exist O
as O
33441.5 O
and O
33474.4 O
Da O
proteins O
, O
which O
corresponded O
with O
the O
34-kDa O
band O
observed O
via O
SDS-PAGE O
. O
The O
thermal O
stabilities O
of O
these O
enzymes O
were O
stronger O
than O
snake O
venom O
. O
Using O
an O
in O
vivo O
assay O
, O
no O
difference O
was O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves O
a O
1s O
revealed O
that O
the O
Ves O
a O
1 O
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves O
a O
1 O
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves B
a I
1s I
. O

oxymetazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha O
1A-adrenoceptor O
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha B
1A-adrenoceptor I
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha O
1B-adrenoceptors O
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

ALA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
alpha-Linolenic O
acid O
, O
Delta6-desaturase O
gene O
polymorphism O
, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O
adipose O
tissue O
samples O
. O
Least-squares O
means O
from O
generalized O
linear O
models O
and O
odds O
ratios O
(ORs) O
and O
95% O
CIs O
from O
multiple O
conditional O
logistic O
regression O
models O
were O
estimated O
. O
RESULTS O
: O
The O
prevalence O
of O
the O
variant O
T/- O
allele O
was O
48% O
. O
Eicosapentaenoic O
acid O
, O
gamma-linolenic O
acid O
, O
and O
arachidonic O
acid O
decreased O
in O
adipose O
tissue O
and O
plasma O
with O
increasing O
number O
of O
copies O
of O
the O
variant O
allele O
with O
a O
monotonic O
trend O
(P O
< O
0.05 O
for O
all) O
. O
Fasting O
plasma O
triacylglycerols O
by O
genotype O
were O
2.08 O
mmol/L O
for O
TT O
, O
2.16 O
mmol/L O
for O
T- O
, O
and O
2.26 O
mmol/L O
for O
- O
- O
[ie O
, O
homozygous O
for O
the O
variant O
(deletion) O
allele] O
(P O
= O
0.03) O
. O
The O
FADS2 O
deletion O
was O
not O
associated O
with O
MI O
and O
did O
not O
significantly O
modify O
the O
association O
between O
adipose O
tissue O
ALA O
and O
the O
risk O
of O
MI O
. O
CONCLUSIONS O
: O
The O
FADS2 O
deletion O
may O
prevent O
the O
conversion O
of O
ALA O
into O
very-long-chain O
PUFAs O
. O
However O
, O
this O
metabolic O
effect O
is O
not O
translated O
into O
an O
attenuated O
risk O
between O
ALA O
and O
MI O
among O
carriers O
of O
the O
variant O
. O
It O
is O
possible O
that O
, O
at O
current O
intakes O
of O
ALA O
, O
any O
potential O
defect O
in O
the O
transcription O
of O
the O
gene O
is O
masked O
by O
the O
availability O
of O
substrate O
. O
Further O
research O
in O
populations O
deficient O
in O
ALA O
intake O
is O
warranted O
. O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Lanthanum O
(III) O
regulates O
the O
nitrogen O
assimilation O
in O
soybean O
seedlings O
under O
ultraviolet-B O
radiation.Ultraviolet-B O
(UV-B O
, O
280-320 O
nm) O
radiation O
has O
seriously O
affected O
the O
growth O
of O
plants O
. O
Finding O
the O
technology/method O
to O
alleviate O
the O
damage O
of O
UV-B O
radiation O
has O
become O
a O
frontal O
topic O
in O
the O
field O
of O
environmental O
science O
. O
The O
pretreatment O
with O
rare O
earth O
elements O
(REEs) O
is O
an O
effective O
method O
, O
but O
the O
regulation O
mechanism O
of O
REEs O
is O
unknown O
. O
Here O
, O
the O
regulation O
effects O
of O
lanthanum O
(La(III)) O
on O
nitrogen O
assimilation O
in O
soybean O
seedlings O
(Glycine O
max O
L.) O
under O
ultraviolet-B O
radiation O
were O
investigated O
to O
elucidate O
the O
regulation O
mechanism O
of O
REEs O
on O
plants O
under O
UV-B O
radiation O
. O
UV-B O
radiation O
led O
to O
the O
inhibition O
in O
the O
activities O
of O
the O
key O
enzymes O
(nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase) O
in O
the O
nitrogen O
assimilation O
, O
the O
decrease O
in O
the O
contents O
of O
nitrate O
and O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino O
acid O
in O
soybean O
seedlings O
. O
The O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine B
synthetase I
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O
at O
the O
high O
level O
. O
The O
results O
indicated O
that O
the O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
inhibition O
of O
UV-B O
radiation O
on O
nitrogen O
assimilation O
in O
soybean O
seedlings O
. O

ingenol O
3-angelate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein B
kinase I
C I
.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O
PKC O
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A O
and O
phorbol O
12-myristate O
13-acetate O
(PMA) O
in O
WEHI-231 O
, O
HOP-92 O
, O
and O
Colo-205 O
cells O
. O
In O
all O
of O
the O
three O
cell O
types O
, O
I3A O
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA O
. O
In O
intact O
CHO-K1 O
cells O
, O
I3A O
was O
able O
to O
translocate O
different O
green O
fluorescent O
protein-tagged O
PKC O
isoforms O
, O
visualized O
by O
confocal O
microscopy O
, O
with O
equal O
or O
higher O
potency O
than O
PMA O
. O
PKC-delta O
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A O
and O
PMA O
. O
I3A O
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O
. O

mimosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosine O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O
spiralis O
, O
a O
nematode O
parasite O
, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 O
and O
MIP-2 B
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O
by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10 O
, O
20 O
, O
30 O
and O
40 O
days O
post-treatment O
. O
In O
these O
experiments O
, O
mimosine O
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced O
. O
In O
addition O
, O
we O
found O
that O
MCP-1 O
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine O
, O
while O
MIP-2 O
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O
inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T O
. O
spiralis O
. O
Our O
studies O
suggest O
that O
mimosine O
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O
cell O
cycle O
of O
white O
blood O
cells O
. O
This O
study O
suggests O
for O
the O
first O
time O
the O
premise O
that O
mimosine O
acts O
as O
an O
anti-inflammatory O
compound O
. O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 B
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

Agmatine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Agmatine O
: O
an O
endogenous O
clonidine-displacing O
substance O
in O
the O
brain.Clonidine O
, O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
. O
The O
endogenous O
ligand O
for O
imidazoline O
receptors O
may O
be O
a O
clonidine-displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha B
2-adrenergic I
and I
imidazoline I
receptors I
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
, O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
, O
a O
noncatecholamine O
ligand O
at O
alpha O
2-adrenergic O
receptors O
and O
may O
act O
as O
a O
neurotransmitter O
. O

spermine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Properties O
of O
purified O
recombinant O
human O
polyamine O
oxidase O
, O
PAOh1/SMO.The O
discovery O
of O
an O
inducible O
oxidase O
whose O
apparent O
substrate O
preference O
is O
spermine O
indicates O
that O
polyamine O
catabolism O
is O
more O
complex O
than O
that O
originally O
proposed O
. O
To O
facilitate O
the O
study O
of O
this O
enzyme O
, O
the O
purification O
and O
characterization O
of O
the O
recombinant O
human O
PAOh1/SMO O
polyamine O
oxidase O
are O
reported O
. O
Purified O
PAOh1 B
/ O
SMO O
oxidizes O
both O
spermine O
(K(m)=1.6 O
microM) O
and O
N(1)-acetylspermine O
(K(m)=51 O
microM) O
, O
but O
does O
not O
oxidize O
spermidine O
. O
The O
purified O
human O
enzyme O
also O
does O
not O
oxidize O
eight O
representative O
antitumor O
polyamine O
analogues; O
however O
, O
specific O
oligamine O
analogues O
were O
found O
to O
be O
potent O
inhibitors O
of O
the O
oxidation O
of O
spermine O
by O
PAOh1/SMO O
. O
The O
results O
of O
these O
studies O
are O
consistent O
with O
the O
hypothesis O
that O
PAOh1/SMO O
represents O
a O
new O
addition O
to O
the O
polyamine O
metabolic O
pathway O
that O
may O
represent O
a O
new O
target O
for O
antineoplastic O
drug O
development O
. O

tamoxifen O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Chemoprevention O
for O
high-risk O
women O
: O
tamoxifen O
and O
beyond.The O
demonstration O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
Project O
(NSABP) O
that O
5 O
years O
of O
tamoxifen O
therapy O
is O
associated O
with O
an O
approximate O
50% O
reduction O
in O
breast O
cancer O
incidence O
in O
high-risk O
women O
was O
a O
milestone O
in O
breast O
cancer O
prevention O
. O
Because O
tamoxifen O
is O
associated O
with O
increased O
risk O
of O
side-effects O
such O
as O
hot O
flashes O
, O
menstrual O
abnormalities O
, O
uterine O
cancer O
, O
and O
thromboembolic O
phenomena O
, O
its O
use O
will O
not O
be O
advisable O
or O
acceptable O
for O
all O
high-risk O
women O
. O
Women O
over O
50 O
years O
of O
age O
appear O
to O
be O
at O
highest O
risk O
for O
serious O
adverse O
events O
, O
such O
as O
uterine O
cancer O
and O
thromboembolic O
phenomena O
. O
Individuals O
in O
whom O
tamoxifen-associated O
breast O
cancer O
risk O
reduction O
appears O
to O
outweigh O
risk O
of O
serious O
side-effects O
include O
women O
with O
prior O
in O
situ O
or O
estrogen O
receptor O
(ER)-positive O
invasive O
cancer O
, O
atypical O
hyperplasia O
, O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7% O
, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 B
mutations O
, O
although O
preliminary O
evidence O
favors O
benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER O
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive O
cancers O
. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O
specific O
classes O
of O
preventive O
agents O
, O
(c) O
drugs O
with O
fewer O
side-effects O
and/or O
effective O
in O
ER-negative O
or O
ER-positive O
tamoxifen-resistant O
precancerous O
disease O
, O
and O
(d) O
efficient O
clinical O
trial O
models O
to O
assess O
new O
agent O
efficacy O
. O
Breast O
intraepithelial O
neoplasia O
(IEN) O
may O
be O
sampled O
by O
minimally O
invasive O
techniques O
and O
is O
an O
attractive O
short-term O
risk O
biomarker O
. O
Molecular O
abnormalities O
observed O
in O
IEN O
may O
be O
used O
to O
select O
potential O
agents O
for O
testing/therapy O
, O
and O
modulation O
of O
these O
abnormalities O
may O
be O
used O
in O
phase O
I O
trials O
to O
select O
appropriate O
doses O
and O
in O
phase O
II O
trials O
to O
assess O
response O
. O
Breast O
density O
volume O
and O
certain O
serum O
markers O
such O
as O
insulin-like O
growth O
factor-1 O
are O
also O
being O
studied O
as O
potential O
risk O
and O
response O
biomarkers O
. O
Reversal O
or O
prevention O
of O
advanced O
IEN O
as O
well O
as O
modulation O
of O
other O
risk O
biomarkers O
in O
randomized O
phase O
II O
and O
phase O
III O
trials O
is O
being O
evaluated O
as O
a O
means O
of O
more O
efficiently O
evaluating O
prevention O
drugs O
in O
the O
future O
. O
A O
number O
of O
agents O
are O
being O
developed O
that O
target O
molecular O
abnormalities O
in O
IEN O
, O
have O
fewer O
or O
different O
side O
effects O
than O
tamoxifen O
, O
and O
may O
be O
effective O
in O
ER-negative O
or O
tamoxifen-resistant O
disease O
. O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparison O
of O
vaginal O
aminopeptidase O
enzymatic O
activities O
in O
various O
animals O
and O
in O
humans.The O
specific O
enzymatic O
activity O
of O
four O
different O
aminopeptidases O
(aminopeptidase O
N O
, O
leucine O
aminopeptidase O
, O
aminopeptidase O
A O
and O
aminopeptidase O
B) O
in O
vaginal O
homogenates O
from O
rabbit O
, O
rat O
, O
guinea-pig O
, O
sheep O
and O
humans O
was O
compared O
. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase B
A I
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O
vaginal O
homogenates O
in O
the O
order O
: O
sheep O
> O
guinea-pig O
> O
rabbit O
> O
or O
= O
human O
> O
or O
= O
rat O
. O
Based O
on O
the O
results O
of O
the O
hydrolysis O
and O
inhibition O
of O
the O
4-methoxy-2-naphthylamide O
substrates O
, O
it O
was O
difficult O
to O
have O
an O
exact O
decision O
on O
the O
aminopeptidase O
type O
in O
the O
vaginal O
homogenates O
from O
the O
species O
studied O
. O
It O
was O
found O
that O
the O
aminopeptidase O
activity O
in O
rat O
, O
rabbit O
and O
humans O
was O
not O
statistically O
different O
. O
Therefore O
, O
we O
suggest O
that O
rats O
and O
rabbits O
could O
be O
used O
as O
model O
animals O
for O
vaginal O
enzymatic O
activity O
studies O
and O
for O
determination O
of O
the O
degradation O
of O
protein O
and O
peptide O
drugs O
in O
the O
vagina O
. O

triacylglycerol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Acyl-CoA O
synthetase O
isoforms O
1 O
, O
4 O
, O
and O
5 O
are O
present O
in O
different O
subcellular O
membranes O
in O
rat O
liver O
and O
can O
be O
inhibited O
independently.Inhibition O
studies O
have O
suggested O
that O
acyl-CoA O
synthetase O
(ACS O
, O
EC O
) O
isoforms O
might O
regulate O
the O
use O
of O
acyl-CoAs O
by O
different O
metabolic O
pathways O
. O
In O
order O
to O
determine O
whether O
the O
subcellular O
locations O
differed O
for O
each O
of O
the O
three O
ACSs O
present O
in O
liver O
and O
whether O
these O
isoforms O
were O
regulated O
independently O
, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
. O
ACS1 O
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS O
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O
ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 B
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS O
isoforms O
in O
unique O
subcellular O
locations O
. O

BH(4) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Oral O
administration O
of O
tetrahydrobiopterin O
prevents O
endothelial O
dysfunction O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats.We O
have O
reported O
that O
a O
deficiency O
of O
tetrahydrobiopterin O
(BH(4)) O
, O
an O
active O
cofactor O
of O
endothelial O
NO O
synthase O
(eNOS) O
, O
contributes O
to O
the O
endothelial O
dysfunction O
through O
reduced O
eNOS O
activity O
and O
increased O
superoxide O
anion O
(O(2)(-)) O
generation O
in O
the O
insulin-resistant O
state O
. O
To O
further O
confirm O
this O
hypothesis O
, O
we O
investigated O
the O
effects O
of O
dietary O
treatment O
with O
BH(4) O
on O
endothelium-dependent O
arterial O
relaxation O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats O
. O
Oral O
supplementation O
of O
BH(4) O
(10 O
mg O
. O
kg(-1) O
. O
d(-1)) O
for O
8 O
weeks O
significantly O
increased O
the O
BH(4) O
content O
in O
cardiovascular O
tissues O
of O
rats O
fed O
high O
levels O
of O
fructose O
(fructose-fed O
rats) O
. O
Impairment O
of O
endothelium-dependent O
arterial O
relaxation O
in O
the O
aortic O
strips O
of O
the O
fructose-fed O
rats O
was O
reversed O
with O
BH(4) O
treatment O
. O
The O
BH(4) O
treatment O
was O
associated O
with O
a O
2-fold O
increase O
in O
eNOS O
activity O
as O
well O
as O
a O
70% O
reduction O
in O
endothelial O
O(2)(-) O
production O
compared O
with O
those O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
also O
partially O
improved O
the O
insulin O
sensitivity O
and O
blood O
pressure O
, O
as O
well O
as O
the O
serum O
triglyceride O
concentration O
, O
in O
the O
fructose-fed O
rats O
. O
Moreover O
, O
BH(4) O
treatment O
of O
the O
fructose-fed O
rats O
markedly O
reduced O
the O
lipid O
peroxide O
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O
the O
activation O
of O
2 O
redox-sensitive O
transcription O
factors O
, O
nuclear O
factor-kappaB O
and O
activating O
protein-1 O
, O
which O
were O
increased O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
of O
control O
rats O
did O
not O
have O
any O
significant O
effects O
on O
these O
parameters O
. O
These O
results O
indicate O
that O
BH(4) O
augmentation O
is O
essential O
for O
the O
restoration O
of O
eNOS B
function O
and O
the O
reduction O
of O
vascular O
oxidative O
stress O
in O
insulin-resistant O
rats O
. O

Sulindac O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 B
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

tunicamycin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
TCF7L2 O
Variation O
and O
Proliferative O
Diabetic O
Retinopathy.Proliferative O
diabetic O
retinopathy O
(PDR) O
is O
the O
most O
severe O
vision-threatening O
complication O
of O
diabetes O
. O
To O
investigated O
genetic O
association O
between O
TCF7L2 O
and O
PDR O
in O
Caucasian O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
its O
functional O
consequences O
, O
383 O
T2DM O
patients O
with O
PDR O
(T2DM-PDR) O
and O
756 O
T2DM O
patients O
without O
diabetic O
retinopathy O
(T2DM-no O
DR) O
were O
genotyped O
with O
rs7903146 O
in O
TCF7L2 O
. O
We O
found O
that O
risk O
allele O
(T) O
frequency O
of O
rs7903146 O
was O
significantly O
higher O
in O
T2DM-PDR O
patients O
(allelic O
P O
= O
2.52E-04) O
. O
In O
lymphoblastoid O
cells O
induced O
to O
undergo O
endoplasmic O
reticulum O
(ER) O
stress O
by O
treatment O
of O
tunicamycin O
, O
higher O
fold O
change O
of O
TCF7L2 O
and O
VEGFA B
mRNA O
levels O
were O
observed O
in O
rs7903146-TT O
cells O
than O
that O
in O
rs7903146-CC O
cells O
(P O
= O
0.02 O
for O
TCF7L2; O
P O
= O
0.004 O
for O
VEGFA) O
, O
suggesting O
ER O
stress O
plays O
a O
role O
in O
PDR O
pathogenesis O
. O
Silencing O
TCF7L2 O
resulted O
in O
decreased O
mRNA O
levels O
of O
both O
TCF7L2 O
and O
VEGFA O
(P O
< O
0.001) O
. O
Retinas O
of O
oxygen-induced O
retinopathy O
(OIR) O
mice O
(a O
model O
for O
PDR) O
had O
higher O
TCF7L2 O
and O
VEGFA O
mRNA O
levels O
than O
controls O
(P O
= O
2.9E-04 O
for O
TCF7L2; O
P O
= O
1.9E-07 O
for O
VEGFA) O
. O
Together O
, O
our O
study O
showed O
that O
TCF7L2-rs7903146 O
is O
associated O
with O
PDR O
in O
Caucasian O
T2DM O
and O
suggested O
TCF7L2 O
promoted O
pathological O
retinal O
neovascularization O
via O
ER O
stress-dependent O
upregulation O
of O
VEGFA O
. O

ceramides O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt B
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

phenformin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Role O
of O
organic B
cation/carnitine I
transporter I
1 I
in O
uptake O
of O
phenformin O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria O
. O
Uptake O
of O
phenformin O
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria O
. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds O
, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s) O
. O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; O
however O
, O
uptake O
of O
phenformin O
into O
mitochondria O
of O
organic O
cation/carnitine O
transporter O
1 O
(OCTN1) O
knockout O
mice O
was O
lower O
than O
that O
in O
wild-type O
mice O
, O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex O
I O
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 O
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ B
channels I
.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ O
channels O
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

Cyclopentenone O
prostaglandins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cyclopentenone O
prostaglandins O
suppress O
activation O
of O
microglia O
: O
down-regulation O
of O
inducible O
nitric-oxide O
synthase O
by O
15-deoxy-Delta12,14-prostaglandin O
J2.Mechanisms O
leading O
to O
down-regulation O
of O
activated O
microglia O
and O
astrocytes O
are O
poorly O
understood O
, O
in O
spite O
of O
the O
potentially O
detrimental O
role O
of O
activated O
glia O
in O
neurodegeneration O
. O
Prostaglandins O
, O
produced O
both O
by O
neurons O
and O
glia O
, O
may O
serve O
as O
mediators O
of O
glial O
and O
neuronal O
functions O
. O
We O
examined O
the O
influence O
of O
cyclopentenone O
prostaglandins O
and O
their O
precursors O
on O
activated O
glia O
. O
As O
models O
of O
glial O
activation O
, O
production O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
was O
studied O
in O
lipopolysaccharide-stimulated O
rat O
microglia O
, O
a O
murine O
microglial O
cell O
line O
BV-2 O
, O
and O
IL-1beta-stimulated O
rat O
astrocytes O
. O
Cyclopentenone O
prostaglandins O
were O
potent O
inhibitors O
of O
iNOS B
induction O
and O
were O
more O
effective O
than O
their O
precursors O
, O
prostaglandins O
E2 O
and O
D2 O
. O
15-Deoxy-Delta12,14-prostaglandin O
J2 O
(15d-PGJ2) O
was O
the O
most O
potent O
prostaglandin O
among O
those O
tested O
. O
In O
activated O
microglia O
, O
15d-PGJ2 O
suppressed O
iNOS O
promoter O
activity O
, O
iNOS O
mRNA O
, O
and O
protein O
levels O
. O
The O
action O
of O
15d-PGJ2 O
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O
because O
troglitazone O
, O
a O
specific O
ligand O
of O
PPARgamma O
, O
was O
unable O
to O
inhibit O
iNOS O
induction O
, O
and O
neither O
troglitazone O
nor O
15d-PGJ2 O
could O
stimulate O
the O
activity O
of O
a O
PPAR-dependent O
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma O
. O
15d-PGJ2 O
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O
transcription O
factor O
NFkappaB O
, O
but O
it O
did O
inhibit O
the O
activity O
of O
an O
NFkappaB O
reporter O
construct O
, O
suggesting O
that O
the O
mechanism O
of O
suppression O
of O
microglial O
iNOS O
by O
15d-PGJ2 O
may O
involve O
interference O
with O
NFkappaB O
transcriptional O
activity O
in O
the O
nucleus O
. O
Thus O
, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
mediated O
by O
cyclopentenone O
prostaglandins O
, O
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O
glial O
responses O
in O
the O
brain O
. O

1400W O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS B
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Quinone O
compounds O
regulate O
the O
level O
of O
ROS O
production O
by O
the O
NADPH O
oxidase O
Nox4.NADPH O
oxidase O
Nox4 O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 O
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
(Cys226 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 B
. O
Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones O
and O
Nox4 O
are O
implicated O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
the O
liver O
and O
muscle O
isoforms O
of O
ovine O
carnitine O
palmitoyltransferase O
1 O
: O
residues O
within O
the O
N-terminus O
of O
the O
muscle O
isoform O
influence O
the O
kinetic O
properties O
of O
the O
enzyme.The O
nucleotide O
sequence O
data O
reported O
will O
appear O
in O
DDBJ O
, O
EMBL O
, O
GenBank(R) O
and O
GSDB O
Nucleotide O
Sequence O
Databases; O
the O
sequences O
of O
ovine O
CPT1A O
and O
CPT1B O
cDNAs O
have O
the O
accession O
numbers O
Y18387 O
and O
AJ272435 O
respectively O
and O
the O
partial O
adipose O
tissue O
and O
liver O
CPT1A O
clones O
have O
the O
accession O
numbers O
Y18830 O
and O
Y18829 O
respectively O
. O
Fatty O
acid O
and O
ketone O
body O
metabolism O
differ O
considerably O
between O
monogastric O
and O
ruminant O
species O
. O
The O
regulation O
of O
the O
key O
enzymes O
involved O
may O
differ O
accordingly O
. O
Carnitine O
palmitoyltransferase O
1 O
(CPT O
1) O
is O
the O
key O
locus O
for O
the O
control O
of O
long-chain O
fatty O
acid O
beta-oxidation O
and O
liver O
ketogenesis O
. O
Previously O
we O
showed O
that O
CPT O
1 O
kinetics O
in O
sheep O
and O
rat O
liver O
mitochondria O
differ O
. O
We O
cloned O
cDNAs O
for O
both O
isoforms O
[liver- O
(L-) O
and O
muscle- O
(M-)] O
of O
ovine O
CPT O
1 O
in O
order O
to O
elucidate O
the O
structural O
features O
of O
these O
proteins O
and O
their O
genes O
( O
CPT1A O
and O
CPT1B O
) O
. O
Their O
deduced O
amino O
acid O
sequences O
show O
a O
high O
degree O
of O
conservation O
compared O
with O
orthologues O
from O
other O
mammalian O
species O
, O
with O
the O
notable O
exception O
of O
the O
N-terminus O
of O
ovine O
M-CPT O
1 O
. O
These O
differences O
were O
also O
present O
in O
bovine B
M-CPT I
1 I
, O
whose O
N-terminal O
sequence O
we O
determined O
. O
In O
addition O
, O
the O
5'-end O
of O
the O
sheep O
CPT1B O
cDNA O
suggested O
a O
different O
promoter O
architecture O
when O
compared O
with O
previously O
characterized O
CPT1B O
genes O
. O
Northern O
blotting O
revealed O
differences O
in O
tissue O
distribution O
for O
both O
CPT1A O
and O
CPT1B O
transcripts O
compared O
with O
other O
species O
. O
In O
particular O
, O
ovine O
CPT1B O
mRNA O
was O
less O
tissue O
restricted O
, O
and O
the O
predominant O
transcript O
in O
the O
pancreas O
was O
CPT1B O
. O
Expression O
in O
yeast O
allowed O
kinetic O
characterization O
of O
the O
two O
native O
enzymes O
, O
and O
of O
a O
chimaera O
in O
which O
the O
distinctive O
N-terminal O
segment O
of O
ovine O
M-CPT O
1 O
was O
replaced O
with O
that O
from O
rat O
M-CPT O
1 O
. O
The O
ovine O
N-terminal O
segment O
influences O
the O
kinetics O
of O
the O
enzyme O
for O
both O
its O
substrates O
, O
such O
that O
the O
K O
(m) O
for O
palmitoyl-CoA O
is O
decreased O
and O
that O
for O
carnitine O
is O
increased O
for O
the O
chimaera O
, O
relative O
to O
the O
parental O
ovine O
M-CPT O
1 O
. O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase B
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
( O
cyt B
b5) I
 O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Plerixafor O
, O
a O
CXCR4 O
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells.Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine B
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O
combination O
of O
plerixafor O
and O
G-CSF O
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF O
mobilization O
alone O
. O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
clinical O
profile O
of O
the O
angiotensin O
II O
receptor O
blocker O
eprosartan.Angiotensin O
II O
receptor O
antagonists O
block O
angiotensin O
II O
type O
1 O
(AT1) O
receptors O
and O
reduce O
the O
pressor O
effects O
of O
angiotensin O
in O
the O
vasculature O
. O
By O
this O
mechanism O
, O
they O
induce O
similar O
pharmacological O
effects O
to O
angiotensin-converting O
enzyme O
(ACE) O
inhibitors O
, O
resulting O
in O
a O
lowering O
of O
blood O
pressure O
(BP) O
. O
However O
, O
AT1 O
antagonists O
differ O
from O
ACE O
inhibitors O
with O
respect O
to O
side O
effects O
, O
and O
induce O
less O
cough O
, O
which O
is O
related O
to O
bradykinin O
activation O
. O
Within O
the O
class O
of O
angiotensin O
II O
antagonists O
, O
eprosartan O
differs O
from O
other O
currently O
clinically O
available O
agents O
in O
terms O
of O
its O
chemical O
structure O
and O
its O
dual O
pharmacological O
mode O
of O
action O
. O
Eprosartan O
acts O
not O
only O
at O
vascular O
AT1 O
receptors O
but O
also O
at O
presynaptic O
AT1 B
receptors O
, O
causing O
inhibition O
of O
sympathetically O
stimulated O
noradrenaline O
release O
. O
Eprosartan O
is O
not O
metabolized O
by O
cytochrome O
P450 O
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
, O
which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O
on O
multiple O
drugs O
. O
In O
clinical O
trials O
eprosartan O
has O
proven O
to O
be O
at O
least O
as O
effective O
as O
the O
ACE O
inhibitor O
enalapril O
in O
reducing O
BP O
, O
but O
with O
a O
significantly O
lower O
incidence O
of O
side O
effects O
. O
Eprosartan O
is O
safe O
, O
effective O
and O
well O
tolerated O
in O
long-term O
treatment O
, O
either O
as O
monotherapy O
or O
in O
combination O
with O
other O
antihypertensive O
drugs O
such O
as O
hydrochlorothiazide O
. O

sibutramine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O
4.1-fold O
increase O
in O
the O
AUC O
in O
S-enantiomer O
and O
1.8-fold O
versus O
2.0-fold O
for O
the O
R-enantiomer O
, O
respectively O
. O
The O
AUCs O
of O
S- O
and O
R-desmethyl O
metabolites O
changed O
significantly O
during O
the O
clopidogrel O
phase O
(P O
< O
.001 O
and O
P O
< O
.001 O
, O
respectively) O
but O
not O
during O
the O
clarithromycin O
phase O
(P O
= O
.099 O
and O
P O
= O
.090 O
, O
respectively) O
. O
Exposure O
to O
sibutramine O
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 O
genotypes O
. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine O
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 O
and O
CYP3A B
activity O
in O
vivo O
. O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
2-(2-Aminoethyl)-quinoline O
(D-1997) O
: O
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like O
receptors O
in O
the O
canine O
basilar O
artery.This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline O
derivative O
, O
2-(2-aminoethyl)-quinoline O
(D-1997) O
, O
in O
the O
canine O
isolated O
basilar O
artery O
. O
For O
comparison O
, O
the O
effects O
of O
D-1997 O
were O
also O
evaluated O
on O
rat O
aorta O
. O
Canine O
basilar O
artery O
and O
rat O
aortic O
rings O
were O
prepared O
and O
mounted O
in O
organ O
baths O
to O
record O
isometric O
tension O
changes O
. O
The O
contractile O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
compared O
with O
those O
produced O
by O
5-hydroxytryptamine O
(5-HT) O
and O
the O
5-HT O
receptor O
agonist O
quipazine O
. O
Thus O
, O
4-HT O
(10(-10)-10(-6)M) O
, O
D-1997 O
(3.1 O
x O
10(-8)-10(-4) O
M) O
and O
quipazine O
(3.1 O
x O
10(-7)-10(-4) O
M) O
each O
caused O
concentration-dependent O
contractions O
of O
the O
canine O
basilar O
artery O
with O
a O
rank O
order O
of O
agonist O
potency O
of O
5-HT O
> O
D-1997 O
> O
quipazine O
. O
5-HT O
and O
D-1997 O
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 B
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumarin O
by O
recombinant O
human O
UDP-glucuronosyltransferases O
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
(HFC) O
for O
several O
UGTs B
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras O
homologous O
A O
protein O
(Rho O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 B
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatment O
. O

Glutaraldehyde O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase O
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin B
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles O
. O
17864-L(x) O
loaded O
EGa1-PEG O
nanoparticles O
were O
internalized O
by O
clathrin-mediated O
endocytosis O
and O
ultimately O
digested O
in O
lysosomes O
. O
The O
intracellular O
routing O
of O
EGa1 O
targeted O
nanoparticles O
leads O
to O
a O
successful O
release O
of O
the O
kinase O
inhibitor O
in O
the O
cell O
and O
inhibition O
of O
proliferation O
whereas O
the O
non-targeted O
formulations O
had O
no O
antiproliferative O
effects O
on O
14C O
cells O
. O
The O
drug O
loaded O
targeted O
nanoparticles O
were O
as O
effective O
as O
the O
free O
drug O
in O
vitro O
. O
These O
results O
demonstrate O
that O
multikinase O
inhibitor O
loaded O
nanoparticles O
are O
interesting O
nanomedicines O
for O
the O
treatment O
of O
EGFR-positive O
cancers O
. O

LY O
344864 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Both O
5-HT1B O
and O
5-HT1F O
receptors O
modulate O
c-fos O
expression O
within O
rat O
trigeminal O
nucleus O
caudalis.A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan O
is O
inhibition O
of O
the O
trigeminovascular O
pathway O
. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B O
, O
5-HT1D O
or O
5-HT1F O
receptors O
. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes O
, O
we O
compared O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F O
receptor O
agonist O
(LY O
344864) O
on O
c-fos O
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos-like O
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat O
5-HT1B O
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F B
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

β-ionone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT B
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

EtOH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 O
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group O
, O
HbA1c B
level O
in O
EtOH+DM8W O
group O
was O
lower O
than O
in O
DM8W O
group O
. O
Compared O
with O
control O
group O
, O
there O
were O
no O
changes O
of O
LVDP O
, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group O
, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Interacting O
Glutamate O
Receptor-Like O
Proteins O
in O
Phloem O
Regulate O
Lateral O
Root O
Initiation O
in O
Arabidopsis.Molecular O
, O
genetic O
, O
and O
electrophysiological O
evidence O
indicates O
that O
at O
least O
one O
of O
the O
plant O
Glu O
receptor-like O
molecules O
, O
GLR3.4 O
, O
functions O
as O
an O
amino O
acid-gated O
Ca(2+) O
channel O
at O
the O
plasma O
membrane O
. O
The O
aspect O
of O
plant O
physiology O
, O
growth O
, O
or O
development O
to O
which O
GLR3.4 O
contributes O
is O
an O
open O
question O
. O
Protein O
localization O
studies O
performed O
here O
provide O
important O
information O
. O
In O
roots O
, O
GLR3.4 O
and O
the O
related O
GLR3.2 O
protein O
were O
present O
primarily O
in O
the O
phloem O
, O
especially O
in O
the O
vicinity O
of O
the O
sieve O
plates O
. O
GLR3.3 O
was O
expressed O
in O
most O
cells O
of O
the O
growing O
primary O
root O
but O
was O
not O
enriched O
in O
the O
phloem O
, O
including O
the O
sieve O
plate O
area O
. O
GLR3.2 O
and O
GLR3.4 O
physically O
interacted O
with O
each O
other O
better O
than O
with O
themselves O
as O
evidenced O
by O
a O
biophotonic O
assay O
performed O
in O
human O
embryonic O
kidney O
cells O
and O
Nicotiana O
benthamiana O
leaf O
cells O
. O
GLR3.3 O
interacted O
poorly O
with O
itself O
or O
the O
other O
two O
GLRs O
. O
Mutations O
in O
GLR3.2 O
, O
GLR3.4 O
, O
or O
GLR3.2 O
and O
GLR3.4 O
caused O
the O
same O
and O
equally O
severe O
phenotype O
, O
namely O
, O
a O
large O
overproduction O
and O
aberrant O
placement O
of O
lateral O
root O
primordia O
. O
Loss O
of O
GLR3.3 O
did O
not O
affect O
lateral O
root O
primordia O
. O
These O
results O
support O
the O
hypothesis O
that O
apoplastic O
amino O
acids O
acting O
through O
heteromeric O
GLR3.2 O
/ O
GLR3.4 B
channels O
affect O
lateral O
root O
development O
via O
Ca(2+) O
signaling O
in O
the O
phloem O
. O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
High-glucose O
environment O
enhanced O
oxidative O
stress O
and O
increased O
interleukin-8 O
secretion O
from O
keratinocytes O
: O
New O
insights O
on O
impaired O
diabetic O
wound O
healing.Impaired O
wound O
healing O
frequently O
occurs O
in O
patients O
with O
diabetes O
. O
Interluekin-8 O
(IL-8) O
production O
by O
keratinocyte O
is O
responsible O
for O
recruiting O
neutrophils O
during O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high-glucose O
environment O
enhanced O
IL-8 B
production O
via O
epidermal O
growth O
factor O
receptor O
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK O
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O
represented O
by O
expression O
of O
myeloperoxidase O
level O
, O
was O
also O
significantly O
higher O
in O
diabetic O
rats O
. O
Treating O
diabetic O
rats O
with O
dapsone O
, O
an O
agent O
known O
to O
inhibit O
neutrophil O
function O
, O
was O
associated O
with O
improved O
healing O
. O
In O
conclusion O
, O
IL-8 O
production O
and O
neutrophil O
infiltration O
are O
increased O
in O
high-glucose O
environment O
due O
to O
elevated O
ROS O
level O
and O
contributed O
to O
impaired O
wound O
healing O
in O
diabetic O
skin O
. O
Targeting O
these O
dysfunctions O
may O
present O
novel O
therapeutic O
approaches O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A- B
mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

thioperamide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine B
H3 I
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

5-Methyl-urapidil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha B
1A I
adrenoceptors I
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O
and O
7.8 O
respectively) O
. O
The O
selective O
alpha O
1D O
antagonist O
BMY O
7378 O
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors O
. O
5 O
. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha O
1D-adrenoceptors O
(r O
= O
0.96) O
, O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O
1B O
(r O
= O
0.46) O
subtypes O
. O
6 O
. O
Noradrenaline-mediated O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

paclitaxel O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
( O
MRP2 B
/ O
cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS O
. O
Since O
both O
siRNAs O
showed O
biological O
activity O
, O
for O
stable O
inhibition O
of O
ABCC2 O
a O
corresponding O
short O
hairpin O
RNA O
(shRNA)-encoding O
expression O
vector O
was O
designed O
. O
By O
treatment O
of O
A2780RCIS O
cells O
with O
this O
construct O
, O
the O
expressions O
of O
the O
targeted O
ABCC2 O
encoding O
mRNA O
and O
transport O
protein O
were O
inhibited O
. O
These O
effects O
were O
accompanied O
by O
reversal O
of O
resistance O
against O
cisplatin O
and O
paclitaxel O
. O
Thus O
, O
the O
data O
demonstrate O
the O
utility O
of O
the O
analyzed O
RNAs O
as O
powerful O
laboratory O
tools O
and O
indicate O
that O
siRNA- O
and O
shRNA-mediated O
RNAi-based O
gene O
therapeutic O
approaches O
may O
be O
applicable O
in O
preventing O
and O
reversing O
ABCC2-depending O
drug O
resistance O
. O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

LY O
344864 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Both O
5-HT1B O
and O
5-HT1F O
receptors O
modulate O
c-fos O
expression O
within O
rat O
trigeminal O
nucleus O
caudalis.A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan O
is O
inhibition O
of O
the O
trigeminovascular O
pathway O
. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B O
, O
5-HT1D O
or O
5-HT1F O
receptors O
. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes O
, O
we O
compared O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F B
receptor O
agonist O
(LY O
344864) O
on O
c-fos O
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos-like O
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat O
5-HT1B O
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F O
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 B
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

CR O
1409 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK B
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v O
. O
CCK-8 O
or O
ceruletide O
(caerulein) O
. O
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 O
in O
the O
rat O
and O
is O
protective O
against O
ceruletide- O
, O
taurocholate- O
and O
diet-induced O
pancreatitis O
. O
Lorglumide O
is O
therefore O
a O
useful O
pharmacological O
tool O
to O
study O
the O
functions O
of O
CCK O
. O
For O
its O
pharmacological O
properties O
, O
its O
relatively O
low O
toxicity O
and O
because O
it O
is O
active O
also O
after O
oral O
administration O
, O
lorglumide O
is O
a O
candidate O
for O
diagnostic O
or O
therapeutic O
use O
in O
man O
when O
an O
involvement O
of O
CCK O
is O
suspected O
. O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras O
homologous O
A O
protein O
(Rho O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras B
homologous I
protein I
A I
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatment O
. O

Statins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Statins O
increase O
p21 O
through O
inhibition O
of O
histone B
deacetylase I
activity O
and O
release O
of O
promoter-associated O
HDAC1/2.Statins O
are O
3-hydroxy-3-methylglutaryl-CoA O
reductase O
inhibitors O
broadly O
used O
for O
the O
control O
of O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 O
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O
protein O
binding O
assay O
and O
chromatin O
immunoprecipitation O
assay O
showed O
the O
dissociation O
of O
HDAC1/2 O
and O
association O
of O
CBP O
, O
leading O
to O
the O
histone-H3 O
acetylation O
on O
the O
Sp1 O
sites O
of O
p21 O
promoter O
. O
In O
vitro O
cell O
proliferation O
and O
in O
vivo O
tumor O
growth O
were O
both O
inhibited O
by O
statins O
. O
These O
results O
suggest O
a O
novel O
mechanism O
for O
statins O
through O
abrogation O
of O
the O
HDAC O
activity O
and O
promoter O
histone-H3 O
acetylation O
to O
regulate O
p21 O
expression O
. O
Therefore O
, O
statins O
might O
serve O
as O
novel O
HDAC O
inhibitors O
for O
cancer O
therapy O
and O
chemoprevention O
. O

pyridostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase B
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

prunetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
prunetin O
via O
the O
suppression O
of O
NF-κB O
pathway.Prunetin O
is O
an O
O-methylated O
isoflavone O
, O
which O
is O
found O
in O
Prunus O
yedoensis O
. O
To O
date O
no O
report O
has O
been O
published O
on O
anti-inflammatory O
activities O
of O
prunetin O
. O
In O
the O
present O
study O
, O
the O
anti-inflammatory O
effect O
of O
prunetin O
on O
LPS-stimulated O
RAW O
264.7 O
macrophage O
and O
LPS-induced O
septic O
shock O
model O
were O
investigated O
. O
Inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-6 O
(IL-6) O
, O
and O
interleukin-1β O
(IL-1β) O
expressions O
were O
determined O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR) O
. O
To O
elucidate O
its O
underlying O
mechanism O
, O
nuclear O
factor-kappa O
B O
(NF-κb) O
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines B
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

Pterostilbene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2 O
/STAT3 B
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

Dexamethasone O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Species-specific O
differences O
in O
the O
glucocorticoid O
receptor O
transactivation O
function O
upon O
binding O
with O
betamethasone-esters.Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases O
. O
A O
number O
of O
adverse O
side O
effects O
, O
however O
, O
limit O
chronic O
treatment O
with O
GCs O
. O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human B
or I
rat I
GR I
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O
involution O
and O
body O
weight O
loss O
, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats O
. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM O
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O
in O
receptor O
binding O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS B
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

Ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Withdrawal O
from O
free-choice O
ethanol O
consumption O
results O
in O
increased O
packing O
density O
of O
glutamine O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O
interruption O
of O
ethanol O
drinking O
, O
subjected O
to O
a O
3-day O
withdrawal O
period O
at O
the O
end O
of O
2 O
months O
, O
or O
subjected O
to O
three O
3-day O
withdrawal O
periods O
along O
6 O
months O
. O
At O
2 O
months O
, O
P O
rats O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS O
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP- B
IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS O
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

[3H]EBOB O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated B
chloride I
ion I
channel I
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl O
GABA O
receptor O
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride O
channel O
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
. O

methylphenidate O
acts O
as O
NOT O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O
current O
study O
, O
SHR O
, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT O
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT B
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 B
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

methysergide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1 O
/ O
5-HT2 B
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

LY541850 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptors O
using O
LY541850 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 B
agonist O
and O
mGlu3 O
antagonist O
. O
We O
have O
verified O
this O
pharmacological O
profile O
of O
LY541850 O
in O
hippocampal O
slices O
. O
Field O
excitatory O
post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O
moleculare O
(SLM) O
were O
inhibited O
by O
LY541850 O
in O
mGlu3-/- O
mice O
(EC(50) O
38 O
nM) O
and O
wild-type O
littermates O
(EC(50) O
42 O
nM) O
to O
a O
similar O
extent O
but O
were O
not O
significantly O
affected O
in O
mGlu2-/- O
mice O
. O
The O
group O
II O
agonist O
, O
DCG-IV O
, O
inhibited O
the O
fEPSP O
in O
all O
three O
genotypes O
. O
Co-application O
of O
DCG-IV O
and O
LY541850 O
in O
mGlu3-/- O
and O
wild-type O
littermates O
resulted O
in O
an O
additive O
effect O
, O
whereas O
in O
mGlu2-/- O
mice O
, O
LY541850 O
reversed O
the O
inhibitory O
action O
of O
DCG-IV O
. O
These O
results O
confirm O
the O
selective O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
actions O
of O
LY541850 O
. O
A O
similar O
profile O
of O
activity O
was O
seen O
in O
medial O
perforant O
path O
synapse O
to O
the O
dentate O
gyrus O
. O
Systemic O
administration O
of O
LY541850 O
to O
wild-type O
mice O
, O
reduced O
the O
increase O
in O
locomotor O
activity O
following O
both O
phencyclidine O
and O
amphetamine O
administration O
. O
These O
data O
support O
the O
hypothesis O
that O
mGlu2 O
receptors O
mediate O
the O
antipsychotic O
effects O
of O
mixed O
group O
II O
agonists O
. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic O
Glutamate O
Receptors' O
. O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src O
/ERK B
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Pegylated O
recombinant O
human O
arginase O
(rhArg-peg5,000mw) O
inhibits O
the O
in O
vitro O
and O
in O
vivo O
proliferation O
of O
human O
hepatocellular O
carcinoma O
through O
arginine O
depletion.Hepatocellular O
carcinoma O
(HCC) O
is O
believed O
to O
be O
auxotrophic O
for O
arginine O
through O
the O
lack O
of O
expression O
of O
argininosuccinate O
synthetase O
(ASS) O
. O
The O
successful O
use O
of O
the O
arginine-depleting O
enzyme O
arginine O
deiminase O
(ADI) O
to O
treat O
ASS-deficient O
tumors O
has O
opened O
up O
new O
possibilities O
for O
effective O
cancer O
therapy O
. O
Nevertheless O
, O
many O
ASS-positive O
HCC O
cell O
lines O
are O
found O
to O
be O
resistant O
to O
ADI O
treatment O
, O
although O
most O
require O
arginine O
for O
proliferation O
. O
Thus O
far O
, O
an O
arginine-depleting O
enzyme O
for O
killing O
ASS-positive O
tumors O
has O
not O
been O
reported O
. O
Here O
, O
we O
provide O
direct O
evidence O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting B
enzymes I
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O
rhArg O
(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O
Hep3B O
tumor O
cells O
(ASS-positive O
and O
ADI-resistant) O
in O
mice O
was O
inhibited O
by O
treatment O
with O
rhArg-peg(5,000mw) O
, O
which O
is O
active O
alone O
and O
is O
synergistic O
in O
combination O
with O
5-fluorouracil O
. O
Thus O
, O
our O
data O
suggest O
that O
rhArg-peg(5,000mw) O
is O
a O
novel O
agent O
for O
effective O
cancer O
therapy O
. O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Purification O
and O
structural O
characterisation O
of O
phospholipase O
A1 O
(Vespapase O
, O
Ves O
a O
1) O
from O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
venom.The O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
is O
one O
of O
the O
most O
dangerous O
vespid O
species O
in O
Southeast O
Asia O
, O
and O
stinging O
accidents O
involving O
this O
species O
still O
cause O
fatalities O
. O
In O
the O
present O
study O
, O
four O
forms O
of O
V O
. O
affinis O
phospholipase O
A(1) O
were O
identified O
through O
a O
proteomics O
approach O
. O
Two O
of O
these O
enzymes O
were O
purified O
by O
reverse-phase O
chromatography O
, O
and O
their O
biochemical O
properties O
were O
characterised O
. O
These O
enzymes O
, O
designated O
Ves O
a O
1s O
, O
are O
not O
glycoproteins O
and O
exist O
as O
33441.5 O
and O
33474.4 O
Da O
proteins O
, O
which O
corresponded O
with O
the O
34-kDa O
band O
observed O
via O
SDS-PAGE O
. O
The O
thermal O
stabilities O
of O
these O
enzymes O
were O
stronger O
than O
snake O
venom O
. O
Using O
an O
in O
vivo O
assay O
, O
no O
difference O
was O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves O
a O
1s O
revealed O
that O
the O
Ves O
a O
1 O
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves O
a O
1 O
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves B
a I
1 I
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
. O

vanadium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome B
P450 I
1 I
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

123I-3-iodo-6-methoxybenzamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2-receptor O
imaging O
with O
123I-iodobenzamide O
SPECT O
in O
migraine O
patients O
abusing O
ergotamine O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine B
D2-receptor I
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
(123I-IBZM) O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine O
D2-receptor O
binding O
potential O
. O
No O
differences O
were O
found O
in O
striatal O
uptake O
of O
123I-IBZM O
between O
healthy O
controls O
and O
the O
patients O
when O
on O
or O
off O
ergotamine O
. O
Preliminary O
evidence O
suggests O
that O
ergotamine O
may O
not O
occupy O
striatal O
dopamine O
D2-receptors O
to O
a O
large O
extent O
and O
thus O
may O
not O
cross O
the O
blood O
brain O
barrier O
in O
large O
quantities O
. O

pyrano[2,3-b]quinolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
( O
AChE) B
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene B
A(4) I
hydrolase I
.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H O
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases O
, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
(IBD) O
. O

[3H]adenosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 B
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

W13 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Involvement O
of O
EP1 O
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandins O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O
(which O
stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
specific) O
. O
Consistent O
with O
the O
involvement O
of O
Gs O
coupled O
EP2 O
receptors O
, O
is O
that O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKAI O
expression O
vector O
(encoding O
the O
protein O
kinase O
A O
(PKA) O
inhibitory O
protein) O
, O
as O
well O
as O
by O
the O
myristolated O
PKA O
inhibitory O
peptide O
PKI O
. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 O
receptors) O
, O
evidence O
for O
the O
involvement O
of O
EP1 O
receptors O
in O
the O
PGE1 O
mediated O
stimulation O
of O
Na,K-ATPase O
beta O
subunit O
gene O
transcription O
includes O
the O
stimulatory O
effect O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
, O
as O
well O
as O
the O
calmodulin B
antagonists O
W7 O
and O
W13 O
. O

Mn(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K- O
Gal-T1 B
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT O
/ O
DAT B
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

2-chloro-6-methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 O
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human B
COX-2 I
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Auranofin O
, O
as O
an O
anti-rheumatic O
gold O
compound O
, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4.Toll-like O
receptors O
(TLRs) O
, O
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules O
, O
evoke O
immune O
and O
inflammatory O
responses O
. O
TLR O
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB B
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O
pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

PI(4)P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cis-silencing O
of O
PIP5K1B O
evidenced O
in O
Friedreich's O
ataxia O
patient O
cells O
results O
in O
cytoskeleton O
anomalies.Friedreich's O
ataxia O
(FRDA) O
is O
a O
progressive O
neurodegenerative O
disease O
characterized O
by O
ataxia O
, O
variously O
associating O
heart O
disease O
, O
diabetes O
mellitus O
and/or O
glucose O
intolerance O
. O
It O
results O
from O
intronic O
expansion O
of O
GAA O
triplet O
repeats O
at O
the O
FXN O
locus O
. O
Homozygous O
expansions O
cause O
silencing O
of O
the O
FXN O
gene O
and O
subsequent O
decreased O
expression O
of O
the O
encoded O
mitochondrial O
frataxin O
. O
Detailed O
analyses O
in O
fibroblasts O
and O
neuronal O
tissues O
from O
FRDA O
patients O
have O
revealed O
profound O
cytoskeleton O
anomalies O
. O
So O
far O
, O
however O
, O
the O
molecular O
mechanism O
underlying O
these O
cytoskeleton O
defects O
remains O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
( O
pip5k1β) B
 O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O
suppressed O
this O
phenotype O
in O
FRDA O
cells O
. O
In O
addition O
to O
provide O
new O
insights O
into O
the O
consequences O
of O
the O
FXN O
gene O
expansion O
, O
these O
findings O
raise O
the O
question O
whether O
PIP5K1B O
silencing O
may O
contribute O
to O
the O
variable O
manifestation O
of O
this O
complex O
disease O
. O

thiourea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thiourea O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
, O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA O
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB B
. O

2-deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Energy O
depletion O
of O
bovine O
mammary O
epithelial O
cells O
activates O
AMPK O
and O
suppresses O
protein O
synthesis O
through O
inhibition O
of O
mTORC1 O
signaling.The O
molecular O
mechanisms O
by O
which O
cellular O
energy O
status O
regulates O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK O
at O
Thr172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α B
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O
associated O
with O
a O
marked O
increase O
in O
Ser792 O
phosphorylation O
on O
raptor O
. O
Collectively O
, O
the O
results O
suggest O
that O
activation O
of O
AMPK O
represses O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
through O
inhibition O
of O
mTORC1 O
signaling O
. O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
( O
hGSTA4-4) B
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST-4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

adenosine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reduction O
of O
dimethylarsinic O
acid O
to O
the O
highly O
toxic O
dimethylarsinous O
acid O
by O
rats O
and O
rat O
liver O
cytosol.Dimethylarsinic O
acid O
(DMAs(V)) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
(DMAs(III)) O
, O
is O
highly O
toxic O
. O
Although O
glutathione O
S-transferase O
omega O
1 O
(GSTO1) O
and O
arsenic O
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) O
reduction O
, O
their O
role O
in O
DMAs(V) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O
Therefore O
, O
the O
reduction O
of O
DMAs(V) O
to O
DMAs(III) O
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O
To O
assess O
DMAs(V) O
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O
the O
accumulation O
of O
red O
blood O
cell O
(RBC)-bound O
dimethylarsenic O
(DMAs) O
, O
which O
represents O
DMAs(III) O
, O
in O
the O
blood O
of O
DMAs(V)-injected O
anesthetized O
rats O
. O
These O
studies O
indicated O
that O
rats O
reduced O
DMAs(V) O
to O
DMAs(III) O
to O
a O
significant O
extent O
, O
as O
in O
90 O
min O
31% O
of O
the O
injected O
50 O
μmol/kg O
DMAs(V) O
dose O
was O
converted O
to O
DMAs(III) O
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes O
. O
Pretreatment O
of O
rats O
with O
glutathione O
(GSH) O
depletors O
(phorone O
or O
BSO) O
delayed O
the O
elimination O
of O
DMAs(V) O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase B
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
(TRR) O
inhibitors O
(aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O
also O
suggested O
that O
the O
reducing O
enzyme O
was O
larger O
than O
100 O
kDa O
and O
was O
not O
GSTO1 O
. O
In O
summary O
, O
reduction O
of O
DMAs(V) O
to O
the O
highly O
toxic O
DMAs(III) O
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH-dependent O
enzymatic O
process O
, O
yet O
its O
mechanism O
remains O
uncertain O
. O

Dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O
mechanism O
has O
been O
obscured O
by O
its O
instability O
. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC O
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC B
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
[Short O
QT O
syndrome].Short O
QT O
syndrome O
is O
a O
new O
genetic O
disorder O
associated O
with O
familial O
atrial O
fibrillation O
and/or O
sudden O
death O
or O
syncope O
. O
To O
date O
, O
different O
mutations O
in O
genes O
encoding O
for O
cardiac O
ion O
channels O
(KCNH2 O
, O
KCNQ1 O
, O
and O
KCNJ2) O
have O
been O
identified O
to O
cause O
the O
short O
QT O
syndrome O
. O
The O
mutations O
lead O
to O
a O
gain O
of O
function O
of O
the O
affected O
current O
(IKr O
, O
IKs O
, O
and O
IK1) O
. O
The O
phenotype O
is O
characterized O
by O
a O
shortened O
QT O
interval<335 O
ms O
after O
correction O
for O
heart O
rate O
at O
rates<80 O
beats/min O
. O
Furthermore O
, O
the O
QT O
interval O
poorly O
adapts O
to O
heart O
rate O
. O
Patients O
exhibit O
shortened O
atrial O
and O
ventricular O
effective O
refractory O
periods O
and O
, O
in O
the O
majority O
, O
inducibility O
of O
ventricular O
fibrillation O
. O
Death O
occurs O
already O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
( O
HERG) B
 O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O
of O
mibefradil O
with O
inactivated O
Nav1.5 O
channels O
. O
Neither O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
( O
Nav1.5 B
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O
state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O
mV O
, O
mibefradil O
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 O
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) O
that O
slow-inactivates O
more O
completely O
. O
Our O
results O
suggest O
that O
mibefradil O
blocks O
Na+ O
channels O
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s) O
. O

[(3)H] O
dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human B
dopamine I
transporter I
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

D-Serine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Mouse O
brain O
serine O
racemase O
catalyzes O
specific O
elimination O
of O
L-serine O
to O
pyruvate.D-Serine O
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' O
site O
of O
the O
N-methyl-D-aspartate B
(NMDA)-type I
receptors I
. O
Racemization O
of O
serine O
is O
catalyzed O
by O
serine O
racemase O
, O
a O
pyridoxal O
5'-phosphate-dependent O
enzyme O
expressed O
mainly O
in O
brain O
and O
liver O
. O
NMDA O
receptor O
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine O
racemase O
are O
thus O
potentially O
interesting O
targets O
for O
therapy O
. O
We O
expressed O
recombinant O
mouse O
serine O
racemase O
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity O
. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+) O
, O
Ca(2+) O
or O
Mn(2+) O
for O
activity O
but O
not O
for O
dimerization O
. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O
of O
L-Ser O
to O
pyruvate O
. O
D-Serine O
is O
eliminated O
much O
less O
efficiently O
. O
Both O
L-serine O
racemization O
and O
elimination O
activities O
of O
serine O
racemase O
are O
of O
comparable O
magnitude O
, O
display O
alkaline O
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5 O
. O

capecitabine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme O
expression O
profiles O
suggest O
the O
novel O
tumor-activated O
fluoropyrimidine O
carbamate O
capecitabine O
(Xeloda) O
might O
be O
effective O
against O
papillary O
thyroid O
cancers O
of O
children O
and O
young O
adults.PURPOSE O
: O
The O
fluoropyrimidine O
carbamate O
(capecitabine) O
is O
converted O
to O
5-fluorouracil O
(5-FU) O
by O
thymidine B
phosphorylase I
(TP) O
inside O
target O
tissues O
. O
5-FU O
interferes O
with O
DNA O
synthesis O
by O
blocking O
thymidylate O
synthase O
(TS) O
but O
is O
inactivated O
by O
dihydropyrimidine O
dehydrogenase O
(DPD) O
. O
Favorable O
enzyme O
profiles O
(high O
TP O
and O
low O
DPD) O
generate O
high O
intratumor O
levels O
of O
5-FU O
that O
are O
effective O
against O
many O
tumors O
, O
especially O
those O
with O
low O
TS O
. O
Capecitabine O
has O
not O
been O
tested O
against O
thyroid O
cancers O
, O
and O
it O
is O
not O
known O
to O
what O
extent O
thyroid O
cancers O
express O
TP O
, O
TS O
or O
DPD O
. O
METHODS O
: O
To O
test O
this O
, O
we O
determined O
TP O
, O
TS O
and O
DPD O
in O
19 O
thyroid O
cancers O
from O
young O
patients O
(14 O
papillary O
, O
4 O
follicular O
, O
1 O
medullary) O
by O
immunohistochemistry O
. O
After O
approval O
by O
the O
Human O
Use O
Committee O
, O
the O
intensity O
of O
TP O
, O
TS O
, O
and O
DPD O
staining O
was O
determined O
by O
two O
independent O
examiners O
and O
graded O
(absent=0 O
to O
intense=3) O
with O
>90% O
concordance O
. O
RESULTS O
: O
TS O
was O
detected O
in O
7/19 O
cancers O
(37%) O
, O
TP O
in O
14/19 O
cancers O
(74%) O
and O
DPD O
in O
14/19 O
cancers O
(74%) O
. O
In O
six O
tumors O
, O
TP O
was O
more O
intense O
that O
DPD O
, O
suggesting O
capecitabine O
sensitivity O
. O
Only O
five O
tumors O
failed O
to O
express O
TP O
but O
four O
of O
these O
expressed O
DPD O
, O
suggesting O
capecitabine O
resistance O
. O
Overall O
, O
6/19 O
tumors O
(32% O
of O
the O
total) O
had O
a O
favorable O
expression O
profile O
, O
and O
all O
of O
them O
were O
papillary O
cancers O
. O
CONCLUSIONS O
: O
We O
conclude O
that O
the O
majority O
of O
differentiated O
thyroid O
cancers O
(74%) O
express O
TP O
and O
low O
levels O
of O
TS O
(63% O
undetectable) O
. O
The O
results O
support O
the O
hypothesis O
that O
capecitabine O
is O
activated O
in O
the O
majority O
of O
differentiated O
thyroid O
cancers O
and O
that O
32% O
have O
favorable O
expression O
of O
all O
three O
enzymes O
(TP O
, O
TS O
, O
and O
DPD) O
. O

5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NHE3 O
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat.We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ O
exchange O
(NHE) O
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation O
. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
, O
significantly O
increased O
DBS O
. O
Moreover O
, O
S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affecting O
intracellular O
pH O
. O
Coperfusion O
with O
0.1 O
microM O
indomethacin O
, O
0.5 O
mM O
DIDS O
, O
or O
1 O
mM O
methazolamide O
did O
not O
affect O
S3226-induced O
DBS O
. O
Nevertheless O
, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
( O
CFTR) B
 O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O
formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O
by O
altering O
anion O
transporter O
function O
. O

troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 B
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Rosmarinic O
acid O
ameliorates O
acute O
liver O
damage O
and O
fibrogenesis O
in O
carbon O
tetrachloride-intoxicated O
mice.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
therapeutic O
potential O
of O
rosmarinic O
acid O
(RA) O
, O
a O
natural O
phenolic O
, O
in O
the O
treatment O
of O
acute O
liver O
toxicity O
. O
RA O
at O
10 O
, O
25 O
and O
50mg/kg O
was O
administered O
by O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear B
factor-kappaB I
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O
growth O
factor-beta1 O
(TGF-β1) O
and O
alpha-smooth O
muscle O
actin O
(α-SMA) O
expression O
, O
suggesting O
suppression O
of O
profibrotic O
response O
. O
Furthermore O
, O
RA O
significantly O
inhibited O
the O
CCl(4)-induced O
apoptosis O
, O
which O
was O
evident O
from O
decreased O
cleavage O
of O
caspase-3 O
. O
The O
hepatoprotective O
activity O
of O
RA O
coincided O
with O
enhanced O
NF-E2-related O
factor O
2 O
(Nrf2) O
and O
heme O
oxygenase-1 O
(HO-1) O
expression O
. O
The O
results O
of O
this O
study O
indicates O
that O
RA O
possesses O
antioxidant O
, O
anti-inflammatory O
, O
antiapoptotic O
and O
antifibrotic O
activity O
against O
acute O
liver O
toxicity O
. O

ethanol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxone O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
(CREB) O
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v) O
, O
for O
one O
month O
. O
Changes O
in O
the O
levels O
of O
CREB O
and O
phospho-CREB O
(p-CREB) O
protein O
in O
the O
nucleus O
accumbens O
were O
measured O
by O
immunohistochemistry O
methods O
. O
RESULTS O
: O
Ethanol O
given O
to O
rats O
in O
drinking O
water O
decreased O
the O
level O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(-75 O
%) O
at O
the O
time O
of O
exposure O
to O
ethanol O
. O
The O
decrement O
of O
p-CREB B
protein O
in O
the O
nucleus O
accumbens O
remained O
at O
24 O
h O
(-35 O
%) O
and O
72 O
h O
(-28 O
%) O
of O
ethanol O
withdrawal O
, O
which O
recovered O
toward O
control O
level O
after O
7 O
d O
of O
ethanol O
withdrawal O
. O
However O
, O
chronic O
ethanol O
, O
as O
well O
as O
ethanol O
withdrawal O
failed O
to O
produce O
any O
significant O
alteration O
in O
the O
level O
of O
CREB O
protein O
in O
the O
nucleus O
accumbens O
. O
Naloxone O
(alone) O
treatment O
of O
rats O
had O
no O
effect O
on O
the O
levels O
of O
CREB O
and O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
. O
However O
, O
when O
naloxone O
was O
administered O
concurrently O
with O
ethanol O
treatment O
, O
it O
antagonized O
the O
down-regulation O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(142 O
%) O
of O
rats O
exposed O
to O
ethanol O
. O
CONCLUSION O
: O
A O
long-term O
intake O
of O
ethanol O
solution O
down-regulates O
the O
phosphorylation O
of O
CREB O
in O
the O
nucleus O
accumbens O
, O
and O
those O
changes O
can O
be O
reversed O
by O
naloxone O
, O
which O
may O
be O
one O
kind O
of O
the O
molecular O
mechanisms O
associated O
with O
ethanol O
dependence O
. O

cetirizine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Compared O
pharmacological O
characteristics O
in O
humans O
of O
racemic O
cetirizine O
and O
levocetirizine O
, O
two O
histamine O
H1-receptor O
antagonists.The O
potent O
histamine B
H(1)-receptor I
antagonist O
cetirizine O
(Zyrtec) O
is O
a O
racemic O
mixture O
of O
levocetirizine O
(now O
available O
under O
the O
trademark O
Xyzal O
and O
dextrocetirizine O
. O
In O
this O
Commentary O
, O
we O
examine O
some O
biological O
properties O
of O
cetirizine O
and O
levocetirizine O
, O
namely O
enantioselectivity O
in O
pharmacological O
activity O
and O
pharmacokinetic O
properties O
, O
with O
emphasis O
on O
the O
possibility O
of O
racemization O
, O
the O
compared O
behavior O
of O
the O
two O
enantiomers O
, O
and O
the O
potential O
for O
interactions O
with O
other O
drugs O
. O
Recent O
data O
demonstrate O
that O
the O
antihistaminergic O
activity O
of O
the O
racemate O
is O
primarily O
due O
to O
levocetirizine O
. O
Levocetirizine O
is O
rapidly O
and O
extensively O
absorbed O
, O
poorly O
metabolized O
, O
and O
not O
subject O
to O
racemization O
. O
Its O
pharmacokinetic O
characteristics O
are O
comparable O
after O
administration O
alone O
or O
in O
the O
racemate O
. O
Its O
apparent O
volume O
of O
distribution O
is O
smaller O
than O
that O
of O
dextrocetirizine O
(0.41 O
L O
kg(-1) O
vs O
. O
0.60 O
L O
kg(-1)) O
. O
Moreover O
, O
the O
non-renal O
(mostly O
hepatic) O
clearance O
of O
levocetirizine O
is O
also O
significantly O
lower O
than O
that O
of O
dextrocetirizine O
(11.8 O
mL O
min(-1) O
vs O
. O
29.2 O
mL O
min(-1)) O
. O
Our O
conclusion O
is O
that O
levocetirizine O
is O
indeed O
the O
eutomer O
of O
cetirizine O
. O
The O
evidence O
reviewed O
here O
confirms O
preclinical O
findings O
and O
offers O
a O
rationale O
for O
the O
chiral O
switch O
from O
the O
racemate O
to O
levocetirizine O
. O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 B
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

BM O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Species-specific O
differences O
in O
the O
glucocorticoid O
receptor O
transactivation O
function O
upon O
binding O
with O
betamethasone-esters.Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases O
. O
A O
number O
of O
adverse O
side O
effects O
, O
however O
, O
limit O
chronic O
treatment O
with O
GCs O
. O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat B
GR I
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O
involution O
and O
body O
weight O
loss O
, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats O
. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM O
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O
in O
receptor O
binding O
. O

CPPHA O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
A O
novel O
metabotropic O
glutamate O
receptor O
5 O
positive O
allosteric O
modulator O
acts O
at O
a O
unique O
site O
and O
confers O
stimulus O
bias O
to O
mGlu5 O
signaling.Metabotropic O
glutamate O
receptor O
5 O
(mGlu5) O
is O
a O
target O
for O
the O
treatment O
of O
central O
nervous O
system O
(CNS) O
disorders O
, O
such O
as O
schizophrenia O
and O
Alzheimer's O
disease O
. O
Furthermore O
, O
mGlu5 O
has O
been O
shown O
to O
play O
an O
important O
role O
in O
hippocampal O
synaptic O
plasticity O
, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O
PAMs O
may O
have O
similar O
responses O
in O
some O
systems O
, O
they O
can O
induce O
differential O
effects O
on O
mGlu5-mediated O
physiologic O
responses O
in O
the O
CNS O
. O
Such O
stimulus O
bias O
by O
mGlu5 O
PAMs O
may O
complicate O
drug O
discovery O
efforts O
but O
would O
also O
allow O
for O
specifically O
tailored O
therapies O
, O
if O
pharmacological O
biases O
can O
be O
attributed O
to O
different O
therapeutic O
outcomes O
. O

remikiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pretreatment O
renal O
vascular O
tone O
predicts O
the O
effect O
of O
specific O
renin O
inhibition O
on O
natriuresis O
in O
essential O
hypertension.BACKGROUND O
: O
In O
essential O
hypertension O
an O
elevated O
renal O
vascular O
resistance O
(RVR) O
may O
be O
a O
marker O
of O
renin-angiotensin-aldosterone O
system-mediated O
impairment O
of O
renal O
sodium O
excretion O
. O
This O
hypothesis O
was O
tested O
by O
investigating O
whether O
, O
in O
subjects O
with O
essential O
hypertension O
, O
the O
natriuretic O
response O
to O
specific O
renin- O
angiotensin- B
aldosterone O
system O
(RAAS) O
blockade O
by O
renin-inhibitor O
remikiren O
could O
be O
predicted O
from O
pretreatment O
renal O
vascular O
tone O
. O
MATERIALS O
AND O
METHODS O
: O
Renal O
hemodynamics O
, O
and O
the O
effects O
of O
single O
(n O
= O
17) O
and O
multiple O
doses O
(n O
= O
8 O
, O
8 O
days) O
of O
remikiren O
(600 O
mg O
day-1) O
on O
sodium O
excretion O
were O
studied O
under O
conditions O
of O
carefully O
controlled O
sodium O
balance O
. O
RESULTS O
: O
Pretreatment O
renal O
vascular O
tone O
showed O
considerable O
individual O
differences O
: O
filtration O
fraction O
(FF) O
ranged O
from O
21.2 O
to O
30.3% O
and O
RVR O
from O
18.8 O
to O
33.5 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
single O
dose O
study O
, O
and O
FF O
from O
20.8 O
to O
24.9% O
and O
RVR O
from O
14.8 O
to O
28.8 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
multiple O
dose O
study O
. O
Remikiren O
induced O
a O
fall O
in O
blood O
pressure O
, O
FF O
and O
RVR O
, O
with O
considerable O
interindividual O
variability O
in O
natriuretic O
response O
. O
During O
single O
dose O
, O
cumulative O
sodium O
loss O
was O
5.1 O
mmol O
per O
5 O
h O
(-8.8 O
to O
+24.6) O
, O
whereas O
after O
8 O
days O
treatment O
cumulative O
sodium O
loss O
was O
72 O
+/- O
30 O
mmol O
(-46 O
to O
+187) O
. O
The O
natriuretic O
response O
to O
remikiren O
during O
single O
as O
well O
as O
multiple O
dose O
significantly O
correlated O
with O
pretreatment O
renal O
vascular O
tone O
(estimated O
from O
FF O
and O
RVR) O
but O
not O
with O
remikiren-induced O
changes O
in O
renal O
hemodynamics O
or O
in O
hormonal O
parameters O
. O
Cumulative O
sodium O
loss O
was O
largest O
in O
patients O
with O
a O
higher O
pretreatment O
FF O
and O
RVR O
(r O
= O
0.74 O
, O
P O
< O
0.001 O
and O
r O
= O
0.52 O
, O
P O
< O
0.05 O
, O
respectively O
, O
single O
dose; O
and O
r O
= O
0.75 O
, O
P O
< O
0.05 O
and O
r O
= O
0.73 O
, O
P O
< O
0.05 O
, O
respectively O
, O
multiple O
dose) O
. O
CONCLUSION O
: O
These O
data O
support O
the O
hypothesis O
that O
in O
essential O
hypertension O
an O
elevated O
renal O
vascular O
tone O
is O
a O
marker O
of O
RAAS-mediated O
impairment O
of O
sodium O
excretion O
. O

telmisartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
A O
systematic O
comparison O
of O
the O
properties O
of O
clinically O
used O
angiotensin O
II O
type O
1 O
receptor O
antagonists.Angiotensin O
II O
type O
1 O
receptor O
antagonists O
(ARBs) O
have O
become O
an O
important O
drug O
class O
in O
the O
treatment O
of O
hypertension O
and O
heart O
failure O
and O
the O
protection O
from O
diabetic O
nephropathy O
. O
Eight O
ARBs O
are O
clinically O
available O
[azilsartan O
, O
candesartan O
, O
eprosartan O
, O
irbesartan O
, O
losartan O
, O
olmesartan O
, O
telmisartan O
, O
valsartan] O
. O
Azilsartan O
(in O
some O
countries) O
, O
candesartan O
, O
and O
olmesartan O
are O
orally O
administered O
as O
prodrugs O
, O
whereas O
the O
blocking O
action O
of O
some O
is O
mediated O
through O
active O
metabolites O
. O
On O
the O
basis O
of O
their O
chemical O
structures O
, O
ARBs O
use O
different O
binding O
pockets O
in O
the O
receptor O
, O
which O
are O
associated O
with O
differences O
in O
dissociation O
times O
and O
, O
in O
most O
cases O
, O
apparently O
insurmountable O
antagonism O
. O
The O
physicochemical O
differences O
between O
ARBs O
also O
manifest O
in O
different O
tissue O
penetration O
, O
including O
passage O
through O
the O
blood-brain O
barrier O
. O
Differences O
in O
binding O
mode O
and O
tissue O
penetration O
are O
also O
associated O
with O
differences O
in O
pharmacokinetic O
profile O
, O
particularly O
duration O
of O
action O
. O
Although O
generally O
highly O
specific O
for O
angiotensin B
II I
type I
1 I
receptors I
, O
some O
ARBs O
, O
particularly O
telmisartan O
, O
are O
partial O
agonists O
at O
peroxisome O
proliferator-activated O
receptor-γ O
. O
All O
of O
these O
properties O
are O
comprehensively O
reviewed O
in O
this O
article O
. O
Although O
there O
is O
general O
consensus O
that O
a O
continuous O
receptor O
blockade O
over O
a O
24-hour O
period O
is O
desirable O
, O
the O
clinical O
relevance O
of O
other O
pharmacological O
differences O
between O
individual O
ARBs O
remains O
to O
be O
assessed O
. O

dioscin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Dioscin-induced O
autophagy O
mitigates O
cell O
apoptosis O
through O
modulation O
of O
PI3K/Akt O
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines.Our O
previous O
study O
has O
revealed O
that O
dioscin O
, O
a O
compound O
with O
anti-inflammatory O
, O
lipid-lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O
that O
is O
essential O
for O
cell O
survival O
and O
tissue O
homeostasis O
. O
In O
this O
study O
, O
the O
role O
of O
autophagy O
and O
related O
signaling O
pathways O
during O
dioscin-induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O
Results O
from O
4'-6-diamidino-2-phenylindole O
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- O
and O
caspase-8-dependent O
, O
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O
dioscin O
treatment O
. O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II B
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

PAH O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
EROD O
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic O
aromatic O
hydrocarbons.Little O
is O
known O
in O
terms O
of O
multi-matrix O
cytochrome B
P450 I
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
(PHH O
, O
PAH) O
. O
In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene O
, O
pyrene O
and O
benzo(a)pyrene O
at O
0 O
, O
6 O
or O
600μg/day O
. O
EROD O
activity O
, O
reflecting O
almost O
exclusively O
CYP1A1 O
and O
CYP1B1 O
activities O
, O
was O
measured O
in O
brain O
and O
liver O
microsomes O
as O
well O
as O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
All O
induction O
kinetics O
could O
be O
appropriately O
fitted O
using O
logistic-like O
models O
. O
After O
28days O
of O
exposure O
to O
a O
6μg/day O
dose O
, O
EROD O
activity O
was O
found O
to O
be O
91 O
, O
152 O
and O
94-fold O
increased O
in O
lymphocytes O
, O
liver O
and O
brain O
, O
respectively O
, O
compared O
to O
day O
0 O
. O
Plateau O
activities O
could O
be O
appropriately O
fitted O
versus O
ingested O
doses O
using O
Hill O
or O
Michaelis-Menten O
models O
. O
Correlations O
between O
matrices O
made O
it O
possible O
to O
conclude O
that O
EROD O
activity O
in O
PBL O
should O
be O
considered O
as O
a O
sensitive O
, O
convenient O
and O
non-destructive O
approach O
for O
(i) O
evaluating O
EROD O
activity O
in O
liver O
, O
which O
was O
found O
to O
represent O
98% O
of O
the O
observed O
EROD O
activities O
in O
the O
three O
tested O
matrices O
and O
(ii) O
evaluating O
oral O
exposure O
of O
homogeneous O
groups O
of O
farm O
animals O
(race O
, O
diet) O
to O
CYP O
inducing O
PAH O
and O
PHH O
. O

quinine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cloning O
, O
functional O
expression O
and O
brain O
localization O
of O
a O
novel O
unconventional O
outward O
rectifier O
K+ O
channel.Human O
TWIK-1 O
, O
which O
has O
been O
cloned O
recently O
, O
is O
a O
new O
structural O
type O
of O
weak O
inward O
rectifier O
K+ O
channel O
. O
Here O
we O
report O
the O
structural O
and O
functional O
properties O
of O
TREK-1 O
, O
a O
mammalian O
TWIK-1-related O
K+ O
channel O
. O
Despite O
a O
low O
amino O
acid O
identity O
between O
TWIK-1 O
and O
TREK-1 O
(approximately O
28%) O
, O
both O
channel O
proteins O
share O
the O
same O
overall O
structural O
arrangement O
consisting O
of O
two O
pore-forming O
domains O
and O
four O
transmembrane O
segments O
(TMS) O
. O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 O
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 B
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O
been O
studied O
by O
in O
situ O
hybridization O
. O
TREK-1 O
expression O
is O
high O
in O
the O
olfactory O
bulb O
, O
hippocampus O
and O
cerebellum O
. O
These O
results O
provide O
the O
first O
evidence O
for O
the O
existence O
of O
a O
K+ O
channel O
family O
with O
four O
TMS O
and O
two O
pore O
domains O
in O
the O
nervous O
system O
of O
mammals O
. O
They O
also O
show O
that O
different O
members O
in O
this O
structural O
family O
can O
have O
totally O
different O
functional O
properties O
. O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
5-HT1B O
receptors O
, O
alpha2A/2C- O
and O
, O
to O
a O
lesser O
extent O
, O
alpha1-adrenoceptors O
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow O
. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v O
. O
bolus O
injection O
of O
, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control) O
, O
or O
the O
antagonists O
SB224289 O
(300 O
microg/kg; O
5-HT1B) O
, O
BRL15572 O
(300 O
microg/kg; O
5-HT1D) O
, O
rauwolscine O
(300 O
microg/kg; O
alpha2) O
, O
SB224289 O
+ O
BRL15572 O
(300 O
microg/kg O
each) O
, O
SB224289 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
BRL15572 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg; O
alpha1) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
BRL44408 O
(1,000 O
microg/kg; O
alpha2A) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg)+ O
imiloxan O
(1,000 O
microg/kg; O
alpha2B) O
, O
or O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
MK912 O
(300 O
microg/kg; O
alpha2C) O
. O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine O
(0.56 O
, O
1 O
, O
1.8 O
, O
3.1 O
, O
5.6 O
, O
10 O
and O
18 O
microg/min) O
, O
following O
a O
cumulative O
schedule O
. O
In O
saline-pretreated O
animals O
, O
ergotamine O
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate O
. O
These O
control O
responses O
were O
: O
unaffected O
by O
SB224289 O
, O
BRL15572 O
, O
rauwolscine O
or O
the O
combinations O
of O
SB224289 O
+ O
BRL15572 O
, O
BRL15572 O
+ O
rauwolscine O
, O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
, O
or O
SB224289 O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B B
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors O
. O

TAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2 B
/ O
SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR B
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

(S)-naproxen-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 B
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
( O
AKRs) B
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

kinsenoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
vascular O
protective O
properties O
of O
kinsenoside O
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose O
condition.Anoectochilus O
roxburghii O
is O
a O
traditional O
Chinese O
herb O
used O
for O
the O
treatment O
of O
diabetes O
and O
some O
other O
diseases O
. O
The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix B
metalloproteinases- I
the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes-related O
changes O
in O
mice O
aortas O
after O
kinsenoside O
(20 O
and O
50μg/mL) O
treatment O
. O
These O
results O
indicated O
that O
kinsenoside O
might O
be O
a O
promising O
agent O
for O
the O
treatment O
of O
diabetic O
vascular O
disease O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 B
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 B
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

Gly O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
( O
GDC B
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

remikiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pretreatment O
renal O
vascular O
tone O
predicts O
the O
effect O
of O
specific O
renin O
inhibition O
on O
natriuresis O
in O
essential O
hypertension.BACKGROUND O
: O
In O
essential O
hypertension O
an O
elevated O
renal O
vascular O
resistance O
(RVR) O
may O
be O
a O
marker O
of O
renin-angiotensin-aldosterone O
system-mediated O
impairment O
of O
renal O
sodium O
excretion O
. O
This O
hypothesis O
was O
tested O
by O
investigating O
whether O
, O
in O
subjects O
with O
essential O
hypertension O
, O
the O
natriuretic O
response O
to O
specific O
renin-angiotensin-aldosterone O
system O
(RAAS) O
blockade O
by O
renin- B
inhibitor O
remikiren O
could O
be O
predicted O
from O
pretreatment O
renal O
vascular O
tone O
. O
MATERIALS O
AND O
METHODS O
: O
Renal O
hemodynamics O
, O
and O
the O
effects O
of O
single O
(n O
= O
17) O
and O
multiple O
doses O
(n O
= O
8 O
, O
8 O
days) O
of O
remikiren O
(600 O
mg O
day-1) O
on O
sodium O
excretion O
were O
studied O
under O
conditions O
of O
carefully O
controlled O
sodium O
balance O
. O
RESULTS O
: O
Pretreatment O
renal O
vascular O
tone O
showed O
considerable O
individual O
differences O
: O
filtration O
fraction O
(FF) O
ranged O
from O
21.2 O
to O
30.3% O
and O
RVR O
from O
18.8 O
to O
33.5 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
single O
dose O
study O
, O
and O
FF O
from O
20.8 O
to O
24.9% O
and O
RVR O
from O
14.8 O
to O
28.8 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
multiple O
dose O
study O
. O
Remikiren O
induced O
a O
fall O
in O
blood O
pressure O
, O
FF O
and O
RVR O
, O
with O
considerable O
interindividual O
variability O
in O
natriuretic O
response O
. O
During O
single O
dose O
, O
cumulative O
sodium O
loss O
was O
5.1 O
mmol O
per O
5 O
h O
(-8.8 O
to O
+24.6) O
, O
whereas O
after O
8 O
days O
treatment O
cumulative O
sodium O
loss O
was O
72 O
+/- O
30 O
mmol O
(-46 O
to O
+187) O
. O
The O
natriuretic O
response O
to O
remikiren O
during O
single O
as O
well O
as O
multiple O
dose O
significantly O
correlated O
with O
pretreatment O
renal O
vascular O
tone O
(estimated O
from O
FF O
and O
RVR) O
but O
not O
with O
remikiren-induced O
changes O
in O
renal O
hemodynamics O
or O
in O
hormonal O
parameters O
. O
Cumulative O
sodium O
loss O
was O
largest O
in O
patients O
with O
a O
higher O
pretreatment O
FF O
and O
RVR O
(r O
= O
0.74 O
, O
P O
< O
0.001 O
and O
r O
= O
0.52 O
, O
P O
< O
0.05 O
, O
respectively O
, O
single O
dose; O
and O
r O
= O
0.75 O
, O
P O
< O
0.05 O
and O
r O
= O
0.73 O
, O
P O
< O
0.05 O
, O
respectively O
, O
multiple O
dose) O
. O
CONCLUSION O
: O
These O
data O
support O
the O
hypothesis O
that O
in O
essential O
hypertension O
an O
elevated O
renal O
vascular O
tone O
is O
a O
marker O
of O
RAAS-mediated O
impairment O
of O
sodium O
excretion O
. O

tetrahydropyrazolopyridinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PF-04859989 O
as O
a O
template O
for O
structure-based O
drug O
design O
: O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT B
II I
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole O
analogs O
, O
with O
a O
k(inact)/K(i) O
value O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O
8.53 O
. O
The O
X-ray O
crystal O
structure O
of O
20 O
with O
KAT O
II O
demonstrates O
key O
features O
that O
contribute O
to O
this O
remarkable O
potency O
and O
binding O
efficiency O
. O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC B
4.1.1.15) I
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 B
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
( O
TS) B
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O
study O
, O
we O
used O
immunohistochemistry O
to O
investigate O
the O
expression O
of O
TK-1 O
and O
TS O
in O
various O
types O
of O
cancer O
. O
TK-1 O
and O
TS O
expression O
was O
markedly O
different O
between O
cancer O
types O
. O
High O
TK-1 O
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS O
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
. O
In O
non-small O
cell O
lung O
cancers O
, O
high O
TK-1 O
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas O
, O
but O
not O
in O
adenocarcinomas O
. O
This O
result O
suggests O
that O
TAS-102 O
efficacy O
and O
the O
pyrimidine O
synthetic O
pathway O
may O
differ O
depending O
on O
histological O
type O
. O
Our O
results O
indicate O
that O
administration O
of O
TAS-102 O
could O
be O
selected O
on O
the O
basis O
of O
the O
immunohistochemical O
evaluation O
of O
TK-1 O
and O
TS O
. O

DHP O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC B
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

captopril O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase O
A O
(MMP-2 B
) O
by O
batimastat O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril O
, O
on O
metalloproteinase O
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro O
, O
and O
on O
local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice O
. O
The O
effect O
of O
BB-94 O
and O
captopril O
on O
the O
survival O
of O
the O
3LL-tumor-bearing O
mice O
was O
also O
examined O
. O
Here O
we O
report O
that O
captopril O
treatment O
resulted O
in O
decreased O
transcription O
and O
protein O
levels O
of O
gelatinase O
A O
by O
3LL O
cells O
. O
Both O
BB-94 O
and O
captopril O
also O
prevented O
substrate O
degradation O
by O
gelatinase O
A O
and O
B O
released O
in O
conditioned O
medium O
by O
cultured O
cells O
. O
Treatment O
of O
tumor-bearing O
animals O
with O
BB-94 O
(i.p.) O
or O
captopril O
(in O
drinking O
water) O
resulted O
in O
significant O
inhibition O
of O
the O
mean O
tumor O
volume O
(25 O
and O
33% O
respectively) O
and O
of O
the O
mean O
lung O
metastasis O
number O
(26 O
and O
29% O
respectively) O
. O
When O
both O
agents O
were O
given O
, O
they O
acted O
in O
synergy O
, O
resulting O
in O
51 O
and O
80% O
inhibition O
of O
tumor O
growth O
and O
metastasis O
. O
The O
survival O
time O
of O
the O
mice O
treated O
with O
both O
BB-94 O
and O
captopril O
was O
also O
significantly O
longer O
compared O
with O
the O
groups O
treated O
with O
each O
agent O
alone O
or O
with O
the O
vehicle O
. O
Our O
data O
support O
the O
hypothesis O
of O
an O
essential O
role O
of O
metalloproteinase(s) O
in O
the O
metastatic O
process O
. O
Moreover O
, O
blockade O
of O
invasion O
, O
angiogenesis O
and O
other O
processes O
mediated O
by O
metalloproteinases O
may O
underlie O
the O
anti-tumor O
and O
anti-metastatic O
effect O
of O
BB-94 O
and O
captopril O
and O
their O
combination O
. O
It O
is O
conceivable O
that O
this O
combination O
could O
be O
tested O
in O
selected O
clinical O
conditions O
as O
an O
adjuvant O
modality O
to O
cytotoxic O
therapy O
. O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
( O
COX) B
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O
E O
synthase-1 O
, O
and O
EP(1) O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O
treated O
with O
COX O
inhibitors O
. O
This O
study O
suggests O
that O
PGE(2) O
is O
important O
for O
MB O
growth O
and O
that O
therapies O
targeting O
the O
prostanoid O
metabolic O
pathway O
are O
potentially O
beneficial O
and O
should O
be O
tested O
in O
clinical O
settings O
for O
treatment O
of O
children O
with O
MB O
. O

D-1997 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
2-(2-Aminoethyl)-quinoline O
(D-1997) O
: O
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like O
receptors O
in O
the O
canine O
basilar O
artery.This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline O
derivative O
, O
2-(2-aminoethyl)-quinoline O
(D-1997) O
, O
in O
the O
canine O
isolated O
basilar O
artery O
. O
For O
comparison O
, O
the O
effects O
of O
D-1997 O
were O
also O
evaluated O
on O
rat O
aorta O
. O
Canine O
basilar O
artery O
and O
rat O
aortic O
rings O
were O
prepared O
and O
mounted O
in O
organ O
baths O
to O
record O
isometric O
tension O
changes O
. O
The O
contractile O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
compared O
with O
those O
produced O
by O
5-hydroxytryptamine O
(5-HT) O
and O
the O
5-HT O
receptor O
agonist O
quipazine O
. O
Thus O
, O
4-HT O
(10(-10)-10(-6)M) O
, O
D-1997 O
(3.1 O
x O
10(-8)-10(-4) O
M) O
and O
quipazine O
(3.1 O
x O
10(-7)-10(-4) O
M) O
each O
caused O
concentration-dependent O
contractions O
of O
the O
canine O
basilar O
artery O
with O
a O
rank O
order O
of O
agonist O
potency O
of O
5-HT O
> O
D-1997 O
> O
quipazine O
. O
5-HT O
and O
D-1997 O
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like B
receptors I
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K- O
Gal-T1) B
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase O
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
(SCH O
900229) O
, O
a O
potent O
, O
PS1- B
selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Norethisterone O
metabolites O
modulate O
the O
uteroglobin O
and O
progesterone O
receptor O
gene O
expression O
in O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin B
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

apomorphine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 B
receptors I
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
monoamine O
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia O
. O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT B
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

sibutramine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O
4.1-fold O
increase O
in O
the O
AUC O
in O
S-enantiomer O
and O
1.8-fold O
versus O
2.0-fold O
for O
the O
R-enantiomer O
, O
respectively O
. O
The O
AUCs O
of O
S- O
and O
R-desmethyl O
metabolites O
changed O
significantly O
during O
the O
clopidogrel O
phase O
(P O
< O
.001 O
and O
P O
< O
.001 O
, O
respectively) O
but O
not O
during O
the O
clarithromycin O
phase O
(P O
= O
.099 O
and O
P O
= O
.090 O
, O
respectively) O
. O
Exposure O
to O
sibutramine O
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 O
genotypes O
. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine O
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 B
and O
CYP3A O
activity O
in O
vivo O
. O

Betaxolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
, O
reduces O
Na(+) O
influx O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) O
channels O
: O
comparison O
with O
other O
beta-adrenoceptor O
antagonists.Betaxolol O
, O
a O
beta(1)-adrenoceptor B
antagonist O
used O
for O
the O
treatment O
of O
glaucoma O
, O
is O
known O
to O
be O
neuroprotective O
in O
paradigms O
of O
ischaemia/excitotoxicity O
. O
In O
this O
study O
, O
we O
examined O
whether O
betaxolol O
and O
other O
beta-adrenoceptor O
antagonists O
interact O
directly O
with O
neurotoxin O
binding O
to O
sites O
1 O
and O
2 O
of O
the O
voltage-sensitive O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM O
. O
Comparison O
of O
all O
the O
beta-adrenoceptor O
antagonists O
tested O
revealed O
a O
potency O
order O
of O
propranolol>betaxolol O
approximately O
levobetaxolol>levobunolol O
approximately O
carteolol>/=timolol>atenolol O
. O
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin O
binding O
to O
neurotoxin O
receptor O
site O
1 O
, O
even O
at O
concentrations O
as O
high O
as O
250 O
microM O
. O
Saturation O
experiments O
showed O
that O
betaxolol O
increased O
the O
K(D) O
of O
[(3)H]-BTX-B O
binding O
but O
had O
no O
effect O
on O
the O
B(max) O
. O
The O
association O
kinetics O
of O
[(3)H]-BTX-B O
were O
unaffected O
by O
betaxolol O
, O
but O
the O
drug O
significantly O
accelerated O
the O
dissociation O
rate O
of O
the O
radioligand O
. O
These O
findings O
argue O
for O
a O
competitive O
, O
indirect O
, O
allosteric O
mode O
of O
inhibition O
of O
[(3)H]-BTX-B O
binding O
by O
betaxolol O
. O
Betaxolol O
inhibited O
veratridine-stimulated O
Na(+) O
influx O
in O
rat O
cortical O
synaptosomes O
with O
an O
IC(50) O
value O
of O
28 O
. O
3 O
microM O
. O
Carteolol O
, O
levobunolol O
, O
timolol O
and O
atenolol O
were O
significantly O
less O
effective O
than O
betaxolol O
at O
reducing O
veratridine-evoked O
Na(+) O
influx O
. O
The O
ability O
of O
betaxolol O
to O
interact O
with O
neurotoxin O
site O
2 O
of O
the O
Na(+) O
channel O
and O
inhibit O
Na(+) O
influx O
may O
have O
a O
role O
in O
its O
neuroprotective O
action O
in O
paradigms O
of O
excitotoxicity/ischaemia O
and O
in O
its O
therapeutic O
effect O
in O
glaucoma O
. O

NO O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
essential O
oil O
and O
its O
constituents O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
through O
blocking O
JNK O
, O
ERK O
and O
NF-κB O
signaling O
pathways O
in O
LPS-activated O
RAW O
264.7 O
cells.We O
investigated O
the O
composition O
of O
essential O
oil O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible B
nitric I
oxide I
synthase I
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O
N-terminal O
kinase O
(JNK) O
and O
extracellular O
signal-regulated O
kinase O
(ERK) O
but O
not O
that O
of O
p38 O
mitogen-activated O
protein O
kinase O
. O
These O
results O
indicate O
that O
FCEO O
inhibits O
LPS-stimulated O
inflammation O
by O
blocking O
the O
NF-κB O
, O
JNK O
, O
and O
ERK O
pathways O
in O
macrophages O
, O
and O
demonstrate O
that O
FCEO O
possesses O
anti-inflammatory O
properties O
. O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin B
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine-induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O
chromatography O
(IMAC) O
, O
with O
two-dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN-/- O
, O
MK-/- O
and O
wild O
type O
(WT) O
mice O
treated O
with O
amphetamine O
. O
We O
identified O
13 O
differentially O
expressed O
phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN O
and O
MK O
against O
amphetamine-induced O
neurotoxicity O
. O
It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins O
, O
annexin O
A7 O
(ANXA7) O
, O
COP9 O
signalosome O
subunit O
5 O
(COPS5) O
, O
aldehyde O
dehydrogenase O
family O
1 O
member O
A1 O
(ALDH1A1) O
and O
creatine O
kinase O
U-type O
(CKMT1) O
, O
are O
known O
to O
be O
involved O
in O
Parkinson's O
disease O
, O
a O
result O
of O
significant O
importance O
since O
PTN O
and O
MK O
have O
been O
also O
demonstrated O
to O
limit O
Parkinson's O
disease O
(PD) O
progress O
and O
have O
been O
suggested O
to O
be O
among O
the O
important O
genetic O
factors O
possibly O
preventing O
the O
development O
of O
PD O
in O
methamphetamine O
abusers O
. O
The O
data O
identify O
phosphoproteins O
differentially O
regulated O
by O
amphetamine O
treatment O
and/or O
the O
presence O
of O
endogenous O
PTN/MK O
which O
may O
be O
relevant O
mediators O
of O
PTN/MK O
neuroprotective O
effects O
against O
amphetamine-induced O
neurotoxicity O
. O
The O
data O
support O
further O
studies O
to O
validate O
the O
phosphoproteins O
here O
identified O
as O
possible O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
A O
novel O
tyrosine O
kinase O
switch O
is O
a O
mechanism O
of O
imatinib O
resistance O
in O
gastrointestinal O
stromal O
tumors.KIT O
or O
alpha-platelet-derived O
growth O
factor O
receptor O
(alpha-PDGFR) O
activating O
mutations O
are O
the O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT O
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O
GIST-S O
and O
GIST-R O
cells O
confirmed O
the O
switch O
from O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL B
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain B
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

CdCl2 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Hepatocytes O
display O
a O
compensatory O
survival O
response O
against O
cadmium O
toxicity O
by O
a O
mechanism O
mediated O
by O
EGFR O
and O
Src.Although O
the O
liver O
is O
a O
cadmium-target O
organ O
, O
hepatocyte O
response O
involved O
in O
its O
toxicity O
is O
not O
yet O
elucidated O
. O
A O
link O
between O
this O
heavy O
metal O
treatment O
and O
Stat3 O
signaling O
pathways O
was O
examined O
in O
primary O
mouse O
hepatocytes O
. O
We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH O
oxidase O
and O
Stat3 O
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1/2 O
. O
Cadmium O
activates O
NADPH O
oxidase O
. O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 B
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) B
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

5 O
alpha-NET O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Norethisterone O
metabolites O
modulate O
the O
uteroglobin O
and O
progesterone O
receptor O
gene O
expression O
in O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

oxantel O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Fumarate O
reductase O
is O
essential O
for O
Helicobacter O
pylori O
colonization O
of O
the O
mouse O
stomach.Fumarate O
reductase O
(FRD) O
is O
the O
key O
enzyme O
in O
fumarate O
respiration O
induced O
by O
anaerobic O
growth O
of O
bacteria O
. O
In O
Helicobacter O
pylori O
, O
this O
enzyme O
appears O
to O
be O
constitutively O
expressed O
under O
microaerobic O
conditions O
and O
is O
not O
essential O
for O
its O
survival O
in O
vitro O
. O
In O
this O
study O
, O
the O
role O
of O
FRD O
in O
the O
colonization O
of O
H O
. O
pylori O
was O
investigated O
using O
a O
mouse O
model O
. O
The O
frdA O
gene O
coding O
for O
subunit O
A O
of O
FRD O
, O
and O
two O
control O
genes O
, O
copA O
and O
copP O
associated O
with O
the O
export O
of O
copper O
out O
of O
H O
. O
pylori O
, O
were O
inactivated O
by O
insertion O
of O
the O
chloramphenicol O
acetyltransferase O
cassette O
into O
these O
individual O
genes O
. O
The O
isogenic O
mutants O
of O
H O
. O
pylori O
strain O
AH244 O
were O
obtained O
by O
natural O
transformation O
. O
Seventy-five O
ICR O
mice O
(15 O
mice/group) O
were O
orogastrically O
dosed O
with O
either O
the O
wild O
type O
H O
. O
pylori O
strain O
AH244 O
, O
its O
isogenic O
mutants O
, O
or O
Brucella O
broth O
(negative O
control) O
. O
Five O
mice O
from O
each O
group O
were O
killed O
at O
2 O
, O
4 O
and O
8 O
weeks O
post-inoculation O
(WPI) O
, O
respectively O
. O
H O
. O
pylori O
colonization O
was O
not O
detected O
in O
mouse O
gastric O
mucosa O
infected O
with O
the O
frdA O
mutant O
at O
any O
time O
point O
in O
the O
study O
by O
both O
quantitative O
culture O
and O
PCR O
. O
In O
contrast O
, O
the O
mice O
inoculated O
with O
either O
wild O
type O
AH244 O
, O
copA O
or O
copPH O
. O
pylori O
mutants O
became O
readily O
infected O
. O
These O
data O
indicate O
that O
FRD O
plays O
a O
crucial O
role O
in O
H O
. O
pylori O
survival O
in O
the O
gastric O
mucosa O
of O
mice O
. O
Given O
that O
FRD B
, O
present O
in O
all O
H O
. O
pylori O
strains O
, O
is O
immunogenic O
in O
H O
. O
pylori O
-infected O
patients O
and O
H O
. O
pylori O
growth O
in O
vitro O
can O
be O
inhibited O
by O
three O
anthelmintics O
(morantel O
, O
oxantel O
and O
thiabendazole) O
, O
this O
enzyme O
could O
potentially O
be O
used O
both O
as O
a O
novel O
drug O
target O
as O
well O
as O
in O
the O
development O
of O
vaccines O
for O
H O
. O
pylori O
prevention O
and O
eradication O
. O

cilazapril O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Altered O
vasoreactivity O
to O
angiotensin O
II O
in O
experimental O
diabetic O
neuropathy O
: O
role O
of O
nitric O
oxide.We O
evaluated O
the O
effects O
of O
angiotensin B
II I
and O
an O
angiotensin-converting O
enzyme O
inhibitor O
(cilazapril) O
on O
nerve O
blood O
flow O
(NBF) O
and O
electrophysiology O
in O
control O
and O
diabetic O
rats O
. O
When O
applied O
locally O
to O
the O
sciatic O
nerve O
, O
the O
dose-response O
curve O
of O
angiotensin O
II O
was O
more O
potent O
in O
experimental O
diabetic O
neuropathy O
(EDN) O
than O
control O
rats O
. O
No O
difference O
existed O
in O
plasma O
angiotensin O
II O
levels O
between O
EDN O
and O
controls O
. O
The O
rats O
were O
given O
typical O
rat O
pellets O
or O
pellets O
treated O
with O
10 O
mg/kg O
per O
day O
cilazapril O
for O
4 O
weeks O
. O
Diabetes O
caused O
a O
significant O
reduction O
in O
NBF O
, O
nerve O
conduction O
velocity O
, O
and O
compound O
muscle O
action O
potential O
(CMAP) O
amplitudes O
. O
NBF O
was O
significantly O
increased O
in O
diabetic O
rats O
supplemented O
with O
cilazapril O
diet O
, O
and O
nerve O
conduction O
velocity O
and O
amplitudes O
of O
the O
CMAP O
were O
also O
improved O
after O
4 O
weeks O
on O
this O
diet O
. O
Direct O
application O
10(-3) O
mol/L O
cilazapril O
on O
sciatic O
nerve O
did O
not O
increase O
NBF O
in O
normal O
and O
EDN O
rats O
. O
We O
topically O
applied O
the O
nitric O
oxide O
synthase O
(NOS) O
inhibitor O
, O
NG-nitro-L-arginine O
, O
on O
sciatic O
nerve O
and O
observed O
reduced O
inhibition O
of O
NBF O
in O
EDN O
, O
which O
was O
correctable O
with O
a O
cilazapril O
diet O
. O
These O
results O
suggest O
that O
diabetic O
neuropathy O
may O
have O
an O
increasing O
vasopressor O
action O
with O
angiotensin O
II O
and O
this O
is O
likely O
to O
be O
the O
mechanism O
of O
NOS O
inhibition O
. O
Angiotensin O
II-converting O
enzyme O
inhibitors O
may O
have O
potential O
in O
the O
treatment O
of O
diabetic O
neuropathy O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
( O
Rspo2 B
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic B
acid I
decarboxylase I
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

Phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformin O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial B
respiratory I
chain I
complex I
I I
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria O
. O
Uptake O
of O
phenformin O
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria O
. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds O
, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s) O
. O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; O
however O
, O
uptake O
of O
phenformin O
into O
mitochondria O
of O
organic O
cation/carnitine O
transporter O
1 O
(OCTN1) O
knockout O
mice O
was O
lower O
than O
that O
in O
wild-type O
mice O
, O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex O
I O
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 O
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

Tolbutamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) B
channel I
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
A O
novel O
benzo[d]imidazole O
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 O
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
, O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
, O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β B
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Norethisterone O
metabolites O
modulate O
the O
uteroglobin O
and O
progesterone O
receptor O
gene O
expression O
in O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone B
receptor I
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

silymarin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Protective O
Effects O
of O
a O
Purified O
Saponin O
Mixture O
from O
Astragalus O
corniculatus O
Bieb. O
, O
in O
vivo O
Hepatotoxicity O
Models.In O
this O
study O
, O
the O
in O
vivo O
effects O
of O
a O
purified O
saponin O
mixture O
(PSM) O
, O
obtained O
from O
Astragalus O
corniculatus O
Bieb. O
, O
were O
investigated O
using O
two O
in O
vivo O
hepatotoxicity O
models O
based O
on O
liver O
damage O
caused O
by O
paracetamol O
(PC) O
and O
carbon O
tetrachloride O
(CCl4 O
) O
. O
The O
effects O
of O
PSM O
were O
compared O
with O
silymarin O
. O
Male O
Wistar O
rats O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate O
dehydrogenase O
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase B
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

microcystin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Crystal O
structures O
of O
protein O
phosphatase-1 O
bound O
to O
motuporin O
and O
dihydromicrocystin-LA O
: O
elucidation O
of O
the O
mechanism O
of O
enzyme O
inhibition O
by O
cyanobacterial O
toxins.The O
microcystins O
and O
nodularins O
are O
tumour O
promoting O
hepatotoxins O
that O
are O
responsible O
for O
global O
adverse O
human O
health O
effects O
and O
wildlife O
fatalities O
in O
countries O
where O
drinking O
water O
supplies O
contain O
cyanobacteria O
. O
The O
toxins O
function O
by O
inhibiting O
broad O
specificity O
Ser/Thr O
protein O
phosphatases O
in O
the O
host O
cells O
, O
thereby O
disrupting O
signal O
transduction O
pathways O
. O
A O
previous O
crystal O
structure O
of O
a O
microcystin O
bound O
to O
the O
catalytic O
subunit O
of O
protein B
phosphatase-1 I
(PP-1c) O
showed O
distinct O
changes O
in O
the O
active O
site O
region O
when O
compared O
with O
protein O
phosphatase-1 O
structures O
bound O
to O
other O
toxins O
. O
We O
have O
elucidated O
the O
crystal O
structures O
of O
the O
cyanotoxins O
, O
motuporin O
(nodularin-V) O
and O
dihydromicrocystin-LA O
bound O
to O
human O
protein O
phosphatase-1c O
(gamma O
isoform) O
. O
The O
atomic O
structures O
of O
these O
complexes O
reveal O
the O
structural O
basis O
for O
inhibition O
of O
protein O
phosphatases O
by O
these O
toxins O
. O
Comparisons O
of O
the O
structures O
of O
the O
cyanobacterial O
toxin:phosphatase O
complexes O
explain O
the O
biochemical O
mechanism O
by O
which O
microcystins O
but O
not O
nodularins O
permanently O
modify O
their O
protein O
phosphatase O
targets O
by O
covalent O
addition O
to O
an O
active O
site O
cysteine O
residue O
. O

losartan O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
Long O
range O
effect O
of O
mutations O
on O
specific O
conformational O
changes O
in O
the O
extracellular O
loop O
2 O
of O
angiotensin O
II O
type O
1 O
receptor.The O
topology O
of O
the O
second O
extracellular O
loop O
(ECL2) O
and O
its O
interaction O
with O
ligands O
is O
unique O
in O
each O
G O
protein-coupled O
receptor O
. O
When O
the O
orthosteric O
ligand O
pocket O
located O
in O
the O
transmembrane O
(TM) O
domain O
is O
occupied O
, O
ligand-specific O
conformational O
changes O
occur O
in O
the O
ECL2 O
. O
In O
more O
than O
90% O
of O
G O
protein-coupled O
receptors O
, O
ECL2 O
is O
tethered O
to O
the O
third O
TM O
helix O
via O
a O
disulfide O
bond O
. O
Therefore O
, O
understanding O
the O
extent O
to O
which O
the O
TM O
domain O
and O
ECL2 O
conformations O
are O
coupled O
is O
useful O
. O
To O
investigate O
this O
, O
we O
examined O
conformational O
changes O
in O
ECL2 O
of O
the O
angiotensin O
II O
type O
1 O
receptor O
(AT1R) O
by O
introducing O
mutations O
in O
distant O
sites O
that O
alter O
the O
activation O
state O
equilibrium O
of O
the O
AT1R O
. O
Differential O
accessibility O
of O
reporter O
cysteines O
introduced O
at O
four O
conformation-sensitive O
sites O
in O
ECL2 O
of O
these O
mutants O
was O
measured O
. O
Binding O
of O
the O
agonist O
angiotensin O
II O
(AngII) O
and O
inverse O
agonist O
losartan O
in O
wild-type O
AT1R B
changed O
the O
accessibility O
of O
reporter O
cysteines O
, O
and O
the O
pattern O
was O
consistent O
with O
ligand-specific O
"lid" O
conformations O
of O
ECL2 O
. O
Without O
agonist O
stimulation O
, O
the O
ECL2 O
in O
the O
gain O
of O
function O
mutant O
N111G O
assumed O
a O
lid O
conformation O
similar O
to O
AngII-bound O
wild-type O
AT1R O
. O
In O
the O
presence O
of O
inverse O
agonists O
, O
the O
conformation O
of O
ECL2 O
in O
the O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Alcohol O
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 B
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
development O
. O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
( O
mTOR) B
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

MDMA O
acts O
as O
NOT O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT B
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

all-trans-7,8-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 O
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O
which O
could O
have O
signaling O
functions O
. O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Characterization O
of O
insulin-like O
growth O
factor-binding O
protein-related O
proteins O
(IGFBP-rPs) O
1 O
, O
2 O
, O
and O
3 O
in O
human O
prostate O
epithelial O
cells O
: O
potential O
roles O
for O
IGFBP-rP1 O
and O
2 O
in O
senescence O
of O
the O
prostatic O
epithelium O
. O
Insulin-like B
growth I
factor I
(IGF)-binding I
protein I
(IGFBP)-related I
proteins I
(IGFBP-rPs) O
are O
newly O
described O
cysteine-rich O
proteins O
that O
share O
significant O
aminoterminal O
structural O
similarity O
with O
the O
conventional O
IGFBPs O
and O
are O
involved O
in O
a O
diversity O
of O
biological O
functions O
, O
including O
growth O
regulation O
. O
IGFBP-rP1 O
(MAC25/Angiomodulin/prostacyclin-stimulating O
factor) O
is O
a O
potential O
tumor-suppressor O
gene O
that O
is O
differentially O
expressed O
in O
meningiomas O
, O
mammary O
and O
prostatic O
cancers O
, O
compared O
with O
their O
malignant O
counterparts O
. O
We O
have O
previously O
shown O
that O
IGFBP-rP1 O
is O
preferentially O
produced O
by O
primary O
cultures O
of O
human O
prostate O
epithelial O
cells O
(HPECs) O
and O
by O
poorly O
tumorigenic O
P69SV40T O
cells O
, O
compared O
with O
the O
cancerous O
prostatic O
LNCaP O
, O
DU145 O
, O
PC-3 O
, O
and O
M12 O
cells O
. O
We O
now O
show O
that O
IGFBP-rP1 O
increases O
during O
senescence O
of O
HPEC O
. O
IGFBP-rP2 O
(also O
known O
as O
connective O
tissue O
growth O
factor) O
, O
a O
downstream O
effector O
of O
transforming O
growth O
factor O
(TGF)-beta O
and O
modulator O
of O
growth O
for O
both O
fibroblasts O
and O
endothelial O
cells O
, O
was O
detected O
in O
most O
of O
the O
normal O
and O
malignant O
prostatic O
epithelial O
cells O
tested O
, O
with O
a O
marked O
up-regulation O
of O
IGFBP-rP2 O
during O
senescence O
of O
HPEC O
. O
Moreover O
, O
IGFBP-rP2 O
noticeably O
increased O
in O
response O
to O
TGF-beta1 O
and O
all-trans O
retinoic O
acid O
(atRA) O
in O
HPEC O
and O
PC-3 O
cells O
, O
and O
it O
decreased O
in O
response O
to O
IGF-I O
in O
HPEC O
. O
IGFBP-rP3 O
[nephroblastoma O
overexpressed O
(NOV)] O
, O
the O
protein O
product O
of O
the O
NOV O
protooncogene O
, O
was O
not O
detected O
in O
HPEC O
but O
was O
expressed O
in O
the O
tumorigenic O
DU145 O
and O
PC-3 O
cells O
. O
It O
was O
also O
synthesized O
by O
the O
SV40-T O
antigen-transformed O
P69 O
and O
malignant O
M12 O
cells O
, O
where O
it O
was O
down-regulated O
by O
atRA O
. O
These O
observations O
suggest O
biological O
roles O
of O
IGFBP-rPs O
in O
the O
human O
prostate O
. O
IGFBP-rP1 O
and O
IGFBP-rP2 O
are O
likely O
to O
negatively O
regulate O
growth O
, O
because O
they O
seem O
to O
increase O
during O
senescence O
of O
the O
prostate O
epithelium O
and O
in O
response O
to O
growth O
inhibitors O
(TGF-beta1 O
and O
atRA) O
. O
Although O
the O
data O
collected O
on O
IGFBP-rP3 O
in O
prostate O
are O
modest O
, O
its O
role O
as O
a O
growth O
stimulator O
and/or O
protooncogene O
is O
supported O
by O
its O
preferential O
expression O
in O
cancerous O
cells O
and O
its O
down-regulation O
by O
atRA O
. O

tetracyclines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dose-response O
effect O
of O
tetracyclines O
on O
cerebral O
matrix O
metalloproteinase-9 O
after O
vascular O
endothelial O
growth O
factor O
hyperstimulation.Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder O
. O
Matrix O
metalloproteinase O
(MMP)-9 O
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens O
. O
Doxycycline O
was O
shown O
to O
decrease O
cerebral O
MMP-9 O
activities O
and O
angiogenesis O
induced O
by O
vascular O
endothelial O
growth O
factor O
(VEGF) O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline O
and O
minocycline O
on O
cerebral O
MMP-9 O
using O
our O
mouse O
model O
with O
VEGF O
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O
brain O
. O
Mice O
were O
treated O
with O
doxycycline O
or O
minocycline O
, O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 O
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 O
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O
effect O
at O
a O
lower O
dose O
, O
1 O
mg/kg/day O
(P<0.02) O
. O
The O
inhibition O
of O
cerebral O
MMP-9 O
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue O
. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O
in O
vitro O
to O
elucidate O
the O
mechanisms O
underlying O
the O
MMP-9 B
inhibition O
by O
tetracyclines O
. O
In O
vitro O
, O
minocycline O
, O
but O
not O
doxycycline O
, O
inhibits O
MMP-9 O
, O
at O
least O
in O
part O
, O
via O
the O
extracellular O
signaling-related O
kinase O
1/2 O
(ERK1/2)-mediated O
pathway O
. O
This O
study O
provided O
the O
evidence O
that O
the O
tetracyclines O
inhibit O
stimulated O
cerebral O
MMP-9 O
at O
multiple O
levels O
and O
are O
effective O
at O
very O
low O
doses O
, O
offering O
great O
potential O
for O
therapeutic O
use O
. O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J O
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J B
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O
that O
encode O
polypeptides O
with O
62-84% O
identity O
with O
the O
three O
previously O
identified O
mouse O
CYP2Js O
. O
All O
four O
new O
CYP2J O
proteins O
were O
expressed O
in O
Sf21 O
insect O
cells O
. O
Each O
recombinant O
protein O
metabolized O
AA O
and O
LA O
to O
epoxides O
and O
hydroxy O
derivatives O
. O
Specific O
antibodies O
, O
mRNA O
probes O
, O
and O
polymerase O
chain O
reaction O
primer O
sets O
were O
developed O
for O
each O
mouse O
CYP2J O
to O
examine O
their O
tissue O
distribution O
. O
CYP2J8 O
transcripts O
were O
found O
in O
the O
kidney O
, O
liver O
, O
and O
brain O
, O
and O
protein O
expression O
was O
confirmed O
in O
the O
kidney O
and O
brain O
(neuropil) O
. O
CYP2J11 O
transcripts O
were O
most O
abundant O
in O
the O
kidney O
and O
heart O
, O
with O
protein O
detected O
primarily O
in O
the O
kidney O
(proximal O
convoluted O
tubules) O
, O
liver O
, O
and O
heart O
(cardiomyocytes) O
. O
CYP2J12 O
transcripts O
were O
prominently O
present O
in O
the O
brain O
, O
and O
CYP2J13 O
transcripts O
were O
detected O
in O
multiple O
tissues O
, O
with O
the O
highest O
expression O
in O
the O
kidney O
. O
CYP2J12 O
and O
CYP2J13 O
protein O
expression O
could O
not O
be O
determined O
because O
the O
antibodies O
developed O
were O
not O
immunospecific O
. O
We O
conclude O
that O
the O
four O
new O
CYP2J O
isoforms O
might O
be O
involved O
in O
the O
metabolism O
of O
AA O
and O
LA O
to O
bioactive O
lipids O
in O
mouse O
hepatic O
and O
extrahepatic O
tissues O
. O

memantine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
neuropharmacological O
basis O
for O
the O
use O
of O
memantine O
in O
the O
treatment O
of O
Alzheimer's O
disease.Memantine O
has O
been O
demonstrated O
to O
be O
safe O
and O
effective O
in O
the O
symptomatic O
treatment O
of O
Alzheimer's O
disease O
(AD) O
. O
While O
the O
neurobiological O
basis O
for O
the O
therapeutic O
activity O
of O
memantine O
is O
not O
fully O
understood O
, O
the O
drug O
is O
not O
a O
cholinesterase O
inhibitor O
and O
, O
therefore O
, O
acts O
differently O
from O
current O
AD O
therapies O
. O
Memantine O
can O
interact O
with O
a O
variety O
of O
ligand-gated O
ion O
channels O
. O
However O
, O
NMDA O
receptors O
appear O
to O
be O
a O
key O
target O
of O
memantine O
at O
therapeutic O
concentrations O
. O
Memantine O
is O
an O
uncompetitive O
(channel O
blocking) O
NMDA O
receptor O
antagonist O
. O
Like O
other O
NMDA O
receptor O
antagonists O
, O
memantine O
at O
high O
concentrations O
can O
inhibit O
mechanisms O
of O
synaptic O
plasticity O
that O
are O
believed O
to O
underlie O
learning O
and O
memory O
. O
However O
, O
at O
lower O
, O
clinically O
relevant O
concentrations O
memantine O
can O
under O
some O
circumstances O
promote O
synaptic O
plasticity O
and O
preserve O
or O
enhance O
memory O
in O
animal O
models O
of O
AD O
. O
In O
addition O
, O
memantine O
can O
protect O
against O
the O
excitotoxic O
destruction O
of O
cholinergic O
neurons O
. O
Blockade O
of O
NMDA B
receptors I
by O
memantine O
could O
theoretically O
confer O
disease-modifying O
activity O
in O
AD O
by O
inhibiting O
the O
"weak" O
NMDA O
receptor-dependent O
excitotoxicity O
that O
has O
been O
hypothesized O
to O
play O
a O
role O
in O
the O
progressive O
neuronal O
loss O
that O
underlies O
the O
evolving O
dementia O
. O
Moreover O
, O
recent O
in O
vitro O
studies O
suggest O
that O
memantine O
abrogates O
beta-amyloid O
(Abeta) O
toxicity O
and O
possibly O
inhibits O
Abeta O
production O
. O
Considerable O
attention O
has O
focused O
on O
the O
investigation O
of O
theories O
to O
explain O
the O
better O
tolerability O
of O
memantine O
over O
other O
NMDA O
receptor O
antagonists O
, O
particularly O
those O
that O
act O
by O
a O
similar O
channel O
blocking O
mechanism O
such O
as O
dissociative O
anesthetic-like O
agents O
(phencyclidine O
, O
ketamine O
, O
MK-801) O
. O
A O
variety O
of O
channel-level O
factors O
could O
be O
relevant O
, O
including O
fast O
channel-blocking O
kinetics O
and O
strong O
voltage-dependence O
(allowing O
rapid O
relief O
of O
block O
during O
synaptic O
activity) O
, O
as O
well O
as O
reduced O
trapping O
(permitting O
egress O
from O
closed O
channels) O
. O
These O
factors O
may O
allow O
memantine O
to O
block O
channel O
activity O
induced O
by O
low O
, O
tonic O
levels O
of O
glutamate--an O
action O
that O
might O
contribute O
to O
symptomatic O
improvement O
and O
could O
theoretically O
protect O
against O
weak O
excitotoxicity--while O
sparing O
synaptic O
responses O
required O
for O
normal O
behavioral O
functioning O
, O
cognition O
and O
memory O
. O

mimosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosine O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O
spiralis O
, O
a O
nematode O
parasite O
, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 B
and O
MIP-2 O
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O
by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10 O
, O
20 O
, O
30 O
and O
40 O
days O
post-treatment O
. O
In O
these O
experiments O
, O
mimosine O
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced O
. O
In O
addition O
, O
we O
found O
that O
MCP-1 O
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine O
, O
while O
MIP-2 O
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O
inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T O
. O
spiralis O
. O
Our O
studies O
suggest O
that O
mimosine O
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O
cell O
cycle O
of O
white O
blood O
cells O
. O
This O
study O
suggests O
for O
the O
first O
time O
the O
premise O
that O
mimosine O
acts O
as O
an O
anti-inflammatory O
compound O
. O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl B
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl O
GABA O
receptor O
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride O
channel O
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
. O

fenofibrate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
fenofibrate O
, O
a O
PPAR-α B
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII O
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion O
. O
The O
effects O
of O
PE O
and O
AII O
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated O
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O
for O
ET1 O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII O
and O
ET1 O
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

fenofibrate O
acts O
as O
NOT O
for O
what O
entity O
? O
Effects O
of O
fenofibrate O
, O
a O
PPAR-α O
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII O
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion O
. O
The O
effects O
of O
PE O
and O
AII O
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated O
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O
for O
ET1 O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII B
and O
ET1 O
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

Ser O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC O
/ O
SHMT B
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

5-Fluorouracil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
(F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate B
synthase I
(TS) O
. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O
and O
the O
mechanism O
of O
resistance O
to O
the O
drugs O
. O
When O
cells O
were O
incubated O
with O
the O
3 O
drugs O
for O
72 O
h O
, O
the O
resistance O
ratio O
to O
parental O
DLD-1 O
human O
colorectal O
tumor O
cells O
was O
65.2 O
for O
DLD-1/5-FU O
, O
9.7 O
for O
DLD-1/FdUrd O
and O
448.6 O
for O
DLD-1/F3(d)Thd O
cells O
. O
DLD-1/5-FU O
cells O
did O
not O
show O
any O
cross-resistance O
against O
FdUrd O
and O
F(3)dThd O
. O
However O
, O
DLD-1/FdUrd O
cells O
showed O
3- O
and O
9-fold O
increased O
resistance O
to O
5-FU O
and O
F3(d)Thd O
, O
respectively O
, O
and O
DLD-1/F3(d)Thd O
cells O
also O
showed O
about O
90-fold O
resistance O
to O
FdUrd O
. O
Analysis O
of O
enzyme O
activities O
and O
gene O
expression O
associated O
with O
pyrimidine O
metabolism O
indicated O
that O
a O
significant O
decrease O
in O
orotate O
phosphoribosyltransferase O
activity O
in O
DLD-1/5-FU O
cells O
, O
a O
7-fold O
increase O
of O
TS O
mRNA O
in O
DLD-1/FdUrd O
cells O
, O
and O
a O
37-fold O
decrease O
in O
thymidine O
kinase O
activity O
of O
DLD-1/F3(d)Thd O
cells O
were O
the O
major O
mechanisms O
of O
drug O
resistance O
. O
These O
findings O
were O
closely O
associated O
with O
the O
cytotoxicity O
of O
5-FU O
, O
FdUrd O
and O
F3(d)Thd O
against O
the O
established O
5-FU- O
, O
FdUrd- O
or O
F3(d)Thd-resistant O
cells O
. O
When O
DLD-1/FdUrd O
cells O
expressing O
increased O
TS O
mRNA O
were O
treated O
with O
FdUrd O
and O
F3(d)Thd O
for O
only O
4 O
h O
, O
the O
resistance O
ratios O
of O
DLD-1/FdUrd O
cells O
to O
parental O
DLD-1 O
cells O
were O
markedly O
different O
for O
FdUrd O
and O
F3(d)Thd O
, O
suggesting O
that O
the O
cytotoxicity O
with O
short-time O
exposure O
to O
F3(d)Thd O
is O
due O
to O
a O
mechanism O
other O
than O
TS O
inhibition O
, O
although O
the O
cytotoxicity O
of O
F3(d)Thd O
in O
the O
short-time O
is O
low O
compared O
to O
that O
of O
long-time O
exposure O
. O
In O
conclusion O
, O
F3(d)Thd O
, O
an O
antimetabolite O
that O
inhibits O
TS O
activity O
, O
may O
be O
effective O
against O
5-FU O
and/or O
FdUrd-resistance O
in O
colorectal O
cancer O
cells O
caused O
by O
amplification O
of O
TS O
and/or O
deletion O
of O
orotate O
phosphoribosyltransferase O
. O

CO(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH B
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

topiramate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Selective O
antagonism O
of O
GluR5 O
kainate-receptor-mediated O
synaptic O
currents O
by O
topiramate O
in O
rat O
basolateral O
amygdala O
neurons.Topiramate O
is O
a O
widely O
used O
antiepileptic O
agent O
whose O
mechanism O
of O
action O
is O
poorly O
understood O
. O
The O
drug O
has O
been O
reported O
to O
interact O
with O
various O
ion O
channel O
types O
, O
including O
AMPA/kainate O
receptors O
. O
In O
whole-cell O
voltage-clamp O
recordings O
from O
principal O
neurons O
of O
the O
rat O
basolateral O
amygdala O
, O
topiramate O
at O
low O
concentrations O
(IC50 O
, O
approximately O
0.5 O
microm) O
selectively O
inhibited O
pharmacologically O
isolated O
excitatory O
synaptic O
currents O
mediated O
by O
kainate O
receptors O
containing O
the O
GluR5 O
subunit O
. O
Topiramate O
also O
partially O
depressed O
predominantly O
AMPA-receptor-mediated O
EPSCs O
, O
but O
with O
lower O
efficacy O
. O
Topiramate O
did O
not O
alter O
the O
degree O
of O
facilitation O
in O
paired-pulse O
experiments O
, O
and O
it O
reduced O
the O
amplitude O
of O
miniature O
EPSCs O
without O
affecting O
their O
frequency O
, O
demonstrating O
that O
the O
block O
of O
synaptic O
responses O
occurs O
postsynaptically O
. O
Inhibition O
of O
GluR5 O
kainate B
receptors I
could O
represent O
a O
key O
mechanism O
underlying O
the O
anticonvulsant O
activity O
of O
topiramate O
. O
Moreover O
, O
these O
results O
support O
the O
concept O
that O
GluR5 O
kainate O
receptors O
represent O
a O
novel O
target O
for O
antiepileptic O
drug O
development O
. O

lanreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Acromegaly O
: O
molecular O
expression O
of O
somatostatin O
receptor O
subtypes O
and O
treatment O
outcome.About O
a O
third O
of O
acromegalic O
patients O
are O
resistant O
to O
the O
currently O
commercially O
available O
somatostatin O
analogs O
(SA) O
octreotide O
and O
lanreotide O
. O
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 O
and O
SSTR5 O
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 B
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O
somatostatin O
subtypes O
analogs O
, O
mainly O
for O
SSTR5 O
, O
of O
a O
SSTR2-SSTR5 O
bispecific O
compound O
, O
and O
of O
a O
"universal" O
analog O
with O
high O
affinity O
to O
SSTR1 O
, O
2 O
, O
3 O
, O
and O
5 O
showed O
preliminary O
, O
albeit O
promising O
results O
for O
the O
treatment O
of O
resistant O
somatotropic O
adenomas O
. O

gefitinib O
acts O
as O
UNDEFINED O
for O
what O
entity O
? O
Structural O
basis O
for O
the O
altered O
drug O
sensitivities O
of O
non-small O
cell O
lung O
cancer-associated O
mutants O
of O
human O
epidermal O
growth O
factor O
receptor.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
has O
an O
essential O
role O
in O
multiple O
signaling O
pathways O
, O
including O
cell O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine O
kinase O
(TK) O
domain O
. O
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR O
mutants O
, O
L858R O
and O
G719S O
, O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK O
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met790 O
side O
chain O
of O
the O
G719S/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR B
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR O
mutations O
. O

atrazine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transcriptome O
alterations O
following O
developmental O
atrazine O
exposure O
in O
zebrafish O
are O
associated O
with O
disruption O
of O
neuroendocrine O
and O
reproductive O
system O
function O
, O
cell O
cycle O
, O
and O
carcinogenesis.Atrazine O
, O
a O
herbicide O
commonly O
applied O
to O
agricultural O
areas O
and O
a O
common O
contaminant O
of O
potable O
water O
supplies O
, O
is O
implicated O
as O
an O
endocrine-disrupting O
chemical O
(EDC) O
and O
potential O
carcinogen O
. O
Studies O
show O
that O
EDCs O
can O
cause O
irreversible O
changes O
in O
tissue O
formation O
, O
decreased O
reproductive O
potential O
, O
obesity O
, O
and O
cancer O
. O
The O
U.S O
. O
Environmental O
Protection O
Agency O
considers O
an O
atrazine O
concentration O
of O
≤ O
3 O
ppb O
in O
drinking O
water O
safe O
for O
consumption O
. O
The O
specific O
adverse O
human O
health O
effects O
associated O
with O
a O
developmental O
atrazine O
exposure O
and O
the O
underlying O
genetic O
mechanisms O
of O
these O
effects O
are O
not O
well O
defined O
. O
In O
this O
study O
, O
zebrafish O
embryos O
were O
exposed O
to O
a O
range O
of O
atrazine O
concentrations O
to O
establish O
toxicity O
. O
Morphological O
, O
transcriptomic O
, O
and O
protein O
alterations O
were O
then O
assessed O
at O
72h O
postfertilization O
following O
developmental O
atrazine O
exposure O
at O
0 O
, O
0.3 O
, O
3 O
, O
or O
30 O
ppb O
. O
A O
significant O
increase O
in O
head O
length O
was O
observed O
in O
all O
three O
atrazine O
treatments O
. O
Transcriptomic O
profiles O
revealed O
21 O
, O
62 O
, O
and O
64 O
genes O
with O
altered O
expression O
in O
the O
0.3 O
, O
3 O
, O
and O
30 O
ppb O
atrazine O
treatments O
, O
respectively O
. O
Altered O
genes O
were O
associated O
with O
neuroendocrine O
and O
reproductive O
system O
development O
, O
function O
, O
and O
disease; O
cell O
cycle O
control; O
and O
carcinogenesis O
. O
There O
was O
a O
significant O
overlap O
(42 O
genes) O
between O
the O
3 O
and O
30 O
ppb O
differentially O
expressed O
gene O
lists O
, O
with O
two O
of O
these O
genes O
(CYP17A1 O
and O
SAMHD1) B
present O
in O
all O
three O
atrazine O
treatments O
. O
Increased O
transcript O
levels O
were O
translated O
to O
significant O
upregulation O
in O
protein O
expression O
. O
Overall O
, O
this O
study O
identifies O
genetic O
and O
molecular O
targets O
altered O
in O
response O
to O
a O
developmental O
atrazine O
exposure O
to O
further O
define O
the O
biological O
pathways O
and O
mechanisms O
of O
toxicity O
. O

tabun O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
investigation O
of O
efficacy O
of O
new O
reactivators O
on O
OPC O
inhibited O
rat O
brain O
acetylcholinesterase.Organophosphorus O
compounds O
(OPC) O
were O
developed O
as O
warfare O
nerve O
agents O
. O
They O
are O
also O
widely O
used O
as O
pesticides O
. O
The O
drug O
therapy O
of O
intoxication O
with O
OPC O
includes O
mainly O
combination O
of O
cholinesterase O
(ChE) O
reactivators O
and O
cholinolytics O
. O
There O
is O
no O
single O
ChE O
reactivator O
having O
an O
ability O
to O
reactivate O
sufficiently O
the O
inhibited O
enzyme O
due O
to O
the O
high O
variability O
of O
chemical O
structure O
of O
the O
inhibitors O
. O
The O
difficulties O
in O
reactivation O
of O
ChE O
activity O
and O
slight O
antidote O
effect O
regarding O
intoxication O
with O
some O
OPC O
are O
some O
of O
the O
reasons O
for O
continuous O
efforts O
to O
obtain O
new O
reactivators O
of O
ChE O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
some O
ChE O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor B
receptor I
tyrosine I
kinase I
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O
benefits O
in O
advanced O
MTC O
, O
and O
it O
has O
recently O
been O
approved O
for O
locally O
advanced O
or O
metastatic O
MTC O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
(April O
2011) O
and O
the O
European O
Medicines O
Agency O
(February O
2012) O
. O
This O
review O
, O
starting O
from O
the O
phases O
II O
and O
III O
efficacy O
and O
safety O
data O
that O
led O
to O
these O
approvals O
, O
explores O
important O
issues O
related O
to O
dosing O
, O
patient O
selection O
, O
and O
strategies O
for O
managing O
the O
substantial O
risk O
of O
toxicity O
associated O
with O
the O
drug O
(including O
life-threatening O
cardiac O
events O
that O
are O
the O
subject O
of O
a O
black-box O
warning O
in O
the O
United O
States) O
. O
All O
these O
issues O
still O
remain O
to O
be O
defined O
. O
Vandetanib O
is O
becoming O
a O
standard O
of O
care O
for O
symptomatic O
, O
progressive O
, O
metastatic O
MTCs O
, O
to O
be O
used O
selectively O
in O
those O
patients O
who O
are O
likely O
to O
benefit O
from O
it O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine O
transporter O
(DAT) O
in O
control O
and O
DAT O
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn-induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
( O
DAT) B
 O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT O
. O
DA O
toxicity O
was O
saturable O
suggesting O
that O
transport O
may O
be O
rate O
limiting O
. O
When O
Mn O
and O
DA O
were O
added O
simultaneously O
to O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O
Mn O
may O
suppress O
DA O
uptake O
in O
the O
DAT O
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

quinoxalines O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Discovery O
and O
structure-activity O
relationships O
of O
small O
molecules O
that O
block O
the O
human O
immunoglobulin O
G-human O
neonatal O
Fc O
receptor O
(hIgG-hFcRn) O
protein-protein O
interaction.The O
neonatal O
Fc O
receptor O
, O
FcRn O
, O
prolongs O
the O
half-life O
of O
IgG O
in O
the O
serum O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease O
. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human O
IgG-human O
FcRn O
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment O
. O
A O
novel O
class O
of O
quinoxalines O
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG B
: O
FcRn O
protein-protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand-based O
screen O
. O

carboxylate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T B
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

epinephrine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Enhanced O
beta2-adrenergic O
receptor O
(beta2AR) O
signaling O
by O
adeno-associated O
viral O
(AAV)-mediated O
gene O
transfer.BACKGROUND O
: O
Beta2-adrenergic O
receptors O
(beta2AR) O
play O
important O
regulatory O
roles O
in O
a O
variety O
of O
cells O
and O
organ O
systems O
and O
are O
important O
therapeutic O
targets O
in O
the O
treatment O
of O
airway O
and O
cardiovascular O
disease O
. O
Prolonged O
use O
of O
beta-agonists O
results O
in O
tolerance O
secondary O
to O
receptor O
down-regulation O
resulting O
in O
reduced O
therapeutic O
efficiency O
. O
The O
purpose O
of O
this O
work O
is O
to O
evaluate O
the O
signaling O
capabilities O
of O
the O
beta2AR O
expressed O
by O
a O
recombinant O
adeno-associated O
viral O
(AAV) O
vector O
that O
also O
included O
an O
enhanced O
green O
fluorescent O
protein O
(EGFP) O
gene O
(AAV-beta2AR/EGFP) O
. O
RESULTS O
: O
By O
epifluorescence O
microscopy O
, O
approximately O
40% O
of O
infected O
HEK O
293 O
cells O
demonstrated O
EGFP O
expression O
. O
beta2AR O
density O
measured O
with O
[3H]dihydroalprenolol O
([3H]DHA) O
increased O
either O
13- O
or O
77-fold O
in O
infected O
cells O
compared O
to O
mock O
infected O
controls O
depending O
on O
the O
culture O
conditions O
used O
. O
The O
[3H]DHA O
binding O
was O
to O
a O
single O
receptor O
population O
with O
a O
dissociation O
constant O
of O
0.42 O
nM O
, O
as O
would O
be O
expected O
for O
wild-type O
beta2AR O
. O
Agonist O
competition O
assays O
with O
[3H]DHA O
showed O
the O
following O
rank O
order O
of O
potency O
: O
isoproterenol>epinephrine> O
norepinephrine O
, O
consistent O
with O
beta2AR B
interaction O
. O
Isoproterenol-stimulated O
cyclic O
AMP O
levels O
were O
5-fold O
higher O
in O
infected O
cells O
compared O
to O
controls O
(314 O
+/- O
43 O
vs O
. O
63.4 O
+/- O
9.6 O
nmol/dish; O
n O
= O
3) O
. O
Receptor O
trafficking O
demonstrated O
surface O
expression O
of O
beta2AR O
with O
vehicle O
treatment O
and O
internalization O
following O
isoproterenol O
treatment O
. O
CONCLUSIONS O
: O
We O
conclude O
that O
HEK O
293 O
cells O
infected O
with O
AAV-beta2AR/EGFP O
effectively O
express O
beta2AR O
and O
that O
increased O
expression O
of O
these O
receptors O
results O
in O
enhanced O
beta2AR O
signaling O
. O
This O
method O
of O
gene O
transfer O
may O
provide O
an O
important O
means O
to O
enhance O
function O
in O
in O
vivo O
systems O
. O

atRA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
All-trans O
retinoic O
acid O
protects O
hepatocellular O
carcinoma O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
upregulating O
collagen O
8A2.As O
a O
therapeutic O
or O
chemopreventative O
agent O
for O
various O
cancers O
, O
all-trans O
retinoic O
acid O
(atRA) O
has O
been O
reported O
to O
inhibit O
growth O
, O
induce O
apoptosis O
or O
cause O
differentiation O
. O
It O
was O
found O
that O
atRA O
could O
protect O
hepatocellular O
carcinoma O
(HCC) O
cells O
against O
cell O
death O
induced O
by O
serum O
starvation O
. O
Furthermore O
, O
it O
was O
found O
that O
atRA O
could O
enhance O
cell O
adhesion O
, O
but O
had O
no O
effect O
on O
the O
cell O
cycle O
and O
apoptosis O
. O
Using O
an O
Illumina O
Human O
HT-12 O
v4 O
expression O
microarray O
, O
207 O
upregulated O
and O
173 O
downregulated O
genes O
were O
identified O
in O
HepG2 O
cells O
treated O
with O
atRA O
. O
The O
most O
upregulated O
genes O
are O
cytochrome O
P450 O
family O
26 O
subfamily O
A O
polypeptide O
1 O
(CYP26A1) O
, O
histidine O
triad O
nucleotide O
binding O
protein O
3 O
(HINT3) O
, O
miR-1282 O
and O
cytochrome O
P450 O
family O
26 O
subfamily O
B O
polypeptide O
1 O
(CYP26B1) O
, O
which O
showed O
more O
than O
fivefold O
greater O
expression O
. O
Using O
Gene O
Ontology O
analysis O
, O
the O
greatest O
significance O
was O
found O
in O
extracellular-matrix-related O
molecular O
functions O
and O
the O
cellular O
component O
in O
upregulated O
genes O
. O
The O
upregulation O
of O
collagen O
8A2 O
(COL8A2) O
was O
further O
confirmed O
using O
quantitative O
RT-PCR O
and O
western O
blotting O
. O
Knockdown O
of O
COL8A2 O
blocked O
enhancement O
in O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA O
treatment O
. O
Re-expression O
of O
COL8A2 O
in O
COL8A2-knocked-down O
HCC O
cells O
reversed O
the O
effect O
of O
small O
interfering O
RNA-COL8A2 O
. O
In O
addition O
, O
COL8A2 O
could O
increase O
HCC O
cell O
migration O
and O
invasion O
. O
Thus O
, O
COL8A2 B
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA O
under O
serum-free O
conditions O
. O
In O
conclusion O
, O
atRA O
protects O
HCC O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
enhancing O
cell O
adhesion O
, O
and O
COL8A2 O
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion O
. O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
role O
of O
rasagiline O
in O
the O
treatment O
of O
Parkinson's O
disease.Parkinson's O
disease O
(PD) O
is O
the O
second O
most O
common O
neurodegenerative O
disorder O
, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years O
. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O
neuroprotective O
strategies O
have O
remained O
elusive O
. O
Rasagiline O
is O
a O
novel O
, O
potent O
, O
and O
irreversible O
monoamine B
oxidase I
type I
B I
(MAO-B) O
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD O
. O
Rasagiline O
inhibits O
MAO-B O
more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing O
. O
In O
several O
large O
, O
randomized O
, O
placebo-controlled O
trials O
, O
rasagiline O
has O
demonstrated O
efficacy O
as O
monotherapy O
in O
early O
PD O
and O
as O
adjunctive O
therapy O
in O
advanced O
PD O
. O
In O
addition O
, O
rasagiline O
has O
been O
shown O
to O
have O
neuroprotective O
effects O
in O
in O
vitro O
and O
in O
vivo O
studies O
. O
The O
recently O
completed O
delayed-start O
ADAGIO O
(Attenuation O
of O
Disease O
Progression O
with O
Azilect O
Given O
Once-daily) O
trial O
suggests O
a O
potential O
disease-modifying O
effect O
for O
rasagiline O
1 O
mg/day O
, O
though O
the O
clinical O
import O
of O
this O
finding O
has O
yet O
to O
be O
established O
. O

ATP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase B
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced O
inflammatory O
activation O
is O
mediated O
by O
intracellular O
free O
calcium O
in O
microglial O
cells.2,3,7,8-Tetrachlorodibenzo-p-dioxin O
(TCDD) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O
However O
, O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB O
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine B
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

lovastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structural O
basis O
for O
LFA-1 B
inhibition O
upon O
lovastatin O
binding O
to O
the O
CD11a O
I-domain.The O
lymphocyte O
function-associated O
antigen O
(LFA-1) O
belongs O
to O
the O
family O
of O
beta2-integrins O
and O
plays O
an O
important O
role O
in O
T-cell O
activation O
and O
leukocyte O
migration O
to O
sites O
of O
inflammation O
. O
We O
report O
here O
that O
lovastatin O
, O
a O
drug O
clinically O
used O
for O
lowering O
cholesterol O
levels O
, O
inhibits O
the O
interaction O
of O
human O
LFA-1 O
with O
its O
counter-receptor O
intercellular O
adhesion O
molecule-1 O
. O
Using O
nuclear O
magnetic O
resonance O
spectroscopy O
and O
X-ray O
crystallography O
we O
show O
that O
the O
inhibitor O
binds O
to O
a O
highly O
conserved O
domain O
of O
the O
LFA-1 O
alpha-chain O
called O
the O
I-domain O
. O
The O
first O
three-dimensional O
structure O
of O
an O
integrin O
inhibitor O
bound O
to O
its O
receptor O
reveals O
atomic O
details O
for O
a O
hitherto O
unknown O
mode O
of O
LFA-1 O
inhibition O
. O
It O
also O
sheds O
light O
into O
possible O
mechanisms O
of O
LFA-1 O
mediated O
signalling O
and O
will O
support O
the O
design O
of O
novel O
anti-adhesive O
and O
immunosuppressive O
drugs O
. O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated B
protein-light I
chain I
3 I
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Safrole-2',3'-oxide O
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein O
E-knockout O
mice.Safrole-2',3'-oxide O
(SFO) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole O
(4-allyl-1 O
, O
2-methylenedioxybenzene) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO-induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha B
chemokine I
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

terbinafine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Molecular O
mechanism O
of O
terbinafine O
resistance O
in O
Saccharomyces O
cerevisiae.Ten O
mutants O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
resistant O
to O
the O
antimycotic O
terbinafine O
were O
isolated O
after O
chemical O
or O
UV O
mutagenesis O
. O
Molecular O
analysis O
of O
these O
mutants O
revealed O
single O
base O
pair O
exchanges O
in O
the O
ERG1 O
gene O
coding O
for O
squalene B
epoxidase I
, O
the O
target O
of O
terbinafine O
. O
The O
mutants O
did O
not O
show O
cross-resistance O
to O
any O
of O
the O
substrates O
of O
various O
pleiotropic O
drug O
resistance O
efflux O
pumps O
tested O
. O
The O
ERG1 O
mRNA O
levels O
in O
the O
mutants O
did O
not O
differ O
from O
those O
in O
the O
wild-type O
parent O
strains O
. O
Terbinafine O
resistance O
was O
transmitted O
with O
the O
mutated O
alleles O
in O
gene O
replacement O
experiments O
, O
proving O
that O
single O
amino O
acid O
substitutions O
in O
the O
Erg1 O
protein O
were O
sufficient O
to O
confer O
the O
resistance O
phenotype O
. O
The O
amino O
acid O
changes O
caused O
by O
the O
point O
mutations O
were O
clustered O
in O
two O
regions O
of O
the O
Erg1 O
protein O
. O
Seven O
mutants O
carried O
the O
amino O
acid O
substitutions O
F402L O
(one O
mutant) O
, O
F420L O
(one O
mutant) O
, O
and O
P430S O
(five O
mutants) O
in O
the O
C-terminal O
part O
of O
the O
protein; O
and O
three O
mutants O
carried O
an O
L251F O
exchange O
in O
the O
central O
part O
of O
the O
protein O
. O
Interestingly O
, O
all O
exchanges O
identified O
involved O
amino O
acids O
which O
are O
conserved O
in O
the O
squalene O
epoxidases O
of O
yeasts O
and O
mammals O
. O
Two O
mutations O
that O
were O
generated O
by O
PCR O
mutagenesis O
of O
the O
ERG1 O
gene O
and O
that O
conferred O
terbinafine O
resistance O
mapped O
in O
the O
same O
regions O
of O
the O
Erg1 O
protein O
, O
with O
one O
resulting O
in O
an O
L251F O
exchange O
and O
the O
other O
resulting O
in O
an O
F433S O
exchange O
. O
The O
results O
strongly O
indicate O
that O
these O
regions O
are O
responsible O
for O
the O
interaction O
of O
yeast O
squalene O
epoxidase O
with O
terbinafine O
. O

polyinosinic:polycytidylic O
acid O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
IFNα O
converts O
IL-22 O
into O
a O
cytokine O
efficiently O
activating O
STAT1 O
and O
its O
downstream O
targets.Besides O
their O
antiviral O
activity O
, O
type O
I O
Interferons O
(IFN) O
display O
context-specific O
immunomodulation O
. O
In O
contrast O
to O
long-known O
IFNα/β O
, O
Interleukin O
(IL)-22 O
is O
an O
anti-bacterial O
, O
largely O
tissue O
protective O
cytokine O
that O
recently O
gained O
attention O
. O
Herein O
, O
cellular O
IFNα/IL-22 O
interactions O
are O
investigated O
. O
We O
report O
that O
pre-conditioning O
of O
epithelial O
cells O
with O
IFNα O
initiated O
dramatic O
changes O
in O
IL-22 O
signaling O
normally O
dominated O
by O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT)-3 O
. O
Specifically O
, O
by O
using O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β B
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O
characteristics O
of O
IFNα/β O
in O
clinical O
therapy O
and O
expose O
margins O
of O
tissue O
protection O
by O
IL-22 O
application O
. O

oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Oxysterols O
in O
cancer O
cell O
proliferation O
and O
death.Oxysterols O
have O
been O
shown O
to O
interfere O
with O
proliferation O
and O
cause O
the O
death O
of O
many O
cancer O
cell O
types O
, O
such O
as O
leukaemia O
, O
glioblastoma O
, O
colon O
, O
breast O
and O
prostate O
cancer O
cells O
, O
while O
they O
have O
little O
or O
no O
effect O
on O
senescent O
cells O
. O
The O
mechanisms O
by O
which O
oxysterols O
may O
influence O
proliferation O
are O
manifold O
: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol O
synthesis O
, O
3-hydroxy-3-methylglutaryl O
CoA O
reductase O
, O
by O
binding O
to O
Insig-1 O
, O
Insig-2 O
and O
liver O
X O
receptors O
. O
Oxysterols O
are O
thought O
to O
be O
generated O
in O
proportion O
to O
the O
rate O
of O
cholesterol O
synthesis O
. O
Although O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins B
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O
oxysterol O
action O
that O
seem O
important O
for O
cancer O
treatment O
, O
cytostaticity O
and O
cytotoxicity O
, O
will O
be O
discussed O
. O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

L-proline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
L-proline O
accumulation O
and O
freeze O
tolerance O
of O
Saccharomyces O
cerevisiae O
are O
caused O
by O
a O
mutation O
in O
the O
PRO1 O
gene O
encoding O
gamma-glutamyl O
kinase.We O
previously O
isolated O
a O
mutant O
which O
showed O
a O
high O
tolerance O
to O
freezing O
that O
correlated O
with O
higher O
levels O
of O
intracellular O
L-proline O
derived O
from O
L-proline O
analogue-resistant O
mutants O
. O
The O
mutation O
responsible O
for O
the O
analogue O
resistance O
and O
L-proline O
accumulation O
was O
a O
single O
nuclear O
dominant O
mutation O
. O
By O
introducing O
the O
mutant-derived O
genomic O
library O
into O
a O
non-L-proline-utilizing O
strain O
, O
the O
mutant O
was O
found O
to O
carry O
an O
allele O
of O
the O
wild-type O
PRO1 O
gene O
encoding O
gamma-glutamyl O
kinase O
, O
which O
resulted O
in O
a O
single O
amino O
acid O
replacement; O
Asp O
(GAC) O
at O
position O
154 O
was O
replaced O
by O
Asn O
(AAC) O
. O
Interestingly O
, O
the O
allele O
of O
PRO1 O
was O
shown O
to O
enhance O
the O
activities O
of O
gamma-glutamyl B
kinase I
and O
gamma-glutamyl O
phosphate O
reductase O
, O
both O
of O
which O
catalyze O
the O
first O
two O
steps O
of O
L-proline O
synthesis O
from O
L-glutamate O
and O
which O
together O
may O
form O
a O
complex O
in O
vivo O
. O
When O
cultured O
in O
liquid O
minimal O
medium O
, O
yeast O
cells O
expressing O
the O
mutated O
gamma-glutamyl O
kinase O
were O
found O
to O
accumulate O
intracellular O
L-proline O
and O
showed O
a O
prominent O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O
wild-type O
PRO1 O
gene O
. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl O
kinase O
results O
in O
stabilization O
of O
the O
complex O
or O
has O
an O
indirect O
effect O
on O
gamma-glutamyl O
phosphate O
reductase O
activity O
, O
which O
leads O
to O
an O
increase O
in O
L-proline O
production O
in O
Saccharomyces O
cerevisiae O
. O
The O
approach O
described O
in O
this O
paper O
could O
be O
a O
practical O
method O
for O
breeding O
novel O
freeze-tolerant O
yeast O
strains O
. O

Butein O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Butein O
protects O
human O
dental O
pulp O
cells O
from O
hydrogen O
peroxide-induced O
oxidative O
toxicity O
via O
Nrf2 B
pathway-dependent O
heme O
oxygenase-1 O
expressions.Rhus O
verniciflua O
Stokes O
is O
a O
plant O
that O
is O
native O
to O
East O
Asian O
countries O
, O
such O
as O
Korea O
, O
China O
, O
and O
Japan O
. O
Butein O
, O
a O
plant O
polyphenol O
, O
is O
one O
of O
the O
major O
active O
components O
of O
R O
. O
verniciflua O
. O
Reactive O
oxygen O
species O
(ROS) O
, O
produced O
via O
dental O
adhesive O
bleaching O
agents O
and O
pulpal O
disease O
, O
can O
cause O
oxidative O
stress O
. O
Here O
, O
we O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

betaxolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
, O
reduces O
Na(+) O
influx O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) O
channels O
: O
comparison O
with O
other O
beta-adrenoceptor O
antagonists.Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
used O
for O
the O
treatment O
of O
glaucoma O
, O
is O
known O
to O
be O
neuroprotective O
in O
paradigms O
of O
ischaemia/excitotoxicity O
. O
In O
this O
study O
, O
we O
examined O
whether O
betaxolol O
and O
other O
beta-adrenoceptor B
antagonists O
interact O
directly O
with O
neurotoxin O
binding O
to O
sites O
1 O
and O
2 O
of O
the O
voltage-sensitive O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM O
. O
Comparison O
of O
all O
the O
beta-adrenoceptor O
antagonists O
tested O
revealed O
a O
potency O
order O
of O
propranolol>betaxolol O
approximately O
levobetaxolol>levobunolol O
approximately O
carteolol>/=timolol>atenolol O
. O
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin O
binding O
to O
neurotoxin O
receptor O
site O
1 O
, O
even O
at O
concentrations O
as O
high O
as O
250 O
microM O
. O
Saturation O
experiments O
showed O
that O
betaxolol O
increased O
the O
K(D) O
of O
[(3)H]-BTX-B O
binding O
but O
had O
no O
effect O
on O
the O
B(max) O
. O
The O
association O
kinetics O
of O
[(3)H]-BTX-B O
were O
unaffected O
by O
betaxolol O
, O
but O
the O
drug O
significantly O
accelerated O
the O
dissociation O
rate O
of O
the O
radioligand O
. O
These O
findings O
argue O
for O
a O
competitive O
, O
indirect O
, O
allosteric O
mode O
of O
inhibition O
of O
[(3)H]-BTX-B O
binding O
by O
betaxolol O
. O
Betaxolol O
inhibited O
veratridine-stimulated O
Na(+) O
influx O
in O
rat O
cortical O
synaptosomes O
with O
an O
IC(50) O
value O
of O
28 O
. O
3 O
microM O
. O
Carteolol O
, O
levobunolol O
, O
timolol O
and O
atenolol O
were O
significantly O
less O
effective O
than O
betaxolol O
at O
reducing O
veratridine-evoked O
Na(+) O
influx O
. O
The O
ability O
of O
betaxolol O
to O
interact O
with O
neurotoxin O
site O
2 O
of O
the O
Na(+) O
channel O
and O
inhibit O
Na(+) O
influx O
may O
have O
a O
role O
in O
its O
neuroprotective O
action O
in O
paradigms O
of O
excitotoxicity/ischaemia O
and O
in O
its O
therapeutic O
effect O
in O
glaucoma O
. O

[6]-Gingerol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
[6]-gingerol O
: O
a O
novel O
AT₁ O
antagonist O
for O
the O
treatment O
of O
cardiovascular O
disease.Considering O
the O
prevalence O
of O
cardiovascular O
disease O
in O
public O
health O
and O
the O
limited O
validated O
therapeutic O
options O
, O
this O
study O
aimed O
to O
find O
novel O
compounds O
targeting O
the O
angiotensin O
II O
type O
1 O
receptor O
, O
accepted O
as O
a O
therapeutic O
target O
in O
cardiovascular O
disease O
. O
A O
small O
library O
consisting O
of O
89 O
compounds O
from O
39 O
Chinese O
herbs O
was O
profiled O
using O
a O
cell-based O
calcium O
mobilization O
assay O
which O
was O
developed O
and O
characterized O
for O
high-throughput O
screening O
. O
[6]-Gingerol O
derived O
from O
Zingiber O
officinale O
Roscoe O
(ginger) O
was O
identified O
as O
a O
novel O
angiotensin B
II I
type I
1 I
receptor I
antagonist O
, O
with O
an O
IC50 O
value O
of O
8.173 O
µM O
. O
The O
hit O
was O
further O
tested O
by O
a O
specificity O
assay O
indicating O
that O
it O
had O
no O
antagonistic O
effects O
on O
other O
evaluated O
GPCRs O
, O
such O
as O
endothelin O
receptors O
. O
The O
major O
ingredient O
of O
ginger O
, O
[6]-gingerol O
, O
could O
inhibit O
angiotensin O
II O
type O
1 O
receptor O
activation O
, O
which O
partially O
clarified O
the O
mechanism O
of O
ginger O
regulating O
blood O
pressure O
and O
strengthening O
heart O
in O
the O
cardiovascular O
system O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP B
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

sulindac O
sulfide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated O
kinase O
1/2 O
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 B
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

UDP-Gal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
( O
beta4Gal-T1) B
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

all-trans-retinoic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic B
acid I
receptor I
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 O
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat O
A O
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O
which O
could O
have O
signaling O
functions O
. O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK- O
mTOR B
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

Warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Warfarin O
dose O
and O
the O
pharmacogenomics O
of O
CYP2C9 B
and O
VKORC1 O
- O
rationale O
and O
perspectives.Warfarin O
is O
the O
most O
widely O
prescribed O
oral O
anticoagulant O
, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O
VKORC1) O
, O
demographic O
, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin O
dosage O
, O
could O
potentially O
minimize O
the O
risk O
of O
over O
dose O
during O
warfarin O
induction O
. O

torasemide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Torasemide O
inhibits O
angiotensin O
II-induced O
vasoconstriction O
and O
intracellular O
calcium O
increase O
in O
the O
aorta O
of O
spontaneously O
hypertensive O
rats.Torasemide O
is O
a O
loop O
diuretic O
that O
is O
effective O
at O
low O
once-daily O
doses O
in O
the O
treatment O
of O
arterial O
hypertension O
. O
Because O
its O
antihypertensive O
mechanism O
of O
action O
may O
not O
be O
based O
entirely O
on O
the O
elimination O
of O
salt O
and O
water O
from O
the O
body O
, O
a O
vasodilator O
effect O
of O
this O
drug O
can O
be O
considered O
. O
In O
the O
present O
study O
, O
the O
ability O
of O
different O
concentrations O
of O
torasemide O
to O
modify O
angiotensin O
II O
(Ang O
II)-induced O
vascular O
responses O
was O
examined O
, O
with O
the O
use O
of O
an O
organ O
bath O
system O
, O
in O
endothelium-denuded O
aortic O
rings O
from O
spontaneously O
hypertensive O
rats O
. O
Ang O
II-induced O
increases O
of O
intracellular O
free O
calcium O
concentration O
([Ca(2+)](i)) O
were O
also O
examined O
by O
image O
analysis O
in O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
from O
spontaneously O
hypertensive O
rats O
. O
A O
dose-response O
curve O
to O
Ang O
II O
was O
plotted O
for O
cumulative O
concentrations O
(from O
10(-9) O
to O
10(-6) O
mol/L) O
in O
endothelium-denuded O
aortic O
rings O
(pD(2)=7.5+/-0.3) O
. O
Isometric O
contraction O
induced O
by O
a O
submaximal O
concentration O
of O
Ang O
II O
(10(-7) O
mol/L) O
was O
reduced O
in O
a O
dose-dependent O
way O
by O
torasemide O
(IC(50)=0.5+/-0.04 O
micromol/L) O
. O
Incubation O
of O
VSMCs O
with O
different O
concentrations O
of O
Ang O
II O
(from O
10(-10) O
to O
10(-6) O
mol/L) O
resulted O
in O
a O
dose-dependent O
rise O
of O
[Ca(2+)](i) O
(pD(2)=7.5+/-0.3) O
. O
The O
stimulatory O
effect O
of O
[Ca(2+)](i) O
induced O
by O
a O
submaximal O
concentration O
of O
Ang B
II I
(10(-7) O
mol/L) O
was O
blocked O
by O
torasemide O
(IC(50)=0.5+/-0.3 O
nmol/L) O
. O
Our O
findings O
suggest O
that O
torasemide O
blocks O
the O
vasoconstrictor O
action O
of O
Ang O
II O
in O
vitro O
. O
This O
action O
can O
be O
related O
to O
the O
ability O
of O
torasemide O
to O
block O
the O
increase O
of O
[Ca(2+)](i) O
induced O
by O
Ang O
II O
in O
VSMCs O
. O
It O
is O
proposed O
that O
these O
actions O
might O
be O
involved O
in O
the O
antihypertensive O
effect O
of O
torasemide O
observed O
in O
vivo O
. O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE B
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

phenytoin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Genetic O
predictors O
of O
the O
maximum O
doses O
patients O
receive O
during O
clinical O
use O
of O
the O
anti-epileptic O
drugs O
carbamazepine O
and O
phenytoin.Phenytoin O
and O
carbamazepine O
are O
effective O
and O
inexpensive O
anti-epileptic O
drugs O
(AEDs) O
. O
As O
with O
many O
AEDs O
, O
a O
broad O
range O
of O
doses O
is O
used O
, O
with O
the O
final O
"maintenance" O
dose O
normally O
determined O
by O
trial O
and O
error O
. O
Although O
many O
genes O
could O
influence O
response O
to O
these O
medicines O
, O
there O
are O
obvious O
candidates O
. O
Both O
drugs O
target O
the O
alpha-subunit O
of O
the O
sodium O
channel O
, O
encoded O
by O
the O
SCN O
family O
of O
genes O
. O
Phenytoin O
is O
principally O
metabolized O
by O
CYP2C9 O
, O
and O
both O
are O
probable O
substrates O
of O
the O
drug O
transporter O
P-glycoprotein O
. O
We O
therefore O
assessed O
whether O
variation O
in O
these O
genes O
associates O
with O
the O
clinical O
use O
of O
carbamazepine O
and O
phenytoin O
in O
cohorts O
of O
425 O
and O
281 O
patients O
, O
respectively O
. O
We O
report O
that O
a O
known O
functional O
polymorphism O
in O
CYP2C9 O
is O
highly O
associated O
with O
the O
maximum O
dose O
of O
phenytoin O
(P O
= O
0.0066) O
. O
We O
also O
show O
that O
an O
intronic O
polymorphism O
in O
the O
SCN1A B
gene O
shows O
significant O
association O
with O
maximum O
doses O
in O
regular O
usage O
of O
both O
carbamazepine O
and O
phenytoin O
(P O
= O
0.0051 O
and O
P O
= O
0.014 O
, O
respectively) O
. O
This O
polymorphism O
disrupts O
the O
consensus O
sequence O
of O
the O
5' O
splice O
donor O
site O
of O
a O
highly O
conserved O
alternative O
exon O
(5N) O
, O
and O
it O
significantly O
affects O
the O
proportions O
of O
the O
alternative O
transcripts O
in O
individuals O
with O
a O
history O
of O
epilepsy O
. O
These O
results O
provide O
evidence O
of O
a O
drug O
target O
polymorphism O
associated O
with O
the O
clinical O
use O
of O
AEDs O
and O
set O
the O
stage O
for O
a O
prospective O
evaluation O
of O
how O
pharmacogenetic O
diagnostics O
can O
be O
used O
to O
improve O
dosing O
decisions O
in O
the O
use O
of O
phenytoin O
and O
carbamazepine O
. O
Although O
the O
case O
made O
here O
is O
compelling O
, O
our O
results O
cannot O
be O
considered O
definitive O
or O
ready O
for O
clinical O
application O
until O
they O
are O
confirmed O
by O
independent O
replication O
. O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 B
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

ergotamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
5-HT1B O
receptors O
, O
alpha2A/2C- O
and O
, O
to O
a O
lesser O
extent O
, O
alpha1-adrenoceptors O
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow O
. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v O
. O
bolus O
injection O
of O
, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control) O
, O
or O
the O
antagonists O
SB224289 O
(300 O
microg/kg; O
5-HT1B) O
, O
BRL15572 O
(300 O
microg/kg; O
5-HT1D) O
, O
rauwolscine O
(300 O
microg/kg; O
alpha2) O
, O
SB224289 O
+ O
BRL15572 O
(300 O
microg/kg O
each) O
, O
SB224289 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
BRL15572 O
+ O
rauwolscine O
(300 O
microg/kg O
each) O
, O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg; O
alpha1) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
rauwolscine O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
BRL44408 O
(1,000 O
microg/kg; O
alpha2A) O
, O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg)+ O
imiloxan O
(1,000 O
microg/kg; O
alpha2B) O
, O
or O
SB224289 O
(300 O
microg/kg) O
+ O
prazosin O
(100 O
microg/kg) O
+ O
MK912 O
(300 O
microg/kg; O
alpha2C) O
. O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine O
(0.56 O
, O
1 O
, O
1.8 O
, O
3.1 O
, O
5.6 O
, O
10 O
and O
18 O
microg/min) O
, O
following O
a O
cumulative O
schedule O
. O
In O
saline-pretreated O
animals O
, O
ergotamine O
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate O
. O
These O
control O
responses O
were O
: O
unaffected O
by O
SB224289 O
, O
BRL15572 O
, O
rauwolscine O
or O
the O
combinations O
of O
SB224289 O
+ O
BRL15572 O
, O
BRL15572 O
+ O
rauwolscine O
, O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
, O
or O
SB224289 O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors B
. O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
jaspamide O
on O
human O
cardiomyocyte O
function O
and O
cardiac O
ion O
channel O
activity.Jaspamide O
(jasplakinolide; O
NSC-613009) O
is O
a O
cyclodepsipeptide O
that O
has O
antitumor O
activity O
. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 B
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O
amplitude O
, O
putative O
measurements O
of O
cell O
viability O
and O
cardiac O
contractility O
, O
respectively O
. O
Concentration-dependent O
increases O
in O
rhythmic O
beating O
rate O
were O
noted O
at O
≤ O
6 O
h O
of O
treatment O
, O
followed O
by O
dose-dependent O
decreases O
after O
6 O
and O
72 O
h O
exposure O
. O
The O
toxic O
effects O
of O
jaspamide O
were O
compared O
with O
that O
of O
the O
known O
cardiotoxicant O
mitoxantrone O
, O
and O
confirmed O
by O
multiparameter O
fluorescence O
imaging O
analysis O
. O
These O
results O
support O
the O
hypothesis O
that O
the O
toxicity O
observed O
in O
rats O
and O
dogs O
is O
due O
to O
toxic O
effects O
of O
jaspamide O
on O
cardiomyocytes O
. O

Thiazolidinediones O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome B
proliferator-activated I
receptor I
gamma I
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

[(18)F]setoperone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
PET O
study O
of O
dopamine O
D2 O
and O
serotonin O
5-HT2 O
receptor O
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone.OBJECTIVE O
: O
Ziprasidone O
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin O
5-HT(2) O
receptors O
compared O
with O
dopamine O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O
in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) O
occupancy O
(using O
[(11)C]raclopride) O
and O
5-HT(2) B
occupancy O
(using O
[(18)F]setoperone) O
in O
brain O
regions O
of O
interest O
in O
16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40 O
, O
80 O
, O
120 O
, O
or O
160 O
mg/day O
of O
ziprasidone O
, O
which O
reflected O
the O
recommended O
dose O
range O
. O
PET O
scanning O
was O
done O
after O
3 O
weeks O
of O
administration O
and O
at O
trough O
plasma O
levels O
, O
i.e. O
, O
12-16 O
hours O
after O
the O
last O
dose O
. O
RESULTS O
: O
The O
mean O
5-HT(2) O
receptor O
occupancy O
was O
significantly O
higher O
than O
the O
mean O
D(2) O
receptor O
occupancy O
(mean=76% O
, O
SD=15% O
, O
and O
mean=56% O
, O
SD=18% O
, O
respectively) O
. O
The O
estimated O
plasma O
ziprasidone O
concentration O
associated O
with O
50% O
maximal O
5-HT(2) O
receptor O
occupancy O
was O
almost O
four O
times O
lower O
than O
that O
for O
D(2) O
receptor O
occupancy O
. O
CONCLUSIONS O
: O
These O
data O
affirm O
that O
ziprasidone O
is O
similar O
to O
other O
novel O
antipsychotics O
in O
having O
greater O
5-HT(2) O
than O
D(2) O
receptor O
occupancy O
at O
therapeutic O
doses O
and O
suggest O
that O
the O
optimal O
effective O
dose O
of O
ziprasidone O
is O
closer O
to O
120 O
mg/day O
than O
to O
the O
lower O
doses O
suggested O
by O
previous O
PET O
studies O
. O
The O
relatively O
high O
D(2) O
receptor O
occupancy O
, O
even O
at O
trough O
plasma O
levels O
, O
suggests O
that O
ziprasidone O
is O
more O
similar O
to O
risperidone O
and O
olanzapine O
in O
receptor O
occupancy O
profile O
than O
to O
clozapine O
and O
quetiapine O
. O
Since O
ziprasidone O
plasma O
levels O
show O
significant O
(more O
than O
twofold) O
variation O
within O
a O
single O
dose O
cycle O
, O
studies O
that O
are O
aimed O
at O
peak O
plasma O
levels O
(6 O
hours O
after O
the O
last O
dose) O
and O
that O
examine O
extrastriatal O
regions O
are O
required O
to O
fully O
characterize O
the O
in O
vivo O
occupancy O
profile O
of O
ziprasidone O
. O

doxazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Alpha1-adrenergic O
receptors O
and O
their O
inhibitors O
in O
lower O
urinary O
tract O
symptoms O
and O
benign O
prostatic O
hyperplasia.PURPOSE O
: O
We O
provide O
a O
comprehensive O
overview O
of O
the O
role O
of O
alpha1-adrenergic O
receptors O
(alpha1ARs) O
as O
critical O
mediators O
of O
lower O
urinary O
tract O
symptoms O
(LUTS) O
and O
pathophysiology O
in O
benign O
prostatic O
hyperplasia O
(BPH) O
, O
and O
we O
review O
the O
pharmacological O
antagonists O
of O
alpha1ARs O
. O
MATERIALS O
AND O
METHODS O
: O
A O
review O
was O
performed O
of O
pertinent O
studies O
in O
the O
literature O
relating O
to O
the O
pathophysiology O
of O
LUTS O
and O
BPH O
, O
focusing O
on O
the O
role O
of O
alpha1ARs O
, O
and O
of O
clinical O
trial O
and O
practice O
data O
evaluating O
the O
different O
agents O
that O
inhibit O
these O
receptors O
. O
RESULTS O
: O
Further O
characterization O
of O
the O
alpha1AR O
gene O
family O
indicates O
that O
3 O
receptor O
subtypes O
exist O
in O
humans O
. O
Their O
different O
distribution O
between O
urinary O
tract O
and O
cardiovascular O
tissues O
has O
provided O
a O
strategy O
for O
the O
development O
of O
improved O
therapeutic O
agents O
. O
Since O
excessive O
activity O
of O
the O
alpha1aAR O
and O
alpha1dAR O
subtypes O
appears O
to O
be O
a O
common O
feature O
in O
symptomatic O
BPH O
and O
alpha1aARs O
are O
enriched O
in O
prostatic O
tissue O
, O
drugs O
that O
demonstrate O
high O
alpha1aAR O
selectivity O
have O
attracted O
attention O
. O
Tamsulosin O
, O
which O
has O
high O
affinity O
for O
alpha1aAR B
and O
alpha1dAR O
subtypes O
but O
not O
for O
alpha1bAR O
, O
shows O
efficacy O
similar O
to O
the O
nonsubtype O
selective O
agents O
terazosin O
and O
doxazosin O
. O
It O
is O
associated O
with O
fewer O
cardiovascular O
side O
effects O
, O
although O
it O
has O
some O
ejaculatory O
side O
effects O
. O
The O
nonsubtype O
selective O
agent O
alfuzosin O
also O
demonstrates O
efficacy O
and O
offers O
an O
enhanced O
side O
effect O
profile O
, O
particularly O
minimizing O
hypotension O
. O
Other O
agents O
with O
super O
selective O
specificity O
for O
the O
alpha1aAR O
subtype O
are O
under O
investigation O
. O
CONCLUSIONS O
: O
Further O
advances O
in O
the O
treatment O
of O
LUTS O
associated O
with O
BPH O
may O
depend O
not O
only O
on O
receptor O
subtype O
selectivity O
, O
but O
also O
on O
other O
pharmacokinetic O
and O
pharmacodynamic O
factors O
. O

Conivaptan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Conivaptan O
: O
a O
dual O
vasopressin B
receptor I
v1a/v2 I
antagonist O
[corrected].Several O
fluid O
retentive O
states O
such O
as O
heart O
failure O
, O
cirrhosis O
of O
the O
liver O
, O
and O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
secretion O
are O
associated O
with O
inappropriate O
elevation O
in O
plasma O
levels O
of O
arginine O
vasopressin O
(AVP) O
, O
a O
neuropeptide O
that O
is O
secreted O
by O
the O
hypothalamus O
and O
plays O
a O
critical O
role O
in O
the O
regulation O
of O
serum O
osmolality O
and O
in O
circulatory O
homeostasis O
. O
The O
actions O
of O
AVP O
are O
mediated O
by O
three O
receptor O
subtypes O
V1a O
, O
V2 O
, O
and O
V1b O
. O
The O
V1a O
receptor O
regulates O
vasodilation O
and O
cellular O
hypertrophy O
while O
the O
V2 O
receptor O
regulates O
free O
water O
excretion O
. O
The O
V1b O
receptor O
regulates O
adrenocorticotropin O
hormone O
release O
. O
Conivaptan O
is O
a O
nonpeptide O
dual O
V1a/V2 O
AVP O
receptor O
antagonist O
. O
It O
binds O
with O
high O
affinity O
, O
competitively O
, O
and O
reversibly O
to O
the O
V1a/V2 O
receptor O
subtypes; O
its O
antagonistic O
effect O
is O
concentration O
dependent O
. O
It O
inhibits O
CYP3A4 O
liver O
enzyme O
and O
elevates O
plasma O
levels O
of O
other O
drugs O
metabolized O
by O
this O
enzyme O
. O
It O
is O
approved O
only O
for O
short-term O
intravenous O
use O
. O
Infusion O
site O
reaction O
is O
the O
most O
common O
reason O
for O
discontinuation O
of O
the O
drug O
. O
In O
animals O
conivaptan O
increased O
urine O
volume O
and O
free O
water O
clearance O
. O
In O
heart O
failure O
models O
it O
improved O
hemodynamic O
parameters O
and O
free O
water O
excretion O
. O
Conivaptan O
has O
been O
shown O
to O
correct O
hyponatremia O
in O
euvolemic O
or O
hypervolemic O
patients O
. O
Its O
efficacy O
and O
safety O
for O
short-term O
use O
have O
led O
to O
the O
Food O
and O
Drug O
Administration O
(FDA) O
approval O
of O
its O
intravenous O
form O
for O
the O
correction O
of O
hyponatremia O
in O
euvolemic O
and O
hypervolemic O
states O
. O
Despite O
its O
ability O
to O
block O
the O
action O
of O
AVP O
on O
V1a O
receptors O
, O
no O
demonstrable O
benefit O
from O
this O
action O
was O
noted O
in O
patients O
with O
chronic O
compensated O
heart O
failure O
and O
it O
is O
not O
approved O
for O
this O
indication O
. O
Consideration O
should O
be O
given O
to O
further O
evaluation O
of O
its O
potential O
benefits O
in O
patients O
with O
acute O
decompensated O
heart O
failure O
. O

5-methyl-urapidil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha B
1A-adrenoceptor I
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine B
transporter I
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

resveratrol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
SIRT1 O
inhibits O
NADPH O
oxidase O
activation O
and O
protects O
endothelial O
function O
in O
the O
rat O
aorta O
: O
Implications O
for O
vascular O
aging.Vascular O
aging O
is O
characterized O
by O
up-regulation O
of O
NADPH O
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 B
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC-1α O
acetylation O
and O
the O
subsequent O
PPARα O
activation O
, O
resulting O
in O
both O
decreased O
NADPH O
oxidase-driven O
ROS O
production O
and O
NO O
inactivation O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
TCDD O
inhibition O
of O
canonical O
wnt O
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus.In O
mice O
, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- O
dioxin O
(TCDD) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 B
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

meclofenamate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Meclofenamic O
acid O
and O
diclofenac O
, O
novel O
templates O
of O
KCNQ2/Q3 O
potassium O
channel O
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O
voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current O
. O
Furthermore O
, O
the O
KCNQ2 O
and O
KCNQ3 O
channel O
alpha O
subunits O
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 B
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics O
. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O
KCNQ2 O
than O
on O
KCNQ3 O
channel O
alpha O
subunits O
. O
In O
contrast O
, O
they O
did O
not O
enhance O
KCNQ1 O
K(+) O
currents O
. O
Both O
openers O
increased O
KCNQ2/Q3 O
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential O
. O
In O
cultured O
cortical O
neurons O
, O
meclofenamate O
and O
diclofenac O
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials O
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pain O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
G O
protein-coupled O
receptors O
as O
direct O
targets O
of O
inhaled O
anesthetics.The O
molecular O
pharmacology O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine B
rhodopsin I
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O
revealed O
that O
halothane O
contacts O
an O
amino O
acid O
residue O
(Trp265) O
lining O
the O
ligand O
binding O
cavity O
in O
the O
transmembrane O
core O
of O
the O
receptor O
. O
The O
predicted O
functional O
consequence O
, O
competition O
between O
halothane O
and O
the O
ligand O
retinal O
, O
was O
shown O
here O
by O
spectroscopy O
and O
is O
known O
to O
exist O
in O
vivo O
. O
These O
data O
suggest O
that O
competition O
with O
endogenous O
ligands O
may O
be O
a O
general O
mechanism O
of O
the O
action O
of O
halothane O
at O
this O
large O
family O
of O
signaling O
proteins O
. O

lithium O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 B
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

Dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dexamethasone O
suppresses O
histamine O
synthesis O
by O
repressing O
both O
transcription O
and O
activity O
of O
HDC B
in O
allergic O
rats.BACKGROUND O
: O
Histamine O
synthesized O
by O
histidine O
decarboxylase O
(HDC) O
from O
L-histidine O
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity O
. O
However O
the O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation O
. O
Histamine O
content O
and O
HDC O
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography O
. O
The O
expression O
of O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity O
. O
Repression O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
by O
dexamethasone O
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy O
. O

troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 B
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

Cl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase B
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O
a O
difluoromethylene O
linker O
, O
replacement O
of O
the O
para-cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole O
derivative O
with O
IC50 O
values O
against O
aromatase O
and O
steroid O
sulfatase O
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM O
, O
respectively O
. O
The O
parent O
phenol O
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay O
. O

H2biopterin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Tyrosine O
hydroxylase O
binds O
tetrahydrobiopterin O
cofactor O
with O
negative O
cooperativity O
, O
as O
shown O
by O
kinetic O
analyses O
and O
surface O
plasmon O
resonance O
detection.Kinetic O
studies O
of O
tetrameric O
recombinant O
human O
tyrosine O
hydroxylase O
isoform O
1 O
(hTH1) O
have O
revealed O
properties O
so O
far O
not O
reported O
for O
this O
enzyme O
. O
Firstly O
, O
with O
the O
natural O
cofactor O
(6R)-Lerythro-5,6,7 O
, O
8-tetrahydrobiopterin O
(H4biopterin) O
a O
time-dependent O
change O
(burst) O
in O
enzyme O
activity O
was O
observed O
, O
with O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient O
. O
Secondly O
, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin O
with O
a O
pronounced O
negative O
cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM) O
. O
On O
phosphorylation O
of O
Ser40 O
by O
protein O
kinase O
A O
, O
the O
affinity O
for O
H4biopterin O
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O
negative O
cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03) O
. O
The O
dimeric O
C-terminal O
deletion O
mutant O
(Delta473-528) O
of O
hTH1 O
also O
showed O
negative O
cooperativity O
of O
H4biopterin O
binding O
(h O
= O
0.4) O
. O
Cooperativity O
was O
not O
observed O
with O
the O
cofactor O
analogues O
6-methyl-5,6,7,8-tetrahydropterin O
(h O
= O
0.9 O
+/- O
0.1; O
Km O
= O
62.7 O
+/- O
5.7 O
microM) O
and O
3-methyl-5,6,7 O
, O
8-tetrahydropterin O
(H43-methyl-pterin)(h O
= O
1.0 O
+/- O
0.1; O
Km O
= O
687 O
+/- O
50 O
microM) O
. O
In O
the O
presence O
of O
1 O
mM O
H43-methyl-pterin O
, O
used O
as O
a O
competitive O
cofactor O
analogue O
to O
BH4 O
, O
hyperbolic O
saturation O
curves O
were O
also O
found O
for O
H4biopterin O
(h O
= O
1.0) O
, O
thus O
confirming O
the O
genuine O
nature O
of O
the O
kinetic O
negative O
cooperativity O
. O
This O
cooperativity O
was O
confirmed O
by O
real-time O
biospecific O
interaction O
analysis O
by O
surface O
plasmon O
resonance O
detection O
. O
The O
equilibrium O
binding O
of O
H4biopterin O
to O
the O
immobilized O
iron-free O
apoenzyme O
results O
in O
a O
saturable O
positive O
resonance O
unit O
(DeltaRU) O
response O
with O
negative O
cooperativity O
(h O
= O
0.52-0.56) O
. O
Infrared O
spectroscopic O
studies O
revealed O
a O
reduced O
thermal O
stability O
both O
of O
the O
apo-and O
the O
holo- O
hTH1 B
on O
binding O
of O
H4biopterin O
and O
Lerythro-dihydrobiopterin O
(H2biopterin) O
. O
Moreover O
, O
the O
ligand-bound O
forms O
of O
the O
enzyme O
also O
showed O
a O
decreased O
resistance O
to O
limited O
tryptic O
proteolysis O
. O
These O
findings O
indicate O
that O
the O
binding O
of O
H4biopterin O
at O
the O
active O
site O
induces O
a O
destabilizing O
conformational O
change O
in O
the O
enzyme O
which O
could O
be O
related O
to O
the O
observed O
negative O
cooperativity O
. O
Thus O
, O
our O
studies O
provide O
new O
insight O
into O
the O
regulation O
of O
TH O
by O
the O
concentration O
of O
H4biopterin O
which O
may O
have O
significant O
implications O
for O
the O
physiological O
regulation O
of O
catecholamine O
biosynthesis O
in O
neuroendocrine O
cells O
. O

ceramides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

methoxy O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine B
transporter I
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

thromboxane O
A2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

triacylglycerol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Acyl-CoA O
synthetase O
isoforms O
1 O
, O
4 O
, O
and O
5 O
are O
present O
in O
different O
subcellular O
membranes O
in O
rat O
liver O
and O
can O
be O
inhibited O
independently.Inhibition O
studies O
have O
suggested O
that O
acyl-CoA O
synthetase O
(ACS O
, O
EC O
) O
isoforms O
might O
regulate O
the O
use O
of O
acyl-CoAs O
by O
different O
metabolic O
pathways O
. O
In O
order O
to O
determine O
whether O
the O
subcellular O
locations O
differed O
for O
each O
of O
the O
three O
ACSs O
present O
in O
liver O
and O
whether O
these O
isoforms O
were O
regulated O
independently O
, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
. O
ACS1 O
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS O
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O
ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 B
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS O
isoforms O
in O
unique O
subcellular O
locations O
. O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 B
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

chloroquine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
R740S O
mutation O
in O
the O
V-ATPase O
a3 O
subunit O
increases O
lysosomal O
pH O
, O
impairs O
NFATc1 O
translocation O
, O
and O
decreases O
in O
vitro O
osteoclastogenesis.Vacuolar O
H(+) O
-ATPase O
(V-ATPase) O
, O
a O
multisubunit O
enzyme O
located O
at O
the O
ruffled O
border O
and O
in O
lysosomes O
of O
osteoclasts O
, O
is O
necessary O
for O
bone O
resorption O
. O
We O
previously O
showed O
that O
heterozygous O
mice O
with O
an O
R740S O
mutation O
in O
the O
a3 O
subunit O
of O
V-ATPase O
(+/R740S) O
have O
mild O
osteopetrosis O
resulting O
from O
an O
∼90% O
reduction O
in O
proton O
translocation O
across O
osteoclast O
membranes O
. O
Here O
we O
show O
that O
lysosomal O
pH O
is O
also O
higher O
in O
+/R740S O
compared O
with O
wild-type O
(+/+) O
osteoclasts O
. O
Both O
osteoclast O
number O
and O
size O
were O
decreased O
in O
cultures O
of O
+/R740S O
compared O
with O
+/+ O
bone O
marrow O
cells O
, O
with O
concomitant O
decreased O
expression O
of O
key O
osteoclast O
markers O
(TRAP O
, O
cathepsin O
K O
, O
OSCAR O
, O
DC-STAMP O
, O
and O
NFATc1) O
, O
suggesting O
that O
low O
lysosomal O
pH O
plays O
an O
important O
role O
in O
osteoclastogenesis O
. O
To O
elucidate O
the O
molecular O
mechanism O
of O
this O
inhibition O
, O
NFATc1 O
activation O
was O
assessed O
. O
NFATc1 O
nuclear O
translocation O
was O
significantly O
reduced O
in O
+/R740S O
compared O
with O
+/+ O
cells; O
however O
, O
this O
was O
not O
because O
of O
impaired O
enzymatic O
activity O
of O
calcineurin O
, O
the O
phosphatase O
responsible O
for O
NFATc1 O
dephosphorylation O
. O
Protein O
and O
RNA O
expression O
levels O
of O
regulator O
of O
calcineurin O
1 O
(RCAN1) O
, O
an O
endogenous O
inhibitor O
of O
NFATc1 O
activation O
and O
a O
protein O
degraded O
in O
lysosomes O
, O
were O
not O
significantly O
different O
between O
+/R740S O
and O
+/+ O
osteoclasts O
, O
but O
the O
RCAN1/NFATc1 O
ratio O
was O
significantly O
higher O
in O
+/R740S O
versus O
+/+ O
cells O
. O
The O
lysosomal O
inhibitor O
chloroquine O
significantly O
increased O
RCAN1 B
accumulation O
in O
+/+ O
cells O
, O
consistent O
with O
the O
hypothesis O
that O
higher O
lysosomal O
pH O
impairs O
RCAN1 O
degradation O
, O
leading O
to O
a O
higher O
RCAN1/NFATc1 O
ratio O
and O
consequently O
NFATc1 O
inhibition O
. O
Our O
data O
indicate O
that O
increased O
lysosomal O
pH O
in O
osteoclasts O
leads O
to O
decreased O
NFATc1 O
signaling O
and O
nuclear O
translocation O
, O
resulting O
in O
a O
cell O
autonomous O
impairment O
of O
osteoclastogenesis O
in O
vitro O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine B
beta-1,4-galactosyltransferase I
I I
.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA B
II I
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Rapid O
glucocorticoid O
receptor-mediated O
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin O
releasing O
hormone O
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone O
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol O
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH B
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 B
 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O
cloned O
from O
a O
human O
brain O
library O
. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart O
, O
liver O
and O
lung O
. O
Within O
the O
brain O
, O
erg3 O
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal O
, O
parietal O
and O
occipital O
lobes O
. O
Transient O
expression O
of O
erg3 O
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) O
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 O
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs O
. O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Artemisinic O
acid O
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP O
α-dependent O
expression O
of O
HMG-CoA O
reductase O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
( O
c-KIT B
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O
cloned O
from O
a O
human O
brain O
library O
. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart O
, O
liver O
and O
lung O
. O
Within O
the O
brain O
, O
erg3 O
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal O
, O
parietal O
and O
occipital O
lobes O
. O
Transient O
expression O
of O
erg3 O
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) O
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 B
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs O
. O

phthalide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO B
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO O
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

Sulindac O
sulfide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Sulindac O
sulfide O
inhibits O
epidermal O
growth O
factor-induced O
phosphorylation O
of O
extracellular-regulated B
kinase I
1/2 I
and O
Bad O
in O
human O
colon O
cancer O
cells.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States O
. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac O
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer O
. O
Sulindac O
and O
selective O
cyclooxygenase O
(COX)-2 O
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients O
. O
Sulindac O
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O
In O
tumor O
cells O
, O
activation O
of O
extracellular-regulated O
kinase O
(ERK) O
1/2 O
results O
in O
phosphorylation O
of O
several O
ERK1/2 O
effectors O
, O
including O
the O
proapoptotic O
protein O
Bad O
. O
Phosphorylation O
of O
Ser112 O
by O
ERK1/2 O
inactivates O
Bad O
and O
protects O
the O
tumor O
cell O
from O
apoptosis O
. O
Sulindac O
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 O
phosphorylation O
in O
human O
colon O
cancer O
cells O
. O
In O
this O
study O
we O
show O
that O
epidermal O
growth O
factor O
(EGF) O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl O
peptidase-IV O
(DPP-IV) O
by O
atorvastatin.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine B
DPP-IV I
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

saxitoxin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
An O
overview O
on O
the O
marine O
neurotoxin O
, O
saxitoxin O
: O
genetics O
, O
molecular O
targets O
, O
methods O
of O
detection O
and O
ecological O
functions.Marine O
neurotoxins O
are O
natural O
products O
produced O
by O
phytoplankton O
and O
select O
species O
of O
invertebrates O
and O
fish O
. O
These O
compounds O
interact O
with O
voltage-gated O
sodium O
, O
potassium O
and O
calcium O
channels O
and O
modulate O
the O
flux O
of O
these O
ions O
into O
various O
cell O
types O
. O
This O
review O
provides O
a O
summary O
of O
marine O
neurotoxins O
, O
including O
their O
structures O
, O
molecular O
targets O
and O
pharmacologies O
. O
Saxitoxin O
and O
its O
derivatives O
, O
collectively O
referred O
to O
as O
paralytic O
shellfish O
toxins O
(PSTs) O
, O
are O
unique O
among O
neurotoxins O
in O
that O
they O
are O
found O
in O
both O
marine O
and O
freshwater O
environments O
by O
organisms O
inhabiting O
two O
kingdoms O
of O
life O
. O
Prokaryotic O
cyanobacteria O
are O
responsible O
for O
PST O
production O
in O
freshwater O
systems O
, O
while O
eukaryotic O
dinoflagellates O
are O
the O
main O
producers O
in O
marine O
waters O
. O
Bioaccumulation O
by O
filter-feeding O
bivalves O
and O
fish O
and O
subsequent O
transfer O
through O
the O
food O
web O
results O
in O
the O
potentially O
fatal O
human O
illnesses O
, O
paralytic O
shellfish O
poisoning O
and O
saxitoxin O
pufferfish O
poisoning O
. O
These O
illnesses O
are O
a O
result O
of O
saxitoxin's O
ability O
to O
bind O
to O
the O
voltage-gated O
sodium O
channel O
, O
blocking O
the O
passage O
of O
nerve O
impulses O
and O
leading O
to O
death O
via O
respiratory O
paralysis O
. O
Recent O
advances O
in O
saxitoxin O
research O
are O
discussed O
, O
including O
the O
molecular O
biology O
of O
toxin O
synthesis O
, O
new O
protein O
targets O
, O
association O
with O
metal-binding B
motifs I
and O
methods O
of O
detection O
. O
The O
eco-evolutionary O
role(s) O
PSTs O
may O
serve O
for O
phytoplankton O
species O
that O
produce O
them O
are O
also O
discussed O
. O

Felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Felbamate O
block O
of O
recombinant O
N-methyl-D-aspartate O
receptors O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O
the O
specificity O
of O
felbamate O
block O
of O
recombinant O
NMDA O
receptors O
composed O
of O
the O
NR1a O
subunit O
and O
various O
NR2 O
subunits O
. O
Felbamate O
produced O
a O
rapid O
, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA O
and O
10 O
microM O
glycine O
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat O
NR1a O
subunit O
, O
and O
either O
the O
NR2A O
, O
NR2B O
or O
NR2C B
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6 O
, O
0.52 O
and O
2.4 O
mM O
, O
respectively O
(holding O
potential O
, O
- O
60 O
mV) O
. O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and O
, O
in O
kinetic O
analyses O
, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O
functions O
, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
basis O
for O
the O
altered O
drug O
sensitivities O
of O
non-small O
cell O
lung O
cancer-associated O
mutants O
of O
human O
epidermal O
growth O
factor O
receptor.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
has O
an O
essential O
role O
in O
multiple O
signaling O
pathways O
, O
including O
cell O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine O
kinase O
(TK) O
domain O
. O
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR O
mutants O
, O
L858R O
and O
G719S O
, O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK O
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S B
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met790 O
side O
chain O
of O
the O
G719S/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR O
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR O
mutations O
. O

5'-MABN O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindole-derived O
ligands O
at O
the O
κ-opioid O
receptor.Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid O
receptor O
antagonists O
in O
the O
treatment O
of O
mood O
disorders O
. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action O
, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor B
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O
effects O
in O
mice O
, O
reducing O
the O
antinociceptive O
actions O
of O
U50,488 O
(10 O
mg/kg) O
at O
28 O
and O
21 O
days O
post-injection O
, O
respectively O
. O
Interestingly O
, O
while O
5'-AMN O
and O
5'-MABN O
were O
not O
κ-selective O
, O
both O
compounds O
did O
show O
significant O
antidepressant- O
and O
anxiolytic-like O
effects O
at O
7-14 O
days O
post-injection O
in O
mice O
. O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP B
phosphodiesterase I
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

TFP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Phenothiazines O
inhibit O
S100A4 O
function O
by O
inducing O
protein O
oligomerization.S100A4 O
, O
a O
member O
of O
the O
S100 O
family O
of O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 B
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

linuron O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Screening O
for O
(anti)androgenic O
properties O
using O
a O
standard O
operation O
protocol O
based O
on O
the O
human O
stably O
transfected O
androgen O
sensitive O
PALM O
cell O
line O
. O
First O
steps O
towards O
validation.Despite O
more O
than O
a O
decade O
of O
research O
in O
the O
field O
of O
endocrine O
active O
compounds O
targeting O
the O
androgen O
receptor O
(AR) O
, O
and O
although O
suitable O
cell O
lines O
can O
be O
obtained O
, O
no O
validated O
human O
stably O
transfected O
androgen O
sensitive O
transactivation O
assay O
is O
available O
. O
Bayer O
Schering O
Pharma O
(BSP) O
and O
the O
Flemish O
Institute O
for O
Technological O
Research O
(VITO) O
, O
partners O
within O
the O
EU-sponsored O
6th O
framework O
project O
ReProTect O
, O
made O
first O
steps O
towards O
such O
a O
validation O
. O
A O
standard O
operation O
protocol O
(SOP) O
developed O
at O
BSP O
based O
on O
the O
androgen O
sensitive O
PALM O
cell O
line O
was O
transferred O
to O
VITO O
and O
its O
performance O
and O
transferability O
were O
thoroughly O
studied O
. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
(17alpha-MT) O
, O
vinclozolin O
and O
linuron O
, O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR B
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O
the O
final O
screening O
. O
All O
other O
compounds O
were O
tested O
according O
to O
the O
generic O
protocol O
: O
Compounds O
screened O
for O
agonism O
were O
the O
reference O
androgen O
17alpha-methyldihydrotestosterone O
(MDHT) O
, O
levonorgestrel O
, O
norethynodrel O
, O
progesterone O
, O
o,p'-DDT O
, O
and O
dibutylphthalate O
(DBP) O
, O
while O
compounds O
screened O
for O
antagonism O
were O
the O
reference O
anti-androgen O
flutamide O
, O
prochloraz O
, O
o,p'-DDT O
, O
progesterone O
, O
norethynodrel O
, O
and O
DBP O
. O
Cytotoxicity O
was O
assessed O
in O
parallel O
as O
lactate O
dehydrogenase O
release O
. O
The O
prescreen O
classified O
17alpha-MT O
as O
androgenic O
, O
vinclozolin O
and O
linuron O
as O
anti-androgenic O
and O
compounds O
were O
tested O
accordingly O
. O
In O
the O
absence O
of O
cytotoxicity O
, O
appropriate O
androgenic O
properties O
of O
reference O
and O
test O
compounds O
were O
detected O
by O
both O
laboratories O
, O
o,p'-DDT O
and O
DBP O
had O
no O
androgenic O
activity O
. O
Across O
the O
two O
laboratories O
EC(50)-values O
for O
MDHT O
, O
17alpha-MT O
, O
and O
levonorgestrel O
varied O
by O
not O
more O
than O
a O
factor O
of O
3.4 O
, O
for O
norethynodrel O
by O
a O
factor O
of O
9.7 O
. O
Progesterone O
effects O
could O
not O
fully O
be O
evaluated O
, O
as O
frequently O
concentration O
response O
curves O
were O
incomplete O
. O
In O
the O
absence O
of O
cytotoxicity O
anti-androgenic O
properties O
of O
reference O
and O
test O
compounds O
were O
also O
detected O
in O
both O
laboratories O
. O
DBP O
, O
the O
putative O
negative O
reference O
compound O
, O
was O
inactive O
, O
norethynodrel O
rather O
showed O
agonistic O
properties O
. O
Progesterone O
was O
an O
antagonist O
at O
low O
concentrations O
, O
but O
agonistic O
properties O
were O
observed O
in O
one O
laboratory O
at O
high O
concentrations O
. O
Since O
the O
highest O
test O
concentration O
was O
limited O
to O
10 O
microM O
, O
for O
some O
compounds O
no O
complete O
concentration O
response O
curves O
were O
obtained O
and O
estimation O
of O
EC(50)-values O
was O
less O
robust O
. O
Our O
data O
demonstrated O
that O
the O
SOP O
was O
transferable O
, O
and O
that O
the O
assay O
was O
able O
to O
rank O
compounds O
with O
strong O
, O
weak O
, O
and O
without O
affinity O
for O
the O
AR O
and O
to O
discriminate O
agonists O
and O
antagonists O
. O
The O
sensitivity O
of O
the O
assay O
could O
be O
improved O
further O
, O
if O
the O
limit O
of O
solubility O
or O
beginning O
cytotoxicity O
was O
chosen O
as O
the O
highest O
test O
concentration O
. O
The O
assay O
avoids O
the O
use O
of O
tissues O
from O
laboratory O
animals O
, O
and O
thus O
contributes O
to O
the O
3R O
concept O
. O
Furthermore O
, O
it O
could O
be O
adjusted O
to O
an O
intermediate/high O
throughput O
format O
. O
On O
the O
whole O
, O
this O
PALM O
assay O
is O
a O
promising O
candidate O
for O
further O
validation O
. O

CP-101,606 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Brain O
but O
not O
spinal O
NR2B O
receptor O
is O
responsible O
for O
the O
anti-allodynic O
effect O
of O
an O
NR2B O
subunit-selective O
antagonist O
CP-101,606 O
in O
a O
rat O
chronic O
constriction O
injury O
model.In O
order O
to O
examine O
the O
site O
of O
action O
of O
an O
NR2B O
subtype-selective O
NMDA B
antagonist O
CP-101,606 O
, O
we O
investigated O
its O
analgesic O
effect O
in O
a O
rat O
model O
of O
neuropathic O
pain O
at O
various O
routes O
of O
administration O
. O
Mechanical O
allodynia O
was O
induced O
by O
chronic O
constriction O
injury O
(CCI) O
of O
the O
sciatic O
nerve O
in O
male O
Sprague-Dawley O
rats O
. O
Subcutaneous O
treatment O
of O
the O
animals O
with O
CP-101,606 O
at O
10 O
mg/kg O
significantly O
inhibited O
CCI-induced O
mechanical O
allodynia O
. O
Intracerebroventricular O
injection O
of O
CP-101,606 O
at O
10 O
, O
30 O
and O
100 O
nmol O
also O
inhibited O
the O
mechanical O
allodynia O
in O
a O
dose-dependent O
manner O
, O
the O
statistically O
significant O
effect O
being O
achieved O
at O
the O
highest O
dose O
tested O
(100 O
nmol) O
without O
producing O
any O
behavioral O
abnormalities O
. O
However O
, O
intrathecal O
injection O
of O
CP-101,606 O
at O
a O
dose O
of O
300 O
nmol O
failed O
to O
inhibit O
CCI-induced O
allodynia O
. O
A O
receptor O
binding O
assay O
using O
rat O
forebrain O
and O
spinal O
cord O
membrane O
preparations O
demonstrated O
that O
[3H]CP-101,606 O
bound O
to O
the O
brain O
NR2B O
receptor O
with O
a O
greater O
extent O
compared O
to O
the O
spinal O
cord O
one O
. O
These O
findings O
suggest O
that O
the O
anti-allodynia O
effect O
of O
CP-101,606 O
is O
ascribable O
to O
blockade O
of O
NR2B O
receptors O
at O
the O
brain O
, O
but O
not O
at O
the O
spinal O
cord O
. O
In O
contrast O
, O
intrathecal O
injection O
of O
a O
non-selective O
NMDA O
antagonist O
, O
memantine O
, O
significantly O
inhibited O
CCI-induced O
mechanical O
allodynia O
at O
a O
dose O
of O
300 O
nmol O
, O
indicating O
the O
difference O
in O
the O
site O
of O
action O
between O
the O
non-selective O
NMDA O
antagonist O
and O
the O
NR2B-specific O
NMDA O
antagonist O
. O

GW572016 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Truncated O
ErbB2 O
receptor O
(p95ErbB2) O
is O
regulated O
by O
heregulin O
through O
heterodimer O
formation O
with O
ErbB3 O
yet O
remains O
sensitive O
to O
the O
dual O
EGFR/ErbB2 O
kinase O
inhibitor O
GW572016.The O
expression O
of O
the O
NH2 O
terminally O
truncated O
ErbB2 O
receptor O
(p95ErbB2) O
in O
breast O
cancer O
correlates O
with O
metastatic O
disease O
progression O
compared O
with O
the O
expression O
of O
full-length O
p185ErbB2 O
. O
We O
now O
show O
that O
heregulin O
(HRG) O
, O
but O
not O
EGF O
, O
stimulates O
p95ErbB2 O
phosphorylation O
in O
BT474 O
breast O
cancer O
cells O
. O
Furthermore O
, O
phospho-p95ErbB2 O
forms O
heterodimers O
with O
ErbB3 O
, O
but O
not O
EGFR O
, O
while O
p185ErbB2 O
heterodimerizes O
with O
both O
EGFR O
and O
ErbB3 O
. O
The O
predilection O
of O
p95ErbB2 O
to O
heterodimerize O
with O
ErbB3 O
provides O
an O
explanation O
for O
its O
regulation O
by O
HRG O
, O
an O
ErbB3 O
ligand O
. O
GW572016 O
, O
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR O
and O
ErbB2 O
tyrosine O
kinases O
, O
inhibits O
baseline O
p95ErbB2 O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O
GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho- O
Erk1/2 B
, O
phospho-AKT O
, O
and O
cyclin O
D O
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O
in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
or O
cyclin O
D O
. O
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O
by O
the O
selection O
of O
p95ErbB2-expressing O
breast O
cancer O
cells O
capable O
of O
exerting O
potent O
growth O
and O
prosurvival O
signals O
through O
p95ErbB2-ErbB3 O
heterodimers O
. O
Thus O
, O
p95ErbB2 O
represents O
a O
target O
for O
therapeutic O
intervention O
, O
and O
one O
that O
is O
sensitive O
to O
GW572016 O
therapy O
. O

prednisone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
IL-2 O
receptor O
expression O
in O
renal O
allograft O
recipients O
treated O
with O
an O
anti-IL-2-receptor O
antibody.Patients O
were O
entered O
into O
a O
randomized O
trial O
of O
prophylaxis O
for O
renal O
allograft O
rejection O
by O
the O
administration O
of O
an O
anti-human O
IL-2 O
receptor O
antibody O
, O
anti-Tac O
, O
during O
the O
first O
ten O
days O
posttransplant O
. O
Interleukin-2 O
receptor O
(IL-2 O
R) O
expression O
was O
measured O
using O
two O
anti-IL-2 O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 O
R-positive O
cells O
at O
day O
of O
peak O
IL-2 O
R O
expression O
56.0 O
+/- O
20.8% O
in O
group O
A O
, O
65.2 O
+/- O
26.6% O
in O
group O
B O
, O
21.0 O
+/- O
7.4% O
in O
group O
C) O
. O
IL-2 O
R O
expression O
did O
not O
correlate O
with O
clinical O
activity O
, O
and O
the O
presence O
or O
accessibility O
of O
epitopes O
on O
the O
same O
55 O
kD O
chain O
varied O
dramatically O
from O
patient O
to O
patient O
. O

clopidogrel-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 B
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4- B
mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data O
. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 O
and O
CYP3A4 O
, O
respectively O
. O
The O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 O
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme-ketamine O
binding O
and O
catalytic O
activity O
. O

17-phenyl-trinor-PGE2 O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

AACOCF3 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 B
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

baicalin O
acts O
as O
NOT O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D B
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
( O
PDGFR-beta B
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR B
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 B
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

all-trans-7,8-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 O
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat O
A O
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 B
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O
which O
could O
have O
signaling O
functions O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

alkyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
( O
DAT) B
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1- B
mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI O
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
The O
tricyclic O
antidepressant O
clomipramine O
increases O
plasma O
glucose O
levels O
of O
mice.Effects O
of O
the O
tricyclic O
antidepressant O
clomipramine O
on O
plasma O
glucose O
levels O
in O
mice O
were O
studied O
. O
Clomipramine O
at O
doses O
ranging O
5 O
- O
20 O
mg/kg O
elicited O
significant O
hyperglycemia O
in O
mice O
. O
Hyperglycemia O
elicited O
by O
clomipramine O
was O
not O
reduced O
by O
pretreatment O
with O
the O
5-hydroxytryptamine O
(5-HT) O
depleter O
p-chlorophenylalanine O
. O
The O
5-HT(1/2/5/7)-receptor O
antagonist O
methysergide O
and O
the O
5-HT(2A/2B/2C)-receptor O
antagonist O
LY O
53857 O
enhanced O
clomipramine-induced O
hyperglycemia O
, O
while O
the O
5-HT(1A/1B)-receptor O
antagonist O
(-)-propranolol O
and O
the O
5-HT(3/4)-receptor B
antagonist O
tropisetron O
did O
not O
affect O
it O
. O
The O
5-HT(2B/2C)-receptor O
antagonist O
SB O
206553 O
facilitated O
hyperglycemia O
induced O
by O
clomipramine O
, O
although O
the O
5-HT(2A)-receptor O
antagonist O
ketanserin O
was O
without O
effect O
. O
Clomipramine-induced O
hyperglycemia O
was O
reduced O
by O
prior O
adrenalectomy O
. O
These O
results O
suggest O
that O
clomipramine O
induces O
hyperglycemia O
in O
mice O
by O
blocking O
the O
5-HT(2B O
)and/or O
5-HT(2C) O
receptors O
, O
which O
results O
in O
facilitation O
of O
adrenaline O
release O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 B
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Discriminative O
stimulus O
effects O
of O
esteratic O
local O
anesthetics O
in O
squirrel O
monkeys.A O
number O
of O
esteratic O
local O
anesthetics O
serve O
as O
positive O
reinforcers O
and O
produce O
cocaine-like O
discriminative O
stimulus O
effects O
in O
animals O
. O
It O
has O
been O
suggested O
that O
the O
affinity O
of O
these O
compounds O
for O
a O
site O
on O
the O
dopamine O
transporter O
, O
and O
not O
their O
local O
anesthetic O
actions O
, O
is O
responsible O
for O
these O
abuse-related O
behavioral O
effects O
. O
In O
the O
present O
study O
, O
three O
local O
anesthetics O
previously O
shown O
to O
be O
self-administered O
in O
animals O
were O
examined O
in O
squirrel O
monkeys O
trained O
to O
discriminate O
cocaine O
(0.3 O
mg/kg) O
from O
saline O
in O
a O
two-lever O
, O
food-reinforced O
procedure O
. O
Dimethocaine O
(0.1-3.0 O
mg/kg) O
fully O
and O
dose-dependently O
substituted O
for O
cocaine O
. O
Doses O
of O
dimethocaine O
(1.7 O
mg/kg) O
and O
cocaine O
(0.3 O
mg/kg) O
which O
produced O
full O
(> O
80%) O
substitution O
for O
cocaine O
were O
administered O
in O
combination O
with O
the O
dopamine B
D1 I
receptor I
antagonist O
SCH O
39166 O
((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine) O
and O
the O
dopamine O
D2 O
receptor O
antagonist O
raclopride O
(both O
at O
0.003-0.03 O
mg/kg) O
. O
SCH O
39166 O
fully O
blocked O
the O
cocaine-like O
discriminative O
stimulus O
effects O
of O
dimethocaine O
and O
cocaine O
, O
but O
raclopride O
produced O
only O
partial O
antagonism O
of O
cocaine-lever O
selection O
. O
In O
addition O
, O
there O
was O
some O
evidence O
that O
raclopride O
blocked O
cocaine-lever O
responding O
produced O
by O
a O
lower O
dose O
of O
dimethocaine O
. O
In O
substitution O
studies O
, O
neither O
procaine O
(1-10 O
mg/kg) O
nor O
chloroprocaine O
(1-30 O
mg/kg) O
produced O
cocaine-like O
effects O
. O
These O
results O
support O
a O
role O
for O
dopamine O
in O
the O
behavioral O
effects O
of O
some O
local O
anesthetics O
. O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo B
II I
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

sulfonylurea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
SUR-dependent O
modulation O
of O
KATP O
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N- O
and O
C-terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O
(P(O(max))) O
and O
attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O
did O
not O
affect O
significantly O
the O
mean O
open O
or O
"fast," O
K(+) O
driving O
force-dependent O
, O
intraburst O
closed O
times O
, O
verifying O
that O
Ntp O
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times O
. O
Ctp O
and O
Rnp O
, O
a O
randomized O
Ntp O
, O
had O
no O
effect O
, O
indicating O
that O
the O
effects O
of O
Ntp O
are O
structure O
specific O
. O
Ntp O
opened O
K(IR)6.1/SUR1 O
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) O
and O
attenuated O
the O
coupling O
of O
high-affinity O
sulfonylurea O
binding O
with O
K(ATP) B
pore O
closure O
. O
These O
effects O
resemble O
those O
seen O
with O
N-terminal O
deletions O
(DeltaN) O
of O
K(IR)6.0 O
, O
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) O
channels O
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP O
in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O
the O
channel O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O
core O
of O
SUR O
with O
the O
K(IR) O
pore O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Purification O
and O
structural O
characterisation O
of O
phospholipase O
A1 O
(Vespapase O
, O
Ves O
a O
1) O
from O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
venom.The O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
is O
one O
of O
the O
most O
dangerous O
vespid O
species O
in O
Southeast O
Asia O
, O
and O
stinging O
accidents O
involving O
this O
species O
still O
cause O
fatalities O
. O
In O
the O
present O
study O
, O
four O
forms O
of O
V O
. O
affinis O
phospholipase O
A(1) O
were O
identified O
through O
a O
proteomics O
approach O
. O
Two O
of O
these O
enzymes O
were O
purified O
by O
reverse-phase O
chromatography O
, O
and O
their O
biochemical O
properties O
were O
characterised O
. O
These O
enzymes O
, O
designated O
Ves O
a O
1s O
, O
are O
not O
glycoproteins O
and O
exist O
as O
33441.5 O
and O
33474.4 O
Da O
proteins O
, O
which O
corresponded O
with O
the O
34-kDa O
band O
observed O
via O
SDS-PAGE O
. O
The O
thermal O
stabilities O
of O
these O
enzymes O
were O
stronger O
than O
snake O
venom O
. O
Using O
an O
in O
vivo O
assay O
, O
no O
difference O
was O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves O
a O
1s O
revealed O
that O
the O
Ves B
a I
1 I
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves O
a O
1 O
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
. O

CoPP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

tolbutamide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

LBH589 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
HISTONE O
DEACETYLASE O
INHIBITION O
AFFECTS O
SODIUM O
IODIDE O
SYMPORTER O
(NIS) O
EXPRESSION O
AND O
INDUCES O
¹³¹I O
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS.Background O
: O
Anaplastic O
thyroid O
cancers O
(ATC) O
represent O
only O
1-2% O
of O
all O
thyroid O
tumors O
, O
but O
they O
account O
for O
up O
to O
50% O
of O
the O
mortality O
. O
Treatment O
of O
differentiated O
thyroid O
carcinomas O
is O
well O
standardized O
and O
the O
use O
of O
radioiodine O
represents O
an O
essential O
step; O
in O
contrast O
, O
there O
is O
no O
standardized O
therapeutic O
approach O
for O
anaplastic O
tumors O
and O
their O
prognosis O
is O
poor O
. O
The O
resistance O
of O
anaplastic O
thyroid O
cancer O
to O
radioiodine O
treatment O
is O
principally O
due O
to O
the O
absence O
of O
expression O
of O
the O
sodium O
iodide O
symporter O
(NIS) O
, O
mainly O
due O
to O
epigenetic O
silencing O
. O
The O
acetylation O
status O
of O
histones O
is O
involved O
in O
the O
epigenetic O
control O
of O
gene O
expression O
and O
is O
usually O
disrupted O
in O
advanced O
thyroid O
cancer O
. O
Histone O
deacetylase O
inhibitors O
have O
been O
demonstrated O
as O
potent O
anticancer O
drugs O
with O
several O
different O
effects O
on O
cell O
viability O
and O
differentiation O
. O
Methods O
: O
Stabilized O
anaplastic O
thyroid O
cancer O
cell O
lines O
(BHT-101 O
and O
CAL-62) O
and O
primary O
cultures O
from O
patients O
who O
underwent O
thyroidectomy O
for O
anaplastic O
thyroid O
cancer O
were O
treated O
with O
the O
histone O
deacetylase O
inhibitor O
LBH589 O
. O
After O
treatment O
, O
we O
evaluated O
the O
expression O
and O
function O
of O
NIS O
. O
Gene O
expression O
was O
evaluated O
by O
real-time O
PCR O
(RT-PCR); O
NIS O
promoter O
activity O
was O
determined O
with O
a O
luciferase O
reporter O
assay; O
and O
protein O
expression O
was O
assessed O
through O
immunofluorescence O
. O
We O
tested O
the O
protein O
function O
by O
125I O
uptake O
and O
efflux O
experiments; O
finally O
the O
cytotoxic O
effect O
of O
131I O
was O
determined O
with O
a O
clonogenic O
assay O
. O
Results O
: O
Our O
results O
demonstrate O
that O
treatment O
with O
LBH589 O
leads O
to O
NIS B
RNA O
expression O
as O
shown O
by O
RT-PCR O
and O
luciferase O
assay O
, O
and O
to O
protein O
expression O
as O
determined O
by O
immunofluorescence O
in O
vitro O
and O
by O
immunohistochemistry O
in O
xenograft O
tumors O
. O
Moreover O
, O
125I O
uptake O
and O
efflux O
experiments O
show O
the O
correct O
protein O
function O
and O
iodine O
retention O
, O
that O
translate O
into O
cytotoxicity O
effects O
, O
as O
demonstrated O
by O
a O
clonogenic O
assay O
with O
131I O
 O
. O
Conclusions O
: O
This O
study O
supplies O
a O
new O
potential O
strategy O
for O
the O
treatment O
of O
ATC O
by O
modifying O
gene O
expression O
with O
the O
aim O
of O
inducing O
responsiveness O
towards O
radioiodine O
therapy O
. O

sumatriptan O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Both O
5-HT1B O
and O
5-HT1F O
receptors O
modulate O
c-fos O
expression O
within O
rat O
trigeminal O
nucleus O
caudalis.A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan O
is O
inhibition O
of O
the O
trigeminovascular O
pathway O
. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B O
, O
5-HT1D O
or O
5-HT1F O
receptors O
. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes O
, O
we O
compared O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F O
receptor O
agonist O
(LY O
344864) O
on O
c-fos B
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos-like O
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat O
5-HT1B O
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F O
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sphingosine-1-phosphate O
promotes O
the O
nuclear O
translocation O
of O
β-catenin O
and O
thereby O
induces O
osteoprotegerin O
gene O
expression O
in O
osteoblast-like O
cell O
lines.Sphingosine-1-phosphate O
(S1P) O
is O
a O
well-known O
signaling O
sphingolipid O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
( O
PI3K) B
/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O
of O
β-catenin O
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin O
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

ethanol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 B
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group O
, O
HbA1c O
level O
in O
EtOH+DM8W O
group O
was O
lower O
than O
in O
DM8W O
group O
. O
Compared O
with O
control O
group O
, O
there O
were O
no O
changes O
of O
LVDP O
, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group O
, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
( O
COX-2) B
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 O
inhibitors O
has O
not O
been O
clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 O
inhibitors O
celecoxib O
and O
rofecoxib O
. O
METHODS O
: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O
(FDA) O
Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
renal O
failure O
submitted O
to O
the O
FDA O
. O
A O
MEDLINE O
search O
of O
the O
English O
language O
literature O
was O
also O
performed O
to O
identify O
published O
cases O
of O
renal O
failure O
associated O
with O
celecoxib O
and O
rofecoxib O
. O
RESULTS O
: O
One O
hundred O
twenty-two O
and O
142 O
domestic O
US O
cases O
of O
celecoxib O
and O
rofecoxib-associated O
renal O
failure O
, O
respectively O
, O
were O
identified O
in O
the O
AERS O
database O
. O
The O
literature O
search O
identified O
19 O
cases O
of O
acute O
renal O
impairment O
in O
association O
with O
celecoxib O
and O
rofecoxib O
. O
In O
addition O
, O
drug O
regulatory O
authorities O
in O
the O
UK O
, O
Canada O
, O
and O
Australia O
have O
received O
about O
50 O
reports O
of O
renal O
failure O
with O
celecoxib O
and O
rofecoxib O
. O
Descriptive O
statistics O
of O
the O
AERS O
cases O
have O
been O
summarised O
in O
this O
report O
. O
CONCLUSIONS O
: O
Data O
from O
AERS O
and O
published O
case O
reports O
suggest O
that O
use O
of O
both O
these O
drugs O
is O
associated O
with O
renal O
effects O
similar O
to O
that O
of O
conventional O
nonselective O
NSAIDs O
. O
Physicians O
should O
be O
aware O
that O
serious O
or O
life-threatening O
renal O
failure O
has O
been O
reported O
in O
patients O
with O
normal O
or O
impaired O
renal O
function O
after O
short-term O
therapy O
with O
celecoxib O
and O
rofecoxib O
. O
Patients O
at O
greatest O
risk O
for O
renal O
injury O
are O
those O
with O
pre-existing O
renal O
impairment O
, O
heart O
failure O
, O
liver O
dysfunction O
, O
those O
taking O
diuretics O
and/or O
ACE O
inhibitors O
, O
and O
the O
elderly O
. O
Kidney O
function O
should O
be O
monitored O
closely O
for O
any O
signs O
of O
potential O
renal O
injuries O
soon O
after O
initiating O
treatment O
with O
these O
agents O
, O
especially O
in O
high-risk O
populations O
. O
In O
addition O
, O
healthcare O
practitioners O
should O
adequately O
warn O
patients O
of O
the O
signs O
and O
symptoms O
of O
serious O
renal O
toxicity O
, O
and O
of O
the O
need O
for O
them O
to O
see O
their O
physician O
promptly O
if O
they O
occur O
. O
Celecoxib O
and O
rofecoxib O
are O
not O
recommended O
for O
use O
in O
patients O
with O
advanced O
renal O
disease O
. O

5-aza-2'-deoxycytidine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 B
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

okadaic O
acid O
acts O
as O
NOT O
for O
what O
entity O
? O
Effects O
of O
serine/threonine O
protein O
phosphatase O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
serine/threonine O
protein O
phosphatase O
(PP) O
inhibitors O
on O
morphine-induced O
antinociception O
in O
the O
tail O
flick O
test O
in O
mice O
, O
and O
on O
[3H]naloxone O
binding O
to O
the O
forebrain O
crude O
synaptosome O
fraction O
. O
Neither O
okadaic O
acid O
nor O
cantharidin O
(1-10000 O
nM) O
displaced O
[3H]naloxone O
from O
its O
specific O
binding O
sites O
, O
which O
indicates O
that O
they O
do O
not O
interact O
at O
the O
opioid B
receptor I
level O
. O
The O
i.c.v O
. O
administration O
of O
very O
low O
doses O
of O
okadaic O
acid O
(0.001-1 O
pg/mouse) O
and O
cantharidin O
(0.001-1 O
ng/mouse) O
, O
which O
inhibit O
PP2A O
, O
produced O
a O
dose-dependent O
antagonism O
of O
the O
antinociception O
induced O
by O
morphine O
(s.c.) O
. O
However O
, O
L-nor-okadaone O
(0.001 O
pg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
an O
analogue O
of O
okadaic O
acid O
lacking O
activity O
against O
protein O
phosphatases O
, O
did O
not O
affect O
the O
antinociceptive O
effect O
of O
morphine O
. O
On O
the O
other O
hand O
, O
high O
doses O
of O
okadaic O
acid O
(10 O
ng/mouse O
, O
i.c.v.) O
and O
cantharidin O
(1 O
microg/mouse O
, O
i.c.v.) O
, O
which O
also O
block O
PP1 O
, O
and O
calyculin-A O
(0.1 O
fg/mouse-1 O
ng/mouse O
, O
i.c.v.) O
, O
which O
inhibits O
equally O
both O
PP1 O
and O
PP2A O
, O
did O
not O
modify O
the O
morphine-induced O
antinociception O
. O
These O
results O
suggest O
that O
the O
activation O
of O
type O
2A O
serine/threonine O
protein O
phosphatases O
may O
play O
a O
role O
in O
the O
antinociceptive O
effect O
of O
morphine O
, O
and O
that O
PP1 O
might O
counterbalace O
this O
activity O
. O

sulprostone O
acts O
as O
AGONIST O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3- B
selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

oxandrolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effect O
of O
anabolic-androgenic O
steroids O
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR O
and O
hGR O
nucleocytoplasmic O
translocation.Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR B
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR O
and O
hGR O
transport O
. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR O
action O
and O
interaction O
with O
other O
regulatory O
proteins O
, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies O
. O

DOI O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A B
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
monoamine O
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia O
. O

delta O
DHEA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Adrenocortical O
reserves O
in O
hyperthyroidism.Explicit O
data O
regarding O
the O
changes O
in O
adrenocortical O
reserves O
during O
hyperthyroidism O
do O
not O
exist O
. O
We O
aimed O
to O
document O
the O
capability O
(response) O
of O
adrenal O
gland O
to O
secrete O
cortisol O
and O
DHEA-S O
during O
hyperthyroidism O
compared O
to O
euthyroidism O
, O
and O
to O
describe O
factors O
associated O
with O
these O
responses O
. O
A O
standard-dose O
(0.25 O
mg/i.v.) O
ACTH O
stimulation O
test O
was O
performed O
to O
the O
same O
patients O
before O
hyperthyroidism O
treatment O
, O
and O
after O
attainment O
of O
euthyroidism O
. O
Baseline O
cortisol O
(Cor0) O
, O
DHEA-S O
(DHEA-S0) O
, O
cortisol O
binding O
globulin O
(CBG) O
, O
ACTH O
, O
calculated O
free O
cortisol O
(by O
Coolen's O
equation O
= O
CFC) O
, O
free O
cortisol O
index O
(FCI) O
, O
60-min O
cortisol O
(Cor60) O
, O
and O
DHEA-S O
(DHEA-S60) O
, O
delta O
cortisol O
(ΔCor) O
, O
delta O
DHEA-S O
(ΔDHEA-S) O
responses O
were O
evaluated O
. O
Forty-one O
patients O
[22 O
females O
, O
49.5 O
± O
15.2 O
years O
old O
, O
32 O
Graves O
disease O
, O
nine O
toxic O
nodular O
goiter] O
had O
similar O
Cor0 O
, O
DHEA-S0 O
, O
CFC O
, O
FCI O
, O
and O
DHEA-S60 O
in O
hyperthyroid O
and O
euthyroid O
states O
. O
Cor60 O
, O
ΔCor O
, O
and O
ΔDHEA-S O
were O
lower O
in O
hyperthyroidism O
. O
In O
four O
(10 O
%) O
patients O
the O
peak O
ACTH-stimulated O
cortisol O
values O
were O
lower O
than O
18 O
μg/dL O
. O
When O
the O
test O
repeated O
after O
attainment O
of O
euthyroidism O
, O
all O
of O
the O
patients O
had O
normal O
cortisol O
response O
. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism O
. O
However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA-S O
levels O
were O
serum O
creatinine O
levels O
in O
hyperthyroidism O
, O
and O
both O
creatinine O
and O
transaminase O
levels O
in O
euthyroidism O
. O
ACTH- B
stimulated O
peak O
cortisol O
, O
delta O
cortisol O
, O
and O
delta O
DHEA-S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O
Since O
about O
10 O
% O
of O
the O
subjects O
with O
hyperthyroidism O
are O
at O
risk O
for O
adrenal O
insufficiency O
, O
clinicians O
dealing O
with O
Graves' O
disease O
should O
be O
alert O
to O
the O
possibility O
of O
adrenal O
insufficiency O
during O
hyperthyroid O
stage O
. O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Bupropion O
inhibits O
nicotine-evoked O
[(3)H]overflow O
from O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
and O
from O
rat O
hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine.Bupropion O
, O
an O
efficacious O
antidepressant O
and O
smoking O
cessation O
agent O
, O
inhibits O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
. O
Recently O
, O
bupropion O
has O
been O
reported O
to O
noncompetitively O
inhibit O
alpha3beta2 O
, O
alpha3beta4 O
, O
and O
alpha4beta2 O
nicotinic O
acetylcholine O
receptors O
(nAChRs) O
expressed O
in O
Xenopus O
oocytes O
or O
established O
cell O
lines O
. O
The O
present O
study O
evaluated O
bupropion-induced O
inhibition O
of O
native O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
using O
functional O
neurotransmitter O
release O
assays O
, O
nicotine-evoked O
[(3)H]overflow O
from O
superfused O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
([(3)H]DA) O
, O
and O
nicotine-evoked O
[(3)H]overflow O
from O
hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine O
([(3)H]NE) O
. O
The O
mechanism O
of O
inhibition O
was O
evaluated O
using O
Schild O
analysis O
. O
To O
eliminate O
the O
interaction O
of O
bupropion O
with O
DAT O
or O
NET O
, O
nomifensine O
or O
desipramine O
, O
respectively O
, O
was O
included O
in O
the O
superfusion O
buffer O
. O
A O
high O
bupropion O
concentration O
(100 O
microM) O
elicited O
intrinsic O
activity O
in O
the O
[(3)H]DA O
release O
assay O
. O
However O
, O
none O
of O
the O
concentrations O
(1 O
nM-100 O
microM) O
examined O
evoked O
[(3)H]NE O
overflow O
and O
, O
thus O
, O
were O
without O
intrinsic O
activity O
in O
this O
assay O
. O
Moreover O
, O
bupropion O
inhibited O
both O
nicotine-evoked O
[(3)H]DA O
overflow O
(IC(50) O
= O
1.27 O
microM) O
and O
nicotine-evoked O
[(3)H]NE O
overflow O
(IC(50) O
= O
323 O
nM) O
at O
bupropion O
concentrations O
well O
below O
those O
eliciting O
intrinsic O
activity O
. O
Results O
from O
Schild O
analyses O
suggest O
that O
bupropion O
competitively O
inhibits O
nicotine-evoked O
[(3)H]DA O
overflow O
, O
whereas O
evidence O
for O
receptor O
reserve O
was O
obtained O
upon O
assessment O
of O
bupropion O
inhibition O
of O
nicotine-evoked O
[(3)H]NE O
overflow O
. O
Thus O
, O
bupropion O
acts O
as O
an O
antagonist O
at O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
in O
rat O
striatum O
and O
hippocampus O
, O
respectively O
, O
across O
the O
same O
concentration O
range O
that O
inhibits O
DAT O
and O
NET B
function O
. O
The O
combination O
of O
nAChR O
and O
transporter O
inhibition O
produced O
by O
bupropion O
may O
contribute O
to O
its O
clinical O
efficacy O
as O
a O
smoking O
cessation O
agent O
. O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F B
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

chelerythrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein B
kinase I
C I
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformin O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria O
. O
Uptake O
of O
phenformin O
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria O
. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds O
, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s) O
. O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; O
however O
, O
uptake O
of O
phenformin O
into O
mitochondria O
of O
organic O
cation/carnitine O
transporter O
1 O
(OCTN1) O
knockout O
mice O
was O
lower O
than O
that O
in O
wild-type O
mice O
, O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex O
I O
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 O
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex B
I I
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

cAMP O
acts O
as O
NOT O
for O
what O
entity O
? O
Alpha-2 O
adrenoceptor O
subtype O
causing O
nitric O
oxide-mediated O
vascular O
relaxation O
in O
rats.The O
alpha-2 O
adrenoceptor O
subtype O
and O
its O
signal O
transduction O
pathway O
mediating O
vascular O
relaxation O
in O
rats O
were O
studied O
in O
vitro O
using O
rings O
of O
superior O
mesenteric O
arteries O
. O
Removal O
of O
endothelium O
or O
incubation O
with O
NG-nitro-L-arginine O
completely O
blocked O
relaxant O
responses O
to O
UK14,304 O
, O
suggesting O
endothelium-derived O
nitric O
oxide O
mediates O
relaxation O
. O
The O
order O
of O
potency O
for O
full O
(F) O
or O
partial O
(P) O
agonists O
causing O
relaxation O
was O
guanabenz O
(P) O
> O
UK14,304 O
(F) O
> O
clonidine O
(P) O
> O
epinephrine O
(F) O
> O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D O
adrenoceptor O
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O
cAMP O
formation O
in O
endothelium O
. O
Forskolin O
did O
not O
affect O
the O
relaxant O
response O
to O
UK14,304 O
, O
suggesting O
that O
cAMP O
is O
not O
involved O
in O
the O
coupling O
of O
alpha-2 B
adrenoceptors I
to O
nitric O
oxide-induced O
vascular O
relaxation O
. O

AACOCF3 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 B
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

Na O
acts O
as O
NOT O
for O
what O
entity O
? O
Preferential O
block O
of O
late O
sodium O
current O
in O
the O
LQT3 O
DeltaKPQ O
mutant O
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide.Flecainide O
block O
of O
Na(+) O
current O
(I(Na)) O
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long O
QT O
syndrome O
3 O
(LQT3) O
sodium O
channel O
alpha O
subunit O
mutation O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ B
I(Na) O
was O
more O
sensitive O
to O
flecainide O
, O
and O
flecainide O
preferentially O
inhibited O
late O
I(Na) O
(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
80 O
+/- O
9 O
and O
19 O
+/- O
2 O
microM O
(n O
= O
31) O
respectively O
. O
UDB O
of O
peak O
I(Na) O
was O
greater O
and O
developed O
more O
slowly O
during O
pulse O
trains O
for O
DeltaKPQ O
than O
for O
WT O
. O
The O
IC(50) O
value O
for O
UDB O
of O
peak O
I(Na) O
for O
WT O
was O
29 O
+/- O
4 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ O
was O
11 O
+/- O
1 O
microM O
(n O
= O
26) O
. O
For O
DeltaKPQ O
, O
UDB O
of O
late O
I(Na) O
was O
greater O
than O
for O
peak O
I(Na) O
. O
Recovery O
from O
block O
was O
slower O
for O
DeltaKPQ O
than O
for O
WT O
. O
We O
conclude O
that O
DeltaKPQ O
interacts O
differently O
with O
flecainide O
than O
with O
WT O
, O
leading O
to O
increased O
block O
and O
slowed O
recovery O
, O
especially O
for O
late O
I(Na) O
. O
These O
data O
provide O
insights O
into O
mechanisms O
for O
flecainide O
block O
and O
provide O
a O
rationale O
at O
the O
cellular O
and O
molecular O
level O
that O
open O
channel O
block O
may O
be O
a O
useful O
pharmacological O
property O
for O
treatment O
of O
LQT3 O
. O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Heteromtoxin O
(HmTx) O
, O
a O
novel O
heterodimeric O
phospholipase O
A(2) O
from O
Heterometrus O
laoticus O
scorpion O
venom.Heteromtoxin O
(HmTx) O
is O
a O
group O
III O
phospholipase O
A(2) O
produced O
in O
Heterometrus O
laoticus O
, O
in O
Thailand O
. O
In O
this O
study O
, O
HmTx O
was O
purified O
from O
venom O
by O
separation O
chromatography O
, O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx B
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

bleomycin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
via O
extracellular O
signal-regulated O
kinase O
contributes O
to O
bleomycin-induced O
oxidative O
stress O
and O
fibrogenesis.Pulmonary O
fibrosis O
is O
a O
serious O
and O
irreversible O
lung O
injury O
with O
obscure O
etiologic O
mechanisms O
and O
no O
effective O
treatment O
to O
date O
. O
This O
study O
explored O
a O
crucial O
link O
between O
oxidative O
stress O
and O
pulmonary O
fibrogenesis O
, O
focusing O
on O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
(Nrf2) O
, O
a O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen O
production O
and O
significantly O
downregulated O
Nrf2 B
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 O
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O
caffeic O
acid O
phenethyl O
ester O
, O
and O
the O
results O
showed O
that O
bleomycin-induced O
fibroblast O
proliferation O
and O
collagen O
content O
were O
attenuated O
through O
improved O
redox O
balance O
. O
Collectively O
, O
these O
results O
disclose O
a O
potential O
regulatory O
mechanism O
in O
pulmonary O
fibrosis O
that O
will O
aid O
the O
development O
of O
new O
therapies O
. O

ammonium O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Influence O
of O
nitrogen O
supply O
on O
the O
production O
of O
higher O
alcohols/esters O
and O
expression O
of O
flavour-related O
genes O
in O
cachaça O
fermentation.This O
study O
provides O
the O
first O
attempt O
to O
analyse O
the O
influence O
of O
ammonium O
supplements O
on O
sugar-cane O
juice O
fermentation O
and O
the O
flavour O
profile O
in O
a O
cachaça O
industrial O
process O
. O
The O
objective O
was O
to O
find O
a O
relationship O
between O
higher O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases B
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol O
acyl-transferase O
EEB1 O
and O
the O
acyl O
esterase O
IAH1 O
. O

reserpine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vesicular O
monoamine O
transporter-1 O
(VMAT-1) O
mRNA O
and O
immunoreactive O
proteins O
in O
mouse O
brain.OBJECTIVE O
: O
Vesicular O
monoamine O
transporter O
1 O
(VMAT-1) O
mRNA O
and O
protein O
were O
examined O
(1) O
to O
determine O
whether O
adult O
mouse O
brain O
expresses O
full-length O
VMAT-1 O
mRNA O
that O
can O
be O
translated O
to O
functional O
transporter O
protein O
and O
(2) O
to O
compare O
immunoreactive O
VMAT-1 O
proteins O
in O
brain O
and O
adrenal O
. O
METHODS O
: O
VMAT-1 O
mRNA O
was O
detected O
in O
mouse O
brain O
with O
RT-PCR O
. O
The O
cDNA O
was O
sequenced O
, O
cloned O
into O
an O
expression O
vector O
, O
transfected O
into O
COS-1 O
cells O
, O
and O
cell O
protein O
was O
assayed O
for O
VMAT-1 O
activity O
. O
Immunoreactive O
proteins O
were O
examined O
on O
western O
blots O
probed O
with O
four O
different O
antibodies O
to O
VMAT-1 O
. O
RESULTS O
: O
Sequencing O
confirmed O
identity O
of O
the O
entire O
coding O
sequences O
of O
VMAT-1 O
cDNA O
from O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT B
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O
cells O
, O
which O
are O
positive O
controls O
for O
rodent O
VMAT-1 O
. O
CONCLUSIONS O
: O
These O
findings O
demonstrate O
that O
a O
functional O
VMAT-1 O
mRNA O
coding O
sequence O
is O
expressed O
in O
mouse O
brain O
and O
suggest O
processing O
of O
VMAT-1 O
protein O
differs O
in O
mouse O
adrenal O
and O
brain O
. O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase B
5 I
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease.As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD) O
, O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase B
(COMT) O
. O
Because O
gastric O
AADC O
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa O
to O
dopamine O
in O
the O
brain O
is O
unknown O
, O
most O
striatal O
AADC O
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals O
. O
Newly O
synthesized O
dopamine O
is O
stored O
in O
the O
terminals O
and O
then O
released O
, O
stimulating O
postsynaptic O
dopamine O
receptors O
and O
mediating O
the O
antiparkinsonian O
action O
of O
levodopa O
. O
Dopamine O
agonists O
act O
directly O
on O
postsynaptic O
dopamine O
receptors O
, O
thus O
obviating O
the O
need O
for O
metabolic O
conversion O
, O
storage O
, O
and O
release O
. O
How O
the O
actions O
of O
dopaminergic O
drugs O
produce O
side O
effects O
and O
how O
these O
side O
effects O
should O
be O
managed O
are O
discussed O
. O

Pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pranlukast O
, O
a O
leukotriene O
receptor O
antagonist O
, O
inhibits O
interleukin-5 B
production O
via O
a O
mechanism O
distinct O
from O
leukotriene O
receptor O
antagonism.BACKGROUND O
: O
Pranlukast O
, O
a O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLTR1) O
antagonist O
, O
inhibits O
not O
only O
airway O
smooth O
muscle O
contraction O
, O
but O
also O
allergic O
inflammation O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
mechanism O
of O
pranlukast-induced O
interleukin-5 O
(IL-5) O
inhibition O
in O
allergic O
inflammation O
. O
METHODS O
: O
Surgically O
resected O
human O
lung O
tissue O
was O
passively O
sensitized O
in O
vitro O
with O
mite-allergen-sensitized O
sera O
, O
followed O
by O
stimulation O
with O
mite O
allergen O
after O
pretreatment O
of O
the O
tissue O
with O
pranlukast O
, O
dexamethasone O
, O
or O
both O
. O
The O
IL-5 O
protein O
level O
in O
the O
culture O
medium O
was O
measured O
, O
and O
in O
situ O
hybridization O
of O
IL-5 O
and O
CysLTR1 O
mRNA O
was O
performed O
using O
lung O
tissues O
. O
RESULTS O
: O
Pretreatment O
of O
lung O
tissues O
with O
pranlukast O
alone O
significantly O
decreased O
the O
amount O
of O
IL-5 O
protein O
in O
the O
culture O
medium O
by O
40% O
. O
The O
combination O
of O
pranlukast O
and O
dexamethasone O
synergistically O
enhanced O
this O
effect O
. O
Quantitative O
in O
situ O
hybridization O
with O
image O
analysis O
revealed O
abundant O
expression O
of O
IL-5 O
mRNA O
in O
eosinophils O
, O
lymphocytes O
, O
and O
mast O
cells O
in O
sensitized O
and O
allergen-stimulated O
lung O
tissues O
. O
CysLTR1 O
mRNA O
was O
detected O
in O
macrophages O
, O
smooth O
muscle O
cells O
, O
eosinophils O
, O
and O
mast O
cells O
, O
but O
was O
less O
expressed O
in O
lymphocytes O
. O
Pranlukast-induced O
inhibition O
of O
IL-5 O
mRNA O
expression O
was O
noted O
in O
various O
cells O
, O
irrespective O
of O
their O
CysLTR1 O
mRNA O
expression O
status O
. O
In O
addition O
, O
cysteinyl O
leukotrienes O
per O
se O
failed O
to O
upregulate O
the O
IL-5 O
production O
. O
CONCLUSION O
: O
Our O
results O
indicate O
that O
pranlukast O
inhibits O
IL-5 O
synthesis O
via O
a O
mechanism O
distinct O
from O
CysLTR1 O
antagonism O
. O

amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 B
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

Fluoride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Sodium O
fluoride O
induces O
apoptosis O
in O
odontoblasts O
via O
a O
JNK-dependent O
mechanism.Sodium O
fluoride O
(NaF) O
is O
widely O
used O
for O
the O
treatment O
of O
dental O
caries O
and O
dentin O
hypersensitivity O
. O
However O
, O
its O
pro-apoptotic O
effect O
on O
odontoblasts O
may O
lead O
to O
harmful O
side-effects O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro-apoptotic O
effects O
of O
NaF O
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms O
. O
NaF O
generated O
cytotoxic O
effects O
in O
odontoblast-lineage O
cell O
(OLC) O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK B
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent O
mitochondrial O
pathway O
. O

choline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT B
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

ATB-429 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Amino-2-hydroxybenzoic O
acid O
4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl O
ester O
(ATB-429) O
, O
a O
hydrogen O
sulfide-releasing O
derivative O
of O
mesalamine O
, O
exerts O
antinociceptive O
effects O
in O
a O
model O
of O
postinflammatory O
hypersensitivity.H(2)S O
functions O
as O
a O
neuromodulator O
and O
exerts O
anti-inflammatory O
activities O
. O
Recent O
data O
indicate O
that O
irritable O
bowel O
syndrome O
(IBS) O
is O
linked O
to O
inflammation O
of O
the O
gastrointestinal O
tract O
. O
In O
this O
study O
, O
we O
have O
investigated O
the O
role O
of O
a O
novel O
H(2)S-releasing O
derivative O
of O
mesalamine O
(5-amino-2-hydroxybenzoic O
acid O
4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl O
ester O
, O
ATB-429) O
in O
modulating O
nociception O
to O
colorectal O
distension O
(CRD) O
, O
a O
model O
that O
mimics O
some O
features O
of O
IBS O
, O
in O
healthy O
and O
postcolitic O
rats O
. O
Four O
graded O
(0.4-1.6 O
ml O
of O
water) O
CRDs O
were O
produced O
in O
conscious O
rats O
, O
and O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos O
expression O
. O
In O
healthy O
rats O
, O
ATB-429 O
dose O
dependently O
(25 O
, O
50 O
, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O
CRD-induced O
overexpression O
of O
spinal O
c-FOS O
mRNA O
, O
whereas O
mesalamine O
had O
no O
effect O
. O
ATB-429-induced O
antinociception O
was O
reversed O
by O
glibenclamide O
, O
a O
ATP-sensitive O
K(+) O
(K(ATP)) O
channel O
inhibitor O
. O
The O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 B
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
. O
ATB-429 O
, O
but O
not O
mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O
postcolitic O
, O
allodynic O
rats O
by O
a O
K(ATP) O
channel-mediated O
mechanism O
. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing O
drugs O
might O
have O
beneficial O
effects O
in O
the O
treatment O
of O
painful O
intestinal O
disorders O
. O

tamoxifen O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Chemoprevention O
for O
high-risk O
women O
: O
tamoxifen O
and O
beyond.The O
demonstration O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
Project O
(NSABP) O
that O
5 O
years O
of O
tamoxifen O
therapy O
is O
associated O
with O
an O
approximate O
50% O
reduction O
in O
breast O
cancer O
incidence O
in O
high-risk O
women O
was O
a O
milestone O
in O
breast O
cancer O
prevention O
. O
Because O
tamoxifen O
is O
associated O
with O
increased O
risk O
of O
side-effects O
such O
as O
hot O
flashes O
, O
menstrual O
abnormalities O
, O
uterine O
cancer O
, O
and O
thromboembolic O
phenomena O
, O
its O
use O
will O
not O
be O
advisable O
or O
acceptable O
for O
all O
high-risk O
women O
. O
Women O
over O
50 O
years O
of O
age O
appear O
to O
be O
at O
highest O
risk O
for O
serious O
adverse O
events O
, O
such O
as O
uterine O
cancer O
and O
thromboembolic O
phenomena O
. O
Individuals O
in O
whom O
tamoxifen-associated O
breast O
cancer O
risk O
reduction O
appears O
to O
outweigh O
risk O
of O
serious O
side-effects O
include O
women O
with O
prior O
in O
situ O
or O
estrogen O
receptor O
(ER)-positive O
invasive O
cancer O
, O
atypical O
hyperplasia O
, O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7% O
, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 O
mutations O
, O
although O
preliminary O
evidence O
favors O
benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER O
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive O
cancers O
. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O
specific O
classes O
of O
preventive O
agents O
, O
(c) O
drugs O
with O
fewer O
side-effects O
and/or O
effective O
in O
ER-negative O
or O
ER-positive O
tamoxifen-resistant O
precancerous O
disease O
, O
and O
(d) O
efficient O
clinical O
trial O
models O
to O
assess O
new O
agent O
efficacy O
. O
Breast O
intraepithelial O
neoplasia O
(IEN) O
may O
be O
sampled O
by O
minimally O
invasive O
techniques O
and O
is O
an O
attractive O
short-term O
risk O
biomarker O
. O
Molecular O
abnormalities O
observed O
in O
IEN O
may O
be O
used O
to O
select O
potential O
agents O
for O
testing/therapy O
, O
and O
modulation O
of O
these O
abnormalities O
may O
be O
used O
in O
phase O
I O
trials O
to O
select O
appropriate O
doses O
and O
in O
phase O
II O
trials O
to O
assess O
response O
. O
Breast O
density O
volume O
and O
certain O
serum O
markers O
such O
as O
insulin-like O
growth O
factor-1 O
are O
also O
being O
studied O
as O
potential O
risk O
and O
response O
biomarkers O
. O
Reversal O
or O
prevention O
of O
advanced O
IEN O
as O
well O
as O
modulation O
of O
other O
risk O
biomarkers O
in O
randomized O
phase O
II O
and O
phase O
III O
trials O
is O
being O
evaluated O
as O
a O
means O
of O
more O
efficiently O
evaluating O
prevention O
drugs O
in O
the O
future O
. O
A O
number O
of O
agents O
are O
being O
developed O
that O
target O
molecular O
abnormalities O
in O
IEN O
, O
have O
fewer O
or O
different O
side O
effects O
than O
tamoxifen O
, O
and O
may O
be O
effective O
in O
ER- B
negative O
or O
tamoxifen-resistant O
disease O
. O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha O
1 O
adrenoceptor O
antagonists O
at O
prostatic O
alpha O
1 O
adrenoceptors O
: O
binding O
, O
functional O
and O
in O
vivo O
studies.1 O
. O
The O
profile O
of O
a O
range O
of O
alpha O
1 O
adrenoceptor O
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human O
alpha O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human B
alpha I
1D I
adrenoceptors I
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O
17053 O
= O
SNAP O
1069 O
. O
4 O
. O
(-)-Tamsulosin O
was O
a O
very O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity O
, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O
this O
model O
. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha O
1 O
adrenoceptor O
mediating O
noradrenaline-induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O
1 O
adrenoceptors O
, O
particularly O
over O
the O
alpha O
1D O
subtype O
, O
appear O
to O
inhibit O
phenylephrine-induced O
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure O
. O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Peroxynitrite O
mediates O
testosterone-induced O
vasodilation O
of O
microvascular O
resistance O
vessels.Our O
knowledge O
of O
how O
androgens O
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete O
, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens O
affect O
resistance O
vessels O
. O
Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone O
(TES) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES-induced O
vasodilation O
. O
Mesenteric O
microvessels O
were O
isolated O
from O
male O
Sprague-Dawley O
rats O
. O
Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration-dependent O
, O
vasodilatory O
response O
to O
TES O
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17β-estradiol O
. O
Dichlorofluorescein O
fluorescence O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine B
oxidase- I
generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

naloxone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Galanin O
attenuates O
cyclic O
AMP O
regulatory O
element-binding O
protein O
(CREB B
) O
phosphorylation O
induced O
by O
chronic O
morphine O
and O
naloxone O
challenge O
in O
Cath.a O
cells O
and O
primary O
striatal O
cultures.Repeated O
morphine O
administration O
leads O
to O
molecular O
alterations O
of O
the O
neural O
circuitry O
in O
the O
locus O
coeruleus O
and O
nucleus O
accumbens O
. O
These O
changes O
include O
increased O
activity O
of O
several O
components O
of O
the O
cAMP O
signaling O
pathway O
that O
are O
thought O
to O
be O
associated O
with O
psychological O
and O
somatic O
signs O
of O
opiate O
withdrawal O
. O
The O
neuropeptide O
galanin O
has O
been O
shown O
to O
attenuate O
cAMP O
signaling O
in O
multiple O
cell O
types O
. O
The O
current O
study O
demonstrates O
that O
acute O
galanin O
treatment O
blocks O
the O
consequences O
of O
increased O
cAMP O
signaling O
following O
chronic O
opiate O
administration O
and O
withdrawal O
in O
Cath.a O
cells O
and O
primary O
cultures O
of O
striatal O
neurons O
as O
measured O
by O
phosphorylation O
of O
the O
transcription O
factor O
cAMP O
regulatory O
element-binding O
protein O
(CREB) O
. O
In O
addition O
, O
galanin-mediated O
attenuation O
of O
CREB O
phosphorylation O
is O
independent O
of O
galanin-induced O
extracellular O
signal-regulated O
kinase O
(ERK) O
1/2 O
phosphorylation O
in O
Cath.a O
cells O
. O
These O
data O
suggest O
that O
galanin O
receptors O
may O
serve O
as O
an O
additional O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
opiate O
withdrawal O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Common O
and O
specific O
determinants O
for O
fibroblast O
growth O
factors O
in O
the O
ectodomain O
of O
the O
receptor O
kinase O
complex.The O
assembly O
and O
activation O
of O
oligomeric O
complexes O
of O
FGF O
, O
the O
transmembrane O
receptor O
kinase O
(FGFR) O
, O
and O
heparan O
sulfate O
transmit O
intracellular O
signals O
regulating O
growth O
and O
function O
of O
cells O
. O
An O
understanding O
of O
the O
structural O
relationships O
between O
the O
three O
subunits O
and O
their O
redundancy O
and O
specificity O
is O
essential O
for O
understanding O
the O
ubiquitous O
FGF O
signaling O
system O
in O
health O
and O
disease O
. O
Previously O
, O
we O
reported O
that O
a O
primary O
heparin O
or O
heparan O
sulfate O
binding O
site O
resides O
in O
a O
distinct O
sequence O
in O
immunoglobulin O
(Ig)-like O
module O
II O
of O
the O
three O
modules O
of O
FGFR O
. O
Here O
we O
report O
that O
in O
the O
absence O
of O
flanking O
sequences O
, O
isolated O
Ig O
module O
II O
of O
FGFR1 O
supports O
the O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
in O
respective O
order O
of O
affinity O
. O
None O
of O
the O
three O
FGFs O
detectably O
bind O
Ig O
module O
I O
or O
the O
IIIb O
and O
IIIc O
splice O
variants O
of O
Ig O
module O
III O
in O
the O
absence O
of O
flanking O
sequences O
. O
Ig O
module O
I O
and O
the O
C-terminus O
of O
Ig O
module O
III O
are O
dispensable O
for O
high-affinity O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
. O
Alterations O
in O
highly O
conserved O
Ig O
module O
II O
in O
the O
heparin O
binding O
domain O
and O
substitution O
of O
individual O
sequence O
domains O
spanning O
the O
entire O
sequence O
of O
Ig O
module O
II O
with O
those O
from O
Ig O
module O
I O
obliterated O
FGF O
binding O
. O
Addition O
of O
a O
specific O
number O
of O
FGFR O
sequences O
to O
the O
C-terminus O
of O
Ig B
module I
II I
resulted O
in O
a O
gain O
in O
affinity O
for O
FGF-7 O
. O
Several O
site-specific O
alterations O
in O
the O
C-terminus O
of O
full-length O
FGFR1IIIc O
, O
an O
isoform O
that O
otherwise O
absolutely O
rejects O
FGF-7 O
, O
resulted O
in O
gain O
of O
FGF-7 O
binding O
. O
These O
results O
suggest O
that O
a O
complex O
of O
Ig O
module O
II O
and O
heparan O
sulfate O
is O
the O
base O
common O
active O
core O
of O
the O
FGFR O
ectodomain O
and O
that O
flanking O
structural O
domains O
modify O
FGF O
affinity O
and O
determine O
specificity O
. O

Δ(9)-tetrahydrocannabinol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Diuretic O
effects O
of O
cannabinoids.In O
vivo O
effects O
of O
cannabinoid O
(CB) O
agonists O
are O
often O
assessed O
using O
four O
well-established O
measures O
: O
locomotor O
activity O
, O
hypothermia O
, O
cataleptic-like O
effects O
, O
and O
analgesia O
. O
The O
present O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 O
agonist O
AM1241 O
[1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole] O
, O
the O
anandamide O
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 O
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

BH4 O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Tetrahydrobiopterin O
in O
nitric O
oxide O
synthesis O
: O
a O
novel O
biological O
role O
for O
pteridines.Ever O
since O
the O
discovery O
that O
(6R)-5,6,7,8-tetrahydro-L-biopterin O
(BH4) O
is O
a O
cofactor O
of O
NOS B
, O
its O
function O
has O
been O
the O
object O
of O
intense O
research O
and O
occasional O
controversy O
. O
Only O
in O
the O
last O
couple O
of O
years O
a O
consensus O
has O
been O
reached O
on O
what O
constitutes O
the O
main O
role O
of O
BH4 O
in O
NO O
synthesis O
. O
In O
this O
review O
we O
aim O
to O
provide O
an O
outline O
of O
the O
various O
ways O
in O
which O
BH4 O
affects O
NOS O
catalysis O
. O
First O
we O
give O
a O
brief O
general O
description O
of O
the O
structure O
and O
catalytic O
mechanism O
of O
NOS O
, O
with O
special O
emphasis O
on O
those O
aspects O
of O
catalysis O
that O
are O
actively O
debated O
, O
and O
that O
directly O
or O
indirectly O
involve O
BH4 O
. O
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis O
, O
i.e O
. O
the O
NOS-catalyzed O
oxidation O
of O
NADPH O
in O
the O
absence O
of O
substrate O
or O
pterin O
that O
does O
not O
result O
in O
NO O
production O
. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O
on O
whether O
NO O
is O
the O
actual O
reaction O
product O
of O
NOS O
catalysis O
, O
as O
well O
as O
the O
phenomenon O
of O
NO-mediated O
autoinhibition O
. O
We O
describe O
the O
function O
of O
BH4 O
in O
aromatic O
amino O
acid O
hydroxylation O
, O
and O
discuss O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O
NOS O
. O
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O
accepted O
as O
the O
central O
function O
of O
BH4 O
: O
its O
capacity O
to O
act O
as O
a O
1-electron O
donor O
during O
reductive O
activation O
of O
the O
oxyferrous O
complex O
of O
the O
heme O
. O
Finally O
, O
we O
illustrate O
how O
BH4 O
might O
transform O
the O
NOS O
dimer O
into O
an O
efficient O
S-nitrosoglutathione O
synthase,and O
briefly O
touch O
on O
some O
more O
speculative O
aspects O
of O
the O
role O
of O
BH4 O
in O
NO O
synthesis O
. O

MG-132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
of O
agonist-induced O
down-regulation O
of O
the O
human O
kappa-opioid O
receptor O
: O
internalization O
is O
required O
for O
down-regulation.Previously O
, O
we O
showed O
that O
the O
human O
kappa-opioid O
receptor O
(hkor) O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O
receptors O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynamin O
I-K44A O
significantly O
reduced O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7-N125I O
blunted O
U50,488H-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
( O
proteasome B
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O
down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes O
for O
degradation O
. O
Thus O
, O
U50,488H-induced O
internalization O
and O
down-regulation O
of O
the O
hkor O
share O
initial O
common O
mechanisms O
. O
To O
the O
best O
of O
our O
knowledge O
, O
these O
results O
represent O
the O
first O
report O
on O
the O
involvement O
of O
both O
rab5 O
and O
rab7 O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O
In O
addition O
, O
this O
study O
is O
among O
the O
first O
to O
show O
the O
involvement O
of O
proteasomes O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Methylphenidate O
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition O
, O
motivated O
behaviors O
, O
appetite O
, O
and O
stress.Thousands O
of O
children O
receive O
methylphenidate O
(MPH; O
Ritalin) O
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD) O
, O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH O
treatment O
are O
unknown O
. O
To O
mimic O
clinical O
Ritalin O
treatment O
in O
children O
, O
male O
rats O
were O
injected O
with O
MPH O
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET- B
ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O
involved O
in O
motivated O
behaviors O
, O
cognition O
, O
appetite O
, O
and O
stress O
. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time O
, O
chronic O
modulation O
of O
young O
brains O
with O
MPH O
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
prunetin O
via O
the O
suppression O
of O
NF-κB O
pathway.Prunetin O
is O
an O
O-methylated O
isoflavone O
, O
which O
is O
found O
in O
Prunus O
yedoensis O
. O
To O
date O
no O
report O
has O
been O
published O
on O
anti-inflammatory O
activities O
of O
prunetin O
. O
In O
the O
present O
study O
, O
the O
anti-inflammatory O
effect O
of O
prunetin O
on O
LPS-stimulated O
RAW O
264.7 O
macrophage O
and O
LPS-induced O
septic O
shock O
model O
were O
investigated O
. O
Inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-6 O
(IL-6) O
, O
and O
interleukin-1β O
(IL-1β) O
expressions O
were O
determined O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR) O
. O
To O
elucidate O
its O
underlying O
mechanism O
, O
nuclear O
factor-kappa O
B O
(NF-κb) O
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
( O
IκBα) B
-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

gemcitabine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cellular O
and O
pharmacogenetics O
foundation O
of O
synergistic O
interaction O
of O
pemetrexed O
and O
gemcitabine O
in O
human O
non-small-cell O
lung O
cancer O
cells.Gemcitabine O
and O
pemetrexed O
are O
effective O
agents O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
(NSCLC) O
, O
and O
the O
present O
study O
investigates O
cellular O
and O
genetic O
aspects O
of O
their O
interaction O
against O
A549 O
, O
Calu-1 O
, O
and O
Calu-6 O
cells O
. O
Cells O
were O
treated O
with O
pemetrexed O
and O
gemcitabine O
, O
and O
their O
interaction O
was O
assessed O
using O
the O
combination O
index O
. O
The O
role O
of O
drug O
metabolism O
in O
gemcitabine O
cytotoxicity O
was O
examined O
with O
inhibitors O
of O
deoxycytidine O
kinase O
(dCK) O
, O
5'-nucleotidase O
, O
and O
cytidine O
deaminase O
, O
whereas O
the O
role O
of O
pemetrexed O
targets O
, O
thymidylate O
synthase O
(TS) O
, O
dihydrofolate O
reductase O
(DHFR) O
, O
and O
glycinamide O
ribonucleotide O
formyltransferase O
(GARFT) O
in O
drug O
chemosensitivity O
was O
analyzed O
in O
cytotoxicity O
rescue O
studies O
. O
The O
effect O
of O
gemcitabine O
and O
pemetrexed O
on O
Akt O
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay O
, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug O
. O
Synergistic O
cytotoxicity O
was O
demonstrated O
, O
and O
pemetrexed O
significantly O
decreased O
the O
amount O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK O
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O
of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O
. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt B
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O
genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed O
enhances O
dCK O
and O
hENT1 O
expression O
, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O
for O
rational O
development O
of O
chemotherapy O
combinations O
. O

sulindac O
sulfide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synergistic O
effects O
of O
new O
chemopreventive O
agents O
and O
conventional O
cytotoxic O
agents O
against O
human O
lung O
cancer O
cell O
lines.Non-small O
cell O
lung O
cancer O
(NSCLC) O
cells O
have O
constitutively O
high O
expression O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
and O
cyclooxygenase O
(COX) O
2 O
. O
These O
NSCLC O
cells O
also O
have O
increased O
prostaglandin O
expression O
(PGE2) O
. O
Many O
lung O
cancers O
also O
express O
12-lipoxygenase O
RNA O
and O
12-lipoxygenase O
protein O
and O
biosynthesize O
12(S)-hydroxyeicosatetraenoic O
acid O
, O
which O
correlates O
with O
their O
metastatic O
potential O
. O
Several O
studies O
have O
demonstrated O
that O
COX-1 O
and O
COX-2 O
inhibitors O
could O
inhibit O
the O
in O
vitro O
growth O
of O
human O
lung O
cancer O
cell O
lines O
. O
In O
this O
report O
, O
we O
evaluated O
the O
growth-inhibitory O
effects O
of O
sulindac O
sulfide O
, O
a O
COX-1 B
and O
COX-2 O
inhibitor; O
exisulind O
(sulindac O
sulfone) O
, O
a O
novel O
proapoptotic O
agent O
that O
does O
not O
inhibit O
COX O
enzymes; O
and O
nordihydroguaiaretic O
acid O
(NDGA) O
, O
a O
lipoxygenase O
inhibitor O
on O
human O
lung O
cancer O
cell O
lines O
. O
We O
compared O
these O
effects O
with O
those O
of O
13-cis-retinoic O
acid O
, O
a O
chemoprevention O
agent O
, O
and O
with O
the O
cytotoxic O
chemotherapeutic O
agents O
paclitaxel O
and O
cisplatin O
, O
alone O
or O
in O
combination O
. O
Our O
goal O
was O
to O
develop O
new O
chemoprevention O
and O
treatment O
strategies O
. O
Each O
of O
the O
six O
agents O
tested O
inhibited O
the O
in O
vitro O
growth O
of O
three O
NSCLC O
and O
three O
SCLC O
cell O
lines O
at O
the O
highest O
concentration O
. O
Paclitaxel O
was O
the O
most O
potent O
agent O
(IC50 O
= O
0.003-0.150 O
microM); O
sulindac O
sulfide O
, O
NDGA O
, O
and O
13-cis-retinoic O
acid O
had O
intermediate O
potency O
(IC50 O
= O
4-80 O
microM) O
, O
and O
cisplatin O
and O
exisulind O
were O
the O
least O
potent O
(IC50 O
= O
150-500 O
microM) O
. O
Combination O
studies O
showed O
synergistic O
interactions O
for O
sulindac O
sulfide O
, O
exisulind O
, O
and O
NDGA O
with O
paclitaxel O
, O
cisplatin O
, O
and O
13-cis-retinoic O
acid O
, O
regardless O
of O
drug-resistance O
phenotype O
. O
At O
high O
concentrations O
, O
the O
combination O
of O
13-cis-retinoic O
acid O
and O
each O
of O
the O
five O
other O
drugs O
resulted O
in O
a O
strong O
synergistic O
effect O
. O
These O
studies O
provide O
a O
rationale O
for O
chemoprevention O
(exisulind O
+/- O
retinoic O
acid O
+/- O
NDGA) O
and O
therapeutic O
(exisulind O
+/- O
paclitaxel O
+/- O
cisplatin) O
studies O
in O
patients O
at O
risk O
for O
, O
or O
with O
, O
lung O
cancer O
. O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O
c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O
may O
modulate O
osteoclast O
activity O
. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts O
, O
we O
thus O
investigated O
the O
effect O
of O
imatinib O
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity O
. O
Our O
findings O
demonstrate O
that O
imatinib O
dose-dependently O
stimulates O
osteoclast O
apoptosis O
, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase O
I O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O
ligand O
( O
RANKL) B
-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
imatinib O
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF O
production O
such O
as O
osteoporosis O
, O
inflammatory-and O
tumor-induced O
osteolysis O
. O

phenytoin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Block O
of O
human B
NaV1.5 I
sodium O
channels O
by O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
phenytoin.Voltage-gated O
sodium O
(Na) O
channels O
are O
a O
critical O
component O
of O
electrically O
excitable O
cells O
. O
Phenytoin O
(diphenylhydantoin O
, O
DPH) O
is O
an O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O
examined O
including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
phenyl O
ring O
substitutions O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O
greater O
activity O
. O
In O
comparison O
to O
diphenylhydantoin O
, O
the O
novel O
chloro-substituted O
alpha-hydroxyphenylamide O
compounds O
produced O
as O
much O
as O
a O
20-fold O
greater O
tonic O
and O
frequency-dependent O
blockade O
of O
Na(V)1.5 O
channels O
with O
an O
IC(50) O
value O
of O
14.5 O
microM O
. O
In O
addition O
, O
the O
chloro-substitutions O
have O
position O
specific O
state O
dependent O
blocking O
properties O
. O
The O
ortho- O
, O
meta- O
and O
para-chloro O
substitutions O
have O
an O
8- O
, O
13- O
and O
3-fold O
increased O
affinity O
for O
the O
inactivated O
state O
, O
respectively O
. O
Molecular O
modeling O
suggests O
that O
these O
differences O
in O
affinity O
are O
due O
to O
a O
direct O
interaction O
with O
the O
receptor O
. O
Comparing O
models O
of O
diphenylhydantoin O
to O
the O
novel O
alpha-hydroxyphenlyamide O
compound O
suggests O
that O
the O
increased O
activity O
may O
be O
due O
to O
an O
optimized O
phenyl O
ring O
position O
and O
increased O
molecular O
volume O
. O
This O
information O
may O
be O
useful O
in O
the O
development O
of O
more O
potent O
sodium O
channel O
blockers O
. O

Tomudex O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Cyclin O
E-cdk2 O
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate O
synthase O
inhibitor O
Tomudex.Tomudex O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O
p53 O
and O
p21(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 O
protein O
expression O
and O
kinase B
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O
cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O
Cyclin O
D1 O
, O
cyclin O
B O
, O
cdk4 O
, O
and O
cdc2 O
protein O
expression O
and O
kinase O
activities O
remain O
constant O
. O
Lack O
of O
activation O
of O
cyclin O
A- O
and O
B-cdc2 O
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases O
. O
Increased O
cyclin O
E-cdk2 O
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days O
. O
Tomudex O
treatment O
resulted O
in O
a O
time-dependent O
induction O
of O
the O
megabase O
DNA O
fragments O
, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation O
. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase O
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis O
. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex O
are O
not O
p53 O
dependent O
. O

(6R)-5,6,7,8-tetrahydro-L-biopterin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Contrasting O
effects O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric B
oxide I
synthases I
(EC O
1.14.13.39) O
. O
Here O
we O
compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine O
reductase O
(EC O
1.6.99.7) O
and O
phenylalanine O
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O
Substitution O
at O
N(5) O
occurs O
at O
a O
position O
critical O
to O
the O
redox O
cycle O
of O
the O
cofactor O
in O
phenylalanine O
hydroxylase/dihydropteridine O
reductase O
. O
We O
also O
included O
N(2)'-methyl O
H(4)biopterin O
, O
a O
derivative O
substituted O
at O
a O
position O
not O
directly O
involved O
in O
redox O
cycling O
, O
as O
a O
control O
. O
As O
compared O
with O
N(5)-methyl O
H(4)biopterin O
, O
N(5)-formyl O
H(4)biopterin O
bound O
with O
twice O
the O
capacity O
but O
stimulated O
nitric O
oxide O
synthase O
to O
a O
lesser O
extent O
. O
Depending O
on O
the O
substituent O
used O
, O
N(5)-substituted O
derivatives O
were O
redox-active O
: O
N(5)-methyl- O
and O
N(5)-hydroxyl O
methyl O
H(4)biopterin O
, O
but O
not O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
, O
reduced O
2,6-dichlorophenol O
indophenol O
. O
N(5)-Substituted O
H(4)biopterin O
derivatives O
were O
not O
oxidized O
to O
products O
serving O
as O
substrates O
for O
dihydropteridine O
reductase O
and,depending O
on O
the O
substituent O
, O
were O
competitive O
inhibitors O
of O
phenylalanine O
hydroxylase O
: O
N(5)-methyl- O
and O
N(5)-hydroxymethyl O
H(4)biopterin O
inhibited O
phenylalanine O
hydroxylase O
, O
whereas O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
had O
no O
effect O
. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine O
hydroxylase O
and O
nitric O
oxide O
synthase O
by O
H(4)biopterin O
. O
They O
are O
compatible O
with O
a O
novel O
, O
non-classical O
, O
redox-active O
contribution O
of O
H(4)biopterin O
to O
the O
catalysis O
of O
the O
nitric O
oxide O
synthase O
reaction O
. O

AMP O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto- O
phosphodiesterase B
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC B
/ O
ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

glyburide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI B
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

prostaglandin O
E(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Comparison O
of O
cyclooxygenase O
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodium.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O
(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase B
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin O
E(2) O
(PGE(2)) O
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human O
recombinant O
COX-1 O
or O
COX-2 O
and O
arachidonic O
acid O
. O
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O
of O
10 O
microg/kg O
lipopolysaccharide O
(LPS) O
. O
In O
study O
animals O
, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) O
ketorolac O
0.4% O
(Acular O
LS) O
or O
bromfenac O
0.09% O
(Xibrom) O
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline O
. O
In O
control O
animals O
, O
both O
eyes O
were O
treated O
with O
vehicle O
. O
All O
animals O
were O
treated O
twice O
: O
2 O
hours O
and O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O
COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran O
leakage O
and O
PGE(2) O
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes O
. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
. O
In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

[(3)H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
alpha(1B) O
adrenergic O
receptors O
in O
gonadotrophin-releasing O
hormone O
neurones O
: O
relation O
to O
Transport-P.1 O
. O
Peptidergic O
neurones O
accumulate O
amines O
via O
an O
unusual O
uptake O
process O
, O
designated O
Transport-P O
. O
[(3)H]-prazosin O
binds O
to O
alpha(1) B
adrenoceptors I
on O
these O
cells O
and O
is O
displaceable O
by O
unlabelled O
prazosin O
in O
concentrations O
up O
to O
10(-7) O
M O
. O
However O
, O
at O
greater O
concentrations O
of O
prazosin O
, O
there O
is O
a O
paradoxical O
accumulation O
of O
[(3)H]-prazosin O
which O
we O
have O
attributed O
to O
Transport-P O
. O
Uptake O
of O
prazosin O
via O
Transport-P O
is O
detectable O
at O
10(-10) O
M O
prazosin O
concentration O
, O
is O
linear O
up O
to O
10(-7) O
M O
and O
at O
greater O
concentrations O
becomes O
non-linear O
. O
In O
contrast O
, O
in O
noradrenergic O
neurones O
, O
noradrenaline O
uptake O
is O
linear O
and O
saturates O
above O
10(-7) O
M O
. O
In O
noradrenergic O
neurones O
and O
in O
non-neuronal O
cells O
, O
there O
is O
no O
uptake O
of O
prazosin O
in O
concentrations O
up O
to O
10(-6) O
M O
, O
suggesting O
that O
Transport-P O
is O
a O
specialised O
function O
of O
peptidergic O
neurones O
. O
2 O
. O
Using O
a O
mouse O
peptidergic O
(gonadotrophin-releasing O
hormone O
, O
GnRH) O
neuronal O
cell O
line O
which O
possesses O
Transport-P O
, O
we O
have O
studied O
the O
interaction O
of O
alpha(1) O
adrenoceptors O
with O
Transport-P O
. O
Polymerase O
chain O
reactions O
and O
DNA O
sequencing O
of O
the O
products O
demonstrated O
that O
only O
the O
alpha(1B) O
sub-type O
of O
adrenoceptors O
is O
present O
in O
GnRH O
cells O
. O
3 O
. O
In O
COS O
cells O
transfected O
with O
alpha(1b) O
adrenoceptor O
cDNA O
and O
in O
DDT(1) O
MF-2 O
cells O
which O
express O
native O
alpha(1B) O
adrenoceptors O
, O
[(3)H]-prazosin O
was O
displaced O
by O
unlabelled O
prazosin O
in O
a O
normal O
equilibrium O
process O
, O
with O
no O
prazosin O
paradox O
in O
concentrations O
up O
to O
10(-6) O
M O
. O
In O
DDT(1) O
MF-2 O
cells O
, O
[(3)H]-prazosin O
was O
displaced O
likewise O
by O
a O
series O
of O
alpha(1) O
adrenergic O
agonists O
, O
none O
of O
which O
increased O
the O
binding O
of O
[(3)H]-prazosin O
. O
Hence O
, O
the O
prazosin O
paradox O
is O
not O
due O
to O
some O
function O
of O
alpha(1) O
adrenoceptors O
, O
such O
as O
internalization O
of O
ligand-receptor O
complexes O
. O
4 O
. O
In O
neurones O
which O
possess O
Transport-P O
, O
transfection O
with O
alpha(1b) O
adrenoceptor O
cDNA O
resulted O
in O
over-expression O
of O
alpha(1B) O
adrenoceptors O
, O
but O
the O
prazosin O
paradox O
was O
unaltered O
. O
Thus O
, O
alpha(1) O
adrenoceptors O
and O
Transport-P O
mediate O
distinct O
functions O
in O
peptidergic O
neurones O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Contribution O
of O
single-minded O
2 O
to O
hyperglycaemia-induced O
neurotoxicity.Diabetes O
mellitus O
is O
associated O
to O
central O
nervous O
system O
damage O
, O
which O
results O
in O
impairment O
of O
brain O
functions O
and O
cognitive O
deficits O
and O
decline O
in O
memory O
. O
However O
, O
the O
mechanisms O
mediating O
the O
actions O
of O
glucose O
on O
the O
neurons O
remained O
elusive O
. O
Single-minded O
2 O
(Sim2) O
, O
a O
basic O
helix-loop-helix O
(bHLH)-PAS O
transcriptional O
repressor O
, O
is O
thought O
to O
be O
involved O
in O
some O
symptoms O
of O
Down O
syndrome O
. O
We O
hypothesized O
that O
Sim2 O
mediated O
hyperglycaemia-induced O
neuronal O
injury O
and O
impairment O
of O
learning O
and O
memory O
. O
It O
was O
found O
that O
expression O
of O
Sim2 O
protein O
in O
cortical O
neurons O
was O
increased O
in O
streptozotocin-induced O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 B
and O
Drebrin O
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O
Moreover O
, O
curcumin O
alleviated O
Sim2 O
expression O
, O
and O
reversely O
raised O
Drebrin O
expression O
in O
neurons O
treated O
with O
hyperglycaemia O
. O
Finally O
, O
we O
found O
that O
silencing O
Sim2 O
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury O
. O
In O
conclusion O
, O
Sim2 O
may O
mediate O
neurotoxicity O
during O
hyperglycaemia O
and O
thereby O
play O
a O
critical O
role O
in O
the O
development O
of O
hyperglycaemia-induced O
cognitive O
deficits O
. O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium O
arsenite.Arsenic O
compounds O
that O
are O
often O
found O
in O
drinking O
water O
increase O
the O
risk O
of O
developmental O
brain O
disorders O
. O
In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro-2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase-3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins; O
enhanced O
cyan O
fluorescence O
protein O
(ECFP) O
and O
Venus O
, O
to O
determine O
whether O
sodium O
arsenite O
(NaAsO(2); O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
μM) O
affects O
both O
neurite O
outgrowth O
and/or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O
We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O
SCAT3-expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
μM O
NaAsO(2) O
, O
but O
not O
by O
1 O
μM O
, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus O
, O
an O
endpoint O
of O
caspase-3 O
activity O
, O
was O
not O
changed O
. O
However O
, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis O
, O
but O
not O
necrosis O
, O
was O
significantly O
induced O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin B
. O
The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
. O

etomidate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Activation O
of O
alpha O
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidate.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor O
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O
intraperitoneal O
injection O
of O
etomidate O
in O
wild-type O
and O
in O
alpha2A-receptor-deficient O
mice O
, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate O
in O
mice O
does O
not O
require O
the O
alpha2A-receptor O
subtype O
. O
Intravenous O
injection O
of O
etomidate O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors B
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O
. O

methazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
: O
aromatic O
and O
heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
with O
strong O
anticonvulsant O
activity.A O
series O
of O
aromatic/heterocyclic O
sulfonamides O
incorporating O
adamantyl O
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic O
aminosulfonamides O
with O
the O
acyl O
chlorides O
derived O
from O
adamantyl-1-carboxylic O
acid O
and O
1-adamantyl-acetic O
acid O
. O
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides O
with O
adamantyl O
isocyanate O
and O
adamantyl O
isothiocyanate O
, O
respectively O
. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human O
CA O
isozymes O
involved O
in O
important O
physiological O
processes O
, O
CA B
I I
, O
and O
CA O
II O
, O
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide O
and O
methazolamide O
. O
The O
lipophilicity O
of O
the O
best O
CA O
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value O
. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35) O
. O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA O
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice O
. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)) O
, O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O
(> O
90%) O
. O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1) O
, O
respectively O
. O

vigabatrin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
( O
GABA-T) B
 O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- O
and O
ALA-elevating O
actions O
. O

dipeptide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human B
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O
produced O
significant O
, O
dose-related O
decreases O
in O
systolic O
and O
diastolic O
blood O
pressure O
(BP) O
in O
hypertensive O
patients O
, O
and O
the O
BP O
response O
was O
enhanced O
by O
pretreatment O
with O
hydrochlorothiazide O
. O
The O
effects O
of O
enalkiren O
on O
PRA O
and O
BP O
are O
prolonged O
despite O
its O
relatively O
short O
elimination O
phase O
plasma O
half-life O
(1.6 O
h) O
. O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients O
. O
The O
observed O
dissociation O
between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements O
, O
despite O
complete O
suppression O
of O
PRA O
, O
are O
unexplained O
phenomena O
. O
The O
results O
of O
clinical O
trials O
with O
enalkiren O
are O
encouraging O
, O
and O
suggest O
that O
renin O
inhibitors O
may O
be O
safe O
, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension O
. O

lumiracoxib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 O
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib- O
COX-2 B
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

Lithium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate B
receptor I
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 B
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

TXA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
(TXA) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen B
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O
low-throughput O
screen O
identified O
5-(4-piperidyl)-3-isoxazolol O
(4-PIOL) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O
Remarkably O
, O
4-PIOL O
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA O
. O

gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
Activity O
of O
Swertiamarin O
is O
due O
to O
an O
Active O
Metabolite O
, O
Gentianine O
, O
that O
Upregulates O
PPAR-γ O
Gene O
Expression O
in O
3T3-L1 O
cells.We O
have O
previously O
shown O
the O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ O
, O
GLUT-4 O
and O
adiponectin B
. O
These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Alcohol O
modulates O
expression O
of O
DNA B
methyltranferases I
and O
methyl O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
development O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine O
transporter O
(DAT) O
in O
control O
and O
DAT O
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn-induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT O
. O
DA O
toxicity O
was O
saturable O
suggesting O
that O
transport O
may O
be O
rate O
limiting O
. O
When O
Mn O
and O
DA O
were O
added O
simultaneously O
to O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O
Mn O
may O
suppress O
DA O
uptake O
in O
the O
DAT O
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O
DAT B
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

trichostatin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 B
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

alcohol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Narirutin O
fraction O
from O
citrus O
peels O
attenuates O
alcoholic O
liver O
disease O
in O
mice.This O
study O
aimed O
to O
demonstrate O
protective O
activities O
of O
the O
narirutin O
fraction O
from O
peels O
of O
Citrus O
unshiu O
against O
ethanol-induced O
hepatic O
damage O
through O
an O
animal O
study O
. O
Citrus O
narirutin O
fraction O
(CNF) O
, O
contained O
75% O
of O
narirutin O
, O
was O
obtained O
by O
an O
ultra-sonicated O
extraction O
and O
further O
purification O
. O
ICR O
mice O
were O
divided O
into O
four O
groups; O
normaldiet O
control O
, O
ethanol O
control O
(6.5g O
ethanol/kg) O
, O
low-CNF O
(ethanol+150mg O
CNF/kg) O
and O
high-CNF O
(ethanol+300mg O
CNF/kg) O
groups O
. O
Consumption O
of O
alcohol O
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate O
transaminase O
, O
alanine O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH O
and O
malondialdehyde O
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O
Chronic O
consumption O
of O
alcohol O
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear B
factor I
(NF)-κB I
, O
tumor O
necrosis O
factor O
(TNF)-α O
and O
interleukin O
(IL)-1β O
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose-dependently O
. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol O
can O
alleviate O
alcohol O
induced O
liver O
damage O
through O
preventing O
lipid O
formation O
, O
protecting O
antioxidant O
system O
and O
suppressing O
productions O
of O
pro-inflammatory O
cytokines O
. O

S-adenosylhomocysteine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Altered O
methionine O
metabolism O
in O
long O
living O
Ames O
dwarf O
mice.Ames O
dwarf O
mice O
(df/df) O
are O
deficient O
in O
growth O
hormone O
, O
prolactin O
, O
and O
thyroid-stimulating O
hormone O
and O
live O
significantly O
longer O
than O
their O
normal O
siblings O
. O
In O
the O
current O
study O
, O
we O
found O
that O
the O
hormone O
deficiencies O
affect O
methionine O
metabolism O
. O
We O
previously O
reported O
that O
the O
dwarf O
mice O
exhibit O
enzyme O
activities O
and O
levels O
that O
combat O
oxidative O
stress O
more O
efficiently O
than O
those O
of O
normal O
mice O
. O
Moreover O
, O
methionine O
or O
metabolites O
of O
methionine O
are O
involved O
in O
antioxidative O
processes O
. O
Thus O
, O
we O
performed O
an O
experiment O
that O
compared O
various O
parameters O
of O
methionine O
metabolism O
between O
18-month O
old O
male O
dwarf O
(N=6) O
and O
wild O
type O
(N=5) O
mice O
. O
The O
specific O
activity O
of O
liver O
methionine O
adenosyltransferase O
(MAT) O
was O
significantly O
elevated O
(205% O
, O
p<0.0001) O
in O
the O
dwarf O
mice O
, O
as O
were O
cystathionine O
synthase O
(50% O
, O
p<0.01) O
, O
cystathionase O
(83% O
, O
p<0.001) O
, O
and O
glycine O
N-methyltransferase O
(GNMT O
, O
91% O
, O
p<0.001) O
activities O
. O
Even O
though O
the O
activities O
of O
MAT O
and O
GNMT B
were O
elevated O
, O
the O
concentration O
of O
liver O
S-adenosylmethionine O
was O
decreased O
(24% O
, O
p<0.001) O
and O
S-adenosylhomocysteine O
increased O
(113% O
, O
p<0.001) O
in O
the O
dwarf O
mice O
. O
These O
data O
indicate O
that O
dwarf O
mice O
, O
compared O
to O
wild O
type O
mice O
, O
have O
a O
markedly O
different O
metabolism O
of O
methionine O
. O
Altered O
methionine O
metabolism O
may O
partially O
explain O
earlier O
reports O
indicating O
less O
oxidative O
damage O
to O
proteins O
in O
dwarf O
mice O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
methionine O
metabolism O
may O
play O
a O
role O
in O
oxidative O
defense O
in O
the O
dwarf O
mouse O
and O
should O
be O
studied O
as O
a O
potential O
mechanism O
of O
extended O
lifespan O
. O

glutamate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate B
receptor I
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

sorafenib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors O
. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF O
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression O
, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery O
. O
A O
novel O
class O
of O
biaryl O
urea O
that O
inhibits O
C-RAF O
kinase O
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches O
. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY O
43-9006 O
(Sorafenib O
, O
Nexavar) O
, O
which O
has O
recently O
been O
approved O
by O
the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials O
. O
Sorafenib O
inhibited O
the O
kinase O
activity O
of O
both O
C-RAF O
and O
B-RAF O
(wild O
type O
and O
V600E O
mutant) O
. O
It O
inhibited O
MEK O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf O
and O
Kit O
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR B
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
sorafenib O
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas O
. O

l-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Biosynthesis O
of O
iron-sulphur O
clusters O
is O
a O
complex O
and O
highly O
conserved O
process.Iron-sulphur O
([Fe-S]) O
clusters O
are O
simple O
inorganic O
prosthetic O
groups O
that O
are O
contained O
in O
a O
variety O
of O
proteins O
having O
functions O
related O
to O
electron O
transfer O
, O
gene O
regulation O
, O
environmental O
sensing O
and O
substrate O
activation O
. O
In O
spite O
of O
their O
simple O
structures O
, O
biological O
[Fe-S] O
clusters O
are O
not O
formed O
spontaneously O
. O
Rather O
, O
a O
consortium O
of O
highly O
conserved O
proteins O
is O
required O
for O
both O
the O
formation O
of O
[Fe-S] O
clusters O
and O
their O
insertion O
into O
various O
protein O
partners O
. O
Among O
the O
[Fe-S] O
cluster O
biosynthetic O
proteins O
are O
included O
a O
pyridoxal O
phosphate-dependent O
enzyme O
( O
NifS) B
that O
is O
involved O
in O
the O
activation O
of O
sulphur O
from O
l-cysteine O
, O
and O
a O
molecular O
scaffold O
protein O
(NifU) O
upon O
which O
[Fe-S] O
cluster O
precursors O
are O
formed O
. O
The O
formation O
or O
transfer O
of O
[Fe-S] O
clusters O
appears O
to O
require O
an O
electron-transfer O
step O
. O
Another O
complexity O
is O
that O
molecular O
chaperones O
homologous O
to O
DnaJ O
and O
DnaK O
are O
involved O
in O
some O
aspect O
of O
the O
maturation O
of O
[Fe-S]-cluster-containing O
proteins O
. O
It O
appears O
that O
the O
basic O
biochemical O
features O
of O
[Fe-S] O
cluster O
formation O
are O
strongly O
conserved O
in O
Nature O
, O
since O
organisms O
from O
all O
three O
life O
Kingdoms O
contain O
the O
same O
consortium O
of O
homologous O
proteins O
required O
for O
[Fe-S] O
cluster O
formation O
that O
were O
discovered O
in O
the O
eubacteria O
. O

lorglumide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK B
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v O
. O
CCK-8 O
or O
ceruletide O
(caerulein) O
. O
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 O
in O
the O
rat O
and O
is O
protective O
against O
ceruletide- O
, O
taurocholate- O
and O
diet-induced O
pancreatitis O
. O
Lorglumide O
is O
therefore O
a O
useful O
pharmacological O
tool O
to O
study O
the O
functions O
of O
CCK O
. O
For O
its O
pharmacological O
properties O
, O
its O
relatively O
low O
toxicity O
and O
because O
it O
is O
active O
also O
after O
oral O
administration O
, O
lorglumide O
is O
a O
candidate O
for O
diagnostic O
or O
therapeutic O
use O
in O
man O
when O
an O
involvement O
of O
CCK O
is O
suspected O
. O

mannose O
6-phosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P O
/IGF2R B
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O
to O
assess O
the O
relevance O
of O
the O
different O
ligand-binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O
this O
cellular O
system O
. O
The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P/IGF2R O
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin-like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells O
. O
In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R O
and O
M6P-modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R O
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P-binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding O
domains O
of O
the O
receptor O
. O

m-CPBG O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Central O
5-HT3 B
receptor O
stimulation O
by O
m-CPBG O
increases O
blood O
glucose O
in O
rats.The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
central O
5-HT3 O
receptors O
on O
the O
control O
of O
blood O
glucose O
in O
stressed O
and O
non-stressed O
rats O
in O
both O
fasted O
and O
fed O
states O
. O
Adult O
Wistar O
male O
rats O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O
the O
experiments O
. O
Injections O
of O
m-CPBG O
, O
a O
selective O
5-HT3 O
receptor O
agonist O
, O
induced O
a O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O
5-HT3 O
receptor O
antagonist O
, O
indicating O
that O
the O
effects O
here O
obtained O
with O
m-CPBG O
were O
a O
result O
of O
its O
interaction O
with O
5-HT3 O
receptors O
. O
Third O
ventricle O
injections O
of O
ondansetron O
alone O
were O
not O
able O
to O
modify O
blood O
glucose O
in O
non-stressed O
animals O
and O
did O
not O
change O
the O
hyperglycemic O
responses O
observed O
after O
immobilization O
stress O
. O
We O
conclude O
that O
pharmacological O
activation O
of O
the O
central O
5-HT3 O
receptor O
induces O
a O
hyperglycemic O
effect O
in O
non-stressed O
animals O
. O

prallethrin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Toxicological O
impact O
of O
inhaled O
electric O
mosquito-repellent O
liquid O
on O
the O
rat O
: O
a O
hematological O
, O
cytokine O
indications O
, O
oxidative O
stress O
and O
tumor O
markers.Abstract O
Context O
: O
High O
malaria O
burden O
has O
led O
to O
the O
increased O
use O
of O
insecticides O
in O
the O
tropics O
and O
subtropics O
. O
This O
study O
thus O
aimed O
at O
assessing O
the O
hematological O
effects O
alteration O
of O
pyrethroid O
insecticide O
exposure O
using O
the O
experimental O
animal O
model O
. O
Objective O
: O
A O
commonly O
available O
Electric O
Mosquito-Repellent O
Liquid O
pyrethroid O
insecticide O
containing O
prallethrin O
1.6% O
w/w O
is O
widely O
used O
for O
mosquito O
control O
in O
Saudi O
Arabia O
. O
The O
immunotoxic O
effects O
after O
inhalation O
exposures O
to O
the O
preparation O
for O
a O
continuous O
period O
of O
24 O
, O
48 O
, O
and O
72 O
h O
were O
investigated O
in O
rats O
. O
Methods O
and O
materials O
: O
Rats O
were O
exposed O
to O
prallethrin O
1.6% O
w/w O
by O
inhalation O
for O
72 O
consecutive O
hours O
. O
Total O
blood O
count O
, O
blood O
indices O
of O
creatine O
kinase O
(CK) O
, O
gamma-glutamyltranspeptidase O
(γ-GT) O
, O
superoxide O
dismutase O
(SOD) O
, O
nitric O
oxide O
(NO) O
, O
malondialdehyde O
(MDA) O
, O
interleukin O
(IL)-2 O
, O
tumor O
necrosis O
factors O
(TNF)α O
, O
alpha-fetoprotein O
(AFP) O
, O
carbohydrate O
antigen O
(CA) O
19.9 O
and O
carcinoembrionic O
antigen O
(CEA) O
were O
assayed O
. O
Results O
: O
The O
administration O
of O
prallethrin O
1.6% O
w/w O
created O
significant O
increased O
changes O
in O
the O
levels O
of O
total O
WBC O
, O
lymphocytes O
, O
RBC O
, O
hemoglobin O
, O
packed O
cell O
volume O
, O
platelets O
, O
mean O
corpuscular O
volume O
, O
and O
mean O
corpuscular O
hemoglobin B
in O
rats O
after O
24 O
, O
48 O
, O
and O
72 O
h O
of O
continuous O
inhalation; O
however O
, O
there O
was O
a O
significant O
reduction O
in O
neutrophils O
at O
transient O
reduction O
in O
the O
monocytes O
after O
24 O
and O
48 O
h O
to O
return O
to O
normal O
after O
72 O
h O
. O
Significant O
increases O
in O
the O
levels O
of O
CK O
, O
γ-GT O
, O
SOD O
, O
NO O
, O
MDA O
, O
AFP O
, O
IL-2 O
, O
and O
TNFα O
were O
recorded O
. O
CA O
and O
CEA O
did O
not O
exhibit O
any O
change O
. O
Conclusions O
: O
Continuous O
inhalation O
to O
prallethrin O
1.6% O
insecticides O
poses O
toxicity O
on O
hematological O
variables O
. O
It O
is O
also O
concluded O
that O
pyrethroid O
group O
of O
insecticide O
may O
cause O
hematological O
, O
biochemical O
, O
cytokine O
disturbances O
and O
possible O
mutagenic O
damage O
to O
the O
tissues O
. O

palmitoylcarnitine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Structural O
model O
of O
carnitine O
palmitoyltransferase O
I O
based O
on O
the O
carnitine O
acetyltransferase O
crystal O
. O
CPT B
I I
(carnitine O
palmitoyltransferase O
I) O
catalyses O
the O
conversion O
of O
palmitoyl-CoA O
into O
palmitoylcarnitine O
in O
the O
presence O
of O
L-carnitine O
, O
facilitating O
the O
entry O
of O
fatty O
acids O
into O
mitochondria O
. O
We O
propose O
a O
3-D O
(three-dimensional) O
structural O
model O
for O
L-CPT O
I O
(liver O
CPT O
I) O
, O
based O
on O
the O
similarity O
of O
this O
enzyme O
to O
the O
recently O
crystallized O
mouse O
carnitine O
acetyltransferase O
. O
The O
model O
includes O
607 O
of O
the O
773 O
amino O
acids O
of O
L-CPT O
I O
, O
and O
the O
positions O
of O
carnitine O
, O
CoA O
and O
the O
palmitoyl O
group O
were O
assigned O
by O
superposition O
and O
docking O
analysis O
. O
Functional O
analysis O
of O
this O
3-D O
model O
included O
the O
mutagenesis O
of O
several O
amino O
acids O
in O
order O
to O
identify O
putative O
catalytic O
residues O
. O
Mutants O
D477A O
, O
D567A O
and O
E590D O
showed O
reduced O
L-CPT O
I O
activity O
. O
In O
addition O
, O
individual O
mutation O
of O
amino O
acids O
forming O
the O
conserved O
Ser685-Thr686-Ser687 O
motif O
abolished O
enzyme O
activity O
in O
mutants O
T686A O
and O
S687A O
and O
altered O
K(m) O
and O
the O
catalytic O
efficiency O
for O
carnitine O
in O
mutant O
S685A O
. O
We O
conclude O
that O
the O
catalytic O
residues O
are O
His473 O
and O
Asp477 O
, O
while O
Ser687 O
probably O
stabilizes O
the O
transition O
state O
. O
Several O
conserved O
lysines O
, O
i.e O
. O
Lys455 O
, O
Lys505 O
, O
Lys560 O
and O
Lys561 O
, O
were O
also O
mutated O
. O
Only O
mutants O
K455A O
and O
K560A O
showed O
decreases O
in O
activity O
of O
50% O
. O
The O
model O
rationalizes O
the O
finding O
of O
nine O
natural O
mutations O
in O
patients O
with O
hereditary O
L-CPT O
I O
deficiencies O
. O

felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Felbamate O
block O
of O
recombinant O
N-methyl-D-aspartate O
receptors O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O
the O
specificity O
of O
felbamate O
block O
of O
recombinant O
NMDA O
receptors O
composed O
of O
the O
NR1a O
subunit O
and O
various O
NR2 O
subunits O
. O
Felbamate O
produced O
a O
rapid O
, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA O
and O
10 O
microM O
glycine O
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat O
NR1a O
subunit O
, O
and O
either O
the O
NR2A O
, O
NR2B O
or O
NR2C O
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6 O
, O
0.52 O
and O
2.4 O
mM O
, O
respectively O
(holding O
potential O
, O
- O
60 O
mV) O
. O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and O
, O
in O
kinetic O
analyses O
, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O
functions O
, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA B
receptors I
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

dipeptide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin B
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin O
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O
produced O
significant O
, O
dose-related O
decreases O
in O
systolic O
and O
diastolic O
blood O
pressure O
(BP) O
in O
hypertensive O
patients O
, O
and O
the O
BP O
response O
was O
enhanced O
by O
pretreatment O
with O
hydrochlorothiazide O
. O
The O
effects O
of O
enalkiren O
on O
PRA O
and O
BP O
are O
prolonged O
despite O
its O
relatively O
short O
elimination O
phase O
plasma O
half-life O
(1.6 O
h) O
. O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients O
. O
The O
observed O
dissociation O
between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements O
, O
despite O
complete O
suppression O
of O
PRA O
, O
are O
unexplained O
phenomena O
. O
The O
results O
of O
clinical O
trials O
with O
enalkiren O
are O
encouraging O
, O
and O
suggest O
that O
renin O
inhibitors O
may O
be O
safe O
, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension O
. O

morphine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Murine O
chromosomal O
location O
of O
the O
mu O
and O
kappa O
opioid O
receptor O
genes O
. O
Opioid B
receptors I
are O
the O
membrane O
proteins O
that O
mediate O
the O
pain-relieving O
effect O
of O
opioid O
drugs O
, O
such O
as O
morphine O
and O
fentanyl O
as O
well O
as O
endogenous O
opioid O
peptides O
enkephalins O
and O
endorphins O
. O
Using O
cDNAs O
for O
the O
mu O
and O
the O
kappa O
opioid O
receptors O
, O
we O
mapped O
the O
chromosomal O
locations O
of O
their O
genes O
in O
mouse O
. O
Multilocus O
cross O
analysis O
located O
the O
mu O
receptor O
gene O
Oprm O
on O
Chr O
10 O
and O
the O
kappa O
receptor O
gene O
Oprk1 O
on O
Chr O
1 O
. O
Both O
genes O
are O
near O
centromere O
, O
with O
no O
markers O
more O
centromeric O
. O
These O
data O
indicate O
that O
the O
two O
opioid O
receptors O
are O
different O
gene O
products O
, O
ruling O
out O
the O
possibility O
that O
they O
may O
be O
differential O
splicing O
products O
from O
the O
same O
gene O
. O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3 O
/β-catenin B
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK- O
hDAT B
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

Met O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT B
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O
choline O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O
, O
CHDH O
activity O
is O
highest O
in O
the O
liver O
and O
kidney O
, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated O
. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed O
, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8) O
, O
an O
l-amino O
acid-defined O
diet O
varying O
in O
l-Met O
(0.125 O
, O
0.3 O
, O
or O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O
dietary O
choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O
to O
these O
diets O
. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O
choline-devoid O
diet O
, O
indicating O
that O
supplemental O
Met O
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline O
in O
growing O
rats O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
A O
Role O
for O
Cargo O
in O
the O
Activation O
of O
ADP-Ribosylation O
Factors O
(Arf) O
and O
Adaptor O
Recruitment.Membrane O
traffic O
requires O
the O
specific O
concentration O
of O
protein O
cargos O
and O
exclusion O
of O
other O
proteins O
into O
nascent O
carriers O
. O
Critical O
components O
of O
this O
selectivity O
are O
the O
protein O
adaptors O
that O
bind O
to O
short O
, O
linear O
motifs O
in O
the O
cytoplasmic O
tails O
of O
transmembrane O
protein O
cargos O
and O
sequester O
them O
into O
nascent O
carriers O
. O
The O
recruitment O
of O
the O
adaptors O
is O
mediated O
by O
activated O
Arf O
GTPases O
and O
the O
Arf-adaptor O
complexes O
mark O
sites O
of O
carrier O
formation O
. O
However O
, O
the O
nature O
of O
the O
signal(s) O
that O
initiate O
carrier O
biogenesis O
remains O
unknown O
. O
We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf-dependent O
adaptors O
(AP-1 O
and O
GGAs) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
(furin O
, O
mannose-6-phosphate O
receptor O
(M6PR) O
and O
M6PR O
lacking O
a O
C-terminal O
domain O
M6PRΔC) B
 O
. O
We O
find O
that O
cargo O
promotes O
the O
recruitment O
of O
specific O
adaptors O
, O
suggesting O
that O
it O
is O
part O
of O
an O
upstream O
signaling O
event O
. O
Cargos O
do O
not O
promote O
adaptor O
recruitment O
to O
all O
compartments O
in O
which O
they O
reside O
and O
thus O
additional O
factors O
regulate O
the O
cargo's O
ability O
to O
promote O
Arf O
activation O
and O
adaptor O
recruitment O
. O
We O
document O
that O
within O
a O
given O
compartment O
different O
cargos O
recruit O
different O
adaptors O
suggesting O
that O
there O
is O
little O
or O
no O
free O
, O
activated O
Arf O
at O
the O
membrane O
and O
that O
Arf O
activation O
is O
spatially O
and O
temporally O
coupled O
to O
the O
cargo O
and O
the O
adaptor O
. O
Using O
temperature O
block O
, O
Brefeldin O
A O
, O
and O
recovery O
from O
each O
, O
we O
found O
that O
the O
cytoplasmic O
tail O
of O
M6PR O
causes O
the O
recruitment O
of O
AP-1 O
and O
GGAs O
to O
recycling O
endosomes O
and O
not O
at O
the O
Golgi O
, O
as O
predicted O
by O
steady O
state O
staining O
profiles O
. O
These O
results O
are O
discussed O
with O
respect O
to O
the O
generation O
of O
novel O
models O
for O
cargo-dependent O
regulation O
of O
membrane O
traffic O
. O

azoles O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
PXR O
antagonists O
and O
implication O
in O
drug O
metabolism.Adopted O
orphan O
nuclear O
receptor O
(NR) O
, O
pregnane O
X O
receptor O
(PXR) O
, O
plays O
a O
central O
role O
in O
the O
regulation O
of O
xeno- O
and O
endobiotic O
metabolism O
. O
Since O
the O
discovery O
of O
the O
functional O
role O
of O
PXR O
in O
1998 O
, O
there O
is O
evolving O
evidence O
for O
the O
role O
of O
PXR O
agonists O
in O
abrogating O
metabolic O
pathophysiology O
(e.g. O
, O
cholestasis O
, O
hypercholesterolemia O
, O
and O
inflammation) O
. O
However O
, O
more O
recently O
, O
it O
is O
clear O
that O
PXR O
is O
also O
an O
important O
mediator O
of O
adverse O
xeno- O
(e.g. O
, O
enhances O
acetaminophen O
toxicity) O
and O
endobiotic O
(e.g. O
, O
hepatic O
steatosis) O
metabolic O
phenotypes O
. O
Moreover O
, O
in O
cancer O
therapeutics O
, O
PXR O
activation O
can O
induce O
drug O
resistance O
, O
and O
there O
is O
growing O
evidence O
for O
tissue-specific O
enhancement O
of O
the O
malignant O
phenotype O
. O
Thus O
, O
in O
these O
instances O
, O
there O
may O
be O
a O
role O
for O
PXR O
antagonists O
. O
However O
, O
as O
opposed O
to O
the O
discovery O
efforts O
for O
PXR O
agonists O
, O
there O
are O
only O
a O
few O
antagonists O
described O
. O
The O
mode O
of O
action O
of O
these O
antagonists O
(e.g. O
, O
sulforaphane) O
remains O
less O
clear O
. O
Our O
laboratory O
efforts O
have O
focused O
on O
this O
question O
. O
Since O
the O
original O
discovery O
of O
azoles O
analogs O
as O
PXR O
antagonists O
, O
we O
have O
preliminarily O
defined O
an O
important O
PXR B
antagonist O
pharmacophore O
and O
developed O
less-toxic O
PXR O
antagonists O
. O
In O
this O
review O
, O
we O
describe O
our O
published O
and O
unpublished O
findings O
on O
recent O
structure-function O
studies O
involving O
the O
azole O
chemical O
scaffold O
. O
Further O
work O
in O
the O
future O
is O
needed O
to O
fully O
define O
potent O
, O
more-selective O
PXR O
antagonists O
that O
may O
be O
useful O
in O
clinical O
application O
. O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O
species O
of O
Pro42Ala O
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step O
. O

Epi O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
WNT6 O
is O
a O
novel O
target O
gene O
of O
caveolin-1 O
promoting O
chemoresistance O
to O
epirubicin O
in O
human O
gastric O
cancer O
cells.Resistance O
to O
chemotherapy O
is O
a O
major O
obstacle O
for O
curative O
treatment O
of O
human O
gastric O
cancer O
(GC) O
. O
However O
, O
the O
underlying O
molecular O
mechanisms O
are O
largely O
unknown O
. O
Wingless-type O
MMTV O
integration O
site O
family O
members O
(WNTs) O
are O
secreted O
glycoproteins O
involved O
in O
embryogenesis O
and O
, O
on O
inappropriate O
expression O
in O
the O
adult O
, O
in O
cancer O
. O
Here O
, O
we O
show O
expression O
of O
WNT6 O
in O
GC O
patient O
specimens O
, O
human O
GC O
cell O
lines O
and O
in O
a O
mouse O
model O
of O
GC O
. O
In O
human O
GC O
cells O
, O
WNT6 O
expression O
was O
enhanced O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
β-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6 B
/ O
Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O
5-fluorouracil) O
chemotherapy O
. O
These O
results O
showed O
that O
WNT6 O
and O
Cav1 O
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline O
drugs O
. O
Understanding O
the O
molecular O
mechanisms O
driving O
WNT6/Cav1-induced O
drug O
resistance O
will O
provide O
benefits O
in O
developing O
new O
therapies O
for O
GC O
. O

isoprenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors B
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor O
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs/cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

